data_6e98_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6e98 _Structure_validation_residue.Date_analyzed 2019-08-02 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 35.3 t . . . . . 0 N--CA 1.45 -0.43 0 N-CA-C 109.155 -0.683 . . . . 1.43 109.155 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.504 ' N ' HD13 ' A' ' 11' ' ' ILE . 4.3 mp -99.27 138.08 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 CA-C-O 121.722 0.772 . . . . 1.56 111.675 176.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.521 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -148.98 167.76 24.92 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.598 -1.183 . . . . 0.91 111.003 178.301 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 37.3 t -116.45 106.71 13.9 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.38 -0.827 . . . . 0.34 109.293 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.8 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 90.4 m -91.8 132.1 36.67 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.753 -0.658 . . . . 0.19 111.597 -173.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.413 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -73.2 -35.97 66.44 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 114.91 -1.041 . . . . 0.39 109.501 173.869 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 19.7 m-20 -128.84 100.57 5.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.051 -0.522 . . . . 1.12 111.334 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.8 t -92.52 99.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.497 -0.557 . . . . 1.04 109.497 173.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.6 m -129.06 140.4 38.5 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 115.761 -0.654 . . . . 1.03 110.863 -174.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.54 ' O ' ' HB3' ' A' ' 22' ' ' SER . 33.4 Cg_exo -58.36 140.9 96.27 Favored 'Trans proline' 0 N--CA 1.464 -0.252 0 C-N-CA 122.371 2.047 . . . . 0.21 111.709 173.313 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.86 -19.47 69.61 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.907 -0.663 . . . . 0.18 112.589 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -103.22 7.43 38.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.388 0.613 . . . . 2.27 109.97 176.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.54 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 13.8 t -73.28 155.78 39.13 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.328 -0.851 . . . . 0.41 110.014 176.658 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -55.93 -41.01 73.95 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.212 0.529 . . . . 1.06 109.685 176.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.72 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.1 mm? -70.11 -60.52 2.24 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 115.325 -0.852 . . . . 1.77 110.694 176.347 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.435 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -56.03 -41.51 85.21 Favored Glycine 0 CA--C 1.517 0.171 0 CA-C-N 116.053 -0.521 . . . . 0.16 113.348 -174.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 91.5 m -67.84 -39.39 83.85 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.916 0.389 . . . . 1.07 110.499 -178.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -64.71 -39.24 93.32 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.244 -0.65 . . . . 1.57 109.244 176.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.72 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.6 mt -68.13 -50.04 57.22 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.701 -0.681 . . . . 1.13 110.987 -176.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.524 HD11 ' N ' ' A' ' 30' ' ' ASP . 3.8 pp -73.18 -23.72 60.45 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.546 -0.462 . . . . 1.08 111.509 -176.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.524 ' N ' HD11 ' A' ' 29' ' ' LEU . 28.2 t70 -68.97 -31.71 70.76 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.58 0.705 . . . . 0.66 109.192 175.64 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -75.04 -15.29 60.64 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-N 114.988 -1.005 . . . . 2.07 109.918 177.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.8 mt -111.7 0.04 16.17 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.932 -1.031 . . . . 1.35 111.464 -174.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.21 34.66 85.32 Favored Glycine 0 C--N 1.333 0.363 0 CA-C-N 115.855 -0.611 . . . . 0.75 113.015 178.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.512 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 53.9 mt -84.07 125.9 40.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.817 0.341 . . . . 1.24 110.828 -176.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 50.4 t -88.17 121.28 38.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.278 -0.638 . . . . 2.41 109.278 175.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.487 HD11 ' O ' ' A' ' 36' ' ' LEU . 1.6 pp -95.23 130.62 41.91 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.425 0.631 . . . . 3.28 111.703 -176.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -90.87 -29.2 17.66 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 108.56 -0.904 . . . . 2.65 108.56 170.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -142.34 96.1 6.47 Favored Pre-proline 0 N--CA 1.442 -0.838 0 N-CA-C 107.724 -1.213 . . . . 2.29 107.724 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -69.84 -5.89 17.34 Favored 'Trans proline' 0 CA--C 1.521 -0.149 0 C-N-CA 122.561 2.174 . . . . 0.77 111.819 -176.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.2 p -95.41 19.14 11.3 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.686 -0.688 . . . . 1.2 111.308 -175.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.464 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 32.7 m -92.09 156.6 3.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.798 -0.637 . . . . 1.08 109.855 173.048 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.525 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.1 mt -88.99 121.68 31.59 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 116.061 -0.518 . . . . 1.06 109.835 176.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 12.1 pt -102.74 133.57 46.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-O 121.247 0.546 . . . . 1.03 110.053 176.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.8 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -105.82 95.31 1.05 Allowed Glycine 0 N--CA 1.439 -1.166 0 CA-C-N 115.546 -0.752 . . . . 0.31 112.832 -174.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -76.83 141.91 40.48 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.235 -0.654 . . . . 0.57 109.235 176.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 70.57 38.8 68.44 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 119.71 -1.233 . . . . 0.25 111.825 -177.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -107.36 116.28 31.66 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.17 0.51 . . . . 0.25 111.351 -172.98 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.4 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 19.9 m-20 -102.02 134.52 20.04 Favored Pre-proline 0 C--N 1.317 -0.838 0 CA-C-N 115.632 -0.713 . . . . 2.21 109.362 175.453 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.417 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 16.5 Cg_exo -62.79 126.97 19.31 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.613 2.209 . . . . 0.6 111.351 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.406 HG13 ' HA ' ' A' ' 12' ' ' GLN . 47.1 mt . . . . . 0 C--N 1.326 -0.418 0 CA-C-O 120.958 0.409 . . . . 1.13 110.551 -175.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.8 t . . . . . 0 N--CA 1.451 -0.402 0 N-CA-C 110.278 -0.268 . . . . 1.02 110.278 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.3 p -100.79 -26.19 13.86 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.087 -0.506 . . . . 2.56 111.906 -177.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -105.74 -80.56 0.55 Allowed 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 121.067 -0.253 . . . . 1.07 111.585 -177.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 15.1 m -147.19 129.17 15.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.582 0.229 . . . . 1.05 110.797 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.411 ' HB1' ' O ' ' A' ' 82' ' ' VAL . . . -86.21 131.87 34.14 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.902 0.382 . . . . 1.07 110.372 -178.108 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.725 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -144.4 171.82 6.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.238 0.542 . . . . 1.01 111.431 -176.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 42.0 t -139.28 106.26 5.44 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.301 -0.863 . . . . 0.39 109.744 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.745 ' SG ' ' HB2' ' A' ' 76' ' ' ALA . 1.5 m -88.41 134.57 33.8 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.472 0.653 . . . . 0.65 112.214 -177.474 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.8 m -85.42 -18.53 33.37 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.856 -1.066 . . . . 1.83 111.1 -179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -100.75 160.18 14.57 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.456 -0.572 . . . . 1.6 109.456 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -112.2 -7.89 14.01 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.962 0.411 . . . . 3.24 110.859 -176.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 34.5 t30 -75.71 108.24 8.41 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.077 -0.51 . . . . 2.99 110.862 -178.143 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.1 m -118.87 143.74 29.09 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.726 0 CA-C-N 116.078 -0.51 . . . . 1.68 110.257 177.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.619 ' OG ' HG12 ' A' ' 75' ' ' ILE . 90.7 p -84.5 -2.0 56.61 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.093 0.473 . . . . 1.88 110.494 -179.707 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.61 -32.18 3.58 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.669 -0.696 . . . . 0.56 112.288 -177.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 15.7 m -136.63 -16.07 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.533 -0.467 . . . . 1.18 112.043 178.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.619 HG12 ' OG ' ' A' ' 72' ' ' SER . 20.3 pt -87.75 -176.17 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.541 0.686 . . . . 1.12 111.884 -177.187 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.745 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -150.35 142.2 23.8 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-N 114.231 -1.35 . . . . 1.11 108.765 175.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 63.0 mt -117.75 130.22 72.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 120.594 -0.442 . . . . 1.1 111.646 -176.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.06 51.75 6.06 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.068 -0.587 . . . . 0.2 111.871 177.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.525 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.2 m -99.1 129.61 45.37 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.378 0.609 . . . . 0.65 112.072 -176.143 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.41 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 96.5 mt -98.97 132.19 24.08 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.517 -0.765 . . . . 1.1 109.664 173.087 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 13.8 Cg_exo -68.16 123.24 10.38 Favored 'Trans proline' 0 N--CA 1.463 -0.303 0 C-N-CA 122.78 2.32 . . . . 0.25 112.037 -179.071 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.411 ' O ' ' HB1' ' A' ' 63' ' ' ALA . 5.2 m . . . . . 0 N--CA 1.441 -0.879 0 CA-C-N 116.09 -0.505 . . . . 1.12 110.399 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.2 m . . . . . 0 N--CA 1.442 -0.848 0 CA-C-O 120.732 0.301 . . . . 1.43 110.376 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 40.4 mt -90.93 137.66 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.804 0.811 . . . . 1.56 110.869 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.449 ' HA ' HG13 ' A' ' 50' ' ' ILE . 0.1 OUTLIER -145.74 158.05 43.89 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 114.605 -1.179 . . . . 0.91 109.958 -175.903 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.486 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 37.8 t -110.51 103.3 11.89 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-O 121.134 0.492 . . . . 0.34 110.009 -177.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.629 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 63.8 m -86.63 136.05 33.19 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.311 -0.858 . . . . 0.19 111.057 -175.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.466 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -73.33 -32.9 64.83 Favored 'General case' 0 N--CA 1.445 -0.69 0 CA-C-N 115.167 -0.924 . . . . 0.39 108.643 173.762 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . 0.475 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 3.7 t-20 -128.36 135.42 49.54 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.59 -0.732 . . . . 1.12 109.468 178.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 87.2 t -126.43 106.11 15.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 109.706 -0.479 . . . . 1.04 109.706 174.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.3 m -135.24 142.41 41.56 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 115.656 -0.702 . . . . 1.03 111.127 -173.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.533 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.8 Cg_exo -57.75 139.76 91.35 Favored 'Trans proline' 0 N--CA 1.462 -0.345 0 C-N-CA 122.257 1.971 . . . . 0.21 111.329 171.251 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.7 -23.12 70.51 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.839 -0.696 . . . . 0.18 112.31 -179.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -95.65 -1.47 50.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.95 0.405 . . . . 2.27 109.932 177.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.533 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 22.9 t -68.28 150.67 47.96 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.002 -0.544 . . . . 0.41 109.579 176.592 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -58.48 -32.56 68.88 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.2 0.524 . . . . 1.06 110.106 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.646 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.6 mm? -69.01 -64.56 0.85 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.433 -0.803 . . . . 1.77 110.701 172.009 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.44 -40.84 78.76 Favored Glycine 0 C--N 1.33 0.225 0 CA-C-N 115.959 -0.564 . . . . 0.16 113.364 -174.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 30.1 m -67.32 -41.15 85.77 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.168 -0.308 . . . . 1.07 110.168 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -64.91 -40.14 94.6 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.408 -0.59 . . . . 1.57 109.408 177.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.646 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.7 mt -67.92 -44.62 76.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.044 -0.526 . . . . 1.13 110.849 -175.168 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.519 HD13 ' N ' ' A' ' 30' ' ' ASP . 3.8 pp -77.69 -25.1 49.21 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.372 -0.531 . . . . 1.08 110.899 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.519 ' N ' HD13 ' A' ' 29' ' ' LEU . 24.6 t70 -64.88 -36.7 85.21 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.766 0.793 . . . . 0.66 109.178 172.144 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -74.86 -12.13 60.3 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 114.149 -1.387 . . . . 2.07 110.388 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.5 mt -108.66 -9.95 15.24 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.146 -0.934 . . . . 1.35 111.259 -178.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 71.22 35.09 64.02 Favored Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.887 -0.597 . . . . 0.75 112.518 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.512 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 43.4 mt -91.55 131.05 39.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.709 0.255 . . . . 1.24 110.704 -178.159 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 p -91.87 112.75 26.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.42 0.629 . . . . 2.41 109.959 173.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.451 ' H ' ' HG ' ' A' ' 36' ' ' LEU . 0.9 OUTLIER -81.62 134.29 35.47 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.92 -0.582 . . . . 3.28 110.908 -179.573 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -87.32 -35.42 18.42 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.828 -0.804 . . . . 2.65 108.828 173.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -143.71 102.5 4.97 Favored Pre-proline 0 N--CA 1.444 -0.745 0 N-CA-C 107.947 -1.131 . . . . 2.29 107.947 176.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.41 ' HB3' HD22 ' A' ' 36' ' ' LEU . 51.8 Cg_endo -69.53 -3.48 11.95 Favored 'Trans proline' 0 C--O 1.226 -0.119 0 C-N-CA 122.365 2.043 . . . . 0.77 111.673 -175.036 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.0 p -85.73 7.95 21.68 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.633 -0.712 . . . . 1.2 111.88 -174.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.5 m -92.18 158.42 2.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.958 0.408 . . . . 1.08 110.327 177.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.533 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 94.9 mt -89.07 121.76 31.73 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.076 -0.511 . . . . 1.06 110.084 178.494 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 22.4 pt -108.86 145.73 15.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.238 0.542 . . . . 1.03 110.44 177.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.629 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.02 142.09 17.18 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.667 -0.778 . . . . 0.31 112.338 -177.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.475 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 9.5 t70 -105.17 151.79 23.62 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.305 -0.998 . . . . 0.57 108.305 172.314 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.407 ' HA3' ' HB3' ' A' ' 15' ' ' GLN . . . 61.02 44.5 98.11 Favored Glycine 0 C--N 1.32 -0.339 0 C-N-CA 120.28 -0.962 . . . . 0.25 112.302 175.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.507 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.34 115.55 30.44 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.056 0.455 . . . . 0.25 110.984 -172.443 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -101.29 129.32 27.25 Favored Pre-proline 0 C--N 1.316 -0.884 0 CA-C-N 115.666 -0.697 . . . . 2.21 109.304 175.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.439 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 17.8 Cg_exo -61.64 122.2 10.69 Favored 'Trans proline' 0 N--CA 1.46 -0.446 0 C-N-CA 122.739 2.293 . . . . 0.6 111.263 178.05 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.449 HG13 ' HA ' ' A' ' 12' ' ' GLN . 10.1 mt . . . . . 0 C--N 1.324 -0.52 0 CA-C-O 121.593 0.711 . . . . 1.13 109.835 -176.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.9 t . . . . . 0 N--CA 1.446 -0.627 0 N-CA-C 110.129 -0.323 . . . . 1.02 110.129 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 17.4 t -109.66 -22.25 12.03 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.518 -0.31 . . . . 2.56 111.143 -177.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.466 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -102.85 -82.06 0.49 Allowed 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.725 -0.39 . . . . 1.07 111.316 -179.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 23.2 m -148.78 127.67 12.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.8 0.333 . . . . 1.05 110.775 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -88.21 133.21 34.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.0 0.429 . . . . 1.07 110.909 -177.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.487 HG23 ' SG ' ' A' ' 14' ' ' CYS . 3.3 m -144.11 170.5 8.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.03 -0.532 . . . . 1.01 111.07 -178.571 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 46.3 t -130.87 115.77 17.01 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.022 -0.536 . . . . 0.39 110.045 178.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.804 ' SG ' ' HB3' ' A' ' 76' ' ' ALA . 4.4 m -101.71 154.88 18.5 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.814 0.816 . . . . 0.65 111.941 -176.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 49.0 m -103.45 -19.58 14.36 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 114.405 -1.27 . . . . 1.83 110.787 -177.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -106.24 142.82 35.28 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.706 -0.679 . . . . 1.6 109.561 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -116.77 2.94 12.95 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.076 0.465 . . . . 3.24 110.663 -176.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -92.62 58.69 3.16 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.62 0.724 . . . . 2.99 109.861 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 33.5 m -80.68 163.96 3.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.062 -0.972 . . . . 1.68 110.83 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.526 ' OG ' HG12 ' A' ' 75' ' ' ILE . 91.7 p -74.25 -8.04 54.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.281 -0.418 . . . . 1.88 111.339 -175.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.9 -32.06 3.56 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.923 -0.656 . . . . 0.56 112.68 -178.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 10.6 m -134.96 -6.12 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.318 -0.553 . . . . 1.18 111.989 178.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.526 HG12 ' OG ' ' A' ' 72' ' ' SER . 29.0 pt -93.92 -176.28 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 C-N-CA 120.063 -0.655 . . . . 1.12 111.419 179.583 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.804 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -144.58 143.23 30.69 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.782 -1.099 . . . . 1.11 109.73 175.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 64.0 mt -126.44 128.55 71.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.931 0.396 . . . . 1.1 111.606 -176.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.471 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 74.82 53.68 6.26 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.744 -0.662 . . . . 0.2 111.621 179.144 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.533 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 0.9 OUTLIER -104.2 141.9 35.45 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 112.652 0.612 . . . . 0.65 112.652 -175.539 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.408 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 84.2 mt -111.36 134.8 21.06 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.512 -0.767 . . . . 1.1 109.787 172.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.426 ' HA ' HG12 ' A' ' 64' ' ' VAL . 19.4 Cg_exo -65.14 124.04 12.42 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 123.067 2.512 . . . . 0.25 112.595 -179.012 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.3 m . . . . . 0 N--CA 1.444 -0.74 0 CA-C-N 116.089 -0.505 . . . . 1.12 110.223 177.619 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 40.1 t . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 110.139 -0.319 . . . . 1.43 110.139 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.3 mt -88.21 139.37 17.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.185 0.517 . . . . 1.56 110.448 172.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.639 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -140.02 164.37 30.2 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.578 -0.737 . . . . 0.91 110.676 176.616 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 28.3 t -107.79 101.91 11.17 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.311 -0.859 . . . . 0.34 109.468 179.718 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.809 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 55.6 m -87.72 126.29 34.9 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.984 -0.553 . . . . 0.19 111.298 -176.057 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.441 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -67.28 -33.4 75.22 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.074 -0.967 . . . . 0.39 109.471 174.878 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -139.43 113.01 8.41 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.953 -0.567 . . . . 1.12 110.501 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 51.2 t -101.17 104.55 16.43 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 109.67 -0.493 . . . . 1.04 109.67 177.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 m -129.97 140.58 39.07 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 116.072 -0.513 . . . . 1.03 111.43 -174.221 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.453 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.1 Cg_exo -59.61 138.44 83.51 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.37 2.047 . . . . 0.21 111.222 171.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -62.79 -26.05 68.27 Favored Glycine 0 C--O 1.227 -0.34 0 C-N-CA 121.272 -0.49 . . . . 0.18 113.146 -176.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -101.13 7.55 43.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.493 0.664 . . . . 2.27 110.245 177.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.453 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 26.6 t -71.31 159.02 35.33 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.52 -0.548 . . . . 0.41 109.52 175.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -53.4 -44.31 68.61 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.168 0.509 . . . . 1.06 109.767 176.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.683 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 6.2 mt -69.09 -60.27 2.47 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.314 -0.857 . . . . 1.77 110.456 178.25 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.425 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -53.51 -38.13 57.49 Favored Glycine 0 C--N 1.33 0.228 0 CA-C-N 116.101 -0.499 . . . . 0.16 113.218 -176.205 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 88.3 m -67.6 -47.61 69.2 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 110.361 -0.237 . . . . 1.07 110.361 -178.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.413 ' O ' HD11 ' A' ' 27' ' ' LEU . 3.1 tm? -62.71 -37.76 87.76 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.66 -0.496 . . . . 1.57 109.66 178.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.683 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.9 mt -69.01 -43.84 74.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.975 -0.557 . . . . 1.13 110.849 -175.543 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.455 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -82.41 -21.31 35.82 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.536 -0.466 . . . . 1.08 111.217 -178.578 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.429 ' N ' HD12 ' A' ' 29' ' ' LEU . 19.4 t70 -66.56 -34.92 78.98 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.634 0.731 . . . . 0.66 109.364 174.313 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -74.15 -32.96 63.35 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.793 -1.094 . . . . 2.07 109.18 179.141 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.4 mt -89.2 -10.56 46.61 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.903 -1.044 . . . . 1.35 111.982 -176.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.96 44.01 92.52 Favored Glycine 0 N--CA 1.452 -0.294 0 CA-C-N 115.849 -0.614 . . . . 0.75 112.766 178.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.455 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 51.3 mt -91.19 128.82 42.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.936 0.398 . . . . 1.24 111.41 -176.28 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.3 p -84.99 122.31 38.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.061 -0.518 . . . . 2.41 109.905 173.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.484 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.3 pp -94.88 131.26 40.97 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.265 0.555 . . . . 3.28 111.589 -176.227 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -90.36 -29.06 18.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.876 -0.787 . . . . 2.65 108.876 173.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -146.89 103.06 3.87 Favored Pre-proline 0 N--CA 1.444 -0.738 0 N-CA-C 107.435 -1.32 . . . . 2.29 107.435 175.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.439 ' HB3' HD21 ' A' ' 36' ' ' LEU . 66.7 Cg_endo -74.89 -1.09 10.73 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.135 1.89 . . . . 0.77 112.603 -174.029 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.3 p -99.6 4.48 45.79 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.176 -0.609 . . . . 1.2 111.092 -173.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.0 m -78.29 163.72 3.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.841 -0.618 . . . . 1.08 110.465 175.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.472 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 88.8 mt -91.5 120.09 32.02 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.933 -0.576 . . . . 1.06 110.011 176.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 17.3 pt -103.0 134.59 43.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 121.229 0.538 . . . . 1.03 110.095 176.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.809 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.94 104.75 2.21 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.699 -0.762 . . . . 0.31 112.878 -175.158 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -83.43 139.69 32.81 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 109.323 -0.621 . . . . 0.57 109.323 176.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.427 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 73.31 38.13 53.73 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.057 -1.068 . . . . 0.25 111.751 -179.846 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.513 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -103.25 116.17 31.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.065 0.46 . . . . 0.25 111.056 -172.708 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.503 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -101.56 134.02 20.48 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-N 115.857 -0.61 . . . . 2.21 109.858 177.371 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -54.57 119.11 5.87 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.747 2.298 . . . . 0.6 111.947 176.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.405 HG13 ' HA ' ' A' ' 12' ' ' GLN . 27.4 mt . . . . . 0 N--CA 1.447 -0.622 0 N-CA-C 108.662 -0.866 . . . . 1.13 108.662 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.4 t . . . . . 0 N--CA 1.447 -0.578 0 CA-C-O 120.727 0.299 . . . . 1.02 110.513 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 20.0 m -101.21 7.37 43.07 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.33 -0.396 . . . . 2.56 111.526 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.441 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -147.0 -83.96 0.12 Allowed 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.914 -0.315 . . . . 1.07 111.81 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 33.8 m -142.27 130.08 21.68 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-O 120.713 0.292 . . . . 1.05 110.99 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.97 129.25 34.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.465 -0.334 . . . . 1.07 110.267 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.646 HG23 ' SG ' ' A' ' 14' ' ' CYS . 4.0 m -140.6 169.9 15.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-O 121.248 0.546 . . . . 1.01 111.959 -176.574 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 29.1 t -132.98 103.66 6.16 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.191 -0.913 . . . . 0.39 110.061 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.747 ' SG ' ' HB2' ' A' ' 76' ' ' ALA . 1.4 m -91.11 138.79 31.33 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.647 0.737 . . . . 0.65 111.882 -178.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 47.9 t -92.8 -19.16 22.02 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 114.635 -1.166 . . . . 1.83 110.736 179.051 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -96.83 159.78 14.73 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.107 -0.497 . . . . 1.6 110.519 -175.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.2 t30 -117.68 -6.41 11.1 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.117 -0.492 . . . . 3.24 111.067 -173.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -81.04 83.25 6.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.249 0.547 . . . . 2.99 110.655 -177.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 30.0 m -101.81 139.57 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-N 116.0 -0.545 . . . . 1.68 110.885 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.566 ' OG ' HG12 ' A' ' 75' ' ' ILE . 99.9 p -80.38 -5.08 55.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.188 -0.46 . . . . 1.88 110.739 -178.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.3 -32.22 3.62 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.841 -0.618 . . . . 0.56 112.179 -177.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 m -135.44 -7.78 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 C-N-CA 120.559 -0.456 . . . . 1.18 111.945 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.566 HG12 ' OG ' ' A' ' 72' ' ' SER . 37.0 pt -97.39 179.78 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.522 0.677 . . . . 1.12 111.779 -178.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.747 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -149.85 140.4 22.49 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.255 -1.338 . . . . 1.11 109.094 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.0 mt -118.63 133.55 65.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.875 0.369 . . . . 1.1 111.333 -177.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 74.9 50.86 8.32 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.962 -0.637 . . . . 0.2 111.828 178.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.472 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.35 133.03 44.23 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.153 0.501 . . . . 0.65 111.89 -176.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.427 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 86.4 mt -108.23 132.1 21.31 Favored Pre-proline 0 C--N 1.318 -0.763 0 CA-C-N 115.728 -0.669 . . . . 1.1 109.811 172.733 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 21.7 Cg_exo -64.02 123.48 11.97 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.713 2.275 . . . . 0.25 111.889 -178.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 m . . . . . 0 N--CA 1.445 -0.693 0 CA-C-O 121.265 0.555 . . . . 1.12 111.274 -178.086 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.1 t . . . . . 0 N--CA 1.453 -0.309 0 N-CA-C 109.778 -0.453 . . . . 1.43 109.778 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 16.6 mt -103.07 130.94 52.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.641 0.734 . . . . 1.56 111.374 174.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.471 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -130.39 168.09 17.52 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 114.656 -1.156 . . . . 0.91 110.138 177.653 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.44 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 36.8 t -110.38 101.93 10.61 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.772 -0.649 . . . . 0.34 109.918 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.831 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 96.5 m -87.45 125.01 34.03 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.788 -0.642 . . . . 0.19 111.459 -175.683 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.477 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -69.13 -31.96 71.0 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.06 -0.973 . . . . 0.39 109.818 175.583 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -136.74 108.38 7.0 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.046 -0.525 . . . . 1.12 110.423 177.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 93.2 t -98.94 105.92 18.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 N-CA-C 109.746 -0.465 . . . . 1.04 109.746 177.121 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 m -131.12 142.88 47.14 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 116.012 -0.54 . . . . 1.03 110.763 -176.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.506 ' O ' ' HB3' ' A' ' 22' ' ' SER . 30.9 Cg_exo -61.19 136.91 67.67 Favored 'Trans proline' 0 N--CA 1.461 -0.396 0 C-N-CA 122.161 1.908 . . . . 0.21 111.434 173.2 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.62 -15.03 68.1 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.665 -0.779 . . . . 0.18 111.972 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -103.09 3.66 36.22 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.592 0.71 . . . . 2.27 109.657 176.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.506 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 21.3 t -74.99 155.78 36.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.186 -0.915 . . . . 0.41 110.031 177.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -53.68 -44.32 69.63 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.829 0.823 . . . . 1.06 109.142 176.54 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.578 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.2 mm? -67.36 -63.19 1.11 Allowed 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 114.25 -1.341 . . . . 1.77 111.002 177.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.496 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.38 -39.21 71.95 Favored Glycine 0 C--N 1.33 0.23 0 CA-C-N 116.217 -0.447 . . . . 0.16 113.392 -175.074 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 98.7 m -67.72 -38.74 84.0 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.87 0.366 . . . . 1.07 110.475 -178.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -75.44 -27.72 59.06 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 120.934 0.397 . . . . 1.57 110.132 178.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.578 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 13.1 mt -69.74 -48.67 58.53 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.185 -0.461 . . . . 1.13 110.182 178.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -76.95 -23.78 52.38 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.571 -0.452 . . . . 1.08 111.549 -175.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.489 ' N ' HD11 ' A' ' 29' ' ' LEU . 18.8 t70 -67.95 -32.81 73.5 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.525 0.678 . . . . 0.66 109.37 175.456 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -75.28 -19.78 59.51 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 114.91 -1.041 . . . . 2.07 109.762 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 80.7 mt -103.37 -6.94 21.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.907 -1.042 . . . . 1.35 111.696 -174.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.97 35.48 84.37 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.958 -0.564 . . . . 0.75 112.566 178.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.541 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 32.2 mt -88.96 138.53 19.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.523 0.201 . . . . 1.24 110.705 -177.683 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.1 p -99.14 110.59 26.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.444 0.64 . . . . 2.41 110.221 175.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.534 HD13 ' O ' ' A' ' 36' ' ' LEU . 1.4 pp -80.74 130.89 35.33 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.915 -0.584 . . . . 3.28 110.725 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -90.34 -29.1 18.3 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.739 -0.837 . . . . 2.65 108.739 173.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -142.23 98.41 6.1 Favored Pre-proline 0 N--CA 1.444 -0.772 0 N-CA-C 107.802 -1.184 . . . . 2.29 107.802 176.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.01 -9.54 21.98 Favored 'Trans proline' 0 N--CA 1.466 -0.143 0 C-N-CA 121.965 1.777 . . . . 0.77 111.588 -175.392 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 p -80.36 -8.9 59.7 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.623 -0.717 . . . . 1.2 111.497 -175.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.467 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.8 m -76.28 159.72 5.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.266 0.555 . . . . 1.08 111.065 -178.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.475 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.6 mt -92.53 128.03 38.24 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.498 -0.774 . . . . 1.06 109.556 176.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.1 pt -106.32 139.12 28.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 116.011 -0.54 . . . . 1.03 109.995 177.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.831 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -107.79 99.37 1.36 Allowed Glycine 0 N--CA 1.437 -1.281 0 C-N-CA 120.633 -0.794 . . . . 0.31 112.967 -175.76 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -78.2 137.12 37.98 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 108.691 -0.855 . . . . 0.57 108.691 173.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.477 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 70.79 39.08 66.01 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 119.914 -1.136 . . . . 0.25 112.252 -177.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.534 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -103.61 111.88 24.55 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.335 0.588 . . . . 0.25 110.831 -174.887 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -94.53 136.47 23.18 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 115.269 -0.878 . . . . 2.21 109.242 178.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -66.1 119.47 6.5 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 122.303 2.002 . . . . 0.6 110.745 176.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.407 HG13 ' HA ' ' A' ' 12' ' ' GLN . 16.8 mt . . . . . 0 C--N 1.326 -0.438 0 CA-C-O 121.62 0.724 . . . . 1.13 110.213 -176.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.6 t . . . . . 0 N--CA 1.449 -0.512 0 N-CA-C 109.994 -0.373 . . . . 1.02 109.994 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.7 m -126.14 18.34 7.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.44 -0.345 . . . . 2.56 111.071 -177.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -163.01 -77.69 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 112.015 0.376 . . . . 1.07 112.015 -178.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 74.8 m -147.61 131.33 16.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.806 0.336 . . . . 1.05 111.417 -176.425 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -88.13 125.72 34.74 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.039 -0.528 . . . . 1.07 109.93 177.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.576 HG21 ' SG ' ' A' ' 14' ' ' CYS . 6.8 m -138.89 159.96 30.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-N 115.964 -0.562 . . . . 1.01 110.949 -178.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 53.6 t -117.91 103.41 9.91 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.602 -0.726 . . . . 0.39 109.727 179.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.75 ' SG ' ' HB2' ' A' ' 76' ' ' ALA . 20.1 m -91.75 132.55 36.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.36 0.6 . . . . 0.65 111.402 -176.35 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 10.9 m -94.78 -15.78 23.53 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.314 -0.857 . . . . 1.83 111.29 -177.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.418 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 9.7 t70 -109.98 131.94 54.61 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.623 -0.51 . . . . 1.6 109.623 -178.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -108.12 20.95 18.05 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.489 0.551 . . . . 3.24 112.489 -172.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 50.8 m-80 -83.38 61.91 6.44 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.5 0.667 . . . . 2.99 110.123 177.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 m -73.66 149.01 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 CA-C-N 115.541 -0.754 . . . . 1.68 111.181 -178.481 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.595 ' OG ' HG12 ' A' ' 75' ' ' ILE . 82.0 p -95.4 -5.93 42.09 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.887 -0.597 . . . . 1.88 110.34 179.035 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.12 -31.84 3.57 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.675 -0.693 . . . . 0.56 112.409 -176.022 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.0 m -136.59 -8.22 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 117.185 0.493 . . . . 1.18 111.961 177.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.595 HG12 ' OG ' ' A' ' 72' ' ' SER . 21.7 pt -94.63 179.7 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.642 0.734 . . . . 1.12 111.979 -178.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.75 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -150.22 145.33 26.17 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.007 -1.452 . . . . 1.11 108.502 176.179 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.418 ' HB ' ' HB3' ' A' ' 68' ' ' ASP . 58.9 mt -125.75 142.19 43.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 120.717 -0.393 . . . . 1.1 111.402 -175.321 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.467 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 69.34 50.55 31.96 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.115 -0.564 . . . . 0.2 111.898 178.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.53 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 9.0 m -103.86 131.55 50.96 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.158 0.504 . . . . 0.65 111.8 -173.292 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.427 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.8 mt -105.9 134.68 19.62 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.735 -0.666 . . . . 1.1 109.859 173.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 17.1 Cg_exo -66.09 122.58 10.14 Favored 'Trans proline' 0 N--CA 1.465 -0.204 0 C-N-CA 122.75 2.3 . . . . 0.25 111.789 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.324 -0.536 0 CA-C-O 121.445 0.641 . . . . 1.12 111.35 -177.446 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.4 t . . . . . 0 N--CA 1.451 -0.38 0 N-CA-C 109.14 -0.689 . . . . 1.43 109.14 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 40.6 mt -100.72 135.02 38.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.711 0.767 . . . . 1.56 111.122 176.436 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.592 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -132.28 165.61 23.78 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.702 -1.136 . . . . 0.91 109.82 177.058 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.5 t -112.29 101.39 9.61 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.891 -0.595 . . . . 0.34 109.409 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.794 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 68.5 m -84.32 130.22 34.82 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 115.326 -0.852 . . . . 0.19 110.988 -176.374 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.48 -30.63 68.56 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.26 -0.882 . . . . 0.39 109.053 172.849 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -141.16 121.02 13.54 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.972 -0.558 . . . . 1.12 110.538 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.6 t -109.06 107.78 23.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 109.969 -0.382 . . . . 1.04 109.969 176.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 20.8 m -133.39 145.97 58.77 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.153 -0.476 . . . . 1.03 110.777 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.443 ' O ' ' HB3' ' A' ' 22' ' ' SER . 22.5 Cg_exo -63.42 137.37 59.84 Favored 'Trans proline' 0 N--CA 1.463 -0.309 0 C-N-CA 121.936 1.757 . . . . 0.21 110.934 171.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.45 -26.94 71.1 Favored Glycine 0 C--O 1.228 -0.232 0 C-N-CA 121.018 -0.611 . . . . 0.18 112.501 -177.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -98.18 9.15 43.62 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.099 0.476 . . . . 2.27 110.249 177.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.443 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 30.7 t -78.53 155.82 29.56 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 115.786 -0.643 . . . . 0.41 109.816 176.088 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -54.31 -41.68 69.25 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.001 0.429 . . . . 1.06 109.922 178.155 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.689 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.1 mm? -69.37 -60.27 2.45 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.648 -0.706 . . . . 1.77 110.94 177.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.93 -39.58 69.14 Favored Glycine 0 C--N 1.328 0.126 0 CA-C-N 116.203 -0.453 . . . . 0.16 113.216 -176.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.6 m -70.36 -41.48 73.09 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.974 0.416 . . . . 1.07 110.388 -177.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.1 tm? -63.75 -40.42 96.67 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.308 -0.627 . . . . 1.57 109.308 177.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.689 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.5 mt -68.05 -43.75 77.96 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.533 -0.758 . . . . 1.13 110.857 -175.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.506 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -76.54 -24.34 53.64 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.944 -0.302 . . . . 1.08 111.051 -178.005 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.482 ' N ' HD11 ' A' ' 29' ' ' LEU . 24.6 t70 -67.38 -31.28 71.4 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.406 0.622 . . . . 0.66 109.647 175.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -74.51 -38.7 62.75 Favored 'General case' 0 N--CA 1.443 -0.796 0 CA-C-N 115.037 -0.983 . . . . 2.07 109.513 177.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.7 mt -79.08 -20.17 49.44 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.522 -1.217 . . . . 1.35 111.921 -177.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.08 48.18 6.17 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.177 -0.535 . . . . 0.75 112.164 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.506 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 16.3 mt -110.92 142.83 22.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 110.449 -0.204 . . . . 1.24 110.449 -178.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.5 p -126.54 103.47 11.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.596 0.712 . . . . 2.41 110.16 174.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.2 mt -87.6 137.25 32.5 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.825 -0.625 . . . . 3.28 110.824 -178.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -68.67 -36.78 78.98 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.661 -0.7 . . . . 2.65 109.442 175.072 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -132.88 88.86 36.21 Favored Pre-proline 0 N--CA 1.444 -0.764 0 N-CA-C 108.849 -0.797 . . . . 2.29 108.849 175.527 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -72.23 3.38 4.1 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.361 2.041 . . . . 0.77 111.56 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.2 p -75.77 -8.31 56.55 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.62 -0.718 . . . . 1.2 111.063 -178.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.1 m -82.41 162.76 3.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 116.055 -0.52 . . . . 1.08 110.561 176.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 94.8 mt -83.69 126.17 32.61 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.048 -0.524 . . . . 1.06 110.328 177.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 24.1 pt -107.6 140.77 24.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.244 0.545 . . . . 1.03 110.226 175.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.794 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -111.99 105.21 1.75 Allowed Glycine 0 N--CA 1.44 -1.094 0 C-N-CA 120.57 -0.824 . . . . 0.31 112.87 -177.11 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -83.06 132.39 35.12 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.057 -0.72 . . . . 0.57 109.057 176.009 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.93 38.01 24.24 Favored Glycine 0 N--CA 1.443 -0.86 0 C-N-CA 119.89 -1.148 . . . . 0.25 111.709 -178.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.52 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.93 111.76 24.54 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.043 0.449 . . . . 0.25 111.22 -174.017 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -100.61 134.67 20.45 Favored Pre-proline 0 C--N 1.315 -0.925 0 CA-C-N 115.647 -0.706 . . . . 2.21 109.269 174.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -59.96 130.8 36.23 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.908 2.405 . . . . 0.6 111.609 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.416 HG13 ' HA ' ' A' ' 12' ' ' GLN . 21.1 mt . . . . . 0 C--N 1.326 -0.435 0 CA-C-O 121.68 0.753 . . . . 1.13 109.475 -179.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.7 t . . . . . 0 N--CA 1.454 -0.272 0 CA-C-O 120.71 0.291 . . . . 1.02 110.858 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 27.3 p -117.06 5.38 12.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.179 -0.464 . . . . 2.56 111.509 -179.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -146.8 -80.99 0.14 Allowed 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 120.966 -0.293 . . . . 1.07 111.776 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 28.4 m -142.05 126.88 18.16 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.815 0.341 . . . . 1.05 111.234 -178.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.411 ' HB2' ' O ' ' A' ' 82' ' ' VAL . . . -86.67 128.98 35.04 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.926 0.393 . . . . 1.07 110.254 179.319 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.655 HG21 ' SG ' ' A' ' 14' ' ' CYS . 4.6 m -142.4 165.96 16.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.138 -0.483 . . . . 1.01 111.208 -177.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . 0.548 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 40.6 t -127.72 109.27 11.49 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.819 -0.628 . . . . 0.39 110.259 -178.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.744 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.6 m -97.46 140.49 31.83 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.397 0.618 . . . . 0.65 111.808 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 65.2 m -99.85 -12.73 19.62 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.14 -0.936 . . . . 1.83 111.501 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -110.33 149.99 29.4 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.02 -0.363 . . . . 1.6 110.02 -178.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 42.8 m-80 -120.35 12.42 11.69 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.639 0.607 . . . . 3.24 112.639 -173.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -81.62 71.84 8.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.773 0.796 . . . . 2.99 109.37 177.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 34.3 m -94.35 152.18 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 CA-C-N 115.457 -0.792 . . . . 1.68 111.172 -175.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.512 ' OG ' HG12 ' A' ' 75' ' ' ILE . 90.4 p -86.97 -8.68 56.98 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.657 -0.701 . . . . 1.88 110.309 178.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.92 -32.02 3.74 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 115.285 -0.87 . . . . 0.56 111.954 -176.471 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.9 m -132.84 -2.58 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 C-N-CA 120.517 -0.473 . . . . 1.18 112.007 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.512 HG12 ' OG ' ' A' ' 72' ' ' SER . 23.5 pt -100.73 178.77 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.495 0.664 . . . . 1.12 111.924 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.744 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -148.26 139.71 23.54 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.575 -1.193 . . . . 1.11 109.393 177.061 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 68.9 mt -121.73 130.19 74.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.938 0.399 . . . . 1.1 111.301 -176.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 82.0 46.43 6.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.995 -0.621 . . . . 0.2 111.777 178.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -99.38 144.25 28.71 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.288 0.566 . . . . 0.65 112.387 -175.153 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 87.7 mt -119.81 134.11 23.91 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.246 -0.888 . . . . 1.1 109.743 172.092 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 21.6 Cg_exo -64.67 121.47 9.03 Favored 'Trans proline' 0 C--O 1.234 0.298 0 C-N-CA 123.034 2.489 . . . . 0.25 112.348 -179.347 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.411 ' O ' ' HB2' ' A' ' 63' ' ' ALA . 5.8 m . . . . . 0 N--CA 1.444 -0.762 0 CA-C-N 116.039 -0.528 . . . . 1.12 110.629 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 109.014 -0.736 . . . . 1.43 109.014 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 51.5 mt -99.9 134.75 38.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.606 0.717 . . . . 1.56 111.344 178.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.616 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -142.95 162.22 36.05 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.063 -0.971 . . . . 0.91 111.043 178.996 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.53 ' HB3' ' OD2' ' A' ' 48' ' ' ASP . 19.4 t -106.68 102.26 11.65 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.46 -0.791 . . . . 0.34 109.483 178.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.882 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 57.6 m -86.75 133.54 33.65 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.934 -0.575 . . . . 0.19 111.017 -175.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.12 -30.42 49.41 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.185 -0.916 . . . . 0.39 109.435 177.016 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . 0.589 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 17.1 m-20 -134.28 103.21 5.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.438 -0.346 . . . . 1.12 111.306 175.172 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.1 t -92.52 101.68 12.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.214 0.53 . . . . 1.04 109.727 174.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 m -131.71 140.38 38.11 Favored Pre-proline 0 C--N 1.319 -0.717 0 CA-C-N 115.748 -0.66 . . . . 1.03 110.75 -174.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.512 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.7 Cg_exo -57.94 138.75 87.56 Favored 'Trans proline' 0 N--CA 1.463 -0.302 0 C-N-CA 122.195 1.93 . . . . 0.21 111.304 172.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.29 -21.99 68.84 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.939 -0.648 . . . . 0.18 112.596 -178.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -101.2 4.94 42.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.239 0.542 . . . . 2.27 109.837 176.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.512 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 16.6 t -69.32 153.95 42.81 Favored 'General case' 0 CA--C 1.514 -0.438 0 CA-C-N 115.778 -0.646 . . . . 0.41 109.68 175.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -56.63 -38.42 72.09 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-O 121.122 0.487 . . . . 1.06 110.035 178.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.672 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 5.3 mt -70.19 -63.45 1.08 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.58 -0.737 . . . . 1.77 110.853 174.06 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.54 -40.87 55.52 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 116.035 -0.53 . . . . 0.16 113.443 -174.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 93.4 m -68.16 -44.53 75.77 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.761 0.315 . . . . 1.07 110.484 -178.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.4 tt -63.43 -35.52 80.71 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.075 -0.511 . . . . 1.57 110.814 178.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.672 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.3 mt -72.49 -46.09 56.41 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.096 -0.502 . . . . 1.13 110.365 -177.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.568 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -75.03 -21.76 58.85 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.71 -0.396 . . . . 1.08 110.934 -178.133 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -66.24 -32.22 73.51 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.708 0.766 . . . . 0.66 109.712 173.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -77.37 -47.7 19.19 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 114.906 -1.043 . . . . 2.07 109.261 177.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 72.4 mt -78.22 -13.11 59.99 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.705 -1.134 . . . . 1.35 112.893 -174.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.49 37.57 90.04 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-N 116.131 -0.486 . . . . 0.75 112.473 178.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.568 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 55.8 mt -75.46 137.35 23.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.104 0.478 . . . . 1.24 111.718 -173.265 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.4 p -88.11 113.55 25.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.687 -0.688 . . . . 2.41 110.762 175.471 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.2 pp -103.0 134.6 46.17 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.03 -0.532 . . . . 3.28 110.796 177.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -90.06 -32.28 16.79 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.021 -1.104 . . . . 2.65 108.021 171.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -139.93 106.76 6.86 Favored Pre-proline 0 N--CA 1.446 -0.631 0 CA-C-N 114.588 -1.187 . . . . 2.29 108.227 174.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -71.9 -2.24 11.19 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.072 1.848 . . . . 0.77 111.327 -178.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.6 p -94.94 20.2 9.23 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.479 -0.782 . . . . 1.2 111.157 -175.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.2 m -105.77 160.83 5.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.81 -0.632 . . . . 1.08 110.226 178.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 95.6 mt -81.29 119.81 24.12 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.034 -0.53 . . . . 1.06 110.244 175.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 19.4 pt -104.06 137.11 34.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.871 -0.604 . . . . 1.03 109.684 175.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.882 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.91 106.75 1.78 Allowed Glycine 0 N--CA 1.438 -1.176 0 C-N-CA 120.538 -0.839 . . . . 0.31 113.05 -174.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.589 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 26.0 t70 -77.48 145.18 37.2 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 108.887 -0.783 . . . . 0.57 108.887 174.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 69.71 37.3 76.45 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 119.884 -1.15 . . . . 0.25 112.221 177.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -101.35 114.4 28.36 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.387 0.613 . . . . 0.25 111.215 -172.712 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.53 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 0.7 OUTLIER -101.54 130.98 23.56 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 115.4 -0.818 . . . . 2.21 109.702 177.438 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -56.48 120.39 8.24 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 C-N-CA 122.436 2.091 . . . . 0.6 111.102 177.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.411 HG13 ' HA ' ' A' ' 12' ' ' GLN . 43.7 mt . . . . . 0 C--N 1.326 -0.418 0 CA-C-O 121.158 0.504 . . . . 1.13 110.587 -174.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 40.1 t . . . . . 0 C--O 1.235 0.309 0 CA-C-O 120.94 0.4 . . . . 1.02 111.261 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 8.9 t -119.11 -13.63 9.37 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.974 -0.557 . . . . 2.56 110.782 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.12 -83.59 0.57 Allowed 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 121.121 -0.232 . . . . 1.07 110.86 -179.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 54.4 m -150.39 127.45 11.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.699 0.285 . . . . 1.05 110.551 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.44 140.58 29.85 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.03 0.443 . . . . 1.07 110.483 -178.049 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.65 HG21 ' SG ' ' A' ' 14' ' ' CYS . 2.7 m -147.78 170.38 3.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.229 0.538 . . . . 1.01 111.404 -176.651 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . 0.542 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 50.3 t -129.6 107.97 9.86 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.319 -0.855 . . . . 0.39 109.788 178.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.721 ' SG ' ' HB3' ' A' ' 76' ' ' ALA . 1.5 m -99.58 138.89 36.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.286 0.565 . . . . 0.65 111.82 -177.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 50.4 m -99.69 -19.1 16.95 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.492 -0.776 . . . . 1.83 111.731 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.408 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 16.4 t70 -101.54 148.95 24.6 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.925 -0.398 . . . . 1.6 109.925 -177.051 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -120.18 18.51 12.31 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.581 0.586 . . . . 3.24 112.581 -173.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.9 m-80 -79.24 63.9 4.0 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.544 0.688 . . . . 2.99 109.967 176.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.607 HG11 ' H ' ' A' ' 73' ' ' GLY . 87.2 t -90.37 136.19 24.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.414 -0.812 . . . . 1.68 111.23 -173.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.566 ' H ' HG12 ' A' ' 75' ' ' ILE . 87.3 p -79.2 -3.01 43.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.345 -0.843 . . . . 1.88 110.939 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.607 ' H ' HG11 ' A' ' 71' ' ' VAL . . . 127.85 -31.56 3.69 Favored Glycine 0 N--CA 1.443 -0.868 0 CA-C-N 115.367 -0.833 . . . . 0.56 112.195 -176.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 17.2 m -138.68 -7.62 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 112.641 0.608 . . . . 1.18 112.641 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.566 HG12 ' H ' ' A' ' 72' ' ' SER . 7.2 pt -84.97 -178.54 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.581 0.705 . . . . 1.12 112.142 -178.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.721 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -149.43 139.2 21.83 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.639 -1.164 . . . . 1.11 109.51 175.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.408 ' HB ' ' HB3' ' A' ' 68' ' ' ASP . 65.3 mt -124.49 134.99 65.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.931 0.396 . . . . 1.1 111.364 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.501 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 79.21 47.98 7.17 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 121.002 -0.618 . . . . 0.2 111.785 179.377 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.542 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -100.14 136.73 39.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.24 0.543 . . . . 0.65 112.456 -175.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 93.7 mt -108.1 134.08 20.28 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 115.474 -0.784 . . . . 1.1 109.345 168.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.408 ' HA ' HG13 ' A' ' 64' ' ' VAL . 20.5 Cg_exo -64.3 128.35 21.29 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.937 2.424 . . . . 0.25 112.474 -178.45 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.441 -0.911 0 CA-C-N 115.878 -0.601 . . . . 1.12 109.658 177.012 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 28.6 t . . . . . 0 N--CA 1.45 -0.425 0 N-CA-C 109.87 -0.418 . . . . 1.43 109.87 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.6 mt -91.65 133.35 33.49 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.559 0 CA-C-O 121.737 0.78 . . . . 1.56 110.547 177.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.485 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -142.92 162.29 35.85 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 114.585 -1.189 . . . . 0.91 110.569 -175.006 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.455 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 26.6 t -111.44 101.69 10.12 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.846 -0.615 . . . . 0.34 109.847 -176.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.776 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 86.7 m -87.31 134.45 33.56 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.232 -0.895 . . . . 0.19 110.89 -175.561 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.424 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -76.1 -27.68 57.23 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 115.37 -0.832 . . . . 0.39 109.665 178.404 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -143.78 103.94 4.12 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.769 -0.651 . . . . 1.12 110.473 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 67.4 t -93.57 108.14 20.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 CA-C-N 116.062 -0.517 . . . . 1.04 109.688 178.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.05 146.12 60.3 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 116.032 -0.531 . . . . 1.03 110.757 -175.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.495 ' O ' ' HB3' ' A' ' 22' ' ' SER . 22.6 Cg_exo -62.79 136.94 60.35 Favored 'Trans proline' 0 N--CA 1.461 -0.401 0 C-N-CA 122.12 1.88 . . . . 0.21 111.181 173.05 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.93 -23.03 72.58 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.946 -0.645 . . . . 0.18 112.64 -176.472 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -101.07 9.92 41.58 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.724 0.774 . . . . 2.27 109.813 177.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.6 t -78.77 156.36 28.87 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.52 -0.764 . . . . 0.41 109.921 175.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -53.9 -40.94 67.07 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.201 0.524 . . . . 1.06 109.773 176.029 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.662 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER -67.88 -63.1 1.13 Allowed 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 115.462 -0.79 . . . . 1.77 111.046 176.796 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.409 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -57.01 -38.74 87.27 Favored Glycine 0 C--N 1.33 0.24 0 CA-C-N 115.999 -0.546 . . . . 0.16 113.304 -175.031 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.0 m -69.22 -40.64 77.85 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.646 0.26 . . . . 1.07 110.462 -178.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.401 HD12 ' O ' ' A' ' 27' ' ' LEU . 2.8 tm? -62.99 -38.62 91.9 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.41 -0.589 . . . . 1.57 109.41 176.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.662 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.3 mt -67.82 -53.5 26.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.809 -0.632 . . . . 1.13 110.84 -177.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.516 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -70.87 -20.82 62.48 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.992 -0.283 . . . . 1.08 111.363 -176.584 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.419 ' N ' HD12 ' A' ' 29' ' ' LEU . 24.1 t70 -62.87 -38.95 92.9 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.602 0.715 . . . . 0.66 110.039 173.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -73.36 -16.97 61.33 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 114.816 -1.084 . . . . 2.07 109.615 -179.217 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.8 mt -105.86 -13.9 15.38 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.808 -1.087 . . . . 1.35 111.917 -174.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 71.82 42.71 52.65 Favored Glycine 0 C--N 1.331 0.302 0 CA-C-N 115.722 -0.672 . . . . 0.75 112.868 178.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.516 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 32.7 mt -101.2 124.92 55.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.689 0.28 . . . . 1.24 111.066 -176.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.6 p -110.43 102.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.814 0.816 . . . . 2.41 110.36 176.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.1 mt -85.95 141.9 29.2 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.556 -0.747 . . . . 3.28 111.094 -178.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -74.65 -23.58 58.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.552 0.692 . . . . 2.65 109.701 175.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.401 ' C ' ' H ' ' A' ' 40' ' ' THR . 8.2 m-20 -136.37 91.52 16.39 Favored Pre-proline 0 N--CA 1.447 -0.616 0 N-CA-C 108.22 -1.03 . . . . 2.29 108.22 172.512 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -66.18 -2.87 7.62 Favored 'Trans proline' 0 C--O 1.224 -0.22 0 C-N-CA 122.367 2.045 . . . . 0.77 111.808 -177.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.401 ' H ' ' C ' ' A' ' 38' ' ' ASP . 25.2 p -78.59 -12.67 60.03 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.577 -0.738 . . . . 1.2 111.322 -177.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 33.3 m -70.55 156.63 7.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.152 0.501 . . . . 1.08 111.295 -178.465 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 95.4 mt -86.38 129.09 34.97 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.778 -0.646 . . . . 1.06 110.333 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 23.7 pt -112.23 144.33 20.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.991 -0.55 . . . . 1.03 110.115 176.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.776 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.61 106.67 1.42 Allowed Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.48 -0.866 . . . . 0.31 113.102 -176.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -78.33 140.55 38.78 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.252 -0.647 . . . . 0.57 109.252 175.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 73.59 39.42 49.43 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.141 -1.028 . . . . 0.25 111.999 179.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.75 115.89 31.09 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.275 0.559 . . . . 0.25 111.346 -172.774 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.451 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.8 t70 -102.33 136.67 19.36 Favored Pre-proline 0 C--N 1.318 -0.78 0 CA-C-N 115.427 -0.806 . . . . 2.21 110.383 173.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 16.5 Cg_exo -60.79 119.61 6.87 Favored 'Trans proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.176 2.584 . . . . 0.6 111.03 178.393 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.431 HG13 ' HA ' ' A' ' 12' ' ' GLN . 43.0 mt . . . . . 0 C--N 1.329 -0.325 0 CA-C-O 121.297 0.57 . . . . 1.13 110.224 -175.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.7 t . . . . . 0 N--CA 1.453 -0.29 0 N-CA-C 109.942 -0.392 . . . . 1.02 109.942 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.5 t -117.31 15.06 14.84 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.737 -0.211 . . . . 2.56 111.532 -176.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.424 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -157.05 -78.0 0.08 Allowed 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.87 -0.332 . . . . 1.07 111.581 178.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 21.6 m -148.59 129.43 14.27 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.774 0.321 . . . . 1.05 110.77 -179.075 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.456 ' HB2' ' O ' ' A' ' 82' ' ' VAL . . . -90.41 135.88 33.4 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.864 -0.421 . . . . 1.07 109.864 -179.424 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.536 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 6.7 m -143.87 158.55 16.17 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-O 121.277 0.561 . . . . 1.01 111.156 -177.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 15.0 t -109.35 104.51 13.64 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.338 -0.846 . . . . 0.39 109.476 175.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.773 ' SG ' ' HB3' ' A' ' 76' ' ' ALA . 61.3 m -91.16 120.96 32.53 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.169 0.509 . . . . 0.65 111.108 -178.035 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 17.6 t -78.22 -21.53 49.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.28 -0.873 . . . . 1.83 110.295 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.7 t0 -105.81 149.09 26.8 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.224 -0.658 . . . . 1.6 109.224 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.504 ' C ' HD21 ' A' ' 69' ' ' ASN . 0.3 OUTLIER -118.84 5.64 11.47 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 112.559 0.577 . . . . 3.24 112.559 -175.092 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.432 ' ND2' HD11 ' A' ' 77' ' ' ILE . 1.3 p30 -82.39 112.18 19.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.921 0.867 . . . . 2.99 109.563 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.607 HG12 ' H ' ' A' ' 73' ' ' GLY . 70.8 t -122.12 137.28 56.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.364 -0.835 . . . . 1.68 110.858 -172.485 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.502 ' OG ' HG12 ' A' ' 75' ' ' ILE . 95.0 p -76.88 -1.41 28.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.654 -0.703 . . . . 1.88 110.94 -178.185 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.607 ' H ' HG12 ' A' ' 71' ' ' VAL . . . 127.88 -31.82 3.62 Favored Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 115.43 -0.804 . . . . 0.56 112.372 -176.521 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.2 m -138.77 -5.92 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.203 0 N-CA-C 112.849 0.685 . . . . 1.18 112.849 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.502 HG12 ' OG ' ' A' ' 72' ' ' SER . 5.1 pt -92.82 -177.1 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 113.359 0.874 . . . . 1.12 113.359 -174.236 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.773 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -150.68 142.59 23.87 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 114.117 -1.401 . . . . 1.11 108.602 174.669 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.432 HD11 ' ND2' ' A' ' 70' ' ' ASN . 66.5 mt -126.67 139.94 50.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.275 0.472 . . . . 1.1 112.275 -175.617 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 68.58 51.82 28.96 Favored Glycine 0 C--N 1.335 0.48 0 CA-C-N 115.736 -0.666 . . . . 0.2 111.682 177.411 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.536 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 8.3 m -109.0 138.94 44.55 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.049 0.452 . . . . 0.65 111.84 -172.369 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.422 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.8 mt -109.15 132.45 21.22 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.801 -0.636 . . . . 1.1 110.057 173.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.454 ' HA ' HG11 ' A' ' 64' ' ' VAL . 24.5 Cg_exo -63.23 123.06 11.51 Favored 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.194 2.596 . . . . 0.25 113.308 -177.18 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.456 ' O ' ' HB2' ' A' ' 63' ' ' ALA . 9.2 m . . . . . 0 N--CA 1.445 -0.723 0 CA-C-N 116.018 -0.537 . . . . 1.12 110.063 177.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 32.3 t . . . . . 0 N--CA 1.454 -0.264 0 N-CA-C 109.704 -0.48 . . . . 1.43 109.704 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 21.0 mt -105.31 133.72 48.79 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.453 0 CA-C-O 121.651 0.739 . . . . 1.56 111.231 177.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.613 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -141.47 161.68 37.33 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 114.854 -1.066 . . . . 0.91 110.684 178.885 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.418 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 24.8 t -110.98 103.31 11.77 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.415 -0.812 . . . . 0.34 109.107 178.311 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.782 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 81.8 m -85.75 138.81 31.83 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.461 -0.79 . . . . 0.19 110.678 -175.531 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.405 ' HB3' ' HA3' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -73.98 -35.15 64.45 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.711 -0.848 . . . . 0.39 108.711 175.374 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . 0.775 ' ND2' ' HB3' ' A' ' 45' ' ' ASP . 0.1 OUTLIER -130.02 150.35 51.33 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 109.532 -0.544 . . . . 1.12 109.532 170.909 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.6 t -130.6 101.79 6.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 109.139 -0.689 . . . . 1.04 109.139 173.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.499 HG23 ' OD1' ' A' ' 16' ' ' ASN . 8.8 m -130.8 143.51 49.66 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.981 -0.554 . . . . 1.03 111.513 -173.073 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.421 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.4 Cg_exo -59.2 140.13 93.4 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.499 2.133 . . . . 0.21 111.853 172.8 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.85 -20.96 67.06 Favored Glycine 0 N--CA 1.453 -0.199 0 C-N-CA 120.979 -0.629 . . . . 0.18 112.603 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -103.91 14.98 29.68 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.736 0.779 . . . . 2.27 109.711 176.789 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.421 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.2 t -84.24 154.56 22.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.599 -0.728 . . . . 0.41 109.902 176.555 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -52.25 -41.01 62.44 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.185 0.517 . . . . 1.06 110.496 178.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.666 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 7.6 mt -71.96 -63.17 1.19 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.737 -0.665 . . . . 1.77 110.674 176.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.33 -40.39 53.21 Favored Glycine 0 C--N 1.33 0.212 0 CA-C-N 116.067 -0.515 . . . . 0.16 113.266 -175.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 96.5 m -68.62 -45.12 72.74 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.878 0.37 . . . . 1.07 110.826 -177.454 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.414 HD13 ' O ' ' A' ' 27' ' ' LEU . 1.8 tm? -65.38 -37.56 87.35 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.435 -0.58 . . . . 1.57 109.435 178.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.666 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.0 mt -69.42 -43.51 73.23 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.012 -0.54 . . . . 1.13 110.588 -176.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.546 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.3 pp -72.23 -26.54 62.07 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.662 -0.415 . . . . 1.08 110.765 -178.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.416 ' N ' HD11 ' A' ' 29' ' ' LEU . 19.5 t70 -66.19 -33.56 76.05 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.711 0.767 . . . . 0.66 109.066 173.399 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 29.3 mm-40 -80.22 -11.62 59.71 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.509 -1.223 . . . . 2.07 111.143 179.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.1 mt -115.41 -14.51 11.59 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.899 -0.591 . . . . 1.35 112.187 -174.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 78.88 39.68 19.71 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.139 -0.553 . . . . 0.75 112.751 177.054 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.546 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 15.9 mt -96.62 138.39 21.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.624 0.249 . . . . 1.24 110.761 -176.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.3 p -119.39 102.73 13.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.468 0.651 . . . . 2.41 110.264 174.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 20.0 mt -86.99 140.09 29.91 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.973 -0.558 . . . . 3.28 110.802 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -75.33 -27.74 59.37 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.936 -0.574 . . . . 2.65 109.752 174.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 61.1 t0 -139.02 104.31 7.36 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 108.663 -0.866 . . . . 2.29 108.663 175.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -72.12 4.03 3.57 Favored 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.518 2.145 . . . . 0.77 112.901 -176.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 64.9 p -93.04 2.55 56.72 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 120.445 -0.502 . . . . 1.2 110.936 -177.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.2 m -83.63 159.76 3.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.102 -0.499 . . . . 1.08 110.425 178.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.1 mt -88.7 122.24 31.91 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.832 -0.622 . . . . 1.06 110.475 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.5 pt -106.17 134.4 47.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 115.987 -0.551 . . . . 1.03 110.073 176.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.782 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -111.16 107.83 2.26 Favored Glycine 0 N--CA 1.443 -0.882 0 C-N-CA 120.593 -0.813 . . . . 0.31 112.908 -176.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.775 ' HB3' ' ND2' ' A' ' 16' ' ' ASN . 20.9 t70 -81.44 138.64 35.53 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.441 -0.577 . . . . 0.57 109.441 176.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.405 ' HA3' ' HB3' ' A' ' 15' ' ' GLN . . . 78.7 36.66 28.63 Favored Glycine 0 N--CA 1.443 -0.88 0 C-N-CA 120.248 -0.977 . . . . 0.25 111.787 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.4 OUTLIER -105.15 112.75 25.99 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.344 0.592 . . . . 0.25 111.559 -172.4 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -102.82 134.33 19.91 Favored Pre-proline 0 C--N 1.317 -0.828 0 CA-C-N 115.364 -0.834 . . . . 2.21 109.535 173.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -59.28 127.2 23.15 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.759 2.306 . . . . 0.6 111.616 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 19.1 mt . . . . . 0 C--N 1.326 -0.444 0 CA-C-O 121.479 0.657 . . . . 1.13 109.253 -179.842 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.1 t . . . . . 0 N--CA 1.455 -0.198 0 N-CA-C 110.071 -0.344 . . . . 1.02 110.071 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 8.3 p -102.4 -26.56 13.23 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.313 0.486 . . . . 2.56 112.313 -175.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.477 ' HB2' ' O ' ' A' ' 14' ' ' CYS . . . -123.14 -75.99 0.59 Allowed 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.56 -0.456 . . . . 1.07 111.91 -176.578 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 31.8 m -146.77 128.73 15.46 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.908 0.385 . . . . 1.05 111.39 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.67 137.89 32.1 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.261 -0.427 . . . . 1.07 110.512 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.6 HG23 ' SG ' ' A' ' 14' ' ' CYS . 2.7 m -146.3 170.45 4.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.037 -0.529 . . . . 1.01 111.302 -177.294 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 41.3 t -132.64 109.68 9.9 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.351 -0.841 . . . . 0.39 109.589 177.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.753 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -95.91 137.67 34.64 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.454 0.645 . . . . 0.65 112.041 -178.074 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 33.0 t -82.88 -18.91 38.58 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 114.865 -1.061 . . . . 1.83 110.586 178.245 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -110.84 147.29 34.85 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.101 0.477 . . . . 1.6 111.151 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -115.62 4.48 14.14 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.637 -0.71 . . . . 3.24 110.522 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -75.67 73.81 2.66 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.34 0.591 . . . . 2.99 110.446 178.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 33.6 m -89.57 146.8 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 CA-C-N 115.801 -0.636 . . . . 1.68 110.947 -177.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 44.8 m -89.52 10.43 22.89 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.084 -0.507 . . . . 1.88 110.703 178.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.26 -33.93 3.2 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.561 -0.745 . . . . 0.56 113.552 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.6 m -140.57 -2.85 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 117.743 0.772 . . . . 1.18 112.218 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 16.4 pt -93.71 -176.45 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.769 0.795 . . . . 1.12 112.567 -176.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.753 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -147.53 137.82 23.13 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 114.206 -1.361 . . . . 1.11 108.745 174.049 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 70.4 mt -117.52 126.39 74.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.002 0.43 . . . . 1.1 111.628 -176.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.51 52.62 5.45 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.845 -0.616 . . . . 0.2 111.798 177.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.406 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 1.3 m -99.03 137.52 37.44 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 112.424 0.527 . . . . 0.65 112.424 -176.257 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 86.3 mt -105.36 131.49 21.71 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.505 -0.771 . . . . 1.1 109.719 170.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_exo -65.81 121.95 9.44 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.973 2.449 . . . . 0.25 112.303 -179.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.3 m . . . . . 0 N--CA 1.443 -0.78 0 CA-C-N 116.275 -0.421 . . . . 1.12 110.147 178.801 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.0 t . . . . . 0 N--CA 1.452 -0.374 0 N-CA-C 109.137 -0.69 . . . . 1.43 109.137 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 45.9 mt -102.08 136.76 32.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.629 0.728 . . . . 1.56 111.544 -179.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.529 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -144.13 169.27 18.18 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.97 -1.014 . . . . 0.91 110.556 -179.717 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 14.7 t -118.15 103.51 9.94 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.708 -0.678 . . . . 0.34 109.731 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.815 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 98.9 m -85.68 134.67 33.96 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.397 -0.819 . . . . 0.19 111.196 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.77 -30.05 63.8 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.162 -0.926 . . . . 0.39 109.082 174.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -139.66 115.74 10.36 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.611 -0.722 . . . . 1.12 110.369 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 88.9 t -105.53 105.45 18.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-O 120.927 0.394 . . . . 1.04 110.048 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.6 m -132.37 139.92 36.34 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 115.936 -0.574 . . . . 1.03 111.147 -175.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.441 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.4 Cg_exo -58.55 141.99 97.83 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.442 2.095 . . . . 0.21 111.717 171.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.51 -19.52 70.94 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.878 -0.677 . . . . 0.18 111.965 179.432 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -102.15 9.83 39.88 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.218 0.532 . . . . 2.27 110.009 176.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.441 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.5 t -80.8 154.62 27.07 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 115.628 -0.714 . . . . 0.41 109.728 175.575 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -54.56 -40.13 68.43 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.96 0.41 . . . . 1.06 110.357 179.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.654 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 5.1 mt -70.75 -62.19 1.48 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.686 -0.688 . . . . 1.77 110.529 176.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.56 -38.71 63.97 Favored Glycine 0 C--N 1.33 0.242 0 CA-C-N 116.052 -0.522 . . . . 0.16 113.421 -175.031 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 85.7 m -66.35 -42.71 87.69 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.798 0.333 . . . . 1.07 110.745 -178.215 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.452 ' O ' HD12 ' A' ' 27' ' ' LEU . 2.6 tm? -69.97 -34.82 73.88 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.327 -0.62 . . . . 1.57 109.327 177.672 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.654 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.6 mt -65.04 -46.2 82.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.053 -0.521 . . . . 1.13 110.483 -178.131 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.46 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.64 -21.03 52.85 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.473 -0.491 . . . . 1.08 111.004 -178.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.448 ' N ' HD12 ' A' ' 29' ' ' LEU . 32.4 t70 -66.15 -37.81 86.59 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.391 0.615 . . . . 0.66 109.572 173.181 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -75.98 -12.85 60.21 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.029 -0.987 . . . . 2.07 109.928 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 75.3 mt -106.09 -12.03 15.91 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.195 -0.911 . . . . 1.35 111.318 -179.269 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.09 39.36 96.25 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.575 -0.738 . . . . 0.75 112.343 -178.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.46 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 53.9 mt -82.19 133.23 29.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 O-C-N 122.645 -0.326 . . . . 1.24 111.057 -176.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 11.4 p -87.45 116.43 29.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 109.336 -0.616 . . . . 2.41 109.336 172.393 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.438 ' O ' HD12 ' A' ' 36' ' ' LEU . 0.9 OUTLIER -91.79 131.33 37.23 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.918 -0.583 . . . . 3.28 111.003 -179.454 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 45.2 tt0 -88.23 -34.27 17.82 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.261 -1.014 . . . . 2.65 108.261 173.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -145.06 102.75 4.43 Favored Pre-proline 0 N--CA 1.445 -0.711 0 CA-C-N 114.835 -1.075 . . . . 2.29 108.324 174.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.413 ' HB3' HD23 ' A' ' 36' ' ' LEU . 41.4 Cg_endo -67.71 -4.39 12.11 Favored 'Trans proline' 0 C--O 1.225 -0.152 0 C-N-CA 122.586 2.191 . . . . 0.77 112.075 -174.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 15.3 p -82.53 -10.05 59.16 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.823 -0.626 . . . . 1.2 111.407 -174.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.8 m -74.18 160.54 5.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.159 0.504 . . . . 1.08 111.01 -178.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.404 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 92.3 mt -91.52 129.81 37.44 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.795 -0.639 . . . . 1.06 110.397 179.195 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.2 pt -112.52 137.64 44.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.159 0.504 . . . . 1.03 110.433 176.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.815 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.8 103.31 1.32 Allowed Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 120.478 -0.867 . . . . 0.31 113.133 -175.338 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -79.11 139.91 37.96 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 109.445 -0.576 . . . . 0.57 109.445 177.078 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.74 39.82 38.92 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.077 -1.058 . . . . 0.25 111.804 -179.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.521 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -108.28 112.98 25.72 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.098 0.475 . . . . 0.25 111.717 -171.69 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -101.83 137.13 19.45 Favored Pre-proline 0 C--N 1.318 -0.763 0 CA-C-N 115.395 -0.82 . . . . 2.21 109.581 175.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -59.88 133.98 54.12 Favored 'Trans proline' 0 C--O 1.233 0.244 0 C-N-CA 122.86 2.373 . . . . 0.6 112.076 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 40.6 mt . . . . . 0 C--N 1.327 -0.387 0 CA-C-O 121.209 0.528 . . . . 1.13 109.881 -179.787 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.3 t . . . . . 0 N--CA 1.451 -0.405 0 N-CA-C 109.923 -0.399 . . . . 1.02 109.923 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 10.0 t -107.08 -28.68 9.85 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.557 -0.292 . . . . 2.56 111.085 -178.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -112.05 -80.2 0.59 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.837 -0.345 . . . . 1.07 111.783 -176.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 16.4 m -145.1 128.13 16.54 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.84 0.352 . . . . 1.05 111.154 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.48 136.91 32.92 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.903 0.382 . . . . 1.07 110.276 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.631 HG23 ' SG ' ' A' ' 14' ' ' CYS . 3.2 m -145.85 167.92 7.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.089 0.471 . . . . 1.01 111.59 -175.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 17.8 t -130.54 105.94 8.18 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.45 -0.796 . . . . 0.39 110.121 178.013 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.731 ' SG ' ' HB3' ' A' ' 76' ' ' ALA . 1.8 m -92.45 133.58 35.77 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.698 0.761 . . . . 0.65 111.985 -179.28 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 8.7 t -86.16 -13.44 47.07 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.521 -1.218 . . . . 1.83 110.423 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -107.82 156.67 18.88 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.866 -0.606 . . . . 1.6 110.2 -179.145 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 30.4 p-10 -120.9 -15.1 8.38 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 113.084 0.772 . . . . 3.24 113.084 -172.443 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -88.16 73.21 9.01 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 121.985 0.898 . . . . 2.99 111.072 -173.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.7 m -85.68 164.77 2.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.049 -0.978 . . . . 1.68 110.999 -178.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.546 ' OG ' HG12 ' A' ' 75' ' ' ILE . 88.7 p -84.59 -2.72 57.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.051 -0.522 . . . . 1.88 111.66 -175.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.64 -31.89 3.83 Favored Glycine 0 CA--C 1.505 -0.592 0 C-N-CA 120.721 -0.752 . . . . 0.56 112.304 -178.071 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.4 m -135.49 -12.15 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.488 -0.485 . . . . 1.18 111.935 178.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.546 HG12 ' OG ' ' A' ' 72' ' ' SER . 35.4 pt -90.02 -175.14 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 119.986 -0.686 . . . . 1.12 111.581 -179.156 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.731 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -147.78 143.46 27.54 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.398 -1.273 . . . . 1.11 108.665 175.085 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 64.0 mt -122.55 131.23 73.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.966 0.412 . . . . 1.1 111.585 -175.41 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.44 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 76.38 50.71 7.18 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.097 -0.573 . . . . 0.2 112.188 177.751 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.461 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.92 141.84 31.19 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 112.826 0.676 . . . . 0.65 112.826 -175.013 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 95.0 mt -108.57 132.06 21.37 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.223 -0.899 . . . . 1.1 109.269 168.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.411 ' HA ' HG13 ' A' ' 64' ' ' VAL . 15.8 Cg_exo -67.29 128.4 18.33 Favored 'Trans proline' 0 C--O 1.234 0.297 0 C-N-CA 122.757 2.304 . . . . 0.25 112.292 -179.257 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.0 m . . . . . 0 N--CA 1.444 -0.729 0 CA-C-N 116.02 -0.536 . . . . 1.12 110.12 178.239 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.1 t . . . . . 0 N--CA 1.45 -0.457 0 N-CA-C 110.128 -0.323 . . . . 1.43 110.128 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 23.7 mt -112.1 135.92 49.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-O 121.482 0.658 . . . . 1.56 110.825 173.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.676 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -153.91 170.29 21.39 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 114.968 -1.015 . . . . 0.91 110.873 -177.187 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.567 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 42.1 t -118.69 108.59 15.1 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.434 -0.803 . . . . 0.34 109.593 177.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.863 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 60.9 m -90.11 129.62 36.38 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.311 0.577 . . . . 0.19 111.599 -172.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.434 ' HB3' ' HA3' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -75.54 -26.71 58.25 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 114.946 -1.025 . . . . 0.39 110.252 177.851 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . 0.588 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 1.6 t-20 -135.86 99.15 4.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.445 -0.343 . . . . 1.12 110.818 175.266 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 61.8 t -92.66 102.0 13.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.002 0.429 . . . . 1.04 110.039 177.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.6 m -133.42 142.92 45.89 Favored Pre-proline 0 C--N 1.32 -0.701 0 CA-C-N 115.896 -0.593 . . . . 1.03 110.905 -174.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.477 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.5 Cg_exo -61.1 139.38 83.79 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.086 1.858 . . . . 0.21 111.164 171.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.08 -24.42 70.3 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.84 -0.695 . . . . 0.18 112.627 -178.262 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -97.61 4.45 50.2 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.147 0.498 . . . . 2.27 110.048 177.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.2 t -73.2 152.99 40.86 Favored 'General case' 0 CA--C 1.513 -0.48 0 CA-C-N 115.758 -0.655 . . . . 0.41 109.994 177.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -54.31 -39.36 66.94 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.098 0.475 . . . . 1.06 110.227 178.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.687 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.7 mm? -70.89 -62.33 1.43 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.646 -0.706 . . . . 1.77 110.818 175.788 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.3 -40.34 60.44 Favored Glycine 0 C--N 1.33 0.232 0 CA-C-N 116.171 -0.468 . . . . 0.16 113.296 -175.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.1 m -69.0 -44.36 72.96 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.857 0.36 . . . . 1.07 110.692 -177.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.02 -38.95 93.23 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.316 -0.624 . . . . 1.57 109.316 178.443 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.687 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.2 mt -69.11 -44.4 72.48 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.668 -0.696 . . . . 1.13 110.764 -177.129 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.544 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.4 pp -76.02 -26.16 56.37 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.798 -0.361 . . . . 1.08 111.068 -178.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.439 ' N ' HD12 ' A' ' 29' ' ' LEU . 31.9 t70 -64.24 -34.44 78.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.859 0.837 . . . . 0.66 109.035 172.267 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -80.66 -12.27 59.51 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 114.152 -1.386 . . . . 2.07 111.162 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 88.5 mt -111.86 -13.55 13.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.969 -0.56 . . . . 1.35 112.065 -176.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.9 41.35 18.97 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.238 -0.506 . . . . 0.75 112.898 178.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.544 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 15.4 mt -104.16 140.58 21.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.824 0.345 . . . . 1.24 110.811 -177.551 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.0 p -123.96 102.6 11.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.513 0.673 . . . . 2.41 110.002 173.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 24.1 mt -78.06 141.41 38.85 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.851 -0.613 . . . . 3.28 110.986 -177.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -69.76 -33.22 72.13 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.348 -0.842 . . . . 2.65 109.124 175.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 -131.58 104.74 14.46 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 115.189 -0.914 . . . . 2.29 108.653 172.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.87 -1.72 6.52 Favored 'Trans proline' 0 CA--C 1.528 0.187 0 C-N-CA 122.119 1.879 . . . . 0.77 111.812 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.8 p -87.09 -7.65 57.83 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.709 -0.678 . . . . 1.2 111.261 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.42 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 17.7 m -77.31 159.37 5.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 CA-C-O 121.204 0.526 . . . . 1.08 110.82 -179.589 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 85.6 mt -90.3 123.5 34.12 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.74 -0.664 . . . . 1.06 110.153 177.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.2 pt -105.25 139.27 26.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 115.94 -0.573 . . . . 1.03 109.957 176.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.863 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.32 106.69 1.44 Allowed Glycine 0 N--CA 1.44 -1.037 0 C-N-CA 120.51 -0.852 . . . . 0.31 113.174 -175.037 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.588 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 12.6 t70 -73.41 148.65 43.11 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.015 -0.735 . . . . 0.57 109.015 175.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.434 ' HA3' ' HB3' ' A' ' 15' ' ' GLN . . . 60.6 45.16 96.87 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.44 -0.886 . . . . 0.25 112.58 175.561 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.567 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -100.96 117.35 34.83 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.322 0.582 . . . . 0.25 110.701 -174.662 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.504 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 3.5 p-10 -100.84 131.55 23.31 Favored Pre-proline 0 C--N 1.318 -0.772 0 CA-C-N 115.528 -0.76 . . . . 2.21 110.333 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -60.84 118.22 5.06 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 121.909 1.74 . . . . 0.6 110.076 173.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 13.6 mt . . . . . 0 C--N 1.326 -0.456 0 CA-C-O 121.364 0.602 . . . . 1.13 110.935 -172.581 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 15.3 p . . . . . 0 N--CA 1.451 -0.385 0 N-CA-C 109.576 -0.527 . . . . 1.02 109.576 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 23.9 p -114.17 12.11 17.71 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.01 0.374 . . . . 2.56 112.01 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -134.78 -149.72 0.36 Allowed 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 121.227 -0.189 . . . . 1.07 110.95 -179.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 19.5 m -87.85 134.77 33.63 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.779 0.323 . . . . 1.05 111.055 -177.449 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.71 126.87 34.3 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.878 -0.416 . . . . 1.07 109.878 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.705 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -139.42 173.77 10.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.63 0 CA-C-O 121.51 0.671 . . . . 1.01 111.642 -176.083 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 48.8 t -141.82 103.76 4.4 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.974 -1.012 . . . . 0.39 109.165 -178.065 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.734 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.3 m -92.71 155.52 17.65 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.471 0.653 . . . . 0.65 111.913 -176.095 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 6.4 m -106.18 -13.98 15.27 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.264 -0.88 . . . . 1.83 110.879 -178.077 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.407 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 5.5 t70 -103.38 162.32 13.11 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.142 -0.481 . . . . 1.6 109.748 -178.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -120.85 -7.3 9.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.049 0.452 . . . . 3.24 111.14 -176.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -83.35 83.79 7.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.225 0.536 . . . . 2.99 111.403 -175.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 34.2 m -91.36 156.11 3.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.819 -0.628 . . . . 1.68 110.903 179.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.551 ' OG ' HG12 ' A' ' 75' ' ' ILE . 89.2 p -95.36 3.53 54.3 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.075 0.464 . . . . 1.88 110.53 179.435 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.31 -33.32 3.19 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.463 -0.79 . . . . 0.56 112.123 -176.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.5 m -140.31 -21.69 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.325 0 N-CA-C 112.478 0.548 . . . . 1.18 112.478 174.022 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.551 HG12 ' OG ' ' A' ' 72' ' ' SER . 20.4 pt -71.75 172.99 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.373 0 CA-C-O 121.58 0.705 . . . . 1.12 112.187 -174.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.734 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -144.05 140.95 29.81 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.168 -1.378 . . . . 1.11 109.068 176.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.407 ' HB ' ' HB3' ' A' ' 68' ' ' ASP . 71.2 mt -119.5 129.33 75.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.032 0.444 . . . . 1.1 111.455 -176.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.452 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.08 51.93 5.96 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.972 -0.632 . . . . 0.2 112.035 178.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.92 139.04 35.17 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.135 0.493 . . . . 0.65 112.237 -176.503 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 97.9 mt -109.49 132.13 21.48 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 115.564 -0.744 . . . . 1.1 109.142 169.562 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 14.9 Cg_exo -68.01 119.37 6.38 Favored 'Trans proline' 0 N--CA 1.464 -0.246 0 C-N-CA 122.76 2.306 . . . . 0.25 112.058 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 N--CA 1.443 -0.787 0 CA-C-N 115.969 -0.56 . . . . 1.12 110.747 -177.983 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 31.4 t . . . . . 0 N--CA 1.454 -0.233 0 N-CA-C 109.967 -0.383 . . . . 1.43 109.967 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.3 mt -103.58 140.17 22.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.155 0.503 . . . . 1.56 110.678 175.602 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.671 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -150.16 163.71 37.53 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.571 0.701 . . . . 0.91 111.732 -179.557 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.8 t -116.03 105.07 12.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.162 -0.926 . . . . 0.34 108.901 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.849 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 90.1 m -85.16 139.65 31.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.409 -0.814 . . . . 0.19 111.308 -173.174 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.402 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -75.84 -30.32 58.92 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 115.065 -0.971 . . . . 0.39 109.086 175.252 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . 0.544 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 3.2 t-20 -136.13 111.52 9.16 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.797 -0.638 . . . . 1.12 110.618 178.532 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 85.5 t -102.15 106.16 19.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.022 0 N-CA-C 109.71 -0.478 . . . . 1.04 109.71 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.4 m -134.76 142.03 40.87 Favored Pre-proline 0 C--N 1.32 -0.676 0 CA-C-N 115.82 -0.627 . . . . 1.03 110.54 -178.078 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.493 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.5 Cg_exo -59.22 137.33 78.28 Favored 'Trans proline' 0 N--CA 1.46 -0.442 0 C-N-CA 122.31 2.007 . . . . 0.21 111.157 172.427 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.12 -25.55 69.66 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 121.111 -0.566 . . . . 0.18 112.666 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -100.52 6.55 44.3 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.612 0.72 . . . . 2.27 110.198 176.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.493 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 21.0 t -68.88 154.83 41.32 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.352 -0.61 . . . . 0.41 109.352 173.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -53.42 -43.2 67.78 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.098 0.475 . . . . 1.06 109.744 177.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.612 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.6 mm? -72.05 -57.72 4.04 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.318 -0.856 . . . . 1.77 111.097 177.776 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.479 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -53.71 -40.96 64.87 Favored Glycine 0 C--N 1.33 0.21 0 C-N-CA 121.225 -0.512 . . . . 0.16 112.962 -176.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 84.3 m -67.73 -39.3 84.27 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.731 0.301 . . . . 1.07 110.383 -179.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.422 ' O ' HD12 ' A' ' 27' ' ' LEU . 2.5 tm? -68.25 -36.44 79.45 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.434 -0.58 . . . . 1.57 109.434 178.428 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.612 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 13.3 mt -67.57 -47.55 69.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.742 -0.663 . . . . 1.13 110.372 -177.614 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.532 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -77.56 -22.68 50.63 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.746 -0.382 . . . . 1.08 111.364 -178.562 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.491 ' N ' HD13 ' A' ' 29' ' ' LEU . 26.6 t70 -69.06 -31.53 70.37 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.422 0.63 . . . . 0.66 109.418 175.404 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -70.42 -24.29 62.89 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 114.79 -1.096 . . . . 2.07 109.305 176.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.1 mt -98.53 -15.58 19.49 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.585 -1.189 . . . . 1.35 111.71 -175.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.57 31.18 51.31 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 121.226 -0.512 . . . . 0.75 112.68 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.532 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 31.1 mt -95.38 140.66 16.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.721 0.296 . . . . 1.24 110.753 -178.072 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.9 t -124.75 101.41 8.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 109.708 -0.478 . . . . 2.41 109.708 176.081 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 30.7 mt -74.77 134.76 41.77 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.106 -0.497 . . . . 3.28 111.451 -177.48 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -70.34 -27.22 64.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.489 -0.778 . . . . 2.65 109.285 174.275 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.428 ' C ' ' H ' ' A' ' 40' ' ' THR . 26.9 m-20 -128.11 90.83 46.26 Favored Pre-proline 0 N--CA 1.446 -0.634 0 N-CA-C 108.38 -0.97 . . . . 2.29 108.38 176.001 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.5 8.36 0.96 Allowed 'Trans proline' 0 C--O 1.223 -0.248 0 C-N-CA 122.416 2.077 . . . . 0.77 112.408 -177.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.428 ' H ' ' C ' ' A' ' 38' ' ' ASP . 16.5 p -99.94 7.91 44.47 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.094 0.473 . . . . 1.2 110.996 -178.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.518 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 27.8 m -91.98 155.75 3.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.078 -0.51 . . . . 1.08 110.99 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.472 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.5 mt -86.56 127.12 34.87 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.663 -0.699 . . . . 1.06 109.875 176.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.4 pt -106.78 141.75 21.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.122 -0.49 . . . . 1.03 110.095 176.236 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.849 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.48 108.59 1.71 Allowed Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 120.523 -0.846 . . . . 0.31 113.419 -174.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.505 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 8.8 t70 -74.49 146.16 42.96 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.757 -0.831 . . . . 0.57 108.757 174.229 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 60.63 47.2 92.37 Favored Glycine 0 C--N 1.318 -0.453 0 C-N-CA 120.281 -0.961 . . . . 0.25 112.712 175.59 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.511 ' SG ' ' HB2' ' A' ' 12' ' ' GLN . 0.5 OUTLIER -108.61 111.59 23.49 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.116 0.484 . . . . 0.25 111.568 -171.771 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.438 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 4.6 t70 -101.67 135.5 19.76 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.633 -0.712 . . . . 2.21 110.916 176.309 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.438 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 35.1 Cg_exo -54.76 123.52 13.93 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 124.032 3.155 . . . . 0.6 112.211 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 42.0 mt . . . . . 0 C--N 1.328 -0.368 0 CA-C-O 121.595 0.712 . . . . 1.13 109.402 -179.969 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.1 t . . . . . 0 N--CA 1.451 -0.405 0 CA-C-O 120.674 0.273 . . . . 1.02 110.556 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.1 p -106.89 -22.11 12.8 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.185 -0.461 . . . . 2.56 111.774 -178.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.402 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -117.09 -82.65 0.63 Allowed 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 121.016 -0.274 . . . . 1.07 111.129 -179.532 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 11.9 m -139.77 129.91 25.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.689 0.28 . . . . 1.05 111.363 -179.038 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.4 128.19 34.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.979 0.419 . . . . 1.07 110.777 -177.428 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.62 HG22 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -143.09 173.93 5.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.489 0.661 . . . . 1.01 111.579 -177.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 39.0 t -140.96 107.57 5.33 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.387 -0.824 . . . . 0.39 109.146 -177.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.746 ' SG ' ' HB2' ' A' ' 76' ' ' ALA . 1.5 m -93.56 138.08 32.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.62 0.724 . . . . 0.65 112.58 -174.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.6 t -85.8 -22.49 27.63 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 114.731 -1.122 . . . . 1.83 110.691 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.409 ' HB2' ' O ' ' A' ' 77' ' ' ILE . 1.2 m-20 -102.53 136.76 41.77 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.164 -0.471 . . . . 1.6 110.813 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -100.44 -4.45 28.89 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.757 -0.656 . . . . 3.24 110.036 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -75.56 90.29 2.76 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.556 -0.747 . . . . 2.99 110.495 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 26.7 m -105.95 156.53 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.579 0 CA-C-N 116.102 -0.499 . . . . 1.68 111.29 -177.125 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.621 ' OG ' HG12 ' A' ' 75' ' ' ILE . 82.5 p -85.83 -4.56 59.2 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.886 -0.597 . . . . 1.88 110.529 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.47 -32.34 3.56 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.594 -0.73 . . . . 0.56 112.436 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 m -136.48 -11.57 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 C-N-CA 120.251 -0.58 . . . . 1.18 112.094 179.105 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.621 HG12 ' OG ' ' A' ' 72' ' ' SER . 25.8 pt -92.54 -178.2 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.602 0.715 . . . . 1.12 111.928 -178.337 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.746 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -143.04 141.09 31.23 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.031 -1.441 . . . . 1.11 109.279 175.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.409 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 68.0 mt -121.17 129.12 75.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.867 0.365 . . . . 1.1 111.447 -177.088 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.518 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 79.59 50.24 5.76 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.803 -0.713 . . . . 0.2 111.816 178.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.472 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.2 m -99.67 133.55 43.85 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 112.453 0.538 . . . . 0.65 112.453 -175.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 92.4 mt -105.53 133.87 19.97 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 115.538 -0.755 . . . . 1.1 109.636 171.065 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -63.59 125.75 16.16 Favored 'Trans proline' 0 C--O 1.234 0.3 0 C-N-CA 122.807 2.338 . . . . 0.25 112.022 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 10.3 m . . . . . 0 N--CA 1.444 -0.747 0 CA-C-N 116.153 -0.476 . . . . 1.12 110.697 -178.445 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.451 -0.403 0 N-CA-C 109.296 -0.631 . . . . 1.43 109.296 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 18.3 mt -96.19 130.48 44.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.702 0.763 . . . . 1.56 111.281 176.264 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.665 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -137.7 166.55 23.68 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.528 -1.215 . . . . 0.91 110.329 176.6 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.656 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 16.2 t -106.85 100.9 10.37 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.294 -0.866 . . . . 0.34 109.853 179.086 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.802 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 58.1 m -87.01 131.8 33.98 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.148 0.499 . . . . 0.19 110.747 -177.251 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.97 -29.72 35.27 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.285 -0.87 . . . . 0.39 109.593 178.23 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . 0.615 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 2.7 m-20 -134.78 104.01 5.85 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.395 -0.366 . . . . 1.12 110.843 176.464 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 59.1 t -95.99 103.07 14.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.152 0.501 . . . . 1.04 110.01 176.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.98 142.68 46.03 Favored Pre-proline 0 C--N 1.32 -0.71 0 CA-C-N 115.731 -0.668 . . . . 1.03 110.704 -175.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.457 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.6 Cg_exo -58.9 137.74 81.62 Favored 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.103 1.868 . . . . 0.21 111.19 172.302 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.88 -23.76 69.53 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.831 -0.7 . . . . 0.18 112.041 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -96.64 7.58 46.21 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.016 0.436 . . . . 2.27 110.286 176.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.457 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.6 t -80.5 152.4 28.73 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.015 -0.539 . . . . 0.41 110.001 177.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -53.12 -37.35 61.7 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.074 0.464 . . . . 1.06 110.709 178.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.677 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.9 mm? -70.53 -65.95 0.67 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.763 -0.653 . . . . 1.77 110.545 175.011 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.67 -40.04 55.3 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.951 -0.568 . . . . 0.16 113.428 -174.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 63.8 m -68.28 -45.13 73.93 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.909 0.385 . . . . 1.07 110.666 -177.196 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -65.97 -36.63 83.84 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.399 -0.593 . . . . 1.57 109.399 178.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.677 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 17.5 mt -66.56 -49.28 66.92 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.836 -0.62 . . . . 1.13 110.326 -178.304 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.566 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.1 pp -74.4 -25.71 59.64 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.42 -0.355 . . . . 1.08 111.622 -175.047 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.509 ' N ' HD13 ' A' ' 29' ' ' LEU . 31.7 t70 -65.66 -34.49 78.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.673 0.749 . . . . 0.66 109.536 176.055 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -78.82 -34.5 45.24 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 114.713 -1.13 . . . . 2.07 109.412 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 82.3 mt -82.63 -10.73 58.82 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.033 -0.985 . . . . 1.35 112.037 -177.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.63 47.71 20.12 Favored Glycine 0 N--CA 1.452 -0.282 0 CA-C-N 115.855 -0.611 . . . . 0.75 112.631 178.117 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.566 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 10.6 mt -109.75 139.01 34.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.723 0.297 . . . . 1.24 110.471 -179.077 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.0 p -123.59 105.37 15.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.396 0.617 . . . . 2.41 110.125 174.387 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 21.6 mt -81.6 144.08 31.5 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.879 -0.601 . . . . 3.28 111.191 -178.063 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 25.5 mm-40 -79.41 -21.16 45.98 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.608 -0.724 . . . . 2.65 109.356 174.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -138.2 99.35 8.97 Favored Pre-proline 0 N--CA 1.445 -0.696 0 N-CA-C 107.707 -1.22 . . . . 2.29 107.707 173.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.72 -1.45 9.29 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.272 1.982 . . . . 0.77 112.453 -175.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.2 p -101.37 20.26 16.24 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.21 0.528 . . . . 1.2 111.277 -176.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.444 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 33.4 m -93.01 161.63 2.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.978 -0.556 . . . . 1.08 110.094 174.723 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.413 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 96.4 mt -87.57 120.63 29.07 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.284 -0.416 . . . . 1.06 110.043 176.04 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 14.8 pt -103.66 138.35 28.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 116.078 -0.51 . . . . 1.03 110.092 176.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.802 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -115.55 107.4 1.72 Allowed Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.572 -0.823 . . . . 0.31 113.252 -175.401 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.615 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 12.7 t70 -74.82 146.52 41.96 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.488 -0.93 . . . . 0.57 108.488 174.59 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 67.18 36.87 90.78 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 119.882 -1.152 . . . . 0.25 112.165 176.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.656 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -100.34 111.31 23.57 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.376 0.608 . . . . 0.25 110.607 -174.497 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.6 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 1.6 p-10 -101.46 130.32 25.0 Favored Pre-proline 0 C--N 1.314 -0.956 0 CA-C-N 115.547 -0.751 . . . . 2.21 109.876 178.094 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -58.55 118.11 4.94 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.18 1.92 . . . . 0.6 110.911 177.079 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 8.6 mt . . . . . 0 N--CA 1.448 -0.555 0 N-CA-C 108.581 -0.896 . . . . 1.13 108.581 -179.299 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 35.4 t . . . . . 0 N--CA 1.449 -0.515 0 CA-C-O 120.51 0.195 . . . . 1.02 110.737 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 73.9 m -119.78 -3.45 10.26 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.34 -0.391 . . . . 2.56 111.226 176.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.46 -84.4 0.1 Allowed 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.076 -0.712 . . . . 1.07 109.076 172.292 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 29.9 m -151.96 129.27 11.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.913 0.387 . . . . 1.05 111.067 171.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.7 132.58 33.83 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.383 -0.599 . . . . 1.07 109.383 176.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.699 HG22 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -141.95 169.8 13.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.488 0.661 . . . . 1.01 112.334 -174.094 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 14.2 t -130.95 100.53 5.28 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.66 -1.155 . . . . 0.39 109.459 179.306 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.776 ' SG ' ' HB3' ' A' ' 76' ' ' ALA . 1.4 m -88.88 125.52 34.97 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.79 0.805 . . . . 0.65 111.872 -178.429 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 10.0 t -85.26 -18.38 34.13 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 114.281 -1.327 . . . . 1.83 110.252 -179.057 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -110.82 140.81 44.94 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.64 -0.709 . . . . 1.6 109.577 178.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -119.74 24.64 10.47 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 120.975 -0.29 . . . . 3.24 111.695 -173.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 49.1 m-80 -86.5 56.82 4.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.333 0.587 . . . . 2.99 110.187 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 35.8 m -73.95 139.79 18.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.505 -0.771 . . . . 1.68 111.574 -175.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 19.6 m -90.86 10.83 24.67 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.013 -0.54 . . . . 1.88 111.431 -178.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.62 -34.76 2.94 Favored Glycine 0 C--O 1.228 -0.265 0 C-N-CA 120.944 -0.646 . . . . 0.56 113.995 173.167 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.5 m -139.98 -7.11 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 117.936 0.868 . . . . 1.18 111.264 176.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 11.2 pt -89.87 178.5 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.336 0.589 . . . . 1.12 111.347 -179.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.776 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -144.31 144.17 31.34 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 114.563 -1.199 . . . . 1.11 109.177 175.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 67.4 mt -123.01 132.52 71.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.915 0.388 . . . . 1.1 111.549 -176.163 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.444 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 74.22 50.22 10.75 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.743 -0.741 . . . . 0.2 112.017 177.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.485 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.2 m -98.46 136.07 39.13 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-O 121.177 0.513 . . . . 0.65 111.785 -176.336 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.435 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.2 mt -107.63 130.18 23.18 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.472 -0.785 . . . . 1.1 109.258 170.048 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 15.7 Cg_exo -67.12 121.41 8.57 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.808 2.339 . . . . 0.25 112.651 -177.569 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.0 m . . . . . 0 N--CA 1.442 -0.852 0 CA-C-N 115.686 -0.688 . . . . 1.12 109.346 176.838 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.8 t . . . . . 0 N--CA 1.451 -0.396 0 N-CA-C 109.186 -0.672 . . . . 1.43 109.186 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 23.8 mt -113.05 130.79 66.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.822 0.82 . . . . 1.56 111.196 177.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.556 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -146.72 170.64 16.57 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 114.363 -1.29 . . . . 0.91 110.479 -178.792 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 39.5 t -120.03 107.11 12.68 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.834 -0.621 . . . . 0.34 109.657 177.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.868 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 97.4 m -84.92 127.41 34.15 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.297 -0.865 . . . . 0.19 110.863 -176.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.451 ' HA ' ' HB1' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -67.79 -36.06 79.76 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-N 115.181 -0.918 . . . . 0.39 109.403 173.77 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -133.9 111.55 10.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 1.12 110.631 177.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 92.8 t -97.97 106.85 19.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.786 -0.45 . . . . 1.04 109.786 176.28 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.1 m -131.79 140.49 38.42 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 116.31 -0.404 . . . . 1.03 111.013 -176.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.422 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.5 Cg_exo -60.36 140.31 91.1 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.389 2.059 . . . . 0.21 111.75 172.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.8 -19.81 69.8 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 121.02 -0.609 . . . . 0.18 112.488 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -100.76 5.45 43.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.112 0.482 . . . . 2.27 109.899 176.579 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.422 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 30.1 t -77.17 152.8 34.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.834 -0.621 . . . . 0.41 110.015 177.294 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -51.29 -41.02 60.17 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.959 0.409 . . . . 1.06 110.365 178.741 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.703 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 3.1 mm? -72.77 -62.91 1.28 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.757 -0.656 . . . . 1.77 110.618 178.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.47 -39.03 52.13 Favored Glycine 0 C--N 1.331 0.271 0 CA-C-N 116.153 -0.476 . . . . 0.16 113.15 -175.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.8 m -66.96 -47.8 70.5 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.728 0.299 . . . . 1.07 110.514 -178.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.435 HD13 ' O ' ' A' ' 27' ' ' LEU . 2.4 tm? -65.75 -33.84 76.8 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.751 -0.463 . . . . 1.57 109.751 178.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.703 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 17.2 mt -67.92 -44.26 77.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 1.13 110.738 -178.012 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.546 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -79.62 -23.08 42.88 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.75 -0.38 . . . . 1.08 110.595 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.414 ' N ' HD12 ' A' ' 29' ' ' LEU . 15.0 t70 -64.09 -35.17 79.86 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.872 0.844 . . . . 0.66 109.568 172.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -74.85 -38.62 61.92 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 114.53 -1.214 . . . . 2.07 109.875 179.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 69.5 mt -81.88 -20.11 39.51 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 114.745 -1.116 . . . . 1.35 112.298 -176.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.86 34.39 30.91 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 121.183 -0.532 . . . . 0.75 112.347 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.546 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 40.4 mt -85.79 131.12 35.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.802 0.334 . . . . 1.24 110.929 -176.721 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 48.2 t -89.61 100.68 11.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 116.294 -0.412 . . . . 2.41 109.958 175.204 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.591 ' O ' HD13 ' A' ' 36' ' ' LEU . 1.2 pp -72.06 126.36 29.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.426 0.632 . . . . 3.28 110.705 179.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -78.4 -35.62 46.91 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 108.695 -0.854 . . . . 2.65 108.695 172.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -144.46 108.35 4.83 Favored Pre-proline 0 N--CA 1.442 -0.837 0 CA-C-N 114.606 -1.179 . . . . 2.29 107.892 176.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.88 -4.71 15.33 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.22 1.946 . . . . 0.77 111.522 -176.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 24.2 p -88.35 14.0 10.49 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.456 -0.793 . . . . 1.2 111.412 -174.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 19.3 m -102.84 158.36 4.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.045 -0.525 . . . . 1.08 110.448 179.143 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.41 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 92.6 mt -86.0 119.6 26.48 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.79 -0.641 . . . . 1.06 109.955 177.257 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.5 pt -102.81 134.13 44.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.213 0.53 . . . . 1.03 110.056 176.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.868 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -105.39 101.47 1.87 Allowed Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 120.531 -0.842 . . . . 0.31 112.944 -175.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -81.62 129.44 34.69 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.792 -0.818 . . . . 0.57 108.792 175.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.12 35.94 16.55 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 119.793 -1.194 . . . . 0.25 111.48 -175.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.521 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.79 110.02 22.2 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.194 0.521 . . . . 0.25 110.995 -174.373 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.433 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.4 t70 -101.96 135.77 19.63 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-N 115.424 -0.807 . . . . 2.21 110.495 175.089 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 12.4 Cg_exo -61.95 122.13 10.5 Favored 'Trans proline' 0 N--CA 1.462 -0.377 0 C-N-CA 123.453 2.769 . . . . 0.6 111.734 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 22.1 mt . . . . . 0 C--N 1.327 -0.372 0 CA-C-O 121.4 0.619 . . . . 1.13 109.433 -178.389 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 45.5 t . . . . . 0 N--CA 1.452 -0.329 0 N-CA-C 109.225 -0.657 . . . . 1.02 109.225 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.4 t -107.62 -3.75 18.96 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.177 0.436 . . . . 2.56 112.177 -171.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.451 ' HB1' ' HA ' ' A' ' 15' ' ' GLN . . . -77.78 -89.09 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 C-N-CA 120.605 -0.438 . . . . 1.07 111.201 -179.357 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 28.4 m -151.08 125.75 9.62 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.684 0.278 . . . . 1.05 110.528 178.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.91 132.17 34.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.02 0.438 . . . . 1.07 110.066 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.741 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.4 m -143.14 172.04 8.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.261 0.553 . . . . 1.01 111.247 -177.7 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 51.9 t -138.11 104.72 5.3 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.238 -0.892 . . . . 0.39 109.3 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.754 ' SG ' ' HB3' ' A' ' 76' ' ' ALA . 1.3 m -89.24 132.38 34.91 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.555 0.693 . . . . 0.65 111.629 -178.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 33.5 t -76.22 -24.87 54.65 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.96 -1.018 . . . . 1.83 109.906 177.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -110.61 133.91 52.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.648 -0.705 . . . . 1.6 110.482 176.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -100.35 18.14 19.68 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.385 0.612 . . . . 3.24 109.968 179.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 -77.89 94.84 4.62 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.487 -0.779 . . . . 2.99 109.872 178.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 28.3 m -106.6 140.87 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 CA-C-N 116.166 -0.47 . . . . 1.68 111.739 -176.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.431 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 19.5 m -91.96 10.32 29.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.046 -0.525 . . . . 1.88 110.853 176.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.37 -34.63 3.01 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.159 -0.543 . . . . 0.56 113.668 174.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.0 m -140.7 -2.63 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 117.965 0.882 . . . . 1.18 111.692 176.426 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.483 ' HA ' ' O ' ' A' ' 44' ' ' GLY . 3.8 pt -95.99 -177.64 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-O 121.431 0.634 . . . . 1.12 112.322 -175.034 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.754 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -150.51 140.44 21.92 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.368 -1.287 . . . . 1.11 108.783 174.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.0 mt -117.14 126.08 74.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.982 0.42 . . . . 1.1 111.675 -175.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 79.15 52.02 5.07 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.957 -0.64 . . . . 0.2 111.825 177.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.465 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.28 132.29 43.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.396 0.617 . . . . 0.65 112.164 -176.46 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.412 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 87.9 mt -102.19 129.86 25.41 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.427 -0.806 . . . . 1.1 109.538 171.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 15.9 Cg_exo -67.33 120.16 7.2 Favored 'Trans proline' 0 C--O 1.235 0.361 0 C-N-CA 122.859 2.373 . . . . 0.25 112.111 -178.79 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 11.2 m . . . . . 0 N--CA 1.441 -0.902 0 CA-C-N 115.813 -0.63 . . . . 1.12 110.015 179.848 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 30.4 t . . . . . 0 N--CA 1.453 -0.31 0 N-CA-C 109.915 -0.402 . . . . 1.43 109.915 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 28.0 mt -108.65 132.93 55.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.782 0.801 . . . . 1.56 111.325 177.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.577 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -140.34 165.53 27.16 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.559 -1.201 . . . . 0.91 110.501 179.843 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.457 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 40.1 t -110.81 104.22 12.82 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.666 -0.697 . . . . 0.34 109.443 178.327 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.769 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 69.3 m -90.73 130.6 36.7 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.012 -0.54 . . . . 0.19 111.585 -174.474 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.407 HE21 ' HB2' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -73.42 -28.94 62.26 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.069 -0.969 . . . . 0.39 110.007 176.374 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . 0.435 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 5.2 t-20 -138.44 104.05 5.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.35 -0.386 . . . . 1.12 110.75 179.327 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 80.9 t -99.96 104.67 16.42 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 N-CA-C 109.917 -0.401 . . . . 1.04 109.917 178.122 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.0 m -132.37 143.86 50.64 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 116.064 -0.516 . . . . 1.03 110.976 -175.495 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.469 ' O ' ' HB3' ' A' ' 22' ' ' SER . 35.4 Cg_exo -60.85 136.61 67.23 Favored 'Trans proline' 0 N--CA 1.463 -0.307 0 C-N-CA 122.152 1.901 . . . . 0.21 111.36 172.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.38 -22.13 69.13 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 121.046 -0.597 . . . . 0.18 112.462 -178.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -98.15 3.14 49.08 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.144 0.497 . . . . 2.27 110.1 176.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.8 t -75.38 154.85 36.96 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.838 -0.619 . . . . 0.41 109.795 176.107 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -54.53 -41.03 69.23 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.367 0.603 . . . . 1.06 109.619 177.039 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.625 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.2 mm? -65.14 -65.05 0.72 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.875 -1.057 . . . . 1.77 110.698 175.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.4 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -56.6 -40.2 87.11 Favored Glycine 0 C--N 1.33 0.241 0 CA-C-N 115.972 -0.558 . . . . 0.16 113.614 -174.337 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 61.6 m -66.12 -42.06 89.7 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.918 0.39 . . . . 1.07 110.236 -178.586 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -65.92 -38.17 87.98 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.378 -0.601 . . . . 1.57 109.378 177.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.625 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.2 mt -65.4 -47.21 77.1 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 116.032 -0.531 . . . . 1.13 110.716 -176.7 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.513 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.87 -22.57 49.63 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.603 -0.439 . . . . 1.08 111.539 -176.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.483 ' N ' HD11 ' A' ' 29' ' ' LEU . 33.9 t70 -69.39 -34.58 74.72 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.518 0.675 . . . . 0.66 109.471 175.529 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -80.92 -10.71 59.69 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.058 -0.973 . . . . 2.07 110.118 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -108.93 -1.77 18.81 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.504 -0.771 . . . . 1.35 111.276 -178.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.51 43.48 98.96 Favored Glycine 0 C--N 1.331 0.272 0 CA-C-N 115.662 -0.699 . . . . 0.75 113.024 178.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.513 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 30.4 mt -95.36 137.96 22.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.962 0.41 . . . . 1.24 111.026 -177.211 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -97.99 103.19 14.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.867 -0.606 . . . . 2.41 110.055 175.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.468 HD13 ' O ' ' A' ' 36' ' ' LEU . 1.2 pp -74.31 133.28 42.57 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.356 0.598 . . . . 3.28 111.136 -179.523 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -88.78 -32.02 18.09 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 108.378 -0.971 . . . . 2.65 108.378 174.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -145.84 109.66 4.41 Favored Pre-proline 0 N--CA 1.439 -0.982 0 N-CA-C 107.269 -1.382 . . . . 2.29 107.269 175.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -74.24 -3.97 14.66 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 121.937 1.758 . . . . 0.77 112.429 -174.085 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 65.2 p -97.43 21.71 9.78 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.49 0.662 . . . . 1.2 111.188 -174.26 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.419 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 23.8 m -99.8 156.19 4.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.467 -0.788 . . . . 1.08 110.096 174.829 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.425 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.5 mt -85.07 124.18 31.46 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.24 -0.437 . . . . 1.06 110.123 177.215 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 14.4 pt -106.35 133.69 50.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.184 0.516 . . . . 1.03 110.134 175.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.769 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.38 100.48 1.08 Allowed Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.613 -0.803 . . . . 0.31 112.803 -176.087 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -80.6 146.44 31.22 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 109.564 -0.532 . . . . 0.57 109.564 177.217 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.404 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 74.18 36.46 50.88 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.07 -1.062 . . . . 0.25 111.571 -178.673 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.493 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -102.9 118.53 37.03 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.262 0.553 . . . . 0.25 111.456 -173.061 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.53 139.21 20.21 Favored Pre-proline 0 C--N 1.32 -0.697 0 CA-C-N 115.468 -0.787 . . . . 2.21 109.157 175.018 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -71.12 123.24 9.47 Favored 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 122.095 1.863 . . . . 0.6 111.287 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.403 HG13 ' HA ' ' A' ' 12' ' ' GLN . 13.1 mt . . . . . 0 C--N 1.325 -0.497 0 CA-C-O 121.645 0.736 . . . . 1.13 109.853 -176.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.1 t . . . . . 0 N--CA 1.448 -0.536 0 N-CA-C 110.014 -0.365 . . . . 1.02 110.014 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.2 p -90.61 -22.97 20.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.983 -0.553 . . . . 2.56 111.707 -178.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -129.49 -87.95 0.52 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 120.7 -0.4 . . . . 1.07 112.012 -177.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 60.3 m -131.28 130.67 43.12 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.808 0.337 . . . . 1.05 111.616 -175.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.73 131.64 34.08 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.34 -0.391 . . . . 1.07 109.962 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.622 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -143.06 166.67 14.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.062 0.458 . . . . 1.01 111.494 -175.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 31.5 t -128.27 104.64 7.85 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.435 -0.802 . . . . 0.39 110.15 178.485 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.753 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.6 m -93.2 136.92 33.01 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.61 0.719 . . . . 0.65 111.79 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.7 t -89.01 -20.52 24.3 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 114.784 -1.098 . . . . 1.83 110.458 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.467 ' HB3' ' OD1' ' A' ' 70' ' ' ASN . 44.6 m-20 -103.53 148.09 26.38 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.902 -0.59 . . . . 1.6 110.401 -177.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.6 m120 -119.75 3.75 11.09 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.511 -0.313 . . . . 3.24 111.155 -179.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.467 ' OD1' ' HB3' ' A' ' 68' ' ' ASP . 18.2 p-10 -79.56 63.29 4.11 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.736 0.779 . . . . 2.99 110.21 178.446 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.9 m -97.41 162.48 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.709 0 CA-C-N 115.372 -0.831 . . . . 1.68 111.29 -176.108 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.487 ' H ' HG12 ' A' ' 75' ' ' ILE . 87.9 p -85.14 -2.51 58.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.692 -0.685 . . . . 1.88 111.105 -177.554 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.42 -32.67 4.24 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.799 -0.715 . . . . 0.56 112.13 -179.108 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.6 m -130.86 -11.88 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.399 -0.52 . . . . 1.18 111.859 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.487 HG12 ' H ' ' A' ' 72' ' ' SER . 29.1 pt -87.69 178.88 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 C-N-CA 119.879 -0.729 . . . . 1.12 110.976 177.146 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.753 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -148.0 137.94 22.61 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 114.685 -1.143 . . . . 1.11 108.826 176.568 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 61.7 mt -120.05 130.74 73.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.874 0.368 . . . . 1.1 111.322 -175.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.58 50.52 6.52 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 121.139 -0.553 . . . . 0.2 112.042 178.528 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -99.41 136.07 39.89 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 112.446 0.535 . . . . 0.65 112.446 -175.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.433 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 97.4 mt -106.62 129.47 24.39 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.562 -0.745 . . . . 1.1 109.478 169.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 15.3 Cg_exo -67.63 124.89 12.51 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 123.092 2.528 . . . . 0.25 112.567 -177.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.8 m . . . . . 0 N--CA 1.444 -0.746 0 CA-C-N 116.128 -0.487 . . . . 1.12 110.273 179.696 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.9 t . . . . . 0 N--CA 1.451 -0.378 0 N-CA-C 109.492 -0.558 . . . . 1.43 109.492 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 22.6 mt -105.63 131.47 54.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.682 0.753 . . . . 1.56 111.0 175.621 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.525 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -141.53 163.14 33.74 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.736 -1.12 . . . . 0.91 110.941 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.519 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 47.3 t -107.61 101.66 10.97 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.305 -0.861 . . . . 0.34 109.523 178.477 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.809 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 60.2 m -85.68 129.78 34.73 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.177 0.513 . . . . 0.19 111.281 -175.838 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.416 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -75.28 -30.17 60.33 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 115.17 -0.923 . . . . 0.39 109.644 177.311 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . 0.409 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 4.8 t-20 -135.43 110.11 8.63 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.832 -0.622 . . . . 1.12 110.091 178.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.7 t -105.85 104.55 17.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.998 0.428 . . . . 1.04 109.887 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.0 m -135.86 146.31 56.45 Favored Pre-proline 0 C--N 1.322 -0.623 0 CA-C-N 115.984 -0.553 . . . . 1.03 111.191 -173.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.461 ' O ' ' HB3' ' A' ' 22' ' ' SER . 26.6 Cg_exo -62.18 137.98 69.48 Favored 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.16 1.907 . . . . 0.21 110.996 170.601 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.26 -30.16 76.68 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.002 -0.618 . . . . 0.18 112.547 -178.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -96.66 10.45 38.57 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.089 0.471 . . . . 2.27 110.272 177.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.461 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.9 t -77.59 154.85 31.93 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.502 -0.555 . . . . 0.41 109.502 174.436 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -49.69 -46.08 49.59 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.534 -0.543 . . . . 1.06 109.534 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.678 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.0 OUTLIER -64.07 -64.47 0.88 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 114.934 -1.03 . . . . 1.77 110.921 178.821 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.91 -37.65 62.92 Favored Glycine 0 C--N 1.331 0.298 0 CA-C-N 115.972 -0.558 . . . . 0.16 113.317 -175.135 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.1 m -69.54 -39.9 77.19 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.888 0.375 . . . . 1.07 110.666 -177.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -66.05 -39.76 90.39 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.024 -0.732 . . . . 1.57 109.024 177.04 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.678 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 18.9 mt -64.6 -53.41 48.12 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 114.848 -1.069 . . . . 1.13 110.914 -177.188 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.516 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -71.65 -22.88 61.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.445 -0.343 . . . . 1.08 111.307 -175.455 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.464 ' N ' HD13 ' A' ' 29' ' ' LEU . 20.6 t70 -63.59 -38.19 90.17 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.507 0.67 . . . . 0.66 109.915 174.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -76.34 -29.76 57.36 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.128 -0.942 . . . . 2.07 109.64 -178.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.5 mt -85.62 -12.01 52.5 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 114.779 -1.1 . . . . 1.35 111.451 -177.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.25 32.38 52.21 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.929 -0.578 . . . . 0.75 112.747 177.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.516 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 11.9 mt -94.11 141.59 14.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.664 0.269 . . . . 1.24 110.498 -177.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.9 p -128.11 102.85 9.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.497 0.665 . . . . 2.41 110.078 174.232 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.0 mt -94.58 145.6 24.7 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.898 -0.592 . . . . 3.28 110.557 -178.454 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -76.38 -27.88 56.53 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.924 -0.58 . . . . 2.65 109.892 178.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.426 ' C ' ' H ' ' A' ' 40' ' ' THR . 12.8 m-20 -139.31 92.52 10.52 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 115.621 -0.718 . . . . 2.29 109.251 174.814 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.44 6.61 1.82 Allowed 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.492 2.128 . . . . 0.77 111.749 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.426 ' H ' ' C ' ' A' ' 38' ' ' ASP . 7.5 p -75.01 -7.26 53.16 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.668 -0.696 . . . . 1.2 111.188 -179.084 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.4 m -83.02 163.04 3.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.858 -0.61 . . . . 1.08 110.711 178.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.436 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.3 mt -87.56 123.05 32.03 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.994 -0.548 . . . . 1.06 110.469 178.287 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.7 pt -105.33 138.26 31.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.073 -0.512 . . . . 1.03 110.092 175.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.809 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -116.64 102.71 1.06 Allowed Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.654 -0.784 . . . . 0.31 112.918 -175.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -81.06 143.59 32.36 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.397 -0.594 . . . . 0.57 109.397 177.019 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 72.28 38.8 58.51 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 119.958 -1.115 . . . . 0.25 111.752 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.519 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -103.94 116.57 32.49 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.969 0.414 . . . . 0.25 110.999 -173.273 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.461 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 2.5 p-10 -101.35 131.41 23.12 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 115.969 -0.56 . . . . 2.21 110.16 177.336 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -58.87 119.44 6.7 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.31 2.007 . . . . 0.6 110.642 175.075 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 14.4 mt . . . . . 0 C--N 1.327 -0.401 0 CA-C-O 121.597 0.713 . . . . 1.13 110.131 -175.114 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.5 t . . . . . 0 N--CA 1.446 -0.665 0 N-CA-C 109.861 -0.422 . . . . 1.02 109.861 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 19.9 m -92.6 -24.05 18.83 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.479 -0.328 . . . . 2.56 111.377 -179.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.416 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -97.72 -86.42 0.34 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.841 -0.344 . . . . 1.07 111.675 -177.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 33.4 m -148.46 126.65 12.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.762 0.315 . . . . 1.05 110.83 -178.256 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.4 ' HB2' ' O ' ' A' ' 82' ' ' VAL . . . -86.73 132.39 33.87 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.877 0.37 . . . . 1.07 110.14 -178.062 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.652 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.7 m -142.77 172.17 8.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-O 121.352 0.596 . . . . 1.01 111.521 -176.092 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 38.1 t -133.26 104.69 6.59 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.023 -0.99 . . . . 0.39 109.645 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.763 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -92.56 130.4 38.22 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.667 0.746 . . . . 0.65 111.828 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 55.0 m -76.93 -32.4 57.33 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.613 -1.176 . . . . 1.83 110.948 178.699 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -109.64 138.57 45.81 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.659 -0.701 . . . . 1.6 109.855 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -120.85 23.76 10.55 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.813 0.339 . . . . 3.24 111.453 -174.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 25.3 p-10 -81.31 56.89 3.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.858 0.837 . . . . 2.99 109.813 176.122 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 18.1 m -83.01 158.55 3.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 114.967 -1.015 . . . . 1.68 112.197 -171.14 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.471 ' OG ' HG12 ' A' ' 75' ' ' ILE . 95.1 p -82.75 -3.04 56.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.27 -0.877 . . . . 1.88 111.05 -178.2 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.84 -32.2 3.71 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 121.04 -0.6 . . . . 0.56 112.465 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.3 m -136.15 -7.56 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 C-N-CA 120.5 -0.48 . . . . 1.18 111.899 179.169 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.471 HG12 ' OG ' ' A' ' 72' ' ' SER . 32.2 pt -92.0 -177.45 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 C-N-CA 120.006 -0.678 . . . . 1.12 111.369 178.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.763 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.38 140.37 21.98 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 114.791 -1.095 . . . . 1.11 109.161 177.295 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 68.4 mt -122.02 123.94 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.071 0.462 . . . . 1.1 111.657 -175.508 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 81.95 51.85 4.32 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.904 -0.665 . . . . 0.2 111.596 179.361 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.436 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.23 136.43 39.2 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.244 0.545 . . . . 0.65 112.187 -175.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.435 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 92.1 mt -110.66 131.28 22.17 Favored Pre-proline 0 C--N 1.321 -0.65 0 CA-C-N 115.54 -0.754 . . . . 1.1 109.703 171.653 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 22.6 Cg_exo -64.93 131.87 30.38 Favored 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 123.137 2.558 . . . . 0.25 112.868 -177.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.4 ' O ' ' HB2' ' A' ' 63' ' ' ALA . 3.4 m . . . . . 0 N--CA 1.446 -0.666 0 CA-C-N 115.75 -0.659 . . . . 1.12 109.58 177.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.7 t . . . . . 0 N--CA 1.455 -0.182 0 N-CA-C 109.656 -0.498 . . . . 1.43 109.656 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 22.8 mt -104.43 133.61 48.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.664 0.745 . . . . 1.56 111.619 178.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.462 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -144.28 163.03 34.89 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 114.524 -1.216 . . . . 0.91 110.121 178.165 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 34.6 t -114.92 109.36 18.02 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.076 -0.713 . . . . 0.34 109.076 176.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.783 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 96.8 m -88.96 134.93 33.8 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.392 -0.822 . . . . 0.19 111.35 -173.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.438 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -75.39 -28.25 59.39 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.158 -0.928 . . . . 0.39 109.775 178.461 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -141.77 103.52 4.37 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.147 -0.479 . . . . 1.12 110.73 177.555 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 98.6 t -93.85 105.93 17.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 116.178 -0.465 . . . . 1.04 109.787 177.235 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.41 142.42 45.33 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.149 -0.478 . . . . 1.03 111.067 -176.144 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.546 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.4 Cg_exo -58.92 139.21 89.84 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.382 2.054 . . . . 0.21 111.392 172.167 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.37 -20.01 71.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.824 -0.703 . . . . 0.18 112.317 -179.187 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 17.2 p-10 -101.87 7.4 41.61 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.311 0.577 . . . . 2.27 109.962 176.316 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.546 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 13.5 t -74.12 154.27 39.21 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.554 -0.748 . . . . 0.41 109.78 174.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -56.28 -39.88 73.37 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.955 0.407 . . . . 1.06 110.08 177.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.641 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER -70.45 -60.19 2.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.545 -0.752 . . . . 1.77 110.431 175.825 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.488 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.43 -41.5 80.71 Favored Glycine 0 C--N 1.331 0.252 0 CA-C-N 115.922 -0.581 . . . . 0.16 113.33 -175.497 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.4 m -66.05 -41.73 90.43 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.748 0.308 . . . . 1.07 110.37 -178.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -64.76 -37.58 88.08 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.561 -0.533 . . . . 1.57 109.561 177.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.641 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.4 mt -66.16 -49.65 66.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.924 -0.58 . . . . 1.13 110.637 -177.596 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.523 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -76.32 -21.76 55.79 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.481 -0.327 . . . . 1.08 111.172 -177.377 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.489 ' N ' HD13 ' A' ' 29' ' ' LEU . 29.8 t70 -66.51 -33.36 75.52 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.723 0.773 . . . . 0.66 109.64 175.007 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -76.21 -25.07 54.73 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.586 -1.188 . . . . 2.07 109.361 179.092 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 94.6 mt -94.46 -17.19 22.7 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.814 -1.084 . . . . 1.35 111.811 -175.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 80.44 35.69 25.47 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.155 -0.545 . . . . 0.75 112.582 178.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.523 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 22.7 mt -98.52 130.83 46.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.684 0.278 . . . . 1.24 110.713 -177.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.401 HG13 ' O ' ' A' ' 35' ' ' VAL . 5.6 p -118.72 100.05 9.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.917 0.865 . . . . 2.41 110.569 176.29 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 23.0 mt -82.57 143.44 31.03 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.469 -0.787 . . . . 3.28 111.558 -176.593 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -71.02 -38.47 72.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.225 -0.898 . . . . 2.65 109.254 174.157 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.427 ' C ' ' H ' ' A' ' 40' ' ' THR . 6.8 m-20 -125.15 91.63 48.83 Favored Pre-proline 0 N--CA 1.447 -0.583 0 CA-C-N 115.069 -0.969 . . . . 2.29 108.438 174.017 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.02 4.12 1.66 Allowed 'Trans proline' 0 C--O 1.225 -0.147 0 C-N-CA 122.54 2.16 . . . . 0.77 111.971 -178.076 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.427 ' H ' ' C ' ' A' ' 38' ' ' ASP . 18.3 p -82.79 -10.9 58.66 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.931 -0.577 . . . . 1.2 111.1 -177.777 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.9 m -71.24 160.56 5.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 1.08 111.331 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 97.4 mt -91.17 127.42 36.59 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.855 -0.611 . . . . 1.06 110.505 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.8 pt -107.41 136.85 41.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.098 0.475 . . . . 1.03 110.335 176.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.783 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -110.2 98.82 1.12 Allowed Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 120.815 -0.707 . . . . 0.31 113.199 -175.156 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -79.63 141.68 36.28 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.439 -0.578 . . . . 0.57 109.439 177.421 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.438 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 71.99 41.41 54.88 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.151 -1.023 . . . . 0.25 112.161 -179.347 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.533 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.74 117.94 35.34 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.196 0.522 . . . . 0.25 111.614 -172.533 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.485 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 1.6 t70 -101.91 136.03 19.59 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 115.401 -0.818 . . . . 2.21 110.35 174.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.485 ' HD2' ' OD1' ' A' ' 48' ' ' ASP . 1.3 Cg_endo -67.6 120.94 7.98 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.046 2.497 . . . . 0.6 111.868 -177.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 17.7 mt . . . . . 0 C--N 1.327 -0.387 0 CA-C-O 121.277 0.56 . . . . 1.13 109.962 -177.909 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 42.6 t . . . . . 0 N--CA 1.456 -0.135 0 CA-C-O 120.788 0.328 . . . . 1.02 110.887 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 20.2 m -90.48 -15.53 30.63 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 112.133 0.42 . . . . 2.56 112.133 -176.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' A' ' 14' ' ' CYS . . . -133.14 -83.25 0.47 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.349 -0.54 . . . . 1.07 112.254 -177.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 23.0 m -138.5 129.57 26.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.787 0.327 . . . . 1.05 111.608 -175.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.24 129.28 34.9 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-O 120.981 0.42 . . . . 1.07 110.319 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.547 HG23 ' SG ' ' A' ' 14' ' ' CYS . 6.4 m -141.64 157.87 21.28 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 121.446 0.641 . . . . 1.01 111.236 -177.249 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 35.3 t -116.18 111.2 19.87 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.206 -0.906 . . . . 0.39 108.722 173.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.624 ' HA ' ' HA ' ' A' ' 79' ' ' CYS . 0.5 OUTLIER -103.71 135.91 44.4 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.744 0.783 . . . . 0.65 111.91 -173.043 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 32.2 t -81.53 -35.22 30.58 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 114.55 -1.205 . . . . 1.83 111.309 -174.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -91.95 131.62 37.12 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.01 0.433 . . . . 1.6 110.419 -179.701 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.428 HD21 ' N ' ' A' ' 69' ' ' ASN . 0.9 OUTLIER -106.11 11.11 31.77 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.94 -0.573 . . . . 3.24 111.034 -177.749 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -95.28 72.57 3.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.468 0.651 . . . . 2.99 109.786 -178.507 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 35.2 m -74.97 153.06 6.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.35 -0.841 . . . . 1.68 111.606 -176.429 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -90.72 8.25 35.46 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.807 -0.633 . . . . 1.88 110.148 179.507 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.98 -34.08 3.2 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.63 -0.714 . . . . 0.56 112.83 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 m -140.99 -17.05 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 117.218 0.509 . . . . 1.18 111.958 176.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 18.3 pt -81.95 -175.41 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.478 0.656 . . . . 1.12 112.298 -176.28 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.4 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -151.05 141.73 22.71 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.236 -1.347 . . . . 1.11 107.874 173.548 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.2 mt -119.05 123.54 71.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 118.32 0.509 . . . . 1.1 112.226 -174.272 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.85 53.29 4.62 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.926 -0.654 . . . . 0.2 111.547 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.624 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 3.8 m -99.94 143.34 30.27 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.153 0.501 . . . . 0.65 111.305 -176.804 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 80.3 mt -109.25 131.76 21.65 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 115.484 -0.78 . . . . 1.1 110.372 175.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.403 ' HA ' HG13 ' A' ' 64' ' ' VAL . 15.9 Cg_exo -67.41 121.99 9.17 Favored 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.891 2.394 . . . . 0.25 111.902 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.8 m . . . . . 0 N--CA 1.445 -0.699 0 CA-C-O 121.674 0.75 . . . . 1.12 111.167 -178.773 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.6 t . . . . . 0 N--CA 1.45 -0.47 0 N-CA-C 108.852 -0.796 . . . . 1.43 108.852 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.541 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.1 mp -98.47 141.96 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 121.652 0.739 . . . . 1.56 111.509 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.594 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -145.75 166.39 26.01 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 114.793 -1.094 . . . . 0.91 110.723 178.75 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 37.1 t -114.83 104.93 12.43 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.613 -0.721 . . . . 0.34 109.552 179.286 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.765 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 63.4 m -87.69 133.06 33.9 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.519 -0.764 . . . . 0.19 111.199 -175.505 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.406 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -71.27 -27.31 63.35 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 115.251 -0.886 . . . . 0.39 108.939 173.529 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -145.63 128.39 16.27 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.64 -0.709 . . . . 1.12 110.135 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.6 t -115.73 106.09 19.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.906 0.384 . . . . 1.04 110.27 177.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.9 m -131.91 143.35 48.67 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.026 -0.534 . . . . 1.03 110.922 -175.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.479 ' O ' ' HA3' ' A' ' 25' ' ' GLY . 26.6 Cg_exo -62.8 139.85 76.89 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.225 1.95 . . . . 0.21 111.339 172.258 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.9 -22.57 70.43 Favored Glycine 0 C--N 1.329 0.159 0 C-N-CA 120.967 -0.635 . . . . 0.18 112.62 -177.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -100.39 5.83 44.39 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.636 0.732 . . . . 2.27 109.793 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.6 t -75.13 155.11 37.39 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.656 -0.702 . . . . 0.41 110.272 177.114 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -54.51 -41.31 69.49 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.185 0.517 . . . . 1.06 110.116 177.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.668 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.7 mm? -73.34 -57.75 3.79 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.692 -0.685 . . . . 1.77 110.66 177.427 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.479 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -54.52 -40.06 68.33 Favored Glycine 0 C--N 1.33 0.205 0 C-N-CA 121.249 -0.5 . . . . 0.16 113.095 -176.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 90.7 m -69.81 -40.75 75.74 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.7 0.286 . . . . 1.07 110.311 -178.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.441 ' O ' HD12 ' A' ' 27' ' ' LEU . 2.6 tm? -66.85 -36.85 83.27 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.539 -0.541 . . . . 1.57 109.539 177.059 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.668 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 12.5 mt -68.21 -47.32 68.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.89 -0.595 . . . . 1.13 110.801 -177.13 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.531 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.5 pp -74.11 -23.67 59.34 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.808 -0.357 . . . . 1.08 110.676 -179.063 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -61.68 -36.61 81.35 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.474 0.654 . . . . 0.66 109.762 173.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -73.95 -29.63 62.11 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-N 114.983 -1.008 . . . . 2.07 110.03 179.418 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 90.9 mt -93.13 -16.53 24.81 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.832 -1.076 . . . . 1.35 112.157 -172.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.76 35.8 34.74 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 121.263 -0.494 . . . . 0.75 112.624 178.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.531 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 18.4 mt -94.25 139.8 17.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.702 0.287 . . . . 1.24 110.63 -177.145 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.9 t -122.16 98.17 5.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 109.83 -0.433 . . . . 2.41 109.83 176.287 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 22.7 mt -83.13 135.56 34.77 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.17 -0.468 . . . . 3.28 111.251 -177.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 -73.36 -24.18 60.3 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.717 -0.674 . . . . 2.65 109.907 174.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -136.77 89.57 17.52 Favored Pre-proline 0 N--CA 1.446 -0.659 0 N-CA-C 108.026 -1.102 . . . . 2.29 108.026 178.285 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.29 -1.04 9.03 Favored 'Trans proline' 0 CA--C 1.519 -0.27 0 C-N-CA 122.193 1.929 . . . . 0.77 112.096 -177.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.7 p -93.36 20.57 6.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.407 0.622 . . . . 1.2 111.246 -177.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.411 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 32.0 m -101.75 162.72 3.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.551 -0.75 . . . . 1.08 110.064 174.176 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.43 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.7 mt -86.62 121.47 29.19 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.142 -0.481 . . . . 1.06 109.969 176.413 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 17.5 pt -104.15 137.69 31.93 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 CA-C-O 121.208 0.528 . . . . 1.03 110.132 176.301 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.765 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -107.42 110.05 3.13 Favored Glycine 0 N--CA 1.44 -1.059 0 C-N-CA 120.605 -0.807 . . . . 0.31 112.82 -176.608 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -86.05 132.73 33.99 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.032 -0.729 . . . . 0.57 109.032 175.278 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.43 37.69 26.93 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.001 -1.095 . . . . 0.25 111.734 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.537 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.23 116.42 32.14 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.139 0.495 . . . . 0.25 111.368 -173.373 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.424 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 6.6 m-20 -100.35 131.9 23.31 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.405 -0.816 . . . . 2.21 109.158 175.099 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.471 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 12.4 Cg_exo -63.87 123.28 11.71 Favored 'Trans proline' 0 N--CA 1.461 -0.408 0 C-N-CA 122.742 2.294 . . . . 0.6 110.965 178.39 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.465 HG13 ' HA ' ' A' ' 12' ' ' GLN . 24.8 mt . . . . . 0 C--N 1.326 -0.422 0 CA-C-O 121.498 0.666 . . . . 1.13 110.417 -175.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.0 t . . . . . 0 N--CA 1.454 -0.252 0 CA-C-O 120.939 0.4 . . . . 1.02 110.837 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.6 p -102.71 -40.78 6.45 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.98 -0.554 . . . . 2.56 111.604 -179.333 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.406 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -101.14 -85.99 0.41 Allowed 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 121.051 -0.26 . . . . 1.07 111.567 -176.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 26.9 m -132.47 129.18 38.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.666 0.269 . . . . 1.05 111.302 -177.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -86.63 130.57 34.43 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.911 0.386 . . . . 1.07 110.142 179.249 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.665 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.7 m -143.06 169.82 11.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.259 0.552 . . . . 1.01 111.415 -176.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . 0.413 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 38.0 t -137.29 107.67 6.47 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.478 -0.783 . . . . 0.39 109.862 -178.669 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.759 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.8 m -93.48 137.63 32.57 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.442 0.639 . . . . 0.65 111.735 -177.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.2 t -87.24 -20.09 27.41 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.128 -0.942 . . . . 1.83 110.955 179.45 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.4 t70 -98.92 160.41 14.28 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.161 -0.472 . . . . 1.6 109.993 -177.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -118.67 5.72 11.59 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 111.928 0.344 . . . . 3.24 111.928 -173.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -84.7 89.63 7.54 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.014 0.435 . . . . 2.99 110.764 -179.019 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.9 m -100.06 130.93 48.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.03 0.443 . . . . 1.68 111.327 179.275 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.429 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 9.2 t -80.5 -1.47 41.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.046 -0.524 . . . . 1.88 110.484 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.2 -33.89 3.21 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.833 -0.621 . . . . 0.56 112.585 178.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.7 m -140.72 4.58 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 117.202 0.501 . . . . 1.18 111.788 175.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.489 ' HA ' ' O ' ' A' ' 44' ' ' GLY . 19.2 pt -100.2 176.63 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.466 0.651 . . . . 1.12 112.039 179.726 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.759 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -145.93 140.57 27.04 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 114.291 -1.322 . . . . 1.11 109.411 174.722 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 71.0 mt -120.84 127.22 75.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.894 0.378 . . . . 1.1 111.461 -177.377 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.528 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 81.77 48.92 5.61 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 121.026 -0.607 . . . . 0.2 112.064 177.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.43 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.3 140.42 33.5 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 112.665 0.617 . . . . 0.65 112.665 -175.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.414 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.9 mt -111.34 132.75 21.63 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.43 -0.805 . . . . 1.1 109.603 170.546 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 16.9 Cg_exo -66.6 121.75 9.04 Favored 'Trans proline' 0 C--O 1.232 0.217 0 C-N-CA 122.974 2.449 . . . . 0.25 112.638 -178.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.423 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 6.2 m . . . . . 0 N--CA 1.446 -0.671 0 CA-C-N 115.917 -0.583 . . . . 1.12 110.042 -179.607 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 41.1 t . . . . . 0 N--CA 1.455 -0.222 0 N-CA-C 110.299 -0.26 . . . . 1.43 110.299 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 41.3 mt -102.83 137.49 30.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.517 0.675 . . . . 1.56 110.709 173.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.54 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -144.08 159.34 42.78 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.01 -0.995 . . . . 0.91 110.531 179.007 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.458 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 41.7 t -105.5 102.58 12.04 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.794 -0.639 . . . . 0.34 109.686 178.598 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.796 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 81.9 m -85.77 135.43 33.74 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.489 -0.778 . . . . 0.19 110.817 -176.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.74 -31.04 59.41 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 115.408 -0.815 . . . . 0.39 109.298 174.708 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -138.12 118.29 13.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.81 -0.632 . . . . 1.12 110.245 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.3 t -110.69 103.04 14.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 121.042 0.448 . . . . 1.04 110.094 178.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.0 m -133.31 142.67 45.11 Favored Pre-proline 0 C--N 1.32 -0.688 0 CA-C-N 115.83 -0.623 . . . . 1.03 110.993 -174.392 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.462 ' O ' ' HB3' ' A' ' 22' ' ' SER . 38.3 Cg_exo -60.17 139.9 89.55 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.161 1.907 . . . . 0.21 111.407 172.58 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.23 -21.78 70.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.814 -0.708 . . . . 0.18 112.342 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -94.22 -4.97 48.0 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.211 0.529 . . . . 2.27 110.524 175.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.462 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 30.0 t -68.79 154.5 41.88 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.813 -0.63 . . . . 0.41 110.54 179.041 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -52.42 -44.27 65.33 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.332 0.587 . . . . 1.06 110.1 178.067 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.649 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.2 mm? -70.6 -58.05 4.09 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.503 -0.771 . . . . 1.77 110.847 178.197 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.461 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.56 -39.41 74.66 Favored Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.227 -0.511 . . . . 0.16 113.307 -176.452 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 87.1 m -67.84 -42.1 81.95 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 120.827 0.346 . . . . 1.07 110.325 -179.015 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -61.89 -43.1 99.53 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.216 -0.661 . . . . 1.57 109.216 175.222 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.649 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.7 mt -61.46 -51.55 68.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.135 -0.939 . . . . 1.13 111.125 -175.633 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.508 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -76.37 -23.89 54.14 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.723 -0.391 . . . . 1.08 111.677 -175.322 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.5 ' N ' HD13 ' A' ' 29' ' ' LEU . 11.8 t70 -68.11 -33.49 74.61 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.512 0.672 . . . . 0.66 109.363 176.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -78.33 -23.83 46.85 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.287 -0.869 . . . . 2.07 109.962 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.7 mt -97.34 -5.24 36.95 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.193 -0.912 . . . . 1.35 111.878 -174.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 68.31 44.48 74.59 Favored Glycine 0 N--CA 1.453 -0.229 0 CA-C-N 115.74 -0.663 . . . . 0.75 112.896 177.348 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.508 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 23.3 mt -97.57 145.53 9.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.673 0.273 . . . . 1.24 110.637 -178.43 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.8 t -107.88 116.27 50.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.127 -0.488 . . . . 2.41 109.695 176.06 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.556 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.5 pp -90.81 129.95 36.83 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.25 0.547 . . . . 3.28 111.25 -179.241 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -90.96 -26.79 19.08 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.917 -0.771 . . . . 2.65 108.917 170.289 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -139.42 94.92 9.3 Favored Pre-proline 0 N--CA 1.447 -0.613 0 CA-C-N 114.92 -1.037 . . . . 2.29 108.495 177.369 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -68.43 -3.93 11.94 Favored 'Trans proline' 0 N--CA 1.466 -0.137 0 C-N-CA 122.256 1.971 . . . . 0.77 111.564 -177.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.8 p -87.89 6.2 36.73 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.337 -0.847 . . . . 1.2 111.45 -175.497 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.41 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.9 m -92.73 158.26 2.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.209 0.528 . . . . 1.08 110.875 179.407 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.9 mt -88.21 128.62 35.46 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.476 -0.784 . . . . 1.06 109.806 175.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 10.2 pt -106.83 133.07 52.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.203 0.525 . . . . 1.03 110.091 176.118 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.796 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.78 98.16 1.3 Allowed Glycine 0 N--CA 1.438 -1.19 0 CA-C-N 115.385 -0.825 . . . . 0.31 113.02 -175.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -77.4 137.84 38.94 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.583 -0.525 . . . . 0.57 109.583 177.286 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 71.48 41.08 58.82 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.431 -0.89 . . . . 0.25 112.072 -178.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.54 ' SG ' ' HB2' ' A' ' 12' ' ' GLN . 0.1 OUTLIER -105.14 111.28 23.99 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.294 0.569 . . . . 0.25 111.225 -175.312 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.432 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.5 t70 -101.43 138.53 19.93 Favored Pre-proline 0 C--N 1.316 -0.849 0 CA-C-N 115.483 -0.781 . . . . 2.21 110.927 175.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 25.7 Cg_exo -58.9 119.3 6.46 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 123.626 2.884 . . . . 0.6 111.628 177.671 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 29.7 mt . . . . . 0 C--N 1.327 -0.388 0 CA-C-O 121.054 0.454 . . . . 1.13 110.501 -177.205 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.8 t . . . . . 0 N--CA 1.451 -0.389 0 N-CA-C 109.786 -0.45 . . . . 1.02 109.786 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 28.5 t -94.4 -37.76 11.29 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.381 -0.372 . . . . 2.56 111.101 -178.205 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -86.59 -86.46 0.15 Allowed 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 121.181 -0.208 . . . . 1.07 111.499 -176.655 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 19.2 m -149.89 130.98 14.41 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.773 0.321 . . . . 1.05 111.145 -178.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.448 ' HB1' ' O ' ' A' ' 82' ' ' VAL . . . -94.95 139.47 31.29 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.852 0.358 . . . . 1.07 110.4 -178.284 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.523 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 7.2 m -145.55 162.97 11.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.315 0.578 . . . . 1.01 111.285 -177.6 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . 0.439 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 30.2 t -115.44 107.8 15.67 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.122 -0.944 . . . . 0.39 109.703 175.678 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.653 ' SG ' ' HB2' ' A' ' 76' ' ' ALA . 28.3 m -100.12 140.04 34.93 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.212 0.53 . . . . 0.65 111.441 -176.682 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 40.0 m -97.35 -20.54 17.76 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.633 -0.712 . . . . 1.83 111.241 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -110.43 139.59 45.49 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.997 -0.547 . . . . 1.6 110.372 -176.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -117.14 25.8 10.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.4 -0.364 . . . . 3.24 111.939 -175.033 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 54.8 t30 -80.55 71.61 7.41 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.597 0.713 . . . . 2.99 109.635 176.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 32.7 m -84.66 146.57 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 CA-C-N 115.541 -0.754 . . . . 1.68 112.125 -173.549 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.553 ' OG ' HG12 ' A' ' 75' ' ' ILE . 80.2 p -95.4 5.26 52.1 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.387 -0.824 . . . . 1.88 110.222 177.457 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.71 -32.7 3.43 Favored Glycine 0 N--CA 1.445 -0.711 0 CA-C-N 115.361 -0.836 . . . . 0.56 111.88 -176.253 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.3 m -140.24 -21.42 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 112.558 0.577 . . . . 1.18 112.558 176.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.553 HG12 ' OG ' ' A' ' 72' ' ' SER . 7.4 pt -73.21 175.45 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.707 0.765 . . . . 1.12 112.343 -173.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.653 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -150.21 141.39 23.12 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.233 -1.348 . . . . 1.11 108.565 178.312 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.5 mt -120.78 140.27 45.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 C-N-CA 120.514 -0.474 . . . . 1.1 111.484 -175.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.41 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 72.06 52.75 10.49 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-N 115.95 -0.568 . . . . 0.2 111.908 178.163 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.523 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 12.2 m -106.58 145.03 32.4 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.04 0.448 . . . . 0.65 111.969 -174.079 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.403 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 91.3 mt -115.92 132.2 23.33 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 115.514 -0.766 . . . . 1.1 109.811 173.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.443 ' HA ' HG12 ' A' ' 64' ' ' VAL . 18.3 Cg_exo -64.77 129.06 22.41 Favored 'Trans proline' 0 C--O 1.234 0.297 0 C-N-CA 123.19 2.593 . . . . 0.25 112.982 -176.686 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.448 ' O ' ' HB1' ' A' ' 63' ' ' ALA . 5.4 m . . . . . 0 N--CA 1.447 -0.596 0 CA-C-N 115.812 -0.631 . . . . 1.12 110.333 178.532 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.1 p . . . . . 0 N--CA 1.447 -0.611 0 N-CA-C 110.62 -0.141 . . . . 1.43 110.62 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 27.7 mt -102.72 133.99 44.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.843 0.83 . . . . 1.56 111.338 175.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.53 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -138.75 159.97 40.81 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.599 -1.182 . . . . 0.91 109.797 177.042 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.402 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 41.1 t -109.46 108.45 18.96 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.428 -0.582 . . . . 0.34 109.428 178.084 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.796 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 94.1 m -90.62 129.96 36.69 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.523 -0.762 . . . . 0.19 111.404 -174.597 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.76 -34.65 72.04 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.028 -0.987 . . . . 0.39 109.622 174.433 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -130.91 116.29 17.69 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.87 -0.604 . . . . 1.12 110.085 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 99.3 t -110.2 102.6 14.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.058 0.456 . . . . 1.04 109.981 178.606 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.7 m -130.11 143.59 49.75 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 115.896 -0.593 . . . . 1.03 111.231 -174.053 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.507 ' O ' ' HB3' ' A' ' 22' ' ' SER . 35.5 Cg_exo -61.83 141.11 88.94 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.42 2.08 . . . . 0.21 111.36 171.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.96 -25.52 72.02 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.987 -0.625 . . . . 0.18 112.584 -178.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -97.87 7.1 46.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.238 0.542 . . . . 2.27 110.118 177.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.507 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 28.9 t -75.13 154.23 37.86 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.523 -0.762 . . . . 0.41 109.753 176.168 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -58.69 -31.94 68.69 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.18 0.514 . . . . 1.06 110.389 178.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.68 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.1 mm? -73.39 -64.52 0.97 Allowed 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 115.722 -0.672 . . . . 1.77 110.408 173.076 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.78 -38.35 64.17 Favored Glycine 0 C--N 1.33 0.223 0 CA-C-N 115.788 -0.642 . . . . 0.16 113.707 -174.013 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 87.7 m -68.43 -44.72 74.35 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.818 0.342 . . . . 1.07 110.692 -177.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.422 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.7 tm? -64.72 -36.89 85.74 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.261 -0.644 . . . . 1.57 109.261 177.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.68 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 18.9 mt -65.56 -49.54 68.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.881 -0.599 . . . . 1.13 110.436 -178.272 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.456 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -75.31 -22.08 57.97 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.469 -0.332 . . . . 1.08 111.584 -176.257 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.443 ' N ' HD11 ' A' ' 29' ' ' LEU . 19.8 t70 -66.56 -34.81 78.72 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.325 0.584 . . . . 0.66 109.656 175.697 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -72.92 -20.21 61.11 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.126 -0.943 . . . . 2.07 109.594 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.5 mt -98.14 -19.58 17.83 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.346 -1.297 . . . . 1.35 111.308 -176.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.42 24.55 60.71 Favored Glycine 0 N--CA 1.452 -0.271 0 CA-C-N 115.891 -0.595 . . . . 0.75 112.609 179.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.456 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 28.7 mt -78.9 133.28 30.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.967 0.413 . . . . 1.24 110.913 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.5 t -113.1 97.96 6.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.018 -0.537 . . . . 2.41 110.038 176.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.4 mt -93.73 138.26 32.11 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.169 -0.468 . . . . 3.28 110.739 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -78.96 -23.81 44.28 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.279 0.561 . . . . 2.65 109.589 175.505 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.43 ' C ' ' H ' ' A' ' 40' ' ' THR . 24.7 m-20 -133.05 92.21 26.22 Favored Pre-proline 0 N--CA 1.446 -0.628 0 CA-C-N 115.446 -0.797 . . . . 2.29 109.117 176.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -72.8 6.96 2.16 Favored 'Trans proline' 0 N--CA 1.463 -0.287 0 C-N-CA 122.262 1.975 . . . . 0.77 111.445 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.43 ' H ' ' C ' ' A' ' 38' ' ' ASP . 17.7 p -83.71 -8.25 59.31 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.534 -0.757 . . . . 1.2 110.878 -178.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.458 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 33.4 m -78.54 151.08 5.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.909 -0.587 . . . . 1.08 110.792 179.283 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.0 mt -81.61 120.78 25.51 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.609 -0.723 . . . . 1.06 110.094 177.191 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 12.6 pt -102.52 131.85 49.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.29 0.567 . . . . 1.03 110.119 176.107 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.796 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.11 99.9 1.58 Allowed Glycine 0 N--CA 1.438 -1.207 0 CA-C-N 115.529 -0.76 . . . . 0.31 113.175 -174.54 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -80.67 139.15 36.33 Favored 'General case' 0 C--N 1.314 -0.953 0 N-CA-C 109.028 -0.731 . . . . 0.57 109.028 175.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.33 34.64 35.9 Favored Glycine 0 N--CA 1.444 -0.82 0 C-N-CA 119.629 -1.272 . . . . 0.25 111.523 -178.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.53 ' SG ' ' HB2' ' A' ' 12' ' ' GLN . 0.1 OUTLIER -102.4 118.72 37.47 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.144 0.497 . . . . 0.25 111.121 -174.315 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -100.55 134.5 20.59 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 115.669 -0.696 . . . . 2.21 109.412 175.148 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -63.98 123.13 11.43 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.589 2.193 . . . . 0.6 110.967 177.423 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.447 HG13 ' HA ' ' A' ' 12' ' ' GLN . 12.4 mt . . . . . 0 N--CA 1.45 -0.467 0 CA-C-O 121.482 0.658 . . . . 1.13 109.75 -178.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.3 t . . . . . 0 N--CA 1.449 -0.508 0 CA-C-O 120.854 0.359 . . . . 1.02 110.063 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 51.1 m -108.25 17.17 22.52 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.225 -0.443 . . . . 2.56 111.735 -177.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -144.52 -82.18 0.16 Allowed 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.752 -0.379 . . . . 1.07 111.536 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 87.1 m -150.11 123.96 9.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.864 0.364 . . . . 1.05 110.825 -179.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.462 ' HB2' ' O ' ' A' ' 82' ' ' VAL . . . -86.44 129.59 34.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.057 0.456 . . . . 1.07 110.209 -177.433 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.529 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 6.4 m -140.88 161.58 23.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 115.937 -0.574 . . . . 1.01 111.023 -177.702 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 52.8 t -120.18 110.33 16.48 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.633 -0.712 . . . . 0.39 109.389 177.092 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.786 ' SG ' ' HB2' ' A' ' 76' ' ' ALA . 15.8 m -97.57 132.23 43.43 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.133 0.492 . . . . 0.65 111.286 -176.292 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.4 m -84.11 -25.78 29.45 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.583 -0.735 . . . . 1.83 111.04 -178.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -102.01 134.66 44.88 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.791 -0.64 . . . . 1.6 110.145 -177.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -100.99 10.1 41.49 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.322 -0.399 . . . . 3.24 111.311 -174.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -79.57 103.21 9.32 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.086 0.47 . . . . 2.99 110.131 179.427 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.605 HG13 ' H ' ' A' ' 73' ' ' GLY . 73.0 t -122.84 133.04 70.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.019 -0.537 . . . . 1.68 111.244 -173.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.543 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 88.8 p -80.12 2.58 23.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.531 -0.758 . . . . 1.88 111.257 -177.296 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.605 ' H ' HG13 ' A' ' 71' ' ' VAL . . . 126.57 -32.31 3.73 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.664 -0.698 . . . . 0.56 112.04 -178.387 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.0 m -138.69 -9.77 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 112.315 0.487 . . . . 1.18 112.315 -179.381 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.543 ' CG1' ' H ' ' A' ' 72' ' ' SER . 4.1 pt -88.79 -179.43 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.707 0.765 . . . . 1.12 112.705 -175.546 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.786 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -151.51 142.17 22.73 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 114.287 -1.324 . . . . 1.11 108.798 174.308 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.9 mt -120.4 137.1 55.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.915 0.388 . . . . 1.1 111.945 -175.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.458 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 69.89 52.14 20.89 Favored Glycine 0 C--N 1.333 0.371 0 CA-C-N 115.922 -0.581 . . . . 0.2 111.778 177.723 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.529 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 12.8 m -103.02 134.35 46.62 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.274 0.559 . . . . 0.65 111.909 -173.634 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.409 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 90.4 mt -107.79 131.82 21.46 Favored Pre-proline 0 C--N 1.322 -0.614 0 CA-C-N 115.563 -0.744 . . . . 1.1 110.032 175.202 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.412 ' HA ' HG11 ' A' ' 64' ' ' VAL . 25.4 Cg_exo -63.24 120.67 8.22 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.917 2.412 . . . . 0.25 112.678 -179.315 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.462 ' O ' ' HB2' ' A' ' 63' ' ' ALA . 4.3 m . . . . . 0 N--CA 1.447 -0.601 0 CA-C-N 115.968 -0.56 . . . . 1.12 110.201 178.23 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 34.1 t . . . . . 0 N--CA 1.45 -0.445 0 N-CA-C 109.502 -0.555 . . . . 1.43 109.502 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.1 mt -95.7 137.16 24.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 121.664 0.745 . . . . 1.56 110.989 178.058 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . 0.535 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -132.24 163.06 29.43 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.775 -1.102 . . . . 0.91 109.949 176.781 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.527 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 42.0 t -106.28 99.49 9.07 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.809 -0.632 . . . . 0.34 109.556 179.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.853 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 54.0 m -86.01 130.66 34.47 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-N 115.707 -0.678 . . . . 0.19 111.352 -175.554 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.445 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -77.82 -30.87 51.37 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.196 -0.911 . . . . 0.39 109.77 177.506 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . 0.597 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 19.3 m-20 -133.3 98.59 4.29 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.117 -0.492 . . . . 1.12 111.256 175.609 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 71.8 t -89.48 100.85 11.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.162 0.506 . . . . 1.04 109.732 174.234 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 29.6 m -128.45 141.1 40.35 Favored Pre-proline 0 C--N 1.318 -0.768 0 CA-C-N 115.843 -0.617 . . . . 1.03 110.697 -174.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.44 ' HB2' ' HB2' ' A' ' 22' ' ' SER . 31.9 Cg_exo -59.24 135.58 66.65 Favored 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 122.073 1.849 . . . . 0.21 111.521 172.741 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.8 -15.22 64.23 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.888 -0.673 . . . . 0.18 112.136 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -103.44 4.56 36.25 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.053 0.454 . . . . 2.27 110.248 175.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.44 ' HB2' ' HB2' ' A' ' 19' ' ' PRO . 29.0 t -78.53 158.35 28.59 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.051 -0.522 . . . . 0.41 109.898 177.717 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -53.19 -42.79 66.61 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.974 0.416 . . . . 1.06 109.991 176.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.685 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.9 mm? -67.7 -65.08 0.74 Allowed 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 115.669 -0.696 . . . . 1.77 110.493 178.259 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.69 -36.44 59.29 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.983 -0.553 . . . . 0.16 113.329 -174.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 84.9 m -68.55 -45.67 71.53 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.79 0.329 . . . . 1.07 110.298 -178.175 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.418 ' O ' HD11 ' A' ' 27' ' ' LEU . 1.3 tm? -65.96 -36.38 83.17 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.15 -0.685 . . . . 1.57 109.15 178.212 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.685 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.7 mt -67.34 -46.55 73.12 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.603 -0.726 . . . . 1.13 111.033 -177.363 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.485 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.26 -22.87 51.49 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 120.321 -0.551 . . . . 1.08 111.137 -178.695 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.472 ' N ' HD12 ' A' ' 29' ' ' LEU . 13.0 t70 -67.98 -35.8 78.97 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.044 -0.724 . . . . 0.66 109.044 173.135 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -69.1 -33.22 73.16 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 114.717 -1.129 . . . . 2.07 109.429 178.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 67.6 mt -91.87 -10.86 38.13 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.56 -1.2 . . . . 1.35 111.867 -176.412 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.29 35.71 88.33 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.767 -0.651 . . . . 0.75 112.6 179.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.485 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 56.5 mt -76.08 129.0 37.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 120.814 0.34 . . . . 1.24 111.163 -176.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.2 p -86.56 101.0 10.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.746 0.784 . . . . 2.41 109.415 172.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.504 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.8 pp -76.29 132.7 39.98 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.722 -0.672 . . . . 3.28 111.18 -177.358 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -86.83 -29.73 22.01 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.745 -0.835 . . . . 2.65 108.745 172.248 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -144.96 112.33 4.84 Favored Pre-proline 0 N--CA 1.443 -0.803 0 N-CA-C 107.493 -1.299 . . . . 2.29 107.493 174.01 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -75.52 -1.5 11.4 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.197 1.931 . . . . 0.77 112.808 -173.228 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 35.2 p -106.55 20.51 18.89 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.261 0.553 . . . . 1.2 111.121 -175.727 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.44 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 34.8 m -87.72 156.59 3.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.589 -0.732 . . . . 1.08 110.081 175.143 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.44 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.9 mt -85.6 121.26 28.04 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.808 -0.442 . . . . 1.06 109.808 176.638 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 22.2 pt -106.41 140.75 23.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.101 0.477 . . . . 1.03 110.256 177.493 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.853 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.2 107.35 1.55 Allowed Glycine 0 N--CA 1.439 -1.111 0 C-N-CA 120.586 -0.816 . . . . 0.31 112.949 -175.102 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.597 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 9.4 t70 -80.62 147.91 30.5 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.693 -0.854 . . . . 0.57 108.693 175.257 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 67.46 37.81 90.34 Favored Glycine 0 C--N 1.317 -0.515 0 C-N-CA 120.162 -1.018 . . . . 0.25 111.958 178.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.527 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -102.63 115.44 30.59 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.01 0.433 . . . . 0.25 111.088 -172.895 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.45 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 2.1 p-10 -100.84 132.07 22.63 Favored Pre-proline 0 C--N 1.318 -0.796 0 CA-C-N 115.698 -0.683 . . . . 2.21 110.161 177.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.94 119.55 6.87 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.399 2.066 . . . . 0.6 110.696 175.058 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.403 HG13 ' HA ' ' A' ' 12' ' ' GLN . 12.9 mt . . . . . 0 N--CA 1.449 -0.488 0 CA-C-O 121.879 0.847 . . . . 1.13 109.913 -177.098 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.5 t . . . . . 0 N--CA 1.451 -0.387 0 CA-C-O 120.848 0.356 . . . . 1.02 110.28 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 12.8 p -93.6 -15.37 25.46 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.089 -0.505 . . . . 2.56 111.742 -177.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.445 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -128.44 -83.44 0.58 Allowed 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.623 0.601 . . . . 1.07 112.623 -175.172 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.8 m -142.11 131.59 23.8 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.783 0.325 . . . . 1.05 111.301 -176.147 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.94 125.98 34.4 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.031 0.443 . . . . 1.07 110.125 178.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.655 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -141.33 164.99 19.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.119 -0.492 . . . . 1.01 110.806 -177.546 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 29.3 t -131.28 113.0 13.27 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 116.172 -0.467 . . . . 0.39 109.935 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . 0.775 ' SG ' ' HB3' ' A' ' 76' ' ' ALA . 1.5 m -95.53 136.73 35.54 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.647 0.737 . . . . 0.65 112.233 -175.406 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.7 m -89.44 -18.45 26.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.641 -1.163 . . . . 1.83 110.806 -179.281 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.467 ' HB2' ' O ' ' A' ' 77' ' ' ILE . 19.8 m-20 -98.31 151.71 20.21 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.887 -0.597 . . . . 1.6 110.332 178.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -103.68 -12.28 17.12 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.019 -0.537 . . . . 3.24 110.581 -178.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -67.84 110.2 3.72 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.892 -0.594 . . . . 2.99 110.915 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.5 m -125.19 150.29 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 CA-C-N 116.158 -0.473 . . . . 1.68 110.932 177.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.451 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 8.1 t -95.31 10.58 35.66 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.651 0.738 . . . . 1.88 109.636 177.008 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.15 -33.42 5.31 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 115.476 -0.784 . . . . 0.56 112.748 177.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.5 m -138.01 -0.52 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.644 -0.422 . . . . 1.18 111.64 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.451 ' CG1' ' H ' ' A' ' 72' ' ' SER . 24.3 pt -100.21 173.84 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 C-N-CA 120.187 -0.605 . . . . 1.12 111.63 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . 0.775 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -141.41 141.08 33.76 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 114.485 -1.234 . . . . 1.11 109.35 176.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.467 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 67.0 mt -122.02 131.93 72.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.742 0.306 . . . . 1.1 111.342 -177.43 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.44 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 75.53 51.68 7.11 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.978 -0.629 . . . . 0.2 111.911 178.638 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.2 m -99.89 138.74 36.55 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.231 0.538 . . . . 0.65 112.232 -176.345 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 92.1 mt -106.98 133.01 20.46 Favored Pre-proline 0 C--N 1.32 -0.689 0 CA-C-N 115.475 -0.784 . . . . 1.1 109.445 170.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -65.77 124.62 12.99 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.82 2.347 . . . . 0.25 111.961 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.6 m . . . . . 0 N--CA 1.442 -0.828 0 CA-C-O 121.033 0.444 . . . . 1.12 110.659 -179.828 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.754 0 N-CA-C 111.918 -0.473 . . . . 5.98 111.918 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.0 m -142.86 116.24 9.05 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.815 0.341 . . . . 4.6 110.983 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.415 ' HA ' ' O ' ' A' ' 50' ' ' ILE . 20.4 m95 -81.78 -55.9 4.33 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.949 -0.569 . . . . 5.43 110.216 175.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.09 163.2 13.67 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 111.119 -0.793 . . . . 2.46 111.119 -178.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 53.3 tp60 -89.44 107.11 18.89 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.871 0.336 . . . . 4.59 110.263 -178.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 44.0 t 176.7 115.69 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.562 -0.744 . . . . 1.88 110.381 177.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 35.1 m -99.5 14.92 28.18 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.106 0.479 . . . . 2.6 110.265 178.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.2 m -84.03 -8.44 59.13 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.366 0.603 . . . . 4.25 110.508 178.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 162.89 -125.98 1.48 Allowed Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.769 -0.729 . . . . 1.12 112.051 178.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 35.3 t -112.86 149.6 32.89 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.155 -0.683 . . . . 1.43 109.155 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.504 ' N ' HD13 ' A' ' 11' ' ' ILE . 4.3 mp -99.27 138.08 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 CA-C-O 121.722 0.772 . . . . 1.56 111.675 176.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.521 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -148.98 167.76 24.92 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.598 -1.183 . . . . 0.91 111.003 178.301 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 37.3 t -116.45 106.71 13.9 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.38 -0.827 . . . . 0.34 109.293 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.8 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 90.4 m -91.8 132.1 36.67 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.753 -0.658 . . . . 0.19 111.597 -173.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.413 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -73.2 -35.97 66.44 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 114.91 -1.041 . . . . 0.39 109.501 173.869 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 19.7 m-20 -128.84 100.57 5.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.051 -0.522 . . . . 1.12 111.334 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.8 t -92.52 99.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.497 -0.557 . . . . 1.04 109.497 173.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.6 m -129.06 140.4 38.5 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 115.761 -0.654 . . . . 1.03 110.863 -174.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.54 ' O ' ' HB3' ' A' ' 22' ' ' SER . 33.4 Cg_exo -58.36 140.9 96.27 Favored 'Trans proline' 0 N--CA 1.464 -0.252 0 C-N-CA 122.371 2.047 . . . . 0.21 111.709 173.313 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.86 -19.47 69.61 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.907 -0.663 . . . . 0.18 112.589 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -103.22 7.43 38.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.388 0.613 . . . . 2.27 109.97 176.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.54 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 13.8 t -73.28 155.78 39.13 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.328 -0.851 . . . . 0.41 110.014 176.658 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -55.93 -41.01 73.95 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.212 0.529 . . . . 1.06 109.685 176.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.72 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.1 mm? -70.11 -60.52 2.24 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 115.325 -0.852 . . . . 1.77 110.694 176.347 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.435 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -56.03 -41.51 85.21 Favored Glycine 0 CA--C 1.517 0.171 0 CA-C-N 116.053 -0.521 . . . . 0.16 113.348 -174.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 91.5 m -67.84 -39.39 83.85 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.916 0.389 . . . . 1.07 110.499 -178.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -64.71 -39.24 93.32 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.244 -0.65 . . . . 1.57 109.244 176.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.72 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.6 mt -68.13 -50.04 57.22 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.701 -0.681 . . . . 1.13 110.987 -176.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.524 HD11 ' N ' ' A' ' 30' ' ' ASP . 3.8 pp -73.18 -23.72 60.45 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.546 -0.462 . . . . 1.08 111.509 -176.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.524 ' N ' HD11 ' A' ' 29' ' ' LEU . 28.2 t70 -68.97 -31.71 70.76 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.58 0.705 . . . . 0.66 109.192 175.64 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -75.04 -15.29 60.64 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-N 114.988 -1.005 . . . . 2.07 109.918 177.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.8 mt -111.7 0.04 16.17 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.932 -1.031 . . . . 1.35 111.464 -174.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.21 34.66 85.32 Favored Glycine 0 C--N 1.333 0.363 0 CA-C-N 115.855 -0.611 . . . . 0.75 113.015 178.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.512 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 53.9 mt -84.07 125.9 40.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.817 0.341 . . . . 1.24 110.828 -176.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 50.4 t -88.17 121.28 38.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.278 -0.638 . . . . 2.41 109.278 175.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.487 HD11 ' O ' ' A' ' 36' ' ' LEU . 1.6 pp -95.23 130.62 41.91 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.425 0.631 . . . . 3.28 111.703 -176.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -90.87 -29.2 17.66 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 108.56 -0.904 . . . . 2.65 108.56 170.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -142.34 96.1 6.47 Favored Pre-proline 0 N--CA 1.442 -0.838 0 N-CA-C 107.724 -1.213 . . . . 2.29 107.724 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -69.84 -5.89 17.34 Favored 'Trans proline' 0 CA--C 1.521 -0.149 0 C-N-CA 122.561 2.174 . . . . 0.77 111.819 -176.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.2 p -95.41 19.14 11.3 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.686 -0.688 . . . . 1.2 111.308 -175.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.464 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 32.7 m -92.09 156.6 3.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.798 -0.637 . . . . 1.08 109.855 173.048 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.525 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.1 mt -88.99 121.68 31.59 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 116.061 -0.518 . . . . 1.06 109.835 176.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 12.1 pt -102.74 133.57 46.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-O 121.247 0.546 . . . . 1.03 110.053 176.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.8 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -105.82 95.31 1.05 Allowed Glycine 0 N--CA 1.439 -1.166 0 CA-C-N 115.546 -0.752 . . . . 0.31 112.832 -174.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -76.83 141.91 40.48 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.235 -0.654 . . . . 0.57 109.235 176.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 70.57 38.8 68.44 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 119.71 -1.233 . . . . 0.25 111.825 -177.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -107.36 116.28 31.66 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.17 0.51 . . . . 0.25 111.351 -172.98 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.4 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 19.9 m-20 -102.02 134.52 20.04 Favored Pre-proline 0 C--N 1.317 -0.838 0 CA-C-N 115.632 -0.713 . . . . 2.21 109.362 175.453 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.417 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 16.5 Cg_exo -62.79 126.97 19.31 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.613 2.209 . . . . 0.6 111.351 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 3' ' ' TRP . 47.1 mt -80.81 103.42 7.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 120.958 0.409 . . . . 1.13 110.551 -175.753 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 7.5 t -138.74 20.24 2.68 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.755 0.788 . . . . 1.22 109.871 179.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 9.9 p -128.34 161.58 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 CA-C-N 115.234 -0.894 . . . . 1.92 109.832 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . 73.18 -63.98 0.41 Allowed 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 123.344 0.658 . . . . 3.46 112.09 175.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 64.85 40.45 97.3 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.304 -0.95 . . . . 3.5 111.459 -175.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 29.1 m -149.34 -167.47 2.84 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.242 -0.651 . . . . 5.24 109.242 -178.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 13.8 p -61.96 -33.9 75.14 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.923 0.392 . . . . 4.31 110.934 178.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -82.16 25.27 0.6 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 3.13 111.752 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.408 ' HB3' ' CG2' ' A' ' 50' ' ' ILE . . . -80.53 -11.3 59.68 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.282 0.563 . . . . 1.6 110.65 178.707 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.8 t -146.58 135.16 22.08 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.633 -0.712 . . . . 1.02 110.278 178.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.3 p -100.79 -26.19 13.86 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.087 -0.506 . . . . 2.56 111.906 -177.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -105.74 -80.56 0.55 Allowed 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 121.067 -0.253 . . . . 1.07 111.585 -177.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 15.1 m -147.19 129.17 15.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.582 0.229 . . . . 1.05 110.797 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.411 ' HB1' ' O ' ' A' ' 82' ' ' VAL . . . -86.21 131.87 34.14 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.902 0.382 . . . . 1.07 110.372 -178.108 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.725 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -144.4 171.82 6.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.238 0.542 . . . . 1.01 111.431 -176.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 42.0 t -139.28 106.26 5.44 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.301 -0.863 . . . . 0.39 109.744 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.745 ' SG ' ' HB2' ' A' ' 76' ' ' ALA . 1.5 m -88.41 134.57 33.8 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.472 0.653 . . . . 0.65 112.214 -177.474 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.8 m -85.42 -18.53 33.37 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.856 -1.066 . . . . 1.83 111.1 -179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -100.75 160.18 14.57 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.456 -0.572 . . . . 1.6 109.456 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -112.2 -7.89 14.01 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.962 0.411 . . . . 3.24 110.859 -176.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 34.5 t30 -75.71 108.24 8.41 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.077 -0.51 . . . . 2.99 110.862 -178.143 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.1 m -118.87 143.74 29.09 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.726 0 CA-C-N 116.078 -0.51 . . . . 1.68 110.257 177.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.619 ' OG ' HG12 ' A' ' 75' ' ' ILE . 90.7 p -84.5 -2.0 56.61 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.093 0.473 . . . . 1.88 110.494 -179.707 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.61 -32.18 3.58 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.669 -0.696 . . . . 0.56 112.288 -177.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 15.7 m -136.63 -16.07 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.533 -0.467 . . . . 1.18 112.043 178.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.619 HG12 ' OG ' ' A' ' 72' ' ' SER . 20.3 pt -87.75 -176.17 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.541 0.686 . . . . 1.12 111.884 -177.187 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.745 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -150.35 142.2 23.8 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-N 114.231 -1.35 . . . . 1.11 108.765 175.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 63.0 mt -117.75 130.22 72.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 120.594 -0.442 . . . . 1.1 111.646 -176.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.06 51.75 6.06 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.068 -0.587 . . . . 0.2 111.871 177.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.525 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.2 m -99.1 129.61 45.37 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.378 0.609 . . . . 0.65 112.072 -176.143 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.41 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 96.5 mt -98.97 132.19 24.08 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.517 -0.765 . . . . 1.1 109.664 173.087 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 13.8 Cg_exo -68.16 123.24 10.38 Favored 'Trans proline' 0 N--CA 1.463 -0.303 0 C-N-CA 122.78 2.32 . . . . 0.25 112.037 -179.071 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.411 ' O ' ' HB1' ' A' ' 63' ' ' ALA . 5.2 m -124.9 157.19 33.47 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 CA-C-N 116.09 -0.505 . . . . 1.12 110.399 179.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.402 HG23 ' HG ' ' A' ' 84' ' ' LEU . 25.5 m -156.07 139.75 16.04 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.9 -0.591 . . . . 2.18 109.426 176.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.402 ' HG ' HG23 ' A' ' 83' ' ' THR . 98.3 mt . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.851 -0.595 . . . . 4.14 110.916 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.511 0 N-CA-C 111.603 -0.599 . . . . 5.98 111.603 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.4 p -82.59 -14.94 53.94 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.862 0.363 . . . . 4.6 111.139 -177.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 48.3 m95 -102.91 38.0 1.83 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.049 0.452 . . . . 5.43 110.137 -178.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.57 149.76 24.32 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.994 -0.622 . . . . 2.46 112.274 -179.39 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.3 mm100 -87.08 109.26 19.3 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.24 -0.281 . . . . 4.59 110.24 178.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.454 ' HB3' ' O ' ' A' ' 9' ' ' GLY . 42.3 t -156.6 136.61 12.7 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.963 0.411 . . . . 1.88 110.645 -178.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 11.0 p -83.6 -17.79 40.44 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.976 -0.556 . . . . 2.6 111.075 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.408 ' HB ' ' SG ' ' A' ' 65' ' ' CYS . 91.6 m -82.46 -24.32 34.31 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.123 -0.49 . . . . 4.25 110.937 178.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.454 ' O ' ' HB3' ' A' ' 6' ' ' CYS . . . 153.63 -139.41 6.84 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.658 -0.782 . . . . 1.12 112.465 178.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.2 m -92.51 139.1 30.93 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-O 120.732 0.301 . . . . 1.43 110.376 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 40.4 mt -90.93 137.66 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.804 0.811 . . . . 1.56 110.869 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.449 ' HA ' HG13 ' A' ' 50' ' ' ILE . 0.1 OUTLIER -145.74 158.05 43.89 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 114.605 -1.179 . . . . 0.91 109.958 -175.903 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.486 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 37.8 t -110.51 103.3 11.89 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-O 121.134 0.492 . . . . 0.34 110.009 -177.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.629 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 63.8 m -86.63 136.05 33.19 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.311 -0.858 . . . . 0.19 111.057 -175.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.466 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -73.33 -32.9 64.83 Favored 'General case' 0 N--CA 1.445 -0.69 0 CA-C-N 115.167 -0.924 . . . . 0.39 108.643 173.762 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.475 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 3.7 t-20 -128.36 135.42 49.54 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.59 -0.732 . . . . 1.12 109.468 178.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 87.2 t -126.43 106.11 15.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 109.706 -0.479 . . . . 1.04 109.706 174.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.3 m -135.24 142.41 41.56 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 115.656 -0.702 . . . . 1.03 111.127 -173.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.533 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.8 Cg_exo -57.75 139.76 91.35 Favored 'Trans proline' 0 N--CA 1.462 -0.345 0 C-N-CA 122.257 1.971 . . . . 0.21 111.329 171.251 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.7 -23.12 70.51 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.839 -0.696 . . . . 0.18 112.31 -179.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -95.65 -1.47 50.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.95 0.405 . . . . 2.27 109.932 177.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.533 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 22.9 t -68.28 150.67 47.96 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.002 -0.544 . . . . 0.41 109.579 176.592 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -58.48 -32.56 68.88 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.2 0.524 . . . . 1.06 110.106 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.646 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.6 mm? -69.01 -64.56 0.85 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.433 -0.803 . . . . 1.77 110.701 172.009 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.44 -40.84 78.76 Favored Glycine 0 C--N 1.33 0.225 0 CA-C-N 115.959 -0.564 . . . . 0.16 113.364 -174.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 30.1 m -67.32 -41.15 85.77 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.168 -0.308 . . . . 1.07 110.168 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -64.91 -40.14 94.6 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.408 -0.59 . . . . 1.57 109.408 177.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.646 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.7 mt -67.92 -44.62 76.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.044 -0.526 . . . . 1.13 110.849 -175.168 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.519 HD13 ' N ' ' A' ' 30' ' ' ASP . 3.8 pp -77.69 -25.1 49.21 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.372 -0.531 . . . . 1.08 110.899 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.519 ' N ' HD13 ' A' ' 29' ' ' LEU . 24.6 t70 -64.88 -36.7 85.21 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.766 0.793 . . . . 0.66 109.178 172.144 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -74.86 -12.13 60.3 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 114.149 -1.387 . . . . 2.07 110.388 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.5 mt -108.66 -9.95 15.24 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.146 -0.934 . . . . 1.35 111.259 -178.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 71.22 35.09 64.02 Favored Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.887 -0.597 . . . . 0.75 112.518 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.512 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 43.4 mt -91.55 131.05 39.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.709 0.255 . . . . 1.24 110.704 -178.159 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 p -91.87 112.75 26.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.42 0.629 . . . . 2.41 109.959 173.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.451 ' H ' ' HG ' ' A' ' 36' ' ' LEU . 0.9 OUTLIER -81.62 134.29 35.47 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.92 -0.582 . . . . 3.28 110.908 -179.573 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -87.32 -35.42 18.42 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.828 -0.804 . . . . 2.65 108.828 173.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -143.71 102.5 4.97 Favored Pre-proline 0 N--CA 1.444 -0.745 0 N-CA-C 107.947 -1.131 . . . . 2.29 107.947 176.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.41 ' HB3' HD22 ' A' ' 36' ' ' LEU . 51.8 Cg_endo -69.53 -3.48 11.95 Favored 'Trans proline' 0 C--O 1.226 -0.119 0 C-N-CA 122.365 2.043 . . . . 0.77 111.673 -175.036 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.0 p -85.73 7.95 21.68 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.633 -0.712 . . . . 1.2 111.88 -174.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.5 m -92.18 158.42 2.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.958 0.408 . . . . 1.08 110.327 177.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.533 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 94.9 mt -89.07 121.76 31.73 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.076 -0.511 . . . . 1.06 110.084 178.494 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 22.4 pt -108.86 145.73 15.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.238 0.542 . . . . 1.03 110.44 177.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.629 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.02 142.09 17.18 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.667 -0.778 . . . . 0.31 112.338 -177.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.475 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 9.5 t70 -105.17 151.79 23.62 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.305 -0.998 . . . . 0.57 108.305 172.314 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.407 ' HA3' ' HB3' ' A' ' 15' ' ' GLN . . . 61.02 44.5 98.11 Favored Glycine 0 C--N 1.32 -0.339 0 C-N-CA 120.28 -0.962 . . . . 0.25 112.302 175.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.507 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.34 115.55 30.44 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.056 0.455 . . . . 0.25 110.984 -172.443 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -101.29 129.32 27.25 Favored Pre-proline 0 C--N 1.316 -0.884 0 CA-C-N 115.666 -0.697 . . . . 2.21 109.304 175.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.439 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 17.8 Cg_exo -61.64 122.2 10.69 Favored 'Trans proline' 0 N--CA 1.46 -0.446 0 C-N-CA 122.739 2.293 . . . . 0.6 111.263 178.05 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.449 HG13 ' HA ' ' A' ' 12' ' ' GLN . 10.1 mt -82.32 88.55 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.593 0.711 . . . . 1.13 109.835 -176.363 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 12.4 t -125.08 9.76 8.09 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.968 -1.015 . . . . 1.22 110.293 -177.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.5 p -89.58 131.07 37.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 115.577 -0.738 . . . . 1.92 110.652 -177.295 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -98.75 133.52 42.95 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.088 -0.505 . . . . 3.46 110.582 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 99.39 35.28 4.76 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.877 -0.677 . . . . 3.5 111.809 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 8.5 t -138.12 106.59 5.83 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.864 0.364 . . . . 5.24 110.168 -177.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.4 m -75.56 -37.84 59.68 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.142 0.496 . . . . 4.31 109.711 177.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -97.78 58.43 1.4 Allowed 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 109.133 -0.692 . . . . 3.13 109.133 173.014 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -70.25 -14.95 62.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.333 -0.849 . . . . 1.6 111.216 -176.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.9 t -132.1 131.36 42.29 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.506 -0.77 . . . . 1.02 110.129 176.586 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 17.4 t -109.66 -22.25 12.03 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.518 -0.31 . . . . 2.56 111.143 -177.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.466 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -102.85 -82.06 0.49 Allowed 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.725 -0.39 . . . . 1.07 111.316 -179.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 23.2 m -148.78 127.67 12.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.8 0.333 . . . . 1.05 110.775 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -88.21 133.21 34.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.0 0.429 . . . . 1.07 110.909 -177.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.487 HG23 ' SG ' ' A' ' 14' ' ' CYS . 3.3 m -144.11 170.5 8.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.03 -0.532 . . . . 1.01 111.07 -178.571 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 46.3 t -130.87 115.77 17.01 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.022 -0.536 . . . . 0.39 110.045 178.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.804 ' SG ' ' HB3' ' A' ' 76' ' ' ALA . 4.4 m -101.71 154.88 18.5 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.814 0.816 . . . . 0.65 111.941 -176.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 49.0 m -103.45 -19.58 14.36 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 114.405 -1.27 . . . . 1.83 110.787 -177.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -106.24 142.82 35.28 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.706 -0.679 . . . . 1.6 109.561 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -116.77 2.94 12.95 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.076 0.465 . . . . 3.24 110.663 -176.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -92.62 58.69 3.16 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.62 0.724 . . . . 2.99 109.861 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 33.5 m -80.68 163.96 3.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.062 -0.972 . . . . 1.68 110.83 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.526 ' OG ' HG12 ' A' ' 75' ' ' ILE . 91.7 p -74.25 -8.04 54.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.281 -0.418 . . . . 1.88 111.339 -175.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.9 -32.06 3.56 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.923 -0.656 . . . . 0.56 112.68 -178.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 10.6 m -134.96 -6.12 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.318 -0.553 . . . . 1.18 111.989 178.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.526 HG12 ' OG ' ' A' ' 72' ' ' SER . 29.0 pt -93.92 -176.28 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 C-N-CA 120.063 -0.655 . . . . 1.12 111.419 179.583 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.804 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -144.58 143.23 30.69 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.782 -1.099 . . . . 1.11 109.73 175.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 64.0 mt -126.44 128.55 71.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.931 0.396 . . . . 1.1 111.606 -176.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.471 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 74.82 53.68 6.26 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.744 -0.662 . . . . 0.2 111.621 179.144 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.533 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 0.9 OUTLIER -104.2 141.9 35.45 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 112.652 0.612 . . . . 0.65 112.652 -175.539 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.408 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 84.2 mt -111.36 134.8 21.06 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.512 -0.767 . . . . 1.1 109.787 172.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.426 ' HA ' HG12 ' A' ' 64' ' ' VAL . 19.4 Cg_exo -65.14 124.04 12.42 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 123.067 2.512 . . . . 0.25 112.595 -179.012 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.3 m -125.59 157.67 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 CA-C-N 116.089 -0.505 . . . . 1.12 110.223 177.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.443 HG21 HD11 ' A' ' 84' ' ' LEU . 39.0 m -110.15 132.05 54.51 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 116.171 -0.468 . . . . 2.18 110.452 -179.729 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.443 HD11 HG21 ' A' ' 83' ' ' THR . 10.9 mp . . . . . 0 C--O 1.25 1.126 0 O-C-N 123.939 0.775 . . . . 4.14 111.761 -178.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.81 0 N-CA-C 111.756 -0.538 . . . . 5.98 111.756 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 50.4 m 54.38 52.56 12.25 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 121.393 0.616 . . . . 4.6 110.301 -176.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 32.2 t-105 -138.89 -76.24 0.37 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.488 -0.778 . . . . 5.43 109.906 -177.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 134.86 69.45 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.533 0 N-CA-C 111.279 -0.728 . . . . 2.46 111.279 -174.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -92.18 114.84 27.49 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-O 121.309 0.576 . . . . 4.59 110.458 -178.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 5.8 p -93.1 -45.16 8.02 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.462 -0.79 . . . . 1.88 110.465 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 79.9 p -144.96 -155.44 0.61 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.259 -0.882 . . . . 2.6 108.688 -178.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.3 m -62.26 -23.38 66.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.184 0.516 . . . . 4.25 110.214 175.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -83.45 -135.26 2.59 Favored Glycine 0 N--CA 1.447 -0.58 0 CA-C-N 115.725 -0.67 . . . . 1.12 112.479 178.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 40.1 t -150.07 153.09 35.84 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 110.139 -0.319 . . . . 1.43 110.139 -176.246 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.3 mt -88.21 139.37 17.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.185 0.517 . . . . 1.56 110.448 172.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.639 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -140.02 164.37 30.2 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.578 -0.737 . . . . 0.91 110.676 176.616 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 28.3 t -107.79 101.91 11.17 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.311 -0.859 . . . . 0.34 109.468 179.718 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.809 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 55.6 m -87.72 126.29 34.9 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.984 -0.553 . . . . 0.19 111.298 -176.057 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.441 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -67.28 -33.4 75.22 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.074 -0.967 . . . . 0.39 109.471 174.878 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -139.43 113.01 8.41 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.953 -0.567 . . . . 1.12 110.501 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 51.2 t -101.17 104.55 16.43 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 109.67 -0.493 . . . . 1.04 109.67 177.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 m -129.97 140.58 39.07 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 116.072 -0.513 . . . . 1.03 111.43 -174.221 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.453 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.1 Cg_exo -59.61 138.44 83.51 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.37 2.047 . . . . 0.21 111.222 171.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -62.79 -26.05 68.27 Favored Glycine 0 C--O 1.227 -0.34 0 C-N-CA 121.272 -0.49 . . . . 0.18 113.146 -176.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -101.13 7.55 43.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.493 0.664 . . . . 2.27 110.245 177.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.453 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 26.6 t -71.31 159.02 35.33 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.52 -0.548 . . . . 0.41 109.52 175.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -53.4 -44.31 68.61 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.168 0.509 . . . . 1.06 109.767 176.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.683 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 6.2 mt -69.09 -60.27 2.47 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.314 -0.857 . . . . 1.77 110.456 178.25 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.425 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -53.51 -38.13 57.49 Favored Glycine 0 C--N 1.33 0.228 0 CA-C-N 116.101 -0.499 . . . . 0.16 113.218 -176.205 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 88.3 m -67.6 -47.61 69.2 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 110.361 -0.237 . . . . 1.07 110.361 -178.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.413 ' O ' HD11 ' A' ' 27' ' ' LEU . 3.1 tm? -62.71 -37.76 87.76 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.66 -0.496 . . . . 1.57 109.66 178.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.683 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.9 mt -69.01 -43.84 74.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.975 -0.557 . . . . 1.13 110.849 -175.543 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.455 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -82.41 -21.31 35.82 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.536 -0.466 . . . . 1.08 111.217 -178.578 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.429 ' N ' HD12 ' A' ' 29' ' ' LEU . 19.4 t70 -66.56 -34.92 78.98 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.634 0.731 . . . . 0.66 109.364 174.313 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -74.15 -32.96 63.35 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.793 -1.094 . . . . 2.07 109.18 179.141 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.4 mt -89.2 -10.56 46.61 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.903 -1.044 . . . . 1.35 111.982 -176.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.96 44.01 92.52 Favored Glycine 0 N--CA 1.452 -0.294 0 CA-C-N 115.849 -0.614 . . . . 0.75 112.766 178.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.455 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 51.3 mt -91.19 128.82 42.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.936 0.398 . . . . 1.24 111.41 -176.28 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.3 p -84.99 122.31 38.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.061 -0.518 . . . . 2.41 109.905 173.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.484 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.3 pp -94.88 131.26 40.97 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.265 0.555 . . . . 3.28 111.589 -176.227 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -90.36 -29.06 18.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.876 -0.787 . . . . 2.65 108.876 173.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -146.89 103.06 3.87 Favored Pre-proline 0 N--CA 1.444 -0.738 0 N-CA-C 107.435 -1.32 . . . . 2.29 107.435 175.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.439 ' HB3' HD21 ' A' ' 36' ' ' LEU . 66.7 Cg_endo -74.89 -1.09 10.73 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.135 1.89 . . . . 0.77 112.603 -174.029 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.3 p -99.6 4.48 45.79 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.176 -0.609 . . . . 1.2 111.092 -173.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.0 m -78.29 163.72 3.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.841 -0.618 . . . . 1.08 110.465 175.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.472 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 88.8 mt -91.5 120.09 32.02 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.933 -0.576 . . . . 1.06 110.011 176.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 17.3 pt -103.0 134.59 43.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 121.229 0.538 . . . . 1.03 110.095 176.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.809 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.94 104.75 2.21 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.699 -0.762 . . . . 0.31 112.878 -175.158 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -83.43 139.69 32.81 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 109.323 -0.621 . . . . 0.57 109.323 176.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.427 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 73.31 38.13 53.73 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.057 -1.068 . . . . 0.25 111.751 -179.846 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.513 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -103.25 116.17 31.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.065 0.46 . . . . 0.25 111.056 -172.708 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.503 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -101.56 134.02 20.48 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-N 115.857 -0.61 . . . . 2.21 109.858 177.371 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -54.57 119.11 5.87 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.747 2.298 . . . . 0.6 111.947 176.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.405 HG13 ' HA ' ' A' ' 12' ' ' GLN . 27.4 mt -82.59 105.4 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 N-CA-C 108.662 -0.866 . . . . 1.13 108.662 177.451 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.9 t -119.7 19.4 12.53 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 121.778 0.799 . . . . 1.22 110.224 -177.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.4 p -107.25 133.09 52.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.358 -0.837 . . . . 1.92 110.081 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -86.88 78.82 8.96 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.376 0.608 . . . . 3.46 110.189 177.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -167.14 69.51 0.18 Allowed Glycine 0 N--CA 1.447 -0.633 0 N-CA-C 110.799 -0.92 . . . . 3.5 110.799 179.184 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 11.4 t -61.05 -18.72 59.35 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 122.643 0.377 . . . . 5.24 111.981 -172.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 2.2 p -52.8 -41.88 64.56 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.843 0.354 . . . . 4.31 110.838 176.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -152.51 70.44 0.9 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.503 0.668 . . . . 3.13 109.459 174.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -106.68 -1.69 22.48 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.495 -0.775 . . . . 1.6 110.539 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.4 t -140.36 140.3 35.54 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.672 -0.694 . . . . 1.02 110.513 -178.403 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 20.0 m -101.21 7.37 43.07 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.33 -0.396 . . . . 2.56 111.526 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.441 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -147.0 -83.96 0.12 Allowed 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.914 -0.315 . . . . 1.07 111.81 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 33.8 m -142.27 130.08 21.68 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-O 120.713 0.292 . . . . 1.05 110.99 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.97 129.25 34.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.465 -0.334 . . . . 1.07 110.267 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.646 HG23 ' SG ' ' A' ' 14' ' ' CYS . 4.0 m -140.6 169.9 15.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-O 121.248 0.546 . . . . 1.01 111.959 -176.574 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 29.1 t -132.98 103.66 6.16 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.191 -0.913 . . . . 0.39 110.061 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.747 ' SG ' ' HB2' ' A' ' 76' ' ' ALA . 1.4 m -91.11 138.79 31.33 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.647 0.737 . . . . 0.65 111.882 -178.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 47.9 t -92.8 -19.16 22.02 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 114.635 -1.166 . . . . 1.83 110.736 179.051 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -96.83 159.78 14.73 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.107 -0.497 . . . . 1.6 110.519 -175.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.2 t30 -117.68 -6.41 11.1 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.117 -0.492 . . . . 3.24 111.067 -173.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -81.04 83.25 6.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.249 0.547 . . . . 2.99 110.655 -177.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 30.0 m -101.81 139.57 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-N 116.0 -0.545 . . . . 1.68 110.885 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.566 ' OG ' HG12 ' A' ' 75' ' ' ILE . 99.9 p -80.38 -5.08 55.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.188 -0.46 . . . . 1.88 110.739 -178.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.3 -32.22 3.62 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.841 -0.618 . . . . 0.56 112.179 -177.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 m -135.44 -7.78 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 C-N-CA 120.559 -0.456 . . . . 1.18 111.945 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.566 HG12 ' OG ' ' A' ' 72' ' ' SER . 37.0 pt -97.39 179.78 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.522 0.677 . . . . 1.12 111.779 -178.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.747 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -149.85 140.4 22.49 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.255 -1.338 . . . . 1.11 109.094 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.0 mt -118.63 133.55 65.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.875 0.369 . . . . 1.1 111.333 -177.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 74.9 50.86 8.32 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.962 -0.637 . . . . 0.2 111.828 178.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.472 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.35 133.03 44.23 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.153 0.501 . . . . 0.65 111.89 -176.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.427 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 86.4 mt -108.23 132.1 21.31 Favored Pre-proline 0 C--N 1.318 -0.763 0 CA-C-N 115.728 -0.669 . . . . 1.1 109.811 172.733 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 21.7 Cg_exo -64.02 123.48 11.97 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.713 2.275 . . . . 0.25 111.889 -178.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 m -114.53 160.12 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 CA-C-O 121.265 0.555 . . . . 1.12 111.274 -178.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.8 m -142.29 137.0 30.31 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.252 -0.885 . . . . 2.18 109.494 176.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 96.5 mt . . . . . 0 C--O 1.245 0.862 0 O-C-N 123.725 0.641 . . . . 4.14 111.264 -179.25 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.535 0 N-CA-C 111.773 -0.531 . . . . 5.98 111.773 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.441 ' HB3' HG22 ' A' ' 50' ' ' ILE . 25.8 t -71.93 -36.65 70.01 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 110.313 -0.254 . . . . 4.6 110.313 178.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.4 ' HB2' ' O ' ' A' ' 2' ' ' SER . 69.4 m95 70.27 -70.84 0.14 Allowed 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.63 -0.714 . . . . 5.43 111.985 178.414 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 80.16 87.19 0.57 Allowed Glycine 0 N--CA 1.444 -0.781 0 C-N-CA 120.373 -0.918 . . . . 2.46 111.339 -173.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 17.1 mm100 -72.58 133.29 44.65 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.927 0.394 . . . . 4.59 110.439 -179.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.417 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 31.4 t -126.58 -87.88 0.58 Allowed 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.905 -0.589 . . . . 1.88 110.431 -178.013 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 48.8 m -159.22 -76.02 0.07 Allowed 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.677 -0.49 . . . . 2.6 109.677 176.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 28.4 p -120.73 -27.28 5.1 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.077 0.465 . . . . 4.25 110.649 177.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -92.21 179.58 40.83 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.67 -0.695 . . . . 1.12 112.486 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.1 t -98.14 151.63 20.2 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.778 -0.453 . . . . 1.43 109.778 -178.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.417 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 16.6 mt -103.07 130.94 52.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.641 0.734 . . . . 1.56 111.374 174.292 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.471 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -130.39 168.09 17.52 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 114.656 -1.156 . . . . 0.91 110.138 177.653 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.44 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 36.8 t -110.38 101.93 10.61 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.772 -0.649 . . . . 0.34 109.918 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.831 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 96.5 m -87.45 125.01 34.03 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.788 -0.642 . . . . 0.19 111.459 -175.683 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.477 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -69.13 -31.96 71.0 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.06 -0.973 . . . . 0.39 109.818 175.583 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -136.74 108.38 7.0 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.046 -0.525 . . . . 1.12 110.423 177.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 93.2 t -98.94 105.92 18.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 N-CA-C 109.746 -0.465 . . . . 1.04 109.746 177.121 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 m -131.12 142.88 47.14 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 116.012 -0.54 . . . . 1.03 110.763 -176.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.506 ' O ' ' HB3' ' A' ' 22' ' ' SER . 30.9 Cg_exo -61.19 136.91 67.67 Favored 'Trans proline' 0 N--CA 1.461 -0.396 0 C-N-CA 122.161 1.908 . . . . 0.21 111.434 173.2 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.62 -15.03 68.1 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.665 -0.779 . . . . 0.18 111.972 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -103.09 3.66 36.22 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.592 0.71 . . . . 2.27 109.657 176.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.506 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 21.3 t -74.99 155.78 36.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.186 -0.915 . . . . 0.41 110.031 177.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -53.68 -44.32 69.63 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.829 0.823 . . . . 1.06 109.142 176.54 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.578 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.2 mm? -67.36 -63.19 1.11 Allowed 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 114.25 -1.341 . . . . 1.77 111.002 177.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.496 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.38 -39.21 71.95 Favored Glycine 0 C--N 1.33 0.23 0 CA-C-N 116.217 -0.447 . . . . 0.16 113.392 -175.074 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 98.7 m -67.72 -38.74 84.0 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.87 0.366 . . . . 1.07 110.475 -178.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -75.44 -27.72 59.06 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 120.934 0.397 . . . . 1.57 110.132 178.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.578 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 13.1 mt -69.74 -48.67 58.53 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.185 -0.461 . . . . 1.13 110.182 178.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -76.95 -23.78 52.38 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.571 -0.452 . . . . 1.08 111.549 -175.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.489 ' N ' HD11 ' A' ' 29' ' ' LEU . 18.8 t70 -67.95 -32.81 73.5 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.525 0.678 . . . . 0.66 109.37 175.456 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -75.28 -19.78 59.51 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 114.91 -1.041 . . . . 2.07 109.762 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 80.7 mt -103.37 -6.94 21.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.907 -1.042 . . . . 1.35 111.696 -174.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.97 35.48 84.37 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.958 -0.564 . . . . 0.75 112.566 178.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.541 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 32.2 mt -88.96 138.53 19.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.523 0.201 . . . . 1.24 110.705 -177.683 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.1 p -99.14 110.59 26.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.444 0.64 . . . . 2.41 110.221 175.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.534 HD13 ' O ' ' A' ' 36' ' ' LEU . 1.4 pp -80.74 130.89 35.33 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.915 -0.584 . . . . 3.28 110.725 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -90.34 -29.1 18.3 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.739 -0.837 . . . . 2.65 108.739 173.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -142.23 98.41 6.1 Favored Pre-proline 0 N--CA 1.444 -0.772 0 N-CA-C 107.802 -1.184 . . . . 2.29 107.802 176.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.01 -9.54 21.98 Favored 'Trans proline' 0 N--CA 1.466 -0.143 0 C-N-CA 121.965 1.777 . . . . 0.77 111.588 -175.392 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 p -80.36 -8.9 59.7 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.623 -0.717 . . . . 1.2 111.497 -175.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.467 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.8 m -76.28 159.72 5.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.266 0.555 . . . . 1.08 111.065 -178.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.475 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.6 mt -92.53 128.03 38.24 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.498 -0.774 . . . . 1.06 109.556 176.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.1 pt -106.32 139.12 28.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 116.011 -0.54 . . . . 1.03 109.995 177.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.831 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -107.79 99.37 1.36 Allowed Glycine 0 N--CA 1.437 -1.281 0 C-N-CA 120.633 -0.794 . . . . 0.31 112.967 -175.76 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -78.2 137.12 37.98 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 108.691 -0.855 . . . . 0.57 108.691 173.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.477 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 70.79 39.08 66.01 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 119.914 -1.136 . . . . 0.25 112.252 -177.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.534 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -103.61 111.88 24.55 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.335 0.588 . . . . 0.25 110.831 -174.887 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -94.53 136.47 23.18 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 115.269 -0.878 . . . . 2.21 109.242 178.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -66.1 119.47 6.5 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 122.303 2.002 . . . . 0.6 110.745 176.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.441 HG22 ' HB3' ' A' ' 2' ' ' SER . 16.8 mt -77.23 88.25 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 121.62 0.724 . . . . 1.13 110.213 -176.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 13.4 t -134.27 8.09 3.68 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.244 -0.889 . . . . 1.22 110.156 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.5 p -98.77 160.13 3.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.304 -0.862 . . . . 1.92 109.201 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . 63.51 -172.15 0.17 Allowed 'General case' 0 C--O 1.233 0.211 0 O-C-N 123.665 0.603 . . . . 3.46 111.099 177.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.91 -1.55 6.85 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 121.032 -0.604 . . . . 3.5 111.663 176.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 42.1 m -97.25 149.16 22.36 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.783 0.325 . . . . 5.24 110.228 179.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 15.1 m -67.12 -26.83 66.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.041 -0.527 . . . . 4.31 110.7 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -83.27 57.68 4.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 122.043 0.925 . . . . 3.13 109.855 178.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -104.04 18.32 22.28 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.786 -1.097 . . . . 1.6 109.485 176.121 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.6 t -111.24 153.95 25.14 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.02 -0.991 . . . . 1.02 109.994 -177.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.7 m -126.14 18.34 7.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.44 -0.345 . . . . 2.56 111.071 -177.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -163.01 -77.69 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 112.015 0.376 . . . . 1.07 112.015 -178.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 74.8 m -147.61 131.33 16.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.806 0.336 . . . . 1.05 111.417 -176.425 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -88.13 125.72 34.74 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.039 -0.528 . . . . 1.07 109.93 177.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.576 HG21 ' SG ' ' A' ' 14' ' ' CYS . 6.8 m -138.89 159.96 30.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-N 115.964 -0.562 . . . . 1.01 110.949 -178.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 53.6 t -117.91 103.41 9.91 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.602 -0.726 . . . . 0.39 109.727 179.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.75 ' SG ' ' HB2' ' A' ' 76' ' ' ALA . 20.1 m -91.75 132.55 36.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.36 0.6 . . . . 0.65 111.402 -176.35 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 10.9 m -94.78 -15.78 23.53 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.314 -0.857 . . . . 1.83 111.29 -177.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.418 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 9.7 t70 -109.98 131.94 54.61 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.623 -0.51 . . . . 1.6 109.623 -178.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -108.12 20.95 18.05 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.489 0.551 . . . . 3.24 112.489 -172.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 50.8 m-80 -83.38 61.91 6.44 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.5 0.667 . . . . 2.99 110.123 177.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 m -73.66 149.01 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 CA-C-N 115.541 -0.754 . . . . 1.68 111.181 -178.481 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.595 ' OG ' HG12 ' A' ' 75' ' ' ILE . 82.0 p -95.4 -5.93 42.09 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.887 -0.597 . . . . 1.88 110.34 179.035 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.12 -31.84 3.57 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.675 -0.693 . . . . 0.56 112.409 -176.022 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.0 m -136.59 -8.22 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 117.185 0.493 . . . . 1.18 111.961 177.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.595 HG12 ' OG ' ' A' ' 72' ' ' SER . 21.7 pt -94.63 179.7 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.642 0.734 . . . . 1.12 111.979 -178.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.75 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -150.22 145.33 26.17 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.007 -1.452 . . . . 1.11 108.502 176.179 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.418 ' HB ' ' HB3' ' A' ' 68' ' ' ASP . 58.9 mt -125.75 142.19 43.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 120.717 -0.393 . . . . 1.1 111.402 -175.321 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.467 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 69.34 50.55 31.96 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.115 -0.564 . . . . 0.2 111.898 178.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.53 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 9.0 m -103.86 131.55 50.96 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.158 0.504 . . . . 0.65 111.8 -173.292 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.427 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.8 mt -105.9 134.68 19.62 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.735 -0.666 . . . . 1.1 109.859 173.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 17.1 Cg_exo -66.09 122.58 10.14 Favored 'Trans proline' 0 N--CA 1.465 -0.204 0 C-N-CA 122.75 2.3 . . . . 0.25 111.789 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.1 m -111.55 153.06 13.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.445 0.641 . . . . 1.12 111.35 -177.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 49.3 m -157.52 128.36 6.57 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.927 -1.033 . . . . 2.18 109.914 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 11.0 mp . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.396 -0.811 . . . . 4.14 112.281 178.763 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.877 0 N-CA-C 112.276 -0.33 . . . . 5.98 112.276 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.9 m -79.82 -68.54 0.66 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.744 0.272 . . . . 4.6 110.757 -178.368 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -135.48 16.04 3.41 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-O 121.069 0.461 . . . . 5.43 110.396 -179.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.49 ' HA3' ' HB ' ' A' ' 11' ' ' ILE . . . 89.31 110.19 1.23 Allowed Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 115.631 -0.713 . . . . 2.46 112.44 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 13.4 mm-40 -76.13 109.52 9.87 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.642 -0.503 . . . . 4.59 109.642 177.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 14.1 t -131.78 -70.95 0.56 Allowed 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.42 -0.355 . . . . 1.88 111.077 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.7 p -168.05 -81.73 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.892 0.377 . . . . 2.6 110.568 -177.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.8 m -120.5 -31.05 4.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.935 0.398 . . . . 4.25 110.91 178.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -88.78 -132.05 4.17 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.955 -0.64 . . . . 1.12 113.232 -176.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.4 t -145.36 152.63 40.18 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.14 -0.689 . . . . 1.43 109.14 -175.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.49 ' HB ' ' HA3' ' A' ' 4' ' ' GLY . 40.6 mt -100.72 135.02 38.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.711 0.767 . . . . 1.56 111.122 176.436 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.592 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -132.28 165.61 23.78 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.702 -1.136 . . . . 0.91 109.82 177.058 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.5 t -112.29 101.39 9.61 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.891 -0.595 . . . . 0.34 109.409 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.794 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 68.5 m -84.32 130.22 34.82 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 115.326 -0.852 . . . . 0.19 110.988 -176.374 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.48 -30.63 68.56 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.26 -0.882 . . . . 0.39 109.053 172.849 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -141.16 121.02 13.54 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.972 -0.558 . . . . 1.12 110.538 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.6 t -109.06 107.78 23.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 109.969 -0.382 . . . . 1.04 109.969 176.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 20.8 m -133.39 145.97 58.77 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.153 -0.476 . . . . 1.03 110.777 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.443 ' O ' ' HB3' ' A' ' 22' ' ' SER . 22.5 Cg_exo -63.42 137.37 59.84 Favored 'Trans proline' 0 N--CA 1.463 -0.309 0 C-N-CA 121.936 1.757 . . . . 0.21 110.934 171.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.45 -26.94 71.1 Favored Glycine 0 C--O 1.228 -0.232 0 C-N-CA 121.018 -0.611 . . . . 0.18 112.501 -177.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -98.18 9.15 43.62 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.099 0.476 . . . . 2.27 110.249 177.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.443 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 30.7 t -78.53 155.82 29.56 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 115.786 -0.643 . . . . 0.41 109.816 176.088 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -54.31 -41.68 69.25 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.001 0.429 . . . . 1.06 109.922 178.155 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.689 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.1 mm? -69.37 -60.27 2.45 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.648 -0.706 . . . . 1.77 110.94 177.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.93 -39.58 69.14 Favored Glycine 0 C--N 1.328 0.126 0 CA-C-N 116.203 -0.453 . . . . 0.16 113.216 -176.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.6 m -70.36 -41.48 73.09 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.974 0.416 . . . . 1.07 110.388 -177.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.1 tm? -63.75 -40.42 96.67 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.308 -0.627 . . . . 1.57 109.308 177.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.689 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.5 mt -68.05 -43.75 77.96 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.533 -0.758 . . . . 1.13 110.857 -175.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.506 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -76.54 -24.34 53.64 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.944 -0.302 . . . . 1.08 111.051 -178.005 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.482 ' N ' HD11 ' A' ' 29' ' ' LEU . 24.6 t70 -67.38 -31.28 71.4 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.406 0.622 . . . . 0.66 109.647 175.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -74.51 -38.7 62.75 Favored 'General case' 0 N--CA 1.443 -0.796 0 CA-C-N 115.037 -0.983 . . . . 2.07 109.513 177.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.7 mt -79.08 -20.17 49.44 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.522 -1.217 . . . . 1.35 111.921 -177.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.08 48.18 6.17 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.177 -0.535 . . . . 0.75 112.164 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.506 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 16.3 mt -110.92 142.83 22.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 110.449 -0.204 . . . . 1.24 110.449 -178.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.5 p -126.54 103.47 11.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.596 0.712 . . . . 2.41 110.16 174.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.2 mt -87.6 137.25 32.5 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.825 -0.625 . . . . 3.28 110.824 -178.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -68.67 -36.78 78.98 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.661 -0.7 . . . . 2.65 109.442 175.072 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -132.88 88.86 36.21 Favored Pre-proline 0 N--CA 1.444 -0.764 0 N-CA-C 108.849 -0.797 . . . . 2.29 108.849 175.527 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -72.23 3.38 4.1 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.361 2.041 . . . . 0.77 111.56 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.2 p -75.77 -8.31 56.55 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.62 -0.718 . . . . 1.2 111.063 -178.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.1 m -82.41 162.76 3.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 116.055 -0.52 . . . . 1.08 110.561 176.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 94.8 mt -83.69 126.17 32.61 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.048 -0.524 . . . . 1.06 110.328 177.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 24.1 pt -107.6 140.77 24.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.244 0.545 . . . . 1.03 110.226 175.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.794 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -111.99 105.21 1.75 Allowed Glycine 0 N--CA 1.44 -1.094 0 C-N-CA 120.57 -0.824 . . . . 0.31 112.87 -177.11 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -83.06 132.39 35.12 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.057 -0.72 . . . . 0.57 109.057 176.009 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.93 38.01 24.24 Favored Glycine 0 N--CA 1.443 -0.86 0 C-N-CA 119.89 -1.148 . . . . 0.25 111.709 -178.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.52 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.93 111.76 24.54 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.043 0.449 . . . . 0.25 111.22 -174.017 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -100.61 134.67 20.45 Favored Pre-proline 0 C--N 1.315 -0.925 0 CA-C-N 115.647 -0.706 . . . . 2.21 109.269 174.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -59.96 130.8 36.23 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.908 2.405 . . . . 0.6 111.609 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.416 HG13 ' HA ' ' A' ' 12' ' ' GLN . 21.1 mt -83.78 88.94 2.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.68 0.753 . . . . 1.13 109.475 -179.468 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 8.8 t -114.46 28.42 8.75 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.789 -1.096 . . . . 1.22 109.3 -178.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 14.6 p -107.22 143.8 17.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.511 -1.222 . . . . 1.92 109.827 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -87.24 -25.01 24.2 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.445 -0.343 . . . . 3.46 111.6 -177.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -74.4 109.91 2.93 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.975 -0.631 . . . . 3.5 112.015 178.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 19.4 m -70.49 -17.9 62.97 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.862 0.363 . . . . 5.24 111.517 -176.4 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 22.9 t -70.79 -28.11 64.41 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.338 -0.392 . . . . 4.31 110.872 -178.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -124.8 27.88 6.67 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.933 0.397 . . . . 3.13 110.715 -178.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -67.63 -30.04 69.51 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.252 0.549 . . . . 1.6 111.495 -177.102 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.7 t -154.16 146.17 23.61 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.887 -0.597 . . . . 1.02 110.858 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 27.3 p -117.06 5.38 12.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.179 -0.464 . . . . 2.56 111.509 -179.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -146.8 -80.99 0.14 Allowed 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 120.966 -0.293 . . . . 1.07 111.776 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 28.4 m -142.05 126.88 18.16 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.815 0.341 . . . . 1.05 111.234 -178.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.411 ' HB2' ' O ' ' A' ' 82' ' ' VAL . . . -86.67 128.98 35.04 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.926 0.393 . . . . 1.07 110.254 179.319 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.655 HG21 ' SG ' ' A' ' 14' ' ' CYS . 4.6 m -142.4 165.96 16.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.138 -0.483 . . . . 1.01 111.208 -177.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . 0.548 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 40.6 t -127.72 109.27 11.49 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.819 -0.628 . . . . 0.39 110.259 -178.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.744 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.6 m -97.46 140.49 31.83 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.397 0.618 . . . . 0.65 111.808 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 65.2 m -99.85 -12.73 19.62 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.14 -0.936 . . . . 1.83 111.501 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -110.33 149.99 29.4 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.02 -0.363 . . . . 1.6 110.02 -178.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 42.8 m-80 -120.35 12.42 11.69 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.639 0.607 . . . . 3.24 112.639 -173.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -81.62 71.84 8.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.773 0.796 . . . . 2.99 109.37 177.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 34.3 m -94.35 152.18 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 CA-C-N 115.457 -0.792 . . . . 1.68 111.172 -175.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.512 ' OG ' HG12 ' A' ' 75' ' ' ILE . 90.4 p -86.97 -8.68 56.98 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.657 -0.701 . . . . 1.88 110.309 178.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.92 -32.02 3.74 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 115.285 -0.87 . . . . 0.56 111.954 -176.471 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.9 m -132.84 -2.58 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 C-N-CA 120.517 -0.473 . . . . 1.18 112.007 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.512 HG12 ' OG ' ' A' ' 72' ' ' SER . 23.5 pt -100.73 178.77 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.495 0.664 . . . . 1.12 111.924 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.744 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -148.26 139.71 23.54 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.575 -1.193 . . . . 1.11 109.393 177.061 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 68.9 mt -121.73 130.19 74.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.938 0.399 . . . . 1.1 111.301 -176.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 82.0 46.43 6.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.995 -0.621 . . . . 0.2 111.777 178.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -99.38 144.25 28.71 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.288 0.566 . . . . 0.65 112.387 -175.153 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 87.7 mt -119.81 134.11 23.91 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.246 -0.888 . . . . 1.1 109.743 172.092 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 21.6 Cg_exo -64.67 121.47 9.03 Favored 'Trans proline' 0 C--O 1.234 0.298 0 C-N-CA 123.034 2.489 . . . . 0.25 112.348 -179.347 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.411 ' O ' ' HB2' ' A' ' 63' ' ' ALA . 5.8 m -123.03 150.59 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 CA-C-N 116.039 -0.528 . . . . 1.12 110.629 -179.724 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 3.0 t -161.11 159.58 29.27 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.864 -0.607 . . . . 2.18 109.785 177.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 11.1 mp . . . . . 0 C--O 1.247 0.96 0 CA-C-O 118.1 -0.953 . . . . 4.14 111.579 -179.281 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.819 0 N-CA-C 112.149 -0.38 . . . . 5.98 112.149 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 34.3 t -133.91 105.74 6.91 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.692 -0.485 . . . . 4.6 109.692 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.574 ' HB2' ' HA ' ' A' ' 51' ' ' THR . 69.2 t-105 -79.64 83.0 5.67 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.378 -0.601 . . . . 5.43 109.378 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 129.72 128.5 3.03 Favored Glycine 0 N--CA 1.442 -0.911 0 N-CA-C 110.924 -0.87 . . . . 2.46 110.924 -175.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -78.81 119.24 21.73 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.964 0.412 . . . . 4.59 110.607 -177.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.435 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 34.5 t -79.3 -67.63 0.74 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.801 -0.636 . . . . 1.88 110.129 178.067 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.7 p -176.02 -76.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.924 -0.58 . . . . 2.6 110.229 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.4 m -118.57 -28.32 5.7 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.934 0.397 . . . . 4.25 111.165 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -103.08 -145.78 15.99 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.581 -0.819 . . . . 1.12 113.376 -176.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.1 t -128.05 153.43 46.79 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 109.014 -0.736 . . . . 1.43 109.014 -177.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.435 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 51.5 mt -99.9 134.75 38.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.606 0.717 . . . . 1.56 111.344 178.079 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.616 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -142.95 162.22 36.05 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.063 -0.971 . . . . 0.91 111.043 178.996 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.53 ' HB3' ' OD2' ' A' ' 48' ' ' ASP . 19.4 t -106.68 102.26 11.65 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.46 -0.791 . . . . 0.34 109.483 178.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.882 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 57.6 m -86.75 133.54 33.65 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.934 -0.575 . . . . 0.19 111.017 -175.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.12 -30.42 49.41 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.185 -0.916 . . . . 0.39 109.435 177.016 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.589 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 17.1 m-20 -134.28 103.21 5.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.438 -0.346 . . . . 1.12 111.306 175.172 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.1 t -92.52 101.68 12.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.214 0.53 . . . . 1.04 109.727 174.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 m -131.71 140.38 38.11 Favored Pre-proline 0 C--N 1.319 -0.717 0 CA-C-N 115.748 -0.66 . . . . 1.03 110.75 -174.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.512 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.7 Cg_exo -57.94 138.75 87.56 Favored 'Trans proline' 0 N--CA 1.463 -0.302 0 C-N-CA 122.195 1.93 . . . . 0.21 111.304 172.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.29 -21.99 68.84 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.939 -0.648 . . . . 0.18 112.596 -178.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -101.2 4.94 42.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.239 0.542 . . . . 2.27 109.837 176.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.512 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 16.6 t -69.32 153.95 42.81 Favored 'General case' 0 CA--C 1.514 -0.438 0 CA-C-N 115.778 -0.646 . . . . 0.41 109.68 175.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -56.63 -38.42 72.09 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-O 121.122 0.487 . . . . 1.06 110.035 178.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.672 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 5.3 mt -70.19 -63.45 1.08 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.58 -0.737 . . . . 1.77 110.853 174.06 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.54 -40.87 55.52 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 116.035 -0.53 . . . . 0.16 113.443 -174.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 93.4 m -68.16 -44.53 75.77 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.761 0.315 . . . . 1.07 110.484 -178.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.4 tt -63.43 -35.52 80.71 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.075 -0.511 . . . . 1.57 110.814 178.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.672 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.3 mt -72.49 -46.09 56.41 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.096 -0.502 . . . . 1.13 110.365 -177.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.568 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -75.03 -21.76 58.85 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.71 -0.396 . . . . 1.08 110.934 -178.133 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -66.24 -32.22 73.51 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.708 0.766 . . . . 0.66 109.712 173.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -77.37 -47.7 19.19 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 114.906 -1.043 . . . . 2.07 109.261 177.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 72.4 mt -78.22 -13.11 59.99 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.705 -1.134 . . . . 1.35 112.893 -174.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.49 37.57 90.04 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-N 116.131 -0.486 . . . . 0.75 112.473 178.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.568 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 55.8 mt -75.46 137.35 23.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.104 0.478 . . . . 1.24 111.718 -173.265 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.4 p -88.11 113.55 25.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.687 -0.688 . . . . 2.41 110.762 175.471 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.2 pp -103.0 134.6 46.17 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.03 -0.532 . . . . 3.28 110.796 177.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -90.06 -32.28 16.79 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.021 -1.104 . . . . 2.65 108.021 171.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -139.93 106.76 6.86 Favored Pre-proline 0 N--CA 1.446 -0.631 0 CA-C-N 114.588 -1.187 . . . . 2.29 108.227 174.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -71.9 -2.24 11.19 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.072 1.848 . . . . 0.77 111.327 -178.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.6 p -94.94 20.2 9.23 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.479 -0.782 . . . . 1.2 111.157 -175.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.2 m -105.77 160.83 5.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.81 -0.632 . . . . 1.08 110.226 178.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 95.6 mt -81.29 119.81 24.12 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.034 -0.53 . . . . 1.06 110.244 175.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 19.4 pt -104.06 137.11 34.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.871 -0.604 . . . . 1.03 109.684 175.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.882 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.91 106.75 1.78 Allowed Glycine 0 N--CA 1.438 -1.176 0 C-N-CA 120.538 -0.839 . . . . 0.31 113.05 -174.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.589 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 26.0 t70 -77.48 145.18 37.2 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 108.887 -0.783 . . . . 0.57 108.887 174.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 69.71 37.3 76.45 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 119.884 -1.15 . . . . 0.25 112.221 177.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -101.35 114.4 28.36 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.387 0.613 . . . . 0.25 111.215 -172.712 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.53 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 0.7 OUTLIER -101.54 130.98 23.56 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 115.4 -0.818 . . . . 2.21 109.702 177.438 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -56.48 120.39 8.24 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 C-N-CA 122.436 2.091 . . . . 0.6 111.102 177.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.411 HG13 ' HA ' ' A' ' 12' ' ' GLN . 43.7 mt -80.18 101.66 5.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.158 0.504 . . . . 1.13 110.587 -174.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.574 ' HA ' ' HB2' ' A' ' 3' ' ' TRP . 4.4 t -139.3 18.37 2.58 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 122.159 0.981 . . . . 1.22 109.989 177.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 12.2 p -91.55 142.97 12.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.042 -0.981 . . . . 1.92 109.655 175.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -107.42 120.06 41.13 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.882 0.372 . . . . 3.46 110.776 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -163.45 -154.09 7.56 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 111.662 -0.575 . . . . 3.5 111.662 179.159 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -94.34 -58.82 2.1 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.567 -0.531 . . . . 5.24 109.567 178.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.2 t -130.24 22.3 5.23 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.814 -0.81 . . . . 4.31 108.814 174.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -73.41 -15.95 61.34 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.81 -1.086 . . . . 3.13 111.037 -177.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -61.07 -31.22 70.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.804 -0.635 . . . . 1.6 112.467 -173.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 40.1 t -165.12 146.83 7.73 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-O 120.94 0.4 . . . . 1.02 111.261 -177.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 8.9 t -119.11 -13.63 9.37 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.974 -0.557 . . . . 2.56 110.782 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.12 -83.59 0.57 Allowed 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 121.121 -0.232 . . . . 1.07 110.86 -179.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 54.4 m -150.39 127.45 11.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.699 0.285 . . . . 1.05 110.551 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.44 140.58 29.85 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.03 0.443 . . . . 1.07 110.483 -178.049 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.65 HG21 ' SG ' ' A' ' 14' ' ' CYS . 2.7 m -147.78 170.38 3.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.229 0.538 . . . . 1.01 111.404 -176.651 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . 0.542 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 50.3 t -129.6 107.97 9.86 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.319 -0.855 . . . . 0.39 109.788 178.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.721 ' SG ' ' HB3' ' A' ' 76' ' ' ALA . 1.5 m -99.58 138.89 36.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.286 0.565 . . . . 0.65 111.82 -177.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 50.4 m -99.69 -19.1 16.95 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.492 -0.776 . . . . 1.83 111.731 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.408 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 16.4 t70 -101.54 148.95 24.6 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.925 -0.398 . . . . 1.6 109.925 -177.051 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -120.18 18.51 12.31 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.581 0.586 . . . . 3.24 112.581 -173.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.9 m-80 -79.24 63.9 4.0 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.544 0.688 . . . . 2.99 109.967 176.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.607 HG11 ' H ' ' A' ' 73' ' ' GLY . 87.2 t -90.37 136.19 24.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.414 -0.812 . . . . 1.68 111.23 -173.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.566 ' H ' HG12 ' A' ' 75' ' ' ILE . 87.3 p -79.2 -3.01 43.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.345 -0.843 . . . . 1.88 110.939 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.607 ' H ' HG11 ' A' ' 71' ' ' VAL . . . 127.85 -31.56 3.69 Favored Glycine 0 N--CA 1.443 -0.868 0 CA-C-N 115.367 -0.833 . . . . 0.56 112.195 -176.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 17.2 m -138.68 -7.62 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 112.641 0.608 . . . . 1.18 112.641 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.566 HG12 ' H ' ' A' ' 72' ' ' SER . 7.2 pt -84.97 -178.54 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.581 0.705 . . . . 1.12 112.142 -178.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.721 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -149.43 139.2 21.83 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.639 -1.164 . . . . 1.11 109.51 175.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.408 ' HB ' ' HB3' ' A' ' 68' ' ' ASP . 65.3 mt -124.49 134.99 65.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.931 0.396 . . . . 1.1 111.364 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.501 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 79.21 47.98 7.17 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 121.002 -0.618 . . . . 0.2 111.785 179.377 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.542 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -100.14 136.73 39.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.24 0.543 . . . . 0.65 112.456 -175.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 93.7 mt -108.1 134.08 20.28 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 115.474 -0.784 . . . . 1.1 109.345 168.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.408 ' HA ' HG13 ' A' ' 64' ' ' VAL . 20.5 Cg_exo -64.3 128.35 21.29 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.937 2.424 . . . . 0.25 112.474 -178.45 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.0 m -133.05 160.51 42.56 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.911 0 CA-C-N 115.878 -0.601 . . . . 1.12 109.658 177.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.415 HG21 ' HG ' ' A' ' 84' ' ' LEU . 50.6 m -144.58 149.37 35.69 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 110.25 -0.278 . . . . 2.18 110.25 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.415 ' HG ' HG21 ' A' ' 83' ' ' THR . 86.3 mt . . . . . 0 C--O 1.246 0.899 0 CA-C-O 117.953 -1.022 . . . . 4.14 110.897 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.846 0 N-CA-C 111.76 -0.536 . . . . 5.98 111.76 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 39.4 m 59.2 79.44 0.22 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.338 0.59 . . . . 4.6 110.057 -176.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.406 ' HA ' ' HA ' ' A' ' 51' ' ' THR . 34.4 p90 -111.6 179.83 3.91 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.5 -0.773 . . . . 5.43 111.062 -175.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -63.52 106.09 1.26 Allowed Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 121.07 -0.586 . . . . 2.46 112.404 179.132 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -82.38 110.44 17.53 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.997 0.427 . . . . 4.59 110.206 178.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.467 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 52.2 t -94.89 -64.65 1.04 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.886 -0.597 . . . . 1.88 110.896 -176.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 7.5 t -172.04 -69.98 0.02 OUTLIER 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 116.215 -0.448 . . . . 2.6 110.145 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 12.1 m -121.42 -30.93 4.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.241 0.543 . . . . 4.25 111.013 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -90.45 -136.85 6.69 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.818 -0.705 . . . . 1.12 112.138 -178.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 28.6 t -145.92 144.27 30.07 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.87 -0.418 . . . . 1.43 109.87 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.467 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 38.6 mt -91.65 133.35 33.49 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.559 0 CA-C-O 121.737 0.78 . . . . 1.56 110.547 177.77 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.485 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -142.92 162.29 35.85 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 114.585 -1.189 . . . . 0.91 110.569 -175.006 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.455 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 26.6 t -111.44 101.69 10.12 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.846 -0.615 . . . . 0.34 109.847 -176.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.776 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 86.7 m -87.31 134.45 33.56 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.232 -0.895 . . . . 0.19 110.89 -175.561 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.424 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -76.1 -27.68 57.23 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 115.37 -0.832 . . . . 0.39 109.665 178.404 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -143.78 103.94 4.12 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.769 -0.651 . . . . 1.12 110.473 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 67.4 t -93.57 108.14 20.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 CA-C-N 116.062 -0.517 . . . . 1.04 109.688 178.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.05 146.12 60.3 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 116.032 -0.531 . . . . 1.03 110.757 -175.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.495 ' O ' ' HB3' ' A' ' 22' ' ' SER . 22.6 Cg_exo -62.79 136.94 60.35 Favored 'Trans proline' 0 N--CA 1.461 -0.401 0 C-N-CA 122.12 1.88 . . . . 0.21 111.181 173.05 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.93 -23.03 72.58 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.946 -0.645 . . . . 0.18 112.64 -176.472 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -101.07 9.92 41.58 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.724 0.774 . . . . 2.27 109.813 177.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.6 t -78.77 156.36 28.87 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.52 -0.764 . . . . 0.41 109.921 175.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -53.9 -40.94 67.07 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.201 0.524 . . . . 1.06 109.773 176.029 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.662 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER -67.88 -63.1 1.13 Allowed 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 115.462 -0.79 . . . . 1.77 111.046 176.796 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.409 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -57.01 -38.74 87.27 Favored Glycine 0 C--N 1.33 0.24 0 CA-C-N 115.999 -0.546 . . . . 0.16 113.304 -175.031 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.0 m -69.22 -40.64 77.85 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.646 0.26 . . . . 1.07 110.462 -178.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.401 HD12 ' O ' ' A' ' 27' ' ' LEU . 2.8 tm? -62.99 -38.62 91.9 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.41 -0.589 . . . . 1.57 109.41 176.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.662 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.3 mt -67.82 -53.5 26.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.809 -0.632 . . . . 1.13 110.84 -177.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.516 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -70.87 -20.82 62.48 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.992 -0.283 . . . . 1.08 111.363 -176.584 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.419 ' N ' HD12 ' A' ' 29' ' ' LEU . 24.1 t70 -62.87 -38.95 92.9 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.602 0.715 . . . . 0.66 110.039 173.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -73.36 -16.97 61.33 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 114.816 -1.084 . . . . 2.07 109.615 -179.217 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.8 mt -105.86 -13.9 15.38 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.808 -1.087 . . . . 1.35 111.917 -174.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 71.82 42.71 52.65 Favored Glycine 0 C--N 1.331 0.302 0 CA-C-N 115.722 -0.672 . . . . 0.75 112.868 178.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.516 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 32.7 mt -101.2 124.92 55.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.689 0.28 . . . . 1.24 111.066 -176.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.6 p -110.43 102.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.814 0.816 . . . . 2.41 110.36 176.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.1 mt -85.95 141.9 29.2 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.556 -0.747 . . . . 3.28 111.094 -178.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -74.65 -23.58 58.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.552 0.692 . . . . 2.65 109.701 175.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.401 ' C ' ' H ' ' A' ' 40' ' ' THR . 8.2 m-20 -136.37 91.52 16.39 Favored Pre-proline 0 N--CA 1.447 -0.616 0 N-CA-C 108.22 -1.03 . . . . 2.29 108.22 172.512 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -66.18 -2.87 7.62 Favored 'Trans proline' 0 C--O 1.224 -0.22 0 C-N-CA 122.367 2.045 . . . . 0.77 111.808 -177.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.401 ' H ' ' C ' ' A' ' 38' ' ' ASP . 25.2 p -78.59 -12.67 60.03 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.577 -0.738 . . . . 1.2 111.322 -177.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 33.3 m -70.55 156.63 7.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.152 0.501 . . . . 1.08 111.295 -178.465 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 95.4 mt -86.38 129.09 34.97 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.778 -0.646 . . . . 1.06 110.333 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 23.7 pt -112.23 144.33 20.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.991 -0.55 . . . . 1.03 110.115 176.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.776 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.61 106.67 1.42 Allowed Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.48 -0.866 . . . . 0.31 113.102 -176.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -78.33 140.55 38.78 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.252 -0.647 . . . . 0.57 109.252 175.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 73.59 39.42 49.43 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.141 -1.028 . . . . 0.25 111.999 179.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.75 115.89 31.09 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.275 0.559 . . . . 0.25 111.346 -172.774 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.451 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.8 t70 -102.33 136.67 19.36 Favored Pre-proline 0 C--N 1.318 -0.78 0 CA-C-N 115.427 -0.806 . . . . 2.21 110.383 173.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 16.5 Cg_exo -60.79 119.61 6.87 Favored 'Trans proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.176 2.584 . . . . 0.6 111.03 178.393 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.431 HG13 ' HA ' ' A' ' 12' ' ' GLN . 43.0 mt -74.66 89.59 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.297 0.57 . . . . 1.13 110.224 -175.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 3' ' ' TRP . 14.2 t -125.63 8.91 7.66 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 115.234 -0.894 . . . . 1.22 109.862 179.699 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 12.1 p -84.18 149.0 4.56 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.137 -0.938 . . . . 1.92 109.975 178.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -87.18 69.91 10.11 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.014 0.435 . . . . 3.46 110.697 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -101.28 -6.85 50.54 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.823 -0.703 . . . . 3.5 112.287 -178.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 26.7 t 66.08 -84.51 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.051 0.54 . . . . 5.24 110.804 179.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 15.9 m -112.62 -7.91 13.84 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.126 0.489 . . . . 4.31 110.196 178.447 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -119.88 68.52 0.83 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.652 -0.704 . . . . 3.13 109.372 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -117.84 8.83 12.74 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.723 -0.671 . . . . 1.6 111.444 -176.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.7 t -139.08 146.61 40.95 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.197 -0.456 . . . . 1.02 109.942 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.5 t -117.31 15.06 14.84 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.737 -0.211 . . . . 2.56 111.532 -176.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.424 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -157.05 -78.0 0.08 Allowed 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.87 -0.332 . . . . 1.07 111.581 178.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 21.6 m -148.59 129.43 14.27 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.774 0.321 . . . . 1.05 110.77 -179.075 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.456 ' HB2' ' O ' ' A' ' 82' ' ' VAL . . . -90.41 135.88 33.4 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.864 -0.421 . . . . 1.07 109.864 -179.424 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.536 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 6.7 m -143.87 158.55 16.17 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-O 121.277 0.561 . . . . 1.01 111.156 -177.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 15.0 t -109.35 104.51 13.64 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.338 -0.846 . . . . 0.39 109.476 175.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.773 ' SG ' ' HB3' ' A' ' 76' ' ' ALA . 61.3 m -91.16 120.96 32.53 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.169 0.509 . . . . 0.65 111.108 -178.035 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 17.6 t -78.22 -21.53 49.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.28 -0.873 . . . . 1.83 110.295 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.7 t0 -105.81 149.09 26.8 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.224 -0.658 . . . . 1.6 109.224 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.504 ' C ' HD21 ' A' ' 69' ' ' ASN . 0.3 OUTLIER -118.84 5.64 11.47 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 112.559 0.577 . . . . 3.24 112.559 -175.092 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.432 ' ND2' HD11 ' A' ' 77' ' ' ILE . 1.3 p30 -82.39 112.18 19.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.921 0.867 . . . . 2.99 109.563 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.607 HG12 ' H ' ' A' ' 73' ' ' GLY . 70.8 t -122.12 137.28 56.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.364 -0.835 . . . . 1.68 110.858 -172.485 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.502 ' OG ' HG12 ' A' ' 75' ' ' ILE . 95.0 p -76.88 -1.41 28.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.654 -0.703 . . . . 1.88 110.94 -178.185 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.607 ' H ' HG12 ' A' ' 71' ' ' VAL . . . 127.88 -31.82 3.62 Favored Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 115.43 -0.804 . . . . 0.56 112.372 -176.521 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.2 m -138.77 -5.92 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.203 0 N-CA-C 112.849 0.685 . . . . 1.18 112.849 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.502 HG12 ' OG ' ' A' ' 72' ' ' SER . 5.1 pt -92.82 -177.1 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 113.359 0.874 . . . . 1.12 113.359 -174.236 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.773 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -150.68 142.59 23.87 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 114.117 -1.401 . . . . 1.11 108.602 174.669 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.432 HD11 ' ND2' ' A' ' 70' ' ' ASN . 66.5 mt -126.67 139.94 50.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.275 0.472 . . . . 1.1 112.275 -175.617 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 68.58 51.82 28.96 Favored Glycine 0 C--N 1.335 0.48 0 CA-C-N 115.736 -0.666 . . . . 0.2 111.682 177.411 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.536 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 8.3 m -109.0 138.94 44.55 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.049 0.452 . . . . 0.65 111.84 -172.369 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.422 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.8 mt -109.15 132.45 21.22 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.801 -0.636 . . . . 1.1 110.057 173.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.454 ' HA ' HG11 ' A' ' 64' ' ' VAL . 24.5 Cg_exo -63.23 123.06 11.51 Favored 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.194 2.596 . . . . 0.25 113.308 -177.18 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.456 ' O ' ' HB2' ' A' ' 63' ' ' ALA . 9.2 m -128.35 159.48 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 CA-C-N 116.018 -0.537 . . . . 1.12 110.063 177.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.475 HG22 ' HG ' ' A' ' 84' ' ' LEU . 5.5 t -154.65 174.86 14.41 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 110.226 -0.287 . . . . 2.18 110.226 177.514 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.475 ' HG ' HG22 ' A' ' 83' ' ' THR . 82.0 mt . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.307 -0.854 . . . . 4.14 111.005 178.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.699 0 N-CA-C 112.175 -0.37 . . . . 5.98 112.175 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 30.7 t -131.27 160.25 35.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.002 -0.369 . . . . 4.6 110.002 -178.323 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 88.6 m95 -109.57 25.32 11.93 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.973 -0.558 . . . . 5.43 109.709 177.154 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.92 16.0 29.54 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.709 -0.678 . . . . 2.46 111.711 -176.173 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 76.3 mt-30 -76.43 124.64 27.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.556 -0.322 . . . . 4.59 111.088 -176.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.472 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 34.8 t -164.32 142.69 7.11 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.031 -0.531 . . . . 1.88 109.909 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 34.2 m -72.68 -14.57 61.61 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 2.6 111.681 -176.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.823 ' HB ' ' SG ' ' A' ' 65' ' ' CYS . 19.1 m -91.07 -28.21 18.1 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.226 0.536 . . . . 4.25 110.041 176.287 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 159.81 -117.04 0.75 Allowed Glycine 0 N--CA 1.446 -0.657 0 CA-C-N 115.806 -0.634 . . . . 1.12 112.131 -179.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 32.3 t -105.0 152.08 23.15 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.704 -0.48 . . . . 1.43 109.704 -178.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.472 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 21.0 mt -105.31 133.72 48.79 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.453 0 CA-C-O 121.651 0.739 . . . . 1.56 111.231 177.296 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.613 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -141.47 161.68 37.33 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 114.854 -1.066 . . . . 0.91 110.684 178.885 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.418 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 24.8 t -110.98 103.31 11.77 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.415 -0.812 . . . . 0.34 109.107 178.311 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.782 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 81.8 m -85.75 138.81 31.83 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.461 -0.79 . . . . 0.19 110.678 -175.531 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.405 ' HB3' ' HA3' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -73.98 -35.15 64.45 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.711 -0.848 . . . . 0.39 108.711 175.374 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.775 ' ND2' ' HB3' ' A' ' 45' ' ' ASP . 0.1 OUTLIER -130.02 150.35 51.33 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 109.532 -0.544 . . . . 1.12 109.532 170.909 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.6 t -130.6 101.79 6.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 109.139 -0.689 . . . . 1.04 109.139 173.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.499 HG23 ' OD1' ' A' ' 16' ' ' ASN . 8.8 m -130.8 143.51 49.66 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.981 -0.554 . . . . 1.03 111.513 -173.073 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.421 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.4 Cg_exo -59.2 140.13 93.4 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.499 2.133 . . . . 0.21 111.853 172.8 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.85 -20.96 67.06 Favored Glycine 0 N--CA 1.453 -0.199 0 C-N-CA 120.979 -0.629 . . . . 0.18 112.603 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -103.91 14.98 29.68 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.736 0.779 . . . . 2.27 109.711 176.789 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.421 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.2 t -84.24 154.56 22.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.599 -0.728 . . . . 0.41 109.902 176.555 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -52.25 -41.01 62.44 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.185 0.517 . . . . 1.06 110.496 178.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.666 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 7.6 mt -71.96 -63.17 1.19 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.737 -0.665 . . . . 1.77 110.674 176.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.33 -40.39 53.21 Favored Glycine 0 C--N 1.33 0.212 0 CA-C-N 116.067 -0.515 . . . . 0.16 113.266 -175.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 96.5 m -68.62 -45.12 72.74 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.878 0.37 . . . . 1.07 110.826 -177.454 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.414 ' O ' HD13 ' A' ' 27' ' ' LEU . 1.8 tm? -65.38 -37.56 87.35 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.435 -0.58 . . . . 1.57 109.435 178.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.666 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.0 mt -69.42 -43.51 73.23 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.012 -0.54 . . . . 1.13 110.588 -176.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.546 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.3 pp -72.23 -26.54 62.07 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.662 -0.415 . . . . 1.08 110.765 -178.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.416 ' N ' HD11 ' A' ' 29' ' ' LEU . 19.5 t70 -66.19 -33.56 76.05 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.711 0.767 . . . . 0.66 109.066 173.399 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 29.3 mm-40 -80.22 -11.62 59.71 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.509 -1.223 . . . . 2.07 111.143 179.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.1 mt -115.41 -14.51 11.59 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.899 -0.591 . . . . 1.35 112.187 -174.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 78.88 39.68 19.71 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.139 -0.553 . . . . 0.75 112.751 177.054 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.546 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 15.9 mt -96.62 138.39 21.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.624 0.249 . . . . 1.24 110.761 -176.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.3 p -119.39 102.73 13.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.468 0.651 . . . . 2.41 110.264 174.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 20.0 mt -86.99 140.09 29.91 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.973 -0.558 . . . . 3.28 110.802 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -75.33 -27.74 59.37 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.936 -0.574 . . . . 2.65 109.752 174.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 61.1 t0 -139.02 104.31 7.36 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 108.663 -0.866 . . . . 2.29 108.663 175.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -72.12 4.03 3.57 Favored 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.518 2.145 . . . . 0.77 112.901 -176.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 64.9 p -93.04 2.55 56.72 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 120.445 -0.502 . . . . 1.2 110.936 -177.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.2 m -83.63 159.76 3.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.102 -0.499 . . . . 1.08 110.425 178.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.1 mt -88.7 122.24 31.91 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.832 -0.622 . . . . 1.06 110.475 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.5 pt -106.17 134.4 47.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 115.987 -0.551 . . . . 1.03 110.073 176.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.782 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -111.16 107.83 2.26 Favored Glycine 0 N--CA 1.443 -0.882 0 C-N-CA 120.593 -0.813 . . . . 0.31 112.908 -176.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.775 ' HB3' ' ND2' ' A' ' 16' ' ' ASN . 20.9 t70 -81.44 138.64 35.53 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.441 -0.577 . . . . 0.57 109.441 176.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.405 ' HA3' ' HB3' ' A' ' 15' ' ' GLN . . . 78.7 36.66 28.63 Favored Glycine 0 N--CA 1.443 -0.88 0 C-N-CA 120.248 -0.977 . . . . 0.25 111.787 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.4 OUTLIER -105.15 112.75 25.99 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.344 0.592 . . . . 0.25 111.559 -172.4 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -102.82 134.33 19.91 Favored Pre-proline 0 C--N 1.317 -0.828 0 CA-C-N 115.364 -0.834 . . . . 2.21 109.535 173.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -59.28 127.2 23.15 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.759 2.306 . . . . 0.6 111.616 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 19.1 mt -82.97 89.1 2.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.479 0.657 . . . . 1.13 109.253 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.9 t -129.1 9.47 5.73 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.075 -0.966 . . . . 1.22 110.212 -177.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 14.2 p -99.78 144.97 11.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.15 -0.932 . . . . 1.92 109.775 178.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -86.79 44.65 1.18 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.043 0.449 . . . . 3.46 110.686 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.401 ' C ' ' HG ' ' A' ' 55' ' ' SER . . . -83.64 77.52 2.11 Favored Glycine 0 N--CA 1.447 -0.583 0 CA-C-N 115.846 -0.616 . . . . 3.5 112.313 -177.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.401 ' HG ' ' C ' ' A' ' 54' ' ' GLY . 84.4 p 52.24 -163.22 0.08 Allowed 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 123.682 0.793 . . . . 5.24 112.198 178.577 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.3 m -83.59 -16.62 44.63 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.465 0.65 . . . . 4.31 109.555 174.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -94.18 62.43 3.0 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.298 -0.864 . . . . 3.13 109.065 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -94.28 18.15 11.52 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.346 -0.843 . . . . 1.6 111.796 -177.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.1 t -144.44 143.03 30.7 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 110.071 -0.344 . . . . 1.02 110.071 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 8.3 p -102.4 -26.56 13.23 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.313 0.486 . . . . 2.56 112.313 -175.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.477 ' HB2' ' O ' ' A' ' 14' ' ' CYS . . . -123.14 -75.99 0.59 Allowed 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.56 -0.456 . . . . 1.07 111.91 -176.578 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 31.8 m -146.77 128.73 15.46 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.908 0.385 . . . . 1.05 111.39 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.67 137.89 32.1 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.261 -0.427 . . . . 1.07 110.512 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.6 HG23 ' SG ' ' A' ' 14' ' ' CYS . 2.7 m -146.3 170.45 4.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.037 -0.529 . . . . 1.01 111.302 -177.294 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . 0.823 ' SG ' ' HB ' ' A' ' 8' ' ' THR . 41.3 t -132.64 109.68 9.9 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.351 -0.841 . . . . 0.39 109.589 177.127 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.753 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -95.91 137.67 34.64 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.454 0.645 . . . . 0.65 112.041 -178.074 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 33.0 t -82.88 -18.91 38.58 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 114.865 -1.061 . . . . 1.83 110.586 178.245 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -110.84 147.29 34.85 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.101 0.477 . . . . 1.6 111.151 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -115.62 4.48 14.14 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.637 -0.71 . . . . 3.24 110.522 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -75.67 73.81 2.66 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.34 0.591 . . . . 2.99 110.446 178.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 33.6 m -89.57 146.8 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 CA-C-N 115.801 -0.636 . . . . 1.68 110.947 -177.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 44.8 m -89.52 10.43 22.89 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.084 -0.507 . . . . 1.88 110.703 178.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.26 -33.93 3.2 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.561 -0.745 . . . . 0.56 113.552 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.6 m -140.57 -2.85 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 117.743 0.772 . . . . 1.18 112.218 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 16.4 pt -93.71 -176.45 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.769 0.795 . . . . 1.12 112.567 -176.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.753 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -147.53 137.82 23.13 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 114.206 -1.361 . . . . 1.11 108.745 174.049 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 70.4 mt -117.52 126.39 74.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.002 0.43 . . . . 1.1 111.628 -176.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.51 52.62 5.45 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.845 -0.616 . . . . 0.2 111.798 177.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.406 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 1.3 m -99.03 137.52 37.44 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 112.424 0.527 . . . . 0.65 112.424 -176.257 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 86.3 mt -105.36 131.49 21.71 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.505 -0.771 . . . . 1.1 109.719 170.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_exo -65.81 121.95 9.44 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.973 2.449 . . . . 0.25 112.303 -179.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.417 ' O ' ' HB ' ' A' ' 83' ' ' THR . 5.3 m -122.72 152.57 27.25 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 CA-C-N 116.275 -0.421 . . . . 1.12 110.147 178.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.417 ' HB ' ' O ' ' A' ' 82' ' ' VAL . 67.4 m 67.25 137.86 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.448 0 O-C-N 123.761 0.663 . . . . 2.18 111.654 -177.399 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 89.5 mt . . . . . 0 C--O 1.251 1.149 0 CA-C-O 117.977 -1.011 . . . . 4.14 110.994 -178.583 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.798 0 N-CA-C 111.833 -0.507 . . . . 5.98 111.833 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.445 ' O ' ' HA ' ' A' ' 51' ' ' THR . 23.3 t -130.63 100.42 5.3 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.924 -0.399 . . . . 4.6 109.924 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 19.2 m-90 -84.51 127.51 34.08 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.1 -0.5 . . . . 5.43 110.482 -177.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -73.65 115.83 5.17 Favored Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.883 -0.599 . . . . 2.46 111.806 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -70.84 131.79 44.32 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 120.98 0.419 . . . . 4.59 110.319 178.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.402 ' O ' ' HB3' ' A' ' 7' ' ' SER . 30.3 t -119.88 -15.65 8.8 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.759 -0.655 . . . . 1.88 110.971 -177.229 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.402 ' HB3' ' O ' ' A' ' 6' ' ' CYS . 47.4 t 73.02 -50.35 0.7 Allowed 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.383 0.673 . . . . 2.6 110.923 -177.381 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.5 m -65.33 -28.19 69.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.311 0.576 . . . . 4.25 110.264 177.2 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 172.65 -146.39 9.11 Favored Glycine 0 N--CA 1.444 -0.823 0 CA-C-N 115.426 -0.806 . . . . 1.12 111.87 179.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.0 t -101.68 151.74 21.66 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.137 -0.69 . . . . 1.43 109.137 -179.106 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 45.9 mt -102.08 136.76 32.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.629 0.728 . . . . 1.56 111.544 -179.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.529 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -144.13 169.27 18.18 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.97 -1.014 . . . . 0.91 110.556 -179.717 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 14.7 t -118.15 103.51 9.94 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.708 -0.678 . . . . 0.34 109.731 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.815 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 98.9 m -85.68 134.67 33.96 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.397 -0.819 . . . . 0.19 111.196 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.77 -30.05 63.8 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.162 -0.926 . . . . 0.39 109.082 174.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -139.66 115.74 10.36 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.611 -0.722 . . . . 1.12 110.369 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 88.9 t -105.53 105.45 18.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-O 120.927 0.394 . . . . 1.04 110.048 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.6 m -132.37 139.92 36.34 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 115.936 -0.574 . . . . 1.03 111.147 -175.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.441 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.4 Cg_exo -58.55 141.99 97.83 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.442 2.095 . . . . 0.21 111.717 171.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.51 -19.52 70.94 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.878 -0.677 . . . . 0.18 111.965 179.432 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -102.15 9.83 39.88 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.218 0.532 . . . . 2.27 110.009 176.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.441 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.5 t -80.8 154.62 27.07 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 115.628 -0.714 . . . . 0.41 109.728 175.575 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -54.56 -40.13 68.43 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.96 0.41 . . . . 1.06 110.357 179.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.654 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 5.1 mt -70.75 -62.19 1.48 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.686 -0.688 . . . . 1.77 110.529 176.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.56 -38.71 63.97 Favored Glycine 0 C--N 1.33 0.242 0 CA-C-N 116.052 -0.522 . . . . 0.16 113.421 -175.031 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 85.7 m -66.35 -42.71 87.69 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.798 0.333 . . . . 1.07 110.745 -178.215 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.452 ' O ' HD12 ' A' ' 27' ' ' LEU . 2.6 tm? -69.97 -34.82 73.88 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.327 -0.62 . . . . 1.57 109.327 177.672 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.654 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.6 mt -65.04 -46.2 82.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.053 -0.521 . . . . 1.13 110.483 -178.131 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.46 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.64 -21.03 52.85 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.473 -0.491 . . . . 1.08 111.004 -178.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.448 ' N ' HD12 ' A' ' 29' ' ' LEU . 32.4 t70 -66.15 -37.81 86.59 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.391 0.615 . . . . 0.66 109.572 173.181 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -75.98 -12.85 60.21 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.029 -0.987 . . . . 2.07 109.928 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 75.3 mt -106.09 -12.03 15.91 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.195 -0.911 . . . . 1.35 111.318 -179.269 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.09 39.36 96.25 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.575 -0.738 . . . . 0.75 112.343 -178.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.46 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 53.9 mt -82.19 133.23 29.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 O-C-N 122.645 -0.326 . . . . 1.24 111.057 -176.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 11.4 p -87.45 116.43 29.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 109.336 -0.616 . . . . 2.41 109.336 172.393 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.438 ' O ' HD12 ' A' ' 36' ' ' LEU . 0.9 OUTLIER -91.79 131.33 37.23 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.918 -0.583 . . . . 3.28 111.003 -179.454 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 45.2 tt0 -88.23 -34.27 17.82 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.261 -1.014 . . . . 2.65 108.261 173.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -145.06 102.75 4.43 Favored Pre-proline 0 N--CA 1.445 -0.711 0 CA-C-N 114.835 -1.075 . . . . 2.29 108.324 174.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.413 ' HB3' HD23 ' A' ' 36' ' ' LEU . 41.4 Cg_endo -67.71 -4.39 12.11 Favored 'Trans proline' 0 C--O 1.225 -0.152 0 C-N-CA 122.586 2.191 . . . . 0.77 112.075 -174.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 15.3 p -82.53 -10.05 59.16 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.823 -0.626 . . . . 1.2 111.407 -174.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.8 m -74.18 160.54 5.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.159 0.504 . . . . 1.08 111.01 -178.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.404 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 92.3 mt -91.52 129.81 37.44 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.795 -0.639 . . . . 1.06 110.397 179.195 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.2 pt -112.52 137.64 44.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.159 0.504 . . . . 1.03 110.433 176.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.815 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.8 103.31 1.32 Allowed Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 120.478 -0.867 . . . . 0.31 113.133 -175.338 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -79.11 139.91 37.96 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 109.445 -0.576 . . . . 0.57 109.445 177.078 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.74 39.82 38.92 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.077 -1.058 . . . . 0.25 111.804 -179.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.521 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -108.28 112.98 25.72 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.098 0.475 . . . . 0.25 111.717 -171.69 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -101.83 137.13 19.45 Favored Pre-proline 0 C--N 1.318 -0.763 0 CA-C-N 115.395 -0.82 . . . . 2.21 109.581 175.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -59.88 133.98 54.12 Favored 'Trans proline' 0 C--O 1.233 0.244 0 C-N-CA 122.86 2.373 . . . . 0.6 112.076 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 40.6 mt -87.89 106.13 16.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.209 0.528 . . . . 1.13 109.881 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.445 ' HA ' ' O ' ' A' ' 2' ' ' SER . 11.8 t -142.1 19.82 2.1 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.529 -0.76 . . . . 1.22 110.594 -174.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.1 p -152.25 158.44 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 CA-C-N 115.626 -0.715 . . . . 1.92 110.164 -177.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . 58.97 45.77 14.53 Favored 'General case' 0 N--CA 1.464 0.266 0 O-C-N 123.661 0.601 . . . . 3.46 112.372 172.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -59.29 118.58 14.76 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.086 -0.578 . . . . 3.5 112.451 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 36.8 m 65.87 21.61 11.41 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.189 0.519 . . . . 5.24 111.015 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 48.0 m -127.46 26.28 5.99 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.643 -0.708 . . . . 4.31 110.035 -178.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 23.0 t70 76.04 72.36 0.08 Allowed 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 115.215 -0.902 . . . . 3.13 109.381 -175.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -92.36 3.29 55.73 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.965 -1.016 . . . . 1.6 111.261 -176.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.3 t -143.11 143.46 31.84 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.921 -0.581 . . . . 1.02 109.923 179.43 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 10.0 t -107.08 -28.68 9.85 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.557 -0.292 . . . . 2.56 111.085 -178.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -112.05 -80.2 0.59 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.837 -0.345 . . . . 1.07 111.783 -176.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 16.4 m -145.1 128.13 16.54 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.84 0.352 . . . . 1.05 111.154 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.48 136.91 32.92 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.903 0.382 . . . . 1.07 110.276 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.631 HG23 ' SG ' ' A' ' 14' ' ' CYS . 3.2 m -145.85 167.92 7.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.089 0.471 . . . . 1.01 111.59 -175.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 17.8 t -130.54 105.94 8.18 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.45 -0.796 . . . . 0.39 110.121 178.013 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.731 ' SG ' ' HB3' ' A' ' 76' ' ' ALA . 1.8 m -92.45 133.58 35.77 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.698 0.761 . . . . 0.65 111.985 -179.28 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 8.7 t -86.16 -13.44 47.07 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.521 -1.218 . . . . 1.83 110.423 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -107.82 156.67 18.88 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.866 -0.606 . . . . 1.6 110.2 -179.145 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 30.4 p-10 -120.9 -15.1 8.38 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 113.084 0.772 . . . . 3.24 113.084 -172.443 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -88.16 73.21 9.01 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 121.985 0.898 . . . . 2.99 111.072 -173.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.7 m -85.68 164.77 2.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.049 -0.978 . . . . 1.68 110.999 -178.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.546 ' OG ' HG12 ' A' ' 75' ' ' ILE . 88.7 p -84.59 -2.72 57.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.051 -0.522 . . . . 1.88 111.66 -175.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.64 -31.89 3.83 Favored Glycine 0 CA--C 1.505 -0.592 0 C-N-CA 120.721 -0.752 . . . . 0.56 112.304 -178.071 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.4 m -135.49 -12.15 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.488 -0.485 . . . . 1.18 111.935 178.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.546 HG12 ' OG ' ' A' ' 72' ' ' SER . 35.4 pt -90.02 -175.14 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 119.986 -0.686 . . . . 1.12 111.581 -179.156 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.731 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -147.78 143.46 27.54 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.398 -1.273 . . . . 1.11 108.665 175.085 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 64.0 mt -122.55 131.23 73.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.966 0.412 . . . . 1.1 111.585 -175.41 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.44 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 76.38 50.71 7.18 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.097 -0.573 . . . . 0.2 112.188 177.751 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.461 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.92 141.84 31.19 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 112.826 0.676 . . . . 0.65 112.826 -175.013 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 95.0 mt -108.57 132.06 21.37 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.223 -0.899 . . . . 1.1 109.269 168.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.411 ' HA ' HG13 ' A' ' 64' ' ' VAL . 15.8 Cg_exo -67.29 128.4 18.33 Favored 'Trans proline' 0 C--O 1.234 0.297 0 C-N-CA 122.757 2.304 . . . . 0.25 112.292 -179.257 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.0 m -130.42 160.17 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.729 0 CA-C-N 116.02 -0.536 . . . . 1.12 110.12 178.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 23.9 m -132.61 136.55 46.59 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 116.475 -0.33 . . . . 2.18 110.448 177.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 93.3 mt . . . . . 0 C--O 1.249 1.026 0 O-C-N 123.915 0.76 . . . . 4.14 111.338 -179.537 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.661 0 N-CA-C 112.198 -0.361 . . . . 5.98 112.198 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.8 t -134.11 -168.08 2.07 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.808 -0.442 . . . . 4.6 109.808 -177.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 98.5 m95 58.53 -154.21 0.37 Allowed 'General case' 0 C--O 1.234 0.277 0 O-C-N 123.424 0.453 . . . . 5.43 110.531 -178.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.42 159.34 23.28 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.883 -0.675 . . . . 2.46 111.543 177.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -107.92 109.16 20.59 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.528 -0.545 . . . . 4.59 109.528 178.666 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 35.3 t -130.49 -73.19 0.55 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.285 -0.416 . . . . 1.88 111.12 -176.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 66.6 m -157.32 -174.56 4.95 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.638 -0.504 . . . . 2.6 109.638 -177.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 25.0 p -81.37 13.15 3.1 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 112.465 0.543 . . . . 4.25 112.465 -174.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -95.33 -110.58 2.44 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.904 -0.665 . . . . 1.12 111.928 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.1 t -151.04 150.31 30.58 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 110.128 -0.323 . . . . 1.43 110.128 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 23.7 mt -112.1 135.92 49.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-O 121.482 0.658 . . . . 1.56 110.825 173.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.676 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -153.91 170.29 21.39 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 114.968 -1.015 . . . . 0.91 110.873 -177.187 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.567 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 42.1 t -118.69 108.59 15.1 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.434 -0.803 . . . . 0.34 109.593 177.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.863 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 60.9 m -90.11 129.62 36.38 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.311 0.577 . . . . 0.19 111.599 -172.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.434 ' HB3' ' HA3' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -75.54 -26.71 58.25 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 114.946 -1.025 . . . . 0.39 110.252 177.851 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.588 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 1.6 t-20 -135.86 99.15 4.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.445 -0.343 . . . . 1.12 110.818 175.266 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 61.8 t -92.66 102.0 13.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.002 0.429 . . . . 1.04 110.039 177.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.6 m -133.42 142.92 45.89 Favored Pre-proline 0 C--N 1.32 -0.701 0 CA-C-N 115.896 -0.593 . . . . 1.03 110.905 -174.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.477 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.5 Cg_exo -61.1 139.38 83.79 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.086 1.858 . . . . 0.21 111.164 171.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.08 -24.42 70.3 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.84 -0.695 . . . . 0.18 112.627 -178.262 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -97.61 4.45 50.2 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.147 0.498 . . . . 2.27 110.048 177.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.2 t -73.2 152.99 40.86 Favored 'General case' 0 CA--C 1.513 -0.48 0 CA-C-N 115.758 -0.655 . . . . 0.41 109.994 177.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -54.31 -39.36 66.94 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.098 0.475 . . . . 1.06 110.227 178.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.687 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.7 mm? -70.89 -62.33 1.43 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.646 -0.706 . . . . 1.77 110.818 175.788 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.3 -40.34 60.44 Favored Glycine 0 C--N 1.33 0.232 0 CA-C-N 116.171 -0.468 . . . . 0.16 113.296 -175.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.1 m -69.0 -44.36 72.96 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.857 0.36 . . . . 1.07 110.692 -177.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.02 -38.95 93.23 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.316 -0.624 . . . . 1.57 109.316 178.443 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.687 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.2 mt -69.11 -44.4 72.48 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.668 -0.696 . . . . 1.13 110.764 -177.129 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.544 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.4 pp -76.02 -26.16 56.37 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.798 -0.361 . . . . 1.08 111.068 -178.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.439 ' N ' HD12 ' A' ' 29' ' ' LEU . 31.9 t70 -64.24 -34.44 78.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.859 0.837 . . . . 0.66 109.035 172.267 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -80.66 -12.27 59.51 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 114.152 -1.386 . . . . 2.07 111.162 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 88.5 mt -111.86 -13.55 13.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.969 -0.56 . . . . 1.35 112.065 -176.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.9 41.35 18.97 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.238 -0.506 . . . . 0.75 112.898 178.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.544 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 15.4 mt -104.16 140.58 21.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.824 0.345 . . . . 1.24 110.811 -177.551 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.0 p -123.96 102.6 11.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.513 0.673 . . . . 2.41 110.002 173.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 24.1 mt -78.06 141.41 38.85 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.851 -0.613 . . . . 3.28 110.986 -177.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -69.76 -33.22 72.13 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.348 -0.842 . . . . 2.65 109.124 175.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 -131.58 104.74 14.46 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 115.189 -0.914 . . . . 2.29 108.653 172.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.87 -1.72 6.52 Favored 'Trans proline' 0 CA--C 1.528 0.187 0 C-N-CA 122.119 1.879 . . . . 0.77 111.812 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.8 p -87.09 -7.65 57.83 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.709 -0.678 . . . . 1.2 111.261 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.42 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 17.7 m -77.31 159.37 5.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 CA-C-O 121.204 0.526 . . . . 1.08 110.82 -179.589 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 85.6 mt -90.3 123.5 34.12 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.74 -0.664 . . . . 1.06 110.153 177.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.2 pt -105.25 139.27 26.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 115.94 -0.573 . . . . 1.03 109.957 176.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.863 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.32 106.69 1.44 Allowed Glycine 0 N--CA 1.44 -1.037 0 C-N-CA 120.51 -0.852 . . . . 0.31 113.174 -175.037 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.588 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 12.6 t70 -73.41 148.65 43.11 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.015 -0.735 . . . . 0.57 109.015 175.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.434 ' HA3' ' HB3' ' A' ' 15' ' ' GLN . . . 60.6 45.16 96.87 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.44 -0.886 . . . . 0.25 112.58 175.561 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.567 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -100.96 117.35 34.83 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.322 0.582 . . . . 0.25 110.701 -174.662 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.504 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 3.5 p-10 -100.84 131.55 23.31 Favored Pre-proline 0 C--N 1.318 -0.772 0 CA-C-N 115.528 -0.76 . . . . 2.21 110.333 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -60.84 118.22 5.06 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 121.909 1.74 . . . . 0.6 110.076 173.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 13.6 mt -75.08 93.29 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.364 0.602 . . . . 1.13 110.935 -172.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 8.9 t -142.2 26.53 1.82 Allowed 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 122.326 1.06 . . . . 1.22 109.415 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 6.1 p -139.04 132.74 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 114.491 -1.231 . . . . 1.92 109.813 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -95.91 -13.07 24.21 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.633 0.254 . . . . 3.46 111.325 -177.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -75.79 78.07 1.23 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 121.097 -0.573 . . . . 3.5 112.473 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.1 t -163.35 -165.97 1.16 Allowed 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.914 -0.773 . . . . 5.24 108.914 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 13.2 m -57.7 -68.22 0.26 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.916 0.388 . . . . 4.31 110.125 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -118.3 -72.0 0.71 Allowed 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.405 -0.591 . . . . 3.13 109.405 173.004 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -120.22 -19.99 7.5 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.466 -0.788 . . . . 1.6 109.969 173.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 15.3 p -168.67 -178.65 3.51 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.995 -1.002 . . . . 1.02 109.576 -179.166 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 23.9 p -114.17 12.11 17.71 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.01 0.374 . . . . 2.56 112.01 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -134.78 -149.72 0.36 Allowed 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 121.227 -0.189 . . . . 1.07 110.95 -179.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 19.5 m -87.85 134.77 33.63 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.779 0.323 . . . . 1.05 111.055 -177.449 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.71 126.87 34.3 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.878 -0.416 . . . . 1.07 109.878 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.705 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -139.42 173.77 10.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.63 0 CA-C-O 121.51 0.671 . . . . 1.01 111.642 -176.083 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 48.8 t -141.82 103.76 4.4 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.974 -1.012 . . . . 0.39 109.165 -178.065 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.734 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.3 m -92.71 155.52 17.65 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.471 0.653 . . . . 0.65 111.913 -176.095 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 6.4 m -106.18 -13.98 15.27 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.264 -0.88 . . . . 1.83 110.879 -178.077 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.407 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 5.5 t70 -103.38 162.32 13.11 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.142 -0.481 . . . . 1.6 109.748 -178.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -120.85 -7.3 9.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.049 0.452 . . . . 3.24 111.14 -176.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -83.35 83.79 7.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.225 0.536 . . . . 2.99 111.403 -175.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 34.2 m -91.36 156.11 3.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.819 -0.628 . . . . 1.68 110.903 179.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.551 ' OG ' HG12 ' A' ' 75' ' ' ILE . 89.2 p -95.36 3.53 54.3 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.075 0.464 . . . . 1.88 110.53 179.435 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.31 -33.32 3.19 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.463 -0.79 . . . . 0.56 112.123 -176.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.5 m -140.31 -21.69 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.325 0 N-CA-C 112.478 0.548 . . . . 1.18 112.478 174.022 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.551 HG12 ' OG ' ' A' ' 72' ' ' SER . 20.4 pt -71.75 172.99 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.373 0 CA-C-O 121.58 0.705 . . . . 1.12 112.187 -174.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.734 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -144.05 140.95 29.81 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.168 -1.378 . . . . 1.11 109.068 176.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.407 ' HB ' ' HB3' ' A' ' 68' ' ' ASP . 71.2 mt -119.5 129.33 75.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.032 0.444 . . . . 1.1 111.455 -176.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.452 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.08 51.93 5.96 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.972 -0.632 . . . . 0.2 112.035 178.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.92 139.04 35.17 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.135 0.493 . . . . 0.65 112.237 -176.503 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 97.9 mt -109.49 132.13 21.48 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 115.564 -0.744 . . . . 1.1 109.142 169.562 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 14.9 Cg_exo -68.01 119.37 6.38 Favored 'Trans proline' 0 N--CA 1.464 -0.246 0 C-N-CA 122.76 2.306 . . . . 0.25 112.058 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.7 m -112.41 147.25 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 CA-C-N 115.969 -0.56 . . . . 1.12 110.747 -177.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.424 HG23 ' HG ' ' A' ' 84' ' ' LEU . 32.8 m -156.04 134.39 11.53 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.561 -0.745 . . . . 2.18 109.878 178.135 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.424 ' HG ' HG23 ' A' ' 83' ' ' THR . 94.4 mt . . . . . 0 C--O 1.249 1.049 0 O-C-N 123.903 0.752 . . . . 4.14 111.463 -179.306 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.585 0 N-CA-C 112.007 -0.437 . . . . 5.98 112.007 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.584 ' O ' ' HA ' ' A' ' 51' ' ' THR . 17.5 p -80.28 71.95 7.1 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.028 0.442 . . . . 4.6 111.159 -178.58 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 67.3 t-105 -175.0 -66.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.516 -0.765 . . . . 5.43 110.523 174.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.29 -24.6 2.17 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.228 -0.987 . . . . 2.46 113.835 -172.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 77.4 mm-40 -60.3 108.03 0.74 Allowed 'General case' 0 C--O 1.233 0.211 0 CA-C-N 117.479 0.64 . . . . 4.59 111.101 -176.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.428 ' HB2' HD12 ' A' ' 11' ' ' ILE . 5.5 t 165.44 -40.18 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 114.19 -1.368 . . . . 1.88 107.678 -171.619 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.4 t -167.41 -160.57 0.37 Allowed 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.346 -1.297 . . . . 2.6 108.662 178.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.1 m -82.45 -8.46 59.62 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.138 0.494 . . . . 4.25 110.624 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -97.67 -125.93 5.29 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.836 -0.697 . . . . 1.12 113.314 -175.406 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 31.4 t -143.24 153.96 43.33 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 122.673 0.389 . . . . 1.43 109.967 -173.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.428 HD12 ' HB2' ' A' ' 6' ' ' CYS . 48.3 mt -103.58 140.17 22.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.155 0.503 . . . . 1.56 110.678 175.602 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.671 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -150.16 163.71 37.53 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.571 0.701 . . . . 0.91 111.732 -179.557 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.8 t -116.03 105.07 12.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.162 -0.926 . . . . 0.34 108.901 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.849 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 90.1 m -85.16 139.65 31.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.409 -0.814 . . . . 0.19 111.308 -173.174 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.402 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -75.84 -30.32 58.92 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 115.065 -0.971 . . . . 0.39 109.086 175.252 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.544 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 3.2 t-20 -136.13 111.52 9.16 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.797 -0.638 . . . . 1.12 110.618 178.532 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 85.5 t -102.15 106.16 19.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.022 0 N-CA-C 109.71 -0.478 . . . . 1.04 109.71 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.4 m -134.76 142.03 40.87 Favored Pre-proline 0 C--N 1.32 -0.676 0 CA-C-N 115.82 -0.627 . . . . 1.03 110.54 -178.078 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.493 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.5 Cg_exo -59.22 137.33 78.28 Favored 'Trans proline' 0 N--CA 1.46 -0.442 0 C-N-CA 122.31 2.007 . . . . 0.21 111.157 172.427 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.12 -25.55 69.66 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 121.111 -0.566 . . . . 0.18 112.666 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -100.52 6.55 44.3 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.612 0.72 . . . . 2.27 110.198 176.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.493 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 21.0 t -68.88 154.83 41.32 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.352 -0.61 . . . . 0.41 109.352 173.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -53.42 -43.2 67.78 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.098 0.475 . . . . 1.06 109.744 177.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.612 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.6 mm? -72.05 -57.72 4.04 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.318 -0.856 . . . . 1.77 111.097 177.776 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.479 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -53.71 -40.96 64.87 Favored Glycine 0 C--N 1.33 0.21 0 C-N-CA 121.225 -0.512 . . . . 0.16 112.962 -176.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 84.3 m -67.73 -39.3 84.27 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.731 0.301 . . . . 1.07 110.383 -179.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.422 ' O ' HD12 ' A' ' 27' ' ' LEU . 2.5 tm? -68.25 -36.44 79.45 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.434 -0.58 . . . . 1.57 109.434 178.428 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.612 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 13.3 mt -67.57 -47.55 69.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.742 -0.663 . . . . 1.13 110.372 -177.614 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.532 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -77.56 -22.68 50.63 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.746 -0.382 . . . . 1.08 111.364 -178.562 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.491 ' N ' HD13 ' A' ' 29' ' ' LEU . 26.6 t70 -69.06 -31.53 70.37 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.422 0.63 . . . . 0.66 109.418 175.404 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -70.42 -24.29 62.89 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 114.79 -1.096 . . . . 2.07 109.305 176.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.1 mt -98.53 -15.58 19.49 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.585 -1.189 . . . . 1.35 111.71 -175.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.57 31.18 51.31 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 121.226 -0.512 . . . . 0.75 112.68 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.532 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 31.1 mt -95.38 140.66 16.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.721 0.296 . . . . 1.24 110.753 -178.072 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.9 t -124.75 101.41 8.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 109.708 -0.478 . . . . 2.41 109.708 176.081 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 30.7 mt -74.77 134.76 41.77 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.106 -0.497 . . . . 3.28 111.451 -177.48 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -70.34 -27.22 64.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.489 -0.778 . . . . 2.65 109.285 174.275 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.428 ' C ' ' H ' ' A' ' 40' ' ' THR . 26.9 m-20 -128.11 90.83 46.26 Favored Pre-proline 0 N--CA 1.446 -0.634 0 N-CA-C 108.38 -0.97 . . . . 2.29 108.38 176.001 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.5 8.36 0.96 Allowed 'Trans proline' 0 C--O 1.223 -0.248 0 C-N-CA 122.416 2.077 . . . . 0.77 112.408 -177.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.428 ' H ' ' C ' ' A' ' 38' ' ' ASP . 16.5 p -99.94 7.91 44.47 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.094 0.473 . . . . 1.2 110.996 -178.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.518 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 27.8 m -91.98 155.75 3.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.078 -0.51 . . . . 1.08 110.99 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.472 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.5 mt -86.56 127.12 34.87 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.663 -0.699 . . . . 1.06 109.875 176.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.4 pt -106.78 141.75 21.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.122 -0.49 . . . . 1.03 110.095 176.236 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.849 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.48 108.59 1.71 Allowed Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 120.523 -0.846 . . . . 0.31 113.419 -174.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.505 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 8.8 t70 -74.49 146.16 42.96 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.757 -0.831 . . . . 0.57 108.757 174.229 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 60.63 47.2 92.37 Favored Glycine 0 C--N 1.318 -0.453 0 C-N-CA 120.281 -0.961 . . . . 0.25 112.712 175.59 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.511 ' SG ' ' HB2' ' A' ' 12' ' ' GLN . 0.5 OUTLIER -108.61 111.59 23.49 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.116 0.484 . . . . 0.25 111.568 -171.771 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.438 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 4.6 t70 -101.67 135.5 19.76 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.633 -0.712 . . . . 2.21 110.916 176.309 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.438 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 35.1 Cg_exo -54.76 123.52 13.93 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 124.032 3.155 . . . . 0.6 112.211 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 42.0 mt -79.84 88.34 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.595 0.712 . . . . 1.13 109.402 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.584 ' HA ' ' O ' ' A' ' 2' ' ' SER . 9.5 t -109.25 15.93 22.8 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.038 -0.983 . . . . 1.22 109.535 -179.507 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.3 p -131.51 144.41 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 CA-C-N 114.719 -1.128 . . . . 1.92 109.37 178.349 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -107.4 -56.47 2.21 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 110.106 -0.331 . . . . 3.46 110.106 178.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 53.58 -124.93 30.72 Favored Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.865 -0.607 . . . . 3.5 112.334 178.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.1 t -122.87 -70.57 0.77 Allowed 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.644 -0.502 . . . . 5.24 109.644 177.412 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 32.2 m -130.44 23.51 5.13 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.569 0.699 . . . . 4.31 109.403 176.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -109.53 22.78 15.32 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.323 -0.853 . . . . 3.13 111.261 -176.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -86.04 -19.77 29.79 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.409 0.623 . . . . 1.6 110.638 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.1 t -157.21 137.34 12.67 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.422 -0.808 . . . . 1.02 110.556 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.1 p -106.89 -22.11 12.8 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.185 -0.461 . . . . 2.56 111.774 -178.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.402 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -117.09 -82.65 0.63 Allowed 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 121.016 -0.274 . . . . 1.07 111.129 -179.532 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 11.9 m -139.77 129.91 25.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.689 0.28 . . . . 1.05 111.363 -179.038 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.4 128.19 34.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.979 0.419 . . . . 1.07 110.777 -177.428 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.62 HG22 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -143.09 173.93 5.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.489 0.661 . . . . 1.01 111.579 -177.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 39.0 t -140.96 107.57 5.33 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.387 -0.824 . . . . 0.39 109.146 -177.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.746 ' SG ' ' HB2' ' A' ' 76' ' ' ALA . 1.5 m -93.56 138.08 32.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.62 0.724 . . . . 0.65 112.58 -174.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.6 t -85.8 -22.49 27.63 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 114.731 -1.122 . . . . 1.83 110.691 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.409 ' HB2' ' O ' ' A' ' 77' ' ' ILE . 1.2 m-20 -102.53 136.76 41.77 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.164 -0.471 . . . . 1.6 110.813 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -100.44 -4.45 28.89 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.757 -0.656 . . . . 3.24 110.036 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -75.56 90.29 2.76 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.556 -0.747 . . . . 2.99 110.495 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 26.7 m -105.95 156.53 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.579 0 CA-C-N 116.102 -0.499 . . . . 1.68 111.29 -177.125 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.621 ' OG ' HG12 ' A' ' 75' ' ' ILE . 82.5 p -85.83 -4.56 59.2 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.886 -0.597 . . . . 1.88 110.529 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.47 -32.34 3.56 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.594 -0.73 . . . . 0.56 112.436 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 m -136.48 -11.57 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 C-N-CA 120.251 -0.58 . . . . 1.18 112.094 179.105 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.621 HG12 ' OG ' ' A' ' 72' ' ' SER . 25.8 pt -92.54 -178.2 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.602 0.715 . . . . 1.12 111.928 -178.337 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.746 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -143.04 141.09 31.23 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.031 -1.441 . . . . 1.11 109.279 175.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.409 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 68.0 mt -121.17 129.12 75.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.867 0.365 . . . . 1.1 111.447 -177.088 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.518 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 79.59 50.24 5.76 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.803 -0.713 . . . . 0.2 111.816 178.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.472 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.2 m -99.67 133.55 43.85 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 112.453 0.538 . . . . 0.65 112.453 -175.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 92.4 mt -105.53 133.87 19.97 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 115.538 -0.755 . . . . 1.1 109.636 171.065 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -63.59 125.75 16.16 Favored 'Trans proline' 0 C--O 1.234 0.3 0 C-N-CA 122.807 2.338 . . . . 0.25 112.022 -179.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 10.3 m -122.85 161.49 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 CA-C-N 116.153 -0.476 . . . . 1.12 110.697 -178.445 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.415 HG22 ' HG ' ' A' ' 84' ' ' LEU . 25.4 m -145.75 131.03 18.52 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.946 -0.57 . . . . 2.18 110.279 176.148 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.415 ' HG ' HG22 ' A' ' 83' ' ' THR . 96.6 mt . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.266 -0.874 . . . . 4.14 111.593 179.359 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.445 ' HA3' ' O ' ' A' ' 51' ' ' THR . . . . . . . . 0 N--CA 1.482 1.727 0 N-CA-C 111.637 -0.585 . . . . 5.98 111.637 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.3 m -88.78 -1.5 58.12 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.988 0.394 . . . . 4.6 110.917 -178.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 79.4 m95 65.22 178.45 0.19 Allowed 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.66 -0.7 . . . . 5.43 111.269 179.034 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -124.03 76.44 0.37 Allowed Glycine 0 N--CA 1.444 -0.801 0 N-CA-C 110.901 -0.88 . . . . 2.46 110.901 176.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . 0.424 ' HG2' ' O ' ' A' ' 5' ' ' GLN . 0.0 OUTLIER -87.03 121.8 29.98 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.403 0.621 . . . . 4.59 110.867 -173.621 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.506 ' HB3' ' O ' ' A' ' 9' ' ' GLY . 14.3 t -111.3 -81.35 0.58 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.406 -0.815 . . . . 1.88 109.676 178.197 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 12.8 p 177.77 -82.23 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.095 0.474 . . . . 2.6 110.487 179.232 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.8 p -92.96 17.19 11.08 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.608 -0.724 . . . . 4.25 110.293 178.531 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.506 ' O ' ' HB3' ' A' ' 6' ' ' CYS . . . -169.21 176.19 43.34 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 115.166 -0.925 . . . . 1.12 111.633 -179.527 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.1 t -97.98 153.63 18.24 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.296 -0.631 . . . . 1.43 109.296 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.491 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 18.3 mt -96.19 130.48 44.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.702 0.763 . . . . 1.56 111.281 176.264 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.665 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -137.7 166.55 23.68 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.528 -1.215 . . . . 0.91 110.329 176.6 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.656 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 16.2 t -106.85 100.9 10.37 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.294 -0.866 . . . . 0.34 109.853 179.086 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.802 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 58.1 m -87.01 131.8 33.98 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.148 0.499 . . . . 0.19 110.747 -177.251 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.97 -29.72 35.27 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.285 -0.87 . . . . 0.39 109.593 178.23 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.615 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 2.7 m-20 -134.78 104.01 5.85 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.395 -0.366 . . . . 1.12 110.843 176.464 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 59.1 t -95.99 103.07 14.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.152 0.501 . . . . 1.04 110.01 176.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.98 142.68 46.03 Favored Pre-proline 0 C--N 1.32 -0.71 0 CA-C-N 115.731 -0.668 . . . . 1.03 110.704 -175.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.457 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.6 Cg_exo -58.9 137.74 81.62 Favored 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.103 1.868 . . . . 0.21 111.19 172.302 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.88 -23.76 69.53 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.831 -0.7 . . . . 0.18 112.041 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -96.64 7.58 46.21 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.016 0.436 . . . . 2.27 110.286 176.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.457 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.6 t -80.5 152.4 28.73 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.015 -0.539 . . . . 0.41 110.001 177.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -53.12 -37.35 61.7 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.074 0.464 . . . . 1.06 110.709 178.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.677 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.9 mm? -70.53 -65.95 0.67 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.763 -0.653 . . . . 1.77 110.545 175.011 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.67 -40.04 55.3 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.951 -0.568 . . . . 0.16 113.428 -174.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 63.8 m -68.28 -45.13 73.93 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.909 0.385 . . . . 1.07 110.666 -177.196 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -65.97 -36.63 83.84 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.399 -0.593 . . . . 1.57 109.399 178.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.677 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 17.5 mt -66.56 -49.28 66.92 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.836 -0.62 . . . . 1.13 110.326 -178.304 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.566 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.1 pp -74.4 -25.71 59.64 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.42 -0.355 . . . . 1.08 111.622 -175.047 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.509 ' N ' HD13 ' A' ' 29' ' ' LEU . 31.7 t70 -65.66 -34.49 78.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.673 0.749 . . . . 0.66 109.536 176.055 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -78.82 -34.5 45.24 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 114.713 -1.13 . . . . 2.07 109.412 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 82.3 mt -82.63 -10.73 58.82 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.033 -0.985 . . . . 1.35 112.037 -177.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.63 47.71 20.12 Favored Glycine 0 N--CA 1.452 -0.282 0 CA-C-N 115.855 -0.611 . . . . 0.75 112.631 178.117 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.566 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 10.6 mt -109.75 139.01 34.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.723 0.297 . . . . 1.24 110.471 -179.077 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.0 p -123.59 105.37 15.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.396 0.617 . . . . 2.41 110.125 174.387 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 21.6 mt -81.6 144.08 31.5 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.879 -0.601 . . . . 3.28 111.191 -178.063 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 25.5 mm-40 -79.41 -21.16 45.98 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.608 -0.724 . . . . 2.65 109.356 174.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -138.2 99.35 8.97 Favored Pre-proline 0 N--CA 1.445 -0.696 0 N-CA-C 107.707 -1.22 . . . . 2.29 107.707 173.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.72 -1.45 9.29 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.272 1.982 . . . . 0.77 112.453 -175.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.2 p -101.37 20.26 16.24 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.21 0.528 . . . . 1.2 111.277 -176.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.444 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 33.4 m -93.01 161.63 2.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.978 -0.556 . . . . 1.08 110.094 174.723 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.413 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 96.4 mt -87.57 120.63 29.07 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.284 -0.416 . . . . 1.06 110.043 176.04 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 14.8 pt -103.66 138.35 28.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 116.078 -0.51 . . . . 1.03 110.092 176.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.802 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -115.55 107.4 1.72 Allowed Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.572 -0.823 . . . . 0.31 113.252 -175.401 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.615 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 12.7 t70 -74.82 146.52 41.96 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.488 -0.93 . . . . 0.57 108.488 174.59 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 67.18 36.87 90.78 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 119.882 -1.152 . . . . 0.25 112.165 176.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.656 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -100.34 111.31 23.57 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.376 0.608 . . . . 0.25 110.607 -174.497 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.6 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 1.6 p-10 -101.46 130.32 25.0 Favored Pre-proline 0 C--N 1.314 -0.956 0 CA-C-N 115.547 -0.751 . . . . 2.21 109.876 178.094 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -58.55 118.11 4.94 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.18 1.92 . . . . 0.6 110.911 177.079 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 8.6 mt -79.71 110.78 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 108.581 -0.896 . . . . 1.13 108.581 -179.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.445 ' O ' ' HA3' ' A' ' 1' ' ' GLY . 8.8 t -141.72 16.19 2.15 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.442 0.639 . . . . 1.22 110.672 -174.078 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.3 p -77.93 154.85 5.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.485 -0.78 . . . . 1.92 110.459 -177.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -68.57 113.35 6.01 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.178 -0.464 . . . . 3.46 110.278 175.485 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.3 73.03 1.26 Allowed Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 120.951 -0.642 . . . . 3.5 111.613 -176.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 48.9 m -93.19 46.31 1.21 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.02 0.438 . . . . 5.24 111.136 -177.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.6 p -70.25 -40.61 74.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 4.31 110.867 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -154.96 76.91 1.01 Allowed 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.412 0.625 . . . . 3.13 109.588 175.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -105.45 17.98 23.01 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.49 -0.777 . . . . 1.6 109.988 179.242 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 35.4 t -151.71 128.9 11.17 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.351 -0.84 . . . . 1.02 110.737 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 73.9 m -119.78 -3.45 10.26 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.34 -0.391 . . . . 2.56 111.226 176.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.46 -84.4 0.1 Allowed 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.076 -0.712 . . . . 1.07 109.076 172.292 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 29.9 m -151.96 129.27 11.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.913 0.387 . . . . 1.05 111.067 171.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.7 132.58 33.83 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.383 -0.599 . . . . 1.07 109.383 176.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.699 HG22 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -141.95 169.8 13.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.488 0.661 . . . . 1.01 112.334 -174.094 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 14.2 t -130.95 100.53 5.28 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.66 -1.155 . . . . 0.39 109.459 179.306 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.776 ' SG ' ' HB3' ' A' ' 76' ' ' ALA . 1.4 m -88.88 125.52 34.97 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.79 0.805 . . . . 0.65 111.872 -178.429 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 10.0 t -85.26 -18.38 34.13 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 114.281 -1.327 . . . . 1.83 110.252 -179.057 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -110.82 140.81 44.94 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.64 -0.709 . . . . 1.6 109.577 178.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -119.74 24.64 10.47 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 120.975 -0.29 . . . . 3.24 111.695 -173.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 49.1 m-80 -86.5 56.82 4.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.333 0.587 . . . . 2.99 110.187 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 35.8 m -73.95 139.79 18.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.505 -0.771 . . . . 1.68 111.574 -175.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 19.6 m -90.86 10.83 24.67 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.013 -0.54 . . . . 1.88 111.431 -178.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.62 -34.76 2.94 Favored Glycine 0 C--O 1.228 -0.265 0 C-N-CA 120.944 -0.646 . . . . 0.56 113.995 173.167 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.5 m -139.98 -7.11 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 117.936 0.868 . . . . 1.18 111.264 176.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 11.2 pt -89.87 178.5 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.336 0.589 . . . . 1.12 111.347 -179.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.776 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -144.31 144.17 31.34 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 114.563 -1.199 . . . . 1.11 109.177 175.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 67.4 mt -123.01 132.52 71.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.915 0.388 . . . . 1.1 111.549 -176.163 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.444 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 74.22 50.22 10.75 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.743 -0.741 . . . . 0.2 112.017 177.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.485 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.2 m -98.46 136.07 39.13 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-O 121.177 0.513 . . . . 0.65 111.785 -176.336 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.435 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.2 mt -107.63 130.18 23.18 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.472 -0.785 . . . . 1.1 109.258 170.048 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 15.7 Cg_exo -67.12 121.41 8.57 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.808 2.339 . . . . 0.25 112.651 -177.569 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.0 m -111.39 149.15 14.21 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.852 0 CA-C-N 115.686 -0.688 . . . . 1.12 109.346 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.412 HG23 ' HG ' ' A' ' 84' ' ' LEU . 8.9 m -132.46 149.35 52.35 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 116.445 -0.343 . . . . 2.18 110.84 -174.45 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.412 ' HG ' HG23 ' A' ' 83' ' ' THR . 78.5 mt . . . . . 0 C--O 1.252 1.207 0 O-C-N 123.773 0.67 . . . . 4.14 111.298 176.473 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.751 0 N-CA-C 111.774 -0.531 . . . . 5.98 111.774 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.9 t -94.2 136.84 34.06 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.037 -0.357 . . . . 4.6 110.037 -179.546 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 70.4 m95 69.96 -64.54 0.35 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.4 0.68 . . . . 5.43 111.474 -178.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 126.98 169.66 12.75 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 121.228 -0.51 . . . . 2.46 111.875 179.37 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -100.93 112.86 25.39 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.08 -0.341 . . . . 4.59 110.08 178.498 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.451 ' HB2' HD13 ' A' ' 11' ' ' ILE . 33.3 t -150.85 74.05 1.14 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.882 0.372 . . . . 1.88 110.59 177.791 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 12.1 t 55.46 -143.64 0.72 Allowed 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 115.751 -0.659 . . . . 2.6 110.868 176.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.4 p -94.32 20.47 8.16 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.014 0.435 . . . . 4.25 110.839 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -101.29 -165.12 27.55 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.842 -0.694 . . . . 1.12 112.839 -176.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.8 t -123.09 151.44 42.03 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.186 -0.672 . . . . 1.43 109.186 -179.353 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.451 HD13 ' HB2' ' A' ' 6' ' ' CYS . 23.8 mt -113.05 130.79 66.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.822 0.82 . . . . 1.56 111.196 177.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.556 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -146.72 170.64 16.57 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 114.363 -1.29 . . . . 0.91 110.479 -178.792 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 39.5 t -120.03 107.11 12.68 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.834 -0.621 . . . . 0.34 109.657 177.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.868 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 97.4 m -84.92 127.41 34.15 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.297 -0.865 . . . . 0.19 110.863 -176.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.451 ' HA ' ' HB1' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -67.79 -36.06 79.76 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-N 115.181 -0.918 . . . . 0.39 109.403 173.77 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -133.9 111.55 10.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 1.12 110.631 177.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 92.8 t -97.97 106.85 19.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.786 -0.45 . . . . 1.04 109.786 176.28 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.1 m -131.79 140.49 38.42 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 116.31 -0.404 . . . . 1.03 111.013 -176.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.422 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.5 Cg_exo -60.36 140.31 91.1 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.389 2.059 . . . . 0.21 111.75 172.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.8 -19.81 69.8 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 121.02 -0.609 . . . . 0.18 112.488 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -100.76 5.45 43.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.112 0.482 . . . . 2.27 109.899 176.579 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.422 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 30.1 t -77.17 152.8 34.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.834 -0.621 . . . . 0.41 110.015 177.294 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -51.29 -41.02 60.17 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.959 0.409 . . . . 1.06 110.365 178.741 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.703 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 3.1 mm? -72.77 -62.91 1.28 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.757 -0.656 . . . . 1.77 110.618 178.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.47 -39.03 52.13 Favored Glycine 0 C--N 1.331 0.271 0 CA-C-N 116.153 -0.476 . . . . 0.16 113.15 -175.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.8 m -66.96 -47.8 70.5 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.728 0.299 . . . . 1.07 110.514 -178.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.435 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.4 tm? -65.75 -33.84 76.8 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.751 -0.463 . . . . 1.57 109.751 178.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.703 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 17.2 mt -67.92 -44.26 77.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 1.13 110.738 -178.012 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.546 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -79.62 -23.08 42.88 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.75 -0.38 . . . . 1.08 110.595 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.414 ' N ' HD12 ' A' ' 29' ' ' LEU . 15.0 t70 -64.09 -35.17 79.86 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.872 0.844 . . . . 0.66 109.568 172.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -74.85 -38.62 61.92 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 114.53 -1.214 . . . . 2.07 109.875 179.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 69.5 mt -81.88 -20.11 39.51 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 114.745 -1.116 . . . . 1.35 112.298 -176.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.86 34.39 30.91 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 121.183 -0.532 . . . . 0.75 112.347 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.546 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 40.4 mt -85.79 131.12 35.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.802 0.334 . . . . 1.24 110.929 -176.721 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 48.2 t -89.61 100.68 11.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 116.294 -0.412 . . . . 2.41 109.958 175.204 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.591 HD13 ' O ' ' A' ' 36' ' ' LEU . 1.2 pp -72.06 126.36 29.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.426 0.632 . . . . 3.28 110.705 179.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -78.4 -35.62 46.91 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 108.695 -0.854 . . . . 2.65 108.695 172.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -144.46 108.35 4.83 Favored Pre-proline 0 N--CA 1.442 -0.837 0 CA-C-N 114.606 -1.179 . . . . 2.29 107.892 176.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.88 -4.71 15.33 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.22 1.946 . . . . 0.77 111.522 -176.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 24.2 p -88.35 14.0 10.49 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.456 -0.793 . . . . 1.2 111.412 -174.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 19.3 m -102.84 158.36 4.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.045 -0.525 . . . . 1.08 110.448 179.143 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.41 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 92.6 mt -86.0 119.6 26.48 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.79 -0.641 . . . . 1.06 109.955 177.257 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.5 pt -102.81 134.13 44.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.213 0.53 . . . . 1.03 110.056 176.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.868 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -105.39 101.47 1.87 Allowed Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 120.531 -0.842 . . . . 0.31 112.944 -175.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -81.62 129.44 34.69 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.792 -0.818 . . . . 0.57 108.792 175.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.12 35.94 16.55 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 119.793 -1.194 . . . . 0.25 111.48 -175.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.521 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.79 110.02 22.2 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.194 0.521 . . . . 0.25 110.995 -174.373 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.433 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.4 t70 -101.96 135.77 19.63 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-N 115.424 -0.807 . . . . 2.21 110.495 175.089 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 12.4 Cg_exo -61.95 122.13 10.5 Favored 'Trans proline' 0 N--CA 1.462 -0.377 0 C-N-CA 123.453 2.769 . . . . 0.6 111.734 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 22.1 mt -79.22 88.39 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.4 0.619 . . . . 1.13 109.433 -178.389 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 12.5 t -118.03 11.98 13.52 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.427 -0.806 . . . . 1.22 110.248 -178.162 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.78 120.45 48.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.593 -0.73 . . . . 1.92 109.672 175.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -105.04 158.03 16.83 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.812 -0.631 . . . . 3.46 110.748 -176.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 134.74 -34.36 2.35 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.841 -0.695 . . . . 3.5 112.07 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.3 p -137.43 151.06 48.11 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.82 0.343 . . . . 5.24 110.736 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 32.3 t -74.65 -35.6 62.86 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.943 -0.572 . . . . 4.31 109.987 178.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -89.44 57.13 3.85 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.853 0.835 . . . . 3.13 109.53 176.649 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -70.34 -6.46 35.38 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.006 -0.997 . . . . 1.6 111.427 -179.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 45.5 t -162.01 143.33 10.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.564 -0.744 . . . . 1.02 109.225 175.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.4 t -107.62 -3.75 18.96 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.177 0.436 . . . . 2.56 112.177 -171.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.451 ' HB1' ' HA ' ' A' ' 15' ' ' GLN . . . -77.78 -89.09 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 C-N-CA 120.605 -0.438 . . . . 1.07 111.201 -179.357 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 28.4 m -151.08 125.75 9.62 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.684 0.278 . . . . 1.05 110.528 178.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.91 132.17 34.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.02 0.438 . . . . 1.07 110.066 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.741 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.4 m -143.14 172.04 8.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.261 0.553 . . . . 1.01 111.247 -177.7 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 51.9 t -138.11 104.72 5.3 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.238 -0.892 . . . . 0.39 109.3 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.754 ' SG ' ' HB3' ' A' ' 76' ' ' ALA . 1.3 m -89.24 132.38 34.91 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.555 0.693 . . . . 0.65 111.629 -178.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 33.5 t -76.22 -24.87 54.65 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.96 -1.018 . . . . 1.83 109.906 177.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -110.61 133.91 52.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.648 -0.705 . . . . 1.6 110.482 176.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -100.35 18.14 19.68 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.385 0.612 . . . . 3.24 109.968 179.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 -77.89 94.84 4.62 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.487 -0.779 . . . . 2.99 109.872 178.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 28.3 m -106.6 140.87 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 CA-C-N 116.166 -0.47 . . . . 1.68 111.739 -176.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.431 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 19.5 m -91.96 10.32 29.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.046 -0.525 . . . . 1.88 110.853 176.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.37 -34.63 3.01 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.159 -0.543 . . . . 0.56 113.668 174.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.0 m -140.7 -2.63 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 117.965 0.882 . . . . 1.18 111.692 176.426 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.483 ' HA ' ' O ' ' A' ' 44' ' ' GLY . 3.8 pt -95.99 -177.64 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-O 121.431 0.634 . . . . 1.12 112.322 -175.034 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.754 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -150.51 140.44 21.92 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.368 -1.287 . . . . 1.11 108.783 174.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.0 mt -117.14 126.08 74.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.982 0.42 . . . . 1.1 111.675 -175.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 79.15 52.02 5.07 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.957 -0.64 . . . . 0.2 111.825 177.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.465 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.28 132.29 43.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.396 0.617 . . . . 0.65 112.164 -176.46 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.412 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 87.9 mt -102.19 129.86 25.41 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.427 -0.806 . . . . 1.1 109.538 171.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 15.9 Cg_exo -67.33 120.16 7.2 Favored 'Trans proline' 0 C--O 1.235 0.361 0 C-N-CA 122.859 2.373 . . . . 0.25 112.111 -178.79 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 11.2 m -118.96 150.63 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.902 0 CA-C-N 115.813 -0.63 . . . . 1.12 110.015 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.439 HG21 ' HG ' ' A' ' 84' ' ' LEU . 26.0 m -138.61 133.97 33.15 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.277 -0.42 . . . . 2.18 110.155 179.111 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.439 ' HG ' HG21 ' A' ' 83' ' ' THR . 96.5 mt . . . . . 0 C--O 1.246 0.912 0 O-C-N 123.881 0.738 . . . . 4.14 111.128 -179.443 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.634 0 N-CA-C 112.171 -0.372 . . . . 5.98 112.171 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 32.4 t -96.24 4.92 52.02 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.075 0.464 . . . . 4.6 110.397 -179.124 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 71.9 t-105 -152.98 135.89 15.46 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.369 -0.604 . . . . 5.43 109.369 178.213 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.44 ' HA3' ' HB ' ' A' ' 11' ' ' ILE . . . -70.79 95.59 0.55 Allowed Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.93 -0.653 . . . . 2.46 112.589 179.623 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.0 mm-40 -75.76 134.08 40.55 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 110.239 -0.282 . . . . 4.59 110.239 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.438 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 40.6 t -141.28 53.93 1.54 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.956 0.408 . . . . 1.88 110.179 -179.451 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 37.3 m 63.14 -79.37 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 115.438 -0.801 . . . . 2.6 111.707 179.311 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.8 m -116.35 -28.43 6.5 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.965 0.412 . . . . 4.25 110.235 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -94.89 -175.23 38.11 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.828 -0.624 . . . . 1.12 112.968 -175.371 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 30.4 t -114.07 152.06 31.6 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.915 -0.402 . . . . 1.43 109.915 -177.309 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.44 ' HB ' ' HA3' ' A' ' 4' ' ' GLY . 28.0 mt -108.65 132.93 55.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.782 0.801 . . . . 1.56 111.325 177.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.577 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -140.34 165.53 27.16 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.559 -1.201 . . . . 0.91 110.501 179.843 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.457 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 40.1 t -110.81 104.22 12.82 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.666 -0.697 . . . . 0.34 109.443 178.327 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.769 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 69.3 m -90.73 130.6 36.7 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.012 -0.54 . . . . 0.19 111.585 -174.474 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.407 HE21 ' HB2' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -73.42 -28.94 62.26 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.069 -0.969 . . . . 0.39 110.007 176.374 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.435 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 5.2 t-20 -138.44 104.05 5.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.35 -0.386 . . . . 1.12 110.75 179.327 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 80.9 t -99.96 104.67 16.42 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 N-CA-C 109.917 -0.401 . . . . 1.04 109.917 178.122 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.0 m -132.37 143.86 50.64 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 116.064 -0.516 . . . . 1.03 110.976 -175.495 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.469 ' O ' ' HB3' ' A' ' 22' ' ' SER . 35.4 Cg_exo -60.85 136.61 67.23 Favored 'Trans proline' 0 N--CA 1.463 -0.307 0 C-N-CA 122.152 1.901 . . . . 0.21 111.36 172.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.38 -22.13 69.13 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 121.046 -0.597 . . . . 0.18 112.462 -178.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -98.15 3.14 49.08 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.144 0.497 . . . . 2.27 110.1 176.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.8 t -75.38 154.85 36.96 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.838 -0.619 . . . . 0.41 109.795 176.107 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -54.53 -41.03 69.23 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.367 0.603 . . . . 1.06 109.619 177.039 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.625 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.2 mm? -65.14 -65.05 0.72 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.875 -1.057 . . . . 1.77 110.698 175.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.4 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -56.6 -40.2 87.11 Favored Glycine 0 C--N 1.33 0.241 0 CA-C-N 115.972 -0.558 . . . . 0.16 113.614 -174.337 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 61.6 m -66.12 -42.06 89.7 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.918 0.39 . . . . 1.07 110.236 -178.586 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -65.92 -38.17 87.98 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.378 -0.601 . . . . 1.57 109.378 177.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.625 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.2 mt -65.4 -47.21 77.1 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 116.032 -0.531 . . . . 1.13 110.716 -176.7 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.513 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.87 -22.57 49.63 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.603 -0.439 . . . . 1.08 111.539 -176.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.483 ' N ' HD11 ' A' ' 29' ' ' LEU . 33.9 t70 -69.39 -34.58 74.72 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.518 0.675 . . . . 0.66 109.471 175.529 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -80.92 -10.71 59.69 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.058 -0.973 . . . . 2.07 110.118 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -108.93 -1.77 18.81 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.504 -0.771 . . . . 1.35 111.276 -178.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.51 43.48 98.96 Favored Glycine 0 C--N 1.331 0.272 0 CA-C-N 115.662 -0.699 . . . . 0.75 113.024 178.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.513 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 30.4 mt -95.36 137.96 22.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.962 0.41 . . . . 1.24 111.026 -177.211 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -97.99 103.19 14.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.867 -0.606 . . . . 2.41 110.055 175.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.468 HD13 ' O ' ' A' ' 36' ' ' LEU . 1.2 pp -74.31 133.28 42.57 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.356 0.598 . . . . 3.28 111.136 -179.523 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -88.78 -32.02 18.09 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 108.378 -0.971 . . . . 2.65 108.378 174.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -145.84 109.66 4.41 Favored Pre-proline 0 N--CA 1.439 -0.982 0 N-CA-C 107.269 -1.382 . . . . 2.29 107.269 175.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -74.24 -3.97 14.66 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 121.937 1.758 . . . . 0.77 112.429 -174.085 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 65.2 p -97.43 21.71 9.78 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.49 0.662 . . . . 1.2 111.188 -174.26 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.419 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 23.8 m -99.8 156.19 4.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.467 -0.788 . . . . 1.08 110.096 174.829 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.425 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.5 mt -85.07 124.18 31.46 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.24 -0.437 . . . . 1.06 110.123 177.215 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 14.4 pt -106.35 133.69 50.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.184 0.516 . . . . 1.03 110.134 175.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.769 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.38 100.48 1.08 Allowed Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.613 -0.803 . . . . 0.31 112.803 -176.087 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -80.6 146.44 31.22 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 109.564 -0.532 . . . . 0.57 109.564 177.217 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.404 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 74.18 36.46 50.88 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.07 -1.062 . . . . 0.25 111.571 -178.673 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.493 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -102.9 118.53 37.03 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.262 0.553 . . . . 0.25 111.456 -173.061 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.53 139.21 20.21 Favored Pre-proline 0 C--N 1.32 -0.697 0 CA-C-N 115.468 -0.787 . . . . 2.21 109.157 175.018 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -71.12 123.24 9.47 Favored 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 122.095 1.863 . . . . 0.6 111.287 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.403 HG13 ' HA ' ' A' ' 12' ' ' GLN . 13.1 mt -77.29 89.47 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.645 0.736 . . . . 1.13 109.853 -176.83 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 7.9 t -123.54 12.9 9.37 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 114.762 -1.108 . . . . 1.22 110.257 -176.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.5 p -95.31 141.12 15.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.231 -0.895 . . . . 1.92 110.045 177.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -121.43 165.04 16.17 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.275 -0.421 . . . . 3.46 110.765 -178.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 94.99 0.71 63.56 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.93 -0.652 . . . . 3.5 112.512 178.195 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 33.7 t -156.86 124.55 5.43 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.941 -0.392 . . . . 5.24 109.941 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.0 p -73.79 -21.72 60.07 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.094 -0.503 . . . . 4.31 110.47 177.425 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -81.46 52.43 1.86 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 122.017 0.913 . . . . 3.13 109.154 175.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -92.59 17.15 10.61 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.133 -0.94 . . . . 1.6 110.98 -176.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.1 t -138.67 131.44 29.31 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.816 -0.629 . . . . 1.02 110.014 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.2 p -90.61 -22.97 20.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.983 -0.553 . . . . 2.56 111.707 -178.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -129.49 -87.95 0.52 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 120.7 -0.4 . . . . 1.07 112.012 -177.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 60.3 m -131.28 130.67 43.12 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.808 0.337 . . . . 1.05 111.616 -175.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.73 131.64 34.08 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.34 -0.391 . . . . 1.07 109.962 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.622 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -143.06 166.67 14.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.062 0.458 . . . . 1.01 111.494 -175.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 31.5 t -128.27 104.64 7.85 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.435 -0.802 . . . . 0.39 110.15 178.485 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.753 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.6 m -93.2 136.92 33.01 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.61 0.719 . . . . 0.65 111.79 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.7 t -89.01 -20.52 24.3 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 114.784 -1.098 . . . . 1.83 110.458 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.467 ' HB3' ' OD1' ' A' ' 70' ' ' ASN . 44.6 m-20 -103.53 148.09 26.38 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.902 -0.59 . . . . 1.6 110.401 -177.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.6 m120 -119.75 3.75 11.09 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.511 -0.313 . . . . 3.24 111.155 -179.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.467 ' OD1' ' HB3' ' A' ' 68' ' ' ASP . 18.2 p-10 -79.56 63.29 4.11 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.736 0.779 . . . . 2.99 110.21 178.446 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.9 m -97.41 162.48 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.709 0 CA-C-N 115.372 -0.831 . . . . 1.68 111.29 -176.108 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.487 ' H ' HG12 ' A' ' 75' ' ' ILE . 87.9 p -85.14 -2.51 58.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.692 -0.685 . . . . 1.88 111.105 -177.554 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.42 -32.67 4.24 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.799 -0.715 . . . . 0.56 112.13 -179.108 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.6 m -130.86 -11.88 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.399 -0.52 . . . . 1.18 111.859 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.487 HG12 ' H ' ' A' ' 72' ' ' SER . 29.1 pt -87.69 178.88 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 C-N-CA 119.879 -0.729 . . . . 1.12 110.976 177.146 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.753 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -148.0 137.94 22.61 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 114.685 -1.143 . . . . 1.11 108.826 176.568 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 61.7 mt -120.05 130.74 73.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.874 0.368 . . . . 1.1 111.322 -175.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.58 50.52 6.52 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 121.139 -0.553 . . . . 0.2 112.042 178.528 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -99.41 136.07 39.89 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 112.446 0.535 . . . . 0.65 112.446 -175.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.433 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 97.4 mt -106.62 129.47 24.39 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.562 -0.745 . . . . 1.1 109.478 169.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 15.3 Cg_exo -67.63 124.89 12.51 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 123.092 2.528 . . . . 0.25 112.567 -177.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.8 m -126.68 159.91 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 116.128 -0.487 . . . . 1.12 110.273 179.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 22.6 m -124.3 134.47 53.19 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.365 -0.38 . . . . 2.18 110.333 177.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 95.6 mt . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.068 -0.968 . . . . 4.14 111.552 -179.547 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.655 0 N-CA-C 111.735 -0.546 . . . . 5.98 111.735 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.6 m -127.51 123.98 37.2 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.989 -0.375 . . . . 4.6 109.989 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -128.87 8.11 5.68 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.043 0.449 . . . . 5.43 110.902 177.276 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.15 58.5 2.08 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.946 -0.645 . . . . 2.46 113.107 177.395 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -78.98 110.97 14.71 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.829 -0.434 . . . . 4.59 109.829 175.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.456 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 44.4 t -128.22 -64.48 0.95 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.131 -0.486 . . . . 1.88 110.137 -179.224 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.7 p -172.74 -85.49 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.734 -0.666 . . . . 2.6 110.464 178.705 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.2 p -121.31 20.54 11.28 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.348 -0.387 . . . . 4.25 111.254 -179.77 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -139.08 -131.91 2.89 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.345 -0.931 . . . . 1.12 112.858 -176.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.9 t -145.86 152.21 39.11 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.492 -0.558 . . . . 1.43 109.492 -178.055 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.456 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 22.6 mt -105.63 131.47 54.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.682 0.753 . . . . 1.56 111.0 175.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.525 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -141.53 163.14 33.74 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.736 -1.12 . . . . 0.91 110.941 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.519 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 47.3 t -107.61 101.66 10.97 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.305 -0.861 . . . . 0.34 109.523 178.477 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.809 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 60.2 m -85.68 129.78 34.73 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.177 0.513 . . . . 0.19 111.281 -175.838 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.416 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -75.28 -30.17 60.33 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 115.17 -0.923 . . . . 0.39 109.644 177.311 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.409 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 4.8 t-20 -135.43 110.11 8.63 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.832 -0.622 . . . . 1.12 110.091 178.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.7 t -105.85 104.55 17.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.998 0.428 . . . . 1.04 109.887 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.0 m -135.86 146.31 56.45 Favored Pre-proline 0 C--N 1.322 -0.623 0 CA-C-N 115.984 -0.553 . . . . 1.03 111.191 -173.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.461 ' O ' ' HB3' ' A' ' 22' ' ' SER . 26.6 Cg_exo -62.18 137.98 69.48 Favored 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.16 1.907 . . . . 0.21 110.996 170.601 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.26 -30.16 76.68 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.002 -0.618 . . . . 0.18 112.547 -178.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -96.66 10.45 38.57 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.089 0.471 . . . . 2.27 110.272 177.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.461 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.9 t -77.59 154.85 31.93 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.502 -0.555 . . . . 0.41 109.502 174.436 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -49.69 -46.08 49.59 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.534 -0.543 . . . . 1.06 109.534 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.678 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.0 OUTLIER -64.07 -64.47 0.88 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 114.934 -1.03 . . . . 1.77 110.921 178.821 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.91 -37.65 62.92 Favored Glycine 0 C--N 1.331 0.298 0 CA-C-N 115.972 -0.558 . . . . 0.16 113.317 -175.135 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.1 m -69.54 -39.9 77.19 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.888 0.375 . . . . 1.07 110.666 -177.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -66.05 -39.76 90.39 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.024 -0.732 . . . . 1.57 109.024 177.04 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.678 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 18.9 mt -64.6 -53.41 48.12 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 114.848 -1.069 . . . . 1.13 110.914 -177.188 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.516 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -71.65 -22.88 61.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.445 -0.343 . . . . 1.08 111.307 -175.455 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.464 ' N ' HD13 ' A' ' 29' ' ' LEU . 20.6 t70 -63.59 -38.19 90.17 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.507 0.67 . . . . 0.66 109.915 174.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -76.34 -29.76 57.36 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.128 -0.942 . . . . 2.07 109.64 -178.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.5 mt -85.62 -12.01 52.5 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 114.779 -1.1 . . . . 1.35 111.451 -177.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.25 32.38 52.21 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.929 -0.578 . . . . 0.75 112.747 177.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.516 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 11.9 mt -94.11 141.59 14.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.664 0.269 . . . . 1.24 110.498 -177.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.9 p -128.11 102.85 9.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.497 0.665 . . . . 2.41 110.078 174.232 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.0 mt -94.58 145.6 24.7 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.898 -0.592 . . . . 3.28 110.557 -178.454 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -76.38 -27.88 56.53 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.924 -0.58 . . . . 2.65 109.892 178.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.426 ' C ' ' H ' ' A' ' 40' ' ' THR . 12.8 m-20 -139.31 92.52 10.52 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 115.621 -0.718 . . . . 2.29 109.251 174.814 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.44 6.61 1.82 Allowed 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.492 2.128 . . . . 0.77 111.749 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.426 ' H ' ' C ' ' A' ' 38' ' ' ASP . 7.5 p -75.01 -7.26 53.16 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.668 -0.696 . . . . 1.2 111.188 -179.084 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.4 m -83.02 163.04 3.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.858 -0.61 . . . . 1.08 110.711 178.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.436 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.3 mt -87.56 123.05 32.03 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.994 -0.548 . . . . 1.06 110.469 178.287 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.7 pt -105.33 138.26 31.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.073 -0.512 . . . . 1.03 110.092 175.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.809 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -116.64 102.71 1.06 Allowed Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.654 -0.784 . . . . 0.31 112.918 -175.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -81.06 143.59 32.36 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.397 -0.594 . . . . 0.57 109.397 177.019 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 72.28 38.8 58.51 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 119.958 -1.115 . . . . 0.25 111.752 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.519 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -103.94 116.57 32.49 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.969 0.414 . . . . 0.25 110.999 -173.273 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.461 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 2.5 p-10 -101.35 131.41 23.12 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 115.969 -0.56 . . . . 2.21 110.16 177.336 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -58.87 119.44 6.7 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.31 2.007 . . . . 0.6 110.642 175.075 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 14.4 mt -78.4 89.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.597 0.713 . . . . 1.13 110.131 -175.114 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 10.6 t -119.1 16.88 13.28 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.958 -1.019 . . . . 1.22 110.475 -177.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.3 p -85.83 137.82 20.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.483 -0.781 . . . . 1.92 110.584 179.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -111.52 142.82 43.3 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.434 -0.348 . . . . 3.46 110.647 179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 69.51 54.75 11.62 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 121.14 -0.553 . . . . 3.5 112.331 178.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 10.5 t -158.09 118.47 3.36 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 110.225 -0.287 . . . . 5.24 110.225 -178.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 6.2 p -73.68 -32.84 64.16 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.29 0.567 . . . . 4.31 109.614 176.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -83.26 54.39 2.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.91 0.862 . . . . 3.13 109.049 172.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -75.91 -10.84 59.76 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.335 -0.848 . . . . 1.6 109.937 177.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.5 t -157.55 118.47 3.55 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.895 -1.048 . . . . 1.02 109.861 177.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 19.9 m -92.6 -24.05 18.83 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.479 -0.328 . . . . 2.56 111.377 -179.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.416 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -97.72 -86.42 0.34 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.841 -0.344 . . . . 1.07 111.675 -177.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 33.4 m -148.46 126.65 12.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.762 0.315 . . . . 1.05 110.83 -178.256 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.4 ' HB2' ' O ' ' A' ' 82' ' ' VAL . . . -86.73 132.39 33.87 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.877 0.37 . . . . 1.07 110.14 -178.062 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.652 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.7 m -142.77 172.17 8.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-O 121.352 0.596 . . . . 1.01 111.521 -176.092 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 38.1 t -133.26 104.69 6.59 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.023 -0.99 . . . . 0.39 109.645 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.763 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -92.56 130.4 38.22 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.667 0.746 . . . . 0.65 111.828 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 55.0 m -76.93 -32.4 57.33 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.613 -1.176 . . . . 1.83 110.948 178.699 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -109.64 138.57 45.81 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.659 -0.701 . . . . 1.6 109.855 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -120.85 23.76 10.55 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.813 0.339 . . . . 3.24 111.453 -174.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 25.3 p-10 -81.31 56.89 3.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.858 0.837 . . . . 2.99 109.813 176.122 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 18.1 m -83.01 158.55 3.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 114.967 -1.015 . . . . 1.68 112.197 -171.14 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.471 ' OG ' HG12 ' A' ' 75' ' ' ILE . 95.1 p -82.75 -3.04 56.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.27 -0.877 . . . . 1.88 111.05 -178.2 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.84 -32.2 3.71 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 121.04 -0.6 . . . . 0.56 112.465 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.3 m -136.15 -7.56 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 C-N-CA 120.5 -0.48 . . . . 1.18 111.899 179.169 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.471 HG12 ' OG ' ' A' ' 72' ' ' SER . 32.2 pt -92.0 -177.45 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 C-N-CA 120.006 -0.678 . . . . 1.12 111.369 178.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.763 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.38 140.37 21.98 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 114.791 -1.095 . . . . 1.11 109.161 177.295 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 68.4 mt -122.02 123.94 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.071 0.462 . . . . 1.1 111.657 -175.508 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 81.95 51.85 4.32 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.904 -0.665 . . . . 0.2 111.596 179.361 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.436 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.23 136.43 39.2 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.244 0.545 . . . . 0.65 112.187 -175.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.435 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 92.1 mt -110.66 131.28 22.17 Favored Pre-proline 0 C--N 1.321 -0.65 0 CA-C-N 115.54 -0.754 . . . . 1.1 109.703 171.653 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 22.6 Cg_exo -64.93 131.87 30.38 Favored 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 123.137 2.558 . . . . 0.25 112.868 -177.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.4 ' O ' ' HB2' ' A' ' 63' ' ' ALA . 3.4 m -133.71 159.51 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 CA-C-N 115.75 -0.659 . . . . 1.12 109.58 177.275 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.9 m -95.6 112.55 24.25 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 121.13 -0.228 . . . . 2.18 111.171 -179.023 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 10.0 mp . . . . . 0 C--O 1.251 1.168 0 O-C-N 124.549 1.156 . . . . 4.14 112.773 174.246 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.804 0 N-CA-C 112.5 -0.24 . . . . 5.98 112.5 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.6 m -80.16 77.54 6.88 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.04 0.448 . . . . 4.6 111.274 -177.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 97.6 m95 -132.12 27.27 4.52 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.915 -0.584 . . . . 5.43 110.065 177.336 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.17 17.64 80.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.803 -0.713 . . . . 2.46 112.387 -178.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 76.4 mm-40 -84.31 109.57 17.91 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.105 0.479 . . . . 4.59 111.198 -178.196 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.477 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 44.2 t -143.91 142.93 31.04 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.59 -0.732 . . . . 1.88 109.866 179.632 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 12.1 p -72.14 -17.89 61.93 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.0 -0.545 . . . . 2.6 111.785 -175.751 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.6 p -108.47 9.61 27.5 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.709 0.29 . . . . 4.25 111.713 179.154 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 142.86 -127.58 3.18 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.286 -0.959 . . . . 1.12 113.211 177.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.7 t -113.85 153.62 28.86 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.656 -0.498 . . . . 1.43 109.656 -175.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.477 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 22.8 mt -104.43 133.61 48.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.664 0.745 . . . . 1.56 111.619 178.699 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.462 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -144.28 163.03 34.89 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 114.524 -1.216 . . . . 0.91 110.121 178.165 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 34.6 t -114.92 109.36 18.02 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.076 -0.713 . . . . 0.34 109.076 176.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.783 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 96.8 m -88.96 134.93 33.8 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.392 -0.822 . . . . 0.19 111.35 -173.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.438 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -75.39 -28.25 59.39 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.158 -0.928 . . . . 0.39 109.775 178.461 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -141.77 103.52 4.37 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.147 -0.479 . . . . 1.12 110.73 177.555 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 98.6 t -93.85 105.93 17.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 116.178 -0.465 . . . . 1.04 109.787 177.235 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.41 142.42 45.33 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.149 -0.478 . . . . 1.03 111.067 -176.144 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.546 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.4 Cg_exo -58.92 139.21 89.84 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.382 2.054 . . . . 0.21 111.392 172.167 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.37 -20.01 71.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.824 -0.703 . . . . 0.18 112.317 -179.187 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 17.2 p-10 -101.87 7.4 41.61 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.311 0.577 . . . . 2.27 109.962 176.316 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.546 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 13.5 t -74.12 154.27 39.21 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.554 -0.748 . . . . 0.41 109.78 174.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -56.28 -39.88 73.37 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.955 0.407 . . . . 1.06 110.08 177.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.641 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER -70.45 -60.19 2.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.545 -0.752 . . . . 1.77 110.431 175.825 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.488 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.43 -41.5 80.71 Favored Glycine 0 C--N 1.331 0.252 0 CA-C-N 115.922 -0.581 . . . . 0.16 113.33 -175.497 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.4 m -66.05 -41.73 90.43 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.748 0.308 . . . . 1.07 110.37 -178.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -64.76 -37.58 88.08 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.561 -0.533 . . . . 1.57 109.561 177.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.641 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.4 mt -66.16 -49.65 66.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.924 -0.58 . . . . 1.13 110.637 -177.596 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.523 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -76.32 -21.76 55.79 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.481 -0.327 . . . . 1.08 111.172 -177.377 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.489 ' N ' HD13 ' A' ' 29' ' ' LEU . 29.8 t70 -66.51 -33.36 75.52 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.723 0.773 . . . . 0.66 109.64 175.007 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -76.21 -25.07 54.73 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.586 -1.188 . . . . 2.07 109.361 179.092 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 94.6 mt -94.46 -17.19 22.7 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.814 -1.084 . . . . 1.35 111.811 -175.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 80.44 35.69 25.47 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.155 -0.545 . . . . 0.75 112.582 178.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.523 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 22.7 mt -98.52 130.83 46.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.684 0.278 . . . . 1.24 110.713 -177.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.401 HG13 ' O ' ' A' ' 35' ' ' VAL . 5.6 p -118.72 100.05 9.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.917 0.865 . . . . 2.41 110.569 176.29 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 23.0 mt -82.57 143.44 31.03 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.469 -0.787 . . . . 3.28 111.558 -176.593 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -71.02 -38.47 72.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.225 -0.898 . . . . 2.65 109.254 174.157 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.427 ' C ' ' H ' ' A' ' 40' ' ' THR . 6.8 m-20 -125.15 91.63 48.83 Favored Pre-proline 0 N--CA 1.447 -0.583 0 CA-C-N 115.069 -0.969 . . . . 2.29 108.438 174.017 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.02 4.12 1.66 Allowed 'Trans proline' 0 C--O 1.225 -0.147 0 C-N-CA 122.54 2.16 . . . . 0.77 111.971 -178.076 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.427 ' H ' ' C ' ' A' ' 38' ' ' ASP . 18.3 p -82.79 -10.9 58.66 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.931 -0.577 . . . . 1.2 111.1 -177.777 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.9 m -71.24 160.56 5.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 1.08 111.331 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 97.4 mt -91.17 127.42 36.59 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.855 -0.611 . . . . 1.06 110.505 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.8 pt -107.41 136.85 41.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.098 0.475 . . . . 1.03 110.335 176.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.783 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -110.2 98.82 1.12 Allowed Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 120.815 -0.707 . . . . 0.31 113.199 -175.156 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -79.63 141.68 36.28 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.439 -0.578 . . . . 0.57 109.439 177.421 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.438 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 71.99 41.41 54.88 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.151 -1.023 . . . . 0.25 112.161 -179.347 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.533 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.74 117.94 35.34 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.196 0.522 . . . . 0.25 111.614 -172.533 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.485 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 1.6 t70 -101.91 136.03 19.59 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 115.401 -0.818 . . . . 2.21 110.35 174.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.485 ' HD2' ' OD1' ' A' ' 48' ' ' ASP . 1.3 Cg_endo -67.6 120.94 7.98 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.046 2.497 . . . . 0.6 111.868 -177.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 17.7 mt -80.02 92.64 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.277 0.56 . . . . 1.13 109.962 -177.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.6 t -133.66 21.06 3.9 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.556 -0.747 . . . . 1.22 111.026 -176.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.8 p -97.99 128.48 49.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.249 0.547 . . . . 1.92 110.427 176.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -95.83 157.29 15.96 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.854 -0.612 . . . . 3.46 110.341 179.107 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 81.05 -56.84 4.85 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.849 -0.691 . . . . 3.5 112.033 -178.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.9 m -67.9 103.45 1.47 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.956 0.408 . . . . 5.24 110.525 178.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 7.6 m -75.53 -23.61 56.69 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.009 -0.542 . . . . 4.31 110.535 -178.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -82.42 50.96 1.73 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.893 -0.594 . . . . 3.13 109.998 179.131 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -93.8 17.7 11.58 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.785 -0.643 . . . . 1.6 112.61 -172.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 42.6 t -149.38 116.68 6.09 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.825 -0.35 . . . . 1.02 110.887 178.497 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 20.2 m -90.48 -15.53 30.63 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 112.133 0.42 . . . . 2.56 112.133 -176.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' A' ' 14' ' ' CYS . . . -133.14 -83.25 0.47 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.349 -0.54 . . . . 1.07 112.254 -177.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 23.0 m -138.5 129.57 26.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.787 0.327 . . . . 1.05 111.608 -175.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.24 129.28 34.9 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-O 120.981 0.42 . . . . 1.07 110.319 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.547 HG23 ' SG ' ' A' ' 14' ' ' CYS . 6.4 m -141.64 157.87 21.28 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 121.446 0.641 . . . . 1.01 111.236 -177.249 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 35.3 t -116.18 111.2 19.87 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.206 -0.906 . . . . 0.39 108.722 173.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.624 ' HA ' ' HA ' ' A' ' 79' ' ' CYS . 0.5 OUTLIER -103.71 135.91 44.4 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.744 0.783 . . . . 0.65 111.91 -173.043 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 32.2 t -81.53 -35.22 30.58 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 114.55 -1.205 . . . . 1.83 111.309 -174.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -91.95 131.62 37.12 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.01 0.433 . . . . 1.6 110.419 -179.701 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.428 ' N ' HD21 ' A' ' 69' ' ' ASN . 0.9 OUTLIER -106.11 11.11 31.77 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.94 -0.573 . . . . 3.24 111.034 -177.749 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -95.28 72.57 3.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.468 0.651 . . . . 2.99 109.786 -178.507 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 35.2 m -74.97 153.06 6.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.35 -0.841 . . . . 1.68 111.606 -176.429 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -90.72 8.25 35.46 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.807 -0.633 . . . . 1.88 110.148 179.507 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.98 -34.08 3.2 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.63 -0.714 . . . . 0.56 112.83 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 m -140.99 -17.05 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 117.218 0.509 . . . . 1.18 111.958 176.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 18.3 pt -81.95 -175.41 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.478 0.656 . . . . 1.12 112.298 -176.28 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.4 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -151.05 141.73 22.71 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.236 -1.347 . . . . 1.11 107.874 173.548 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.2 mt -119.05 123.54 71.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 118.32 0.509 . . . . 1.1 112.226 -174.272 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.85 53.29 4.62 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.926 -0.654 . . . . 0.2 111.547 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.624 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 3.8 m -99.94 143.34 30.27 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.153 0.501 . . . . 0.65 111.305 -176.804 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 80.3 mt -109.25 131.76 21.65 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 115.484 -0.78 . . . . 1.1 110.372 175.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.403 ' HA ' HG13 ' A' ' 64' ' ' VAL . 15.9 Cg_exo -67.41 121.99 9.17 Favored 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.891 2.394 . . . . 0.25 111.902 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.8 m -115.21 141.68 31.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-O 121.674 0.75 . . . . 1.12 111.167 -178.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 15.3 t -148.46 30.22 0.84 Allowed 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 123.563 1.649 . . . . 2.18 108.892 -178.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 69.6 mt . . . . . 0 C--N 1.296 -1.757 0 CA-C-N 111.88 -2.418 . . . . 4.14 110.007 -175.028 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.811 0 N-CA-C 111.757 -0.537 . . . . 5.98 111.757 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.1 t -126.97 126.65 43.55 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.964 -0.384 . . . . 4.6 109.964 -179.277 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 11.7 m-90 -103.26 -3.51 25.58 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.408 0.623 . . . . 5.43 109.992 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 146.53 176.78 20.63 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.624 -0.99 . . . . 2.46 110.624 -176.165 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 12.3 mm100 -81.98 107.58 14.8 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 117.163 0.482 . . . . 4.59 110.486 -178.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 42.5 t 174.21 158.2 0.15 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.42 -0.809 . . . . 1.88 109.434 -178.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 9.5 p -132.59 16.69 4.37 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.95 0.405 . . . . 2.6 111.258 178.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.402 HG23 ' HB2' ' A' ' 67' ' ' SER . 30.8 m -87.43 -23.28 24.55 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.269 -0.423 . . . . 4.25 111.49 -175.554 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 169.07 -103.87 0.2 Allowed Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.438 -0.887 . . . . 1.12 112.306 -178.674 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.6 t -124.59 144.86 49.92 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 108.852 -0.796 . . . . 1.43 108.852 178.374 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.541 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.1 mp -98.47 141.96 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 121.652 0.739 . . . . 1.56 111.509 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.594 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -145.75 166.39 26.01 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 114.793 -1.094 . . . . 0.91 110.723 178.75 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 37.1 t -114.83 104.93 12.43 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.613 -0.721 . . . . 0.34 109.552 179.286 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.765 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 63.4 m -87.69 133.06 33.9 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.519 -0.764 . . . . 0.19 111.199 -175.505 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.406 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -71.27 -27.31 63.35 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 115.251 -0.886 . . . . 0.39 108.939 173.529 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -145.63 128.39 16.27 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.64 -0.709 . . . . 1.12 110.135 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.6 t -115.73 106.09 19.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.906 0.384 . . . . 1.04 110.27 177.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.9 m -131.91 143.35 48.67 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.026 -0.534 . . . . 1.03 110.922 -175.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.479 ' O ' ' HA3' ' A' ' 25' ' ' GLY . 26.6 Cg_exo -62.8 139.85 76.89 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.225 1.95 . . . . 0.21 111.339 172.258 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.9 -22.57 70.43 Favored Glycine 0 C--N 1.329 0.159 0 C-N-CA 120.967 -0.635 . . . . 0.18 112.62 -177.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -100.39 5.83 44.39 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.636 0.732 . . . . 2.27 109.793 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.6 t -75.13 155.11 37.39 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.656 -0.702 . . . . 0.41 110.272 177.114 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -54.51 -41.31 69.49 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.185 0.517 . . . . 1.06 110.116 177.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.668 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.7 mm? -73.34 -57.75 3.79 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.692 -0.685 . . . . 1.77 110.66 177.427 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.479 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -54.52 -40.06 68.33 Favored Glycine 0 C--N 1.33 0.205 0 C-N-CA 121.249 -0.5 . . . . 0.16 113.095 -176.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 90.7 m -69.81 -40.75 75.74 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.7 0.286 . . . . 1.07 110.311 -178.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.441 ' O ' HD12 ' A' ' 27' ' ' LEU . 2.6 tm? -66.85 -36.85 83.27 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.539 -0.541 . . . . 1.57 109.539 177.059 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.668 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 12.5 mt -68.21 -47.32 68.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.89 -0.595 . . . . 1.13 110.801 -177.13 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.531 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.5 pp -74.11 -23.67 59.34 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.808 -0.357 . . . . 1.08 110.676 -179.063 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -61.68 -36.61 81.35 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.474 0.654 . . . . 0.66 109.762 173.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -73.95 -29.63 62.11 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-N 114.983 -1.008 . . . . 2.07 110.03 179.418 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 90.9 mt -93.13 -16.53 24.81 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.832 -1.076 . . . . 1.35 112.157 -172.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.76 35.8 34.74 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 121.263 -0.494 . . . . 0.75 112.624 178.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.531 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 18.4 mt -94.25 139.8 17.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.702 0.287 . . . . 1.24 110.63 -177.145 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.9 t -122.16 98.17 5.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 109.83 -0.433 . . . . 2.41 109.83 176.287 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 22.7 mt -83.13 135.56 34.77 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.17 -0.468 . . . . 3.28 111.251 -177.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 -73.36 -24.18 60.3 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.717 -0.674 . . . . 2.65 109.907 174.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -136.77 89.57 17.52 Favored Pre-proline 0 N--CA 1.446 -0.659 0 N-CA-C 108.026 -1.102 . . . . 2.29 108.026 178.285 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.29 -1.04 9.03 Favored 'Trans proline' 0 CA--C 1.519 -0.27 0 C-N-CA 122.193 1.929 . . . . 0.77 112.096 -177.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.7 p -93.36 20.57 6.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.407 0.622 . . . . 1.2 111.246 -177.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.411 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 32.0 m -101.75 162.72 3.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.551 -0.75 . . . . 1.08 110.064 174.176 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.43 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.7 mt -86.62 121.47 29.19 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.142 -0.481 . . . . 1.06 109.969 176.413 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 17.5 pt -104.15 137.69 31.93 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 CA-C-O 121.208 0.528 . . . . 1.03 110.132 176.301 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.765 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -107.42 110.05 3.13 Favored Glycine 0 N--CA 1.44 -1.059 0 C-N-CA 120.605 -0.807 . . . . 0.31 112.82 -176.608 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -86.05 132.73 33.99 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.032 -0.729 . . . . 0.57 109.032 175.278 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.43 37.69 26.93 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.001 -1.095 . . . . 0.25 111.734 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.537 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.23 116.42 32.14 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.139 0.495 . . . . 0.25 111.368 -173.373 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.424 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 6.6 m-20 -100.35 131.9 23.31 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.405 -0.816 . . . . 2.21 109.158 175.099 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.471 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 12.4 Cg_exo -63.87 123.28 11.71 Favored 'Trans proline' 0 N--CA 1.461 -0.408 0 C-N-CA 122.742 2.294 . . . . 0.6 110.965 178.39 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.465 HG13 ' HA ' ' A' ' 12' ' ' GLN . 24.8 mt -80.67 89.29 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.498 0.666 . . . . 1.13 110.417 -175.622 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.8 t -126.45 14.02 7.64 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.666 0.746 . . . . 1.22 109.768 177.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 13.0 p -82.01 147.15 6.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.095 -0.957 . . . . 1.92 109.786 178.051 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -80.68 59.94 3.81 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.327 0.584 . . . . 3.46 110.746 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.65 112.6 1.9 Allowed Glycine 0 N--CA 1.445 -0.744 0 CA-C-N 115.648 -0.705 . . . . 3.5 111.662 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 32.4 m -90.08 -29.54 18.29 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 120.902 0.382 . . . . 5.24 110.758 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 28.0 m -90.24 -24.69 20.89 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.912 0.387 . . . . 4.31 110.588 177.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -134.41 80.22 1.84 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.832 -0.622 . . . . 3.13 109.861 -177.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -101.24 -30.18 11.67 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.735 -0.666 . . . . 1.6 111.032 178.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.0 t -147.67 142.47 26.78 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.413 -0.812 . . . . 1.02 110.837 -178.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.6 p -102.71 -40.78 6.45 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.98 -0.554 . . . . 2.56 111.604 -179.333 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.406 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -101.14 -85.99 0.41 Allowed 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 121.051 -0.26 . . . . 1.07 111.567 -176.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 26.9 m -132.47 129.18 38.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.666 0.269 . . . . 1.05 111.302 -177.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -86.63 130.57 34.43 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.911 0.386 . . . . 1.07 110.142 179.249 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.665 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.7 m -143.06 169.82 11.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.259 0.552 . . . . 1.01 111.415 -176.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . 0.413 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 38.0 t -137.29 107.67 6.47 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.478 -0.783 . . . . 0.39 109.862 -178.669 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.759 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.8 m -93.48 137.63 32.57 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.442 0.639 . . . . 0.65 111.735 -177.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.402 ' HB2' HG23 ' A' ' 8' ' ' THR . 38.2 t -87.24 -20.09 27.41 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.128 -0.942 . . . . 1.83 110.955 179.45 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.4 t70 -98.92 160.41 14.28 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.161 -0.472 . . . . 1.6 109.993 -177.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -118.67 5.72 11.59 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 111.928 0.344 . . . . 3.24 111.928 -173.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -84.7 89.63 7.54 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.014 0.435 . . . . 2.99 110.764 -179.019 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.9 m -100.06 130.93 48.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.03 0.443 . . . . 1.68 111.327 179.275 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.429 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 9.2 t -80.5 -1.47 41.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.046 -0.524 . . . . 1.88 110.484 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.2 -33.89 3.21 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.833 -0.621 . . . . 0.56 112.585 178.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.7 m -140.72 4.58 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 117.202 0.501 . . . . 1.18 111.788 175.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.489 ' HA ' ' O ' ' A' ' 44' ' ' GLY . 19.2 pt -100.2 176.63 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.466 0.651 . . . . 1.12 112.039 179.726 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.759 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -145.93 140.57 27.04 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 114.291 -1.322 . . . . 1.11 109.411 174.722 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 71.0 mt -120.84 127.22 75.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.894 0.378 . . . . 1.1 111.461 -177.377 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.528 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 81.77 48.92 5.61 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 121.026 -0.607 . . . . 0.2 112.064 177.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.43 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.3 140.42 33.5 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 112.665 0.617 . . . . 0.65 112.665 -175.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.414 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.9 mt -111.34 132.75 21.63 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.43 -0.805 . . . . 1.1 109.603 170.546 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 16.9 Cg_exo -66.6 121.75 9.04 Favored 'Trans proline' 0 C--O 1.232 0.217 0 C-N-CA 122.974 2.449 . . . . 0.25 112.638 -178.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.423 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 6.2 m -124.22 161.23 27.48 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.671 0 CA-C-N 115.917 -0.583 . . . . 1.12 110.042 -179.607 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 28.8 m -144.98 133.7 22.23 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 116.656 -0.247 . . . . 2.18 110.761 176.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 89.0 mt . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.365 -0.826 . . . . 4.14 111.963 178.632 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.753 0 N-CA-C 112.061 -0.416 . . . . 5.98 112.061 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.4 m -88.56 46.95 1.44 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.805 0.336 . . . . 4.6 111.574 -177.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 28.5 m-90 -117.55 125.31 50.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.797 0.332 . . . . 5.43 110.281 176.002 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -89.58 65.01 3.1 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 121.022 -0.608 . . . . 2.46 111.804 178.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -87.83 133.99 33.78 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.013 0.435 . . . . 4.59 110.437 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.452 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 21.9 t -134.47 143.99 47.83 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.692 -0.686 . . . . 1.88 109.954 -177.209 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 11.9 p -74.04 -10.46 59.65 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.255 -0.43 . . . . 2.6 111.551 -177.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.588 ' HB ' ' SG ' ' A' ' 65' ' ' CYS . 5.5 m -103.19 -8.83 20.11 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.185 0.517 . . . . 4.25 110.367 177.844 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 152.93 -126.19 1.94 Allowed Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.559 -0.829 . . . . 1.12 112.651 -179.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 41.1 t -107.63 151.25 25.89 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 110.299 -0.26 . . . . 1.43 110.299 -177.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.452 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 41.3 mt -102.83 137.49 30.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.517 0.675 . . . . 1.56 110.709 173.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.54 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -144.08 159.34 42.78 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.01 -0.995 . . . . 0.91 110.531 179.007 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.458 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 41.7 t -105.5 102.58 12.04 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.794 -0.639 . . . . 0.34 109.686 178.598 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.796 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 81.9 m -85.77 135.43 33.74 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.489 -0.778 . . . . 0.19 110.817 -176.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.74 -31.04 59.41 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 115.408 -0.815 . . . . 0.39 109.298 174.708 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -138.12 118.29 13.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.81 -0.632 . . . . 1.12 110.245 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.3 t -110.69 103.04 14.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 121.042 0.448 . . . . 1.04 110.094 178.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.0 m -133.31 142.67 45.11 Favored Pre-proline 0 C--N 1.32 -0.688 0 CA-C-N 115.83 -0.623 . . . . 1.03 110.993 -174.392 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.462 ' O ' ' HB3' ' A' ' 22' ' ' SER . 38.3 Cg_exo -60.17 139.9 89.55 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.161 1.907 . . . . 0.21 111.407 172.58 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.23 -21.78 70.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.814 -0.708 . . . . 0.18 112.342 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -94.22 -4.97 48.0 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.211 0.529 . . . . 2.27 110.524 175.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.462 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 30.0 t -68.79 154.5 41.88 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.813 -0.63 . . . . 0.41 110.54 179.041 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -52.42 -44.27 65.33 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.332 0.587 . . . . 1.06 110.1 178.067 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.649 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.2 mm? -70.6 -58.05 4.09 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.503 -0.771 . . . . 1.77 110.847 178.197 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.461 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.56 -39.41 74.66 Favored Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.227 -0.511 . . . . 0.16 113.307 -176.452 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 87.1 m -67.84 -42.1 81.95 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 120.827 0.346 . . . . 1.07 110.325 -179.015 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -61.89 -43.1 99.53 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.216 -0.661 . . . . 1.57 109.216 175.222 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.649 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.7 mt -61.46 -51.55 68.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.135 -0.939 . . . . 1.13 111.125 -175.633 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.508 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -76.37 -23.89 54.14 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.723 -0.391 . . . . 1.08 111.677 -175.322 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.5 ' N ' HD13 ' A' ' 29' ' ' LEU . 11.8 t70 -68.11 -33.49 74.61 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.512 0.672 . . . . 0.66 109.363 176.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -78.33 -23.83 46.85 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.287 -0.869 . . . . 2.07 109.962 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.7 mt -97.34 -5.24 36.95 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.193 -0.912 . . . . 1.35 111.878 -174.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 68.31 44.48 74.59 Favored Glycine 0 N--CA 1.453 -0.229 0 CA-C-N 115.74 -0.663 . . . . 0.75 112.896 177.348 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.508 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 23.3 mt -97.57 145.53 9.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.673 0.273 . . . . 1.24 110.637 -178.43 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.8 t -107.88 116.27 50.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.127 -0.488 . . . . 2.41 109.695 176.06 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.556 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.5 pp -90.81 129.95 36.83 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.25 0.547 . . . . 3.28 111.25 -179.241 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -90.96 -26.79 19.08 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.917 -0.771 . . . . 2.65 108.917 170.289 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -139.42 94.92 9.3 Favored Pre-proline 0 N--CA 1.447 -0.613 0 CA-C-N 114.92 -1.037 . . . . 2.29 108.495 177.369 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -68.43 -3.93 11.94 Favored 'Trans proline' 0 N--CA 1.466 -0.137 0 C-N-CA 122.256 1.971 . . . . 0.77 111.564 -177.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.8 p -87.89 6.2 36.73 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.337 -0.847 . . . . 1.2 111.45 -175.497 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.41 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.9 m -92.73 158.26 2.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.209 0.528 . . . . 1.08 110.875 179.407 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.9 mt -88.21 128.62 35.46 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.476 -0.784 . . . . 1.06 109.806 175.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 10.2 pt -106.83 133.07 52.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.203 0.525 . . . . 1.03 110.091 176.118 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.796 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.78 98.16 1.3 Allowed Glycine 0 N--CA 1.438 -1.19 0 CA-C-N 115.385 -0.825 . . . . 0.31 113.02 -175.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -77.4 137.84 38.94 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.583 -0.525 . . . . 0.57 109.583 177.286 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 71.48 41.08 58.82 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.431 -0.89 . . . . 0.25 112.072 -178.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.54 ' SG ' ' HB2' ' A' ' 12' ' ' GLN . 0.1 OUTLIER -105.14 111.28 23.99 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.294 0.569 . . . . 0.25 111.225 -175.312 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.432 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.5 t70 -101.43 138.53 19.93 Favored Pre-proline 0 C--N 1.316 -0.849 0 CA-C-N 115.483 -0.781 . . . . 2.21 110.927 175.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 25.7 Cg_exo -58.9 119.3 6.46 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 123.626 2.884 . . . . 0.6 111.628 177.671 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 29.7 mt -80.48 102.3 6.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.054 0.454 . . . . 1.13 110.501 -177.205 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.9 t -133.68 16.36 3.96 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.521 0.677 . . . . 1.22 110.601 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 5.4 p -128.68 154.24 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.637 -0.71 . . . . 1.92 109.853 178.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . 70.39 -63.27 0.41 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 123.387 0.675 . . . . 3.46 112.396 175.567 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 174.68 -114.43 0.5 Allowed Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 121.133 -0.556 . . . . 3.5 111.837 -178.505 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 67.8 m -150.83 -37.05 0.14 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.618 0.247 . . . . 5.24 111.186 177.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.1 m -81.52 -62.22 1.71 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.884 0.373 . . . . 4.31 110.522 178.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -89.88 41.7 1.06 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 122.102 0.953 . . . . 3.13 109.656 -179.712 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -129.88 17.81 5.66 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.152 -0.931 . . . . 1.6 110.386 -179.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.8 t -151.34 127.99 10.83 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.77 -0.65 . . . . 1.02 109.786 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 28.5 t -94.4 -37.76 11.29 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.381 -0.372 . . . . 2.56 111.101 -178.205 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -86.59 -86.46 0.15 Allowed 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 121.181 -0.208 . . . . 1.07 111.499 -176.655 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 19.2 m -149.89 130.98 14.41 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.773 0.321 . . . . 1.05 111.145 -178.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.448 ' HB1' ' O ' ' A' ' 82' ' ' VAL . . . -94.95 139.47 31.29 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.852 0.358 . . . . 1.07 110.4 -178.284 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.523 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 7.2 m -145.55 162.97 11.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.315 0.578 . . . . 1.01 111.285 -177.6 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . 0.588 ' SG ' ' HB ' ' A' ' 8' ' ' THR . 30.2 t -115.44 107.8 15.67 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.122 -0.944 . . . . 0.39 109.703 175.678 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.653 ' SG ' ' HB2' ' A' ' 76' ' ' ALA . 28.3 m -100.12 140.04 34.93 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.212 0.53 . . . . 0.65 111.441 -176.682 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 40.0 m -97.35 -20.54 17.76 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.633 -0.712 . . . . 1.83 111.241 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -110.43 139.59 45.49 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.997 -0.547 . . . . 1.6 110.372 -176.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -117.14 25.8 10.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.4 -0.364 . . . . 3.24 111.939 -175.033 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 54.8 t30 -80.55 71.61 7.41 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.597 0.713 . . . . 2.99 109.635 176.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 32.7 m -84.66 146.57 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 CA-C-N 115.541 -0.754 . . . . 1.68 112.125 -173.549 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.553 ' OG ' HG12 ' A' ' 75' ' ' ILE . 80.2 p -95.4 5.26 52.1 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.387 -0.824 . . . . 1.88 110.222 177.457 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.71 -32.7 3.43 Favored Glycine 0 N--CA 1.445 -0.711 0 CA-C-N 115.361 -0.836 . . . . 0.56 111.88 -176.253 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.3 m -140.24 -21.42 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 112.558 0.577 . . . . 1.18 112.558 176.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.553 HG12 ' OG ' ' A' ' 72' ' ' SER . 7.4 pt -73.21 175.45 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.707 0.765 . . . . 1.12 112.343 -173.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.653 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -150.21 141.39 23.12 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.233 -1.348 . . . . 1.11 108.565 178.312 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.5 mt -120.78 140.27 45.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 C-N-CA 120.514 -0.474 . . . . 1.1 111.484 -175.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.41 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 72.06 52.75 10.49 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-N 115.95 -0.568 . . . . 0.2 111.908 178.163 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.523 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 12.2 m -106.58 145.03 32.4 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.04 0.448 . . . . 0.65 111.969 -174.079 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.403 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 91.3 mt -115.92 132.2 23.33 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 115.514 -0.766 . . . . 1.1 109.811 173.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.443 ' HA ' HG12 ' A' ' 64' ' ' VAL . 18.3 Cg_exo -64.77 129.06 22.41 Favored 'Trans proline' 0 C--O 1.234 0.297 0 C-N-CA 123.19 2.593 . . . . 0.25 112.982 -176.686 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.448 ' O ' ' HB1' ' A' ' 63' ' ' ALA . 5.4 m -136.7 157.67 36.62 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.596 0 CA-C-N 115.812 -0.631 . . . . 1.12 110.333 178.532 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.444 HG22 ' N ' ' A' ' 84' ' ' LEU . 85.0 m 65.72 162.79 0.15 Allowed 'General case' 0 CA--C 1.545 0.784 0 O-C-N 123.395 0.434 . . . . 2.18 111.755 176.079 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.444 ' N ' HG22 ' A' ' 83' ' ' THR . 75.6 mt . . . . . 0 C--O 1.248 1.011 0 CA-C-O 119.017 -0.516 . . . . 4.14 111.16 177.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.7 0 N-CA-C 111.75 -0.54 . . . . 5.98 111.75 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 31.8 t -125.19 140.07 53.19 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.88 0.372 . . . . 4.6 110.427 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 44.0 p90 -138.35 31.63 2.35 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.639 0.733 . . . . 5.43 109.439 178.156 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.415 ' HA3' ' HB ' ' A' ' 11' ' ' ILE . . . 91.52 138.67 8.09 Favored Glycine 0 N--CA 1.444 -0.788 0 CA-C-N 115.045 -0.979 . . . . 2.46 111.553 -176.487 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -85.03 108.78 17.79 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-O 120.868 0.366 . . . . 4.59 110.208 -178.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.401 ' HB3' ' O ' ' A' ' 9' ' ' GLY . 46.9 t -151.29 139.84 20.6 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.752 -0.462 . . . . 1.88 109.752 178.537 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 18.1 m -91.32 -17.01 26.6 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.583 -0.28 . . . . 2.6 111.293 -176.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 p -100.52 4.87 43.9 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 112.286 0.476 . . . . 4.25 112.286 -177.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 6' ' ' CYS . . . 149.19 -157.17 27.14 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.442 -0.885 . . . . 1.12 112.927 177.05 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.1 p -85.25 152.31 23.41 Favored 'General case' 0 N--CA 1.447 -0.611 0 C-N-CA 122.745 0.418 . . . . 1.43 110.62 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.415 ' HB ' ' HA3' ' A' ' 4' ' ' GLY . 27.7 mt -102.72 133.99 44.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.843 0.83 . . . . 1.56 111.338 175.739 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.53 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -138.75 159.97 40.81 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.599 -1.182 . . . . 0.91 109.797 177.042 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.402 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 41.1 t -109.46 108.45 18.96 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.428 -0.582 . . . . 0.34 109.428 178.084 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.796 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 94.1 m -90.62 129.96 36.69 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.523 -0.762 . . . . 0.19 111.404 -174.597 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.76 -34.65 72.04 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.028 -0.987 . . . . 0.39 109.622 174.433 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -130.91 116.29 17.69 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.87 -0.604 . . . . 1.12 110.085 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 99.3 t -110.2 102.6 14.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.058 0.456 . . . . 1.04 109.981 178.606 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.7 m -130.11 143.59 49.75 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 115.896 -0.593 . . . . 1.03 111.231 -174.053 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.507 ' O ' ' HB3' ' A' ' 22' ' ' SER . 35.5 Cg_exo -61.83 141.11 88.94 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.42 2.08 . . . . 0.21 111.36 171.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.96 -25.52 72.02 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.987 -0.625 . . . . 0.18 112.584 -178.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -97.87 7.1 46.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.238 0.542 . . . . 2.27 110.118 177.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.507 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 28.9 t -75.13 154.23 37.86 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.523 -0.762 . . . . 0.41 109.753 176.168 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -58.69 -31.94 68.69 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.18 0.514 . . . . 1.06 110.389 178.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.68 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.1 mm? -73.39 -64.52 0.97 Allowed 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 115.722 -0.672 . . . . 1.77 110.408 173.076 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.78 -38.35 64.17 Favored Glycine 0 C--N 1.33 0.223 0 CA-C-N 115.788 -0.642 . . . . 0.16 113.707 -174.013 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 87.7 m -68.43 -44.72 74.35 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.818 0.342 . . . . 1.07 110.692 -177.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.422 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.7 tm? -64.72 -36.89 85.74 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.261 -0.644 . . . . 1.57 109.261 177.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.68 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 18.9 mt -65.56 -49.54 68.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.881 -0.599 . . . . 1.13 110.436 -178.272 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.456 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -75.31 -22.08 57.97 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.469 -0.332 . . . . 1.08 111.584 -176.257 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.443 ' N ' HD11 ' A' ' 29' ' ' LEU . 19.8 t70 -66.56 -34.81 78.72 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.325 0.584 . . . . 0.66 109.656 175.697 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -72.92 -20.21 61.11 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.126 -0.943 . . . . 2.07 109.594 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.5 mt -98.14 -19.58 17.83 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.346 -1.297 . . . . 1.35 111.308 -176.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.42 24.55 60.71 Favored Glycine 0 N--CA 1.452 -0.271 0 CA-C-N 115.891 -0.595 . . . . 0.75 112.609 179.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.456 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 28.7 mt -78.9 133.28 30.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.967 0.413 . . . . 1.24 110.913 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.5 t -113.1 97.96 6.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.018 -0.537 . . . . 2.41 110.038 176.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.4 mt -93.73 138.26 32.11 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.169 -0.468 . . . . 3.28 110.739 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -78.96 -23.81 44.28 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.279 0.561 . . . . 2.65 109.589 175.505 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.43 ' C ' ' H ' ' A' ' 40' ' ' THR . 24.7 m-20 -133.05 92.21 26.22 Favored Pre-proline 0 N--CA 1.446 -0.628 0 CA-C-N 115.446 -0.797 . . . . 2.29 109.117 176.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -72.8 6.96 2.16 Favored 'Trans proline' 0 N--CA 1.463 -0.287 0 C-N-CA 122.262 1.975 . . . . 0.77 111.445 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.43 ' H ' ' C ' ' A' ' 38' ' ' ASP . 17.7 p -83.71 -8.25 59.31 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.534 -0.757 . . . . 1.2 110.878 -178.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.458 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 33.4 m -78.54 151.08 5.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.909 -0.587 . . . . 1.08 110.792 179.283 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.0 mt -81.61 120.78 25.51 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.609 -0.723 . . . . 1.06 110.094 177.191 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 12.6 pt -102.52 131.85 49.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.29 0.567 . . . . 1.03 110.119 176.107 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.796 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.11 99.9 1.58 Allowed Glycine 0 N--CA 1.438 -1.207 0 CA-C-N 115.529 -0.76 . . . . 0.31 113.175 -174.54 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -80.67 139.15 36.33 Favored 'General case' 0 C--N 1.314 -0.953 0 N-CA-C 109.028 -0.731 . . . . 0.57 109.028 175.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.33 34.64 35.9 Favored Glycine 0 N--CA 1.444 -0.82 0 C-N-CA 119.629 -1.272 . . . . 0.25 111.523 -178.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.53 ' SG ' ' HB2' ' A' ' 12' ' ' GLN . 0.1 OUTLIER -102.4 118.72 37.47 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.144 0.497 . . . . 0.25 111.121 -174.315 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -100.55 134.5 20.59 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 115.669 -0.696 . . . . 2.21 109.412 175.148 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -63.98 123.13 11.43 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.589 2.193 . . . . 0.6 110.967 177.423 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.447 HG13 ' HA ' ' A' ' 12' ' ' GLN . 12.4 mt -83.55 89.58 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-O 121.482 0.658 . . . . 1.13 109.75 -178.062 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 10.6 t -119.09 16.68 13.28 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.255 -0.884 . . . . 1.22 109.878 -178.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 13.1 p -92.38 139.91 17.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.34 -0.845 . . . . 1.92 110.312 179.553 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -79.81 145.01 33.03 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.259 -0.428 . . . . 3.46 110.097 177.122 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.96 69.64 1.37 Allowed Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.49 -0.862 . . . . 3.5 111.304 -175.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.0 m -78.85 53.47 1.39 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.995 0.426 . . . . 5.24 111.7 -175.575 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.5 m -85.54 -57.5 3.04 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.301 -0.629 . . . . 4.31 109.301 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -122.34 50.25 1.5 Allowed 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.011 -0.737 . . . . 3.13 109.011 174.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -88.67 -2.84 58.8 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.524 -0.762 . . . . 1.6 110.731 -177.463 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.3 t -140.24 118.58 12.11 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.575 -0.739 . . . . 1.02 110.063 176.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 51.1 m -108.25 17.17 22.52 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.225 -0.443 . . . . 2.56 111.735 -177.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -144.52 -82.18 0.16 Allowed 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.752 -0.379 . . . . 1.07 111.536 178.52 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 87.1 m -150.11 123.96 9.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.864 0.364 . . . . 1.05 110.825 -179.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.462 ' HB2' ' O ' ' A' ' 82' ' ' VAL . . . -86.44 129.59 34.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.057 0.456 . . . . 1.07 110.209 -177.433 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.529 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 6.4 m -140.88 161.58 23.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 115.937 -0.574 . . . . 1.01 111.023 -177.702 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 52.8 t -120.18 110.33 16.48 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.633 -0.712 . . . . 0.39 109.389 177.092 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.786 ' SG ' ' HB2' ' A' ' 76' ' ' ALA . 15.8 m -97.57 132.23 43.43 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.133 0.492 . . . . 0.65 111.286 -176.292 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.4 m -84.11 -25.78 29.45 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.583 -0.735 . . . . 1.83 111.04 -178.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -102.01 134.66 44.88 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.791 -0.64 . . . . 1.6 110.145 -177.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -100.99 10.1 41.49 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.322 -0.399 . . . . 3.24 111.311 -174.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -79.57 103.21 9.32 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.086 0.47 . . . . 2.99 110.131 179.427 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.605 HG13 ' H ' ' A' ' 73' ' ' GLY . 73.0 t -122.84 133.04 70.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.019 -0.537 . . . . 1.68 111.244 -173.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.543 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 88.8 p -80.12 2.58 23.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.531 -0.758 . . . . 1.88 111.257 -177.296 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.605 ' H ' HG13 ' A' ' 71' ' ' VAL . . . 126.57 -32.31 3.73 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.664 -0.698 . . . . 0.56 112.04 -178.387 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.0 m -138.69 -9.77 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 112.315 0.487 . . . . 1.18 112.315 -179.381 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.543 ' CG1' ' H ' ' A' ' 72' ' ' SER . 4.1 pt -88.79 -179.43 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.707 0.765 . . . . 1.12 112.705 -175.546 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.786 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -151.51 142.17 22.73 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 114.287 -1.324 . . . . 1.11 108.798 174.308 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.9 mt -120.4 137.1 55.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.915 0.388 . . . . 1.1 111.945 -175.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.458 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 69.89 52.14 20.89 Favored Glycine 0 C--N 1.333 0.371 0 CA-C-N 115.922 -0.581 . . . . 0.2 111.778 177.723 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.529 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 12.8 m -103.02 134.35 46.62 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.274 0.559 . . . . 0.65 111.909 -173.634 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.409 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 90.4 mt -107.79 131.82 21.46 Favored Pre-proline 0 C--N 1.322 -0.614 0 CA-C-N 115.563 -0.744 . . . . 1.1 110.032 175.202 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.412 ' HA ' HG11 ' A' ' 64' ' ' VAL . 25.4 Cg_exo -63.24 120.67 8.22 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.917 2.412 . . . . 0.25 112.678 -179.315 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.462 ' O ' ' HB2' ' A' ' 63' ' ' ALA . 4.3 m -120.31 140.2 45.16 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 CA-C-N 115.968 -0.56 . . . . 1.12 110.201 178.23 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.426 HG23 ' HG ' ' A' ' 84' ' ' LEU . 95.0 m 63.81 142.59 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 115.799 -0.637 . . . . 2.18 111.681 -176.031 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.426 ' HG ' HG23 ' A' ' 83' ' ' THR . 79.4 mt . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.145 -0.931 . . . . 4.14 111.509 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.645 0 N-CA-C 111.662 -0.575 . . . . 5.98 111.662 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.5 p -88.28 -73.93 0.47 Allowed 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.679 0.239 . . . . 4.6 110.378 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 89.6 m95 58.24 93.55 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.258 0 O-C-N 123.864 0.728 . . . . 5.43 111.384 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -70.06 107.98 2.32 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.884 -0.674 . . . . 2.46 112.432 -179.538 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -110.84 137.55 48.34 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.482 -0.562 . . . . 4.59 109.482 172.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.477 ' SG ' ' N ' ' A' ' 7' ' ' SER . 29.1 p -83.66 -58.51 2.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.805 0.336 . . . . 1.88 110.302 -178.514 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.477 ' N ' ' SG ' ' A' ' 6' ' ' CYS . 65.5 m -163.05 -65.48 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.075 -0.511 . . . . 2.6 109.715 -179.728 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.8 p -100.26 -24.53 14.52 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.247 -0.433 . . . . 4.25 112.015 -177.352 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -128.93 -177.03 14.67 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.675 -0.774 . . . . 1.12 112.518 -178.247 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 34.1 t -90.98 151.24 21.15 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 109.502 -0.555 . . . . 1.43 109.502 177.414 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.1 mt -95.7 137.16 24.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 121.664 0.745 . . . . 1.56 110.989 178.058 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . 0.535 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -132.24 163.06 29.43 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.775 -1.102 . . . . 0.91 109.949 176.781 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.527 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 42.0 t -106.28 99.49 9.07 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.809 -0.632 . . . . 0.34 109.556 179.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.853 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 54.0 m -86.01 130.66 34.47 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-N 115.707 -0.678 . . . . 0.19 111.352 -175.554 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.445 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -77.82 -30.87 51.37 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.196 -0.911 . . . . 0.39 109.77 177.506 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.597 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 19.3 m-20 -133.3 98.59 4.29 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.117 -0.492 . . . . 1.12 111.256 175.609 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 71.8 t -89.48 100.85 11.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.162 0.506 . . . . 1.04 109.732 174.234 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 29.6 m -128.45 141.1 40.35 Favored Pre-proline 0 C--N 1.318 -0.768 0 CA-C-N 115.843 -0.617 . . . . 1.03 110.697 -174.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.44 ' HB2' ' HB2' ' A' ' 22' ' ' SER . 31.9 Cg_exo -59.24 135.58 66.65 Favored 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 122.073 1.849 . . . . 0.21 111.521 172.741 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.8 -15.22 64.23 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.888 -0.673 . . . . 0.18 112.136 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -103.44 4.56 36.25 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.053 0.454 . . . . 2.27 110.248 175.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.44 ' HB2' ' HB2' ' A' ' 19' ' ' PRO . 29.0 t -78.53 158.35 28.59 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.051 -0.522 . . . . 0.41 109.898 177.717 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -53.19 -42.79 66.61 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.974 0.416 . . . . 1.06 109.991 176.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.685 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.9 mm? -67.7 -65.08 0.74 Allowed 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 115.669 -0.696 . . . . 1.77 110.493 178.259 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.69 -36.44 59.29 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.983 -0.553 . . . . 0.16 113.329 -174.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 84.9 m -68.55 -45.67 71.53 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.79 0.329 . . . . 1.07 110.298 -178.175 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.418 ' O ' HD11 ' A' ' 27' ' ' LEU . 1.3 tm? -65.96 -36.38 83.17 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.15 -0.685 . . . . 1.57 109.15 178.212 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.685 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.7 mt -67.34 -46.55 73.12 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.603 -0.726 . . . . 1.13 111.033 -177.363 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.485 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.26 -22.87 51.49 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 120.321 -0.551 . . . . 1.08 111.137 -178.695 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.472 ' N ' HD12 ' A' ' 29' ' ' LEU . 13.0 t70 -67.98 -35.8 78.97 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.044 -0.724 . . . . 0.66 109.044 173.135 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -69.1 -33.22 73.16 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 114.717 -1.129 . . . . 2.07 109.429 178.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 67.6 mt -91.87 -10.86 38.13 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.56 -1.2 . . . . 1.35 111.867 -176.412 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.29 35.71 88.33 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.767 -0.651 . . . . 0.75 112.6 179.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.485 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 56.5 mt -76.08 129.0 37.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 120.814 0.34 . . . . 1.24 111.163 -176.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.2 p -86.56 101.0 10.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.746 0.784 . . . . 2.41 109.415 172.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.504 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.8 pp -76.29 132.7 39.98 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.722 -0.672 . . . . 3.28 111.18 -177.358 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -86.83 -29.73 22.01 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.745 -0.835 . . . . 2.65 108.745 172.248 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -144.96 112.33 4.84 Favored Pre-proline 0 N--CA 1.443 -0.803 0 N-CA-C 107.493 -1.299 . . . . 2.29 107.493 174.01 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -75.52 -1.5 11.4 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.197 1.931 . . . . 0.77 112.808 -173.228 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 35.2 p -106.55 20.51 18.89 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.261 0.553 . . . . 1.2 111.121 -175.727 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.44 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 34.8 m -87.72 156.59 3.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.589 -0.732 . . . . 1.08 110.081 175.143 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.44 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.9 mt -85.6 121.26 28.04 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.808 -0.442 . . . . 1.06 109.808 176.638 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 22.2 pt -106.41 140.75 23.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.101 0.477 . . . . 1.03 110.256 177.493 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.853 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.2 107.35 1.55 Allowed Glycine 0 N--CA 1.439 -1.111 0 C-N-CA 120.586 -0.816 . . . . 0.31 112.949 -175.102 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.597 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 9.4 t70 -80.62 147.91 30.5 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.693 -0.854 . . . . 0.57 108.693 175.257 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 67.46 37.81 90.34 Favored Glycine 0 C--N 1.317 -0.515 0 C-N-CA 120.162 -1.018 . . . . 0.25 111.958 178.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.527 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -102.63 115.44 30.59 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.01 0.433 . . . . 0.25 111.088 -172.895 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.45 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 2.1 p-10 -100.84 132.07 22.63 Favored Pre-proline 0 C--N 1.318 -0.796 0 CA-C-N 115.698 -0.683 . . . . 2.21 110.161 177.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.94 119.55 6.87 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.399 2.066 . . . . 0.6 110.696 175.058 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.403 HG13 ' HA ' ' A' ' 12' ' ' GLN . 12.9 mt -79.53 88.92 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 CA-C-O 121.879 0.847 . . . . 1.13 109.913 -177.098 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.7 t -111.45 17.87 19.69 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.512 -1.222 . . . . 1.22 109.415 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 10.6 p -102.39 145.1 12.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 114.737 -1.119 . . . . 1.92 109.252 175.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -88.06 81.4 7.44 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.852 0.358 . . . . 3.46 110.848 -179.048 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -133.87 128.6 5.01 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.823 -0.703 . . . . 3.5 111.819 179.508 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 19.2 m -72.45 -34.93 68.12 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.888 0.375 . . . . 5.24 111.498 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 23.1 t -130.61 -51.67 1.07 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.837 0.351 . . . . 4.31 110.773 -179.533 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -79.89 43.79 0.61 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.16 0.505 . . . . 3.13 111.55 -176.03 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -112.03 -2.45 15.06 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.944 -0.571 . . . . 1.6 110.547 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.5 t -146.81 130.92 17.33 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.818 -0.628 . . . . 1.02 110.28 -179.265 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 12.8 p -93.6 -15.37 25.46 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.089 -0.505 . . . . 2.56 111.742 -177.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.445 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -128.44 -83.44 0.58 Allowed 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.623 0.601 . . . . 1.07 112.623 -175.172 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.8 m -142.11 131.59 23.8 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.783 0.325 . . . . 1.05 111.301 -176.147 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.94 125.98 34.4 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.031 0.443 . . . . 1.07 110.125 178.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.655 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -141.33 164.99 19.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.119 -0.492 . . . . 1.01 110.806 -177.546 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 29.3 t -131.28 113.0 13.27 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 116.172 -0.467 . . . . 0.39 109.935 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . 0.775 ' SG ' ' HB3' ' A' ' 76' ' ' ALA . 1.5 m -95.53 136.73 35.54 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.647 0.737 . . . . 0.65 112.233 -175.406 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.7 m -89.44 -18.45 26.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.641 -1.163 . . . . 1.83 110.806 -179.281 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.467 ' HB2' ' O ' ' A' ' 77' ' ' ILE . 19.8 m-20 -98.31 151.71 20.21 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.887 -0.597 . . . . 1.6 110.332 178.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -103.68 -12.28 17.12 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.019 -0.537 . . . . 3.24 110.581 -178.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -67.84 110.2 3.72 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.892 -0.594 . . . . 2.99 110.915 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.5 m -125.19 150.29 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 CA-C-N 116.158 -0.473 . . . . 1.68 110.932 177.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.451 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 8.1 t -95.31 10.58 35.66 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.651 0.738 . . . . 1.88 109.636 177.008 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.15 -33.42 5.31 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 115.476 -0.784 . . . . 0.56 112.748 177.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.5 m -138.01 -0.52 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.644 -0.422 . . . . 1.18 111.64 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.451 ' CG1' ' H ' ' A' ' 72' ' ' SER . 24.3 pt -100.21 173.84 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 C-N-CA 120.187 -0.605 . . . . 1.12 111.63 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.775 ' HB3' ' SG ' ' A' ' 66' ' ' CYS . . . -141.41 141.08 33.76 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 114.485 -1.234 . . . . 1.11 109.35 176.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.467 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 67.0 mt -122.02 131.93 72.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.742 0.306 . . . . 1.1 111.342 -177.43 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.44 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 75.53 51.68 7.11 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.978 -0.629 . . . . 0.2 111.911 178.638 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.2 m -99.89 138.74 36.55 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.231 0.538 . . . . 0.65 112.232 -176.345 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 92.1 mt -106.98 133.01 20.46 Favored Pre-proline 0 C--N 1.32 -0.689 0 CA-C-N 115.475 -0.784 . . . . 1.1 109.445 170.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -65.77 124.62 12.99 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.82 2.347 . . . . 0.25 111.961 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.6 m -123.6 159.51 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-O 121.033 0.444 . . . . 1.12 110.659 -179.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 15.2 m -132.76 142.57 49.08 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.585 -0.734 . . . . 2.18 109.52 178.439 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 85.6 mt . . . . . 0 C--O 1.248 0.977 0 O-C-N 123.607 0.567 . . . . 4.14 110.714 179.222 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 35.3 t . . . . . 0 N--CA 1.45 -0.43 0 N-CA-C 109.155 -0.683 . . . . 0.96 109.155 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.507 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.3 mp -99.27 138.08 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 CA-C-O 121.722 0.772 . . . . 0.96 111.675 176.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.525 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -148.98 167.76 24.92 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.598 -1.183 . . . . 0.91 111.003 178.301 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 37.3 t -116.45 106.71 13.9 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.38 -0.827 . . . . 0.34 109.293 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.818 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 90.4 m -91.8 132.1 36.67 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.753 -0.658 . . . . 0.19 111.597 -173.576 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.421 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -73.2 -35.97 66.44 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 114.91 -1.041 . . . . 0.38 109.501 173.869 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 19.7 m-20 -128.84 100.57 5.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.051 -0.522 . . . . 1.03 111.334 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.8 t -92.52 99.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.497 -0.557 . . . . 0.18 109.497 173.432 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.6 m -129.06 140.4 38.5 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 115.761 -0.654 . . . . 0.18 110.863 -174.232 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.557 ' O ' ' HB3' ' A' ' 22' ' ' SER . 33.4 Cg_exo -58.36 140.9 96.27 Favored 'Trans proline' 0 N--CA 1.464 -0.252 0 C-N-CA 122.371 2.047 . . . . 0.19 111.709 173.313 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.86 -19.47 69.61 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.907 -0.663 . . . . 0.18 112.589 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -103.22 7.43 38.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.388 0.613 . . . . 2.27 109.97 176.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.557 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 13.8 t -73.28 155.78 39.13 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.328 -0.851 . . . . 0.24 110.014 176.658 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -55.93 -41.01 73.95 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.212 0.529 . . . . 1.06 109.685 176.814 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.735 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.1 mm? -70.11 -60.52 2.24 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 115.325 -0.852 . . . . 1.11 110.694 176.347 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.44 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -56.03 -41.51 85.21 Favored Glycine 0 CA--C 1.517 0.171 0 CA-C-N 116.053 -0.521 . . . . 0.16 113.348 -174.711 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 91.5 m -67.84 -39.39 83.85 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.916 0.389 . . . . 0.24 110.499 -178.306 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -64.71 -39.24 93.32 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.244 -0.65 . . . . 1.01 109.244 176.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.735 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.6 mt -68.13 -50.04 57.22 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.701 -0.681 . . . . 0.37 110.987 -176.525 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.548 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.8 pp -73.18 -23.72 60.45 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.546 -0.462 . . . . 0.41 111.509 -176.803 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.532 ' N ' HD12 ' A' ' 29' ' ' LEU . 28.2 t70 -68.97 -31.71 70.76 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.58 0.705 . . . . 0.66 109.192 175.64 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -75.04 -15.29 60.64 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-N 114.988 -1.005 . . . . 2.07 109.918 177.842 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.8 mt -111.7 0.04 16.17 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.932 -1.031 . . . . 0.71 111.464 -174.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.21 34.66 85.32 Favored Glycine 0 C--N 1.333 0.363 0 CA-C-N 115.855 -0.611 . . . . 0.75 113.015 178.226 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.548 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 53.9 mt -84.07 125.9 40.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.817 0.341 . . . . 0.68 110.828 -176.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 50.4 t -88.17 121.28 38.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.278 -0.638 . . . . 1.87 109.278 175.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.489 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.6 pp -95.23 130.62 41.91 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.425 0.631 . . . . 2.76 111.703 -176.757 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -90.87 -29.2 17.66 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 108.56 -0.904 . . . . 2.65 108.56 170.25 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -142.34 96.1 6.47 Favored Pre-proline 0 N--CA 1.442 -0.838 0 N-CA-C 107.724 -1.213 . . . . 2.29 107.724 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.428 ' HB3' HD22 ' A' ' 36' ' ' LEU . 50.7 Cg_endo -69.84 -5.89 17.34 Favored 'Trans proline' 0 CA--C 1.521 -0.149 0 C-N-CA 122.561 2.174 . . . . 0.64 111.819 -176.313 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.2 p -95.41 19.14 11.3 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.686 -0.688 . . . . 0.51 111.308 -175.697 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.489 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 32.7 m -92.09 156.6 3.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.798 -0.637 . . . . 0.24 109.855 173.048 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.539 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.1 mt -88.99 121.68 31.59 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 116.061 -0.518 . . . . 0.22 109.835 176.861 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.411 HD13 HD23 ' A' ' 29' ' ' LEU . 12.1 pt -102.74 133.57 46.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-O 121.247 0.546 . . . . 0.15 110.053 176.685 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.818 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -105.82 95.31 1.05 Allowed Glycine 0 N--CA 1.439 -1.166 0 CA-C-N 115.546 -0.752 . . . . 0.31 112.832 -174.858 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -76.83 141.91 40.48 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.235 -0.654 . . . . 0.57 109.235 176.345 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.421 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 70.57 38.8 68.44 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 119.71 -1.233 . . . . 0.21 111.825 -177.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.515 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -107.36 116.28 31.66 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.17 0.51 . . . . 0.25 111.351 -172.98 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.418 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 19.9 m-20 -102.02 134.52 20.04 Favored Pre-proline 0 C--N 1.317 -0.838 0 CA-C-N 115.632 -0.713 . . . . 2.21 109.362 175.453 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.424 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 16.5 Cg_exo -62.79 126.97 19.31 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.613 2.209 . . . . 0.44 111.351 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 47.1 mt . . . . . 0 C--N 1.326 -0.418 0 CA-C-O 120.958 0.409 . . . . 0.46 110.551 -175.753 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.8 t . . . . . 0 N--CA 1.451 -0.402 0 N-CA-C 110.278 -0.268 . . . . 0.74 110.278 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.3 p -100.79 -26.19 13.86 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.087 -0.506 . . . . 2.14 111.906 -177.837 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -105.74 -80.56 0.55 Allowed 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 121.067 -0.253 . . . . 0.54 111.585 -177.137 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 15.1 m -147.19 129.17 15.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.582 0.229 . . . . 0.29 110.797 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.21 131.87 34.14 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.902 0.382 . . . . 0.25 110.372 -178.108 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.735 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -144.4 171.82 6.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.238 0.542 . . . . 0.21 111.431 -176.892 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 42.0 t -139.28 106.26 5.44 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.301 -0.863 . . . . 0.39 109.744 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.731 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -88.41 134.57 33.8 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.472 0.653 . . . . 0.65 112.214 -177.474 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.8 m -85.42 -18.53 33.37 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.856 -1.066 . . . . 1.15 111.1 -179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -100.75 160.18 14.57 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.456 -0.572 . . . . 1.6 109.456 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -112.2 -7.89 14.01 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.962 0.411 . . . . 2.49 110.859 -176.519 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 34.5 t30 -75.71 108.24 8.41 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.077 -0.51 . . . . 2.27 110.862 -178.143 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.1 m -118.87 143.74 29.09 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.726 0 CA-C-N 116.078 -0.51 . . . . 1.1 110.257 177.099 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.619 ' OG ' HG12 ' A' ' 75' ' ' ILE . 90.7 p -84.5 -2.0 56.61 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.093 0.473 . . . . 1.41 110.494 -179.707 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.61 -32.18 3.58 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.669 -0.696 . . . . 0.48 112.288 -177.683 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 15.7 m -136.63 -16.07 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.533 -0.467 . . . . 0.49 112.043 178.013 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.619 HG12 ' OG ' ' A' ' 72' ' ' SER . 20.3 pt -87.75 -176.17 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.541 0.686 . . . . 0.3 111.884 -177.187 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.731 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.35 142.2 23.8 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-N 114.231 -1.35 . . . . 0.18 108.765 175.775 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 63.0 mt -117.75 130.22 72.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 120.594 -0.442 . . . . 0.26 111.646 -176.39 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.505 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.06 51.75 6.06 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.068 -0.587 . . . . 0.17 111.871 177.776 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.539 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.2 m -99.1 129.61 45.37 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.378 0.609 . . . . 0.65 112.072 -176.143 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 96.5 mt -98.97 132.19 24.08 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.517 -0.765 . . . . 0.29 109.664 173.087 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.438 ' HA ' HG12 ' A' ' 64' ' ' VAL . 13.8 Cg_exo -68.16 123.24 10.38 Favored 'Trans proline' 0 N--CA 1.463 -0.303 0 C-N-CA 122.78 2.32 . . . . 0.25 112.037 -179.071 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.2 m . . . . . 0 N--CA 1.441 -0.879 0 CA-C-N 116.09 -0.505 . . . . 0.42 110.399 179.844 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.2 m . . . . . 0 N--CA 1.442 -0.848 0 CA-C-O 120.732 0.301 . . . . 0.96 110.376 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 40.4 mt -90.93 137.66 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.804 0.811 . . . . 0.96 110.869 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.46 ' HA ' HG13 ' A' ' 50' ' ' ILE . 0.1 OUTLIER -145.74 158.05 43.89 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 114.605 -1.179 . . . . 0.91 109.958 -175.903 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 37.8 t -110.51 103.3 11.89 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-O 121.134 0.492 . . . . 0.34 110.009 -177.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.638 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 63.8 m -86.63 136.05 33.19 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.311 -0.858 . . . . 0.19 111.057 -175.814 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.465 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -73.33 -32.9 64.83 Favored 'General case' 0 N--CA 1.445 -0.69 0 CA-C-N 115.167 -0.924 . . . . 0.38 108.643 173.762 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ASN . . . . . 0.501 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 3.7 t-20 -128.36 135.42 49.54 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.59 -0.732 . . . . 1.03 109.468 178.62 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 87.2 t -126.43 106.11 15.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 109.706 -0.479 . . . . 0.18 109.706 174.604 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.3 m -135.24 142.41 41.56 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 115.656 -0.702 . . . . 0.18 111.127 -173.748 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.551 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.8 Cg_exo -57.75 139.76 91.35 Favored 'Trans proline' 0 N--CA 1.462 -0.345 0 C-N-CA 122.257 1.971 . . . . 0.19 111.329 171.251 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.7 -23.12 70.51 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.839 -0.696 . . . . 0.18 112.31 -179.61 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -95.65 -1.47 50.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.95 0.405 . . . . 2.27 109.932 177.0 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.551 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 22.9 t -68.28 150.67 47.96 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.002 -0.544 . . . . 0.24 109.579 176.592 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -58.48 -32.56 68.88 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.2 0.524 . . . . 1.06 110.106 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.658 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.6 mm? -69.01 -64.56 0.85 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.433 -0.803 . . . . 1.11 110.701 172.009 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.44 -40.84 78.76 Favored Glycine 0 C--N 1.33 0.225 0 CA-C-N 115.959 -0.564 . . . . 0.16 113.364 -174.374 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 30.1 m -67.32 -41.15 85.77 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.168 -0.308 . . . . 0.24 110.168 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -64.91 -40.14 94.6 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.408 -0.59 . . . . 1.01 109.408 177.198 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.658 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.7 mt -67.92 -44.62 76.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.044 -0.526 . . . . 0.37 110.849 -175.168 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.547 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.8 pp -77.69 -25.1 49.21 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.372 -0.531 . . . . 0.41 110.899 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.528 ' N ' HD12 ' A' ' 29' ' ' LEU . 24.6 t70 -64.88 -36.7 85.21 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.766 0.793 . . . . 0.66 109.178 172.144 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -74.86 -12.13 60.3 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 114.149 -1.387 . . . . 2.07 110.388 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.5 mt -108.66 -9.95 15.24 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.146 -0.934 . . . . 0.71 111.259 -178.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 71.22 35.09 64.02 Favored Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.887 -0.597 . . . . 0.75 112.518 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.547 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 43.4 mt -91.55 131.05 39.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.709 0.255 . . . . 0.68 110.704 -178.159 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 p -91.87 112.75 26.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.42 0.629 . . . . 1.87 109.959 173.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.543 HD22 ' HB3' ' A' ' 39' ' ' PRO . 0.9 OUTLIER -81.62 134.29 35.47 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.92 -0.582 . . . . 2.76 110.908 -179.573 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -87.32 -35.42 18.42 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.828 -0.804 . . . . 2.65 108.828 173.684 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -143.71 102.5 4.97 Favored Pre-proline 0 N--CA 1.444 -0.745 0 N-CA-C 107.947 -1.131 . . . . 2.29 107.947 176.601 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.543 ' HB3' HD22 ' A' ' 36' ' ' LEU . 51.8 Cg_endo -69.53 -3.48 11.95 Favored 'Trans proline' 0 C--O 1.226 -0.119 0 C-N-CA 122.365 2.043 . . . . 0.64 111.673 -175.036 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.0 p -85.73 7.95 21.68 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.633 -0.712 . . . . 0.51 111.88 -174.49 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.5 m -92.18 158.42 2.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.958 0.408 . . . . 0.24 110.327 177.642 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.546 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 94.9 mt -89.07 121.76 31.73 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.076 -0.511 . . . . 0.22 110.084 178.494 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.501 HD13 HD23 ' A' ' 29' ' ' LEU . 22.4 pt -108.86 145.73 15.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.238 0.542 . . . . 0.15 110.44 177.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.638 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.02 142.09 17.18 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.667 -0.778 . . . . 0.31 112.338 -177.355 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.501 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 9.5 t70 -105.17 151.79 23.62 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.305 -0.998 . . . . 0.57 108.305 172.314 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.404 ' HA3' ' HB3' ' A' ' 15' ' ' GLN . . . 61.02 44.5 98.11 Favored Glycine 0 C--N 1.32 -0.339 0 C-N-CA 120.28 -0.962 . . . . 0.21 112.302 175.806 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.527 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.34 115.55 30.44 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.056 0.455 . . . . 0.25 110.984 -172.443 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.407 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 18.6 m-20 -101.29 129.32 27.25 Favored Pre-proline 0 C--N 1.316 -0.884 0 CA-C-N 115.666 -0.697 . . . . 2.21 109.304 175.744 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.433 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 17.8 Cg_exo -61.64 122.2 10.69 Favored 'Trans proline' 0 N--CA 1.46 -0.446 0 C-N-CA 122.739 2.293 . . . . 0.44 111.263 178.05 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.46 HG13 ' HA ' ' A' ' 12' ' ' GLN . 10.1 mt . . . . . 0 C--N 1.324 -0.52 0 CA-C-O 121.593 0.711 . . . . 0.46 109.835 -176.363 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.9 t . . . . . 0 N--CA 1.446 -0.627 0 N-CA-C 110.129 -0.323 . . . . 0.74 110.129 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 17.4 t -109.66 -22.25 12.03 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.518 -0.31 . . . . 2.14 111.143 -177.588 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.465 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -102.85 -82.06 0.49 Allowed 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.725 -0.39 . . . . 0.54 111.316 -179.484 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 23.2 m -148.78 127.67 12.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.8 0.333 . . . . 0.29 110.775 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -88.21 133.21 34.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.0 0.429 . . . . 0.25 110.909 -177.345 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.495 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.3 m -144.11 170.5 8.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.03 -0.532 . . . . 0.21 111.07 -178.571 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' CYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 46.3 t -130.87 115.77 17.01 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.022 -0.536 . . . . 0.39 110.045 178.788 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.815 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 4.4 m -101.71 154.88 18.5 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.814 0.816 . . . . 0.65 111.941 -176.747 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 49.0 m -103.45 -19.58 14.36 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 114.405 -1.27 . . . . 1.15 110.787 -177.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -106.24 142.82 35.28 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.706 -0.679 . . . . 1.6 109.561 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -116.77 2.94 12.95 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.076 0.465 . . . . 2.49 110.663 -176.749 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -92.62 58.69 3.16 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.62 0.724 . . . . 2.27 109.861 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 33.5 m -80.68 163.96 3.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.062 -0.972 . . . . 1.1 110.83 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.526 ' OG ' HG12 ' A' ' 75' ' ' ILE . 91.7 p -74.25 -8.04 54.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.281 -0.418 . . . . 1.41 111.339 -175.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.9 -32.06 3.56 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.923 -0.656 . . . . 0.48 112.68 -178.078 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 10.6 m -134.96 -6.12 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.318 -0.553 . . . . 0.49 111.989 178.144 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.526 HG12 ' OG ' ' A' ' 72' ' ' SER . 29.0 pt -93.92 -176.28 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 C-N-CA 120.063 -0.655 . . . . 0.3 111.419 179.583 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.815 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -144.58 143.23 30.69 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.782 -1.099 . . . . 0.18 109.73 175.697 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 64.0 mt -126.44 128.55 71.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.931 0.396 . . . . 0.26 111.606 -176.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.472 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 74.82 53.68 6.26 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.744 -0.662 . . . . 0.17 111.621 179.144 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.546 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 0.9 OUTLIER -104.2 141.9 35.45 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 112.652 0.612 . . . . 0.65 112.652 -175.539 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 84.2 mt -111.36 134.8 21.06 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.512 -0.767 . . . . 0.29 109.787 172.4 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.479 ' HA ' HG12 ' A' ' 64' ' ' VAL . 19.4 Cg_exo -65.14 124.04 12.42 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 123.067 2.512 . . . . 0.25 112.595 -179.012 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.3 m . . . . . 0 N--CA 1.444 -0.74 0 CA-C-N 116.089 -0.505 . . . . 0.42 110.223 177.619 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 40.1 t . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 110.139 -0.319 . . . . 0.96 110.139 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.3 mt -88.21 139.37 17.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.185 0.517 . . . . 0.96 110.448 172.152 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.64 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -140.02 164.37 30.2 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.578 -0.737 . . . . 0.91 110.676 176.616 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.53 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 28.3 t -107.79 101.91 11.17 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.311 -0.859 . . . . 0.34 109.468 179.718 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.824 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 55.6 m -87.72 126.29 34.9 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.984 -0.553 . . . . 0.19 111.298 -176.057 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.442 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.1 OUTLIER -67.28 -33.4 75.22 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.074 -0.967 . . . . 0.38 109.471 174.878 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -139.43 113.01 8.41 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.953 -0.567 . . . . 1.03 110.501 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 51.2 t -101.17 104.55 16.43 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 109.67 -0.493 . . . . 0.18 109.67 177.177 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 m -129.97 140.58 39.07 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 116.072 -0.513 . . . . 0.18 111.43 -174.221 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.466 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.1 Cg_exo -59.61 138.44 83.51 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.37 2.047 . . . . 0.19 111.222 171.811 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -62.79 -26.05 68.27 Favored Glycine 0 C--O 1.227 -0.34 0 C-N-CA 121.272 -0.49 . . . . 0.18 113.146 -176.46 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -101.13 7.55 43.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.493 0.664 . . . . 2.27 110.245 177.068 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.466 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 26.6 t -71.31 159.02 35.33 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.52 -0.548 . . . . 0.24 109.52 175.849 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -53.4 -44.31 68.61 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.168 0.509 . . . . 1.06 109.767 176.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.701 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 6.2 mt -69.09 -60.27 2.47 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.314 -0.857 . . . . 1.11 110.456 178.25 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.429 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -53.51 -38.13 57.49 Favored Glycine 0 C--N 1.33 0.228 0 CA-C-N 116.101 -0.499 . . . . 0.16 113.218 -176.205 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 88.3 m -67.6 -47.61 69.2 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 110.361 -0.237 . . . . 0.24 110.361 -178.401 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.419 ' O ' HD13 ' A' ' 27' ' ' LEU . 3.1 tm? -62.71 -37.76 87.76 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.66 -0.496 . . . . 1.01 109.66 178.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.701 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.9 mt -69.01 -43.84 74.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.975 -0.557 . . . . 0.37 110.849 -175.543 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.489 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -82.41 -21.31 35.82 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.536 -0.466 . . . . 0.41 111.217 -178.578 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.44 ' N ' HD12 ' A' ' 29' ' ' LEU . 19.4 t70 -66.56 -34.92 78.98 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.634 0.731 . . . . 0.66 109.364 174.313 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -74.15 -32.96 63.35 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.793 -1.094 . . . . 2.07 109.18 179.141 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.4 mt -89.2 -10.56 46.61 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.903 -1.044 . . . . 0.71 111.982 -176.355 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.96 44.01 92.52 Favored Glycine 0 N--CA 1.452 -0.294 0 CA-C-N 115.849 -0.614 . . . . 0.75 112.766 178.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.489 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 51.3 mt -91.19 128.82 42.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.936 0.398 . . . . 0.68 111.41 -176.28 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.3 p -84.99 122.31 38.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.061 -0.518 . . . . 1.87 109.905 173.107 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.544 HD22 ' HB3' ' A' ' 39' ' ' PRO . 1.3 pp -94.88 131.26 40.97 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.265 0.555 . . . . 2.76 111.589 -176.227 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -90.36 -29.06 18.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.876 -0.787 . . . . 2.65 108.876 173.101 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -146.89 103.06 3.87 Favored Pre-proline 0 N--CA 1.444 -0.738 0 N-CA-C 107.435 -1.32 . . . . 2.29 107.435 175.34 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.544 ' HB3' HD22 ' A' ' 36' ' ' LEU . 66.7 Cg_endo -74.89 -1.09 10.73 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.135 1.89 . . . . 0.64 112.603 -174.029 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.3 p -99.6 4.48 45.79 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.176 -0.609 . . . . 0.51 111.092 -173.874 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.0 m -78.29 163.72 3.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.841 -0.618 . . . . 0.24 110.465 175.741 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.484 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 88.8 mt -91.5 120.09 32.02 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.933 -0.576 . . . . 0.22 110.011 176.486 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.413 HD13 HD23 ' A' ' 29' ' ' LEU . 17.3 pt -103.0 134.59 43.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 121.229 0.538 . . . . 0.15 110.095 176.091 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.824 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.94 104.75 2.21 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.699 -0.762 . . . . 0.31 112.878 -175.158 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -83.43 139.69 32.81 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 109.323 -0.621 . . . . 0.57 109.323 176.502 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.435 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 73.31 38.13 53.73 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.057 -1.068 . . . . 0.21 111.751 -179.846 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.53 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -103.25 116.17 31.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.065 0.46 . . . . 0.25 111.056 -172.708 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.504 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -101.56 134.02 20.48 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-N 115.857 -0.61 . . . . 2.21 109.858 177.371 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -54.57 119.11 5.87 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.747 2.298 . . . . 0.44 111.947 176.167 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.4 mt . . . . . 0 N--CA 1.447 -0.622 0 N-CA-C 108.662 -0.866 . . . . 0.46 108.662 177.451 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.4 t . . . . . 0 N--CA 1.447 -0.578 0 CA-C-O 120.727 0.299 . . . . 0.74 110.513 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 20.0 m -101.21 7.37 43.07 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.33 -0.396 . . . . 2.14 111.526 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.442 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -147.0 -83.96 0.12 Allowed 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.914 -0.315 . . . . 0.54 111.81 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 33.8 m -142.27 130.08 21.68 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-O 120.713 0.292 . . . . 0.29 110.99 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.97 129.25 34.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.465 -0.334 . . . . 0.25 110.267 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.659 HG21 ' SG ' ' A' ' 14' ' ' CYS . 4.0 m -140.6 169.9 15.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-O 121.248 0.546 . . . . 0.21 111.959 -176.574 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 29.1 t -132.98 103.66 6.16 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.191 -0.913 . . . . 0.39 110.061 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.748 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -91.11 138.79 31.33 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.647 0.737 . . . . 0.65 111.882 -178.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 47.9 t -92.8 -19.16 22.02 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 114.635 -1.166 . . . . 1.15 110.736 179.051 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -96.83 159.78 14.73 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.107 -0.497 . . . . 1.6 110.519 -175.196 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.2 t30 -117.68 -6.41 11.1 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.117 -0.492 . . . . 2.49 111.067 -173.676 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 50.5 t30 -81.04 83.25 6.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.249 0.547 . . . . 2.27 110.655 -177.508 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 30.0 m -101.81 139.57 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-N 116.0 -0.545 . . . . 1.1 110.885 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.567 ' OG ' HG12 ' A' ' 75' ' ' ILE . 99.9 p -80.38 -5.08 55.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.188 -0.46 . . . . 1.41 110.739 -178.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.3 -32.22 3.62 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.841 -0.618 . . . . 0.48 112.179 -177.536 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 m -135.44 -7.78 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 C-N-CA 120.559 -0.456 . . . . 0.49 111.945 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.567 HG12 ' OG ' ' A' ' 72' ' ' SER . 37.0 pt -97.39 179.78 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.522 0.677 . . . . 0.3 111.779 -178.893 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.748 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -149.85 140.4 22.49 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.255 -1.338 . . . . 0.18 109.094 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.0 mt -118.63 133.55 65.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.875 0.369 . . . . 0.26 111.333 -177.65 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 74.9 50.86 8.32 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.962 -0.637 . . . . 0.17 111.828 178.678 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.484 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.35 133.03 44.23 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.153 0.501 . . . . 0.65 111.89 -176.791 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.436 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 86.4 mt -108.23 132.1 21.31 Favored Pre-proline 0 C--N 1.318 -0.763 0 CA-C-N 115.728 -0.669 . . . . 0.29 109.811 172.733 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 21.7 Cg_exo -64.02 123.48 11.97 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.713 2.275 . . . . 0.25 111.889 -178.861 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 m . . . . . 0 N--CA 1.445 -0.693 0 CA-C-O 121.265 0.555 . . . . 0.42 111.274 -178.086 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.1 t . . . . . 0 N--CA 1.453 -0.309 0 N-CA-C 109.778 -0.453 . . . . 0.96 109.778 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 16.6 mt -103.07 130.94 52.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.641 0.734 . . . . 0.96 111.374 174.292 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.462 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -130.39 168.09 17.52 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 114.656 -1.156 . . . . 0.91 110.138 177.653 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 36.8 t -110.38 101.93 10.61 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.772 -0.649 . . . . 0.34 109.918 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.849 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 96.5 m -87.45 125.01 34.03 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.788 -0.642 . . . . 0.19 111.459 -175.683 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.479 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.2 OUTLIER -69.13 -31.96 71.0 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.06 -0.973 . . . . 0.38 109.818 175.583 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -136.74 108.38 7.0 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.046 -0.525 . . . . 1.03 110.423 177.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 93.2 t -98.94 105.92 18.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 N-CA-C 109.746 -0.465 . . . . 0.18 109.746 177.121 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 m -131.12 142.88 47.14 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 116.012 -0.54 . . . . 0.18 110.763 -176.826 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.521 ' O ' ' HB3' ' A' ' 22' ' ' SER . 30.9 Cg_exo -61.19 136.91 67.67 Favored 'Trans proline' 0 N--CA 1.461 -0.396 0 C-N-CA 122.161 1.908 . . . . 0.19 111.434 173.2 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.62 -15.03 68.1 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.665 -0.779 . . . . 0.18 111.972 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -103.09 3.66 36.22 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.592 0.71 . . . . 2.27 109.657 176.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.521 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 21.3 t -74.99 155.78 36.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.186 -0.915 . . . . 0.24 110.031 177.198 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -53.68 -44.32 69.63 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.829 0.823 . . . . 1.06 109.142 176.54 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.594 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.2 mm? -67.36 -63.19 1.11 Allowed 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 114.25 -1.341 . . . . 1.11 111.002 177.33 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.38 -39.21 71.95 Favored Glycine 0 C--N 1.33 0.23 0 CA-C-N 116.217 -0.447 . . . . 0.16 113.392 -175.074 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 98.7 m -67.72 -38.74 84.0 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.87 0.366 . . . . 0.24 110.475 -178.679 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -75.44 -27.72 59.06 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 120.934 0.397 . . . . 1.01 110.132 178.594 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.594 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 13.1 mt -69.74 -48.67 58.53 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.185 -0.461 . . . . 0.37 110.182 178.753 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.576 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -76.95 -23.78 52.38 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.571 -0.452 . . . . 0.41 111.549 -175.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.499 ' N ' HD12 ' A' ' 29' ' ' LEU . 18.8 t70 -67.95 -32.81 73.5 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.525 0.678 . . . . 0.66 109.37 175.456 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -75.28 -19.78 59.51 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 114.91 -1.041 . . . . 2.07 109.762 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 80.7 mt -103.37 -6.94 21.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.907 -1.042 . . . . 0.71 111.696 -174.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.97 35.48 84.37 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.958 -0.564 . . . . 0.75 112.566 178.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.576 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 32.2 mt -88.96 138.53 19.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.523 0.201 . . . . 0.68 110.705 -177.683 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.1 p -99.14 110.59 26.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.444 0.64 . . . . 1.87 110.221 175.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.531 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.4 pp -80.74 130.89 35.33 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.915 -0.584 . . . . 2.76 110.725 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -90.34 -29.1 18.3 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.739 -0.837 . . . . 2.65 108.739 173.52 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -142.23 98.41 6.1 Favored Pre-proline 0 N--CA 1.444 -0.772 0 N-CA-C 107.802 -1.184 . . . . 2.29 107.802 176.632 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.01 -9.54 21.98 Favored 'Trans proline' 0 N--CA 1.466 -0.143 0 C-N-CA 121.965 1.777 . . . . 0.64 111.588 -175.392 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 p -80.36 -8.9 59.7 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.623 -0.717 . . . . 0.51 111.497 -175.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.483 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.8 m -76.28 159.72 5.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.266 0.555 . . . . 0.24 111.065 -178.733 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.6 mt -92.53 128.03 38.24 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.498 -0.774 . . . . 0.22 109.556 176.126 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.428 HD13 HD23 ' A' ' 29' ' ' LEU . 15.1 pt -106.32 139.12 28.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 116.011 -0.54 . . . . 0.15 109.995 177.184 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.849 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -107.79 99.37 1.36 Allowed Glycine 0 N--CA 1.437 -1.281 0 C-N-CA 120.633 -0.794 . . . . 0.31 112.967 -175.76 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -78.2 137.12 37.98 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 108.691 -0.855 . . . . 0.57 108.691 173.696 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.479 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 70.79 39.08 66.01 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 119.914 -1.136 . . . . 0.21 112.252 -177.583 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.568 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -103.61 111.88 24.55 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.335 0.588 . . . . 0.25 110.831 -174.887 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -94.53 136.47 23.18 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 115.269 -0.878 . . . . 2.21 109.242 178.025 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -66.1 119.47 6.5 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 122.303 2.002 . . . . 0.44 110.745 176.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.4 HG13 ' HA ' ' A' ' 12' ' ' GLN . 16.8 mt . . . . . 0 C--N 1.326 -0.438 0 CA-C-O 121.62 0.724 . . . . 0.46 110.213 -176.748 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.6 t . . . . . 0 N--CA 1.449 -0.512 0 N-CA-C 109.994 -0.373 . . . . 0.74 109.994 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.7 m -126.14 18.34 7.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.44 -0.345 . . . . 2.14 111.071 -177.354 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.4 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -163.01 -77.69 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 112.015 0.376 . . . . 0.54 112.015 -178.394 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 74.8 m -147.61 131.33 16.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.806 0.336 . . . . 0.29 111.417 -176.425 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -88.13 125.72 34.74 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.039 -0.528 . . . . 0.25 109.93 177.192 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.588 HG21 ' SG ' ' A' ' 14' ' ' CYS . 6.8 m -138.89 159.96 30.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-N 115.964 -0.562 . . . . 0.21 110.949 -178.608 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 53.6 t -117.91 103.41 9.91 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.602 -0.726 . . . . 0.39 109.727 179.597 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.734 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 20.1 m -91.75 132.55 36.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.36 0.6 . . . . 0.65 111.402 -176.35 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 10.9 m -94.78 -15.78 23.53 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.314 -0.857 . . . . 1.15 111.29 -177.564 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.423 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 9.7 t70 -109.98 131.94 54.61 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.623 -0.51 . . . . 1.6 109.623 -178.516 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -108.12 20.95 18.05 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.489 0.551 . . . . 2.49 112.489 -172.707 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 50.8 m-80 -83.38 61.91 6.44 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.5 0.667 . . . . 2.27 110.123 177.023 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 m -73.66 149.01 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 CA-C-N 115.541 -0.754 . . . . 1.1 111.181 -178.481 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.6 ' OG ' HG12 ' A' ' 75' ' ' ILE . 82.0 p -95.4 -5.93 42.09 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.887 -0.597 . . . . 1.41 110.34 179.035 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.12 -31.84 3.57 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.675 -0.693 . . . . 0.48 112.409 -176.022 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.0 m -136.59 -8.22 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 117.185 0.493 . . . . 0.49 111.961 177.68 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.6 HG12 ' OG ' ' A' ' 72' ' ' SER . 21.7 pt -94.63 179.7 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.642 0.734 . . . . 0.3 111.979 -178.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.734 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.22 145.33 26.17 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.007 -1.452 . . . . 0.18 108.502 176.179 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.423 ' HB ' ' HB3' ' A' ' 68' ' ' ASP . 58.9 mt -125.75 142.19 43.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 120.717 -0.393 . . . . 0.26 111.402 -175.321 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.483 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 69.34 50.55 31.96 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.115 -0.564 . . . . 0.17 111.898 178.469 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.566 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 9.0 m -103.86 131.55 50.96 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.158 0.504 . . . . 0.65 111.8 -173.292 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.437 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.8 mt -105.9 134.68 19.62 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.735 -0.666 . . . . 0.29 109.859 173.905 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 17.1 Cg_exo -66.09 122.58 10.14 Favored 'Trans proline' 0 N--CA 1.465 -0.204 0 C-N-CA 122.75 2.3 . . . . 0.25 111.789 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.324 -0.536 0 CA-C-O 121.445 0.641 . . . . 0.42 111.35 -177.446 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.4 t . . . . . 0 N--CA 1.451 -0.38 0 N-CA-C 109.14 -0.689 . . . . 0.96 109.14 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.472 HG22 HD12 ' A' ' 50' ' ' ILE . 40.6 mt -100.72 135.02 38.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.711 0.767 . . . . 0.96 111.122 176.436 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.593 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -132.28 165.61 23.78 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.702 -1.136 . . . . 0.91 109.82 177.058 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.5 t -112.29 101.39 9.61 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.891 -0.595 . . . . 0.34 109.409 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.812 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 68.5 m -84.32 130.22 34.82 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 115.326 -0.852 . . . . 0.19 110.988 -176.374 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -69.48 -30.63 68.56 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.26 -0.882 . . . . 0.38 109.053 172.849 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -141.16 121.02 13.54 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.972 -0.558 . . . . 1.03 110.538 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.6 t -109.06 107.78 23.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 109.969 -0.382 . . . . 0.18 109.969 176.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 20.8 m -133.39 145.97 58.77 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.153 -0.476 . . . . 0.18 110.777 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.471 ' HB2' ' HB2' ' A' ' 22' ' ' SER . 22.5 Cg_exo -63.42 137.37 59.84 Favored 'Trans proline' 0 N--CA 1.463 -0.309 0 C-N-CA 121.936 1.757 . . . . 0.19 110.934 171.547 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.45 -26.94 71.1 Favored Glycine 0 C--O 1.228 -0.232 0 C-N-CA 121.018 -0.611 . . . . 0.18 112.501 -177.295 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -98.18 9.15 43.62 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.099 0.476 . . . . 2.27 110.249 177.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.471 ' HB2' ' HB2' ' A' ' 19' ' ' PRO . 30.7 t -78.53 155.82 29.56 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 115.786 -0.643 . . . . 0.24 109.816 176.088 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -54.31 -41.68 69.25 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.001 0.429 . . . . 1.06 109.922 178.155 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.701 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.1 mm? -69.37 -60.27 2.45 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.648 -0.706 . . . . 1.11 110.94 177.837 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.93 -39.58 69.14 Favored Glycine 0 C--N 1.328 0.126 0 CA-C-N 116.203 -0.453 . . . . 0.16 113.216 -176.255 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.6 m -70.36 -41.48 73.09 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.974 0.416 . . . . 0.24 110.388 -177.413 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.418 HD22 ' HA ' ' A' ' 27' ' ' LEU . 1.1 tm? -63.75 -40.42 96.67 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.308 -0.627 . . . . 1.01 109.308 177.84 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.701 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.5 mt -68.05 -43.75 77.96 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.533 -0.758 . . . . 0.37 110.857 -175.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.545 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -76.54 -24.34 53.64 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.944 -0.302 . . . . 0.41 111.051 -178.005 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.487 ' N ' HD12 ' A' ' 29' ' ' LEU . 24.6 t70 -67.38 -31.28 71.4 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.406 0.622 . . . . 0.66 109.647 175.558 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -74.51 -38.7 62.75 Favored 'General case' 0 N--CA 1.443 -0.796 0 CA-C-N 115.037 -0.983 . . . . 2.07 109.513 177.695 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.7 mt -79.08 -20.17 49.44 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.522 -1.217 . . . . 0.71 111.921 -177.454 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.08 48.18 6.17 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.177 -0.535 . . . . 0.75 112.164 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.545 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 16.3 mt -110.92 142.83 22.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 110.449 -0.204 . . . . 0.68 110.449 -178.473 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.403 HG13 ' O ' ' A' ' 35' ' ' VAL . 6.5 p -126.54 103.47 11.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.596 0.712 . . . . 1.87 110.16 174.161 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.2 mt -87.6 137.25 32.5 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.825 -0.625 . . . . 2.76 110.824 -178.651 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -68.67 -36.78 78.98 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.661 -0.7 . . . . 2.65 109.442 175.072 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -132.88 88.86 36.21 Favored Pre-proline 0 N--CA 1.444 -0.764 0 N-CA-C 108.849 -0.797 . . . . 2.29 108.849 175.527 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -72.23 3.38 4.1 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.361 2.041 . . . . 0.64 111.56 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.2 p -75.77 -8.31 56.55 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.62 -0.718 . . . . 0.51 111.063 -178.435 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.1 m -82.41 162.76 3.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 116.055 -0.52 . . . . 0.24 110.561 176.479 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.407 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 94.8 mt -83.69 126.17 32.61 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.048 -0.524 . . . . 0.22 110.328 177.405 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 24.1 pt -107.6 140.77 24.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.244 0.545 . . . . 0.15 110.226 175.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.812 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -111.99 105.21 1.75 Allowed Glycine 0 N--CA 1.44 -1.094 0 C-N-CA 120.57 -0.824 . . . . 0.31 112.87 -177.11 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -83.06 132.39 35.12 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.057 -0.72 . . . . 0.57 109.057 176.009 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.93 38.01 24.24 Favored Glycine 0 N--CA 1.443 -0.86 0 C-N-CA 119.89 -1.148 . . . . 0.21 111.709 -178.01 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.93 111.76 24.54 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.043 0.449 . . . . 0.25 111.22 -174.017 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -100.61 134.67 20.45 Favored Pre-proline 0 C--N 1.315 -0.925 0 CA-C-N 115.647 -0.706 . . . . 2.21 109.269 174.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -59.96 130.8 36.23 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.908 2.405 . . . . 0.44 111.609 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.472 HD12 HG22 ' A' ' 11' ' ' ILE . 21.1 mt . . . . . 0 C--N 1.326 -0.435 0 CA-C-O 121.68 0.753 . . . . 0.46 109.475 -179.468 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.7 t . . . . . 0 N--CA 1.454 -0.272 0 CA-C-O 120.71 0.291 . . . . 0.74 110.858 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 27.3 p -117.06 5.38 12.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.179 -0.464 . . . . 2.14 111.509 -179.084 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -146.8 -80.99 0.14 Allowed 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 120.966 -0.293 . . . . 0.54 111.776 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 28.4 m -142.05 126.88 18.16 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.815 0.341 . . . . 0.29 111.234 -178.263 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.67 128.98 35.04 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.926 0.393 . . . . 0.25 110.254 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.667 HG21 ' SG ' ' A' ' 14' ' ' CYS . 4.6 m -142.4 165.96 16.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.138 -0.483 . . . . 0.21 111.208 -177.33 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' CYS . . . . . 0.566 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 40.6 t -127.72 109.27 11.49 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.819 -0.628 . . . . 0.39 110.259 -178.531 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.743 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.6 m -97.46 140.49 31.83 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.397 0.618 . . . . 0.65 111.808 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 65.2 m -99.85 -12.73 19.62 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.14 -0.936 . . . . 1.15 111.501 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -110.33 149.99 29.4 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.02 -0.363 . . . . 1.6 110.02 -178.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 42.8 m-80 -120.35 12.42 11.69 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.639 0.607 . . . . 2.49 112.639 -173.363 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -81.62 71.84 8.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.773 0.796 . . . . 2.27 109.37 177.55 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 34.3 m -94.35 152.18 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 CA-C-N 115.457 -0.792 . . . . 1.1 111.172 -175.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.54 ' H ' HG12 ' A' ' 75' ' ' ILE . 90.4 p -86.97 -8.68 56.98 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.657 -0.701 . . . . 1.41 110.309 178.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.92 -32.02 3.74 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 115.285 -0.87 . . . . 0.48 111.954 -176.471 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.9 m -132.84 -2.58 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 C-N-CA 120.517 -0.473 . . . . 0.49 112.007 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.54 HG12 ' H ' ' A' ' 72' ' ' SER . 23.5 pt -100.73 178.77 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.495 0.664 . . . . 0.3 111.924 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.743 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -148.26 139.71 23.54 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.575 -1.193 . . . . 0.18 109.393 177.061 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 68.9 mt -121.73 130.19 74.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.938 0.399 . . . . 0.26 111.301 -176.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 82.0 46.43 6.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.995 -0.621 . . . . 0.17 111.777 178.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.566 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -99.38 144.25 28.71 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.288 0.566 . . . . 0.65 112.387 -175.153 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 87.7 mt -119.81 134.11 23.91 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.246 -0.888 . . . . 0.29 109.743 172.092 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 21.6 Cg_exo -64.67 121.47 9.03 Favored 'Trans proline' 0 C--O 1.234 0.298 0 C-N-CA 123.034 2.489 . . . . 0.25 112.348 -179.347 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.8 m . . . . . 0 N--CA 1.444 -0.762 0 CA-C-N 116.039 -0.528 . . . . 0.42 110.629 -179.724 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 109.014 -0.736 . . . . 0.96 109.014 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 51.5 mt -99.9 134.75 38.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.606 0.717 . . . . 0.96 111.344 178.079 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.628 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -142.95 162.22 36.05 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.063 -0.971 . . . . 0.91 111.043 178.996 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 19.4 t -106.68 102.26 11.65 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.46 -0.791 . . . . 0.34 109.483 178.74 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.893 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 57.6 m -86.75 133.54 33.65 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.934 -0.575 . . . . 0.19 111.017 -175.688 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.12 -30.42 49.41 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.185 -0.916 . . . . 0.38 109.435 177.016 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ASN . . . . . 0.636 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 17.1 m-20 -134.28 103.21 5.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.438 -0.346 . . . . 1.03 111.306 175.172 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.1 t -92.52 101.68 12.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.214 0.53 . . . . 0.18 109.727 174.691 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 m -131.71 140.38 38.11 Favored Pre-proline 0 C--N 1.319 -0.717 0 CA-C-N 115.748 -0.66 . . . . 0.18 110.75 -174.698 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.528 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.7 Cg_exo -57.94 138.75 87.56 Favored 'Trans proline' 0 N--CA 1.463 -0.302 0 C-N-CA 122.195 1.93 . . . . 0.19 111.304 172.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.29 -21.99 68.84 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.939 -0.648 . . . . 0.18 112.596 -178.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -101.2 4.94 42.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.239 0.542 . . . . 2.27 109.837 176.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.528 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 16.6 t -69.32 153.95 42.81 Favored 'General case' 0 CA--C 1.514 -0.438 0 CA-C-N 115.778 -0.646 . . . . 0.24 109.68 175.84 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -56.63 -38.42 72.09 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-O 121.122 0.487 . . . . 1.06 110.035 178.152 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.686 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 5.3 mt -70.19 -63.45 1.08 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.58 -0.737 . . . . 1.11 110.853 174.06 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.54 -40.87 55.52 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 116.035 -0.53 . . . . 0.16 113.443 -174.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 93.4 m -68.16 -44.53 75.77 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.761 0.315 . . . . 0.24 110.484 -178.521 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.4 tt -63.43 -35.52 80.71 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.075 -0.511 . . . . 1.01 110.814 178.375 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.686 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.3 mt -72.49 -46.09 56.41 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.096 -0.502 . . . . 0.37 110.365 -177.543 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.612 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -75.03 -21.76 58.85 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.71 -0.396 . . . . 0.41 110.934 -178.133 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -66.24 -32.22 73.51 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.708 0.766 . . . . 0.66 109.712 173.164 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -77.37 -47.7 19.19 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 114.906 -1.043 . . . . 2.07 109.261 177.103 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 72.4 mt -78.22 -13.11 59.99 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.705 -1.134 . . . . 0.71 112.893 -174.479 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.49 37.57 90.04 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-N 116.131 -0.486 . . . . 0.75 112.473 178.492 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.612 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 55.8 mt -75.46 137.35 23.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.104 0.478 . . . . 0.68 111.718 -173.265 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.4 p -88.11 113.55 25.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.687 -0.688 . . . . 1.87 110.762 175.471 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.457 ' H ' ' HG ' ' A' ' 36' ' ' LEU . 1.2 pp -103.0 134.6 46.17 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.03 -0.532 . . . . 2.76 110.796 177.589 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -90.06 -32.28 16.79 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.021 -1.104 . . . . 2.65 108.021 171.084 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -139.93 106.76 6.86 Favored Pre-proline 0 N--CA 1.446 -0.631 0 CA-C-N 114.588 -1.187 . . . . 2.29 108.227 174.771 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -71.9 -2.24 11.19 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.072 1.848 . . . . 0.64 111.327 -178.011 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.6 p -94.94 20.2 9.23 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.479 -0.782 . . . . 0.51 111.157 -175.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.2 m -105.77 160.83 5.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.81 -0.632 . . . . 0.24 110.226 178.289 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.405 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.6 mt -81.29 119.81 24.12 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.034 -0.53 . . . . 0.22 110.244 175.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 19.4 pt -104.06 137.11 34.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.871 -0.604 . . . . 0.15 109.684 175.026 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.893 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.91 106.75 1.78 Allowed Glycine 0 N--CA 1.438 -1.176 0 C-N-CA 120.538 -0.839 . . . . 0.31 113.05 -174.544 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.636 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 26.0 t70 -77.48 145.18 37.2 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 108.887 -0.783 . . . . 0.57 108.887 174.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 69.71 37.3 76.45 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 119.884 -1.15 . . . . 0.21 112.221 177.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.534 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -101.35 114.4 28.36 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.387 0.613 . . . . 0.25 111.215 -172.712 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.531 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 0.7 OUTLIER -101.54 130.98 23.56 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 115.4 -0.818 . . . . 2.21 109.702 177.438 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -56.48 120.39 8.24 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 C-N-CA 122.436 2.091 . . . . 0.44 111.102 177.638 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.406 HG13 ' HA ' ' A' ' 12' ' ' GLN . 43.7 mt . . . . . 0 C--N 1.326 -0.418 0 CA-C-O 121.158 0.504 . . . . 0.46 110.587 -174.713 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 40.1 t . . . . . 0 C--O 1.235 0.309 0 CA-C-O 120.94 0.4 . . . . 0.74 111.261 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 8.9 t -119.11 -13.63 9.37 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.974 -0.557 . . . . 2.14 110.782 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.12 -83.59 0.57 Allowed 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 121.121 -0.232 . . . . 0.54 110.86 -179.305 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 54.4 m -150.39 127.45 11.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.699 0.285 . . . . 0.29 110.551 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.44 140.58 29.85 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.03 0.443 . . . . 0.25 110.483 -178.049 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.656 HG21 ' SG ' ' A' ' 14' ' ' CYS . 2.7 m -147.78 170.38 3.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.229 0.538 . . . . 0.21 111.404 -176.651 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' CYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 50.3 t -129.6 107.97 9.86 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.319 -0.855 . . . . 0.39 109.788 178.891 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.724 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -99.58 138.89 36.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.286 0.565 . . . . 0.65 111.82 -177.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 50.4 m -99.69 -19.1 16.95 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.492 -0.776 . . . . 1.15 111.731 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.409 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 16.4 t70 -101.54 148.95 24.6 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.925 -0.398 . . . . 1.6 109.925 -177.051 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -120.18 18.51 12.31 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.581 0.586 . . . . 2.49 112.581 -173.685 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.415 ' HB2' HD12 ' A' ' 77' ' ' ILE . 42.9 m-80 -79.24 63.9 4.0 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.544 0.688 . . . . 2.27 109.967 176.489 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.886 HG12 ' H ' ' A' ' 73' ' ' GLY . 87.2 t -90.37 136.19 24.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.414 -0.812 . . . . 1.1 111.23 -173.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.671 ' H ' HG12 ' A' ' 75' ' ' ILE . 87.3 p -79.2 -3.01 43.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.345 -0.843 . . . . 1.41 110.939 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.886 ' H ' HG12 ' A' ' 71' ' ' VAL . . . 127.85 -31.56 3.69 Favored Glycine 0 N--CA 1.443 -0.868 0 CA-C-N 115.367 -0.833 . . . . 0.48 112.195 -176.723 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 17.2 m -138.68 -7.62 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 112.641 0.608 . . . . 0.49 112.641 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.671 HG12 ' H ' ' A' ' 72' ' ' SER . 7.2 pt -84.97 -178.54 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.581 0.705 . . . . 0.3 112.142 -178.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.724 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -149.43 139.2 21.83 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.639 -1.164 . . . . 0.18 109.51 175.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.415 HD12 ' HB2' ' A' ' 70' ' ' ASN . 65.3 mt -124.49 134.99 65.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.931 0.396 . . . . 0.26 111.364 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.512 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 79.21 47.98 7.17 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 121.002 -0.618 . . . . 0.17 111.785 179.377 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.557 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -100.14 136.73 39.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.24 0.543 . . . . 0.65 112.456 -175.367 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 93.7 mt -108.1 134.08 20.28 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 115.474 -0.784 . . . . 0.29 109.345 168.438 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.456 ' HA ' HG12 ' A' ' 64' ' ' VAL . 20.5 Cg_exo -64.3 128.35 21.29 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.937 2.424 . . . . 0.25 112.474 -178.45 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.441 -0.911 0 CA-C-N 115.878 -0.601 . . . . 0.42 109.658 177.012 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 28.6 t . . . . . 0 N--CA 1.45 -0.425 0 N-CA-C 109.87 -0.418 . . . . 0.96 109.87 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.6 mt -91.65 133.35 33.49 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.559 0 CA-C-O 121.737 0.78 . . . . 0.96 110.547 177.77 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.488 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -142.92 162.29 35.85 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 114.585 -1.189 . . . . 0.91 110.569 -175.006 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 26.6 t -111.44 101.69 10.12 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.846 -0.615 . . . . 0.34 109.847 -176.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.787 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 86.7 m -87.31 134.45 33.56 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.232 -0.895 . . . . 0.19 110.89 -175.561 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.43 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -76.1 -27.68 57.23 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 115.37 -0.832 . . . . 0.38 109.665 178.404 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -143.78 103.94 4.12 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.769 -0.651 . . . . 1.03 110.473 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 67.4 t -93.57 108.14 20.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 CA-C-N 116.062 -0.517 . . . . 0.18 109.688 178.253 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.05 146.12 60.3 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 116.032 -0.531 . . . . 0.18 110.757 -175.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.513 ' O ' ' HB3' ' A' ' 22' ' ' SER . 22.6 Cg_exo -62.79 136.94 60.35 Favored 'Trans proline' 0 N--CA 1.461 -0.401 0 C-N-CA 122.12 1.88 . . . . 0.19 111.181 173.05 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.93 -23.03 72.58 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.946 -0.645 . . . . 0.18 112.64 -176.472 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -101.07 9.92 41.58 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.724 0.774 . . . . 2.27 109.813 177.038 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.513 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.6 t -78.77 156.36 28.87 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.52 -0.764 . . . . 0.24 109.921 175.683 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -53.9 -40.94 67.07 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.201 0.524 . . . . 1.06 109.773 176.029 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.674 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER -67.88 -63.1 1.13 Allowed 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 115.462 -0.79 . . . . 1.11 111.046 176.796 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.411 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -57.01 -38.74 87.27 Favored Glycine 0 C--N 1.33 0.24 0 CA-C-N 115.999 -0.546 . . . . 0.16 113.304 -175.031 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.0 m -69.22 -40.64 77.85 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.646 0.26 . . . . 0.24 110.462 -178.314 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -62.99 -38.62 91.9 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.41 -0.589 . . . . 1.01 109.41 176.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.674 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.3 mt -67.82 -53.5 26.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.809 -0.632 . . . . 0.37 110.84 -177.766 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.554 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -70.87 -20.82 62.48 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.992 -0.283 . . . . 0.41 111.363 -176.584 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.425 ' N ' HD12 ' A' ' 29' ' ' LEU . 24.1 t70 -62.87 -38.95 92.9 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.602 0.715 . . . . 0.66 110.039 173.429 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -73.36 -16.97 61.33 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 114.816 -1.084 . . . . 2.07 109.615 -179.217 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.8 mt -105.86 -13.9 15.38 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.808 -1.087 . . . . 0.71 111.917 -174.434 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 71.82 42.71 52.65 Favored Glycine 0 C--N 1.331 0.302 0 CA-C-N 115.722 -0.672 . . . . 0.75 112.868 178.335 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.554 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 32.7 mt -101.2 124.92 55.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.689 0.28 . . . . 0.68 111.066 -176.756 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.6 p -110.43 102.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.814 0.816 . . . . 1.87 110.36 176.362 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.1 mt -85.95 141.9 29.2 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.556 -0.747 . . . . 2.76 111.094 -178.078 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -74.65 -23.58 58.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.552 0.692 . . . . 2.65 109.701 175.846 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -136.37 91.52 16.39 Favored Pre-proline 0 N--CA 1.447 -0.616 0 N-CA-C 108.22 -1.03 . . . . 2.29 108.22 172.512 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -66.18 -2.87 7.62 Favored 'Trans proline' 0 C--O 1.224 -0.22 0 C-N-CA 122.367 2.045 . . . . 0.64 111.808 -177.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 25.2 p -78.59 -12.67 60.03 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.577 -0.738 . . . . 0.51 111.322 -177.294 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 33.3 m -70.55 156.63 7.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.152 0.501 . . . . 0.24 111.295 -178.465 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 95.4 mt -86.38 129.09 34.97 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.778 -0.646 . . . . 0.22 110.333 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.406 HD13 HD23 ' A' ' 29' ' ' LEU . 23.7 pt -112.23 144.33 20.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.991 -0.55 . . . . 0.15 110.115 176.811 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.787 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.61 106.67 1.42 Allowed Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.48 -0.866 . . . . 0.31 113.102 -176.168 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -78.33 140.55 38.78 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.252 -0.647 . . . . 0.57 109.252 175.333 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 73.59 39.42 49.43 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.141 -1.028 . . . . 0.21 111.999 179.277 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.539 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.75 115.89 31.09 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.275 0.559 . . . . 0.25 111.346 -172.774 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.474 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.8 t70 -102.33 136.67 19.36 Favored Pre-proline 0 C--N 1.318 -0.78 0 CA-C-N 115.427 -0.806 . . . . 2.21 110.383 173.773 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.474 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 16.5 Cg_exo -60.79 119.61 6.87 Favored 'Trans proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.176 2.584 . . . . 0.44 111.03 178.393 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.45 HG13 ' HA ' ' A' ' 12' ' ' GLN . 43.0 mt . . . . . 0 C--N 1.329 -0.325 0 CA-C-O 121.297 0.57 . . . . 0.46 110.224 -175.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.7 t . . . . . 0 N--CA 1.453 -0.29 0 N-CA-C 109.942 -0.392 . . . . 0.74 109.942 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.5 t -117.31 15.06 14.84 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.737 -0.211 . . . . 2.14 111.532 -176.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.43 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -157.05 -78.0 0.08 Allowed 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.87 -0.332 . . . . 0.54 111.581 178.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 21.6 m -148.59 129.43 14.27 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.774 0.321 . . . . 0.29 110.77 -179.075 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.436 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -90.41 135.88 33.4 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.864 -0.421 . . . . 0.25 109.864 -179.424 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.569 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 6.7 m -143.87 158.55 16.17 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-O 121.277 0.561 . . . . 0.21 111.156 -177.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' CYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 15.0 t -109.35 104.51 13.64 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.338 -0.846 . . . . 0.39 109.476 175.429 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.776 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 61.3 m -91.16 120.96 32.53 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.169 0.509 . . . . 0.65 111.108 -178.035 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 17.6 t -78.22 -21.53 49.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.28 -0.873 . . . . 1.15 110.295 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.7 t0 -105.81 149.09 26.8 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.224 -0.658 . . . . 1.6 109.224 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.3 p30 -118.84 5.64 11.47 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 112.559 0.577 . . . . 2.49 112.559 -175.092 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.455 ' ND2' HD12 ' A' ' 77' ' ' ILE . 1.3 p30 -82.39 112.18 19.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.921 0.867 . . . . 2.27 109.563 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.945 HG12 ' H ' ' A' ' 73' ' ' GLY . 70.8 t -122.12 137.28 56.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.364 -0.835 . . . . 1.1 110.858 -172.485 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.529 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 95.0 p -76.88 -1.41 28.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.654 -0.703 . . . . 1.41 110.94 -178.185 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.945 ' H ' HG12 ' A' ' 71' ' ' VAL . . . 127.88 -31.82 3.62 Favored Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 115.43 -0.804 . . . . 0.48 112.372 -176.521 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.2 m -138.77 -5.92 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.203 0 N-CA-C 112.849 0.685 . . . . 0.49 112.849 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.529 ' CG1' ' H ' ' A' ' 72' ' ' SER . 5.1 pt -92.82 -177.1 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 113.359 0.874 . . . . 0.3 113.359 -174.236 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.776 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.68 142.59 23.87 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 114.117 -1.401 . . . . 0.18 108.602 174.669 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.455 HD12 ' ND2' ' A' ' 70' ' ' ASN . 66.5 mt -126.67 139.94 50.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.275 0.472 . . . . 0.26 112.275 -175.617 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 68.58 51.82 28.96 Favored Glycine 0 C--N 1.335 0.48 0 CA-C-N 115.736 -0.666 . . . . 0.17 111.682 177.411 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 8.3 m -109.0 138.94 44.55 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.049 0.452 . . . . 0.65 111.84 -172.369 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.434 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.8 mt -109.15 132.45 21.22 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.801 -0.636 . . . . 0.29 110.057 173.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.51 ' HA ' HG12 ' A' ' 64' ' ' VAL . 24.5 Cg_exo -63.23 123.06 11.51 Favored 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.194 2.596 . . . . 0.25 113.308 -177.18 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.436 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 9.2 m . . . . . 0 N--CA 1.445 -0.723 0 CA-C-N 116.018 -0.537 . . . . 0.42 110.063 177.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 32.3 t . . . . . 0 N--CA 1.454 -0.264 0 N-CA-C 109.704 -0.48 . . . . 0.96 109.704 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 21.0 mt -105.31 133.72 48.79 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.453 0 CA-C-O 121.651 0.739 . . . . 0.96 111.231 177.296 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.613 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -141.47 161.68 37.33 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 114.854 -1.066 . . . . 0.91 110.684 178.885 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.431 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 24.8 t -110.98 103.31 11.77 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.415 -0.812 . . . . 0.34 109.107 178.311 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.792 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 81.8 m -85.75 138.81 31.83 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.461 -0.79 . . . . 0.19 110.678 -175.531 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.405 ' HB3' ' HA3' ' A' ' 46' ' ' GLY . 0.1 OUTLIER -73.98 -35.15 64.45 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.711 -0.848 . . . . 0.38 108.711 175.374 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ASN . . . . . 0.783 ' ND2' ' HB3' ' A' ' 45' ' ' ASP . 0.1 OUTLIER -130.02 150.35 51.33 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 109.532 -0.544 . . . . 1.03 109.532 170.909 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.6 t -130.6 101.79 6.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 109.139 -0.689 . . . . 0.18 109.139 173.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.469 HG22 ' OD1' ' A' ' 16' ' ' ASN . 8.8 m -130.8 143.51 49.66 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.981 -0.554 . . . . 0.18 111.513 -173.073 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.435 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.4 Cg_exo -59.2 140.13 93.4 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.499 2.133 . . . . 0.19 111.853 172.8 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.85 -20.96 67.06 Favored Glycine 0 N--CA 1.453 -0.199 0 C-N-CA 120.979 -0.629 . . . . 0.18 112.603 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -103.91 14.98 29.68 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.736 0.779 . . . . 2.27 109.711 176.789 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.435 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.2 t -84.24 154.56 22.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.599 -0.728 . . . . 0.24 109.902 176.555 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -52.25 -41.01 62.44 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.185 0.517 . . . . 1.06 110.496 178.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.68 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 7.6 mt -71.96 -63.17 1.19 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.737 -0.665 . . . . 1.11 110.674 176.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.33 -40.39 53.21 Favored Glycine 0 C--N 1.33 0.212 0 CA-C-N 116.067 -0.515 . . . . 0.16 113.266 -175.48 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 96.5 m -68.62 -45.12 72.74 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.878 0.37 . . . . 0.24 110.826 -177.454 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.432 ' O ' HD13 ' A' ' 27' ' ' LEU . 1.8 tm? -65.38 -37.56 87.35 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.435 -0.58 . . . . 1.01 109.435 178.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.68 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.0 mt -69.42 -43.51 73.23 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.012 -0.54 . . . . 0.37 110.588 -176.726 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.586 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.3 pp -72.23 -26.54 62.07 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.662 -0.415 . . . . 0.41 110.765 -178.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.421 ' N ' HD12 ' A' ' 29' ' ' LEU . 19.5 t70 -66.19 -33.56 76.05 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.711 0.767 . . . . 0.66 109.066 173.399 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 29.3 mm-40 -80.22 -11.62 59.71 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.509 -1.223 . . . . 2.07 111.143 179.452 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.1 mt -115.41 -14.51 11.59 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.899 -0.591 . . . . 0.71 112.187 -174.528 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 78.88 39.68 19.71 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.139 -0.553 . . . . 0.75 112.751 177.054 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.586 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 15.9 mt -96.62 138.39 21.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.624 0.249 . . . . 0.68 110.761 -176.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.3 p -119.39 102.73 13.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.468 0.651 . . . . 1.87 110.264 174.331 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 20.0 mt -86.99 140.09 29.91 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.973 -0.558 . . . . 2.76 110.802 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -75.33 -27.74 59.37 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.936 -0.574 . . . . 2.65 109.752 174.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 61.1 t0 -139.02 104.31 7.36 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 108.663 -0.866 . . . . 2.29 108.663 175.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -72.12 4.03 3.57 Favored 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.518 2.145 . . . . 0.64 112.901 -176.409 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 64.9 p -93.04 2.55 56.72 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 120.445 -0.502 . . . . 0.51 110.936 -177.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.2 m -83.63 159.76 3.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.102 -0.499 . . . . 0.24 110.425 178.036 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.1 mt -88.7 122.24 31.91 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.832 -0.622 . . . . 0.22 110.475 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.5 pt -106.17 134.4 47.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 115.987 -0.551 . . . . 0.15 110.073 176.072 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.792 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -111.16 107.83 2.26 Favored Glycine 0 N--CA 1.443 -0.882 0 C-N-CA 120.593 -0.813 . . . . 0.31 112.908 -176.398 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.783 ' HB3' ' ND2' ' A' ' 16' ' ' ASN . 20.9 t70 -81.44 138.64 35.53 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.441 -0.577 . . . . 0.57 109.441 176.16 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.405 ' HA3' ' HB3' ' A' ' 15' ' ' GLN . . . 78.7 36.66 28.63 Favored Glycine 0 N--CA 1.443 -0.88 0 C-N-CA 120.248 -0.977 . . . . 0.21 111.787 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.4 OUTLIER -105.15 112.75 25.99 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.344 0.592 . . . . 0.25 111.559 -172.4 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -102.82 134.33 19.91 Favored Pre-proline 0 C--N 1.317 -0.828 0 CA-C-N 115.364 -0.834 . . . . 2.21 109.535 173.64 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -59.28 127.2 23.15 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.759 2.306 . . . . 0.44 111.616 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 19.1 mt . . . . . 0 C--N 1.326 -0.444 0 CA-C-O 121.479 0.657 . . . . 0.46 109.253 -179.842 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.1 t . . . . . 0 N--CA 1.455 -0.198 0 N-CA-C 110.071 -0.344 . . . . 0.74 110.071 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 8.3 p -102.4 -26.56 13.23 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.313 0.486 . . . . 2.14 112.313 -175.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 14' ' ' CYS . . . -123.14 -75.99 0.59 Allowed 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.56 -0.456 . . . . 0.54 111.91 -176.578 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 31.8 m -146.77 128.73 15.46 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.908 0.385 . . . . 0.29 111.39 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.67 137.89 32.1 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.261 -0.427 . . . . 0.25 110.512 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.606 HG21 ' SG ' ' A' ' 14' ' ' CYS . 2.7 m -146.3 170.45 4.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.037 -0.529 . . . . 0.21 111.302 -177.294 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' CYS . . . . . 0.411 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 41.3 t -132.64 109.68 9.9 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.351 -0.841 . . . . 0.39 109.589 177.127 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.756 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -95.91 137.67 34.64 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.454 0.645 . . . . 0.65 112.041 -178.074 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 33.0 t -82.88 -18.91 38.58 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 114.865 -1.061 . . . . 1.15 110.586 178.245 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -110.84 147.29 34.85 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.101 0.477 . . . . 1.6 111.151 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -115.62 4.48 14.14 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.637 -0.71 . . . . 2.49 110.522 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -75.67 73.81 2.66 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.34 0.591 . . . . 2.27 110.446 178.532 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 33.6 m -89.57 146.8 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 CA-C-N 115.801 -0.636 . . . . 1.1 110.947 -177.604 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.421 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 44.8 m -89.52 10.43 22.89 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.084 -0.507 . . . . 1.41 110.703 178.212 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.26 -33.93 3.2 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.561 -0.745 . . . . 0.48 113.552 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.6 m -140.57 -2.85 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 117.743 0.772 . . . . 0.49 112.218 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.421 ' CG1' ' H ' ' A' ' 72' ' ' SER . 16.4 pt -93.71 -176.45 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.769 0.795 . . . . 0.3 112.567 -176.432 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.756 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -147.53 137.82 23.13 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 114.206 -1.361 . . . . 0.18 108.745 174.049 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 70.4 mt -117.52 126.39 74.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.002 0.43 . . . . 0.26 111.628 -176.375 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.51 52.62 5.45 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.845 -0.616 . . . . 0.17 111.798 177.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.42 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 1.3 m -99.03 137.52 37.44 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 112.424 0.527 . . . . 0.65 112.424 -176.257 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 86.3 mt -105.36 131.49 21.71 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.505 -0.771 . . . . 0.29 109.719 170.302 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.438 ' HA ' HG12 ' A' ' 64' ' ' VAL . 19.1 Cg_exo -65.81 121.95 9.44 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.973 2.449 . . . . 0.25 112.303 -179.131 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.3 m . . . . . 0 N--CA 1.443 -0.78 0 CA-C-N 116.275 -0.421 . . . . 0.42 110.147 178.801 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.0 t . . . . . 0 N--CA 1.452 -0.374 0 N-CA-C 109.137 -0.69 . . . . 0.96 109.137 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 45.9 mt -102.08 136.76 32.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.629 0.728 . . . . 0.96 111.544 -179.131 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.526 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -144.13 169.27 18.18 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.97 -1.014 . . . . 0.91 110.556 -179.717 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 14.7 t -118.15 103.51 9.94 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.708 -0.678 . . . . 0.34 109.731 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.828 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 98.9 m -85.68 134.67 33.96 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.397 -0.819 . . . . 0.19 111.196 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.407 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -72.77 -30.05 63.8 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.162 -0.926 . . . . 0.38 109.082 174.652 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -139.66 115.74 10.36 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.611 -0.722 . . . . 1.03 110.369 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 88.9 t -105.53 105.45 18.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-O 120.927 0.394 . . . . 0.18 110.048 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.6 m -132.37 139.92 36.34 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 115.936 -0.574 . . . . 0.18 111.147 -175.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.455 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.4 Cg_exo -58.55 141.99 97.83 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.442 2.095 . . . . 0.19 111.717 171.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.51 -19.52 70.94 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.878 -0.677 . . . . 0.18 111.965 179.432 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -102.15 9.83 39.88 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.218 0.532 . . . . 2.27 110.009 176.205 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.455 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.5 t -80.8 154.62 27.07 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 115.628 -0.714 . . . . 0.24 109.728 175.575 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -54.56 -40.13 68.43 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.96 0.41 . . . . 1.06 110.357 179.582 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.67 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 5.1 mt -70.75 -62.19 1.48 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.686 -0.688 . . . . 1.11 110.529 176.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.56 -38.71 63.97 Favored Glycine 0 C--N 1.33 0.242 0 CA-C-N 116.052 -0.522 . . . . 0.16 113.421 -175.031 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 85.7 m -66.35 -42.71 87.69 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.798 0.333 . . . . 0.24 110.745 -178.215 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.456 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.6 tm? -69.97 -34.82 73.88 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.327 -0.62 . . . . 1.01 109.327 177.672 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.67 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.6 mt -65.04 -46.2 82.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.053 -0.521 . . . . 0.37 110.483 -178.131 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.492 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.64 -21.03 52.85 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.473 -0.491 . . . . 0.41 111.004 -178.648 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.456 ' N ' HD12 ' A' ' 29' ' ' LEU . 32.4 t70 -66.15 -37.81 86.59 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.391 0.615 . . . . 0.66 109.572 173.181 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -75.98 -12.85 60.21 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.029 -0.987 . . . . 2.07 109.928 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 75.3 mt -106.09 -12.03 15.91 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.195 -0.911 . . . . 0.71 111.318 -179.269 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.09 39.36 96.25 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.575 -0.738 . . . . 0.75 112.343 -178.709 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.492 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 53.9 mt -82.19 133.23 29.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 O-C-N 122.645 -0.326 . . . . 0.68 111.057 -176.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 11.4 p -87.45 116.43 29.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 109.336 -0.616 . . . . 1.87 109.336 172.393 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.492 HD22 ' HB3' ' A' ' 39' ' ' PRO . 0.9 OUTLIER -91.79 131.33 37.23 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.918 -0.583 . . . . 2.76 111.003 -179.454 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 45.2 tt0 -88.23 -34.27 17.82 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.261 -1.014 . . . . 2.65 108.261 173.575 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -145.06 102.75 4.43 Favored Pre-proline 0 N--CA 1.445 -0.711 0 CA-C-N 114.835 -1.075 . . . . 2.29 108.324 174.739 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.492 ' HB3' HD22 ' A' ' 36' ' ' LEU . 41.4 Cg_endo -67.71 -4.39 12.11 Favored 'Trans proline' 0 C--O 1.225 -0.152 0 C-N-CA 122.586 2.191 . . . . 0.64 112.075 -174.792 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 15.3 p -82.53 -10.05 59.16 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.823 -0.626 . . . . 0.51 111.407 -174.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.418 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.8 m -74.18 160.54 5.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.159 0.504 . . . . 0.24 111.01 -178.612 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.41 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 92.3 mt -91.52 129.81 37.44 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.795 -0.639 . . . . 0.22 110.397 179.195 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.2 pt -112.52 137.64 44.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.159 0.504 . . . . 0.15 110.433 176.569 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.828 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.8 103.31 1.32 Allowed Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 120.478 -0.867 . . . . 0.31 113.133 -175.338 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -79.11 139.91 37.96 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 109.445 -0.576 . . . . 0.57 109.445 177.078 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.74 39.82 38.92 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.077 -1.058 . . . . 0.21 111.804 -179.409 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.539 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -108.28 112.98 25.72 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.098 0.475 . . . . 0.25 111.717 -171.69 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.406 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 12.2 m-20 -101.83 137.13 19.45 Favored Pre-proline 0 C--N 1.318 -0.763 0 CA-C-N 115.395 -0.82 . . . . 2.21 109.581 175.568 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 25.2 Cg_exo -59.88 133.98 54.12 Favored 'Trans proline' 0 C--O 1.233 0.244 0 C-N-CA 122.86 2.373 . . . . 0.44 112.076 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 40.6 mt . . . . . 0 C--N 1.327 -0.387 0 CA-C-O 121.209 0.528 . . . . 0.46 109.881 -179.787 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.3 t . . . . . 0 N--CA 1.451 -0.405 0 N-CA-C 109.923 -0.399 . . . . 0.74 109.923 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 10.0 t -107.08 -28.68 9.85 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.557 -0.292 . . . . 2.14 111.085 -178.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.407 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -112.05 -80.2 0.59 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.837 -0.345 . . . . 0.54 111.783 -176.437 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 16.4 m -145.1 128.13 16.54 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.84 0.352 . . . . 0.29 111.154 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.48 136.91 32.92 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.903 0.382 . . . . 0.25 110.276 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.652 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.2 m -145.85 167.92 7.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.089 0.471 . . . . 0.21 111.59 -175.754 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' CYS . . . . . 0.449 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 17.8 t -130.54 105.94 8.18 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.45 -0.796 . . . . 0.39 110.121 178.013 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.723 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.8 m -92.45 133.58 35.77 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.698 0.761 . . . . 0.65 111.985 -179.28 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 8.7 t -86.16 -13.44 47.07 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.521 -1.218 . . . . 1.15 110.423 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -107.82 156.67 18.88 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.866 -0.606 . . . . 1.6 110.2 -179.145 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 30.4 p-10 -120.9 -15.1 8.38 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 113.084 0.772 . . . . 2.49 113.084 -172.443 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -88.16 73.21 9.01 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 121.985 0.898 . . . . 2.27 111.072 -173.344 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.7 m -85.68 164.77 2.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.049 -0.978 . . . . 1.1 110.999 -178.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.543 ' OG ' HG12 ' A' ' 75' ' ' ILE . 88.7 p -84.59 -2.72 57.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.051 -0.522 . . . . 1.41 111.66 -175.022 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.64 -31.89 3.83 Favored Glycine 0 CA--C 1.505 -0.592 0 C-N-CA 120.721 -0.752 . . . . 0.48 112.304 -178.071 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.4 m -135.49 -12.15 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.488 -0.485 . . . . 0.49 111.935 178.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.543 HG12 ' OG ' ' A' ' 72' ' ' SER . 35.4 pt -90.02 -175.14 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 119.986 -0.686 . . . . 0.3 111.581 -179.156 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.723 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -147.78 143.46 27.54 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.398 -1.273 . . . . 0.18 108.665 175.085 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 64.0 mt -122.55 131.23 73.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.966 0.412 . . . . 0.26 111.585 -175.41 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.448 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 76.38 50.71 7.18 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.097 -0.573 . . . . 0.17 112.188 177.751 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.486 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.92 141.84 31.19 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 112.826 0.676 . . . . 0.65 112.826 -175.013 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 95.0 mt -108.57 132.06 21.37 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.223 -0.899 . . . . 0.29 109.269 168.833 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.432 ' HA ' HG12 ' A' ' 64' ' ' VAL . 15.8 Cg_exo -67.29 128.4 18.33 Favored 'Trans proline' 0 C--O 1.234 0.297 0 C-N-CA 122.757 2.304 . . . . 0.25 112.292 -179.257 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.0 m . . . . . 0 N--CA 1.444 -0.729 0 CA-C-N 116.02 -0.536 . . . . 0.42 110.12 178.239 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.1 t . . . . . 0 N--CA 1.45 -0.457 0 N-CA-C 110.128 -0.323 . . . . 0.96 110.128 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 23.7 mt -112.1 135.92 49.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-O 121.482 0.658 . . . . 0.96 110.825 173.385 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.681 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -153.91 170.29 21.39 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 114.968 -1.015 . . . . 0.91 110.873 -177.187 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.587 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 42.1 t -118.69 108.59 15.1 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.434 -0.803 . . . . 0.34 109.593 177.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.871 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 60.9 m -90.11 129.62 36.38 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.311 0.577 . . . . 0.19 111.599 -172.785 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.442 ' HB3' ' HA3' ' A' ' 46' ' ' GLY . 1.3 tp60 -75.54 -26.71 58.25 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 114.946 -1.025 . . . . 0.38 110.252 177.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ASN . . . . . 0.608 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 1.6 t-20 -135.86 99.15 4.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.445 -0.343 . . . . 1.03 110.818 175.266 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 61.8 t -92.66 102.0 13.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.002 0.429 . . . . 0.18 110.039 177.29 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.6 m -133.42 142.92 45.89 Favored Pre-proline 0 C--N 1.32 -0.701 0 CA-C-N 115.896 -0.593 . . . . 0.18 110.905 -174.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.491 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.5 Cg_exo -61.1 139.38 83.79 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.086 1.858 . . . . 0.19 111.164 171.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.08 -24.42 70.3 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.84 -0.695 . . . . 0.18 112.627 -178.262 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -97.61 4.45 50.2 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.147 0.498 . . . . 2.27 110.048 177.284 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.491 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.2 t -73.2 152.99 40.86 Favored 'General case' 0 CA--C 1.513 -0.48 0 CA-C-N 115.758 -0.655 . . . . 0.24 109.994 177.597 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -54.31 -39.36 66.94 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.098 0.475 . . . . 1.06 110.227 178.406 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.704 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.7 mm? -70.89 -62.33 1.43 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.646 -0.706 . . . . 1.11 110.818 175.788 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.3 -40.34 60.44 Favored Glycine 0 C--N 1.33 0.232 0 CA-C-N 116.171 -0.468 . . . . 0.16 113.296 -175.717 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.1 m -69.0 -44.36 72.96 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.857 0.36 . . . . 0.24 110.692 -177.382 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.02 -38.95 93.23 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.316 -0.624 . . . . 1.01 109.316 178.443 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.704 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.2 mt -69.11 -44.4 72.48 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.668 -0.696 . . . . 0.37 110.764 -177.129 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.581 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.4 pp -76.02 -26.16 56.37 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.798 -0.361 . . . . 0.41 111.068 -178.76 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.447 ' N ' HD12 ' A' ' 29' ' ' LEU . 31.9 t70 -64.24 -34.44 78.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.859 0.837 . . . . 0.66 109.035 172.267 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -80.66 -12.27 59.51 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 114.152 -1.386 . . . . 2.07 111.162 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 88.5 mt -111.86 -13.55 13.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.969 -0.56 . . . . 0.71 112.065 -176.4 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.9 41.35 18.97 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.238 -0.506 . . . . 0.75 112.898 178.277 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.581 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 15.4 mt -104.16 140.58 21.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.824 0.345 . . . . 0.68 110.811 -177.551 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.0 p -123.96 102.6 11.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.513 0.673 . . . . 1.87 110.002 173.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 24.1 mt -78.06 141.41 38.85 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.851 -0.613 . . . . 2.76 110.986 -177.836 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -69.76 -33.22 72.13 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.348 -0.842 . . . . 2.65 109.124 175.81 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 -131.58 104.74 14.46 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 115.189 -0.914 . . . . 2.29 108.653 172.203 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.87 -1.72 6.52 Favored 'Trans proline' 0 CA--C 1.528 0.187 0 C-N-CA 122.119 1.879 . . . . 0.64 111.812 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.8 p -87.09 -7.65 57.83 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.709 -0.678 . . . . 0.51 111.261 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.447 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 17.7 m -77.31 159.37 5.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 CA-C-O 121.204 0.526 . . . . 0.24 110.82 -179.589 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.471 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 85.6 mt -90.3 123.5 34.12 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.74 -0.664 . . . . 0.22 110.153 177.753 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.2 pt -105.25 139.27 26.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 115.94 -0.573 . . . . 0.15 109.957 176.414 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.871 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.32 106.69 1.44 Allowed Glycine 0 N--CA 1.44 -1.037 0 C-N-CA 120.51 -0.852 . . . . 0.31 113.174 -175.037 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.608 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 12.6 t70 -73.41 148.65 43.11 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.015 -0.735 . . . . 0.57 109.015 175.149 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.447 ' H ' HG23 ' A' ' 74' ' ' VAL . . . 60.6 45.16 96.87 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.44 -0.886 . . . . 0.21 112.58 175.561 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.587 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -100.96 117.35 34.83 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.322 0.582 . . . . 0.25 110.701 -174.662 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.504 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 3.5 p-10 -100.84 131.55 23.31 Favored Pre-proline 0 C--N 1.318 -0.772 0 CA-C-N 115.528 -0.76 . . . . 2.21 110.333 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -60.84 118.22 5.06 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 121.909 1.74 . . . . 0.44 110.076 173.878 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 13.6 mt . . . . . 0 C--N 1.326 -0.456 0 CA-C-O 121.364 0.602 . . . . 0.46 110.935 -172.581 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 15.3 p . . . . . 0 N--CA 1.451 -0.385 0 N-CA-C 109.576 -0.527 . . . . 0.74 109.576 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 23.9 p -114.17 12.11 17.71 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.01 0.374 . . . . 2.14 112.01 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -134.78 -149.72 0.36 Allowed 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 121.227 -0.189 . . . . 0.54 110.95 -179.581 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 19.5 m -87.85 134.77 33.63 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.779 0.323 . . . . 0.29 111.055 -177.449 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.71 126.87 34.3 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.878 -0.416 . . . . 0.25 109.878 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.714 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -139.42 173.77 10.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.63 0 CA-C-O 121.51 0.671 . . . . 0.21 111.642 -176.083 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 48.8 t -141.82 103.76 4.4 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.974 -1.012 . . . . 0.39 109.165 -178.065 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.732 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.3 m -92.71 155.52 17.65 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.471 0.653 . . . . 0.65 111.913 -176.095 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 6.4 m -106.18 -13.98 15.27 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.264 -0.88 . . . . 1.15 110.879 -178.077 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.432 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 5.5 t70 -103.38 162.32 13.11 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.142 -0.481 . . . . 1.6 109.748 -178.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -120.85 -7.3 9.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.049 0.452 . . . . 2.49 111.14 -176.182 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -83.35 83.79 7.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.225 0.536 . . . . 2.27 111.403 -175.818 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 34.2 m -91.36 156.11 3.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.819 -0.628 . . . . 1.1 110.903 179.558 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.549 ' OG ' HG12 ' A' ' 75' ' ' ILE . 89.2 p -95.36 3.53 54.3 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.075 0.464 . . . . 1.41 110.53 179.435 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.31 -33.32 3.19 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.463 -0.79 . . . . 0.48 112.123 -176.366 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.447 HG23 ' H ' ' A' ' 46' ' ' GLY . 19.5 m -140.31 -21.69 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.325 0 N-CA-C 112.478 0.548 . . . . 0.49 112.478 174.022 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.549 HG12 ' OG ' ' A' ' 72' ' ' SER . 20.4 pt -71.75 172.99 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.373 0 CA-C-O 121.58 0.705 . . . . 0.3 112.187 -174.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.732 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -144.05 140.95 29.81 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.168 -1.378 . . . . 0.18 109.068 176.842 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.432 ' HB ' ' HB3' ' A' ' 68' ' ' ASP . 71.2 mt -119.5 129.33 75.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.032 0.444 . . . . 0.26 111.455 -176.296 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.458 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.08 51.93 5.96 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.972 -0.632 . . . . 0.17 112.035 178.007 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.503 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.92 139.04 35.17 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.135 0.493 . . . . 0.65 112.237 -176.503 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 97.9 mt -109.49 132.13 21.48 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 115.564 -0.744 . . . . 0.29 109.142 169.562 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 14.9 Cg_exo -68.01 119.37 6.38 Favored 'Trans proline' 0 N--CA 1.464 -0.246 0 C-N-CA 122.76 2.306 . . . . 0.25 112.058 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 N--CA 1.443 -0.787 0 CA-C-N 115.969 -0.56 . . . . 0.42 110.747 -177.983 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 31.4 t . . . . . 0 N--CA 1.454 -0.233 0 N-CA-C 109.967 -0.383 . . . . 0.96 109.967 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.3 mt -103.58 140.17 22.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.155 0.503 . . . . 0.96 110.678 175.602 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.681 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -150.16 163.71 37.53 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.571 0.701 . . . . 0.91 111.732 -179.557 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.8 t -116.03 105.07 12.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.162 -0.926 . . . . 0.34 108.901 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.863 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 90.1 m -85.16 139.65 31.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.409 -0.814 . . . . 0.19 111.308 -173.174 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.84 -30.32 58.92 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 115.065 -0.971 . . . . 0.38 109.086 175.252 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ASN . . . . . 0.555 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 3.2 t-20 -136.13 111.52 9.16 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.797 -0.638 . . . . 1.03 110.618 178.532 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 85.5 t -102.15 106.16 19.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.022 0 N-CA-C 109.71 -0.478 . . . . 0.18 109.71 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.4 m -134.76 142.03 40.87 Favored Pre-proline 0 C--N 1.32 -0.676 0 CA-C-N 115.82 -0.627 . . . . 0.18 110.54 -178.078 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.509 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.5 Cg_exo -59.22 137.33 78.28 Favored 'Trans proline' 0 N--CA 1.46 -0.442 0 C-N-CA 122.31 2.007 . . . . 0.19 111.157 172.427 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.12 -25.55 69.66 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 121.111 -0.566 . . . . 0.18 112.666 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -100.52 6.55 44.3 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.612 0.72 . . . . 2.27 110.198 176.897 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.509 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 21.0 t -68.88 154.83 41.32 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.352 -0.61 . . . . 0.24 109.352 173.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -53.42 -43.2 67.78 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.098 0.475 . . . . 1.06 109.744 177.369 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.626 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.6 mm? -72.05 -57.72 4.04 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.318 -0.856 . . . . 1.11 111.097 177.776 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -53.71 -40.96 64.87 Favored Glycine 0 C--N 1.33 0.21 0 C-N-CA 121.225 -0.512 . . . . 0.16 112.962 -176.863 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 84.3 m -67.73 -39.3 84.27 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.731 0.301 . . . . 0.24 110.383 -179.633 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.429 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.5 tm? -68.25 -36.44 79.45 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.434 -0.58 . . . . 1.01 109.434 178.428 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.626 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 13.3 mt -67.57 -47.55 69.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.742 -0.663 . . . . 0.37 110.372 -177.614 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.566 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -77.56 -22.68 50.63 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.746 -0.382 . . . . 0.41 111.364 -178.562 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.505 ' N ' HD12 ' A' ' 29' ' ' LEU . 26.6 t70 -69.06 -31.53 70.37 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.422 0.63 . . . . 0.66 109.418 175.404 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -70.42 -24.29 62.89 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 114.79 -1.096 . . . . 2.07 109.305 176.423 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.1 mt -98.53 -15.58 19.49 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.585 -1.189 . . . . 0.71 111.71 -175.889 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.57 31.18 51.31 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 121.226 -0.512 . . . . 0.75 112.68 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.566 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 31.1 mt -95.38 140.66 16.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.721 0.296 . . . . 0.68 110.753 -178.072 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.9 t -124.75 101.41 8.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 109.708 -0.478 . . . . 1.87 109.708 176.081 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 30.7 mt -74.77 134.76 41.77 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.106 -0.497 . . . . 2.76 111.451 -177.48 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -70.34 -27.22 64.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.489 -0.778 . . . . 2.65 109.285 174.275 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -128.11 90.83 46.26 Favored Pre-proline 0 N--CA 1.446 -0.634 0 N-CA-C 108.38 -0.97 . . . . 2.29 108.38 176.001 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.5 8.36 0.96 Allowed 'Trans proline' 0 C--O 1.223 -0.248 0 C-N-CA 122.416 2.077 . . . . 0.64 112.408 -177.085 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.5 p -99.94 7.91 44.47 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.094 0.473 . . . . 0.51 110.996 -178.682 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.539 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 27.8 m -91.98 155.75 3.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.078 -0.51 . . . . 0.24 110.99 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.5 mt -86.56 127.12 34.87 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.663 -0.699 . . . . 0.22 109.875 176.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.493 HD13 HD23 ' A' ' 29' ' ' LEU . 13.4 pt -106.78 141.75 21.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.122 -0.49 . . . . 0.15 110.095 176.236 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.863 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.48 108.59 1.71 Allowed Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 120.523 -0.846 . . . . 0.31 113.419 -174.519 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.523 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 8.8 t70 -74.49 146.16 42.96 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.757 -0.831 . . . . 0.57 108.757 174.229 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 60.63 47.2 92.37 Favored Glycine 0 C--N 1.318 -0.453 0 C-N-CA 120.281 -0.961 . . . . 0.21 112.712 175.59 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.515 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -108.61 111.59 23.49 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.116 0.484 . . . . 0.25 111.568 -171.771 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.457 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 4.6 t70 -101.67 135.5 19.76 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.633 -0.712 . . . . 2.21 110.916 176.309 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 35.1 Cg_exo -54.76 123.52 13.93 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 124.032 3.155 . . . . 0.44 112.211 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 42.0 mt . . . . . 0 C--N 1.328 -0.368 0 CA-C-O 121.595 0.712 . . . . 0.46 109.402 -179.969 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.1 t . . . . . 0 N--CA 1.451 -0.405 0 CA-C-O 120.674 0.273 . . . . 0.74 110.556 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.1 p -106.89 -22.11 12.8 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.185 -0.461 . . . . 2.14 111.774 -178.404 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -117.09 -82.65 0.63 Allowed 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 121.016 -0.274 . . . . 0.54 111.129 -179.532 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 11.9 m -139.77 129.91 25.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.689 0.28 . . . . 0.29 111.363 -179.038 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.4 128.19 34.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.979 0.419 . . . . 0.25 110.777 -177.428 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.624 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -143.09 173.93 5.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.489 0.661 . . . . 0.21 111.579 -177.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 39.0 t -140.96 107.57 5.33 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.387 -0.824 . . . . 0.39 109.146 -177.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.75 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -93.56 138.08 32.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.62 0.724 . . . . 0.65 112.58 -174.882 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.6 t -85.8 -22.49 27.63 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 114.731 -1.122 . . . . 1.15 110.691 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.422 ' HB2' ' O ' ' A' ' 77' ' ' ILE . 1.2 m-20 -102.53 136.76 41.77 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.164 -0.471 . . . . 1.6 110.813 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -100.44 -4.45 28.89 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.757 -0.656 . . . . 2.49 110.036 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 52.2 t30 -75.56 90.29 2.76 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.556 -0.747 . . . . 2.27 110.495 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 26.7 m -105.95 156.53 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.579 0 CA-C-N 116.102 -0.499 . . . . 1.1 111.29 -177.125 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.623 ' OG ' HG12 ' A' ' 75' ' ' ILE . 82.5 p -85.83 -4.56 59.2 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.886 -0.597 . . . . 1.41 110.529 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.47 -32.34 3.56 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.594 -0.73 . . . . 0.48 112.436 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 m -136.48 -11.57 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 C-N-CA 120.251 -0.58 . . . . 0.49 112.094 179.105 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.623 HG12 ' OG ' ' A' ' 72' ' ' SER . 25.8 pt -92.54 -178.2 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.602 0.715 . . . . 0.3 111.928 -178.337 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.75 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -143.04 141.09 31.23 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.031 -1.441 . . . . 0.18 109.279 175.505 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.422 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 68.0 mt -121.17 129.12 75.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.867 0.365 . . . . 0.26 111.447 -177.088 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.539 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 79.59 50.24 5.76 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.803 -0.713 . . . . 0.17 111.816 178.111 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.483 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.2 m -99.67 133.55 43.85 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 112.453 0.538 . . . . 0.65 112.453 -175.529 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.404 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 92.4 mt -105.53 133.87 19.97 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 115.538 -0.755 . . . . 0.29 109.636 171.065 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 22.9 Cg_exo -63.59 125.75 16.16 Favored 'Trans proline' 0 C--O 1.234 0.3 0 C-N-CA 122.807 2.338 . . . . 0.25 112.022 -179.409 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 10.3 m . . . . . 0 N--CA 1.444 -0.747 0 CA-C-N 116.153 -0.476 . . . . 0.42 110.697 -178.445 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.451 -0.403 0 N-CA-C 109.296 -0.631 . . . . 0.96 109.296 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 18.3 mt -96.19 130.48 44.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.702 0.763 . . . . 0.96 111.281 176.264 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.678 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -137.7 166.55 23.68 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.528 -1.215 . . . . 0.91 110.329 176.6 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.671 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 16.2 t -106.85 100.9 10.37 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.294 -0.866 . . . . 0.34 109.853 179.086 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.813 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 58.1 m -87.01 131.8 33.98 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.148 0.499 . . . . 0.19 110.747 -177.251 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.97 -29.72 35.27 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.285 -0.87 . . . . 0.38 109.593 178.23 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ASN . . . . . 0.669 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 2.7 m-20 -134.78 104.01 5.85 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.395 -0.366 . . . . 1.03 110.843 176.464 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 59.1 t -95.99 103.07 14.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.152 0.501 . . . . 0.18 110.01 176.565 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.98 142.68 46.03 Favored Pre-proline 0 C--N 1.32 -0.71 0 CA-C-N 115.731 -0.668 . . . . 0.18 110.704 -175.734 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.47 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.6 Cg_exo -58.9 137.74 81.62 Favored 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.103 1.868 . . . . 0.19 111.19 172.302 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.88 -23.76 69.53 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.831 -0.7 . . . . 0.18 112.041 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -96.64 7.58 46.21 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.016 0.436 . . . . 2.27 110.286 176.808 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.47 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.6 t -80.5 152.4 28.73 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.015 -0.539 . . . . 0.24 110.001 177.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -53.12 -37.35 61.7 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.074 0.464 . . . . 1.06 110.709 178.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.692 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.9 mm? -70.53 -65.95 0.67 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.763 -0.653 . . . . 1.11 110.545 175.011 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.67 -40.04 55.3 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.951 -0.568 . . . . 0.16 113.428 -174.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 63.8 m -68.28 -45.13 73.93 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.909 0.385 . . . . 0.24 110.666 -177.196 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -65.97 -36.63 83.84 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.399 -0.593 . . . . 1.01 109.399 178.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.692 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 17.5 mt -66.56 -49.28 66.92 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.836 -0.62 . . . . 0.37 110.326 -178.304 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.612 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.1 pp -74.4 -25.71 59.64 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.42 -0.355 . . . . 0.41 111.622 -175.047 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.516 ' N ' HD12 ' A' ' 29' ' ' LEU . 31.7 t70 -65.66 -34.49 78.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.673 0.749 . . . . 0.66 109.536 176.055 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -78.82 -34.5 45.24 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 114.713 -1.13 . . . . 2.07 109.412 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 82.3 mt -82.63 -10.73 58.82 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.033 -0.985 . . . . 0.71 112.037 -177.602 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.63 47.71 20.12 Favored Glycine 0 N--CA 1.452 -0.282 0 CA-C-N 115.855 -0.611 . . . . 0.75 112.631 178.117 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.612 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 10.6 mt -109.75 139.01 34.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.723 0.297 . . . . 0.68 110.471 -179.077 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.0 p -123.59 105.37 15.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.396 0.617 . . . . 1.87 110.125 174.387 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 21.6 mt -81.6 144.08 31.5 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.879 -0.601 . . . . 2.76 111.191 -178.063 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 25.5 mm-40 -79.41 -21.16 45.98 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.608 -0.724 . . . . 2.65 109.356 174.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -138.2 99.35 8.97 Favored Pre-proline 0 N--CA 1.445 -0.696 0 N-CA-C 107.707 -1.22 . . . . 2.29 107.707 173.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.72 -1.45 9.29 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.272 1.982 . . . . 0.64 112.453 -175.407 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.2 p -101.37 20.26 16.24 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.21 0.528 . . . . 0.51 111.277 -176.608 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.459 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 33.4 m -93.01 161.63 2.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.978 -0.556 . . . . 0.24 110.094 174.723 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.426 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 96.4 mt -87.57 120.63 29.07 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.284 -0.416 . . . . 0.22 110.043 176.04 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 14.8 pt -103.66 138.35 28.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 116.078 -0.51 . . . . 0.15 110.092 176.7 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.813 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -115.55 107.4 1.72 Allowed Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.572 -0.823 . . . . 0.31 113.252 -175.401 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.669 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 12.7 t70 -74.82 146.52 41.96 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.488 -0.93 . . . . 0.57 108.488 174.59 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 67.18 36.87 90.78 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 119.882 -1.152 . . . . 0.21 112.165 176.336 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.671 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -100.34 111.31 23.57 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.376 0.608 . . . . 0.25 110.607 -174.497 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.598 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 1.6 p-10 -101.46 130.32 25.0 Favored Pre-proline 0 C--N 1.314 -0.956 0 CA-C-N 115.547 -0.751 . . . . 2.21 109.876 178.094 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -58.55 118.11 4.94 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.18 1.92 . . . . 0.44 110.911 177.079 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 8.6 mt . . . . . 0 N--CA 1.448 -0.555 0 N-CA-C 108.581 -0.896 . . . . 0.46 108.581 -179.299 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 35.4 t . . . . . 0 N--CA 1.449 -0.515 0 CA-C-O 120.51 0.195 . . . . 0.74 110.737 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 73.9 m -119.78 -3.45 10.26 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.34 -0.391 . . . . 2.14 111.226 176.709 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.46 -84.4 0.1 Allowed 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.076 -0.712 . . . . 0.54 109.076 172.292 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 29.9 m -151.96 129.27 11.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.913 0.387 . . . . 0.29 111.067 171.601 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.7 132.58 33.83 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.383 -0.599 . . . . 0.25 109.383 176.608 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.713 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -141.95 169.8 13.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.488 0.661 . . . . 0.21 112.334 -174.094 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 14.2 t -130.95 100.53 5.28 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.66 -1.155 . . . . 0.39 109.459 179.306 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.775 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -88.88 125.52 34.97 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.79 0.805 . . . . 0.65 111.872 -178.429 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 10.0 t -85.26 -18.38 34.13 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 114.281 -1.327 . . . . 1.15 110.252 -179.057 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -110.82 140.81 44.94 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.64 -0.709 . . . . 1.6 109.577 178.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -119.74 24.64 10.47 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 120.975 -0.29 . . . . 2.49 111.695 -173.421 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 49.1 m-80 -86.5 56.82 4.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.333 0.587 . . . . 2.27 110.187 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 35.8 m -73.95 139.79 18.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.505 -0.771 . . . . 1.1 111.574 -175.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.422 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 19.6 m -90.86 10.83 24.67 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.013 -0.54 . . . . 1.41 111.431 -178.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.62 -34.76 2.94 Favored Glycine 0 C--O 1.228 -0.265 0 C-N-CA 120.944 -0.646 . . . . 0.48 113.995 173.167 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.5 m -139.98 -7.11 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 117.936 0.868 . . . . 0.49 111.264 176.534 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.422 ' CG1' ' H ' ' A' ' 72' ' ' SER . 11.2 pt -89.87 178.5 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.336 0.589 . . . . 0.3 111.347 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.775 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -144.31 144.17 31.34 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 114.563 -1.199 . . . . 0.18 109.177 175.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 67.4 mt -123.01 132.52 71.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.915 0.388 . . . . 0.26 111.549 -176.163 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.459 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 74.22 50.22 10.75 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.743 -0.741 . . . . 0.17 112.017 177.784 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.517 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.2 m -98.46 136.07 39.13 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-O 121.177 0.513 . . . . 0.65 111.785 -176.336 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.441 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.2 mt -107.63 130.18 23.18 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.472 -0.785 . . . . 0.29 109.258 170.048 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 15.7 Cg_exo -67.12 121.41 8.57 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.808 2.339 . . . . 0.25 112.651 -177.569 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.0 m . . . . . 0 N--CA 1.442 -0.852 0 CA-C-N 115.686 -0.688 . . . . 0.42 109.346 176.838 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.8 t . . . . . 0 N--CA 1.451 -0.396 0 N-CA-C 109.186 -0.672 . . . . 0.96 109.186 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 23.8 mt -113.05 130.79 66.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.822 0.82 . . . . 0.96 111.196 177.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.566 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -146.72 170.64 16.57 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 114.363 -1.29 . . . . 0.91 110.479 -178.792 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.434 ' HB2' HD11 ' A' ' 50' ' ' ILE . 39.5 t -120.03 107.11 12.68 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.834 -0.621 . . . . 0.34 109.657 177.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.886 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 97.4 m -84.92 127.41 34.15 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.297 -0.865 . . . . 0.19 110.863 -176.899 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.475 ' HA ' ' HB1' ' A' ' 61' ' ' ALA . 0.2 OUTLIER -67.79 -36.06 79.76 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-N 115.181 -0.918 . . . . 0.38 109.403 173.77 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -133.9 111.55 10.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 1.03 110.631 177.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 92.8 t -97.97 106.85 19.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.786 -0.45 . . . . 0.18 109.786 176.28 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.1 m -131.79 140.49 38.42 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 116.31 -0.404 . . . . 0.18 111.013 -176.787 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.436 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.5 Cg_exo -60.36 140.31 91.1 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.389 2.059 . . . . 0.19 111.75 172.811 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.8 -19.81 69.8 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 121.02 -0.609 . . . . 0.18 112.488 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -100.76 5.45 43.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.112 0.482 . . . . 2.27 109.899 176.579 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.436 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 30.1 t -77.17 152.8 34.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.834 -0.621 . . . . 0.24 110.015 177.294 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -51.29 -41.02 60.17 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.959 0.409 . . . . 1.06 110.365 178.741 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.717 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 3.1 mm? -72.77 -62.91 1.28 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.757 -0.656 . . . . 1.11 110.618 178.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.47 -39.03 52.13 Favored Glycine 0 C--N 1.331 0.271 0 CA-C-N 116.153 -0.476 . . . . 0.16 113.15 -175.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.8 m -66.96 -47.8 70.5 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.728 0.299 . . . . 0.24 110.514 -178.812 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.449 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.4 tm? -65.75 -33.84 76.8 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.751 -0.463 . . . . 1.01 109.751 178.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.717 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 17.2 mt -67.92 -44.26 77.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.37 110.738 -178.012 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.587 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -79.62 -23.08 42.88 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.75 -0.38 . . . . 0.41 110.595 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.423 ' N ' HD12 ' A' ' 29' ' ' LEU . 15.0 t70 -64.09 -35.17 79.86 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.872 0.844 . . . . 0.66 109.568 172.664 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -74.85 -38.62 61.92 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 114.53 -1.214 . . . . 2.07 109.875 179.57 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 69.5 mt -81.88 -20.11 39.51 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 114.745 -1.116 . . . . 0.71 112.298 -176.743 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.86 34.39 30.91 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 121.183 -0.532 . . . . 0.75 112.347 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.587 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 40.4 mt -85.79 131.12 35.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.802 0.334 . . . . 0.68 110.929 -176.721 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 48.2 t -89.61 100.68 11.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 116.294 -0.412 . . . . 1.87 109.958 175.204 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.576 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.2 pp -72.06 126.36 29.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.426 0.632 . . . . 2.76 110.705 179.292 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -78.4 -35.62 46.91 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 108.695 -0.854 . . . . 2.65 108.695 172.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -144.46 108.35 4.83 Favored Pre-proline 0 N--CA 1.442 -0.837 0 CA-C-N 114.606 -1.179 . . . . 2.29 107.892 176.704 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.468 ' HB3' HD22 ' A' ' 36' ' ' LEU . 56.1 Cg_endo -70.88 -4.71 15.33 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.22 1.946 . . . . 0.64 111.522 -176.706 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 24.2 p -88.35 14.0 10.49 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.456 -0.793 . . . . 0.51 111.412 -174.211 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.412 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 19.3 m -102.84 158.36 4.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.045 -0.525 . . . . 0.24 110.448 179.143 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.423 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 92.6 mt -86.0 119.6 26.48 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.79 -0.641 . . . . 0.22 109.955 177.257 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.454 HD13 HD23 ' A' ' 29' ' ' LEU . 13.5 pt -102.81 134.13 44.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.213 0.53 . . . . 0.15 110.056 176.31 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.886 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -105.39 101.47 1.87 Allowed Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 120.531 -0.842 . . . . 0.31 112.944 -175.9 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -81.62 129.44 34.69 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.792 -0.818 . . . . 0.57 108.792 175.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.12 35.94 16.55 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 119.793 -1.194 . . . . 0.21 111.48 -175.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.79 110.02 22.2 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.194 0.521 . . . . 0.25 110.995 -174.373 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.455 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.4 t70 -101.96 135.77 19.63 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-N 115.424 -0.807 . . . . 2.21 110.495 175.089 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 12.4 Cg_exo -61.95 122.13 10.5 Favored 'Trans proline' 0 N--CA 1.462 -0.377 0 C-N-CA 123.453 2.769 . . . . 0.44 111.734 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.434 HD11 ' HB2' ' A' ' 13' ' ' CYS . 22.1 mt . . . . . 0 C--N 1.327 -0.372 0 CA-C-O 121.4 0.619 . . . . 0.46 109.433 -178.389 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 45.5 t . . . . . 0 N--CA 1.452 -0.329 0 N-CA-C 109.225 -0.657 . . . . 0.74 109.225 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.4 t -107.62 -3.75 18.96 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.177 0.436 . . . . 2.14 112.177 -171.811 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.475 ' HB1' ' HA ' ' A' ' 15' ' ' GLN . . . -77.78 -89.09 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 C-N-CA 120.605 -0.438 . . . . 0.54 111.201 -179.357 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 28.4 m -151.08 125.75 9.62 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.684 0.278 . . . . 0.29 110.528 178.554 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.91 132.17 34.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.02 0.438 . . . . 0.25 110.066 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.753 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.4 m -143.14 172.04 8.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.261 0.553 . . . . 0.21 111.247 -177.7 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 51.9 t -138.11 104.72 5.3 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.238 -0.892 . . . . 0.39 109.3 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.74 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.3 m -89.24 132.38 34.91 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.555 0.693 . . . . 0.65 111.629 -178.952 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 33.5 t -76.22 -24.87 54.65 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.96 -1.018 . . . . 1.15 109.906 177.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -110.61 133.91 52.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.648 -0.705 . . . . 1.6 110.482 176.863 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -100.35 18.14 19.68 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.385 0.612 . . . . 2.49 109.968 179.281 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 -77.89 94.84 4.62 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.487 -0.779 . . . . 2.27 109.872 178.077 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 28.3 m -106.6 140.87 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 CA-C-N 116.166 -0.47 . . . . 1.1 111.739 -176.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.481 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 19.5 m -91.96 10.32 29.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.046 -0.525 . . . . 1.41 110.853 176.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.37 -34.63 3.01 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.159 -0.543 . . . . 0.48 113.668 174.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.0 m -140.7 -2.63 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 117.965 0.882 . . . . 0.49 111.692 176.426 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.481 ' CG1' ' H ' ' A' ' 72' ' ' SER . 3.8 pt -95.99 -177.64 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-O 121.431 0.634 . . . . 0.3 112.322 -175.034 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.74 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.51 140.44 21.92 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.368 -1.287 . . . . 0.18 108.783 174.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.0 mt -117.14 126.08 74.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.982 0.42 . . . . 0.26 111.675 -175.831 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 79.15 52.02 5.07 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.957 -0.64 . . . . 0.17 111.825 177.757 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.28 132.29 43.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.396 0.617 . . . . 0.65 112.164 -176.46 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 87.9 mt -102.19 129.86 25.41 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.427 -0.806 . . . . 0.29 109.538 171.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.45 ' HA ' HG12 ' A' ' 64' ' ' VAL . 15.9 Cg_exo -67.33 120.16 7.2 Favored 'Trans proline' 0 C--O 1.235 0.361 0 C-N-CA 122.859 2.373 . . . . 0.25 112.111 -178.79 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 11.2 m . . . . . 0 N--CA 1.441 -0.902 0 CA-C-N 115.813 -0.63 . . . . 0.42 110.015 179.848 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 65' ' ' CYS . 30.4 t . . . . . 0 N--CA 1.453 -0.31 0 N-CA-C 109.915 -0.402 . . . . 0.96 109.915 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 28.0 mt -108.65 132.93 55.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.782 0.801 . . . . 0.96 111.325 177.863 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.58 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -140.34 165.53 27.16 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.559 -1.201 . . . . 0.91 110.501 179.843 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.472 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 40.1 t -110.81 104.22 12.82 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.666 -0.697 . . . . 0.34 109.443 178.327 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.777 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 69.3 m -90.73 130.6 36.7 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.012 -0.54 . . . . 0.19 111.585 -174.474 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.412 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -73.42 -28.94 62.26 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.069 -0.969 . . . . 0.38 110.007 176.374 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ASN . . . . . 0.441 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 5.2 t-20 -138.44 104.05 5.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.35 -0.386 . . . . 1.03 110.75 179.327 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 80.9 t -99.96 104.67 16.42 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 N-CA-C 109.917 -0.401 . . . . 0.18 109.917 178.122 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.0 m -132.37 143.86 50.64 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 116.064 -0.516 . . . . 0.18 110.976 -175.495 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.484 ' O ' ' HB3' ' A' ' 22' ' ' SER . 35.4 Cg_exo -60.85 136.61 67.23 Favored 'Trans proline' 0 N--CA 1.463 -0.307 0 C-N-CA 122.152 1.901 . . . . 0.19 111.36 172.506 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.38 -22.13 69.13 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 121.046 -0.597 . . . . 0.18 112.462 -178.857 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -98.15 3.14 49.08 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.144 0.497 . . . . 2.27 110.1 176.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.484 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.8 t -75.38 154.85 36.96 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.838 -0.619 . . . . 0.24 109.795 176.107 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -54.53 -41.03 69.23 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.367 0.603 . . . . 1.06 109.619 177.039 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.639 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.2 mm? -65.14 -65.05 0.72 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.875 -1.057 . . . . 1.11 110.698 175.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -56.6 -40.2 87.11 Favored Glycine 0 C--N 1.33 0.241 0 CA-C-N 115.972 -0.558 . . . . 0.16 113.614 -174.337 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 61.6 m -66.12 -42.06 89.7 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.918 0.39 . . . . 0.24 110.236 -178.586 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.401 HD22 ' HA ' ' A' ' 27' ' ' LEU . 2.6 tm? -65.92 -38.17 87.98 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.378 -0.601 . . . . 1.01 109.378 177.775 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.639 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.2 mt -65.4 -47.21 77.1 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 116.032 -0.531 . . . . 0.37 110.716 -176.7 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.551 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.87 -22.57 49.63 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.603 -0.439 . . . . 0.41 111.539 -176.203 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.492 ' N ' HD12 ' A' ' 29' ' ' LEU . 33.9 t70 -69.39 -34.58 74.72 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.518 0.675 . . . . 0.66 109.471 175.529 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -80.92 -10.71 59.69 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.058 -0.973 . . . . 2.07 110.118 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -108.93 -1.77 18.81 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.504 -0.771 . . . . 0.71 111.276 -178.61 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.51 43.48 98.96 Favored Glycine 0 C--N 1.331 0.272 0 CA-C-N 115.662 -0.699 . . . . 0.75 113.024 178.216 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.551 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 30.4 mt -95.36 137.96 22.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.962 0.41 . . . . 0.68 111.026 -177.211 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -97.99 103.19 14.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.867 -0.606 . . . . 1.87 110.055 175.732 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.468 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.2 pp -74.31 133.28 42.57 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.356 0.598 . . . . 2.76 111.136 -179.523 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -88.78 -32.02 18.09 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 108.378 -0.971 . . . . 2.65 108.378 174.557 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -145.84 109.66 4.41 Favored Pre-proline 0 N--CA 1.439 -0.982 0 N-CA-C 107.269 -1.382 . . . . 2.29 107.269 175.578 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.428 ' HB3' HD22 ' A' ' 36' ' ' LEU . 61.5 Cg_endo -74.24 -3.97 14.66 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 121.937 1.758 . . . . 0.64 112.429 -174.085 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 65.2 p -97.43 21.71 9.78 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.49 0.662 . . . . 0.51 111.188 -174.26 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.437 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 23.8 m -99.8 156.19 4.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.467 -0.788 . . . . 0.24 110.096 174.829 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.436 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.5 mt -85.07 124.18 31.46 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.24 -0.437 . . . . 0.22 110.123 177.215 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.407 HD13 HD23 ' A' ' 29' ' ' LEU . 14.4 pt -106.35 133.69 50.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.184 0.516 . . . . 0.15 110.134 175.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.777 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.38 100.48 1.08 Allowed Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.613 -0.803 . . . . 0.31 112.803 -176.087 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -80.6 146.44 31.22 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 109.564 -0.532 . . . . 0.57 109.564 177.217 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.412 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 74.18 36.46 50.88 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.07 -1.062 . . . . 0.21 111.571 -178.673 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -102.9 118.53 37.03 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.262 0.553 . . . . 0.25 111.456 -173.061 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.53 139.21 20.21 Favored Pre-proline 0 C--N 1.32 -0.697 0 CA-C-N 115.468 -0.787 . . . . 2.21 109.157 175.018 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -71.12 123.24 9.47 Favored 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 122.095 1.863 . . . . 0.44 111.287 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.406 HG13 ' HA ' ' A' ' 12' ' ' GLN . 13.1 mt . . . . . 0 C--N 1.325 -0.497 0 CA-C-O 121.645 0.736 . . . . 0.46 109.853 -176.83 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.1 t . . . . . 0 N--CA 1.448 -0.536 0 N-CA-C 110.014 -0.365 . . . . 0.74 110.014 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.2 p -90.61 -22.97 20.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.983 -0.553 . . . . 2.14 111.707 -178.772 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -129.49 -87.95 0.52 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 120.7 -0.4 . . . . 0.54 112.012 -177.584 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 60.3 m -131.28 130.67 43.12 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.808 0.337 . . . . 0.29 111.616 -175.099 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.73 131.64 34.08 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.34 -0.391 . . . . 0.25 109.962 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.631 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -143.06 166.67 14.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.062 0.458 . . . . 0.21 111.494 -175.804 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' CYS . . . . . 0.487 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 31.5 t -128.27 104.64 7.85 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.435 -0.802 . . . . 0.39 110.15 178.485 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.746 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.6 m -93.2 136.92 33.01 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.61 0.719 . . . . 0.65 111.79 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.7 t -89.01 -20.52 24.3 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 114.784 -1.098 . . . . 1.15 110.458 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.482 ' HB3' ' OD1' ' A' ' 70' ' ' ASN . 44.6 m-20 -103.53 148.09 26.38 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.902 -0.59 . . . . 1.6 110.401 -177.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -119.75 3.75 11.09 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.511 -0.313 . . . . 2.49 111.155 -179.683 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.482 ' OD1' ' HB3' ' A' ' 68' ' ' ASP . 18.2 p-10 -79.56 63.29 4.11 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.736 0.779 . . . . 2.27 110.21 178.446 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.9 m -97.41 162.48 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.709 0 CA-C-N 115.372 -0.831 . . . . 1.1 111.29 -176.108 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.566 ' H ' HG12 ' A' ' 75' ' ' ILE . 87.9 p -85.14 -2.51 58.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.692 -0.685 . . . . 1.41 111.105 -177.554 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.42 -32.67 4.24 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.799 -0.715 . . . . 0.48 112.13 -179.108 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.6 m -130.86 -11.88 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.399 -0.52 . . . . 0.49 111.859 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.566 HG12 ' H ' ' A' ' 72' ' ' SER . 29.1 pt -87.69 178.88 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 C-N-CA 119.879 -0.729 . . . . 0.3 110.976 177.146 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.746 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -148.0 137.94 22.61 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 114.685 -1.143 . . . . 0.18 108.826 176.568 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 61.7 mt -120.05 130.74 73.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.874 0.368 . . . . 0.26 111.322 -175.834 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.498 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.58 50.52 6.52 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 121.139 -0.553 . . . . 0.17 112.042 178.528 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -99.41 136.07 39.89 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 112.446 0.535 . . . . 0.65 112.446 -175.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 97.4 mt -106.62 129.47 24.39 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.562 -0.745 . . . . 0.29 109.478 169.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 15.3 Cg_exo -67.63 124.89 12.51 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 123.092 2.528 . . . . 0.25 112.567 -177.241 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.8 m . . . . . 0 N--CA 1.444 -0.746 0 CA-C-N 116.128 -0.487 . . . . 0.42 110.273 179.696 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.9 t . . . . . 0 N--CA 1.451 -0.378 0 N-CA-C 109.492 -0.558 . . . . 0.96 109.492 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 22.6 mt -105.63 131.47 54.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.682 0.753 . . . . 0.96 111.0 175.621 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.539 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -141.53 163.14 33.74 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.736 -1.12 . . . . 0.91 110.941 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.535 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 47.3 t -107.61 101.66 10.97 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.305 -0.861 . . . . 0.34 109.523 178.477 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.821 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 60.2 m -85.68 129.78 34.73 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.177 0.513 . . . . 0.19 111.281 -175.838 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.413 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -75.28 -30.17 60.33 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 115.17 -0.923 . . . . 0.38 109.644 177.311 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ASN . . . . . 0.416 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 4.8 t-20 -135.43 110.11 8.63 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.832 -0.622 . . . . 1.03 110.091 178.906 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.7 t -105.85 104.55 17.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.998 0.428 . . . . 0.18 109.887 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.0 m -135.86 146.31 56.45 Favored Pre-proline 0 C--N 1.322 -0.623 0 CA-C-N 115.984 -0.553 . . . . 0.18 111.191 -173.636 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.478 ' O ' ' HB3' ' A' ' 22' ' ' SER . 26.6 Cg_exo -62.18 137.98 69.48 Favored 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.16 1.907 . . . . 0.19 110.996 170.601 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.26 -30.16 76.68 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.002 -0.618 . . . . 0.18 112.547 -178.271 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -96.66 10.45 38.57 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.089 0.471 . . . . 2.27 110.272 177.766 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.478 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.9 t -77.59 154.85 31.93 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.502 -0.555 . . . . 0.24 109.502 174.436 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -49.69 -46.08 49.59 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.534 -0.543 . . . . 1.06 109.534 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.694 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.0 OUTLIER -64.07 -64.47 0.88 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 114.934 -1.03 . . . . 1.11 110.921 178.821 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.91 -37.65 62.92 Favored Glycine 0 C--N 1.331 0.298 0 CA-C-N 115.972 -0.558 . . . . 0.16 113.317 -175.135 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.1 m -69.54 -39.9 77.19 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.888 0.375 . . . . 0.24 110.666 -177.63 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.42 HD22 ' HA ' ' A' ' 27' ' ' LEU . 1.2 tm? -66.05 -39.76 90.39 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.024 -0.732 . . . . 1.01 109.024 177.04 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.694 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 18.9 mt -64.6 -53.41 48.12 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 114.848 -1.069 . . . . 0.37 110.914 -177.188 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.555 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -71.65 -22.88 61.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.445 -0.343 . . . . 0.41 111.307 -175.455 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.474 ' N ' HD12 ' A' ' 29' ' ' LEU . 20.6 t70 -63.59 -38.19 90.17 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.507 0.67 . . . . 0.66 109.915 174.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -76.34 -29.76 57.36 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.128 -0.942 . . . . 2.07 109.64 -178.659 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.5 mt -85.62 -12.01 52.5 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 114.779 -1.1 . . . . 0.71 111.451 -177.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.25 32.38 52.21 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.929 -0.578 . . . . 0.75 112.747 177.397 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.555 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 11.9 mt -94.11 141.59 14.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.664 0.269 . . . . 0.68 110.498 -177.672 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.9 p -128.11 102.85 9.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.497 0.665 . . . . 1.87 110.078 174.232 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.0 mt -94.58 145.6 24.7 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.898 -0.592 . . . . 2.76 110.557 -178.454 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -76.38 -27.88 56.53 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.924 -0.58 . . . . 2.65 109.892 178.475 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -139.31 92.52 10.52 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 115.621 -0.718 . . . . 2.29 109.251 174.814 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.44 6.61 1.82 Allowed 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.492 2.128 . . . . 0.64 111.749 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.5 p -75.01 -7.26 53.16 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.668 -0.696 . . . . 0.51 111.188 -179.084 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.4 m -83.02 163.04 3.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.858 -0.61 . . . . 0.24 110.711 178.23 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.449 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.3 mt -87.56 123.05 32.03 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.994 -0.548 . . . . 0.22 110.469 178.287 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.7 pt -105.33 138.26 31.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.073 -0.512 . . . . 0.15 110.092 175.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.821 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -116.64 102.71 1.06 Allowed Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.654 -0.784 . . . . 0.31 112.918 -175.789 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -81.06 143.59 32.36 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.397 -0.594 . . . . 0.57 109.397 177.019 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.405 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 72.28 38.8 58.51 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 119.958 -1.115 . . . . 0.21 111.752 -179.34 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.535 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -103.94 116.57 32.49 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.969 0.414 . . . . 0.25 110.999 -173.273 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.462 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 2.5 p-10 -101.35 131.41 23.12 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 115.969 -0.56 . . . . 2.21 110.16 177.336 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -58.87 119.44 6.7 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.31 2.007 . . . . 0.44 110.642 175.075 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 14.4 mt . . . . . 0 C--N 1.327 -0.401 0 CA-C-O 121.597 0.713 . . . . 0.46 110.131 -175.114 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.5 t . . . . . 0 N--CA 1.446 -0.665 0 N-CA-C 109.861 -0.422 . . . . 0.74 109.861 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 19.9 m -92.6 -24.05 18.83 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.479 -0.328 . . . . 2.14 111.377 -179.224 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.413 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -97.72 -86.42 0.34 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.841 -0.344 . . . . 0.54 111.675 -177.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 33.4 m -148.46 126.65 12.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.762 0.315 . . . . 0.29 110.83 -178.256 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.73 132.39 33.87 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.877 0.37 . . . . 0.25 110.14 -178.062 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.664 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.7 m -142.77 172.17 8.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-O 121.352 0.596 . . . . 0.21 111.521 -176.092 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 38.1 t -133.26 104.69 6.59 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.023 -0.99 . . . . 0.39 109.645 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.766 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -92.56 130.4 38.22 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.667 0.746 . . . . 0.65 111.828 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 55.0 m -76.93 -32.4 57.33 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.613 -1.176 . . . . 1.15 110.948 178.699 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -109.64 138.57 45.81 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.659 -0.701 . . . . 1.6 109.855 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -120.85 23.76 10.55 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.813 0.339 . . . . 2.49 111.453 -174.152 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 25.3 p-10 -81.31 56.89 3.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.858 0.837 . . . . 2.27 109.813 176.122 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 18.1 m -83.01 158.55 3.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 114.967 -1.015 . . . . 1.1 112.197 -171.14 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.521 ' H ' HG12 ' A' ' 75' ' ' ILE . 95.1 p -82.75 -3.04 56.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.27 -0.877 . . . . 1.41 111.05 -178.2 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.84 -32.2 3.71 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 121.04 -0.6 . . . . 0.48 112.465 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.3 m -136.15 -7.56 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 C-N-CA 120.5 -0.48 . . . . 0.49 111.899 179.169 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.521 HG12 ' H ' ' A' ' 72' ' ' SER . 32.2 pt -92.0 -177.45 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 C-N-CA 120.006 -0.678 . . . . 0.3 111.369 178.765 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.766 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.38 140.37 21.98 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 114.791 -1.095 . . . . 0.18 109.161 177.295 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 68.4 mt -122.02 123.94 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.071 0.462 . . . . 0.26 111.657 -175.508 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 81.95 51.85 4.32 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.904 -0.665 . . . . 0.17 111.596 179.361 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.449 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.23 136.43 39.2 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.244 0.545 . . . . 0.65 112.187 -175.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.446 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 92.1 mt -110.66 131.28 22.17 Favored Pre-proline 0 C--N 1.321 -0.65 0 CA-C-N 115.54 -0.754 . . . . 0.29 109.703 171.653 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 22.6 Cg_exo -64.93 131.87 30.38 Favored 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 123.137 2.558 . . . . 0.25 112.868 -177.769 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.4 m . . . . . 0 N--CA 1.446 -0.666 0 CA-C-N 115.75 -0.659 . . . . 0.42 109.58 177.275 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.7 t . . . . . 0 N--CA 1.455 -0.182 0 N-CA-C 109.656 -0.498 . . . . 0.96 109.656 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 22.8 mt -104.43 133.61 48.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.664 0.745 . . . . 0.96 111.619 178.699 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.452 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -144.28 163.03 34.89 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 114.524 -1.216 . . . . 0.91 110.121 178.165 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.489 ' HB2' HD11 ' A' ' 50' ' ' ILE . 34.6 t -114.92 109.36 18.02 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.076 -0.713 . . . . 0.34 109.076 176.547 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.796 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 96.8 m -88.96 134.93 33.8 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.392 -0.822 . . . . 0.19 111.35 -173.89 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.443 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -75.39 -28.25 59.39 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.158 -0.928 . . . . 0.38 109.775 178.461 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -141.77 103.52 4.37 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.147 -0.479 . . . . 1.03 110.73 177.555 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 98.6 t -93.85 105.93 17.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 116.178 -0.465 . . . . 0.18 109.787 177.235 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.41 142.42 45.33 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.149 -0.478 . . . . 0.18 111.067 -176.144 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.563 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.4 Cg_exo -58.92 139.21 89.84 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.382 2.054 . . . . 0.19 111.392 172.167 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.37 -20.01 71.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.824 -0.703 . . . . 0.18 112.317 -179.187 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 17.2 p-10 -101.87 7.4 41.61 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.311 0.577 . . . . 2.27 109.962 176.316 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.563 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 13.5 t -74.12 154.27 39.21 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.554 -0.748 . . . . 0.24 109.78 174.69 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -56.28 -39.88 73.37 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.955 0.407 . . . . 1.06 110.08 177.17 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.656 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER -70.45 -60.19 2.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.545 -0.752 . . . . 1.11 110.431 175.825 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.491 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.43 -41.5 80.71 Favored Glycine 0 C--N 1.331 0.252 0 CA-C-N 115.922 -0.581 . . . . 0.16 113.33 -175.497 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.4 m -66.05 -41.73 90.43 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.748 0.308 . . . . 0.24 110.37 -178.557 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.407 HD13 ' O ' ' A' ' 27' ' ' LEU . 2.8 tm? -64.76 -37.58 88.08 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.561 -0.533 . . . . 1.01 109.561 177.901 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.656 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.4 mt -66.16 -49.65 66.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.924 -0.58 . . . . 0.37 110.637 -177.596 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.563 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -76.32 -21.76 55.79 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.481 -0.327 . . . . 0.41 111.172 -177.377 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.499 ' N ' HD12 ' A' ' 29' ' ' LEU . 29.8 t70 -66.51 -33.36 75.52 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.723 0.773 . . . . 0.66 109.64 175.007 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -76.21 -25.07 54.73 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.586 -1.188 . . . . 2.07 109.361 179.092 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 94.6 mt -94.46 -17.19 22.7 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.814 -1.084 . . . . 0.71 111.811 -175.504 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 80.44 35.69 25.47 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.155 -0.545 . . . . 0.75 112.582 178.243 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.563 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 22.7 mt -98.52 130.83 46.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.684 0.278 . . . . 0.68 110.713 -177.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.6 p -118.72 100.05 9.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.917 0.865 . . . . 1.87 110.569 176.29 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 23.0 mt -82.57 143.44 31.03 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.469 -0.787 . . . . 2.76 111.558 -176.593 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -71.02 -38.47 72.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.225 -0.898 . . . . 2.65 109.254 174.157 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -125.15 91.63 48.83 Favored Pre-proline 0 N--CA 1.447 -0.583 0 CA-C-N 115.069 -0.969 . . . . 2.29 108.438 174.017 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.02 4.12 1.66 Allowed 'Trans proline' 0 C--O 1.225 -0.147 0 C-N-CA 122.54 2.16 . . . . 0.64 111.971 -178.076 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 18.3 p -82.79 -10.9 58.66 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.931 -0.577 . . . . 0.51 111.1 -177.777 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.9 m -71.24 160.56 5.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.24 111.331 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 97.4 mt -91.17 127.42 36.59 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.855 -0.611 . . . . 0.22 110.505 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.472 HD13 HD23 ' A' ' 29' ' ' LEU . 13.8 pt -107.41 136.85 41.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.098 0.475 . . . . 0.15 110.335 176.372 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.796 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -110.2 98.82 1.12 Allowed Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 120.815 -0.707 . . . . 0.31 113.199 -175.156 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -79.63 141.68 36.28 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.439 -0.578 . . . . 0.57 109.439 177.421 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.443 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 71.99 41.41 54.88 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.151 -1.023 . . . . 0.21 112.161 -179.347 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.551 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.74 117.94 35.34 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.196 0.522 . . . . 0.25 111.614 -172.533 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.488 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 1.6 t70 -101.91 136.03 19.59 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 115.401 -0.818 . . . . 2.21 110.35 174.824 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.488 ' HD2' ' OD1' ' A' ' 48' ' ' ASP . 1.3 Cg_endo -67.6 120.94 7.98 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.046 2.497 . . . . 0.44 111.868 -177.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.489 HD11 ' HB2' ' A' ' 13' ' ' CYS . 17.7 mt . . . . . 0 C--N 1.327 -0.387 0 CA-C-O 121.277 0.56 . . . . 0.46 109.962 -177.909 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 42.6 t . . . . . 0 N--CA 1.456 -0.135 0 CA-C-O 120.788 0.328 . . . . 0.74 110.887 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 20.2 m -90.48 -15.53 30.63 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 112.133 0.42 . . . . 2.14 112.133 -176.512 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 14' ' ' CYS . . . -133.14 -83.25 0.47 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.349 -0.54 . . . . 0.54 112.254 -177.737 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 23.0 m -138.5 129.57 26.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.787 0.327 . . . . 0.29 111.608 -175.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.24 129.28 34.9 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-O 120.981 0.42 . . . . 0.25 110.319 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.556 HG21 ' SG ' ' A' ' 14' ' ' CYS . 6.4 m -141.64 157.87 21.28 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 121.446 0.641 . . . . 0.21 111.236 -177.249 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 35.3 t -116.18 111.2 19.87 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.206 -0.906 . . . . 0.39 108.722 173.713 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.654 ' HA ' ' HA ' ' A' ' 79' ' ' CYS . 0.5 OUTLIER -103.71 135.91 44.4 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.744 0.783 . . . . 0.65 111.91 -173.043 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 32.2 t -81.53 -35.22 30.58 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 114.55 -1.205 . . . . 1.15 111.309 -174.501 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -91.95 131.62 37.12 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.01 0.433 . . . . 1.6 110.419 -179.701 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -106.11 11.11 31.77 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.94 -0.573 . . . . 2.49 111.034 -177.749 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -95.28 72.57 3.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.468 0.651 . . . . 2.27 109.786 -178.507 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 35.2 m -74.97 153.06 6.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.35 -0.841 . . . . 1.1 111.606 -176.429 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -90.72 8.25 35.46 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.807 -0.633 . . . . 1.41 110.148 179.507 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.98 -34.08 3.2 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.63 -0.714 . . . . 0.48 112.83 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 m -140.99 -17.05 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 117.218 0.509 . . . . 0.49 111.958 176.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 18.3 pt -81.95 -175.41 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.478 0.656 . . . . 0.3 112.298 -176.28 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -151.05 141.73 22.71 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.236 -1.347 . . . . 0.18 107.874 173.548 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.2 mt -119.05 123.54 71.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 118.32 0.509 . . . . 0.26 112.226 -174.272 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.85 53.29 4.62 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.926 -0.654 . . . . 0.17 111.547 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.654 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 3.8 m -99.94 143.34 30.27 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.153 0.501 . . . . 0.65 111.305 -176.804 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 80.3 mt -109.25 131.76 21.65 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 115.484 -0.78 . . . . 0.29 110.372 175.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.434 ' HA ' HG12 ' A' ' 64' ' ' VAL . 15.9 Cg_exo -67.41 121.99 9.17 Favored 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.891 2.394 . . . . 0.25 111.902 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.8 m . . . . . 0 N--CA 1.445 -0.699 0 CA-C-O 121.674 0.75 . . . . 0.42 111.167 -178.773 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.6 t . . . . . 0 N--CA 1.45 -0.47 0 N-CA-C 108.852 -0.796 . . . . 0.96 108.852 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.531 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.1 mp -98.47 141.96 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 121.652 0.739 . . . . 0.96 111.509 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.596 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -145.75 166.39 26.01 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 114.793 -1.094 . . . . 0.91 110.723 178.75 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.407 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 37.1 t -114.83 104.93 12.43 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.613 -0.721 . . . . 0.34 109.552 179.286 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.782 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 63.4 m -87.69 133.06 33.9 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.519 -0.764 . . . . 0.19 111.199 -175.505 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.401 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -71.27 -27.31 63.35 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 115.251 -0.886 . . . . 0.38 108.939 173.529 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -145.63 128.39 16.27 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.64 -0.709 . . . . 1.03 110.135 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.6 t -115.73 106.09 19.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.906 0.384 . . . . 0.18 110.27 177.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.9 m -131.91 143.35 48.67 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.026 -0.534 . . . . 0.18 110.922 -175.594 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.489 ' O ' ' HB3' ' A' ' 22' ' ' SER . 26.6 Cg_exo -62.8 139.85 76.89 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.225 1.95 . . . . 0.19 111.339 172.258 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.9 -22.57 70.43 Favored Glycine 0 C--N 1.329 0.159 0 C-N-CA 120.967 -0.635 . . . . 0.18 112.62 -177.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -100.39 5.83 44.39 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.636 0.732 . . . . 2.27 109.793 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.6 t -75.13 155.11 37.39 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.656 -0.702 . . . . 0.24 110.272 177.114 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -54.51 -41.31 69.49 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.185 0.517 . . . . 1.06 110.116 177.828 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.682 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.7 mm? -73.34 -57.75 3.79 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.692 -0.685 . . . . 1.11 110.66 177.427 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -54.52 -40.06 68.33 Favored Glycine 0 C--N 1.33 0.205 0 C-N-CA 121.249 -0.5 . . . . 0.16 113.095 -176.738 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 90.7 m -69.81 -40.75 75.74 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.7 0.286 . . . . 0.24 110.311 -178.438 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.448 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.6 tm? -66.85 -36.85 83.27 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.539 -0.541 . . . . 1.01 109.539 177.059 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.682 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 12.5 mt -68.21 -47.32 68.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.89 -0.595 . . . . 0.37 110.801 -177.13 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.568 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.5 pp -74.11 -23.67 59.34 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.808 -0.357 . . . . 0.41 110.676 -179.063 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.404 ' N ' HD12 ' A' ' 29' ' ' LEU . 25.7 t70 -61.68 -36.61 81.35 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.474 0.654 . . . . 0.66 109.762 173.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -73.95 -29.63 62.11 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-N 114.983 -1.008 . . . . 2.07 110.03 179.418 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 90.9 mt -93.13 -16.53 24.81 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.832 -1.076 . . . . 0.71 112.157 -172.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.76 35.8 34.74 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 121.263 -0.494 . . . . 0.75 112.624 178.627 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.568 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 18.4 mt -94.25 139.8 17.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.702 0.287 . . . . 0.68 110.63 -177.145 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.9 t -122.16 98.17 5.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 109.83 -0.433 . . . . 1.87 109.83 176.287 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 22.7 mt -83.13 135.56 34.77 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.17 -0.468 . . . . 2.76 111.251 -177.141 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 -73.36 -24.18 60.3 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.717 -0.674 . . . . 2.65 109.907 174.264 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -136.77 89.57 17.52 Favored Pre-proline 0 N--CA 1.446 -0.659 0 N-CA-C 108.026 -1.102 . . . . 2.29 108.026 178.285 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.29 -1.04 9.03 Favored 'Trans proline' 0 CA--C 1.519 -0.27 0 C-N-CA 122.193 1.929 . . . . 0.64 112.096 -177.218 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.7 p -93.36 20.57 6.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.407 0.622 . . . . 0.51 111.246 -177.85 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.427 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 32.0 m -101.75 162.72 3.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.551 -0.75 . . . . 0.24 110.064 174.176 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.442 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.7 mt -86.62 121.47 29.19 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.142 -0.481 . . . . 0.22 109.969 176.413 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 17.5 pt -104.15 137.69 31.93 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 CA-C-O 121.208 0.528 . . . . 0.15 110.132 176.301 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.782 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -107.42 110.05 3.13 Favored Glycine 0 N--CA 1.44 -1.059 0 C-N-CA 120.605 -0.807 . . . . 0.31 112.82 -176.608 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -86.05 132.73 33.99 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.032 -0.729 . . . . 0.57 109.032 175.278 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.43 37.69 26.93 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.001 -1.095 . . . . 0.21 111.734 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.557 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.23 116.42 32.14 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.139 0.495 . . . . 0.25 111.368 -173.373 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.432 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 6.6 m-20 -100.35 131.9 23.31 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.405 -0.816 . . . . 2.21 109.158 175.099 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.467 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 12.4 Cg_exo -63.87 123.28 11.71 Favored 'Trans proline' 0 N--CA 1.461 -0.408 0 C-N-CA 122.742 2.294 . . . . 0.44 110.965 178.39 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.455 HG13 ' HA ' ' A' ' 12' ' ' GLN . 24.8 mt . . . . . 0 C--N 1.326 -0.422 0 CA-C-O 121.498 0.666 . . . . 0.46 110.417 -175.622 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.0 t . . . . . 0 N--CA 1.454 -0.252 0 CA-C-O 120.939 0.4 . . . . 0.74 110.837 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.6 p -102.71 -40.78 6.45 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.98 -0.554 . . . . 2.14 111.604 -179.333 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.401 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -101.14 -85.99 0.41 Allowed 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 121.051 -0.26 . . . . 0.54 111.567 -176.864 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 26.9 m -132.47 129.18 38.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.666 0.269 . . . . 0.29 111.302 -177.753 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -86.63 130.57 34.43 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.911 0.386 . . . . 0.25 110.142 179.249 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.675 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.7 m -143.06 169.82 11.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.259 0.552 . . . . 0.21 111.415 -176.829 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' CYS . . . . . 0.43 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 38.0 t -137.29 107.67 6.47 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.478 -0.783 . . . . 0.39 109.862 -178.669 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.765 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.8 m -93.48 137.63 32.57 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.442 0.639 . . . . 0.65 111.735 -177.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.2 t -87.24 -20.09 27.41 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.128 -0.942 . . . . 1.15 110.955 179.45 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.4 t70 -98.92 160.41 14.28 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.161 -0.472 . . . . 1.6 109.993 -177.363 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -118.67 5.72 11.59 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 111.928 0.344 . . . . 2.49 111.928 -173.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -84.7 89.63 7.54 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.014 0.435 . . . . 2.27 110.764 -179.019 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.9 m -100.06 130.93 48.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.03 0.443 . . . . 1.1 111.327 179.275 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.501 ' H ' HG12 ' A' ' 75' ' ' ILE . 9.2 t -80.5 -1.47 41.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.046 -0.524 . . . . 1.41 110.484 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.2 -33.89 3.21 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.833 -0.621 . . . . 0.48 112.585 178.738 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.7 m -140.72 4.58 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 117.202 0.501 . . . . 0.49 111.788 175.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.501 HG12 ' H ' ' A' ' 72' ' ' SER . 19.2 pt -100.2 176.63 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.466 0.651 . . . . 0.3 112.039 179.726 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.765 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -145.93 140.57 27.04 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 114.291 -1.322 . . . . 0.18 109.411 174.722 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 71.0 mt -120.84 127.22 75.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.894 0.378 . . . . 0.26 111.461 -177.377 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.541 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 81.77 48.92 5.61 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 121.026 -0.607 . . . . 0.17 112.064 177.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.442 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.3 140.42 33.5 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 112.665 0.617 . . . . 0.65 112.665 -175.36 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.9 mt -111.34 132.75 21.63 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.43 -0.805 . . . . 0.29 109.603 170.546 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 16.9 Cg_exo -66.6 121.75 9.04 Favored 'Trans proline' 0 C--O 1.232 0.217 0 C-N-CA 122.974 2.449 . . . . 0.25 112.638 -178.835 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.412 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 6.2 m . . . . . 0 N--CA 1.446 -0.671 0 CA-C-N 115.917 -0.583 . . . . 0.42 110.042 -179.607 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 41.1 t . . . . . 0 N--CA 1.455 -0.222 0 N-CA-C 110.299 -0.26 . . . . 0.96 110.299 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 41.3 mt -102.83 137.49 30.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.517 0.675 . . . . 0.96 110.709 173.767 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.528 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -144.08 159.34 42.78 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.01 -0.995 . . . . 0.91 110.531 179.007 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 41.7 t -105.5 102.58 12.04 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.794 -0.639 . . . . 0.34 109.686 178.598 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.814 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 81.9 m -85.77 135.43 33.74 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.489 -0.778 . . . . 0.19 110.817 -176.732 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.74 -31.04 59.41 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 115.408 -0.815 . . . . 0.38 109.298 174.708 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -138.12 118.29 13.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.81 -0.632 . . . . 1.03 110.245 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.3 t -110.69 103.04 14.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 121.042 0.448 . . . . 0.18 110.094 178.789 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.0 m -133.31 142.67 45.11 Favored Pre-proline 0 C--N 1.32 -0.688 0 CA-C-N 115.83 -0.623 . . . . 0.18 110.993 -174.392 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.481 ' O ' ' HB3' ' A' ' 22' ' ' SER . 38.3 Cg_exo -60.17 139.9 89.55 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.161 1.907 . . . . 0.19 111.407 172.58 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.23 -21.78 70.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.814 -0.708 . . . . 0.18 112.342 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -94.22 -4.97 48.0 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.211 0.529 . . . . 2.27 110.524 175.823 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.481 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 30.0 t -68.79 154.5 41.88 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.813 -0.63 . . . . 0.24 110.54 179.041 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -52.42 -44.27 65.33 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.332 0.587 . . . . 1.06 110.1 178.067 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.663 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.2 mm? -70.6 -58.05 4.09 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.503 -0.771 . . . . 1.11 110.847 178.197 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.461 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.56 -39.41 74.66 Favored Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.227 -0.511 . . . . 0.16 113.307 -176.452 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 87.1 m -67.84 -42.1 81.95 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 120.827 0.346 . . . . 0.24 110.325 -179.015 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -61.89 -43.1 99.53 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.216 -0.661 . . . . 1.01 109.216 175.222 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.663 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.7 mt -61.46 -51.55 68.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.135 -0.939 . . . . 0.37 111.125 -175.633 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.543 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -76.37 -23.89 54.14 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.723 -0.391 . . . . 0.41 111.677 -175.322 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.508 ' N ' HD12 ' A' ' 29' ' ' LEU . 11.8 t70 -68.11 -33.49 74.61 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.512 0.672 . . . . 0.66 109.363 176.915 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -78.33 -23.83 46.85 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.287 -0.869 . . . . 2.07 109.962 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.7 mt -97.34 -5.24 36.95 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.193 -0.912 . . . . 0.71 111.878 -174.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 68.31 44.48 74.59 Favored Glycine 0 N--CA 1.453 -0.229 0 CA-C-N 115.74 -0.663 . . . . 0.75 112.896 177.348 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.543 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 23.3 mt -97.57 145.53 9.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.673 0.273 . . . . 0.68 110.637 -178.43 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.8 t -107.88 116.27 50.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.127 -0.488 . . . . 1.87 109.695 176.06 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.555 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.5 pp -90.81 129.95 36.83 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.25 0.547 . . . . 2.76 111.25 -179.241 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -90.96 -26.79 19.08 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.917 -0.771 . . . . 2.65 108.917 170.289 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -139.42 94.92 9.3 Favored Pre-proline 0 N--CA 1.447 -0.613 0 CA-C-N 114.92 -1.037 . . . . 2.29 108.495 177.369 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -68.43 -3.93 11.94 Favored 'Trans proline' 0 N--CA 1.466 -0.137 0 C-N-CA 122.256 1.971 . . . . 0.64 111.564 -177.464 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.8 p -87.89 6.2 36.73 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.337 -0.847 . . . . 0.51 111.45 -175.497 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.428 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.9 m -92.73 158.26 2.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.209 0.528 . . . . 0.24 110.875 179.407 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.9 mt -88.21 128.62 35.46 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.476 -0.784 . . . . 0.22 109.806 175.541 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.431 HD13 HD23 ' A' ' 29' ' ' LEU . 10.2 pt -106.83 133.07 52.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.203 0.525 . . . . 0.15 110.091 176.118 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.814 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.78 98.16 1.3 Allowed Glycine 0 N--CA 1.438 -1.19 0 CA-C-N 115.385 -0.825 . . . . 0.31 113.02 -175.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -77.4 137.84 38.94 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.583 -0.525 . . . . 0.57 109.583 177.286 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.482 ' H ' HG23 ' A' ' 74' ' ' VAL . . . 71.48 41.08 58.82 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.431 -0.89 . . . . 0.21 112.072 -178.615 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.528 ' SG ' ' HB2' ' A' ' 12' ' ' GLN . 0.1 OUTLIER -105.14 111.28 23.99 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.294 0.569 . . . . 0.25 111.225 -175.312 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.454 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.5 t70 -101.43 138.53 19.93 Favored Pre-proline 0 C--N 1.316 -0.849 0 CA-C-N 115.483 -0.781 . . . . 2.21 110.927 175.886 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 25.7 Cg_exo -58.9 119.3 6.46 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 123.626 2.884 . . . . 0.44 111.628 177.671 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 29.7 mt . . . . . 0 C--N 1.327 -0.388 0 CA-C-O 121.054 0.454 . . . . 0.46 110.501 -177.205 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.8 t . . . . . 0 N--CA 1.451 -0.389 0 N-CA-C 109.786 -0.45 . . . . 0.74 109.786 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 28.5 t -94.4 -37.76 11.29 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.381 -0.372 . . . . 2.14 111.101 -178.205 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -86.59 -86.46 0.15 Allowed 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 121.181 -0.208 . . . . 0.54 111.499 -176.655 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 19.2 m -149.89 130.98 14.41 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.773 0.321 . . . . 0.29 111.145 -178.812 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -94.95 139.47 31.29 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.852 0.358 . . . . 0.25 110.4 -178.284 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.552 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 7.2 m -145.55 162.97 11.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.315 0.578 . . . . 0.21 111.285 -177.6 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' CYS . . . . . 0.455 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 30.2 t -115.44 107.8 15.67 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.122 -0.944 . . . . 0.39 109.703 175.678 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.634 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 28.3 m -100.12 140.04 34.93 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.212 0.53 . . . . 0.65 111.441 -176.682 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 40.0 m -97.35 -20.54 17.76 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.633 -0.712 . . . . 1.15 111.241 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -110.43 139.59 45.49 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.997 -0.547 . . . . 1.6 110.372 -176.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -117.14 25.8 10.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.4 -0.364 . . . . 2.49 111.939 -175.033 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 54.8 t30 -80.55 71.61 7.41 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.597 0.713 . . . . 2.27 109.635 176.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.409 HG12 ' O ' ' A' ' 75' ' ' ILE . 32.7 m -84.66 146.57 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 CA-C-N 115.541 -0.754 . . . . 1.1 112.125 -173.549 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.553 ' OG ' HG12 ' A' ' 75' ' ' ILE . 80.2 p -95.4 5.26 52.1 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.387 -0.824 . . . . 1.41 110.222 177.457 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.71 -32.7 3.43 Favored Glycine 0 N--CA 1.445 -0.711 0 CA-C-N 115.361 -0.836 . . . . 0.48 111.88 -176.253 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.482 HG23 ' H ' ' A' ' 46' ' ' GLY . 21.3 m -140.24 -21.42 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 112.558 0.577 . . . . 0.49 112.558 176.162 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.553 HG12 ' OG ' ' A' ' 72' ' ' SER . 7.4 pt -73.21 175.45 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.707 0.765 . . . . 0.3 112.343 -173.839 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.634 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.21 141.39 23.12 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.233 -1.348 . . . . 0.18 108.565 178.312 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.5 mt -120.78 140.27 45.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 C-N-CA 120.514 -0.474 . . . . 0.26 111.484 -175.056 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.428 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 72.06 52.75 10.49 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-N 115.95 -0.568 . . . . 0.17 111.908 178.163 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.552 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 12.2 m -106.58 145.03 32.4 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.04 0.448 . . . . 0.65 111.969 -174.079 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 91.3 mt -115.92 132.2 23.33 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 115.514 -0.766 . . . . 0.29 109.811 173.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.51 ' HA ' HG12 ' A' ' 64' ' ' VAL . 18.3 Cg_exo -64.77 129.06 22.41 Favored 'Trans proline' 0 C--O 1.234 0.297 0 C-N-CA 123.19 2.593 . . . . 0.25 112.982 -176.686 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.403 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 5.4 m . . . . . 0 N--CA 1.447 -0.596 0 CA-C-N 115.812 -0.631 . . . . 0.42 110.333 178.532 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.1 p . . . . . 0 N--CA 1.447 -0.611 0 N-CA-C 110.62 -0.141 . . . . 0.96 110.62 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.453 HG22 HD12 ' A' ' 50' ' ' ILE . 27.7 mt -102.72 133.99 44.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.843 0.83 . . . . 0.96 111.338 175.739 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.519 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -138.75 159.97 40.81 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.599 -1.182 . . . . 0.91 109.797 177.042 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.453 ' HB2' HD11 ' A' ' 50' ' ' ILE . 41.1 t -109.46 108.45 18.96 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.428 -0.582 . . . . 0.34 109.428 178.084 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.81 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 94.1 m -90.62 129.96 36.69 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.523 -0.762 . . . . 0.19 111.404 -174.597 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.401 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.3 OUTLIER -70.76 -34.65 72.04 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.028 -0.987 . . . . 0.38 109.622 174.433 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -130.91 116.29 17.69 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.87 -0.604 . . . . 1.03 110.085 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 99.3 t -110.2 102.6 14.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.058 0.456 . . . . 0.18 109.981 178.606 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.7 m -130.11 143.59 49.75 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 115.896 -0.593 . . . . 0.18 111.231 -174.053 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.521 ' O ' ' HB3' ' A' ' 22' ' ' SER . 35.5 Cg_exo -61.83 141.11 88.94 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.42 2.08 . . . . 0.19 111.36 171.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.96 -25.52 72.02 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.987 -0.625 . . . . 0.18 112.584 -178.642 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -97.87 7.1 46.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.238 0.542 . . . . 2.27 110.118 177.71 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.521 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 28.9 t -75.13 154.23 37.86 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.523 -0.762 . . . . 0.24 109.753 176.168 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -58.69 -31.94 68.69 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.18 0.514 . . . . 1.06 110.389 178.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.697 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.1 mm? -73.39 -64.52 0.97 Allowed 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 115.722 -0.672 . . . . 1.11 110.408 173.076 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.78 -38.35 64.17 Favored Glycine 0 C--N 1.33 0.223 0 CA-C-N 115.788 -0.642 . . . . 0.16 113.707 -174.013 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 87.7 m -68.43 -44.72 74.35 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.818 0.342 . . . . 0.24 110.692 -177.126 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.433 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.7 tm? -64.72 -36.89 85.74 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.261 -0.644 . . . . 1.01 109.261 177.613 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.697 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 18.9 mt -65.56 -49.54 68.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.881 -0.599 . . . . 0.37 110.436 -178.272 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.491 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -75.31 -22.08 57.97 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.469 -0.332 . . . . 0.41 111.584 -176.257 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.45 ' N ' HD12 ' A' ' 29' ' ' LEU . 19.8 t70 -66.56 -34.81 78.72 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.325 0.584 . . . . 0.66 109.656 175.697 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -72.92 -20.21 61.11 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.126 -0.943 . . . . 2.07 109.594 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.5 mt -98.14 -19.58 17.83 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.346 -1.297 . . . . 0.71 111.308 -176.879 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.42 24.55 60.71 Favored Glycine 0 N--CA 1.452 -0.271 0 CA-C-N 115.891 -0.595 . . . . 0.75 112.609 179.495 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.491 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 28.7 mt -78.9 133.28 30.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.967 0.413 . . . . 0.68 110.913 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.5 t -113.1 97.96 6.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.018 -0.537 . . . . 1.87 110.038 176.616 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.4 mt -93.73 138.26 32.11 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.169 -0.468 . . . . 2.76 110.739 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -78.96 -23.81 44.28 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.279 0.561 . . . . 2.65 109.589 175.505 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 24.7 m-20 -133.05 92.21 26.22 Favored Pre-proline 0 N--CA 1.446 -0.628 0 CA-C-N 115.446 -0.797 . . . . 2.29 109.117 176.924 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -72.8 6.96 2.16 Favored 'Trans proline' 0 N--CA 1.463 -0.287 0 C-N-CA 122.262 1.975 . . . . 0.64 111.445 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.7 p -83.71 -8.25 59.31 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.534 -0.757 . . . . 0.51 110.878 -178.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.471 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 33.4 m -78.54 151.08 5.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.909 -0.587 . . . . 0.24 110.792 179.283 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.0 mt -81.61 120.78 25.51 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.609 -0.723 . . . . 0.22 110.094 177.191 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 12.6 pt -102.52 131.85 49.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.29 0.567 . . . . 0.15 110.119 176.107 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.81 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.11 99.9 1.58 Allowed Glycine 0 N--CA 1.438 -1.207 0 CA-C-N 115.529 -0.76 . . . . 0.31 113.175 -174.54 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -80.67 139.15 36.33 Favored 'General case' 0 C--N 1.314 -0.953 0 N-CA-C 109.028 -0.731 . . . . 0.57 109.028 175.919 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.33 34.64 35.9 Favored Glycine 0 N--CA 1.444 -0.82 0 C-N-CA 119.629 -1.272 . . . . 0.21 111.523 -178.731 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.535 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -102.4 118.72 37.47 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.144 0.497 . . . . 0.25 111.121 -174.315 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -100.55 134.5 20.59 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 115.669 -0.696 . . . . 2.21 109.412 175.148 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -63.98 123.13 11.43 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.589 2.193 . . . . 0.44 110.967 177.423 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.453 HD11 ' HB2' ' A' ' 13' ' ' CYS . 12.4 mt . . . . . 0 N--CA 1.45 -0.467 0 CA-C-O 121.482 0.658 . . . . 0.46 109.75 -178.062 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.3 t . . . . . 0 N--CA 1.449 -0.508 0 CA-C-O 120.854 0.359 . . . . 0.74 110.063 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 51.1 m -108.25 17.17 22.52 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.225 -0.443 . . . . 2.14 111.735 -177.163 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.401 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -144.52 -82.18 0.16 Allowed 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.752 -0.379 . . . . 0.54 111.536 178.52 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 87.1 m -150.11 123.96 9.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.864 0.364 . . . . 0.29 110.825 -179.482 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -86.44 129.59 34.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.057 0.456 . . . . 0.25 110.209 -177.433 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.567 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 6.4 m -140.88 161.58 23.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 115.937 -0.574 . . . . 0.21 111.023 -177.702 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' CYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 52.8 t -120.18 110.33 16.48 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.633 -0.712 . . . . 0.39 109.389 177.092 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.782 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 15.8 m -97.57 132.23 43.43 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.133 0.492 . . . . 0.65 111.286 -176.292 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.4 m -84.11 -25.78 29.45 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.583 -0.735 . . . . 1.15 111.04 -178.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -102.01 134.66 44.88 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.791 -0.64 . . . . 1.6 110.145 -177.877 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -100.99 10.1 41.49 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.322 -0.399 . . . . 2.49 111.311 -174.554 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -79.57 103.21 9.32 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.086 0.47 . . . . 2.27 110.131 179.427 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.871 HG12 ' H ' ' A' ' 73' ' ' GLY . 73.0 t -122.84 133.04 70.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.019 -0.537 . . . . 1.1 111.244 -173.888 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.586 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 88.8 p -80.12 2.58 23.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.531 -0.758 . . . . 1.41 111.257 -177.296 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.871 ' H ' HG12 ' A' ' 71' ' ' VAL . . . 126.57 -32.31 3.73 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.664 -0.698 . . . . 0.48 112.04 -178.387 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.0 m -138.69 -9.77 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 112.315 0.487 . . . . 0.49 112.315 -179.381 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.586 ' CG1' ' H ' ' A' ' 72' ' ' SER . 4.1 pt -88.79 -179.43 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.707 0.765 . . . . 0.3 112.705 -175.546 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.782 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -151.51 142.17 22.73 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 114.287 -1.324 . . . . 0.18 108.798 174.308 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.9 mt -120.4 137.1 55.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.915 0.388 . . . . 0.26 111.945 -175.141 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.471 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 69.89 52.14 20.89 Favored Glycine 0 C--N 1.333 0.371 0 CA-C-N 115.922 -0.581 . . . . 0.17 111.778 177.723 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.567 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 12.8 m -103.02 134.35 46.62 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.274 0.559 . . . . 0.65 111.909 -173.634 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 90.4 mt -107.79 131.82 21.46 Favored Pre-proline 0 C--N 1.322 -0.614 0 CA-C-N 115.563 -0.744 . . . . 0.29 110.032 175.202 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.427 ' HA ' HG12 ' A' ' 64' ' ' VAL . 25.4 Cg_exo -63.24 120.67 8.22 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.917 2.412 . . . . 0.25 112.678 -179.315 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.427 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 4.3 m . . . . . 0 N--CA 1.447 -0.601 0 CA-C-N 115.968 -0.56 . . . . 0.42 110.201 178.23 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 34.1 t . . . . . 0 N--CA 1.45 -0.445 0 N-CA-C 109.502 -0.555 . . . . 0.96 109.502 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.418 HG22 HD12 ' A' ' 50' ' ' ILE . 43.1 mt -95.7 137.16 24.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 121.664 0.745 . . . . 0.96 110.989 178.058 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLN . . . . . 0.532 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -132.24 163.06 29.43 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.775 -1.102 . . . . 0.91 109.949 176.781 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 42.0 t -106.28 99.49 9.07 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.809 -0.632 . . . . 0.34 109.556 179.055 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.865 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 54.0 m -86.01 130.66 34.47 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-N 115.707 -0.678 . . . . 0.19 111.352 -175.554 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.445 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -77.82 -30.87 51.37 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.196 -0.911 . . . . 0.38 109.77 177.506 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ASN . . . . . 0.641 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 19.3 m-20 -133.3 98.59 4.29 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.117 -0.492 . . . . 1.03 111.256 175.609 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 71.8 t -89.48 100.85 11.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.162 0.506 . . . . 0.18 109.732 174.234 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 29.6 m -128.45 141.1 40.35 Favored Pre-proline 0 C--N 1.318 -0.768 0 CA-C-N 115.843 -0.617 . . . . 0.18 110.697 -174.761 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.466 ' HB2' ' HB2' ' A' ' 22' ' ' SER . 31.9 Cg_exo -59.24 135.58 66.65 Favored 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 122.073 1.849 . . . . 0.19 111.521 172.741 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.8 -15.22 64.23 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.888 -0.673 . . . . 0.18 112.136 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -103.44 4.56 36.25 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.053 0.454 . . . . 2.27 110.248 175.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.466 ' HB2' ' HB2' ' A' ' 19' ' ' PRO . 29.0 t -78.53 158.35 28.59 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.051 -0.522 . . . . 0.24 109.898 177.717 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -53.19 -42.79 66.61 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.974 0.416 . . . . 1.06 109.991 176.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.701 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.9 mm? -67.7 -65.08 0.74 Allowed 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 115.669 -0.696 . . . . 1.11 110.493 178.259 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.69 -36.44 59.29 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.983 -0.553 . . . . 0.16 113.329 -174.833 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 84.9 m -68.55 -45.67 71.53 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.79 0.329 . . . . 0.24 110.298 -178.175 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.432 ' O ' HD13 ' A' ' 27' ' ' LEU . 1.3 tm? -65.96 -36.38 83.17 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.15 -0.685 . . . . 1.01 109.15 178.212 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.701 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.7 mt -67.34 -46.55 73.12 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.603 -0.726 . . . . 0.37 111.033 -177.363 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.514 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.26 -22.87 51.49 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 120.321 -0.551 . . . . 0.41 111.137 -178.695 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.478 ' N ' HD12 ' A' ' 29' ' ' LEU . 13.0 t70 -67.98 -35.8 78.97 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.044 -0.724 . . . . 0.66 109.044 173.135 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -69.1 -33.22 73.16 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 114.717 -1.129 . . . . 2.07 109.429 178.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 67.6 mt -91.87 -10.86 38.13 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.56 -1.2 . . . . 0.71 111.867 -176.412 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.29 35.71 88.33 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.767 -0.651 . . . . 0.75 112.6 179.129 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.514 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 56.5 mt -76.08 129.0 37.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 120.814 0.34 . . . . 0.68 111.163 -176.528 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.2 p -86.56 101.0 10.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.746 0.784 . . . . 1.87 109.415 172.523 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.516 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.8 pp -76.29 132.7 39.98 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.722 -0.672 . . . . 2.76 111.18 -177.358 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -86.83 -29.73 22.01 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.745 -0.835 . . . . 2.65 108.745 172.248 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -144.96 112.33 4.84 Favored Pre-proline 0 N--CA 1.443 -0.803 0 N-CA-C 107.493 -1.299 . . . . 2.29 107.493 174.01 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.407 ' HB3' HD22 ' A' ' 36' ' ' LEU . 70.9 Cg_endo -75.52 -1.5 11.4 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.197 1.931 . . . . 0.64 112.808 -173.228 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 35.2 p -106.55 20.51 18.89 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.261 0.553 . . . . 0.51 111.121 -175.727 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.46 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 34.8 m -87.72 156.59 3.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.589 -0.732 . . . . 0.24 110.081 175.143 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.454 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.9 mt -85.6 121.26 28.04 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.808 -0.442 . . . . 0.22 109.808 176.638 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 22.2 pt -106.41 140.75 23.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.101 0.477 . . . . 0.15 110.256 177.493 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.865 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.2 107.35 1.55 Allowed Glycine 0 N--CA 1.439 -1.111 0 C-N-CA 120.586 -0.816 . . . . 0.31 112.949 -175.102 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.641 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 9.4 t70 -80.62 147.91 30.5 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.693 -0.854 . . . . 0.57 108.693 175.257 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 67.46 37.81 90.34 Favored Glycine 0 C--N 1.317 -0.515 0 C-N-CA 120.162 -1.018 . . . . 0.21 111.958 178.277 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -102.63 115.44 30.59 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.01 0.433 . . . . 0.25 111.088 -172.895 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.45 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 2.1 p-10 -100.84 132.07 22.63 Favored Pre-proline 0 C--N 1.318 -0.796 0 CA-C-N 115.698 -0.683 . . . . 2.21 110.161 177.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.94 119.55 6.87 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.399 2.066 . . . . 0.44 110.696 175.058 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.418 HD12 HG22 ' A' ' 11' ' ' ILE . 12.9 mt . . . . . 0 N--CA 1.449 -0.488 0 CA-C-O 121.879 0.847 . . . . 0.46 109.913 -177.098 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.5 t . . . . . 0 N--CA 1.451 -0.387 0 CA-C-O 120.848 0.356 . . . . 0.74 110.28 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 12.8 p -93.6 -15.37 25.46 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.089 -0.505 . . . . 2.14 111.742 -177.42 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.445 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -128.44 -83.44 0.58 Allowed 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.623 0.601 . . . . 0.54 112.623 -175.172 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.8 m -142.11 131.59 23.8 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.783 0.325 . . . . 0.29 111.301 -176.147 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.94 125.98 34.4 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.031 0.443 . . . . 0.25 110.125 178.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.663 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -141.33 164.99 19.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.119 -0.492 . . . . 0.21 110.806 -177.546 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' CYS . . . . . 0.401 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 29.3 t -131.28 113.0 13.27 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 116.172 -0.467 . . . . 0.39 109.935 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.783 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -95.53 136.73 35.54 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.647 0.737 . . . . 0.65 112.233 -175.406 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.7 m -89.44 -18.45 26.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.641 -1.163 . . . . 1.15 110.806 -179.281 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.467 ' HB2' ' O ' ' A' ' 77' ' ' ILE . 19.8 m-20 -98.31 151.71 20.21 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.887 -0.597 . . . . 1.6 110.332 178.651 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -103.68 -12.28 17.12 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.019 -0.537 . . . . 2.49 110.581 -178.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -67.84 110.2 3.72 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.892 -0.594 . . . . 2.27 110.915 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.5 m -125.19 150.29 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 CA-C-N 116.158 -0.473 . . . . 1.1 110.932 177.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.506 ' H ' HG12 ' A' ' 75' ' ' ILE . 8.1 t -95.31 10.58 35.66 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.651 0.738 . . . . 1.41 109.636 177.008 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.15 -33.42 5.31 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 115.476 -0.784 . . . . 0.48 112.748 177.083 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.5 m -138.01 -0.52 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.644 -0.422 . . . . 0.49 111.64 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.506 HG12 ' H ' ' A' ' 72' ' ' SER . 24.3 pt -100.21 173.84 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 C-N-CA 120.187 -0.605 . . . . 0.3 111.63 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.783 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -141.41 141.08 33.76 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 114.485 -1.234 . . . . 0.18 109.35 176.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.467 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 67.0 mt -122.02 131.93 72.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.742 0.306 . . . . 0.26 111.342 -177.43 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.46 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 75.53 51.68 7.11 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.978 -0.629 . . . . 0.17 111.911 178.638 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.2 m -99.89 138.74 36.55 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.231 0.538 . . . . 0.65 112.232 -176.345 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 92.1 mt -106.98 133.01 20.46 Favored Pre-proline 0 C--N 1.32 -0.689 0 CA-C-N 115.475 -0.784 . . . . 0.29 109.445 170.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.406 ' HA ' HG12 ' A' ' 64' ' ' VAL . 17.3 Cg_exo -65.77 124.62 12.99 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.82 2.347 . . . . 0.25 111.961 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.6 m . . . . . 0 N--CA 1.442 -0.828 0 CA-C-O 121.033 0.444 . . . . 0.42 110.659 -179.828 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.754 0 N-CA-C 111.918 -0.473 . . . . 5.63 111.918 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.0 m -142.86 116.24 9.05 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.815 0.341 . . . . 4.28 110.983 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.423 ' HA ' ' O ' ' A' ' 50' ' ' ILE . 20.4 m95 -81.78 -55.9 4.33 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.949 -0.569 . . . . 4.74 110.216 175.196 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.09 163.2 13.67 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 111.119 -0.793 . . . . 2.03 111.119 -178.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 53.3 tp60 -89.44 107.11 18.89 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.871 0.336 . . . . 4.17 110.263 -178.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 44.0 t 176.7 115.69 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.562 -0.744 . . . . 1.88 110.381 177.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 35.1 m -99.5 14.92 28.18 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.106 0.479 . . . . 2.4 110.265 178.217 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.2 m -84.03 -8.44 59.13 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.366 0.603 . . . . 3.75 110.508 178.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 162.89 -125.98 1.48 Allowed Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.769 -0.729 . . . . 1.12 112.051 178.373 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 35.3 t -112.86 149.6 32.89 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.155 -0.683 . . . . 0.96 109.155 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.507 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.3 mp -99.27 138.08 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 CA-C-O 121.722 0.772 . . . . 0.96 111.675 176.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.525 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -148.98 167.76 24.92 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.598 -1.183 . . . . 0.91 111.003 178.301 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 37.3 t -116.45 106.71 13.9 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.38 -0.827 . . . . 0.34 109.293 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.818 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 90.4 m -91.8 132.1 36.67 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.753 -0.658 . . . . 0.19 111.597 -173.576 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.421 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -73.2 -35.97 66.44 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 114.91 -1.041 . . . . 0.38 109.501 173.869 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 19.7 m-20 -128.84 100.57 5.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.051 -0.522 . . . . 1.03 111.334 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.8 t -92.52 99.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.497 -0.557 . . . . 0.18 109.497 173.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.6 m -129.06 140.4 38.5 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 115.761 -0.654 . . . . 0.18 110.863 -174.232 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.557 ' O ' ' HB3' ' A' ' 22' ' ' SER . 33.4 Cg_exo -58.36 140.9 96.27 Favored 'Trans proline' 0 N--CA 1.464 -0.252 0 C-N-CA 122.371 2.047 . . . . 0.19 111.709 173.313 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.86 -19.47 69.61 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.907 -0.663 . . . . 0.18 112.589 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -103.22 7.43 38.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.388 0.613 . . . . 2.27 109.97 176.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.557 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 13.8 t -73.28 155.78 39.13 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.328 -0.851 . . . . 0.24 110.014 176.658 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -55.93 -41.01 73.95 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.212 0.529 . . . . 1.06 109.685 176.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.735 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.1 mm? -70.11 -60.52 2.24 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 115.325 -0.852 . . . . 1.11 110.694 176.347 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.44 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -56.03 -41.51 85.21 Favored Glycine 0 CA--C 1.517 0.171 0 CA-C-N 116.053 -0.521 . . . . 0.16 113.348 -174.711 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 91.5 m -67.84 -39.39 83.85 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.916 0.389 . . . . 0.24 110.499 -178.306 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -64.71 -39.24 93.32 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.244 -0.65 . . . . 1.01 109.244 176.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.735 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.6 mt -68.13 -50.04 57.22 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.701 -0.681 . . . . 0.37 110.987 -176.525 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.548 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.8 pp -73.18 -23.72 60.45 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.546 -0.462 . . . . 0.41 111.509 -176.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.532 ' N ' HD12 ' A' ' 29' ' ' LEU . 28.2 t70 -68.97 -31.71 70.76 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.58 0.705 . . . . 0.66 109.192 175.64 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -75.04 -15.29 60.64 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-N 114.988 -1.005 . . . . 2.07 109.918 177.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.8 mt -111.7 0.04 16.17 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.932 -1.031 . . . . 0.71 111.464 -174.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.21 34.66 85.32 Favored Glycine 0 C--N 1.333 0.363 0 CA-C-N 115.855 -0.611 . . . . 0.75 113.015 178.226 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.548 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 53.9 mt -84.07 125.9 40.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.817 0.341 . . . . 0.68 110.828 -176.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 50.4 t -88.17 121.28 38.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.278 -0.638 . . . . 1.87 109.278 175.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.489 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.6 pp -95.23 130.62 41.91 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.425 0.631 . . . . 2.76 111.703 -176.757 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -90.87 -29.2 17.66 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 108.56 -0.904 . . . . 2.65 108.56 170.25 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -142.34 96.1 6.47 Favored Pre-proline 0 N--CA 1.442 -0.838 0 N-CA-C 107.724 -1.213 . . . . 2.29 107.724 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.428 ' HB3' HD22 ' A' ' 36' ' ' LEU . 50.7 Cg_endo -69.84 -5.89 17.34 Favored 'Trans proline' 0 CA--C 1.521 -0.149 0 C-N-CA 122.561 2.174 . . . . 0.64 111.819 -176.313 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.2 p -95.41 19.14 11.3 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.686 -0.688 . . . . 0.51 111.308 -175.697 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.489 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 32.7 m -92.09 156.6 3.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.798 -0.637 . . . . 0.24 109.855 173.048 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.539 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.1 mt -88.99 121.68 31.59 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 116.061 -0.518 . . . . 0.22 109.835 176.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.411 HD13 HD23 ' A' ' 29' ' ' LEU . 12.1 pt -102.74 133.57 46.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-O 121.247 0.546 . . . . 0.15 110.053 176.685 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.818 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -105.82 95.31 1.05 Allowed Glycine 0 N--CA 1.439 -1.166 0 CA-C-N 115.546 -0.752 . . . . 0.31 112.832 -174.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -76.83 141.91 40.48 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.235 -0.654 . . . . 0.57 109.235 176.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.421 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 70.57 38.8 68.44 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 119.71 -1.233 . . . . 0.21 111.825 -177.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.515 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -107.36 116.28 31.66 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.17 0.51 . . . . 0.25 111.351 -172.98 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.418 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 19.9 m-20 -102.02 134.52 20.04 Favored Pre-proline 0 C--N 1.317 -0.838 0 CA-C-N 115.632 -0.713 . . . . 2.21 109.362 175.453 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.424 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 16.5 Cg_exo -62.79 126.97 19.31 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.613 2.209 . . . . 0.44 111.351 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.464 ' CG2' ' HB1' ' A' ' 58' ' ' ALA . 47.1 mt -80.81 103.42 7.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 120.958 0.409 . . . . 0.46 110.551 -175.753 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 7.5 t -138.74 20.24 2.68 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.755 0.788 . . . . 0.88 109.871 179.217 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 9.9 p -128.34 161.58 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 CA-C-N 115.234 -0.894 . . . . 1.44 109.832 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . 73.18 -63.98 0.41 Allowed 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 123.344 0.658 . . . . 2.94 112.09 175.359 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 64.85 40.45 97.3 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.304 -0.95 . . . . 3.5 111.459 -175.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 29.1 m -149.34 -167.47 2.84 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.242 -0.651 . . . . 4.9 109.242 -178.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 13.8 p -61.96 -33.9 75.14 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.923 0.392 . . . . 4.06 110.934 178.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -82.16 25.27 0.6 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 3.13 111.752 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.464 ' HB1' ' CG2' ' A' ' 50' ' ' ILE . . . -80.53 -11.3 59.68 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.282 0.563 . . . . 0.99 110.65 178.707 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.8 t -146.58 135.16 22.08 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.633 -0.712 . . . . 0.74 110.278 178.319 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.3 p -100.79 -26.19 13.86 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.087 -0.506 . . . . 2.14 111.906 -177.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -105.74 -80.56 0.55 Allowed 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 121.067 -0.253 . . . . 0.54 111.585 -177.137 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 15.1 m -147.19 129.17 15.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.582 0.229 . . . . 0.29 110.797 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.21 131.87 34.14 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.902 0.382 . . . . 0.25 110.372 -178.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.735 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -144.4 171.82 6.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.238 0.542 . . . . 0.21 111.431 -176.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 42.0 t -139.28 106.26 5.44 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.301 -0.863 . . . . 0.39 109.744 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.731 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -88.41 134.57 33.8 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.472 0.653 . . . . 0.65 112.214 -177.474 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.8 m -85.42 -18.53 33.37 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.856 -1.066 . . . . 1.15 111.1 -179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -100.75 160.18 14.57 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.456 -0.572 . . . . 1.6 109.456 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -112.2 -7.89 14.01 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.962 0.411 . . . . 2.49 110.859 -176.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 34.5 t30 -75.71 108.24 8.41 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.077 -0.51 . . . . 2.27 110.862 -178.143 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.1 m -118.87 143.74 29.09 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.726 0 CA-C-N 116.078 -0.51 . . . . 1.1 110.257 177.099 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.619 ' OG ' HG12 ' A' ' 75' ' ' ILE . 90.7 p -84.5 -2.0 56.61 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.093 0.473 . . . . 1.41 110.494 -179.707 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.61 -32.18 3.58 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.669 -0.696 . . . . 0.48 112.288 -177.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 15.7 m -136.63 -16.07 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.533 -0.467 . . . . 0.49 112.043 178.013 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.619 HG12 ' OG ' ' A' ' 72' ' ' SER . 20.3 pt -87.75 -176.17 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.541 0.686 . . . . 0.3 111.884 -177.187 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.731 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.35 142.2 23.8 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-N 114.231 -1.35 . . . . 0.18 108.765 175.775 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 63.0 mt -117.75 130.22 72.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 120.594 -0.442 . . . . 0.26 111.646 -176.39 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.505 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.06 51.75 6.06 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.068 -0.587 . . . . 0.17 111.871 177.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.539 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.2 m -99.1 129.61 45.37 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.378 0.609 . . . . 0.65 112.072 -176.143 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 96.5 mt -98.97 132.19 24.08 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.517 -0.765 . . . . 0.29 109.664 173.087 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.438 ' HA ' HG12 ' A' ' 64' ' ' VAL . 13.8 Cg_exo -68.16 123.24 10.38 Favored 'Trans proline' 0 N--CA 1.463 -0.303 0 C-N-CA 122.78 2.32 . . . . 0.25 112.037 -179.071 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.2 m -124.9 157.19 33.47 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 CA-C-N 116.09 -0.505 . . . . 0.42 110.399 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.43 HG22 ' HG ' ' A' ' 84' ' ' LEU . 25.5 m -156.07 139.75 16.04 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.9 -0.591 . . . . 2.07 109.426 176.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.43 ' HG ' HG22 ' A' ' 83' ' ' THR . 98.3 mt . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.851 -0.595 . . . . 3.91 110.916 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.511 0 N-CA-C 111.603 -0.599 . . . . 5.63 111.603 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.4 p -82.59 -14.94 53.94 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.862 0.363 . . . . 4.28 111.139 -177.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 48.3 m95 -102.91 38.0 1.83 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.049 0.452 . . . . 4.74 110.137 -178.421 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.57 149.76 24.32 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.994 -0.622 . . . . 2.03 112.274 -179.39 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.3 mm100 -87.08 109.26 19.3 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.24 -0.281 . . . . 4.17 110.24 178.608 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.455 ' HB3' ' O ' ' A' ' 9' ' ' GLY . 42.3 t -156.6 136.61 12.7 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.963 0.411 . . . . 1.88 110.645 -178.271 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 11.0 p -83.6 -17.79 40.44 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.976 -0.556 . . . . 2.4 111.075 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.431 ' HB ' ' SG ' ' A' ' 65' ' ' CYS . 91.6 m -82.46 -24.32 34.31 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.123 -0.49 . . . . 3.75 110.937 178.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.455 ' O ' ' HB3' ' A' ' 6' ' ' CYS . . . 153.63 -139.41 6.84 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.658 -0.782 . . . . 1.12 112.465 178.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.2 m -92.51 139.1 30.93 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-O 120.732 0.301 . . . . 0.96 110.376 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 40.4 mt -90.93 137.66 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.804 0.811 . . . . 0.96 110.869 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.46 ' HA ' HG13 ' A' ' 50' ' ' ILE . 0.1 OUTLIER -145.74 158.05 43.89 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 114.605 -1.179 . . . . 0.91 109.958 -175.903 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 37.8 t -110.51 103.3 11.89 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-O 121.134 0.492 . . . . 0.34 110.009 -177.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.638 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 63.8 m -86.63 136.05 33.19 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.311 -0.858 . . . . 0.19 111.057 -175.814 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.465 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -73.33 -32.9 64.83 Favored 'General case' 0 N--CA 1.445 -0.69 0 CA-C-N 115.167 -0.924 . . . . 0.38 108.643 173.762 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.501 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 3.7 t-20 -128.36 135.42 49.54 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.59 -0.732 . . . . 1.03 109.468 178.62 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 87.2 t -126.43 106.11 15.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 109.706 -0.479 . . . . 0.18 109.706 174.604 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.3 m -135.24 142.41 41.56 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 115.656 -0.702 . . . . 0.18 111.127 -173.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.551 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.8 Cg_exo -57.75 139.76 91.35 Favored 'Trans proline' 0 N--CA 1.462 -0.345 0 C-N-CA 122.257 1.971 . . . . 0.19 111.329 171.251 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.7 -23.12 70.51 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.839 -0.696 . . . . 0.18 112.31 -179.61 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -95.65 -1.47 50.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.95 0.405 . . . . 2.27 109.932 177.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.551 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 22.9 t -68.28 150.67 47.96 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.002 -0.544 . . . . 0.24 109.579 176.592 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -58.48 -32.56 68.88 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.2 0.524 . . . . 1.06 110.106 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.658 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.6 mm? -69.01 -64.56 0.85 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.433 -0.803 . . . . 1.11 110.701 172.009 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.44 -40.84 78.76 Favored Glycine 0 C--N 1.33 0.225 0 CA-C-N 115.959 -0.564 . . . . 0.16 113.364 -174.374 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 30.1 m -67.32 -41.15 85.77 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.168 -0.308 . . . . 0.24 110.168 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -64.91 -40.14 94.6 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.408 -0.59 . . . . 1.01 109.408 177.198 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.658 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.7 mt -67.92 -44.62 76.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.044 -0.526 . . . . 0.37 110.849 -175.168 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.547 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.8 pp -77.69 -25.1 49.21 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.372 -0.531 . . . . 0.41 110.899 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.528 ' N ' HD12 ' A' ' 29' ' ' LEU . 24.6 t70 -64.88 -36.7 85.21 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.766 0.793 . . . . 0.66 109.178 172.144 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -74.86 -12.13 60.3 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 114.149 -1.387 . . . . 2.07 110.388 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.5 mt -108.66 -9.95 15.24 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.146 -0.934 . . . . 0.71 111.259 -178.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 71.22 35.09 64.02 Favored Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.887 -0.597 . . . . 0.75 112.518 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.547 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 43.4 mt -91.55 131.05 39.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.709 0.255 . . . . 0.68 110.704 -178.159 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 p -91.87 112.75 26.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.42 0.629 . . . . 1.87 109.959 173.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.543 HD22 ' HB3' ' A' ' 39' ' ' PRO . 0.9 OUTLIER -81.62 134.29 35.47 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.92 -0.582 . . . . 2.76 110.908 -179.573 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -87.32 -35.42 18.42 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.828 -0.804 . . . . 2.65 108.828 173.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -143.71 102.5 4.97 Favored Pre-proline 0 N--CA 1.444 -0.745 0 N-CA-C 107.947 -1.131 . . . . 2.29 107.947 176.601 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.543 ' HB3' HD22 ' A' ' 36' ' ' LEU . 51.8 Cg_endo -69.53 -3.48 11.95 Favored 'Trans proline' 0 C--O 1.226 -0.119 0 C-N-CA 122.365 2.043 . . . . 0.64 111.673 -175.036 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.0 p -85.73 7.95 21.68 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.633 -0.712 . . . . 0.51 111.88 -174.49 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.5 m -92.18 158.42 2.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.958 0.408 . . . . 0.24 110.327 177.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.546 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 94.9 mt -89.07 121.76 31.73 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.076 -0.511 . . . . 0.22 110.084 178.494 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.501 HD13 HD23 ' A' ' 29' ' ' LEU . 22.4 pt -108.86 145.73 15.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.238 0.542 . . . . 0.15 110.44 177.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.638 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.02 142.09 17.18 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.667 -0.778 . . . . 0.31 112.338 -177.355 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.501 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 9.5 t70 -105.17 151.79 23.62 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.305 -0.998 . . . . 0.57 108.305 172.314 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.404 ' HA3' ' HB3' ' A' ' 15' ' ' GLN . . . 61.02 44.5 98.11 Favored Glycine 0 C--N 1.32 -0.339 0 C-N-CA 120.28 -0.962 . . . . 0.21 112.302 175.806 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.527 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.34 115.55 30.44 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.056 0.455 . . . . 0.25 110.984 -172.443 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.407 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 18.6 m-20 -101.29 129.32 27.25 Favored Pre-proline 0 C--N 1.316 -0.884 0 CA-C-N 115.666 -0.697 . . . . 2.21 109.304 175.744 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.433 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 17.8 Cg_exo -61.64 122.2 10.69 Favored 'Trans proline' 0 N--CA 1.46 -0.446 0 C-N-CA 122.739 2.293 . . . . 0.44 111.263 178.05 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.46 HG13 ' HA ' ' A' ' 12' ' ' GLN . 10.1 mt -82.32 88.55 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.593 0.711 . . . . 0.46 109.835 -176.363 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 12.4 t -125.08 9.76 8.09 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.968 -1.015 . . . . 0.88 110.293 -177.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.5 p -89.58 131.07 37.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 115.577 -0.738 . . . . 1.44 110.652 -177.295 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -98.75 133.52 42.95 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.088 -0.505 . . . . 2.94 110.582 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 99.39 35.28 4.76 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.877 -0.677 . . . . 3.5 111.809 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 8.5 t -138.12 106.59 5.83 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.864 0.364 . . . . 4.9 110.168 -177.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.4 m -75.56 -37.84 59.68 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.142 0.496 . . . . 4.06 109.711 177.08 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -97.78 58.43 1.4 Allowed 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 109.133 -0.692 . . . . 3.13 109.133 173.014 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -70.25 -14.95 62.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.333 -0.849 . . . . 0.99 111.216 -176.604 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.9 t -132.1 131.36 42.29 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.506 -0.77 . . . . 0.74 110.129 176.586 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 17.4 t -109.66 -22.25 12.03 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.518 -0.31 . . . . 2.14 111.143 -177.588 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.465 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -102.85 -82.06 0.49 Allowed 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.725 -0.39 . . . . 0.54 111.316 -179.484 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 23.2 m -148.78 127.67 12.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.8 0.333 . . . . 0.29 110.775 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -88.21 133.21 34.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.0 0.429 . . . . 0.25 110.909 -177.345 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.495 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.3 m -144.11 170.5 8.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.03 -0.532 . . . . 0.21 111.07 -178.571 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' CYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 46.3 t -130.87 115.77 17.01 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.022 -0.536 . . . . 0.39 110.045 178.788 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.815 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 4.4 m -101.71 154.88 18.5 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.814 0.816 . . . . 0.65 111.941 -176.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 49.0 m -103.45 -19.58 14.36 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 114.405 -1.27 . . . . 1.15 110.787 -177.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -106.24 142.82 35.28 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.706 -0.679 . . . . 1.6 109.561 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -116.77 2.94 12.95 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.076 0.465 . . . . 2.49 110.663 -176.749 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -92.62 58.69 3.16 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.62 0.724 . . . . 2.27 109.861 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 33.5 m -80.68 163.96 3.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.062 -0.972 . . . . 1.1 110.83 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.526 ' OG ' HG12 ' A' ' 75' ' ' ILE . 91.7 p -74.25 -8.04 54.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.281 -0.418 . . . . 1.41 111.339 -175.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.9 -32.06 3.56 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.923 -0.656 . . . . 0.48 112.68 -178.078 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 10.6 m -134.96 -6.12 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.318 -0.553 . . . . 0.49 111.989 178.144 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.526 HG12 ' OG ' ' A' ' 72' ' ' SER . 29.0 pt -93.92 -176.28 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 C-N-CA 120.063 -0.655 . . . . 0.3 111.419 179.583 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.815 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -144.58 143.23 30.69 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.782 -1.099 . . . . 0.18 109.73 175.697 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 64.0 mt -126.44 128.55 71.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.931 0.396 . . . . 0.26 111.606 -176.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.472 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 74.82 53.68 6.26 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.744 -0.662 . . . . 0.17 111.621 179.144 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.546 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 0.9 OUTLIER -104.2 141.9 35.45 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 112.652 0.612 . . . . 0.65 112.652 -175.539 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 84.2 mt -111.36 134.8 21.06 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.512 -0.767 . . . . 0.29 109.787 172.4 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.479 ' HA ' HG12 ' A' ' 64' ' ' VAL . 19.4 Cg_exo -65.14 124.04 12.42 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 123.067 2.512 . . . . 0.25 112.595 -179.012 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.3 m -125.59 157.67 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 CA-C-N 116.089 -0.505 . . . . 0.42 110.223 177.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.585 HG22 HD13 ' A' ' 84' ' ' LEU . 39.0 m -110.15 132.05 54.51 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 116.171 -0.468 . . . . 2.07 110.452 -179.729 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.585 HD13 HG22 ' A' ' 83' ' ' THR . 10.9 mp . . . . . 0 C--O 1.25 1.126 0 O-C-N 123.939 0.775 . . . . 3.91 111.761 -178.567 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.81 0 N-CA-C 111.756 -0.538 . . . . 5.63 111.756 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 50.4 m 54.38 52.56 12.25 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 121.393 0.616 . . . . 4.28 110.301 -176.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 32.2 t-105 -138.89 -76.24 0.37 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.488 -0.778 . . . . 4.74 109.906 -177.201 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 134.86 69.45 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.533 0 N-CA-C 111.279 -0.728 . . . . 2.03 111.279 -174.717 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -92.18 114.84 27.49 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-O 121.309 0.576 . . . . 4.17 110.458 -178.718 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 5.8 p -93.1 -45.16 8.02 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.462 -0.79 . . . . 1.88 110.465 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 79.9 p -144.96 -155.44 0.61 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.259 -0.882 . . . . 2.4 108.688 -178.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.3 m -62.26 -23.38 66.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.184 0.516 . . . . 3.75 110.214 175.178 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -83.45 -135.26 2.59 Favored Glycine 0 N--CA 1.447 -0.58 0 CA-C-N 115.725 -0.67 . . . . 1.12 112.479 178.324 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 40.1 t -150.07 153.09 35.84 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 110.139 -0.319 . . . . 0.96 110.139 -176.246 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.3 mt -88.21 139.37 17.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.185 0.517 . . . . 0.96 110.448 172.152 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.64 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -140.02 164.37 30.2 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.578 -0.737 . . . . 0.91 110.676 176.616 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.53 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 28.3 t -107.79 101.91 11.17 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.311 -0.859 . . . . 0.34 109.468 179.718 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.824 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 55.6 m -87.72 126.29 34.9 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.984 -0.553 . . . . 0.19 111.298 -176.057 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.442 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.1 OUTLIER -67.28 -33.4 75.22 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.074 -0.967 . . . . 0.38 109.471 174.878 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -139.43 113.01 8.41 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.953 -0.567 . . . . 1.03 110.501 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 51.2 t -101.17 104.55 16.43 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 109.67 -0.493 . . . . 0.18 109.67 177.177 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 m -129.97 140.58 39.07 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 116.072 -0.513 . . . . 0.18 111.43 -174.221 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.466 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.1 Cg_exo -59.61 138.44 83.51 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.37 2.047 . . . . 0.19 111.222 171.811 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -62.79 -26.05 68.27 Favored Glycine 0 C--O 1.227 -0.34 0 C-N-CA 121.272 -0.49 . . . . 0.18 113.146 -176.46 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -101.13 7.55 43.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.493 0.664 . . . . 2.27 110.245 177.068 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.466 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 26.6 t -71.31 159.02 35.33 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.52 -0.548 . . . . 0.24 109.52 175.849 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -53.4 -44.31 68.61 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.168 0.509 . . . . 1.06 109.767 176.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.701 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 6.2 mt -69.09 -60.27 2.47 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.314 -0.857 . . . . 1.11 110.456 178.25 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.429 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -53.51 -38.13 57.49 Favored Glycine 0 C--N 1.33 0.228 0 CA-C-N 116.101 -0.499 . . . . 0.16 113.218 -176.205 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 88.3 m -67.6 -47.61 69.2 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 110.361 -0.237 . . . . 0.24 110.361 -178.401 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.419 ' O ' HD13 ' A' ' 27' ' ' LEU . 3.1 tm? -62.71 -37.76 87.76 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.66 -0.496 . . . . 1.01 109.66 178.744 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.701 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.9 mt -69.01 -43.84 74.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.975 -0.557 . . . . 0.37 110.849 -175.543 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.489 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -82.41 -21.31 35.82 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.536 -0.466 . . . . 0.41 111.217 -178.578 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.44 ' N ' HD12 ' A' ' 29' ' ' LEU . 19.4 t70 -66.56 -34.92 78.98 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.634 0.731 . . . . 0.66 109.364 174.313 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -74.15 -32.96 63.35 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.793 -1.094 . . . . 2.07 109.18 179.141 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.4 mt -89.2 -10.56 46.61 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.903 -1.044 . . . . 0.71 111.982 -176.355 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.96 44.01 92.52 Favored Glycine 0 N--CA 1.452 -0.294 0 CA-C-N 115.849 -0.614 . . . . 0.75 112.766 178.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.489 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 51.3 mt -91.19 128.82 42.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.936 0.398 . . . . 0.68 111.41 -176.28 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.3 p -84.99 122.31 38.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.061 -0.518 . . . . 1.87 109.905 173.107 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.544 HD22 ' HB3' ' A' ' 39' ' ' PRO . 1.3 pp -94.88 131.26 40.97 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.265 0.555 . . . . 2.76 111.589 -176.227 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -90.36 -29.06 18.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.876 -0.787 . . . . 2.65 108.876 173.101 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -146.89 103.06 3.87 Favored Pre-proline 0 N--CA 1.444 -0.738 0 N-CA-C 107.435 -1.32 . . . . 2.29 107.435 175.34 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.544 ' HB3' HD22 ' A' ' 36' ' ' LEU . 66.7 Cg_endo -74.89 -1.09 10.73 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.135 1.89 . . . . 0.64 112.603 -174.029 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.3 p -99.6 4.48 45.79 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.176 -0.609 . . . . 0.51 111.092 -173.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.0 m -78.29 163.72 3.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.841 -0.618 . . . . 0.24 110.465 175.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.484 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 88.8 mt -91.5 120.09 32.02 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.933 -0.576 . . . . 0.22 110.011 176.486 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.413 HD13 HD23 ' A' ' 29' ' ' LEU . 17.3 pt -103.0 134.59 43.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 121.229 0.538 . . . . 0.15 110.095 176.091 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.824 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.94 104.75 2.21 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.699 -0.762 . . . . 0.31 112.878 -175.158 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -83.43 139.69 32.81 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 109.323 -0.621 . . . . 0.57 109.323 176.502 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.435 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 73.31 38.13 53.73 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.057 -1.068 . . . . 0.21 111.751 -179.846 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.53 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -103.25 116.17 31.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.065 0.46 . . . . 0.25 111.056 -172.708 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.504 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -101.56 134.02 20.48 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-N 115.857 -0.61 . . . . 2.21 109.858 177.371 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -54.57 119.11 5.87 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.747 2.298 . . . . 0.44 111.947 176.167 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.4 mt -82.59 105.4 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 N-CA-C 108.662 -0.866 . . . . 0.46 108.662 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.9 t -119.7 19.4 12.53 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 121.778 0.799 . . . . 0.88 110.224 -177.598 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.4 p -107.25 133.09 52.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.358 -0.837 . . . . 1.44 110.081 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -86.88 78.82 8.96 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.376 0.608 . . . . 2.94 110.189 177.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -167.14 69.51 0.18 Allowed Glycine 0 N--CA 1.447 -0.633 0 N-CA-C 110.799 -0.92 . . . . 3.5 110.799 179.184 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 11.4 t -61.05 -18.72 59.35 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 122.643 0.377 . . . . 4.9 111.981 -172.347 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 2.2 p -52.8 -41.88 64.56 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.843 0.354 . . . . 4.06 110.838 176.511 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -152.51 70.44 0.9 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.503 0.668 . . . . 3.13 109.459 174.405 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -106.68 -1.69 22.48 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.495 -0.775 . . . . 0.99 110.539 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.4 t -140.36 140.3 35.54 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.672 -0.694 . . . . 0.74 110.513 -178.403 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 20.0 m -101.21 7.37 43.07 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.33 -0.396 . . . . 2.14 111.526 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.442 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -147.0 -83.96 0.12 Allowed 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.914 -0.315 . . . . 0.54 111.81 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 33.8 m -142.27 130.08 21.68 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-O 120.713 0.292 . . . . 0.29 110.99 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.97 129.25 34.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.465 -0.334 . . . . 0.25 110.267 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.659 HG21 ' SG ' ' A' ' 14' ' ' CYS . 4.0 m -140.6 169.9 15.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-O 121.248 0.546 . . . . 0.21 111.959 -176.574 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 29.1 t -132.98 103.66 6.16 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.191 -0.913 . . . . 0.39 110.061 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.748 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -91.11 138.79 31.33 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.647 0.737 . . . . 0.65 111.882 -178.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 47.9 t -92.8 -19.16 22.02 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 114.635 -1.166 . . . . 1.15 110.736 179.051 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -96.83 159.78 14.73 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.107 -0.497 . . . . 1.6 110.519 -175.196 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.2 t30 -117.68 -6.41 11.1 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.117 -0.492 . . . . 2.49 111.067 -173.676 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 50.5 t30 -81.04 83.25 6.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.249 0.547 . . . . 2.27 110.655 -177.508 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 30.0 m -101.81 139.57 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-N 116.0 -0.545 . . . . 1.1 110.885 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.567 ' OG ' HG12 ' A' ' 75' ' ' ILE . 99.9 p -80.38 -5.08 55.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.188 -0.46 . . . . 1.41 110.739 -178.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.3 -32.22 3.62 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.841 -0.618 . . . . 0.48 112.179 -177.536 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 m -135.44 -7.78 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 C-N-CA 120.559 -0.456 . . . . 0.49 111.945 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.567 HG12 ' OG ' ' A' ' 72' ' ' SER . 37.0 pt -97.39 179.78 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.522 0.677 . . . . 0.3 111.779 -178.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.748 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -149.85 140.4 22.49 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.255 -1.338 . . . . 0.18 109.094 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.0 mt -118.63 133.55 65.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.875 0.369 . . . . 0.26 111.333 -177.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 74.9 50.86 8.32 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.962 -0.637 . . . . 0.17 111.828 178.678 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.484 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.35 133.03 44.23 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.153 0.501 . . . . 0.65 111.89 -176.791 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.436 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 86.4 mt -108.23 132.1 21.31 Favored Pre-proline 0 C--N 1.318 -0.763 0 CA-C-N 115.728 -0.669 . . . . 0.29 109.811 172.733 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 21.7 Cg_exo -64.02 123.48 11.97 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.713 2.275 . . . . 0.25 111.889 -178.861 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 m -114.53 160.12 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 CA-C-O 121.265 0.555 . . . . 0.42 111.274 -178.086 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.415 HG22 ' HG ' ' A' ' 84' ' ' LEU . 26.8 m -142.29 137.0 30.31 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.252 -0.885 . . . . 2.07 109.494 176.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.415 ' HG ' HG22 ' A' ' 83' ' ' THR . 96.5 mt . . . . . 0 C--O 1.245 0.862 0 O-C-N 123.725 0.641 . . . . 3.91 111.264 -179.25 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.535 0 N-CA-C 111.773 -0.531 . . . . 5.63 111.773 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.488 ' HB3' HG22 ' A' ' 50' ' ' ILE . 25.8 t -71.93 -36.65 70.01 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 110.313 -0.254 . . . . 4.28 110.313 178.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.413 ' HB2' ' O ' ' A' ' 2' ' ' SER . 69.4 m95 70.27 -70.84 0.14 Allowed 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.63 -0.714 . . . . 4.74 111.985 178.414 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 80.16 87.19 0.57 Allowed Glycine 0 N--CA 1.444 -0.781 0 C-N-CA 120.373 -0.918 . . . . 2.03 111.339 -173.76 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 87.8 mm-40 -72.58 133.29 44.65 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.927 0.394 . . . . 4.17 110.439 -179.004 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.429 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 31.4 t -126.58 -87.88 0.58 Allowed 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.905 -0.589 . . . . 1.88 110.431 -178.013 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 48.8 m -159.22 -76.02 0.07 Allowed 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.677 -0.49 . . . . 2.4 109.677 176.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 28.4 p -120.73 -27.28 5.1 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.077 0.465 . . . . 3.75 110.649 177.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -92.21 179.58 40.83 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.67 -0.695 . . . . 1.12 112.486 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.1 t -98.14 151.63 20.2 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.778 -0.453 . . . . 0.96 109.778 -178.245 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.429 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 16.6 mt -103.07 130.94 52.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.641 0.734 . . . . 0.96 111.374 174.292 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.462 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -130.39 168.09 17.52 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 114.656 -1.156 . . . . 0.91 110.138 177.653 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 36.8 t -110.38 101.93 10.61 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.772 -0.649 . . . . 0.34 109.918 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.849 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 96.5 m -87.45 125.01 34.03 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.788 -0.642 . . . . 0.19 111.459 -175.683 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.479 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.2 OUTLIER -69.13 -31.96 71.0 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.06 -0.973 . . . . 0.38 109.818 175.583 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -136.74 108.38 7.0 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.046 -0.525 . . . . 1.03 110.423 177.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 93.2 t -98.94 105.92 18.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 N-CA-C 109.746 -0.465 . . . . 0.18 109.746 177.121 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 m -131.12 142.88 47.14 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 116.012 -0.54 . . . . 0.18 110.763 -176.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.521 ' O ' ' HB3' ' A' ' 22' ' ' SER . 30.9 Cg_exo -61.19 136.91 67.67 Favored 'Trans proline' 0 N--CA 1.461 -0.396 0 C-N-CA 122.161 1.908 . . . . 0.19 111.434 173.2 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.62 -15.03 68.1 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.665 -0.779 . . . . 0.18 111.972 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -103.09 3.66 36.22 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.592 0.71 . . . . 2.27 109.657 176.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.521 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 21.3 t -74.99 155.78 36.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.186 -0.915 . . . . 0.24 110.031 177.198 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -53.68 -44.32 69.63 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.829 0.823 . . . . 1.06 109.142 176.54 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.594 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.2 mm? -67.36 -63.19 1.11 Allowed 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 114.25 -1.341 . . . . 1.11 111.002 177.33 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.38 -39.21 71.95 Favored Glycine 0 C--N 1.33 0.23 0 CA-C-N 116.217 -0.447 . . . . 0.16 113.392 -175.074 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 98.7 m -67.72 -38.74 84.0 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.87 0.366 . . . . 0.24 110.475 -178.679 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -75.44 -27.72 59.06 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 120.934 0.397 . . . . 1.01 110.132 178.594 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.594 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 13.1 mt -69.74 -48.67 58.53 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.185 -0.461 . . . . 0.37 110.182 178.753 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.576 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -76.95 -23.78 52.38 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.571 -0.452 . . . . 0.41 111.549 -175.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.499 ' N ' HD12 ' A' ' 29' ' ' LEU . 18.8 t70 -67.95 -32.81 73.5 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.525 0.678 . . . . 0.66 109.37 175.456 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -75.28 -19.78 59.51 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 114.91 -1.041 . . . . 2.07 109.762 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 80.7 mt -103.37 -6.94 21.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.907 -1.042 . . . . 0.71 111.696 -174.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.97 35.48 84.37 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.958 -0.564 . . . . 0.75 112.566 178.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.576 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 32.2 mt -88.96 138.53 19.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.523 0.201 . . . . 0.68 110.705 -177.683 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.1 p -99.14 110.59 26.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.444 0.64 . . . . 1.87 110.221 175.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.531 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.4 pp -80.74 130.89 35.33 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.915 -0.584 . . . . 2.76 110.725 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -90.34 -29.1 18.3 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.739 -0.837 . . . . 2.65 108.739 173.52 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -142.23 98.41 6.1 Favored Pre-proline 0 N--CA 1.444 -0.772 0 N-CA-C 107.802 -1.184 . . . . 2.29 107.802 176.632 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.01 -9.54 21.98 Favored 'Trans proline' 0 N--CA 1.466 -0.143 0 C-N-CA 121.965 1.777 . . . . 0.64 111.588 -175.392 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 p -80.36 -8.9 59.7 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.623 -0.717 . . . . 0.51 111.497 -175.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.483 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.8 m -76.28 159.72 5.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.266 0.555 . . . . 0.24 111.065 -178.733 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.6 mt -92.53 128.03 38.24 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.498 -0.774 . . . . 0.22 109.556 176.126 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.428 HD13 HD23 ' A' ' 29' ' ' LEU . 15.1 pt -106.32 139.12 28.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 116.011 -0.54 . . . . 0.15 109.995 177.184 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.849 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -107.79 99.37 1.36 Allowed Glycine 0 N--CA 1.437 -1.281 0 C-N-CA 120.633 -0.794 . . . . 0.31 112.967 -175.76 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -78.2 137.12 37.98 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 108.691 -0.855 . . . . 0.57 108.691 173.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.479 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 70.79 39.08 66.01 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 119.914 -1.136 . . . . 0.21 112.252 -177.583 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.568 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -103.61 111.88 24.55 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.335 0.588 . . . . 0.25 110.831 -174.887 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -94.53 136.47 23.18 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 115.269 -0.878 . . . . 2.21 109.242 178.025 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -66.1 119.47 6.5 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 122.303 2.002 . . . . 0.44 110.745 176.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.488 HG22 ' HB3' ' A' ' 2' ' ' SER . 16.8 mt -77.23 88.25 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 121.62 0.724 . . . . 0.46 110.213 -176.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 13.4 t -134.27 8.09 3.68 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.244 -0.889 . . . . 0.88 110.156 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.5 p -98.77 160.13 3.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.304 -0.862 . . . . 1.44 109.201 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . 63.51 -172.15 0.17 Allowed 'General case' 0 C--O 1.233 0.211 0 O-C-N 123.665 0.603 . . . . 2.94 111.099 177.722 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.91 -1.55 6.85 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 121.032 -0.604 . . . . 3.5 111.663 176.665 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 42.1 m -97.25 149.16 22.36 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.783 0.325 . . . . 4.9 110.228 179.294 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 15.1 m -67.12 -26.83 66.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.041 -0.527 . . . . 4.06 110.7 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -83.27 57.68 4.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 122.043 0.925 . . . . 3.13 109.855 178.673 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -104.04 18.32 22.28 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.786 -1.097 . . . . 0.99 109.485 176.121 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.6 t -111.24 153.95 25.14 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.02 -0.991 . . . . 0.74 109.994 -177.513 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.7 m -126.14 18.34 7.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.44 -0.345 . . . . 2.14 111.071 -177.354 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.4 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -163.01 -77.69 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 112.015 0.376 . . . . 0.54 112.015 -178.394 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 74.8 m -147.61 131.33 16.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.806 0.336 . . . . 0.29 111.417 -176.425 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -88.13 125.72 34.74 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.039 -0.528 . . . . 0.25 109.93 177.192 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.588 HG21 ' SG ' ' A' ' 14' ' ' CYS . 6.8 m -138.89 159.96 30.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-N 115.964 -0.562 . . . . 0.21 110.949 -178.608 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 53.6 t -117.91 103.41 9.91 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.602 -0.726 . . . . 0.39 109.727 179.597 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.734 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 20.1 m -91.75 132.55 36.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.36 0.6 . . . . 0.65 111.402 -176.35 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 10.9 m -94.78 -15.78 23.53 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.314 -0.857 . . . . 1.15 111.29 -177.564 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.423 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 9.7 t70 -109.98 131.94 54.61 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.623 -0.51 . . . . 1.6 109.623 -178.516 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -108.12 20.95 18.05 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.489 0.551 . . . . 2.49 112.489 -172.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 50.8 m-80 -83.38 61.91 6.44 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.5 0.667 . . . . 2.27 110.123 177.023 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 m -73.66 149.01 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 CA-C-N 115.541 -0.754 . . . . 1.1 111.181 -178.481 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.6 ' OG ' HG12 ' A' ' 75' ' ' ILE . 82.0 p -95.4 -5.93 42.09 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.887 -0.597 . . . . 1.41 110.34 179.035 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.12 -31.84 3.57 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.675 -0.693 . . . . 0.48 112.409 -176.022 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.0 m -136.59 -8.22 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 117.185 0.493 . . . . 0.49 111.961 177.68 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.6 HG12 ' OG ' ' A' ' 72' ' ' SER . 21.7 pt -94.63 179.7 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.642 0.734 . . . . 0.3 111.979 -178.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.734 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.22 145.33 26.17 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.007 -1.452 . . . . 0.18 108.502 176.179 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.423 ' HB ' ' HB3' ' A' ' 68' ' ' ASP . 58.9 mt -125.75 142.19 43.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 120.717 -0.393 . . . . 0.26 111.402 -175.321 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.483 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 69.34 50.55 31.96 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.115 -0.564 . . . . 0.17 111.898 178.469 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.566 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 9.0 m -103.86 131.55 50.96 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.158 0.504 . . . . 0.65 111.8 -173.292 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.437 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.8 mt -105.9 134.68 19.62 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.735 -0.666 . . . . 0.29 109.859 173.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 17.1 Cg_exo -66.09 122.58 10.14 Favored 'Trans proline' 0 N--CA 1.465 -0.204 0 C-N-CA 122.75 2.3 . . . . 0.25 111.789 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.1 m -111.55 153.06 13.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.445 0.641 . . . . 0.42 111.35 -177.446 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.499 HG22 HD13 ' A' ' 84' ' ' LEU . 49.3 m -157.52 128.36 6.57 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.927 -1.033 . . . . 2.07 109.914 179.185 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.499 HD13 HG22 ' A' ' 83' ' ' THR . 11.0 mp . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.396 -0.811 . . . . 3.91 112.281 178.763 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.877 0 N-CA-C 112.276 -0.33 . . . . 5.63 112.276 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.9 m -79.82 -68.54 0.66 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.744 0.272 . . . . 4.28 110.757 -178.368 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -135.48 16.04 3.41 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-O 121.069 0.461 . . . . 4.74 110.396 -179.634 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.52 ' HA3' ' HB ' ' A' ' 11' ' ' ILE . . . 89.31 110.19 1.23 Allowed Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 115.631 -0.713 . . . . 2.03 112.44 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 13.4 mm-40 -76.13 109.52 9.87 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.642 -0.503 . . . . 4.17 109.642 177.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 14.1 t -131.78 -70.95 0.56 Allowed 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.42 -0.355 . . . . 1.88 111.077 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.7 p -168.05 -81.73 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.892 0.377 . . . . 2.4 110.568 -177.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.8 m -120.5 -31.05 4.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.935 0.398 . . . . 3.75 110.91 178.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -88.78 -132.05 4.17 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.955 -0.64 . . . . 1.12 113.232 -176.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.4 t -145.36 152.63 40.18 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.14 -0.689 . . . . 0.96 109.14 -175.577 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.52 ' HB ' ' HA3' ' A' ' 4' ' ' GLY . 40.6 mt -100.72 135.02 38.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.711 0.767 . . . . 0.96 111.122 176.436 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.593 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -132.28 165.61 23.78 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.702 -1.136 . . . . 0.91 109.82 177.058 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.5 t -112.29 101.39 9.61 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.891 -0.595 . . . . 0.34 109.409 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.812 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 68.5 m -84.32 130.22 34.82 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 115.326 -0.852 . . . . 0.19 110.988 -176.374 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -69.48 -30.63 68.56 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.26 -0.882 . . . . 0.38 109.053 172.849 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -141.16 121.02 13.54 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.972 -0.558 . . . . 1.03 110.538 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.6 t -109.06 107.78 23.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 109.969 -0.382 . . . . 0.18 109.969 176.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 20.8 m -133.39 145.97 58.77 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.153 -0.476 . . . . 0.18 110.777 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.471 ' HB2' ' HB2' ' A' ' 22' ' ' SER . 22.5 Cg_exo -63.42 137.37 59.84 Favored 'Trans proline' 0 N--CA 1.463 -0.309 0 C-N-CA 121.936 1.757 . . . . 0.19 110.934 171.547 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.45 -26.94 71.1 Favored Glycine 0 C--O 1.228 -0.232 0 C-N-CA 121.018 -0.611 . . . . 0.18 112.501 -177.295 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -98.18 9.15 43.62 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.099 0.476 . . . . 2.27 110.249 177.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.471 ' HB2' ' HB2' ' A' ' 19' ' ' PRO . 30.7 t -78.53 155.82 29.56 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 115.786 -0.643 . . . . 0.24 109.816 176.088 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -54.31 -41.68 69.25 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.001 0.429 . . . . 1.06 109.922 178.155 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.701 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.1 mm? -69.37 -60.27 2.45 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.648 -0.706 . . . . 1.11 110.94 177.837 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.93 -39.58 69.14 Favored Glycine 0 C--N 1.328 0.126 0 CA-C-N 116.203 -0.453 . . . . 0.16 113.216 -176.255 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.6 m -70.36 -41.48 73.09 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.974 0.416 . . . . 0.24 110.388 -177.413 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.418 HD22 ' HA ' ' A' ' 27' ' ' LEU . 1.1 tm? -63.75 -40.42 96.67 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.308 -0.627 . . . . 1.01 109.308 177.84 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.701 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.5 mt -68.05 -43.75 77.96 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.533 -0.758 . . . . 0.37 110.857 -175.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.545 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -76.54 -24.34 53.64 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.944 -0.302 . . . . 0.41 111.051 -178.005 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.487 ' N ' HD12 ' A' ' 29' ' ' LEU . 24.6 t70 -67.38 -31.28 71.4 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.406 0.622 . . . . 0.66 109.647 175.558 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -74.51 -38.7 62.75 Favored 'General case' 0 N--CA 1.443 -0.796 0 CA-C-N 115.037 -0.983 . . . . 2.07 109.513 177.695 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.7 mt -79.08 -20.17 49.44 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.522 -1.217 . . . . 0.71 111.921 -177.454 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.08 48.18 6.17 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.177 -0.535 . . . . 0.75 112.164 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.545 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 16.3 mt -110.92 142.83 22.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 110.449 -0.204 . . . . 0.68 110.449 -178.473 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.403 HG13 ' O ' ' A' ' 35' ' ' VAL . 6.5 p -126.54 103.47 11.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.596 0.712 . . . . 1.87 110.16 174.161 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.2 mt -87.6 137.25 32.5 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.825 -0.625 . . . . 2.76 110.824 -178.651 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -68.67 -36.78 78.98 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.661 -0.7 . . . . 2.65 109.442 175.072 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -132.88 88.86 36.21 Favored Pre-proline 0 N--CA 1.444 -0.764 0 N-CA-C 108.849 -0.797 . . . . 2.29 108.849 175.527 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -72.23 3.38 4.1 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.361 2.041 . . . . 0.64 111.56 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.2 p -75.77 -8.31 56.55 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.62 -0.718 . . . . 0.51 111.063 -178.435 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.1 m -82.41 162.76 3.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 116.055 -0.52 . . . . 0.24 110.561 176.479 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.407 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 94.8 mt -83.69 126.17 32.61 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.048 -0.524 . . . . 0.22 110.328 177.405 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 24.1 pt -107.6 140.77 24.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.244 0.545 . . . . 0.15 110.226 175.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.812 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -111.99 105.21 1.75 Allowed Glycine 0 N--CA 1.44 -1.094 0 C-N-CA 120.57 -0.824 . . . . 0.31 112.87 -177.11 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -83.06 132.39 35.12 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.057 -0.72 . . . . 0.57 109.057 176.009 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.93 38.01 24.24 Favored Glycine 0 N--CA 1.443 -0.86 0 C-N-CA 119.89 -1.148 . . . . 0.21 111.709 -178.01 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.93 111.76 24.54 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.043 0.449 . . . . 0.25 111.22 -174.017 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -100.61 134.67 20.45 Favored Pre-proline 0 C--N 1.315 -0.925 0 CA-C-N 115.647 -0.706 . . . . 2.21 109.269 174.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -59.96 130.8 36.23 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.908 2.405 . . . . 0.44 111.609 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.472 HD12 HG22 ' A' ' 11' ' ' ILE . 21.1 mt -83.78 88.94 2.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.68 0.753 . . . . 0.46 109.475 -179.468 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 8.8 t -114.46 28.42 8.75 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.789 -1.096 . . . . 0.88 109.3 -178.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.445 HG22 ' H ' ' A' ' 54' ' ' GLY . 14.6 p -107.22 143.8 17.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.511 -1.222 . . . . 1.44 109.827 -179.54 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -87.24 -25.01 24.2 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.445 -0.343 . . . . 2.94 111.6 -177.675 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.445 ' H ' HG22 ' A' ' 52' ' ' VAL . . . -74.4 109.91 2.93 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.975 -0.631 . . . . 3.5 112.015 178.456 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 19.4 m -70.49 -17.9 62.97 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.862 0.363 . . . . 4.9 111.517 -176.4 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 22.9 t -70.79 -28.11 64.41 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.338 -0.392 . . . . 4.06 110.872 -178.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -124.8 27.88 6.67 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.933 0.397 . . . . 3.13 110.715 -178.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -67.63 -30.04 69.51 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.252 0.549 . . . . 0.99 111.495 -177.102 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.7 t -154.16 146.17 23.61 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.887 -0.597 . . . . 0.74 110.858 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 27.3 p -117.06 5.38 12.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.179 -0.464 . . . . 2.14 111.509 -179.084 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -146.8 -80.99 0.14 Allowed 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 120.966 -0.293 . . . . 0.54 111.776 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 28.4 m -142.05 126.88 18.16 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.815 0.341 . . . . 0.29 111.234 -178.263 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.67 128.98 35.04 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.926 0.393 . . . . 0.25 110.254 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.667 HG21 ' SG ' ' A' ' 14' ' ' CYS . 4.6 m -142.4 165.96 16.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.138 -0.483 . . . . 0.21 111.208 -177.33 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' CYS . . . . . 0.566 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 40.6 t -127.72 109.27 11.49 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.819 -0.628 . . . . 0.39 110.259 -178.531 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.743 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.6 m -97.46 140.49 31.83 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.397 0.618 . . . . 0.65 111.808 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 65.2 m -99.85 -12.73 19.62 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.14 -0.936 . . . . 1.15 111.501 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -110.33 149.99 29.4 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.02 -0.363 . . . . 1.6 110.02 -178.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 42.8 m-80 -120.35 12.42 11.69 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.639 0.607 . . . . 2.49 112.639 -173.363 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -81.62 71.84 8.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.773 0.796 . . . . 2.27 109.37 177.55 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 34.3 m -94.35 152.18 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 CA-C-N 115.457 -0.792 . . . . 1.1 111.172 -175.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.54 ' H ' HG12 ' A' ' 75' ' ' ILE . 90.4 p -86.97 -8.68 56.98 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.657 -0.701 . . . . 1.41 110.309 178.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.92 -32.02 3.74 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 115.285 -0.87 . . . . 0.48 111.954 -176.471 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.9 m -132.84 -2.58 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 C-N-CA 120.517 -0.473 . . . . 0.49 112.007 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.54 HG12 ' H ' ' A' ' 72' ' ' SER . 23.5 pt -100.73 178.77 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.495 0.664 . . . . 0.3 111.924 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.743 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -148.26 139.71 23.54 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.575 -1.193 . . . . 0.18 109.393 177.061 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 68.9 mt -121.73 130.19 74.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.938 0.399 . . . . 0.26 111.301 -176.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 82.0 46.43 6.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.995 -0.621 . . . . 0.17 111.777 178.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.566 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -99.38 144.25 28.71 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.288 0.566 . . . . 0.65 112.387 -175.153 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 87.7 mt -119.81 134.11 23.91 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.246 -0.888 . . . . 0.29 109.743 172.092 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 21.6 Cg_exo -64.67 121.47 9.03 Favored 'Trans proline' 0 C--O 1.234 0.298 0 C-N-CA 123.034 2.489 . . . . 0.25 112.348 -179.347 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.8 m -123.03 150.59 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 CA-C-N 116.039 -0.528 . . . . 0.42 110.629 -179.724 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 3.0 t -161.11 159.58 29.27 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.864 -0.607 . . . . 2.07 109.785 177.61 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 11.1 mp . . . . . 0 C--O 1.247 0.96 0 CA-C-O 118.1 -0.953 . . . . 3.91 111.579 -179.281 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.819 0 N-CA-C 112.149 -0.38 . . . . 5.63 112.149 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 34.3 t -133.91 105.74 6.91 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.692 -0.485 . . . . 4.28 109.692 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.643 ' HB2' ' HA ' ' A' ' 51' ' ' THR . 69.2 t-105 -79.64 83.0 5.67 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.378 -0.601 . . . . 4.74 109.378 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 129.72 128.5 3.03 Favored Glycine 0 N--CA 1.442 -0.911 0 N-CA-C 110.924 -0.87 . . . . 2.03 110.924 -175.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -78.81 119.24 21.73 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.964 0.412 . . . . 4.17 110.607 -177.858 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.444 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 34.5 t -79.3 -67.63 0.74 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.801 -0.636 . . . . 1.88 110.129 178.067 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.7 p -176.02 -76.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.924 -0.58 . . . . 2.4 110.229 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.4 m -118.57 -28.32 5.7 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.934 0.397 . . . . 3.75 111.165 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -103.08 -145.78 15.99 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.581 -0.819 . . . . 1.12 113.376 -176.452 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.1 t -128.05 153.43 46.79 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 109.014 -0.736 . . . . 0.96 109.014 -177.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.444 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 51.5 mt -99.9 134.75 38.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.606 0.717 . . . . 0.96 111.344 178.079 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.628 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -142.95 162.22 36.05 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.063 -0.971 . . . . 0.91 111.043 178.996 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 19.4 t -106.68 102.26 11.65 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.46 -0.791 . . . . 0.34 109.483 178.74 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.893 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 57.6 m -86.75 133.54 33.65 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.934 -0.575 . . . . 0.19 111.017 -175.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.12 -30.42 49.41 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.185 -0.916 . . . . 0.38 109.435 177.016 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.636 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 17.1 m-20 -134.28 103.21 5.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.438 -0.346 . . . . 1.03 111.306 175.172 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.1 t -92.52 101.68 12.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.214 0.53 . . . . 0.18 109.727 174.691 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 m -131.71 140.38 38.11 Favored Pre-proline 0 C--N 1.319 -0.717 0 CA-C-N 115.748 -0.66 . . . . 0.18 110.75 -174.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.528 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.7 Cg_exo -57.94 138.75 87.56 Favored 'Trans proline' 0 N--CA 1.463 -0.302 0 C-N-CA 122.195 1.93 . . . . 0.19 111.304 172.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.29 -21.99 68.84 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.939 -0.648 . . . . 0.18 112.596 -178.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -101.2 4.94 42.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.239 0.542 . . . . 2.27 109.837 176.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.528 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 16.6 t -69.32 153.95 42.81 Favored 'General case' 0 CA--C 1.514 -0.438 0 CA-C-N 115.778 -0.646 . . . . 0.24 109.68 175.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -56.63 -38.42 72.09 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-O 121.122 0.487 . . . . 1.06 110.035 178.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.686 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 5.3 mt -70.19 -63.45 1.08 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.58 -0.737 . . . . 1.11 110.853 174.06 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.54 -40.87 55.52 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 116.035 -0.53 . . . . 0.16 113.443 -174.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 93.4 m -68.16 -44.53 75.77 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.761 0.315 . . . . 0.24 110.484 -178.521 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.4 tt -63.43 -35.52 80.71 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.075 -0.511 . . . . 1.01 110.814 178.375 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.686 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.3 mt -72.49 -46.09 56.41 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.096 -0.502 . . . . 0.37 110.365 -177.543 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.612 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -75.03 -21.76 58.85 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.71 -0.396 . . . . 0.41 110.934 -178.133 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -66.24 -32.22 73.51 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.708 0.766 . . . . 0.66 109.712 173.164 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -77.37 -47.7 19.19 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 114.906 -1.043 . . . . 2.07 109.261 177.103 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 72.4 mt -78.22 -13.11 59.99 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.705 -1.134 . . . . 0.71 112.893 -174.479 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.49 37.57 90.04 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-N 116.131 -0.486 . . . . 0.75 112.473 178.492 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.612 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 55.8 mt -75.46 137.35 23.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.104 0.478 . . . . 0.68 111.718 -173.265 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.4 p -88.11 113.55 25.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.687 -0.688 . . . . 1.87 110.762 175.471 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.457 ' H ' ' HG ' ' A' ' 36' ' ' LEU . 1.2 pp -103.0 134.6 46.17 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.03 -0.532 . . . . 2.76 110.796 177.589 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -90.06 -32.28 16.79 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.021 -1.104 . . . . 2.65 108.021 171.084 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -139.93 106.76 6.86 Favored Pre-proline 0 N--CA 1.446 -0.631 0 CA-C-N 114.588 -1.187 . . . . 2.29 108.227 174.771 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -71.9 -2.24 11.19 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.072 1.848 . . . . 0.64 111.327 -178.011 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.6 p -94.94 20.2 9.23 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.479 -0.782 . . . . 0.51 111.157 -175.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.2 m -105.77 160.83 5.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.81 -0.632 . . . . 0.24 110.226 178.289 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.405 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.6 mt -81.29 119.81 24.12 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.034 -0.53 . . . . 0.22 110.244 175.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 19.4 pt -104.06 137.11 34.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.871 -0.604 . . . . 0.15 109.684 175.026 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.893 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.91 106.75 1.78 Allowed Glycine 0 N--CA 1.438 -1.176 0 C-N-CA 120.538 -0.839 . . . . 0.31 113.05 -174.544 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.636 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 26.0 t70 -77.48 145.18 37.2 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 108.887 -0.783 . . . . 0.57 108.887 174.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 69.71 37.3 76.45 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 119.884 -1.15 . . . . 0.21 112.221 177.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.534 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -101.35 114.4 28.36 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.387 0.613 . . . . 0.25 111.215 -172.712 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.531 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 0.7 OUTLIER -101.54 130.98 23.56 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 115.4 -0.818 . . . . 2.21 109.702 177.438 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -56.48 120.39 8.24 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 C-N-CA 122.436 2.091 . . . . 0.44 111.102 177.638 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.406 HG13 ' HA ' ' A' ' 12' ' ' GLN . 43.7 mt -80.18 101.66 5.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.158 0.504 . . . . 0.46 110.587 -174.713 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.643 ' HA ' ' HB2' ' A' ' 3' ' ' TRP . 4.4 t -139.3 18.37 2.58 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 122.159 0.981 . . . . 0.88 109.989 177.42 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 12.2 p -91.55 142.97 12.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.042 -0.981 . . . . 1.44 109.655 175.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -107.42 120.06 41.13 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.882 0.372 . . . . 2.94 110.776 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -163.45 -154.09 7.56 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 111.662 -0.575 . . . . 3.5 111.662 179.159 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -94.34 -58.82 2.1 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.567 -0.531 . . . . 4.9 109.567 178.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.2 t -130.24 22.3 5.23 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.814 -0.81 . . . . 4.06 108.814 174.124 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -73.41 -15.95 61.34 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.81 -1.086 . . . . 3.13 111.037 -177.352 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -61.07 -31.22 70.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.804 -0.635 . . . . 0.99 112.467 -173.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 40.1 t -165.12 146.83 7.73 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-O 120.94 0.4 . . . . 0.74 111.261 -177.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 8.9 t -119.11 -13.63 9.37 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.974 -0.557 . . . . 2.14 110.782 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.12 -83.59 0.57 Allowed 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 121.121 -0.232 . . . . 0.54 110.86 -179.305 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 54.4 m -150.39 127.45 11.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.699 0.285 . . . . 0.29 110.551 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.44 140.58 29.85 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.03 0.443 . . . . 0.25 110.483 -178.049 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.656 HG21 ' SG ' ' A' ' 14' ' ' CYS . 2.7 m -147.78 170.38 3.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.229 0.538 . . . . 0.21 111.404 -176.651 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' CYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 50.3 t -129.6 107.97 9.86 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.319 -0.855 . . . . 0.39 109.788 178.891 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.724 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -99.58 138.89 36.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.286 0.565 . . . . 0.65 111.82 -177.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 50.4 m -99.69 -19.1 16.95 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.492 -0.776 . . . . 1.15 111.731 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.409 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 16.4 t70 -101.54 148.95 24.6 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.925 -0.398 . . . . 1.6 109.925 -177.051 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -120.18 18.51 12.31 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.581 0.586 . . . . 2.49 112.581 -173.685 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.415 ' HB2' HD12 ' A' ' 77' ' ' ILE . 42.9 m-80 -79.24 63.9 4.0 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.544 0.688 . . . . 2.27 109.967 176.489 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.886 HG12 ' H ' ' A' ' 73' ' ' GLY . 87.2 t -90.37 136.19 24.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.414 -0.812 . . . . 1.1 111.23 -173.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.671 ' H ' HG12 ' A' ' 75' ' ' ILE . 87.3 p -79.2 -3.01 43.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.345 -0.843 . . . . 1.41 110.939 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.886 ' H ' HG12 ' A' ' 71' ' ' VAL . . . 127.85 -31.56 3.69 Favored Glycine 0 N--CA 1.443 -0.868 0 CA-C-N 115.367 -0.833 . . . . 0.48 112.195 -176.723 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 17.2 m -138.68 -7.62 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 112.641 0.608 . . . . 0.49 112.641 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.671 HG12 ' H ' ' A' ' 72' ' ' SER . 7.2 pt -84.97 -178.54 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.581 0.705 . . . . 0.3 112.142 -178.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.724 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -149.43 139.2 21.83 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.639 -1.164 . . . . 0.18 109.51 175.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.415 HD12 ' HB2' ' A' ' 70' ' ' ASN . 65.3 mt -124.49 134.99 65.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.931 0.396 . . . . 0.26 111.364 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.512 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 79.21 47.98 7.17 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 121.002 -0.618 . . . . 0.17 111.785 179.377 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.557 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -100.14 136.73 39.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.24 0.543 . . . . 0.65 112.456 -175.367 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 93.7 mt -108.1 134.08 20.28 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 115.474 -0.784 . . . . 0.29 109.345 168.438 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.456 ' HA ' HG12 ' A' ' 64' ' ' VAL . 20.5 Cg_exo -64.3 128.35 21.29 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.937 2.424 . . . . 0.25 112.474 -178.45 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.0 m -133.05 160.51 42.56 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.911 0 CA-C-N 115.878 -0.601 . . . . 0.42 109.658 177.012 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.44 HG22 ' HG ' ' A' ' 84' ' ' LEU . 50.6 m -144.58 149.37 35.69 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 110.25 -0.278 . . . . 2.07 110.25 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.44 ' HG ' HG22 ' A' ' 83' ' ' THR . 86.3 mt . . . . . 0 C--O 1.246 0.899 0 CA-C-O 117.953 -1.022 . . . . 3.91 110.897 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.846 0 N-CA-C 111.76 -0.536 . . . . 5.63 111.76 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 39.4 m 59.2 79.44 0.22 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.338 0.59 . . . . 4.28 110.057 -176.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.424 ' HA ' ' HA ' ' A' ' 51' ' ' THR . 34.4 p90 -111.6 179.83 3.91 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.5 -0.773 . . . . 4.74 111.062 -175.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -63.52 106.09 1.26 Allowed Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 121.07 -0.586 . . . . 2.03 112.404 179.132 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -82.38 110.44 17.53 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.997 0.427 . . . . 4.17 110.206 178.528 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.483 ' HB2' HG13 ' A' ' 11' ' ' ILE . 52.2 t -94.89 -64.65 1.04 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.886 -0.597 . . . . 1.88 110.896 -176.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 7.5 t -172.04 -69.98 0.02 OUTLIER 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 116.215 -0.448 . . . . 2.4 110.145 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 12.1 m -121.42 -30.93 4.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.241 0.543 . . . . 3.75 111.013 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -90.45 -136.85 6.69 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.818 -0.705 . . . . 1.12 112.138 -178.647 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 28.6 t -145.92 144.27 30.07 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.87 -0.418 . . . . 0.96 109.87 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.483 HG13 ' HB2' ' A' ' 6' ' ' CYS . 38.6 mt -91.65 133.35 33.49 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.559 0 CA-C-O 121.737 0.78 . . . . 0.96 110.547 177.77 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.488 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -142.92 162.29 35.85 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 114.585 -1.189 . . . . 0.91 110.569 -175.006 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 26.6 t -111.44 101.69 10.12 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.846 -0.615 . . . . 0.34 109.847 -176.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.787 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 86.7 m -87.31 134.45 33.56 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.232 -0.895 . . . . 0.19 110.89 -175.561 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.43 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -76.1 -27.68 57.23 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 115.37 -0.832 . . . . 0.38 109.665 178.404 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -143.78 103.94 4.12 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.769 -0.651 . . . . 1.03 110.473 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 67.4 t -93.57 108.14 20.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 CA-C-N 116.062 -0.517 . . . . 0.18 109.688 178.253 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.05 146.12 60.3 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 116.032 -0.531 . . . . 0.18 110.757 -175.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.513 ' O ' ' HB3' ' A' ' 22' ' ' SER . 22.6 Cg_exo -62.79 136.94 60.35 Favored 'Trans proline' 0 N--CA 1.461 -0.401 0 C-N-CA 122.12 1.88 . . . . 0.19 111.181 173.05 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.93 -23.03 72.58 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.946 -0.645 . . . . 0.18 112.64 -176.472 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -101.07 9.92 41.58 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.724 0.774 . . . . 2.27 109.813 177.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.513 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.6 t -78.77 156.36 28.87 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.52 -0.764 . . . . 0.24 109.921 175.683 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -53.9 -40.94 67.07 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.201 0.524 . . . . 1.06 109.773 176.029 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.674 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER -67.88 -63.1 1.13 Allowed 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 115.462 -0.79 . . . . 1.11 111.046 176.796 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.411 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -57.01 -38.74 87.27 Favored Glycine 0 C--N 1.33 0.24 0 CA-C-N 115.999 -0.546 . . . . 0.16 113.304 -175.031 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.0 m -69.22 -40.64 77.85 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.646 0.26 . . . . 0.24 110.462 -178.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -62.99 -38.62 91.9 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.41 -0.589 . . . . 1.01 109.41 176.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.674 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.3 mt -67.82 -53.5 26.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.809 -0.632 . . . . 0.37 110.84 -177.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.554 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -70.87 -20.82 62.48 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.992 -0.283 . . . . 0.41 111.363 -176.584 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.425 ' N ' HD12 ' A' ' 29' ' ' LEU . 24.1 t70 -62.87 -38.95 92.9 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.602 0.715 . . . . 0.66 110.039 173.429 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -73.36 -16.97 61.33 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 114.816 -1.084 . . . . 2.07 109.615 -179.217 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.8 mt -105.86 -13.9 15.38 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.808 -1.087 . . . . 0.71 111.917 -174.434 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 71.82 42.71 52.65 Favored Glycine 0 C--N 1.331 0.302 0 CA-C-N 115.722 -0.672 . . . . 0.75 112.868 178.335 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.554 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 32.7 mt -101.2 124.92 55.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.689 0.28 . . . . 0.68 111.066 -176.756 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.6 p -110.43 102.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.814 0.816 . . . . 1.87 110.36 176.362 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.1 mt -85.95 141.9 29.2 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.556 -0.747 . . . . 2.76 111.094 -178.078 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -74.65 -23.58 58.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.552 0.692 . . . . 2.65 109.701 175.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -136.37 91.52 16.39 Favored Pre-proline 0 N--CA 1.447 -0.616 0 N-CA-C 108.22 -1.03 . . . . 2.29 108.22 172.512 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -66.18 -2.87 7.62 Favored 'Trans proline' 0 C--O 1.224 -0.22 0 C-N-CA 122.367 2.045 . . . . 0.64 111.808 -177.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 25.2 p -78.59 -12.67 60.03 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.577 -0.738 . . . . 0.51 111.322 -177.294 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 33.3 m -70.55 156.63 7.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.152 0.501 . . . . 0.24 111.295 -178.465 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 95.4 mt -86.38 129.09 34.97 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.778 -0.646 . . . . 0.22 110.333 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.406 HD13 HD23 ' A' ' 29' ' ' LEU . 23.7 pt -112.23 144.33 20.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.991 -0.55 . . . . 0.15 110.115 176.811 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.787 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.61 106.67 1.42 Allowed Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.48 -0.866 . . . . 0.31 113.102 -176.168 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -78.33 140.55 38.78 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.252 -0.647 . . . . 0.57 109.252 175.333 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 73.59 39.42 49.43 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.141 -1.028 . . . . 0.21 111.999 179.277 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.539 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.75 115.89 31.09 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.275 0.559 . . . . 0.25 111.346 -172.774 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.474 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.8 t70 -102.33 136.67 19.36 Favored Pre-proline 0 C--N 1.318 -0.78 0 CA-C-N 115.427 -0.806 . . . . 2.21 110.383 173.773 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.474 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 16.5 Cg_exo -60.79 119.61 6.87 Favored 'Trans proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.176 2.584 . . . . 0.44 111.03 178.393 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.45 HG13 ' HA ' ' A' ' 12' ' ' GLN . 43.0 mt -74.66 89.59 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.297 0.57 . . . . 0.46 110.224 -175.733 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.424 ' HA ' ' HA ' ' A' ' 3' ' ' TRP . 14.2 t -125.63 8.91 7.66 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 115.234 -0.894 . . . . 0.88 109.862 179.699 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 12.1 p -84.18 149.0 4.56 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.137 -0.938 . . . . 1.44 109.975 178.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -87.18 69.91 10.11 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.014 0.435 . . . . 2.94 110.697 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -101.28 -6.85 50.54 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.823 -0.703 . . . . 3.5 112.287 -178.608 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 26.7 t 66.08 -84.51 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.051 0.54 . . . . 4.9 110.804 179.794 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 15.9 m -112.62 -7.91 13.84 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.126 0.489 . . . . 4.06 110.196 178.447 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -119.88 68.52 0.83 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.652 -0.704 . . . . 3.13 109.372 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -117.84 8.83 12.74 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.723 -0.671 . . . . 0.99 111.444 -176.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.7 t -139.08 146.61 40.95 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.197 -0.456 . . . . 0.74 109.942 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.5 t -117.31 15.06 14.84 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.737 -0.211 . . . . 2.14 111.532 -176.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.43 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -157.05 -78.0 0.08 Allowed 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.87 -0.332 . . . . 0.54 111.581 178.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 21.6 m -148.59 129.43 14.27 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.774 0.321 . . . . 0.29 110.77 -179.075 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.436 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -90.41 135.88 33.4 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.864 -0.421 . . . . 0.25 109.864 -179.424 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.569 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 6.7 m -143.87 158.55 16.17 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-O 121.277 0.561 . . . . 0.21 111.156 -177.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' CYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 15.0 t -109.35 104.51 13.64 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.338 -0.846 . . . . 0.39 109.476 175.429 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.776 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 61.3 m -91.16 120.96 32.53 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.169 0.509 . . . . 0.65 111.108 -178.035 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 17.6 t -78.22 -21.53 49.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.28 -0.873 . . . . 1.15 110.295 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.7 t0 -105.81 149.09 26.8 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.224 -0.658 . . . . 1.6 109.224 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.3 p30 -118.84 5.64 11.47 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 112.559 0.577 . . . . 2.49 112.559 -175.092 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.455 ' ND2' HD12 ' A' ' 77' ' ' ILE . 1.3 p30 -82.39 112.18 19.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.921 0.867 . . . . 2.27 109.563 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.945 HG12 ' H ' ' A' ' 73' ' ' GLY . 70.8 t -122.12 137.28 56.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.364 -0.835 . . . . 1.1 110.858 -172.485 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.529 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 95.0 p -76.88 -1.41 28.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.654 -0.703 . . . . 1.41 110.94 -178.185 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.945 ' H ' HG12 ' A' ' 71' ' ' VAL . . . 127.88 -31.82 3.62 Favored Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 115.43 -0.804 . . . . 0.48 112.372 -176.521 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.2 m -138.77 -5.92 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.203 0 N-CA-C 112.849 0.685 . . . . 0.49 112.849 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.529 ' CG1' ' H ' ' A' ' 72' ' ' SER . 5.1 pt -92.82 -177.1 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 113.359 0.874 . . . . 0.3 113.359 -174.236 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.776 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.68 142.59 23.87 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 114.117 -1.401 . . . . 0.18 108.602 174.669 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.455 HD12 ' ND2' ' A' ' 70' ' ' ASN . 66.5 mt -126.67 139.94 50.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.275 0.472 . . . . 0.26 112.275 -175.617 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 68.58 51.82 28.96 Favored Glycine 0 C--N 1.335 0.48 0 CA-C-N 115.736 -0.666 . . . . 0.17 111.682 177.411 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 8.3 m -109.0 138.94 44.55 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.049 0.452 . . . . 0.65 111.84 -172.369 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.434 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.8 mt -109.15 132.45 21.22 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.801 -0.636 . . . . 0.29 110.057 173.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.51 ' HA ' HG12 ' A' ' 64' ' ' VAL . 24.5 Cg_exo -63.23 123.06 11.51 Favored 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.194 2.596 . . . . 0.25 113.308 -177.18 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.436 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 9.2 m -128.35 159.48 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 CA-C-N 116.018 -0.537 . . . . 0.42 110.063 177.831 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.543 HG23 ' HG ' ' A' ' 84' ' ' LEU . 5.5 t -154.65 174.86 14.41 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 110.226 -0.287 . . . . 2.07 110.226 177.514 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.543 ' HG ' HG23 ' A' ' 83' ' ' THR . 82.0 mt . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.307 -0.854 . . . . 3.91 111.005 178.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.699 0 N-CA-C 112.175 -0.37 . . . . 5.63 112.175 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 30.7 t -131.27 160.25 35.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.002 -0.369 . . . . 4.28 110.002 -178.323 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 88.6 m95 -109.57 25.32 11.93 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.973 -0.558 . . . . 4.74 109.709 177.154 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.92 16.0 29.54 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.709 -0.678 . . . . 2.03 111.711 -176.173 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 76.3 mt-30 -76.43 124.64 27.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.556 -0.322 . . . . 4.17 111.088 -176.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.487 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 34.8 t -164.32 142.69 7.11 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.031 -0.531 . . . . 1.88 109.909 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 34.2 m -72.68 -14.57 61.61 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 2.4 111.681 -176.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.829 ' HB ' ' SG ' ' A' ' 65' ' ' CYS . 19.1 m -91.07 -28.21 18.1 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.226 0.536 . . . . 3.75 110.041 176.287 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 159.81 -117.04 0.75 Allowed Glycine 0 N--CA 1.446 -0.657 0 CA-C-N 115.806 -0.634 . . . . 1.12 112.131 -179.704 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 32.3 t -105.0 152.08 23.15 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.704 -0.48 . . . . 0.96 109.704 -178.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.487 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 21.0 mt -105.31 133.72 48.79 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.453 0 CA-C-O 121.651 0.739 . . . . 0.96 111.231 177.296 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.613 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -141.47 161.68 37.33 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 114.854 -1.066 . . . . 0.91 110.684 178.885 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.431 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 24.8 t -110.98 103.31 11.77 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.415 -0.812 . . . . 0.34 109.107 178.311 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.792 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 81.8 m -85.75 138.81 31.83 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.461 -0.79 . . . . 0.19 110.678 -175.531 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.405 ' HB3' ' HA3' ' A' ' 46' ' ' GLY . 0.1 OUTLIER -73.98 -35.15 64.45 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.711 -0.848 . . . . 0.38 108.711 175.374 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.783 ' ND2' ' HB3' ' A' ' 45' ' ' ASP . 0.1 OUTLIER -130.02 150.35 51.33 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 109.532 -0.544 . . . . 1.03 109.532 170.909 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.6 t -130.6 101.79 6.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 109.139 -0.689 . . . . 0.18 109.139 173.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.469 HG22 ' OD1' ' A' ' 16' ' ' ASN . 8.8 m -130.8 143.51 49.66 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.981 -0.554 . . . . 0.18 111.513 -173.073 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.435 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.4 Cg_exo -59.2 140.13 93.4 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.499 2.133 . . . . 0.19 111.853 172.8 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.85 -20.96 67.06 Favored Glycine 0 N--CA 1.453 -0.199 0 C-N-CA 120.979 -0.629 . . . . 0.18 112.603 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -103.91 14.98 29.68 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.736 0.779 . . . . 2.27 109.711 176.789 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.435 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.2 t -84.24 154.56 22.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.599 -0.728 . . . . 0.24 109.902 176.555 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -52.25 -41.01 62.44 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.185 0.517 . . . . 1.06 110.496 178.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.68 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 7.6 mt -71.96 -63.17 1.19 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.737 -0.665 . . . . 1.11 110.674 176.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.33 -40.39 53.21 Favored Glycine 0 C--N 1.33 0.212 0 CA-C-N 116.067 -0.515 . . . . 0.16 113.266 -175.48 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 96.5 m -68.62 -45.12 72.74 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.878 0.37 . . . . 0.24 110.826 -177.454 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.432 ' O ' HD13 ' A' ' 27' ' ' LEU . 1.8 tm? -65.38 -37.56 87.35 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.435 -0.58 . . . . 1.01 109.435 178.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.68 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.0 mt -69.42 -43.51 73.23 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.012 -0.54 . . . . 0.37 110.588 -176.726 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.586 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.3 pp -72.23 -26.54 62.07 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.662 -0.415 . . . . 0.41 110.765 -178.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.421 ' N ' HD12 ' A' ' 29' ' ' LEU . 19.5 t70 -66.19 -33.56 76.05 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.711 0.767 . . . . 0.66 109.066 173.399 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 29.3 mm-40 -80.22 -11.62 59.71 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.509 -1.223 . . . . 2.07 111.143 179.452 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.1 mt -115.41 -14.51 11.59 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.899 -0.591 . . . . 0.71 112.187 -174.528 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 78.88 39.68 19.71 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.139 -0.553 . . . . 0.75 112.751 177.054 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.586 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 15.9 mt -96.62 138.39 21.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.624 0.249 . . . . 0.68 110.761 -176.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.3 p -119.39 102.73 13.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.468 0.651 . . . . 1.87 110.264 174.331 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 20.0 mt -86.99 140.09 29.91 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.973 -0.558 . . . . 2.76 110.802 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -75.33 -27.74 59.37 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.936 -0.574 . . . . 2.65 109.752 174.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 61.1 t0 -139.02 104.31 7.36 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 108.663 -0.866 . . . . 2.29 108.663 175.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -72.12 4.03 3.57 Favored 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.518 2.145 . . . . 0.64 112.901 -176.409 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 64.9 p -93.04 2.55 56.72 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 120.445 -0.502 . . . . 0.51 110.936 -177.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.2 m -83.63 159.76 3.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.102 -0.499 . . . . 0.24 110.425 178.036 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.1 mt -88.7 122.24 31.91 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.832 -0.622 . . . . 0.22 110.475 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.5 pt -106.17 134.4 47.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 115.987 -0.551 . . . . 0.15 110.073 176.072 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.792 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -111.16 107.83 2.26 Favored Glycine 0 N--CA 1.443 -0.882 0 C-N-CA 120.593 -0.813 . . . . 0.31 112.908 -176.398 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.783 ' HB3' ' ND2' ' A' ' 16' ' ' ASN . 20.9 t70 -81.44 138.64 35.53 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.441 -0.577 . . . . 0.57 109.441 176.16 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.405 ' HA3' ' HB3' ' A' ' 15' ' ' GLN . . . 78.7 36.66 28.63 Favored Glycine 0 N--CA 1.443 -0.88 0 C-N-CA 120.248 -0.977 . . . . 0.21 111.787 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.4 OUTLIER -105.15 112.75 25.99 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.344 0.592 . . . . 0.25 111.559 -172.4 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -102.82 134.33 19.91 Favored Pre-proline 0 C--N 1.317 -0.828 0 CA-C-N 115.364 -0.834 . . . . 2.21 109.535 173.64 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -59.28 127.2 23.15 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.759 2.306 . . . . 0.44 111.616 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 19.1 mt -82.97 89.1 2.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.479 0.657 . . . . 0.46 109.253 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.9 t -129.1 9.47 5.73 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.075 -0.966 . . . . 0.88 110.212 -177.464 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 14.2 p -99.78 144.97 11.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.15 -0.932 . . . . 1.44 109.775 178.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -86.79 44.65 1.18 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.043 0.449 . . . . 2.94 110.686 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -83.64 77.52 2.11 Favored Glycine 0 N--CA 1.447 -0.583 0 CA-C-N 115.846 -0.616 . . . . 3.5 112.313 -177.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 84.4 p 52.24 -163.22 0.08 Allowed 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 123.682 0.793 . . . . 4.9 112.198 178.577 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.3 m -83.59 -16.62 44.63 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.465 0.65 . . . . 4.06 109.555 174.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -94.18 62.43 3.0 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.298 -0.864 . . . . 3.13 109.065 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -94.28 18.15 11.52 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.346 -0.843 . . . . 0.99 111.796 -177.36 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.1 t -144.44 143.03 30.7 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 110.071 -0.344 . . . . 0.74 110.071 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 8.3 p -102.4 -26.56 13.23 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.313 0.486 . . . . 2.14 112.313 -175.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 14' ' ' CYS . . . -123.14 -75.99 0.59 Allowed 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.56 -0.456 . . . . 0.54 111.91 -176.578 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 31.8 m -146.77 128.73 15.46 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.908 0.385 . . . . 0.29 111.39 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.67 137.89 32.1 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.261 -0.427 . . . . 0.25 110.512 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.606 HG21 ' SG ' ' A' ' 14' ' ' CYS . 2.7 m -146.3 170.45 4.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.037 -0.529 . . . . 0.21 111.302 -177.294 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' CYS . . . . . 0.829 ' SG ' ' HB ' ' A' ' 8' ' ' THR . 41.3 t -132.64 109.68 9.9 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.351 -0.841 . . . . 0.39 109.589 177.127 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.756 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -95.91 137.67 34.64 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.454 0.645 . . . . 0.65 112.041 -178.074 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 33.0 t -82.88 -18.91 38.58 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 114.865 -1.061 . . . . 1.15 110.586 178.245 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -110.84 147.29 34.85 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.101 0.477 . . . . 1.6 111.151 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -115.62 4.48 14.14 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.637 -0.71 . . . . 2.49 110.522 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -75.67 73.81 2.66 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.34 0.591 . . . . 2.27 110.446 178.532 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 33.6 m -89.57 146.8 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 CA-C-N 115.801 -0.636 . . . . 1.1 110.947 -177.604 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.421 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 44.8 m -89.52 10.43 22.89 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.084 -0.507 . . . . 1.41 110.703 178.212 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.26 -33.93 3.2 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.561 -0.745 . . . . 0.48 113.552 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.6 m -140.57 -2.85 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 117.743 0.772 . . . . 0.49 112.218 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.421 ' CG1' ' H ' ' A' ' 72' ' ' SER . 16.4 pt -93.71 -176.45 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.769 0.795 . . . . 0.3 112.567 -176.432 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.756 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -147.53 137.82 23.13 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 114.206 -1.361 . . . . 0.18 108.745 174.049 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 70.4 mt -117.52 126.39 74.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.002 0.43 . . . . 0.26 111.628 -176.375 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.51 52.62 5.45 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.845 -0.616 . . . . 0.17 111.798 177.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.42 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 1.3 m -99.03 137.52 37.44 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 112.424 0.527 . . . . 0.65 112.424 -176.257 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 86.3 mt -105.36 131.49 21.71 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.505 -0.771 . . . . 0.29 109.719 170.302 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.438 ' HA ' HG12 ' A' ' 64' ' ' VAL . 19.1 Cg_exo -65.81 121.95 9.44 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.973 2.449 . . . . 0.25 112.303 -179.131 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.414 ' O ' ' HB ' ' A' ' 83' ' ' THR . 5.3 m -122.72 152.57 27.25 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 CA-C-N 116.275 -0.421 . . . . 0.42 110.147 178.801 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.416 HG22 ' HG ' ' A' ' 84' ' ' LEU . 67.4 m 67.25 137.86 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.448 0 O-C-N 123.761 0.663 . . . . 2.07 111.654 -177.399 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.416 ' HG ' HG22 ' A' ' 83' ' ' THR . 89.5 mt . . . . . 0 C--O 1.251 1.149 0 CA-C-O 117.977 -1.011 . . . . 3.91 110.994 -178.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.798 0 N-CA-C 111.833 -0.507 . . . . 5.63 111.833 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.466 ' O ' ' HA ' ' A' ' 51' ' ' THR . 23.3 t -130.63 100.42 5.3 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.924 -0.399 . . . . 4.28 109.924 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 19.2 m-90 -84.51 127.51 34.08 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.1 -0.5 . . . . 4.74 110.482 -177.39 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -73.65 115.83 5.17 Favored Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.883 -0.599 . . . . 2.03 111.806 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -70.84 131.79 44.32 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 120.98 0.419 . . . . 4.17 110.319 178.759 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.412 ' O ' ' HB3' ' A' ' 7' ' ' SER . 30.3 t -119.88 -15.65 8.8 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.759 -0.655 . . . . 1.88 110.971 -177.229 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.412 ' HB3' ' O ' ' A' ' 6' ' ' CYS . 47.4 t 73.02 -50.35 0.7 Allowed 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.383 0.673 . . . . 2.4 110.923 -177.381 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.5 m -65.33 -28.19 69.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.311 0.576 . . . . 3.75 110.264 177.2 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 172.65 -146.39 9.11 Favored Glycine 0 N--CA 1.444 -0.823 0 CA-C-N 115.426 -0.806 . . . . 1.12 111.87 179.079 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.0 t -101.68 151.74 21.66 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.137 -0.69 . . . . 0.96 109.137 -179.106 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 45.9 mt -102.08 136.76 32.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.629 0.728 . . . . 0.96 111.544 -179.131 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.526 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -144.13 169.27 18.18 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.97 -1.014 . . . . 0.91 110.556 -179.717 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 14.7 t -118.15 103.51 9.94 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.708 -0.678 . . . . 0.34 109.731 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.828 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 98.9 m -85.68 134.67 33.96 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.397 -0.819 . . . . 0.19 111.196 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.407 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -72.77 -30.05 63.8 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.162 -0.926 . . . . 0.38 109.082 174.652 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -139.66 115.74 10.36 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.611 -0.722 . . . . 1.03 110.369 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 88.9 t -105.53 105.45 18.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-O 120.927 0.394 . . . . 0.18 110.048 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.6 m -132.37 139.92 36.34 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 115.936 -0.574 . . . . 0.18 111.147 -175.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.455 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.4 Cg_exo -58.55 141.99 97.83 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.442 2.095 . . . . 0.19 111.717 171.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.51 -19.52 70.94 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.878 -0.677 . . . . 0.18 111.965 179.432 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -102.15 9.83 39.88 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.218 0.532 . . . . 2.27 110.009 176.205 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.455 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.5 t -80.8 154.62 27.07 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 115.628 -0.714 . . . . 0.24 109.728 175.575 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -54.56 -40.13 68.43 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.96 0.41 . . . . 1.06 110.357 179.582 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.67 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 5.1 mt -70.75 -62.19 1.48 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.686 -0.688 . . . . 1.11 110.529 176.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.56 -38.71 63.97 Favored Glycine 0 C--N 1.33 0.242 0 CA-C-N 116.052 -0.522 . . . . 0.16 113.421 -175.031 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 85.7 m -66.35 -42.71 87.69 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.798 0.333 . . . . 0.24 110.745 -178.215 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.456 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.6 tm? -69.97 -34.82 73.88 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.327 -0.62 . . . . 1.01 109.327 177.672 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.67 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.6 mt -65.04 -46.2 82.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.053 -0.521 . . . . 0.37 110.483 -178.131 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.492 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.64 -21.03 52.85 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.473 -0.491 . . . . 0.41 111.004 -178.648 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.456 ' N ' HD12 ' A' ' 29' ' ' LEU . 32.4 t70 -66.15 -37.81 86.59 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.391 0.615 . . . . 0.66 109.572 173.181 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -75.98 -12.85 60.21 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.029 -0.987 . . . . 2.07 109.928 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 75.3 mt -106.09 -12.03 15.91 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.195 -0.911 . . . . 0.71 111.318 -179.269 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.09 39.36 96.25 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.575 -0.738 . . . . 0.75 112.343 -178.709 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.492 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 53.9 mt -82.19 133.23 29.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 O-C-N 122.645 -0.326 . . . . 0.68 111.057 -176.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 11.4 p -87.45 116.43 29.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 109.336 -0.616 . . . . 1.87 109.336 172.393 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.492 HD22 ' HB3' ' A' ' 39' ' ' PRO . 0.9 OUTLIER -91.79 131.33 37.23 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.918 -0.583 . . . . 2.76 111.003 -179.454 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 45.2 tt0 -88.23 -34.27 17.82 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.261 -1.014 . . . . 2.65 108.261 173.575 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -145.06 102.75 4.43 Favored Pre-proline 0 N--CA 1.445 -0.711 0 CA-C-N 114.835 -1.075 . . . . 2.29 108.324 174.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.492 ' HB3' HD22 ' A' ' 36' ' ' LEU . 41.4 Cg_endo -67.71 -4.39 12.11 Favored 'Trans proline' 0 C--O 1.225 -0.152 0 C-N-CA 122.586 2.191 . . . . 0.64 112.075 -174.792 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 15.3 p -82.53 -10.05 59.16 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.823 -0.626 . . . . 0.51 111.407 -174.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.418 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.8 m -74.18 160.54 5.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.159 0.504 . . . . 0.24 111.01 -178.612 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.41 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 92.3 mt -91.52 129.81 37.44 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.795 -0.639 . . . . 0.22 110.397 179.195 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.2 pt -112.52 137.64 44.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.159 0.504 . . . . 0.15 110.433 176.569 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.828 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.8 103.31 1.32 Allowed Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 120.478 -0.867 . . . . 0.31 113.133 -175.338 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -79.11 139.91 37.96 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 109.445 -0.576 . . . . 0.57 109.445 177.078 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.74 39.82 38.92 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.077 -1.058 . . . . 0.21 111.804 -179.409 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.539 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -108.28 112.98 25.72 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.098 0.475 . . . . 0.25 111.717 -171.69 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.406 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 12.2 m-20 -101.83 137.13 19.45 Favored Pre-proline 0 C--N 1.318 -0.763 0 CA-C-N 115.395 -0.82 . . . . 2.21 109.581 175.568 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 25.2 Cg_exo -59.88 133.98 54.12 Favored 'Trans proline' 0 C--O 1.233 0.244 0 C-N-CA 122.86 2.373 . . . . 0.44 112.076 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.461 HG23 ' HB1' ' A' ' 58' ' ' ALA . 40.6 mt -87.89 106.13 16.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.209 0.528 . . . . 0.46 109.881 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.466 ' HA ' ' O ' ' A' ' 2' ' ' SER . 11.8 t -142.1 19.82 2.1 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.529 -0.76 . . . . 0.88 110.594 -174.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.1 p -152.25 158.44 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 CA-C-N 115.626 -0.715 . . . . 1.44 110.164 -177.591 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . 58.97 45.77 14.53 Favored 'General case' 0 N--CA 1.464 0.266 0 O-C-N 123.661 0.601 . . . . 2.94 112.372 172.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -59.29 118.58 14.76 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.086 -0.578 . . . . 3.5 112.451 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 36.8 m 65.87 21.61 11.41 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.189 0.519 . . . . 4.9 111.015 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 48.0 m -127.46 26.28 5.99 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.643 -0.708 . . . . 4.06 110.035 -178.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 23.0 t70 76.04 72.36 0.08 Allowed 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 115.215 -0.902 . . . . 3.13 109.381 -175.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.461 ' HB1' HG23 ' A' ' 50' ' ' ILE . . . -92.36 3.29 55.73 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.965 -1.016 . . . . 0.99 111.261 -176.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.3 t -143.11 143.46 31.84 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.921 -0.581 . . . . 0.74 109.923 179.43 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 10.0 t -107.08 -28.68 9.85 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.557 -0.292 . . . . 2.14 111.085 -178.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.407 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -112.05 -80.2 0.59 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.837 -0.345 . . . . 0.54 111.783 -176.437 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 16.4 m -145.1 128.13 16.54 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.84 0.352 . . . . 0.29 111.154 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.48 136.91 32.92 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.903 0.382 . . . . 0.25 110.276 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.652 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.2 m -145.85 167.92 7.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.089 0.471 . . . . 0.21 111.59 -175.754 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' CYS . . . . . 0.449 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 17.8 t -130.54 105.94 8.18 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.45 -0.796 . . . . 0.39 110.121 178.013 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.723 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.8 m -92.45 133.58 35.77 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.698 0.761 . . . . 0.65 111.985 -179.28 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 8.7 t -86.16 -13.44 47.07 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.521 -1.218 . . . . 1.15 110.423 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -107.82 156.67 18.88 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.866 -0.606 . . . . 1.6 110.2 -179.145 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 30.4 p-10 -120.9 -15.1 8.38 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 113.084 0.772 . . . . 2.49 113.084 -172.443 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -88.16 73.21 9.01 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 121.985 0.898 . . . . 2.27 111.072 -173.344 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.7 m -85.68 164.77 2.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.049 -0.978 . . . . 1.1 110.999 -178.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.543 ' OG ' HG12 ' A' ' 75' ' ' ILE . 88.7 p -84.59 -2.72 57.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.051 -0.522 . . . . 1.41 111.66 -175.022 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.64 -31.89 3.83 Favored Glycine 0 CA--C 1.505 -0.592 0 C-N-CA 120.721 -0.752 . . . . 0.48 112.304 -178.071 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.4 m -135.49 -12.15 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.488 -0.485 . . . . 0.49 111.935 178.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.543 HG12 ' OG ' ' A' ' 72' ' ' SER . 35.4 pt -90.02 -175.14 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 119.986 -0.686 . . . . 0.3 111.581 -179.156 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.723 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -147.78 143.46 27.54 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.398 -1.273 . . . . 0.18 108.665 175.085 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 64.0 mt -122.55 131.23 73.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.966 0.412 . . . . 0.26 111.585 -175.41 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.448 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 76.38 50.71 7.18 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.097 -0.573 . . . . 0.17 112.188 177.751 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.486 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.92 141.84 31.19 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 112.826 0.676 . . . . 0.65 112.826 -175.013 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 95.0 mt -108.57 132.06 21.37 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.223 -0.899 . . . . 0.29 109.269 168.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.432 ' HA ' HG12 ' A' ' 64' ' ' VAL . 15.8 Cg_exo -67.29 128.4 18.33 Favored 'Trans proline' 0 C--O 1.234 0.297 0 C-N-CA 122.757 2.304 . . . . 0.25 112.292 -179.257 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.0 m -130.42 160.17 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.729 0 CA-C-N 116.02 -0.536 . . . . 0.42 110.12 178.239 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 23.9 m -132.61 136.55 46.59 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 116.475 -0.33 . . . . 2.07 110.448 177.668 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 93.3 mt . . . . . 0 C--O 1.249 1.026 0 O-C-N 123.915 0.76 . . . . 3.91 111.338 -179.537 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.661 0 N-CA-C 112.198 -0.361 . . . . 5.63 112.198 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.8 t -134.11 -168.08 2.07 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.808 -0.442 . . . . 4.28 109.808 -177.278 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 98.5 m95 58.53 -154.21 0.37 Allowed 'General case' 0 C--O 1.234 0.277 0 O-C-N 123.424 0.453 . . . . 4.74 110.531 -178.584 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.42 159.34 23.28 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.883 -0.675 . . . . 2.03 111.543 177.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -107.92 109.16 20.59 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.528 -0.545 . . . . 4.17 109.528 178.666 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 35.3 t -130.49 -73.19 0.55 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.285 -0.416 . . . . 1.88 111.12 -176.042 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 66.6 m -157.32 -174.56 4.95 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.638 -0.504 . . . . 2.4 109.638 -177.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 25.0 p -81.37 13.15 3.1 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 112.465 0.543 . . . . 3.75 112.465 -174.575 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -95.33 -110.58 2.44 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.904 -0.665 . . . . 1.12 111.928 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.1 t -151.04 150.31 30.58 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 110.128 -0.323 . . . . 0.96 110.128 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 23.7 mt -112.1 135.92 49.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-O 121.482 0.658 . . . . 0.96 110.825 173.385 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.681 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -153.91 170.29 21.39 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 114.968 -1.015 . . . . 0.91 110.873 -177.187 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.587 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 42.1 t -118.69 108.59 15.1 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.434 -0.803 . . . . 0.34 109.593 177.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.871 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 60.9 m -90.11 129.62 36.38 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.311 0.577 . . . . 0.19 111.599 -172.785 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.442 ' HB3' ' HA3' ' A' ' 46' ' ' GLY . 1.3 tp60 -75.54 -26.71 58.25 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 114.946 -1.025 . . . . 0.38 110.252 177.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.608 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 1.6 t-20 -135.86 99.15 4.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.445 -0.343 . . . . 1.03 110.818 175.266 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 61.8 t -92.66 102.0 13.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.002 0.429 . . . . 0.18 110.039 177.29 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.6 m -133.42 142.92 45.89 Favored Pre-proline 0 C--N 1.32 -0.701 0 CA-C-N 115.896 -0.593 . . . . 0.18 110.905 -174.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.491 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.5 Cg_exo -61.1 139.38 83.79 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.086 1.858 . . . . 0.19 111.164 171.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.08 -24.42 70.3 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.84 -0.695 . . . . 0.18 112.627 -178.262 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -97.61 4.45 50.2 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.147 0.498 . . . . 2.27 110.048 177.284 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.491 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.2 t -73.2 152.99 40.86 Favored 'General case' 0 CA--C 1.513 -0.48 0 CA-C-N 115.758 -0.655 . . . . 0.24 109.994 177.597 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -54.31 -39.36 66.94 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.098 0.475 . . . . 1.06 110.227 178.406 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.704 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.7 mm? -70.89 -62.33 1.43 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.646 -0.706 . . . . 1.11 110.818 175.788 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.3 -40.34 60.44 Favored Glycine 0 C--N 1.33 0.232 0 CA-C-N 116.171 -0.468 . . . . 0.16 113.296 -175.717 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.1 m -69.0 -44.36 72.96 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.857 0.36 . . . . 0.24 110.692 -177.382 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.02 -38.95 93.23 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.316 -0.624 . . . . 1.01 109.316 178.443 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.704 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.2 mt -69.11 -44.4 72.48 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.668 -0.696 . . . . 0.37 110.764 -177.129 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.581 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.4 pp -76.02 -26.16 56.37 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.798 -0.361 . . . . 0.41 111.068 -178.76 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.447 ' N ' HD12 ' A' ' 29' ' ' LEU . 31.9 t70 -64.24 -34.44 78.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.859 0.837 . . . . 0.66 109.035 172.267 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -80.66 -12.27 59.51 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 114.152 -1.386 . . . . 2.07 111.162 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 88.5 mt -111.86 -13.55 13.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.969 -0.56 . . . . 0.71 112.065 -176.4 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.9 41.35 18.97 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.238 -0.506 . . . . 0.75 112.898 178.277 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.581 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 15.4 mt -104.16 140.58 21.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.824 0.345 . . . . 0.68 110.811 -177.551 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.0 p -123.96 102.6 11.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.513 0.673 . . . . 1.87 110.002 173.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 24.1 mt -78.06 141.41 38.85 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.851 -0.613 . . . . 2.76 110.986 -177.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -69.76 -33.22 72.13 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.348 -0.842 . . . . 2.65 109.124 175.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 -131.58 104.74 14.46 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 115.189 -0.914 . . . . 2.29 108.653 172.203 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.87 -1.72 6.52 Favored 'Trans proline' 0 CA--C 1.528 0.187 0 C-N-CA 122.119 1.879 . . . . 0.64 111.812 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.8 p -87.09 -7.65 57.83 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.709 -0.678 . . . . 0.51 111.261 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.447 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 17.7 m -77.31 159.37 5.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 CA-C-O 121.204 0.526 . . . . 0.24 110.82 -179.589 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.471 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 85.6 mt -90.3 123.5 34.12 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.74 -0.664 . . . . 0.22 110.153 177.753 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.2 pt -105.25 139.27 26.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 115.94 -0.573 . . . . 0.15 109.957 176.414 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.871 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.32 106.69 1.44 Allowed Glycine 0 N--CA 1.44 -1.037 0 C-N-CA 120.51 -0.852 . . . . 0.31 113.174 -175.037 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.608 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 12.6 t70 -73.41 148.65 43.11 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.015 -0.735 . . . . 0.57 109.015 175.149 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.447 ' H ' HG23 ' A' ' 74' ' ' VAL . . . 60.6 45.16 96.87 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.44 -0.886 . . . . 0.21 112.58 175.561 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.587 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -100.96 117.35 34.83 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.322 0.582 . . . . 0.25 110.701 -174.662 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.504 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 3.5 p-10 -100.84 131.55 23.31 Favored Pre-proline 0 C--N 1.318 -0.772 0 CA-C-N 115.528 -0.76 . . . . 2.21 110.333 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -60.84 118.22 5.06 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 121.909 1.74 . . . . 0.44 110.076 173.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 13.6 mt -75.08 93.29 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.364 0.602 . . . . 0.46 110.935 -172.581 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 8.9 t -142.2 26.53 1.82 Allowed 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 122.326 1.06 . . . . 0.88 109.415 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 6.1 p -139.04 132.74 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 114.491 -1.231 . . . . 1.44 109.813 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -95.91 -13.07 24.21 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.633 0.254 . . . . 2.94 111.325 -177.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -75.79 78.07 1.23 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 121.097 -0.573 . . . . 3.5 112.473 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.1 t -163.35 -165.97 1.16 Allowed 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.914 -0.773 . . . . 4.9 108.914 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 13.2 m -57.7 -68.22 0.26 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.916 0.388 . . . . 4.06 110.125 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -118.3 -72.0 0.71 Allowed 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.405 -0.591 . . . . 3.13 109.405 173.004 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -120.22 -19.99 7.5 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.466 -0.788 . . . . 0.99 109.969 173.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 15.3 p -168.67 -178.65 3.51 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.995 -1.002 . . . . 0.74 109.576 -179.166 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 23.9 p -114.17 12.11 17.71 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.01 0.374 . . . . 2.14 112.01 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -134.78 -149.72 0.36 Allowed 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 121.227 -0.189 . . . . 0.54 110.95 -179.581 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 19.5 m -87.85 134.77 33.63 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.779 0.323 . . . . 0.29 111.055 -177.449 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.71 126.87 34.3 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.878 -0.416 . . . . 0.25 109.878 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.714 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -139.42 173.77 10.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.63 0 CA-C-O 121.51 0.671 . . . . 0.21 111.642 -176.083 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 48.8 t -141.82 103.76 4.4 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.974 -1.012 . . . . 0.39 109.165 -178.065 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.732 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.3 m -92.71 155.52 17.65 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.471 0.653 . . . . 0.65 111.913 -176.095 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 6.4 m -106.18 -13.98 15.27 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.264 -0.88 . . . . 1.15 110.879 -178.077 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.432 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 5.5 t70 -103.38 162.32 13.11 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.142 -0.481 . . . . 1.6 109.748 -178.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -120.85 -7.3 9.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.049 0.452 . . . . 2.49 111.14 -176.182 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -83.35 83.79 7.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.225 0.536 . . . . 2.27 111.403 -175.818 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 34.2 m -91.36 156.11 3.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.819 -0.628 . . . . 1.1 110.903 179.558 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.549 ' OG ' HG12 ' A' ' 75' ' ' ILE . 89.2 p -95.36 3.53 54.3 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.075 0.464 . . . . 1.41 110.53 179.435 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.31 -33.32 3.19 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.463 -0.79 . . . . 0.48 112.123 -176.366 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.447 HG23 ' H ' ' A' ' 46' ' ' GLY . 19.5 m -140.31 -21.69 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.325 0 N-CA-C 112.478 0.548 . . . . 0.49 112.478 174.022 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.549 HG12 ' OG ' ' A' ' 72' ' ' SER . 20.4 pt -71.75 172.99 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.373 0 CA-C-O 121.58 0.705 . . . . 0.3 112.187 -174.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.732 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -144.05 140.95 29.81 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.168 -1.378 . . . . 0.18 109.068 176.842 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.432 ' HB ' ' HB3' ' A' ' 68' ' ' ASP . 71.2 mt -119.5 129.33 75.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.032 0.444 . . . . 0.26 111.455 -176.296 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.458 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.08 51.93 5.96 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.972 -0.632 . . . . 0.17 112.035 178.007 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.503 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.92 139.04 35.17 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.135 0.493 . . . . 0.65 112.237 -176.503 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 97.9 mt -109.49 132.13 21.48 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 115.564 -0.744 . . . . 0.29 109.142 169.562 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 14.9 Cg_exo -68.01 119.37 6.38 Favored 'Trans proline' 0 N--CA 1.464 -0.246 0 C-N-CA 122.76 2.306 . . . . 0.25 112.058 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.7 m -112.41 147.25 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 CA-C-N 115.969 -0.56 . . . . 0.42 110.747 -177.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.44 HG22 ' HG ' ' A' ' 84' ' ' LEU . 32.8 m -156.04 134.39 11.53 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.561 -0.745 . . . . 2.07 109.878 178.135 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.44 ' HG ' HG22 ' A' ' 83' ' ' THR . 94.4 mt . . . . . 0 C--O 1.249 1.049 0 O-C-N 123.903 0.752 . . . . 3.91 111.463 -179.306 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.585 0 N-CA-C 112.007 -0.437 . . . . 5.63 112.007 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.61 ' O ' ' HA ' ' A' ' 51' ' ' THR . 17.5 p -80.28 71.95 7.1 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.028 0.442 . . . . 4.28 111.159 -178.58 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 67.3 t-105 -175.0 -66.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.516 -0.765 . . . . 4.74 110.523 174.541 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.29 -24.6 2.17 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.228 -0.987 . . . . 2.03 113.835 -172.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 77.4 mm-40 -60.3 108.03 0.74 Allowed 'General case' 0 C--O 1.233 0.211 0 CA-C-N 117.479 0.64 . . . . 4.17 111.101 -176.734 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.52 ' HB2' HD11 ' A' ' 11' ' ' ILE . 5.5 t 165.44 -40.18 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 114.19 -1.368 . . . . 1.88 107.678 -171.619 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.4 t -167.41 -160.57 0.37 Allowed 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.346 -1.297 . . . . 2.4 108.662 178.341 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.1 m -82.45 -8.46 59.62 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.138 0.494 . . . . 3.75 110.624 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -97.67 -125.93 5.29 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.836 -0.697 . . . . 1.12 113.314 -175.406 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 31.4 t -143.24 153.96 43.33 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 122.673 0.389 . . . . 0.96 109.967 -173.063 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.52 HD11 ' HB2' ' A' ' 6' ' ' CYS . 48.3 mt -103.58 140.17 22.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.155 0.503 . . . . 0.96 110.678 175.602 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.681 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -150.16 163.71 37.53 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.571 0.701 . . . . 0.91 111.732 -179.557 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.8 t -116.03 105.07 12.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.162 -0.926 . . . . 0.34 108.901 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.863 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 90.1 m -85.16 139.65 31.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.409 -0.814 . . . . 0.19 111.308 -173.174 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.84 -30.32 58.92 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 115.065 -0.971 . . . . 0.38 109.086 175.252 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.555 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 3.2 t-20 -136.13 111.52 9.16 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.797 -0.638 . . . . 1.03 110.618 178.532 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 85.5 t -102.15 106.16 19.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.022 0 N-CA-C 109.71 -0.478 . . . . 0.18 109.71 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.4 m -134.76 142.03 40.87 Favored Pre-proline 0 C--N 1.32 -0.676 0 CA-C-N 115.82 -0.627 . . . . 0.18 110.54 -178.078 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.509 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.5 Cg_exo -59.22 137.33 78.28 Favored 'Trans proline' 0 N--CA 1.46 -0.442 0 C-N-CA 122.31 2.007 . . . . 0.19 111.157 172.427 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.12 -25.55 69.66 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 121.111 -0.566 . . . . 0.18 112.666 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -100.52 6.55 44.3 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.612 0.72 . . . . 2.27 110.198 176.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.509 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 21.0 t -68.88 154.83 41.32 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.352 -0.61 . . . . 0.24 109.352 173.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -53.42 -43.2 67.78 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.098 0.475 . . . . 1.06 109.744 177.369 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.626 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.6 mm? -72.05 -57.72 4.04 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.318 -0.856 . . . . 1.11 111.097 177.776 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -53.71 -40.96 64.87 Favored Glycine 0 C--N 1.33 0.21 0 C-N-CA 121.225 -0.512 . . . . 0.16 112.962 -176.863 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 84.3 m -67.73 -39.3 84.27 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.731 0.301 . . . . 0.24 110.383 -179.633 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.429 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.5 tm? -68.25 -36.44 79.45 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.434 -0.58 . . . . 1.01 109.434 178.428 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.626 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 13.3 mt -67.57 -47.55 69.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.742 -0.663 . . . . 0.37 110.372 -177.614 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.566 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -77.56 -22.68 50.63 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.746 -0.382 . . . . 0.41 111.364 -178.562 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.505 ' N ' HD12 ' A' ' 29' ' ' LEU . 26.6 t70 -69.06 -31.53 70.37 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.422 0.63 . . . . 0.66 109.418 175.404 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -70.42 -24.29 62.89 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 114.79 -1.096 . . . . 2.07 109.305 176.423 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.1 mt -98.53 -15.58 19.49 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.585 -1.189 . . . . 0.71 111.71 -175.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.57 31.18 51.31 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 121.226 -0.512 . . . . 0.75 112.68 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.566 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 31.1 mt -95.38 140.66 16.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.721 0.296 . . . . 0.68 110.753 -178.072 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.9 t -124.75 101.41 8.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 109.708 -0.478 . . . . 1.87 109.708 176.081 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 30.7 mt -74.77 134.76 41.77 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.106 -0.497 . . . . 2.76 111.451 -177.48 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -70.34 -27.22 64.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.489 -0.778 . . . . 2.65 109.285 174.275 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -128.11 90.83 46.26 Favored Pre-proline 0 N--CA 1.446 -0.634 0 N-CA-C 108.38 -0.97 . . . . 2.29 108.38 176.001 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.5 8.36 0.96 Allowed 'Trans proline' 0 C--O 1.223 -0.248 0 C-N-CA 122.416 2.077 . . . . 0.64 112.408 -177.085 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.5 p -99.94 7.91 44.47 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.094 0.473 . . . . 0.51 110.996 -178.682 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.539 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 27.8 m -91.98 155.75 3.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.078 -0.51 . . . . 0.24 110.99 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.5 mt -86.56 127.12 34.87 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.663 -0.699 . . . . 0.22 109.875 176.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.493 HD13 HD23 ' A' ' 29' ' ' LEU . 13.4 pt -106.78 141.75 21.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.122 -0.49 . . . . 0.15 110.095 176.236 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.863 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.48 108.59 1.71 Allowed Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 120.523 -0.846 . . . . 0.31 113.419 -174.519 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.523 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 8.8 t70 -74.49 146.16 42.96 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.757 -0.831 . . . . 0.57 108.757 174.229 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 60.63 47.2 92.37 Favored Glycine 0 C--N 1.318 -0.453 0 C-N-CA 120.281 -0.961 . . . . 0.21 112.712 175.59 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.515 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -108.61 111.59 23.49 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.116 0.484 . . . . 0.25 111.568 -171.771 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.457 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 4.6 t70 -101.67 135.5 19.76 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.633 -0.712 . . . . 2.21 110.916 176.309 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 35.1 Cg_exo -54.76 123.52 13.93 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 124.032 3.155 . . . . 0.44 112.211 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 42.0 mt -79.84 88.34 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.595 0.712 . . . . 0.46 109.402 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.61 ' HA ' ' O ' ' A' ' 2' ' ' SER . 9.5 t -109.25 15.93 22.8 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.038 -0.983 . . . . 0.88 109.535 -179.507 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.3 p -131.51 144.41 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 CA-C-N 114.719 -1.128 . . . . 1.44 109.37 178.349 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -107.4 -56.47 2.21 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 110.106 -0.331 . . . . 2.94 110.106 178.593 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 53.58 -124.93 30.72 Favored Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.865 -0.607 . . . . 3.5 112.334 178.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.1 t -122.87 -70.57 0.77 Allowed 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.644 -0.502 . . . . 4.9 109.644 177.412 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 32.2 m -130.44 23.51 5.13 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.569 0.699 . . . . 4.06 109.403 176.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -109.53 22.78 15.32 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.323 -0.853 . . . . 3.13 111.261 -176.4 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -86.04 -19.77 29.79 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.409 0.623 . . . . 0.99 110.638 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.1 t -157.21 137.34 12.67 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.422 -0.808 . . . . 0.74 110.556 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.1 p -106.89 -22.11 12.8 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.185 -0.461 . . . . 2.14 111.774 -178.404 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -117.09 -82.65 0.63 Allowed 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 121.016 -0.274 . . . . 0.54 111.129 -179.532 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 11.9 m -139.77 129.91 25.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.689 0.28 . . . . 0.29 111.363 -179.038 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.4 128.19 34.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.979 0.419 . . . . 0.25 110.777 -177.428 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.624 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -143.09 173.93 5.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.489 0.661 . . . . 0.21 111.579 -177.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 39.0 t -140.96 107.57 5.33 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.387 -0.824 . . . . 0.39 109.146 -177.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.75 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -93.56 138.08 32.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.62 0.724 . . . . 0.65 112.58 -174.882 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.6 t -85.8 -22.49 27.63 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 114.731 -1.122 . . . . 1.15 110.691 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.422 ' HB2' ' O ' ' A' ' 77' ' ' ILE . 1.2 m-20 -102.53 136.76 41.77 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.164 -0.471 . . . . 1.6 110.813 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -100.44 -4.45 28.89 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.757 -0.656 . . . . 2.49 110.036 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 52.2 t30 -75.56 90.29 2.76 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.556 -0.747 . . . . 2.27 110.495 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 26.7 m -105.95 156.53 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.579 0 CA-C-N 116.102 -0.499 . . . . 1.1 111.29 -177.125 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.623 ' OG ' HG12 ' A' ' 75' ' ' ILE . 82.5 p -85.83 -4.56 59.2 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.886 -0.597 . . . . 1.41 110.529 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.47 -32.34 3.56 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.594 -0.73 . . . . 0.48 112.436 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 m -136.48 -11.57 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 C-N-CA 120.251 -0.58 . . . . 0.49 112.094 179.105 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.623 HG12 ' OG ' ' A' ' 72' ' ' SER . 25.8 pt -92.54 -178.2 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.602 0.715 . . . . 0.3 111.928 -178.337 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.75 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -143.04 141.09 31.23 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.031 -1.441 . . . . 0.18 109.279 175.505 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.422 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 68.0 mt -121.17 129.12 75.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.867 0.365 . . . . 0.26 111.447 -177.088 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.539 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 79.59 50.24 5.76 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.803 -0.713 . . . . 0.17 111.816 178.111 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.483 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.2 m -99.67 133.55 43.85 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 112.453 0.538 . . . . 0.65 112.453 -175.529 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.404 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 92.4 mt -105.53 133.87 19.97 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 115.538 -0.755 . . . . 0.29 109.636 171.065 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 22.9 Cg_exo -63.59 125.75 16.16 Favored 'Trans proline' 0 C--O 1.234 0.3 0 C-N-CA 122.807 2.338 . . . . 0.25 112.022 -179.409 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 10.3 m -122.85 161.49 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 CA-C-N 116.153 -0.476 . . . . 0.42 110.697 -178.445 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.453 HG22 ' HG ' ' A' ' 84' ' ' LEU . 25.4 m -145.75 131.03 18.52 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.946 -0.57 . . . . 2.07 110.279 176.148 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.453 ' HG ' HG22 ' A' ' 83' ' ' THR . 96.6 mt . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.266 -0.874 . . . . 3.91 111.593 179.359 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.459 ' HA3' ' O ' ' A' ' 51' ' ' THR . . . . . . . . 0 N--CA 1.482 1.727 0 N-CA-C 111.637 -0.585 . . . . 5.63 111.637 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.3 m -88.78 -1.5 58.12 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.988 0.394 . . . . 4.28 110.917 -178.289 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 79.4 m95 65.22 178.45 0.19 Allowed 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.66 -0.7 . . . . 4.74 111.269 179.034 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -124.03 76.44 0.37 Allowed Glycine 0 N--CA 1.444 -0.801 0 N-CA-C 110.901 -0.88 . . . . 2.03 110.901 176.827 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLN . . . . . 0.42 ' HG2' ' O ' ' A' ' 5' ' ' GLN . 14.9 pm0 -87.03 121.8 29.98 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.403 0.621 . . . . 4.17 110.867 -173.621 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.516 ' HB3' ' O ' ' A' ' 9' ' ' GLY . 14.3 t -111.3 -81.35 0.58 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.406 -0.815 . . . . 1.88 109.676 178.197 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 12.8 p 177.77 -82.23 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.095 0.474 . . . . 2.4 110.487 179.232 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.8 p -92.96 17.19 11.08 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.608 -0.724 . . . . 3.75 110.293 178.531 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.516 ' O ' ' HB3' ' A' ' 6' ' ' CYS . . . -169.21 176.19 43.34 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 115.166 -0.925 . . . . 1.12 111.633 -179.527 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.1 t -97.98 153.63 18.24 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.296 -0.631 . . . . 0.96 109.296 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.51 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 18.3 mt -96.19 130.48 44.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.702 0.763 . . . . 0.96 111.281 176.264 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.678 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -137.7 166.55 23.68 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.528 -1.215 . . . . 0.91 110.329 176.6 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.671 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 16.2 t -106.85 100.9 10.37 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.294 -0.866 . . . . 0.34 109.853 179.086 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.813 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 58.1 m -87.01 131.8 33.98 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.148 0.499 . . . . 0.19 110.747 -177.251 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.97 -29.72 35.27 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.285 -0.87 . . . . 0.38 109.593 178.23 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.669 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 2.7 m-20 -134.78 104.01 5.85 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.395 -0.366 . . . . 1.03 110.843 176.464 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 59.1 t -95.99 103.07 14.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.152 0.501 . . . . 0.18 110.01 176.565 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.98 142.68 46.03 Favored Pre-proline 0 C--N 1.32 -0.71 0 CA-C-N 115.731 -0.668 . . . . 0.18 110.704 -175.734 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.47 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.6 Cg_exo -58.9 137.74 81.62 Favored 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.103 1.868 . . . . 0.19 111.19 172.302 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.88 -23.76 69.53 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.831 -0.7 . . . . 0.18 112.041 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -96.64 7.58 46.21 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.016 0.436 . . . . 2.27 110.286 176.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.47 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.6 t -80.5 152.4 28.73 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.015 -0.539 . . . . 0.24 110.001 177.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -53.12 -37.35 61.7 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.074 0.464 . . . . 1.06 110.709 178.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.692 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.9 mm? -70.53 -65.95 0.67 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.763 -0.653 . . . . 1.11 110.545 175.011 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.67 -40.04 55.3 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.951 -0.568 . . . . 0.16 113.428 -174.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 63.8 m -68.28 -45.13 73.93 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.909 0.385 . . . . 0.24 110.666 -177.196 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -65.97 -36.63 83.84 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.399 -0.593 . . . . 1.01 109.399 178.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.692 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 17.5 mt -66.56 -49.28 66.92 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.836 -0.62 . . . . 0.37 110.326 -178.304 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.612 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.1 pp -74.4 -25.71 59.64 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.42 -0.355 . . . . 0.41 111.622 -175.047 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.516 ' N ' HD12 ' A' ' 29' ' ' LEU . 31.7 t70 -65.66 -34.49 78.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.673 0.749 . . . . 0.66 109.536 176.055 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -78.82 -34.5 45.24 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 114.713 -1.13 . . . . 2.07 109.412 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 82.3 mt -82.63 -10.73 58.82 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.033 -0.985 . . . . 0.71 112.037 -177.602 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.63 47.71 20.12 Favored Glycine 0 N--CA 1.452 -0.282 0 CA-C-N 115.855 -0.611 . . . . 0.75 112.631 178.117 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.612 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 10.6 mt -109.75 139.01 34.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.723 0.297 . . . . 0.68 110.471 -179.077 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.0 p -123.59 105.37 15.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.396 0.617 . . . . 1.87 110.125 174.387 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 21.6 mt -81.6 144.08 31.5 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.879 -0.601 . . . . 2.76 111.191 -178.063 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 25.5 mm-40 -79.41 -21.16 45.98 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.608 -0.724 . . . . 2.65 109.356 174.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -138.2 99.35 8.97 Favored Pre-proline 0 N--CA 1.445 -0.696 0 N-CA-C 107.707 -1.22 . . . . 2.29 107.707 173.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.72 -1.45 9.29 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.272 1.982 . . . . 0.64 112.453 -175.407 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.2 p -101.37 20.26 16.24 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.21 0.528 . . . . 0.51 111.277 -176.608 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.459 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 33.4 m -93.01 161.63 2.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.978 -0.556 . . . . 0.24 110.094 174.723 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.426 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 96.4 mt -87.57 120.63 29.07 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.284 -0.416 . . . . 0.22 110.043 176.04 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 14.8 pt -103.66 138.35 28.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 116.078 -0.51 . . . . 0.15 110.092 176.7 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.813 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -115.55 107.4 1.72 Allowed Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.572 -0.823 . . . . 0.31 113.252 -175.401 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.669 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 12.7 t70 -74.82 146.52 41.96 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.488 -0.93 . . . . 0.57 108.488 174.59 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 67.18 36.87 90.78 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 119.882 -1.152 . . . . 0.21 112.165 176.336 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.671 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -100.34 111.31 23.57 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.376 0.608 . . . . 0.25 110.607 -174.497 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.598 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 1.6 p-10 -101.46 130.32 25.0 Favored Pre-proline 0 C--N 1.314 -0.956 0 CA-C-N 115.547 -0.751 . . . . 2.21 109.876 178.094 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -58.55 118.11 4.94 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.18 1.92 . . . . 0.44 110.911 177.079 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 8.6 mt -79.71 110.78 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 108.581 -0.896 . . . . 0.46 108.581 -179.299 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.459 ' O ' ' HA3' ' A' ' 1' ' ' GLY . 8.8 t -141.72 16.19 2.15 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.442 0.639 . . . . 0.88 110.672 -174.078 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.3 p -77.93 154.85 5.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.485 -0.78 . . . . 1.44 110.459 -177.561 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -68.57 113.35 6.01 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.178 -0.464 . . . . 2.94 110.278 175.485 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.3 73.03 1.26 Allowed Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 120.951 -0.642 . . . . 3.5 111.613 -176.381 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 48.9 m -93.19 46.31 1.21 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.02 0.438 . . . . 4.9 111.136 -177.283 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.6 p -70.25 -40.61 74.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 4.06 110.867 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -154.96 76.91 1.01 Allowed 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.412 0.625 . . . . 3.13 109.588 175.751 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -105.45 17.98 23.01 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.49 -0.777 . . . . 0.99 109.988 179.242 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 35.4 t -151.71 128.9 11.17 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.351 -0.84 . . . . 0.74 110.737 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 73.9 m -119.78 -3.45 10.26 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.34 -0.391 . . . . 2.14 111.226 176.709 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.46 -84.4 0.1 Allowed 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.076 -0.712 . . . . 0.54 109.076 172.292 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 29.9 m -151.96 129.27 11.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.913 0.387 . . . . 0.29 111.067 171.601 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.7 132.58 33.83 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.383 -0.599 . . . . 0.25 109.383 176.608 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.713 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -141.95 169.8 13.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.488 0.661 . . . . 0.21 112.334 -174.094 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 14.2 t -130.95 100.53 5.28 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.66 -1.155 . . . . 0.39 109.459 179.306 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.775 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -88.88 125.52 34.97 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.79 0.805 . . . . 0.65 111.872 -178.429 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 10.0 t -85.26 -18.38 34.13 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 114.281 -1.327 . . . . 1.15 110.252 -179.057 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -110.82 140.81 44.94 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.64 -0.709 . . . . 1.6 109.577 178.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -119.74 24.64 10.47 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 120.975 -0.29 . . . . 2.49 111.695 -173.421 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 49.1 m-80 -86.5 56.82 4.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.333 0.587 . . . . 2.27 110.187 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 35.8 m -73.95 139.79 18.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.505 -0.771 . . . . 1.1 111.574 -175.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.422 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 19.6 m -90.86 10.83 24.67 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.013 -0.54 . . . . 1.41 111.431 -178.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.62 -34.76 2.94 Favored Glycine 0 C--O 1.228 -0.265 0 C-N-CA 120.944 -0.646 . . . . 0.48 113.995 173.167 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.5 m -139.98 -7.11 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 117.936 0.868 . . . . 0.49 111.264 176.534 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.422 ' CG1' ' H ' ' A' ' 72' ' ' SER . 11.2 pt -89.87 178.5 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.336 0.589 . . . . 0.3 111.347 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.775 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -144.31 144.17 31.34 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 114.563 -1.199 . . . . 0.18 109.177 175.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 67.4 mt -123.01 132.52 71.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.915 0.388 . . . . 0.26 111.549 -176.163 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.459 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 74.22 50.22 10.75 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.743 -0.741 . . . . 0.17 112.017 177.784 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.517 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.2 m -98.46 136.07 39.13 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-O 121.177 0.513 . . . . 0.65 111.785 -176.336 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.441 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.2 mt -107.63 130.18 23.18 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.472 -0.785 . . . . 0.29 109.258 170.048 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 15.7 Cg_exo -67.12 121.41 8.57 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.808 2.339 . . . . 0.25 112.651 -177.569 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.0 m -111.39 149.15 14.21 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.852 0 CA-C-N 115.686 -0.688 . . . . 0.42 109.346 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.433 HG22 ' HG ' ' A' ' 84' ' ' LEU . 8.9 m -132.46 149.35 52.35 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 116.445 -0.343 . . . . 2.07 110.84 -174.45 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.433 ' HG ' HG22 ' A' ' 83' ' ' THR . 78.5 mt . . . . . 0 C--O 1.252 1.207 0 O-C-N 123.773 0.67 . . . . 3.91 111.298 176.473 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.751 0 N-CA-C 111.774 -0.531 . . . . 5.63 111.774 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.9 t -94.2 136.84 34.06 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.037 -0.357 . . . . 4.28 110.037 -179.546 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 70.4 m95 69.96 -64.54 0.35 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.4 0.68 . . . . 4.74 111.474 -178.551 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 126.98 169.66 12.75 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 121.228 -0.51 . . . . 2.03 111.875 179.37 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -100.93 112.86 25.39 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.08 -0.341 . . . . 4.17 110.08 178.498 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.542 ' HB2' HD11 ' A' ' 11' ' ' ILE . 33.3 t -150.85 74.05 1.14 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.882 0.372 . . . . 1.88 110.59 177.791 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 12.1 t 55.46 -143.64 0.72 Allowed 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 115.751 -0.659 . . . . 2.4 110.868 176.654 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.4 p -94.32 20.47 8.16 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.014 0.435 . . . . 3.75 110.839 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -101.29 -165.12 27.55 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.842 -0.694 . . . . 1.12 112.839 -176.374 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.8 t -123.09 151.44 42.03 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.186 -0.672 . . . . 0.96 109.186 -179.353 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.542 HD11 ' HB2' ' A' ' 6' ' ' CYS . 23.8 mt -113.05 130.79 66.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.822 0.82 . . . . 0.96 111.196 177.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.566 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -146.72 170.64 16.57 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 114.363 -1.29 . . . . 0.91 110.479 -178.792 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.434 ' HB2' HD11 ' A' ' 50' ' ' ILE . 39.5 t -120.03 107.11 12.68 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.834 -0.621 . . . . 0.34 109.657 177.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.886 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 97.4 m -84.92 127.41 34.15 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.297 -0.865 . . . . 0.19 110.863 -176.899 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.475 ' HA ' ' HB1' ' A' ' 61' ' ' ALA . 0.2 OUTLIER -67.79 -36.06 79.76 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-N 115.181 -0.918 . . . . 0.38 109.403 173.77 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -133.9 111.55 10.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 1.03 110.631 177.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 92.8 t -97.97 106.85 19.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.786 -0.45 . . . . 0.18 109.786 176.28 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.1 m -131.79 140.49 38.42 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 116.31 -0.404 . . . . 0.18 111.013 -176.787 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.436 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.5 Cg_exo -60.36 140.31 91.1 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.389 2.059 . . . . 0.19 111.75 172.811 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.8 -19.81 69.8 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 121.02 -0.609 . . . . 0.18 112.488 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -100.76 5.45 43.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.112 0.482 . . . . 2.27 109.899 176.579 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.436 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 30.1 t -77.17 152.8 34.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.834 -0.621 . . . . 0.24 110.015 177.294 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -51.29 -41.02 60.17 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.959 0.409 . . . . 1.06 110.365 178.741 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.717 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 3.1 mm? -72.77 -62.91 1.28 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.757 -0.656 . . . . 1.11 110.618 178.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.47 -39.03 52.13 Favored Glycine 0 C--N 1.331 0.271 0 CA-C-N 116.153 -0.476 . . . . 0.16 113.15 -175.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.8 m -66.96 -47.8 70.5 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.728 0.299 . . . . 0.24 110.514 -178.812 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.449 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.4 tm? -65.75 -33.84 76.8 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.751 -0.463 . . . . 1.01 109.751 178.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.717 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 17.2 mt -67.92 -44.26 77.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.37 110.738 -178.012 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.587 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -79.62 -23.08 42.88 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.75 -0.38 . . . . 0.41 110.595 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.423 ' N ' HD12 ' A' ' 29' ' ' LEU . 15.0 t70 -64.09 -35.17 79.86 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.872 0.844 . . . . 0.66 109.568 172.664 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -74.85 -38.62 61.92 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 114.53 -1.214 . . . . 2.07 109.875 179.57 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 69.5 mt -81.88 -20.11 39.51 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 114.745 -1.116 . . . . 0.71 112.298 -176.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.86 34.39 30.91 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 121.183 -0.532 . . . . 0.75 112.347 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.587 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 40.4 mt -85.79 131.12 35.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.802 0.334 . . . . 0.68 110.929 -176.721 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 48.2 t -89.61 100.68 11.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 116.294 -0.412 . . . . 1.87 109.958 175.204 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.576 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.2 pp -72.06 126.36 29.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.426 0.632 . . . . 2.76 110.705 179.292 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -78.4 -35.62 46.91 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 108.695 -0.854 . . . . 2.65 108.695 172.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -144.46 108.35 4.83 Favored Pre-proline 0 N--CA 1.442 -0.837 0 CA-C-N 114.606 -1.179 . . . . 2.29 107.892 176.704 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.468 ' HB3' HD22 ' A' ' 36' ' ' LEU . 56.1 Cg_endo -70.88 -4.71 15.33 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.22 1.946 . . . . 0.64 111.522 -176.706 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 24.2 p -88.35 14.0 10.49 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.456 -0.793 . . . . 0.51 111.412 -174.211 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.412 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 19.3 m -102.84 158.36 4.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.045 -0.525 . . . . 0.24 110.448 179.143 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.423 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 92.6 mt -86.0 119.6 26.48 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.79 -0.641 . . . . 0.22 109.955 177.257 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.454 HD13 HD23 ' A' ' 29' ' ' LEU . 13.5 pt -102.81 134.13 44.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.213 0.53 . . . . 0.15 110.056 176.31 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.886 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -105.39 101.47 1.87 Allowed Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 120.531 -0.842 . . . . 0.31 112.944 -175.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -81.62 129.44 34.69 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.792 -0.818 . . . . 0.57 108.792 175.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.12 35.94 16.55 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 119.793 -1.194 . . . . 0.21 111.48 -175.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.79 110.02 22.2 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.194 0.521 . . . . 0.25 110.995 -174.373 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.455 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.4 t70 -101.96 135.77 19.63 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-N 115.424 -0.807 . . . . 2.21 110.495 175.089 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 12.4 Cg_exo -61.95 122.13 10.5 Favored 'Trans proline' 0 N--CA 1.462 -0.377 0 C-N-CA 123.453 2.769 . . . . 0.44 111.734 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.434 HD11 ' HB2' ' A' ' 13' ' ' CYS . 22.1 mt -79.22 88.39 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.4 0.619 . . . . 0.46 109.433 -178.389 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 12.5 t -118.03 11.98 13.52 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.427 -0.806 . . . . 0.88 110.248 -178.162 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.78 120.45 48.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.593 -0.73 . . . . 1.44 109.672 175.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -105.04 158.03 16.83 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.812 -0.631 . . . . 2.94 110.748 -176.581 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 134.74 -34.36 2.35 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.841 -0.695 . . . . 3.5 112.07 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.3 p -137.43 151.06 48.11 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.82 0.343 . . . . 4.9 110.736 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 32.3 t -74.65 -35.6 62.86 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.943 -0.572 . . . . 4.06 109.987 178.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -89.44 57.13 3.85 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.853 0.835 . . . . 3.13 109.53 176.649 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -70.34 -6.46 35.38 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.006 -0.997 . . . . 0.99 111.427 -179.44 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 45.5 t -162.01 143.33 10.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.564 -0.744 . . . . 0.74 109.225 175.728 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.4 t -107.62 -3.75 18.96 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.177 0.436 . . . . 2.14 112.177 -171.811 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.475 ' HB1' ' HA ' ' A' ' 15' ' ' GLN . . . -77.78 -89.09 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 C-N-CA 120.605 -0.438 . . . . 0.54 111.201 -179.357 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 28.4 m -151.08 125.75 9.62 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.684 0.278 . . . . 0.29 110.528 178.554 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.91 132.17 34.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.02 0.438 . . . . 0.25 110.066 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.753 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.4 m -143.14 172.04 8.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.261 0.553 . . . . 0.21 111.247 -177.7 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 51.9 t -138.11 104.72 5.3 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.238 -0.892 . . . . 0.39 109.3 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.74 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.3 m -89.24 132.38 34.91 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.555 0.693 . . . . 0.65 111.629 -178.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 33.5 t -76.22 -24.87 54.65 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.96 -1.018 . . . . 1.15 109.906 177.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -110.61 133.91 52.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.648 -0.705 . . . . 1.6 110.482 176.863 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -100.35 18.14 19.68 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.385 0.612 . . . . 2.49 109.968 179.281 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 -77.89 94.84 4.62 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.487 -0.779 . . . . 2.27 109.872 178.077 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 28.3 m -106.6 140.87 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 CA-C-N 116.166 -0.47 . . . . 1.1 111.739 -176.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.481 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 19.5 m -91.96 10.32 29.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.046 -0.525 . . . . 1.41 110.853 176.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.37 -34.63 3.01 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.159 -0.543 . . . . 0.48 113.668 174.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.0 m -140.7 -2.63 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 117.965 0.882 . . . . 0.49 111.692 176.426 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.481 ' CG1' ' H ' ' A' ' 72' ' ' SER . 3.8 pt -95.99 -177.64 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-O 121.431 0.634 . . . . 0.3 112.322 -175.034 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.74 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.51 140.44 21.92 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.368 -1.287 . . . . 0.18 108.783 174.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.0 mt -117.14 126.08 74.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.982 0.42 . . . . 0.26 111.675 -175.831 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 79.15 52.02 5.07 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.957 -0.64 . . . . 0.17 111.825 177.757 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.28 132.29 43.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.396 0.617 . . . . 0.65 112.164 -176.46 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 87.9 mt -102.19 129.86 25.41 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.427 -0.806 . . . . 0.29 109.538 171.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.45 ' HA ' HG12 ' A' ' 64' ' ' VAL . 15.9 Cg_exo -67.33 120.16 7.2 Favored 'Trans proline' 0 C--O 1.235 0.361 0 C-N-CA 122.859 2.373 . . . . 0.25 112.111 -178.79 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 11.2 m -118.96 150.63 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.902 0 CA-C-N 115.813 -0.63 . . . . 0.42 110.015 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.461 HG22 ' HG ' ' A' ' 84' ' ' LEU . 26.0 m -138.61 133.97 33.15 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.277 -0.42 . . . . 2.07 110.155 179.111 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.461 ' HG ' HG22 ' A' ' 83' ' ' THR . 96.5 mt . . . . . 0 C--O 1.246 0.912 0 O-C-N 123.881 0.738 . . . . 3.91 111.128 -179.443 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.634 0 N-CA-C 112.171 -0.372 . . . . 5.63 112.171 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 32.4 t -96.24 4.92 52.02 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.075 0.464 . . . . 4.28 110.397 -179.124 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 71.9 t-105 -152.98 135.89 15.46 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.369 -0.604 . . . . 4.74 109.369 178.213 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.462 ' HA3' ' HB ' ' A' ' 11' ' ' ILE . . . -70.79 95.59 0.55 Allowed Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.93 -0.653 . . . . 2.03 112.589 179.623 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.0 mm-40 -75.76 134.08 40.55 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 110.239 -0.282 . . . . 4.17 110.239 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.48 ' HB2' HG13 ' A' ' 11' ' ' ILE . 40.6 t -141.28 53.93 1.54 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.956 0.408 . . . . 1.88 110.179 -179.451 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 37.3 m 63.14 -79.37 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 115.438 -0.801 . . . . 2.4 111.707 179.311 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.8 m -116.35 -28.43 6.5 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.965 0.412 . . . . 3.75 110.235 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -94.89 -175.23 38.11 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.828 -0.624 . . . . 1.12 112.968 -175.371 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 65' ' ' CYS . 30.4 t -114.07 152.06 31.6 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.915 -0.402 . . . . 0.96 109.915 -177.309 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.48 HG13 ' HB2' ' A' ' 6' ' ' CYS . 28.0 mt -108.65 132.93 55.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.782 0.801 . . . . 0.96 111.325 177.863 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.58 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -140.34 165.53 27.16 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.559 -1.201 . . . . 0.91 110.501 179.843 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.472 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 40.1 t -110.81 104.22 12.82 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.666 -0.697 . . . . 0.34 109.443 178.327 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.777 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 69.3 m -90.73 130.6 36.7 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.012 -0.54 . . . . 0.19 111.585 -174.474 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.412 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -73.42 -28.94 62.26 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.069 -0.969 . . . . 0.38 110.007 176.374 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.441 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 5.2 t-20 -138.44 104.05 5.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.35 -0.386 . . . . 1.03 110.75 179.327 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 80.9 t -99.96 104.67 16.42 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 N-CA-C 109.917 -0.401 . . . . 0.18 109.917 178.122 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.0 m -132.37 143.86 50.64 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 116.064 -0.516 . . . . 0.18 110.976 -175.495 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.484 ' O ' ' HB3' ' A' ' 22' ' ' SER . 35.4 Cg_exo -60.85 136.61 67.23 Favored 'Trans proline' 0 N--CA 1.463 -0.307 0 C-N-CA 122.152 1.901 . . . . 0.19 111.36 172.506 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.38 -22.13 69.13 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 121.046 -0.597 . . . . 0.18 112.462 -178.857 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -98.15 3.14 49.08 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.144 0.497 . . . . 2.27 110.1 176.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.484 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.8 t -75.38 154.85 36.96 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.838 -0.619 . . . . 0.24 109.795 176.107 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -54.53 -41.03 69.23 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.367 0.603 . . . . 1.06 109.619 177.039 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.639 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.2 mm? -65.14 -65.05 0.72 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.875 -1.057 . . . . 1.11 110.698 175.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -56.6 -40.2 87.11 Favored Glycine 0 C--N 1.33 0.241 0 CA-C-N 115.972 -0.558 . . . . 0.16 113.614 -174.337 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 61.6 m -66.12 -42.06 89.7 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.918 0.39 . . . . 0.24 110.236 -178.586 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.401 HD22 ' HA ' ' A' ' 27' ' ' LEU . 2.6 tm? -65.92 -38.17 87.98 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.378 -0.601 . . . . 1.01 109.378 177.775 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.639 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.2 mt -65.4 -47.21 77.1 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 116.032 -0.531 . . . . 0.37 110.716 -176.7 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.551 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.87 -22.57 49.63 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.603 -0.439 . . . . 0.41 111.539 -176.203 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.492 ' N ' HD12 ' A' ' 29' ' ' LEU . 33.9 t70 -69.39 -34.58 74.72 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.518 0.675 . . . . 0.66 109.471 175.529 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -80.92 -10.71 59.69 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.058 -0.973 . . . . 2.07 110.118 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -108.93 -1.77 18.81 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.504 -0.771 . . . . 0.71 111.276 -178.61 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.51 43.48 98.96 Favored Glycine 0 C--N 1.331 0.272 0 CA-C-N 115.662 -0.699 . . . . 0.75 113.024 178.216 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.551 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 30.4 mt -95.36 137.96 22.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.962 0.41 . . . . 0.68 111.026 -177.211 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -97.99 103.19 14.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.867 -0.606 . . . . 1.87 110.055 175.732 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.468 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.2 pp -74.31 133.28 42.57 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.356 0.598 . . . . 2.76 111.136 -179.523 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -88.78 -32.02 18.09 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 108.378 -0.971 . . . . 2.65 108.378 174.557 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -145.84 109.66 4.41 Favored Pre-proline 0 N--CA 1.439 -0.982 0 N-CA-C 107.269 -1.382 . . . . 2.29 107.269 175.578 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.428 ' HB3' HD22 ' A' ' 36' ' ' LEU . 61.5 Cg_endo -74.24 -3.97 14.66 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 121.937 1.758 . . . . 0.64 112.429 -174.085 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 65.2 p -97.43 21.71 9.78 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.49 0.662 . . . . 0.51 111.188 -174.26 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.437 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 23.8 m -99.8 156.19 4.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.467 -0.788 . . . . 0.24 110.096 174.829 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.436 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.5 mt -85.07 124.18 31.46 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.24 -0.437 . . . . 0.22 110.123 177.215 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.407 HD13 HD23 ' A' ' 29' ' ' LEU . 14.4 pt -106.35 133.69 50.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.184 0.516 . . . . 0.15 110.134 175.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.777 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.38 100.48 1.08 Allowed Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.613 -0.803 . . . . 0.31 112.803 -176.087 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -80.6 146.44 31.22 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 109.564 -0.532 . . . . 0.57 109.564 177.217 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.412 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 74.18 36.46 50.88 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.07 -1.062 . . . . 0.21 111.571 -178.673 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -102.9 118.53 37.03 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.262 0.553 . . . . 0.25 111.456 -173.061 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.53 139.21 20.21 Favored Pre-proline 0 C--N 1.32 -0.697 0 CA-C-N 115.468 -0.787 . . . . 2.21 109.157 175.018 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -71.12 123.24 9.47 Favored 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 122.095 1.863 . . . . 0.44 111.287 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.406 HG13 ' HA ' ' A' ' 12' ' ' GLN . 13.1 mt -77.29 89.47 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.645 0.736 . . . . 0.46 109.853 -176.83 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 7.9 t -123.54 12.9 9.37 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 114.762 -1.108 . . . . 0.88 110.257 -176.563 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.5 p -95.31 141.12 15.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.231 -0.895 . . . . 1.44 110.045 177.613 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -121.43 165.04 16.17 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.275 -0.421 . . . . 2.94 110.765 -178.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 94.99 0.71 63.56 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.93 -0.652 . . . . 3.5 112.512 178.195 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 33.7 t -156.86 124.55 5.43 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.941 -0.392 . . . . 4.9 109.941 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.0 p -73.79 -21.72 60.07 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.094 -0.503 . . . . 4.06 110.47 177.425 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -81.46 52.43 1.86 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 122.017 0.913 . . . . 3.13 109.154 175.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -92.59 17.15 10.61 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.133 -0.94 . . . . 0.99 110.98 -176.718 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.1 t -138.67 131.44 29.31 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.816 -0.629 . . . . 0.74 110.014 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.2 p -90.61 -22.97 20.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.983 -0.553 . . . . 2.14 111.707 -178.772 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -129.49 -87.95 0.52 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 120.7 -0.4 . . . . 0.54 112.012 -177.584 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 60.3 m -131.28 130.67 43.12 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.808 0.337 . . . . 0.29 111.616 -175.099 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.73 131.64 34.08 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.34 -0.391 . . . . 0.25 109.962 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.631 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -143.06 166.67 14.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.062 0.458 . . . . 0.21 111.494 -175.804 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' CYS . . . . . 0.487 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 31.5 t -128.27 104.64 7.85 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.435 -0.802 . . . . 0.39 110.15 178.485 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.746 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.6 m -93.2 136.92 33.01 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.61 0.719 . . . . 0.65 111.79 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.7 t -89.01 -20.52 24.3 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 114.784 -1.098 . . . . 1.15 110.458 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.482 ' HB3' ' OD1' ' A' ' 70' ' ' ASN . 44.6 m-20 -103.53 148.09 26.38 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.902 -0.59 . . . . 1.6 110.401 -177.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -119.75 3.75 11.09 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.511 -0.313 . . . . 2.49 111.155 -179.683 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.482 ' OD1' ' HB3' ' A' ' 68' ' ' ASP . 18.2 p-10 -79.56 63.29 4.11 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.736 0.779 . . . . 2.27 110.21 178.446 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.9 m -97.41 162.48 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.709 0 CA-C-N 115.372 -0.831 . . . . 1.1 111.29 -176.108 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.566 ' H ' HG12 ' A' ' 75' ' ' ILE . 87.9 p -85.14 -2.51 58.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.692 -0.685 . . . . 1.41 111.105 -177.554 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.42 -32.67 4.24 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.799 -0.715 . . . . 0.48 112.13 -179.108 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.6 m -130.86 -11.88 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.399 -0.52 . . . . 0.49 111.859 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.566 HG12 ' H ' ' A' ' 72' ' ' SER . 29.1 pt -87.69 178.88 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 C-N-CA 119.879 -0.729 . . . . 0.3 110.976 177.146 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.746 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -148.0 137.94 22.61 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 114.685 -1.143 . . . . 0.18 108.826 176.568 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 61.7 mt -120.05 130.74 73.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.874 0.368 . . . . 0.26 111.322 -175.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.498 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.58 50.52 6.52 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 121.139 -0.553 . . . . 0.17 112.042 178.528 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -99.41 136.07 39.89 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 112.446 0.535 . . . . 0.65 112.446 -175.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 97.4 mt -106.62 129.47 24.39 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.562 -0.745 . . . . 0.29 109.478 169.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 15.3 Cg_exo -67.63 124.89 12.51 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 123.092 2.528 . . . . 0.25 112.567 -177.241 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.8 m -126.68 159.91 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 116.128 -0.487 . . . . 0.42 110.273 179.696 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.419 HG22 ' HG ' ' A' ' 84' ' ' LEU . 22.6 m -124.3 134.47 53.19 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.365 -0.38 . . . . 2.07 110.333 177.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.419 ' HG ' HG22 ' A' ' 83' ' ' THR . 95.6 mt . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.068 -0.968 . . . . 3.91 111.552 -179.547 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.655 0 N-CA-C 111.735 -0.546 . . . . 5.63 111.735 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.402 ' O ' ' HA ' ' A' ' 51' ' ' THR . 15.6 m -127.51 123.98 37.2 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.989 -0.375 . . . . 4.28 109.989 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -128.87 8.11 5.68 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.043 0.449 . . . . 4.74 110.902 177.276 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.15 58.5 2.08 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.946 -0.645 . . . . 2.03 113.107 177.395 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -78.98 110.97 14.71 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.829 -0.434 . . . . 4.17 109.829 175.789 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.466 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 44.4 t -128.22 -64.48 0.95 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.131 -0.486 . . . . 1.88 110.137 -179.224 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.7 p -172.74 -85.49 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.734 -0.666 . . . . 2.4 110.464 178.705 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.2 p -121.31 20.54 11.28 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.348 -0.387 . . . . 3.75 111.254 -179.77 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -139.08 -131.91 2.89 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.345 -0.931 . . . . 1.12 112.858 -176.47 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.9 t -145.86 152.21 39.11 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.492 -0.558 . . . . 0.96 109.492 -178.055 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.466 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 22.6 mt -105.63 131.47 54.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.682 0.753 . . . . 0.96 111.0 175.621 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.539 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -141.53 163.14 33.74 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.736 -1.12 . . . . 0.91 110.941 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.535 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 47.3 t -107.61 101.66 10.97 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.305 -0.861 . . . . 0.34 109.523 178.477 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.821 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 60.2 m -85.68 129.78 34.73 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.177 0.513 . . . . 0.19 111.281 -175.838 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.413 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -75.28 -30.17 60.33 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 115.17 -0.923 . . . . 0.38 109.644 177.311 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.416 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 4.8 t-20 -135.43 110.11 8.63 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.832 -0.622 . . . . 1.03 110.091 178.906 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.7 t -105.85 104.55 17.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.998 0.428 . . . . 0.18 109.887 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.0 m -135.86 146.31 56.45 Favored Pre-proline 0 C--N 1.322 -0.623 0 CA-C-N 115.984 -0.553 . . . . 0.18 111.191 -173.636 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.478 ' O ' ' HB3' ' A' ' 22' ' ' SER . 26.6 Cg_exo -62.18 137.98 69.48 Favored 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.16 1.907 . . . . 0.19 110.996 170.601 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.26 -30.16 76.68 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.002 -0.618 . . . . 0.18 112.547 -178.271 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -96.66 10.45 38.57 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.089 0.471 . . . . 2.27 110.272 177.766 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.478 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.9 t -77.59 154.85 31.93 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.502 -0.555 . . . . 0.24 109.502 174.436 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -49.69 -46.08 49.59 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.534 -0.543 . . . . 1.06 109.534 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.694 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.0 OUTLIER -64.07 -64.47 0.88 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 114.934 -1.03 . . . . 1.11 110.921 178.821 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.91 -37.65 62.92 Favored Glycine 0 C--N 1.331 0.298 0 CA-C-N 115.972 -0.558 . . . . 0.16 113.317 -175.135 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.1 m -69.54 -39.9 77.19 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.888 0.375 . . . . 0.24 110.666 -177.63 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.42 HD22 ' HA ' ' A' ' 27' ' ' LEU . 1.2 tm? -66.05 -39.76 90.39 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.024 -0.732 . . . . 1.01 109.024 177.04 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.694 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 18.9 mt -64.6 -53.41 48.12 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 114.848 -1.069 . . . . 0.37 110.914 -177.188 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.555 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -71.65 -22.88 61.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.445 -0.343 . . . . 0.41 111.307 -175.455 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.474 ' N ' HD12 ' A' ' 29' ' ' LEU . 20.6 t70 -63.59 -38.19 90.17 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.507 0.67 . . . . 0.66 109.915 174.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -76.34 -29.76 57.36 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.128 -0.942 . . . . 2.07 109.64 -178.659 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.5 mt -85.62 -12.01 52.5 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 114.779 -1.1 . . . . 0.71 111.451 -177.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.25 32.38 52.21 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.929 -0.578 . . . . 0.75 112.747 177.397 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.555 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 11.9 mt -94.11 141.59 14.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.664 0.269 . . . . 0.68 110.498 -177.672 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.9 p -128.11 102.85 9.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.497 0.665 . . . . 1.87 110.078 174.232 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.0 mt -94.58 145.6 24.7 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.898 -0.592 . . . . 2.76 110.557 -178.454 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -76.38 -27.88 56.53 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.924 -0.58 . . . . 2.65 109.892 178.475 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -139.31 92.52 10.52 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 115.621 -0.718 . . . . 2.29 109.251 174.814 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.44 6.61 1.82 Allowed 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.492 2.128 . . . . 0.64 111.749 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.5 p -75.01 -7.26 53.16 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.668 -0.696 . . . . 0.51 111.188 -179.084 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.4 m -83.02 163.04 3.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.858 -0.61 . . . . 0.24 110.711 178.23 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.449 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.3 mt -87.56 123.05 32.03 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.994 -0.548 . . . . 0.22 110.469 178.287 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.7 pt -105.33 138.26 31.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.073 -0.512 . . . . 0.15 110.092 175.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.821 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -116.64 102.71 1.06 Allowed Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.654 -0.784 . . . . 0.31 112.918 -175.789 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -81.06 143.59 32.36 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.397 -0.594 . . . . 0.57 109.397 177.019 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.405 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 72.28 38.8 58.51 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 119.958 -1.115 . . . . 0.21 111.752 -179.34 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.535 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -103.94 116.57 32.49 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.969 0.414 . . . . 0.25 110.999 -173.273 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.462 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 2.5 p-10 -101.35 131.41 23.12 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 115.969 -0.56 . . . . 2.21 110.16 177.336 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -58.87 119.44 6.7 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.31 2.007 . . . . 0.44 110.642 175.075 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 14.4 mt -78.4 89.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.597 0.713 . . . . 0.46 110.131 -175.114 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.402 ' HA ' ' O ' ' A' ' 2' ' ' SER . 10.6 t -119.1 16.88 13.28 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.958 -1.019 . . . . 0.88 110.475 -177.061 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.3 p -85.83 137.82 20.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.483 -0.781 . . . . 1.44 110.584 179.222 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -111.52 142.82 43.3 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.434 -0.348 . . . . 2.94 110.647 179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 69.51 54.75 11.62 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 121.14 -0.553 . . . . 3.5 112.331 178.796 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 10.5 t -158.09 118.47 3.36 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 110.225 -0.287 . . . . 4.9 110.225 -178.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 6.2 p -73.68 -32.84 64.16 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.29 0.567 . . . . 4.06 109.614 176.709 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -83.26 54.39 2.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.91 0.862 . . . . 3.13 109.049 172.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -75.91 -10.84 59.76 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.335 -0.848 . . . . 0.99 109.937 177.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.5 t -157.55 118.47 3.55 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.895 -1.048 . . . . 0.74 109.861 177.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 19.9 m -92.6 -24.05 18.83 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.479 -0.328 . . . . 2.14 111.377 -179.224 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.413 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -97.72 -86.42 0.34 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.841 -0.344 . . . . 0.54 111.675 -177.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 33.4 m -148.46 126.65 12.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.762 0.315 . . . . 0.29 110.83 -178.256 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.73 132.39 33.87 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.877 0.37 . . . . 0.25 110.14 -178.062 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.664 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.7 m -142.77 172.17 8.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-O 121.352 0.596 . . . . 0.21 111.521 -176.092 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 38.1 t -133.26 104.69 6.59 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.023 -0.99 . . . . 0.39 109.645 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.766 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -92.56 130.4 38.22 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.667 0.746 . . . . 0.65 111.828 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 55.0 m -76.93 -32.4 57.33 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.613 -1.176 . . . . 1.15 110.948 178.699 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -109.64 138.57 45.81 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.659 -0.701 . . . . 1.6 109.855 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -120.85 23.76 10.55 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.813 0.339 . . . . 2.49 111.453 -174.152 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 25.3 p-10 -81.31 56.89 3.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.858 0.837 . . . . 2.27 109.813 176.122 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 18.1 m -83.01 158.55 3.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 114.967 -1.015 . . . . 1.1 112.197 -171.14 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.521 ' H ' HG12 ' A' ' 75' ' ' ILE . 95.1 p -82.75 -3.04 56.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.27 -0.877 . . . . 1.41 111.05 -178.2 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.84 -32.2 3.71 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 121.04 -0.6 . . . . 0.48 112.465 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.3 m -136.15 -7.56 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 C-N-CA 120.5 -0.48 . . . . 0.49 111.899 179.169 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.521 HG12 ' H ' ' A' ' 72' ' ' SER . 32.2 pt -92.0 -177.45 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 C-N-CA 120.006 -0.678 . . . . 0.3 111.369 178.765 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.766 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.38 140.37 21.98 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 114.791 -1.095 . . . . 0.18 109.161 177.295 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 68.4 mt -122.02 123.94 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.071 0.462 . . . . 0.26 111.657 -175.508 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 81.95 51.85 4.32 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.904 -0.665 . . . . 0.17 111.596 179.361 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.449 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.23 136.43 39.2 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.244 0.545 . . . . 0.65 112.187 -175.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.446 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 92.1 mt -110.66 131.28 22.17 Favored Pre-proline 0 C--N 1.321 -0.65 0 CA-C-N 115.54 -0.754 . . . . 0.29 109.703 171.653 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 22.6 Cg_exo -64.93 131.87 30.38 Favored 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 123.137 2.558 . . . . 0.25 112.868 -177.769 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.4 m -133.71 159.51 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 CA-C-N 115.75 -0.659 . . . . 0.42 109.58 177.275 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.9 m -95.6 112.55 24.25 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 121.13 -0.228 . . . . 2.07 111.171 -179.023 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 10.0 mp . . . . . 0 C--O 1.251 1.168 0 O-C-N 124.549 1.156 . . . . 3.91 112.773 174.246 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.804 0 N-CA-C 112.5 -0.24 . . . . 5.63 112.5 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.6 m -80.16 77.54 6.88 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.04 0.448 . . . . 4.28 111.274 -177.296 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 97.6 m95 -132.12 27.27 4.52 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.915 -0.584 . . . . 4.74 110.065 177.336 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.17 17.64 80.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.803 -0.713 . . . . 2.03 112.387 -178.765 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 76.4 mm-40 -84.31 109.57 17.91 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.105 0.479 . . . . 4.17 111.198 -178.196 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.497 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 44.2 t -143.91 142.93 31.04 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.59 -0.732 . . . . 1.88 109.866 179.632 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 12.1 p -72.14 -17.89 61.93 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.0 -0.545 . . . . 2.4 111.785 -175.751 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.6 p -108.47 9.61 27.5 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.709 0.29 . . . . 3.75 111.713 179.154 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 142.86 -127.58 3.18 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.286 -0.959 . . . . 1.12 113.211 177.732 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.7 t -113.85 153.62 28.86 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.656 -0.498 . . . . 0.96 109.656 -175.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.497 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 22.8 mt -104.43 133.61 48.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.664 0.745 . . . . 0.96 111.619 178.699 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.452 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -144.28 163.03 34.89 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 114.524 -1.216 . . . . 0.91 110.121 178.165 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.489 ' HB2' HD11 ' A' ' 50' ' ' ILE . 34.6 t -114.92 109.36 18.02 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.076 -0.713 . . . . 0.34 109.076 176.547 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.796 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 96.8 m -88.96 134.93 33.8 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.392 -0.822 . . . . 0.19 111.35 -173.89 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.443 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -75.39 -28.25 59.39 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.158 -0.928 . . . . 0.38 109.775 178.461 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -141.77 103.52 4.37 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.147 -0.479 . . . . 1.03 110.73 177.555 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 98.6 t -93.85 105.93 17.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 116.178 -0.465 . . . . 0.18 109.787 177.235 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.41 142.42 45.33 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.149 -0.478 . . . . 0.18 111.067 -176.144 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.563 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.4 Cg_exo -58.92 139.21 89.84 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.382 2.054 . . . . 0.19 111.392 172.167 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.37 -20.01 71.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.824 -0.703 . . . . 0.18 112.317 -179.187 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 17.2 p-10 -101.87 7.4 41.61 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.311 0.577 . . . . 2.27 109.962 176.316 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.563 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 13.5 t -74.12 154.27 39.21 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.554 -0.748 . . . . 0.24 109.78 174.69 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -56.28 -39.88 73.37 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.955 0.407 . . . . 1.06 110.08 177.17 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.656 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER -70.45 -60.19 2.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.545 -0.752 . . . . 1.11 110.431 175.825 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.491 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.43 -41.5 80.71 Favored Glycine 0 C--N 1.331 0.252 0 CA-C-N 115.922 -0.581 . . . . 0.16 113.33 -175.497 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.4 m -66.05 -41.73 90.43 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.748 0.308 . . . . 0.24 110.37 -178.557 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.407 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.8 tm? -64.76 -37.58 88.08 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.561 -0.533 . . . . 1.01 109.561 177.901 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.656 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.4 mt -66.16 -49.65 66.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.924 -0.58 . . . . 0.37 110.637 -177.596 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.563 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -76.32 -21.76 55.79 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.481 -0.327 . . . . 0.41 111.172 -177.377 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.499 ' N ' HD12 ' A' ' 29' ' ' LEU . 29.8 t70 -66.51 -33.36 75.52 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.723 0.773 . . . . 0.66 109.64 175.007 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -76.21 -25.07 54.73 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.586 -1.188 . . . . 2.07 109.361 179.092 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 94.6 mt -94.46 -17.19 22.7 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.814 -1.084 . . . . 0.71 111.811 -175.504 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 80.44 35.69 25.47 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.155 -0.545 . . . . 0.75 112.582 178.243 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.563 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 22.7 mt -98.52 130.83 46.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.684 0.278 . . . . 0.68 110.713 -177.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.6 p -118.72 100.05 9.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.917 0.865 . . . . 1.87 110.569 176.29 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 23.0 mt -82.57 143.44 31.03 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.469 -0.787 . . . . 2.76 111.558 -176.593 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -71.02 -38.47 72.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.225 -0.898 . . . . 2.65 109.254 174.157 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -125.15 91.63 48.83 Favored Pre-proline 0 N--CA 1.447 -0.583 0 CA-C-N 115.069 -0.969 . . . . 2.29 108.438 174.017 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.02 4.12 1.66 Allowed 'Trans proline' 0 C--O 1.225 -0.147 0 C-N-CA 122.54 2.16 . . . . 0.64 111.971 -178.076 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 18.3 p -82.79 -10.9 58.66 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.931 -0.577 . . . . 0.51 111.1 -177.777 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.9 m -71.24 160.56 5.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.24 111.331 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 97.4 mt -91.17 127.42 36.59 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.855 -0.611 . . . . 0.22 110.505 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.472 HD13 HD23 ' A' ' 29' ' ' LEU . 13.8 pt -107.41 136.85 41.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.098 0.475 . . . . 0.15 110.335 176.372 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.796 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -110.2 98.82 1.12 Allowed Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 120.815 -0.707 . . . . 0.31 113.199 -175.156 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -79.63 141.68 36.28 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.439 -0.578 . . . . 0.57 109.439 177.421 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.443 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 71.99 41.41 54.88 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.151 -1.023 . . . . 0.21 112.161 -179.347 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.551 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.74 117.94 35.34 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.196 0.522 . . . . 0.25 111.614 -172.533 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.488 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 1.6 t70 -101.91 136.03 19.59 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 115.401 -0.818 . . . . 2.21 110.35 174.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.488 ' HD2' ' OD1' ' A' ' 48' ' ' ASP . 1.3 Cg_endo -67.6 120.94 7.98 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.046 2.497 . . . . 0.44 111.868 -177.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.489 HD11 ' HB2' ' A' ' 13' ' ' CYS . 17.7 mt -80.02 92.64 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.277 0.56 . . . . 0.46 109.962 -177.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.6 t -133.66 21.06 3.9 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.556 -0.747 . . . . 0.88 111.026 -176.627 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.8 p -97.99 128.48 49.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.249 0.547 . . . . 1.44 110.427 176.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -95.83 157.29 15.96 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.854 -0.612 . . . . 2.94 110.341 179.107 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 81.05 -56.84 4.85 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.849 -0.691 . . . . 3.5 112.033 -178.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.9 m -67.9 103.45 1.47 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.956 0.408 . . . . 4.9 110.525 178.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 7.6 m -75.53 -23.61 56.69 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.009 -0.542 . . . . 4.06 110.535 -178.841 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -82.42 50.96 1.73 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.893 -0.594 . . . . 3.13 109.998 179.131 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.416 ' HB1' HG23 ' A' ' 50' ' ' ILE . . . -93.8 17.7 11.58 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.785 -0.643 . . . . 0.99 112.61 -172.186 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 42.6 t -149.38 116.68 6.09 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.825 -0.35 . . . . 0.74 110.887 178.497 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 20.2 m -90.48 -15.53 30.63 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 112.133 0.42 . . . . 2.14 112.133 -176.512 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 14' ' ' CYS . . . -133.14 -83.25 0.47 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.349 -0.54 . . . . 0.54 112.254 -177.737 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 23.0 m -138.5 129.57 26.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.787 0.327 . . . . 0.29 111.608 -175.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.24 129.28 34.9 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-O 120.981 0.42 . . . . 0.25 110.319 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.556 HG21 ' SG ' ' A' ' 14' ' ' CYS . 6.4 m -141.64 157.87 21.28 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 121.446 0.641 . . . . 0.21 111.236 -177.249 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 35.3 t -116.18 111.2 19.87 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.206 -0.906 . . . . 0.39 108.722 173.713 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.654 ' HA ' ' HA ' ' A' ' 79' ' ' CYS . 0.5 OUTLIER -103.71 135.91 44.4 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.744 0.783 . . . . 0.65 111.91 -173.043 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 32.2 t -81.53 -35.22 30.58 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 114.55 -1.205 . . . . 1.15 111.309 -174.501 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -91.95 131.62 37.12 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.01 0.433 . . . . 1.6 110.419 -179.701 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -106.11 11.11 31.77 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.94 -0.573 . . . . 2.49 111.034 -177.749 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -95.28 72.57 3.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.468 0.651 . . . . 2.27 109.786 -178.507 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 35.2 m -74.97 153.06 6.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.35 -0.841 . . . . 1.1 111.606 -176.429 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -90.72 8.25 35.46 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.807 -0.633 . . . . 1.41 110.148 179.507 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.98 -34.08 3.2 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.63 -0.714 . . . . 0.48 112.83 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 m -140.99 -17.05 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 117.218 0.509 . . . . 0.49 111.958 176.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 18.3 pt -81.95 -175.41 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.478 0.656 . . . . 0.3 112.298 -176.28 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -151.05 141.73 22.71 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.236 -1.347 . . . . 0.18 107.874 173.548 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.2 mt -119.05 123.54 71.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 118.32 0.509 . . . . 0.26 112.226 -174.272 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.85 53.29 4.62 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.926 -0.654 . . . . 0.17 111.547 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.654 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 3.8 m -99.94 143.34 30.27 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.153 0.501 . . . . 0.65 111.305 -176.804 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 80.3 mt -109.25 131.76 21.65 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 115.484 -0.78 . . . . 0.29 110.372 175.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.434 ' HA ' HG12 ' A' ' 64' ' ' VAL . 15.9 Cg_exo -67.41 121.99 9.17 Favored 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.891 2.394 . . . . 0.25 111.902 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.8 m -115.21 141.68 31.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-O 121.674 0.75 . . . . 0.42 111.167 -178.773 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 15.3 t -148.46 30.22 0.84 Allowed 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 123.563 1.649 . . . . 2.07 108.892 -178.82 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 69.6 mt . . . . . 0 C--N 1.296 -1.757 0 CA-C-N 111.88 -2.418 . . . . 3.91 110.007 -175.028 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.811 0 N-CA-C 111.757 -0.537 . . . . 5.63 111.757 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.1 t -126.97 126.65 43.55 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.964 -0.384 . . . . 4.28 109.964 -179.277 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 11.7 m-90 -103.26 -3.51 25.58 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.408 0.623 . . . . 4.74 109.992 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 146.53 176.78 20.63 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.624 -0.99 . . . . 2.03 110.624 -176.165 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 12.3 mm100 -81.98 107.58 14.8 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 117.163 0.482 . . . . 4.17 110.486 -178.887 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 42.5 t 174.21 158.2 0.15 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.42 -0.809 . . . . 1.88 109.434 -178.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 9.5 p -132.59 16.69 4.37 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.95 0.405 . . . . 2.4 111.258 178.323 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.42 HG22 ' HB2' ' A' ' 67' ' ' SER . 30.8 m -87.43 -23.28 24.55 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.269 -0.423 . . . . 3.75 111.49 -175.554 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 169.07 -103.87 0.2 Allowed Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.438 -0.887 . . . . 1.12 112.306 -178.674 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.6 t -124.59 144.86 49.92 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 108.852 -0.796 . . . . 0.96 108.852 178.374 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.531 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.1 mp -98.47 141.96 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 121.652 0.739 . . . . 0.96 111.509 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.596 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -145.75 166.39 26.01 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 114.793 -1.094 . . . . 0.91 110.723 178.75 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.407 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 37.1 t -114.83 104.93 12.43 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.613 -0.721 . . . . 0.34 109.552 179.286 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.782 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 63.4 m -87.69 133.06 33.9 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.519 -0.764 . . . . 0.19 111.199 -175.505 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.401 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -71.27 -27.31 63.35 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 115.251 -0.886 . . . . 0.38 108.939 173.529 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -145.63 128.39 16.27 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.64 -0.709 . . . . 1.03 110.135 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.6 t -115.73 106.09 19.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.906 0.384 . . . . 0.18 110.27 177.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.9 m -131.91 143.35 48.67 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.026 -0.534 . . . . 0.18 110.922 -175.594 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.489 ' O ' ' HB3' ' A' ' 22' ' ' SER . 26.6 Cg_exo -62.8 139.85 76.89 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.225 1.95 . . . . 0.19 111.339 172.258 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.9 -22.57 70.43 Favored Glycine 0 C--N 1.329 0.159 0 C-N-CA 120.967 -0.635 . . . . 0.18 112.62 -177.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -100.39 5.83 44.39 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.636 0.732 . . . . 2.27 109.793 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.6 t -75.13 155.11 37.39 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.656 -0.702 . . . . 0.24 110.272 177.114 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -54.51 -41.31 69.49 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.185 0.517 . . . . 1.06 110.116 177.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.682 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.7 mm? -73.34 -57.75 3.79 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.692 -0.685 . . . . 1.11 110.66 177.427 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -54.52 -40.06 68.33 Favored Glycine 0 C--N 1.33 0.205 0 C-N-CA 121.249 -0.5 . . . . 0.16 113.095 -176.738 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 90.7 m -69.81 -40.75 75.74 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.7 0.286 . . . . 0.24 110.311 -178.438 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.448 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.6 tm? -66.85 -36.85 83.27 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.539 -0.541 . . . . 1.01 109.539 177.059 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.682 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 12.5 mt -68.21 -47.32 68.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.89 -0.595 . . . . 0.37 110.801 -177.13 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.568 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.5 pp -74.11 -23.67 59.34 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.808 -0.357 . . . . 0.41 110.676 -179.063 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.404 ' N ' HD12 ' A' ' 29' ' ' LEU . 25.7 t70 -61.68 -36.61 81.35 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.474 0.654 . . . . 0.66 109.762 173.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -73.95 -29.63 62.11 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-N 114.983 -1.008 . . . . 2.07 110.03 179.418 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 90.9 mt -93.13 -16.53 24.81 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.832 -1.076 . . . . 0.71 112.157 -172.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.76 35.8 34.74 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 121.263 -0.494 . . . . 0.75 112.624 178.627 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.568 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 18.4 mt -94.25 139.8 17.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.702 0.287 . . . . 0.68 110.63 -177.145 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.9 t -122.16 98.17 5.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 109.83 -0.433 . . . . 1.87 109.83 176.287 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 22.7 mt -83.13 135.56 34.77 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.17 -0.468 . . . . 2.76 111.251 -177.141 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 -73.36 -24.18 60.3 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.717 -0.674 . . . . 2.65 109.907 174.264 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -136.77 89.57 17.52 Favored Pre-proline 0 N--CA 1.446 -0.659 0 N-CA-C 108.026 -1.102 . . . . 2.29 108.026 178.285 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.29 -1.04 9.03 Favored 'Trans proline' 0 CA--C 1.519 -0.27 0 C-N-CA 122.193 1.929 . . . . 0.64 112.096 -177.218 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.7 p -93.36 20.57 6.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.407 0.622 . . . . 0.51 111.246 -177.85 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.427 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 32.0 m -101.75 162.72 3.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.551 -0.75 . . . . 0.24 110.064 174.176 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.442 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.7 mt -86.62 121.47 29.19 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.142 -0.481 . . . . 0.22 109.969 176.413 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 17.5 pt -104.15 137.69 31.93 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 CA-C-O 121.208 0.528 . . . . 0.15 110.132 176.301 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.782 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -107.42 110.05 3.13 Favored Glycine 0 N--CA 1.44 -1.059 0 C-N-CA 120.605 -0.807 . . . . 0.31 112.82 -176.608 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -86.05 132.73 33.99 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.032 -0.729 . . . . 0.57 109.032 175.278 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.43 37.69 26.93 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.001 -1.095 . . . . 0.21 111.734 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.557 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.23 116.42 32.14 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.139 0.495 . . . . 0.25 111.368 -173.373 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.432 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 6.6 m-20 -100.35 131.9 23.31 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.405 -0.816 . . . . 2.21 109.158 175.099 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.467 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 12.4 Cg_exo -63.87 123.28 11.71 Favored 'Trans proline' 0 N--CA 1.461 -0.408 0 C-N-CA 122.742 2.294 . . . . 0.44 110.965 178.39 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.455 HG13 ' HA ' ' A' ' 12' ' ' GLN . 24.8 mt -80.67 89.29 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.498 0.666 . . . . 0.46 110.417 -175.622 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.8 t -126.45 14.02 7.64 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.666 0.746 . . . . 0.88 109.768 177.736 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 13.0 p -82.01 147.15 6.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.095 -0.957 . . . . 1.44 109.786 178.051 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -80.68 59.94 3.81 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.327 0.584 . . . . 2.94 110.746 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.65 112.6 1.9 Allowed Glycine 0 N--CA 1.445 -0.744 0 CA-C-N 115.648 -0.705 . . . . 3.5 111.662 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 32.4 m -90.08 -29.54 18.29 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 120.902 0.382 . . . . 4.9 110.758 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 28.0 m -90.24 -24.69 20.89 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.912 0.387 . . . . 4.06 110.588 177.384 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -134.41 80.22 1.84 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.832 -0.622 . . . . 3.13 109.861 -177.348 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -101.24 -30.18 11.67 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.735 -0.666 . . . . 0.99 111.032 178.814 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.0 t -147.67 142.47 26.78 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.413 -0.812 . . . . 0.74 110.837 -178.348 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.6 p -102.71 -40.78 6.45 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.98 -0.554 . . . . 2.14 111.604 -179.333 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.401 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -101.14 -85.99 0.41 Allowed 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 121.051 -0.26 . . . . 0.54 111.567 -176.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 26.9 m -132.47 129.18 38.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.666 0.269 . . . . 0.29 111.302 -177.753 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -86.63 130.57 34.43 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.911 0.386 . . . . 0.25 110.142 179.249 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.675 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.7 m -143.06 169.82 11.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.259 0.552 . . . . 0.21 111.415 -176.829 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' CYS . . . . . 0.43 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 38.0 t -137.29 107.67 6.47 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.478 -0.783 . . . . 0.39 109.862 -178.669 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.765 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.8 m -93.48 137.63 32.57 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.442 0.639 . . . . 0.65 111.735 -177.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.42 ' HB2' HG22 ' A' ' 8' ' ' THR . 38.2 t -87.24 -20.09 27.41 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.128 -0.942 . . . . 1.15 110.955 179.45 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.4 t70 -98.92 160.41 14.28 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.161 -0.472 . . . . 1.6 109.993 -177.363 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -118.67 5.72 11.59 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 111.928 0.344 . . . . 2.49 111.928 -173.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -84.7 89.63 7.54 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.014 0.435 . . . . 2.27 110.764 -179.019 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.9 m -100.06 130.93 48.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.03 0.443 . . . . 1.1 111.327 179.275 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.501 ' H ' HG12 ' A' ' 75' ' ' ILE . 9.2 t -80.5 -1.47 41.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.046 -0.524 . . . . 1.41 110.484 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.2 -33.89 3.21 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.833 -0.621 . . . . 0.48 112.585 178.738 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.7 m -140.72 4.58 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 117.202 0.501 . . . . 0.49 111.788 175.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.501 HG12 ' H ' ' A' ' 72' ' ' SER . 19.2 pt -100.2 176.63 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.466 0.651 . . . . 0.3 112.039 179.726 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.765 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -145.93 140.57 27.04 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 114.291 -1.322 . . . . 0.18 109.411 174.722 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 71.0 mt -120.84 127.22 75.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.894 0.378 . . . . 0.26 111.461 -177.377 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.541 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 81.77 48.92 5.61 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 121.026 -0.607 . . . . 0.17 112.064 177.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.442 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.3 140.42 33.5 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 112.665 0.617 . . . . 0.65 112.665 -175.36 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.9 mt -111.34 132.75 21.63 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.43 -0.805 . . . . 0.29 109.603 170.546 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 16.9 Cg_exo -66.6 121.75 9.04 Favored 'Trans proline' 0 C--O 1.232 0.217 0 C-N-CA 122.974 2.449 . . . . 0.25 112.638 -178.835 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.412 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 6.2 m -124.22 161.23 27.48 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.671 0 CA-C-N 115.917 -0.583 . . . . 0.42 110.042 -179.607 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.418 HG22 ' HG ' ' A' ' 84' ' ' LEU . 28.8 m -144.98 133.7 22.23 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 116.656 -0.247 . . . . 2.07 110.761 176.828 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.418 ' HG ' HG22 ' A' ' 83' ' ' THR . 89.0 mt . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.365 -0.826 . . . . 3.91 111.963 178.632 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.753 0 N-CA-C 112.061 -0.416 . . . . 5.63 112.061 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.4 m -88.56 46.95 1.44 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.805 0.336 . . . . 4.28 111.574 -177.642 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 28.5 m-90 -117.55 125.31 50.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.797 0.332 . . . . 4.74 110.281 176.002 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -89.58 65.01 3.1 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 121.022 -0.608 . . . . 2.03 111.804 178.502 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -87.83 133.99 33.78 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.013 0.435 . . . . 4.17 110.437 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.474 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 21.9 t -134.47 143.99 47.83 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.692 -0.686 . . . . 1.88 109.954 -177.209 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 11.9 p -74.04 -10.46 59.65 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.255 -0.43 . . . . 2.4 111.551 -177.009 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.6 ' HB ' ' SG ' ' A' ' 65' ' ' CYS . 5.5 m -103.19 -8.83 20.11 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.185 0.517 . . . . 3.75 110.367 177.844 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 152.93 -126.19 1.94 Allowed Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.559 -0.829 . . . . 1.12 112.651 -179.416 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 41.1 t -107.63 151.25 25.89 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 110.299 -0.26 . . . . 0.96 110.299 -177.644 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.474 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 41.3 mt -102.83 137.49 30.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.517 0.675 . . . . 0.96 110.709 173.767 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.528 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -144.08 159.34 42.78 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.01 -0.995 . . . . 0.91 110.531 179.007 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 41.7 t -105.5 102.58 12.04 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.794 -0.639 . . . . 0.34 109.686 178.598 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.814 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 81.9 m -85.77 135.43 33.74 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.489 -0.778 . . . . 0.19 110.817 -176.732 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.74 -31.04 59.41 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 115.408 -0.815 . . . . 0.38 109.298 174.708 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -138.12 118.29 13.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.81 -0.632 . . . . 1.03 110.245 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.3 t -110.69 103.04 14.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 121.042 0.448 . . . . 0.18 110.094 178.789 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.0 m -133.31 142.67 45.11 Favored Pre-proline 0 C--N 1.32 -0.688 0 CA-C-N 115.83 -0.623 . . . . 0.18 110.993 -174.392 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.481 ' O ' ' HB3' ' A' ' 22' ' ' SER . 38.3 Cg_exo -60.17 139.9 89.55 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.161 1.907 . . . . 0.19 111.407 172.58 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.23 -21.78 70.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.814 -0.708 . . . . 0.18 112.342 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -94.22 -4.97 48.0 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.211 0.529 . . . . 2.27 110.524 175.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.481 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 30.0 t -68.79 154.5 41.88 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.813 -0.63 . . . . 0.24 110.54 179.041 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -52.42 -44.27 65.33 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.332 0.587 . . . . 1.06 110.1 178.067 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.663 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.2 mm? -70.6 -58.05 4.09 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.503 -0.771 . . . . 1.11 110.847 178.197 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.461 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.56 -39.41 74.66 Favored Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.227 -0.511 . . . . 0.16 113.307 -176.452 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 87.1 m -67.84 -42.1 81.95 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 120.827 0.346 . . . . 0.24 110.325 -179.015 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -61.89 -43.1 99.53 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.216 -0.661 . . . . 1.01 109.216 175.222 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.663 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.7 mt -61.46 -51.55 68.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.135 -0.939 . . . . 0.37 111.125 -175.633 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.543 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -76.37 -23.89 54.14 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.723 -0.391 . . . . 0.41 111.677 -175.322 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.508 ' N ' HD12 ' A' ' 29' ' ' LEU . 11.8 t70 -68.11 -33.49 74.61 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.512 0.672 . . . . 0.66 109.363 176.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -78.33 -23.83 46.85 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.287 -0.869 . . . . 2.07 109.962 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.7 mt -97.34 -5.24 36.95 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.193 -0.912 . . . . 0.71 111.878 -174.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 68.31 44.48 74.59 Favored Glycine 0 N--CA 1.453 -0.229 0 CA-C-N 115.74 -0.663 . . . . 0.75 112.896 177.348 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.543 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 23.3 mt -97.57 145.53 9.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.673 0.273 . . . . 0.68 110.637 -178.43 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.8 t -107.88 116.27 50.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.127 -0.488 . . . . 1.87 109.695 176.06 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.555 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.5 pp -90.81 129.95 36.83 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.25 0.547 . . . . 2.76 111.25 -179.241 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -90.96 -26.79 19.08 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.917 -0.771 . . . . 2.65 108.917 170.289 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -139.42 94.92 9.3 Favored Pre-proline 0 N--CA 1.447 -0.613 0 CA-C-N 114.92 -1.037 . . . . 2.29 108.495 177.369 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -68.43 -3.93 11.94 Favored 'Trans proline' 0 N--CA 1.466 -0.137 0 C-N-CA 122.256 1.971 . . . . 0.64 111.564 -177.464 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.8 p -87.89 6.2 36.73 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.337 -0.847 . . . . 0.51 111.45 -175.497 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.428 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.9 m -92.73 158.26 2.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.209 0.528 . . . . 0.24 110.875 179.407 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.9 mt -88.21 128.62 35.46 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.476 -0.784 . . . . 0.22 109.806 175.541 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.431 HD13 HD23 ' A' ' 29' ' ' LEU . 10.2 pt -106.83 133.07 52.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.203 0.525 . . . . 0.15 110.091 176.118 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.814 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.78 98.16 1.3 Allowed Glycine 0 N--CA 1.438 -1.19 0 CA-C-N 115.385 -0.825 . . . . 0.31 113.02 -175.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -77.4 137.84 38.94 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.583 -0.525 . . . . 0.57 109.583 177.286 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.482 ' H ' HG23 ' A' ' 74' ' ' VAL . . . 71.48 41.08 58.82 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.431 -0.89 . . . . 0.21 112.072 -178.615 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.528 ' SG ' ' HB2' ' A' ' 12' ' ' GLN . 0.1 OUTLIER -105.14 111.28 23.99 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.294 0.569 . . . . 0.25 111.225 -175.312 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.454 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.5 t70 -101.43 138.53 19.93 Favored Pre-proline 0 C--N 1.316 -0.849 0 CA-C-N 115.483 -0.781 . . . . 2.21 110.927 175.886 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 25.7 Cg_exo -58.9 119.3 6.46 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 123.626 2.884 . . . . 0.44 111.628 177.671 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 29.7 mt -80.48 102.3 6.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.054 0.454 . . . . 0.46 110.501 -177.205 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.9 t -133.68 16.36 3.96 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.521 0.677 . . . . 0.88 110.601 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 5.4 p -128.68 154.24 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.637 -0.71 . . . . 1.44 109.853 178.526 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . 70.39 -63.27 0.41 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 123.387 0.675 . . . . 2.94 112.396 175.567 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 174.68 -114.43 0.5 Allowed Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 121.133 -0.556 . . . . 3.5 111.837 -178.505 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 67.8 m -150.83 -37.05 0.14 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.618 0.247 . . . . 4.9 111.186 177.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.1 m -81.52 -62.22 1.71 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.884 0.373 . . . . 4.06 110.522 178.652 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -89.88 41.7 1.06 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 122.102 0.953 . . . . 3.13 109.656 -179.712 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -129.88 17.81 5.66 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.152 -0.931 . . . . 0.99 110.386 -179.396 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.8 t -151.34 127.99 10.83 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.77 -0.65 . . . . 0.74 109.786 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 28.5 t -94.4 -37.76 11.29 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.381 -0.372 . . . . 2.14 111.101 -178.205 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -86.59 -86.46 0.15 Allowed 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 121.181 -0.208 . . . . 0.54 111.499 -176.655 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 19.2 m -149.89 130.98 14.41 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.773 0.321 . . . . 0.29 111.145 -178.812 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.445 ' HB3' ' HB ' ' A' ' 83' ' ' THR . . . -94.95 139.47 31.29 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.852 0.358 . . . . 0.25 110.4 -178.284 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.552 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 7.2 m -145.55 162.97 11.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.315 0.578 . . . . 0.21 111.285 -177.6 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' CYS . . . . . 0.6 ' SG ' ' HB ' ' A' ' 8' ' ' THR . 30.2 t -115.44 107.8 15.67 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.122 -0.944 . . . . 0.39 109.703 175.678 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.634 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 28.3 m -100.12 140.04 34.93 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.212 0.53 . . . . 0.65 111.441 -176.682 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 40.0 m -97.35 -20.54 17.76 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.633 -0.712 . . . . 1.15 111.241 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -110.43 139.59 45.49 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.997 -0.547 . . . . 1.6 110.372 -176.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -117.14 25.8 10.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.4 -0.364 . . . . 2.49 111.939 -175.033 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 54.8 t30 -80.55 71.61 7.41 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.597 0.713 . . . . 2.27 109.635 176.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.409 HG12 ' O ' ' A' ' 75' ' ' ILE . 32.7 m -84.66 146.57 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 CA-C-N 115.541 -0.754 . . . . 1.1 112.125 -173.549 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.553 ' OG ' HG12 ' A' ' 75' ' ' ILE . 80.2 p -95.4 5.26 52.1 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.387 -0.824 . . . . 1.41 110.222 177.457 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.71 -32.7 3.43 Favored Glycine 0 N--CA 1.445 -0.711 0 CA-C-N 115.361 -0.836 . . . . 0.48 111.88 -176.253 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.482 HG23 ' H ' ' A' ' 46' ' ' GLY . 21.3 m -140.24 -21.42 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 112.558 0.577 . . . . 0.49 112.558 176.162 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.553 HG12 ' OG ' ' A' ' 72' ' ' SER . 7.4 pt -73.21 175.45 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.707 0.765 . . . . 0.3 112.343 -173.839 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.634 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.21 141.39 23.12 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.233 -1.348 . . . . 0.18 108.565 178.312 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.5 mt -120.78 140.27 45.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 C-N-CA 120.514 -0.474 . . . . 0.26 111.484 -175.056 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.428 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 72.06 52.75 10.49 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-N 115.95 -0.568 . . . . 0.17 111.908 178.163 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.552 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 12.2 m -106.58 145.03 32.4 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.04 0.448 . . . . 0.65 111.969 -174.079 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 91.3 mt -115.92 132.2 23.33 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 115.514 -0.766 . . . . 0.29 109.811 173.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.51 ' HA ' HG12 ' A' ' 64' ' ' VAL . 18.3 Cg_exo -64.77 129.06 22.41 Favored 'Trans proline' 0 C--O 1.234 0.297 0 C-N-CA 123.19 2.593 . . . . 0.25 112.982 -176.686 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.403 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 5.4 m -136.7 157.67 36.62 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.596 0 CA-C-N 115.812 -0.631 . . . . 0.42 110.333 178.532 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.471 HG22 ' HG ' ' A' ' 84' ' ' LEU . 85.0 m 65.72 162.79 0.15 Allowed 'General case' 0 CA--C 1.545 0.784 0 O-C-N 123.395 0.434 . . . . 2.07 111.755 176.079 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.471 ' HG ' HG22 ' A' ' 83' ' ' THR . 75.6 mt . . . . . 0 C--O 1.248 1.011 0 CA-C-O 119.017 -0.516 . . . . 3.91 111.16 177.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.7 0 N-CA-C 111.75 -0.54 . . . . 5.63 111.75 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 31.8 t -125.19 140.07 53.19 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.88 0.372 . . . . 4.28 110.427 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 44.0 p90 -138.35 31.63 2.35 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.639 0.733 . . . . 4.74 109.439 178.156 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.434 ' HA3' ' HB ' ' A' ' 11' ' ' ILE . . . 91.52 138.67 8.09 Favored Glycine 0 N--CA 1.444 -0.788 0 CA-C-N 115.045 -0.979 . . . . 2.03 111.553 -176.487 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 48.8 tt0 -85.03 108.78 17.79 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-O 120.868 0.366 . . . . 4.17 110.208 -178.5 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 46.9 t -151.29 139.84 20.6 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.752 -0.462 . . . . 1.88 109.752 178.537 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 18.1 m -91.32 -17.01 26.6 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.583 -0.28 . . . . 2.4 111.293 -176.73 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 p -100.52 4.87 43.9 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 112.286 0.476 . . . . 3.75 112.286 -177.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 149.19 -157.17 27.14 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.442 -0.885 . . . . 1.12 112.927 177.05 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.1 p -85.25 152.31 23.41 Favored 'General case' 0 N--CA 1.447 -0.611 0 C-N-CA 122.745 0.418 . . . . 0.96 110.62 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.453 HG22 HD12 ' A' ' 50' ' ' ILE . 27.7 mt -102.72 133.99 44.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.843 0.83 . . . . 0.96 111.338 175.739 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.519 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -138.75 159.97 40.81 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.599 -1.182 . . . . 0.91 109.797 177.042 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.453 ' HB2' HD11 ' A' ' 50' ' ' ILE . 41.1 t -109.46 108.45 18.96 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.428 -0.582 . . . . 0.34 109.428 178.084 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.81 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 94.1 m -90.62 129.96 36.69 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.523 -0.762 . . . . 0.19 111.404 -174.597 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.401 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.3 OUTLIER -70.76 -34.65 72.04 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.028 -0.987 . . . . 0.38 109.622 174.433 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -130.91 116.29 17.69 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.87 -0.604 . . . . 1.03 110.085 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 99.3 t -110.2 102.6 14.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.058 0.456 . . . . 0.18 109.981 178.606 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.7 m -130.11 143.59 49.75 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 115.896 -0.593 . . . . 0.18 111.231 -174.053 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.521 ' O ' ' HB3' ' A' ' 22' ' ' SER . 35.5 Cg_exo -61.83 141.11 88.94 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.42 2.08 . . . . 0.19 111.36 171.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.96 -25.52 72.02 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.987 -0.625 . . . . 0.18 112.584 -178.642 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -97.87 7.1 46.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.238 0.542 . . . . 2.27 110.118 177.71 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.521 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 28.9 t -75.13 154.23 37.86 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.523 -0.762 . . . . 0.24 109.753 176.168 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -58.69 -31.94 68.69 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.18 0.514 . . . . 1.06 110.389 178.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.697 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.1 mm? -73.39 -64.52 0.97 Allowed 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 115.722 -0.672 . . . . 1.11 110.408 173.076 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.78 -38.35 64.17 Favored Glycine 0 C--N 1.33 0.223 0 CA-C-N 115.788 -0.642 . . . . 0.16 113.707 -174.013 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 87.7 m -68.43 -44.72 74.35 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.818 0.342 . . . . 0.24 110.692 -177.126 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.433 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.7 tm? -64.72 -36.89 85.74 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.261 -0.644 . . . . 1.01 109.261 177.613 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.697 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 18.9 mt -65.56 -49.54 68.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.881 -0.599 . . . . 0.37 110.436 -178.272 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.491 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -75.31 -22.08 57.97 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.469 -0.332 . . . . 0.41 111.584 -176.257 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.45 ' N ' HD12 ' A' ' 29' ' ' LEU . 19.8 t70 -66.56 -34.81 78.72 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.325 0.584 . . . . 0.66 109.656 175.697 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -72.92 -20.21 61.11 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.126 -0.943 . . . . 2.07 109.594 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.5 mt -98.14 -19.58 17.83 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.346 -1.297 . . . . 0.71 111.308 -176.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.42 24.55 60.71 Favored Glycine 0 N--CA 1.452 -0.271 0 CA-C-N 115.891 -0.595 . . . . 0.75 112.609 179.495 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.491 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 28.7 mt -78.9 133.28 30.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.967 0.413 . . . . 0.68 110.913 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.5 t -113.1 97.96 6.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.018 -0.537 . . . . 1.87 110.038 176.616 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.4 mt -93.73 138.26 32.11 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.169 -0.468 . . . . 2.76 110.739 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -78.96 -23.81 44.28 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.279 0.561 . . . . 2.65 109.589 175.505 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 24.7 m-20 -133.05 92.21 26.22 Favored Pre-proline 0 N--CA 1.446 -0.628 0 CA-C-N 115.446 -0.797 . . . . 2.29 109.117 176.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -72.8 6.96 2.16 Favored 'Trans proline' 0 N--CA 1.463 -0.287 0 C-N-CA 122.262 1.975 . . . . 0.64 111.445 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.7 p -83.71 -8.25 59.31 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.534 -0.757 . . . . 0.51 110.878 -178.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.471 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 33.4 m -78.54 151.08 5.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.909 -0.587 . . . . 0.24 110.792 179.283 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.0 mt -81.61 120.78 25.51 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.609 -0.723 . . . . 0.22 110.094 177.191 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 12.6 pt -102.52 131.85 49.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.29 0.567 . . . . 0.15 110.119 176.107 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.81 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.11 99.9 1.58 Allowed Glycine 0 N--CA 1.438 -1.207 0 CA-C-N 115.529 -0.76 . . . . 0.31 113.175 -174.54 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -80.67 139.15 36.33 Favored 'General case' 0 C--N 1.314 -0.953 0 N-CA-C 109.028 -0.731 . . . . 0.57 109.028 175.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.33 34.64 35.9 Favored Glycine 0 N--CA 1.444 -0.82 0 C-N-CA 119.629 -1.272 . . . . 0.21 111.523 -178.731 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.535 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -102.4 118.72 37.47 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.144 0.497 . . . . 0.25 111.121 -174.315 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -100.55 134.5 20.59 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 115.669 -0.696 . . . . 2.21 109.412 175.148 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -63.98 123.13 11.43 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.589 2.193 . . . . 0.44 110.967 177.423 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.453 HD11 ' HB2' ' A' ' 13' ' ' CYS . 12.4 mt -83.55 89.58 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-O 121.482 0.658 . . . . 0.46 109.75 -178.062 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 10.6 t -119.09 16.68 13.28 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.255 -0.884 . . . . 0.88 109.878 -178.304 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 13.1 p -92.38 139.91 17.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.34 -0.845 . . . . 1.44 110.312 179.553 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -79.81 145.01 33.03 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.259 -0.428 . . . . 2.94 110.097 177.122 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.96 69.64 1.37 Allowed Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.49 -0.862 . . . . 3.5 111.304 -175.712 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.0 m -78.85 53.47 1.39 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.995 0.426 . . . . 4.9 111.7 -175.575 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.5 m -85.54 -57.5 3.04 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.301 -0.629 . . . . 4.06 109.301 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -122.34 50.25 1.5 Allowed 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.011 -0.737 . . . . 3.13 109.011 174.782 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -88.67 -2.84 58.8 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.524 -0.762 . . . . 0.99 110.731 -177.463 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.3 t -140.24 118.58 12.11 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.575 -0.739 . . . . 0.74 110.063 176.472 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 51.1 m -108.25 17.17 22.52 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.225 -0.443 . . . . 2.14 111.735 -177.163 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.401 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -144.52 -82.18 0.16 Allowed 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.752 -0.379 . . . . 0.54 111.536 178.52 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 87.1 m -150.11 123.96 9.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.864 0.364 . . . . 0.29 110.825 -179.482 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -86.44 129.59 34.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.057 0.456 . . . . 0.25 110.209 -177.433 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.567 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 6.4 m -140.88 161.58 23.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 115.937 -0.574 . . . . 0.21 111.023 -177.702 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' CYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 52.8 t -120.18 110.33 16.48 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.633 -0.712 . . . . 0.39 109.389 177.092 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.782 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 15.8 m -97.57 132.23 43.43 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.133 0.492 . . . . 0.65 111.286 -176.292 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.4 m -84.11 -25.78 29.45 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.583 -0.735 . . . . 1.15 111.04 -178.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -102.01 134.66 44.88 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.791 -0.64 . . . . 1.6 110.145 -177.877 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -100.99 10.1 41.49 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.322 -0.399 . . . . 2.49 111.311 -174.554 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -79.57 103.21 9.32 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.086 0.47 . . . . 2.27 110.131 179.427 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.871 HG12 ' H ' ' A' ' 73' ' ' GLY . 73.0 t -122.84 133.04 70.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.019 -0.537 . . . . 1.1 111.244 -173.888 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.586 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 88.8 p -80.12 2.58 23.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.531 -0.758 . . . . 1.41 111.257 -177.296 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.871 ' H ' HG12 ' A' ' 71' ' ' VAL . . . 126.57 -32.31 3.73 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.664 -0.698 . . . . 0.48 112.04 -178.387 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.0 m -138.69 -9.77 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 112.315 0.487 . . . . 0.49 112.315 -179.381 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.586 ' CG1' ' H ' ' A' ' 72' ' ' SER . 4.1 pt -88.79 -179.43 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.707 0.765 . . . . 0.3 112.705 -175.546 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.782 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -151.51 142.17 22.73 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 114.287 -1.324 . . . . 0.18 108.798 174.308 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.9 mt -120.4 137.1 55.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.915 0.388 . . . . 0.26 111.945 -175.141 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.471 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 69.89 52.14 20.89 Favored Glycine 0 C--N 1.333 0.371 0 CA-C-N 115.922 -0.581 . . . . 0.17 111.778 177.723 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.567 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 12.8 m -103.02 134.35 46.62 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.274 0.559 . . . . 0.65 111.909 -173.634 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 90.4 mt -107.79 131.82 21.46 Favored Pre-proline 0 C--N 1.322 -0.614 0 CA-C-N 115.563 -0.744 . . . . 0.29 110.032 175.202 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.427 ' HA ' HG12 ' A' ' 64' ' ' VAL . 25.4 Cg_exo -63.24 120.67 8.22 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.917 2.412 . . . . 0.25 112.678 -179.315 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.427 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 4.3 m -120.31 140.2 45.16 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 CA-C-N 115.968 -0.56 . . . . 0.42 110.201 178.23 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.453 HG22 ' HG ' ' A' ' 84' ' ' LEU . 95.0 m 63.81 142.59 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 115.799 -0.637 . . . . 2.07 111.681 -176.031 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.453 ' HG ' HG22 ' A' ' 83' ' ' THR . 79.4 mt . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.145 -0.931 . . . . 3.91 111.509 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.645 0 N-CA-C 111.662 -0.575 . . . . 5.63 111.662 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.5 p -88.28 -73.93 0.47 Allowed 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.679 0.239 . . . . 4.28 110.378 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 89.6 m95 58.24 93.55 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.258 0 O-C-N 123.864 0.728 . . . . 4.74 111.384 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -70.06 107.98 2.32 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.884 -0.674 . . . . 2.03 112.432 -179.538 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -110.84 137.55 48.34 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.482 -0.562 . . . . 4.17 109.482 172.532 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.477 ' SG ' ' N ' ' A' ' 7' ' ' SER . 29.1 p -83.66 -58.51 2.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.805 0.336 . . . . 1.88 110.302 -178.514 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.477 ' N ' ' SG ' ' A' ' 6' ' ' CYS . 65.5 m -163.05 -65.48 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.075 -0.511 . . . . 2.4 109.715 -179.728 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.8 p -100.26 -24.53 14.52 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.247 -0.433 . . . . 3.75 112.015 -177.352 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -128.93 -177.03 14.67 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.675 -0.774 . . . . 1.12 112.518 -178.247 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 34.1 t -90.98 151.24 21.15 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 109.502 -0.555 . . . . 0.96 109.502 177.414 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.418 HG22 HD12 ' A' ' 50' ' ' ILE . 43.1 mt -95.7 137.16 24.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 121.664 0.745 . . . . 0.96 110.989 178.058 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLN . . . . . 0.532 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -132.24 163.06 29.43 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.775 -1.102 . . . . 0.91 109.949 176.781 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 42.0 t -106.28 99.49 9.07 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.809 -0.632 . . . . 0.34 109.556 179.055 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.865 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 54.0 m -86.01 130.66 34.47 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-N 115.707 -0.678 . . . . 0.19 111.352 -175.554 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.445 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -77.82 -30.87 51.37 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.196 -0.911 . . . . 0.38 109.77 177.506 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.641 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 19.3 m-20 -133.3 98.59 4.29 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.117 -0.492 . . . . 1.03 111.256 175.609 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 71.8 t -89.48 100.85 11.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.162 0.506 . . . . 0.18 109.732 174.234 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 29.6 m -128.45 141.1 40.35 Favored Pre-proline 0 C--N 1.318 -0.768 0 CA-C-N 115.843 -0.617 . . . . 0.18 110.697 -174.761 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.466 ' HB2' ' HB2' ' A' ' 22' ' ' SER . 31.9 Cg_exo -59.24 135.58 66.65 Favored 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 122.073 1.849 . . . . 0.19 111.521 172.741 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.8 -15.22 64.23 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.888 -0.673 . . . . 0.18 112.136 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -103.44 4.56 36.25 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.053 0.454 . . . . 2.27 110.248 175.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.466 ' HB2' ' HB2' ' A' ' 19' ' ' PRO . 29.0 t -78.53 158.35 28.59 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.051 -0.522 . . . . 0.24 109.898 177.717 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -53.19 -42.79 66.61 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.974 0.416 . . . . 1.06 109.991 176.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.701 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.9 mm? -67.7 -65.08 0.74 Allowed 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 115.669 -0.696 . . . . 1.11 110.493 178.259 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.69 -36.44 59.29 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.983 -0.553 . . . . 0.16 113.329 -174.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 84.9 m -68.55 -45.67 71.53 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.79 0.329 . . . . 0.24 110.298 -178.175 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.432 ' O ' HD13 ' A' ' 27' ' ' LEU . 1.3 tm? -65.96 -36.38 83.17 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.15 -0.685 . . . . 1.01 109.15 178.212 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.701 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.7 mt -67.34 -46.55 73.12 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.603 -0.726 . . . . 0.37 111.033 -177.363 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.514 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.26 -22.87 51.49 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 120.321 -0.551 . . . . 0.41 111.137 -178.695 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.478 ' N ' HD12 ' A' ' 29' ' ' LEU . 13.0 t70 -67.98 -35.8 78.97 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.044 -0.724 . . . . 0.66 109.044 173.135 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -69.1 -33.22 73.16 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 114.717 -1.129 . . . . 2.07 109.429 178.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 67.6 mt -91.87 -10.86 38.13 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.56 -1.2 . . . . 0.71 111.867 -176.412 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.29 35.71 88.33 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.767 -0.651 . . . . 0.75 112.6 179.129 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.514 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 56.5 mt -76.08 129.0 37.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 120.814 0.34 . . . . 0.68 111.163 -176.528 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.2 p -86.56 101.0 10.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.746 0.784 . . . . 1.87 109.415 172.523 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.516 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.8 pp -76.29 132.7 39.98 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.722 -0.672 . . . . 2.76 111.18 -177.358 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -86.83 -29.73 22.01 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.745 -0.835 . . . . 2.65 108.745 172.248 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -144.96 112.33 4.84 Favored Pre-proline 0 N--CA 1.443 -0.803 0 N-CA-C 107.493 -1.299 . . . . 2.29 107.493 174.01 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.407 ' HB3' HD22 ' A' ' 36' ' ' LEU . 70.9 Cg_endo -75.52 -1.5 11.4 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.197 1.931 . . . . 0.64 112.808 -173.228 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 35.2 p -106.55 20.51 18.89 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.261 0.553 . . . . 0.51 111.121 -175.727 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.46 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 34.8 m -87.72 156.59 3.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.589 -0.732 . . . . 0.24 110.081 175.143 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.454 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.9 mt -85.6 121.26 28.04 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.808 -0.442 . . . . 0.22 109.808 176.638 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 22.2 pt -106.41 140.75 23.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.101 0.477 . . . . 0.15 110.256 177.493 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.865 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.2 107.35 1.55 Allowed Glycine 0 N--CA 1.439 -1.111 0 C-N-CA 120.586 -0.816 . . . . 0.31 112.949 -175.102 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.641 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 9.4 t70 -80.62 147.91 30.5 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.693 -0.854 . . . . 0.57 108.693 175.257 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 67.46 37.81 90.34 Favored Glycine 0 C--N 1.317 -0.515 0 C-N-CA 120.162 -1.018 . . . . 0.21 111.958 178.277 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -102.63 115.44 30.59 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.01 0.433 . . . . 0.25 111.088 -172.895 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.45 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 2.1 p-10 -100.84 132.07 22.63 Favored Pre-proline 0 C--N 1.318 -0.796 0 CA-C-N 115.698 -0.683 . . . . 2.21 110.161 177.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.94 119.55 6.87 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.399 2.066 . . . . 0.44 110.696 175.058 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.418 HD12 HG22 ' A' ' 11' ' ' ILE . 12.9 mt -79.53 88.92 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 CA-C-O 121.879 0.847 . . . . 0.46 109.913 -177.098 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.7 t -111.45 17.87 19.69 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.512 -1.222 . . . . 0.88 109.415 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 10.6 p -102.39 145.1 12.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 114.737 -1.119 . . . . 1.44 109.252 175.502 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -88.06 81.4 7.44 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.852 0.358 . . . . 2.94 110.848 -179.048 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -133.87 128.6 5.01 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.823 -0.703 . . . . 3.5 111.819 179.508 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 19.2 m -72.45 -34.93 68.12 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.888 0.375 . . . . 4.9 111.498 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 23.1 t -130.61 -51.67 1.07 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.837 0.351 . . . . 4.06 110.773 -179.533 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -79.89 43.79 0.61 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.16 0.505 . . . . 3.13 111.55 -176.03 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -112.03 -2.45 15.06 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.944 -0.571 . . . . 0.99 110.547 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.5 t -146.81 130.92 17.33 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.818 -0.628 . . . . 0.74 110.28 -179.265 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 12.8 p -93.6 -15.37 25.46 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.089 -0.505 . . . . 2.14 111.742 -177.42 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.445 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -128.44 -83.44 0.58 Allowed 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.623 0.601 . . . . 0.54 112.623 -175.172 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.8 m -142.11 131.59 23.8 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.783 0.325 . . . . 0.29 111.301 -176.147 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.94 125.98 34.4 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.031 0.443 . . . . 0.25 110.125 178.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.663 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -141.33 164.99 19.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.119 -0.492 . . . . 0.21 110.806 -177.546 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' CYS . . . . . 0.401 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 29.3 t -131.28 113.0 13.27 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 116.172 -0.467 . . . . 0.39 109.935 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.783 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -95.53 136.73 35.54 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.647 0.737 . . . . 0.65 112.233 -175.406 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.7 m -89.44 -18.45 26.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.641 -1.163 . . . . 1.15 110.806 -179.281 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.467 ' HB2' ' O ' ' A' ' 77' ' ' ILE . 19.8 m-20 -98.31 151.71 20.21 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.887 -0.597 . . . . 1.6 110.332 178.651 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -103.68 -12.28 17.12 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.019 -0.537 . . . . 2.49 110.581 -178.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -67.84 110.2 3.72 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.892 -0.594 . . . . 2.27 110.915 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.5 m -125.19 150.29 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 CA-C-N 116.158 -0.473 . . . . 1.1 110.932 177.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.506 ' H ' HG12 ' A' ' 75' ' ' ILE . 8.1 t -95.31 10.58 35.66 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.651 0.738 . . . . 1.41 109.636 177.008 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.15 -33.42 5.31 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 115.476 -0.784 . . . . 0.48 112.748 177.083 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.5 m -138.01 -0.52 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.644 -0.422 . . . . 0.49 111.64 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.506 HG12 ' H ' ' A' ' 72' ' ' SER . 24.3 pt -100.21 173.84 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 C-N-CA 120.187 -0.605 . . . . 0.3 111.63 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.783 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -141.41 141.08 33.76 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 114.485 -1.234 . . . . 0.18 109.35 176.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.467 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 67.0 mt -122.02 131.93 72.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.742 0.306 . . . . 0.26 111.342 -177.43 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.46 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 75.53 51.68 7.11 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.978 -0.629 . . . . 0.17 111.911 178.638 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.2 m -99.89 138.74 36.55 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.231 0.538 . . . . 0.65 112.232 -176.345 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 92.1 mt -106.98 133.01 20.46 Favored Pre-proline 0 C--N 1.32 -0.689 0 CA-C-N 115.475 -0.784 . . . . 0.29 109.445 170.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.406 ' HA ' HG12 ' A' ' 64' ' ' VAL . 17.3 Cg_exo -65.77 124.62 12.99 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.82 2.347 . . . . 0.25 111.961 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.6 m -123.6 159.51 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-O 121.033 0.444 . . . . 0.42 110.659 -179.828 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.4 HG22 ' HG ' ' A' ' 84' ' ' LEU . 15.2 m -132.76 142.57 49.08 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.585 -0.734 . . . . 2.07 109.52 178.439 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.4 ' HG ' HG22 ' A' ' 83' ' ' THR . 85.6 mt . . . . . 0 C--O 1.248 0.977 0 O-C-N 123.607 0.567 . . . . 3.91 110.714 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 35.3 t . . . . . 0 N--CA 1.45 -0.43 0 N-CA-C 109.155 -0.683 . . . . 0.96 109.155 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.507 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.3 mp -99.27 138.08 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 CA-C-O 121.722 0.772 . . . . 0.96 111.675 176.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.525 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -148.98 167.76 24.92 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.598 -1.183 . . . . 0.91 111.003 178.301 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 37.3 t -116.45 106.71 13.9 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.38 -0.827 . . . . 0.34 109.293 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.818 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 90.4 m -91.8 132.1 36.67 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.753 -0.658 . . . . 0.19 111.597 -173.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.421 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -73.2 -35.97 66.44 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 114.91 -1.041 . . . . 0.38 109.501 173.869 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 19.7 m-20 -128.84 100.57 5.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.051 -0.522 . . . . 1.03 111.334 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.8 t -92.52 99.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.497 -0.557 . . . . 0.18 109.497 173.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.6 m -129.06 140.4 38.5 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 115.761 -0.654 . . . . 0.18 110.863 -174.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.557 ' O ' ' HB3' ' A' ' 22' ' ' SER . 33.4 Cg_exo -58.36 140.9 96.27 Favored 'Trans proline' 0 N--CA 1.464 -0.252 0 C-N-CA 122.371 2.047 . . . . 0.19 111.709 173.313 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.86 -19.47 69.61 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.907 -0.663 . . . . 0.18 112.589 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -103.22 7.43 38.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.388 0.613 . . . . 2.27 109.97 176.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.557 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 13.8 t -73.28 155.78 39.13 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.328 -0.851 . . . . 0.24 110.014 176.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -55.93 -41.01 73.95 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.212 0.529 . . . . 1.06 109.685 176.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.735 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.1 mm? -70.11 -60.52 2.24 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 115.325 -0.852 . . . . 1.11 110.694 176.347 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.44 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -56.03 -41.51 85.21 Favored Glycine 0 CA--C 1.517 0.171 0 CA-C-N 116.053 -0.521 . . . . 0.16 113.348 -174.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 91.5 m -67.84 -39.39 83.85 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.916 0.389 . . . . 0.24 110.499 -178.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -64.71 -39.24 93.32 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.244 -0.65 . . . . 1.01 109.244 176.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.735 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.6 mt -68.13 -50.04 57.22 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.701 -0.681 . . . . 0.37 110.987 -176.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.548 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.8 pp -73.18 -23.72 60.45 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.546 -0.462 . . . . 0.41 111.509 -176.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.532 ' N ' HD12 ' A' ' 29' ' ' LEU . 28.2 t70 -68.97 -31.71 70.76 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.58 0.705 . . . . 0.66 109.192 175.64 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -75.04 -15.29 60.64 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-N 114.988 -1.005 . . . . 2.07 109.918 177.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.8 mt -111.7 0.04 16.17 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.932 -1.031 . . . . 0.71 111.464 -174.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.21 34.66 85.32 Favored Glycine 0 C--N 1.333 0.363 0 CA-C-N 115.855 -0.611 . . . . 0.75 113.015 178.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.548 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 53.9 mt -84.07 125.9 40.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.817 0.341 . . . . 0.68 110.828 -176.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 50.4 t -88.17 121.28 38.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.278 -0.638 . . . . 1.87 109.278 175.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.489 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.6 pp -95.23 130.62 41.91 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.425 0.631 . . . . 2.76 111.703 -176.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -90.87 -29.2 17.66 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 108.56 -0.904 . . . . 2.65 108.56 170.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -142.34 96.1 6.47 Favored Pre-proline 0 N--CA 1.442 -0.838 0 N-CA-C 107.724 -1.213 . . . . 2.29 107.724 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.428 ' HB3' HD22 ' A' ' 36' ' ' LEU . 50.7 Cg_endo -69.84 -5.89 17.34 Favored 'Trans proline' 0 CA--C 1.521 -0.149 0 C-N-CA 122.561 2.174 . . . . 0.64 111.819 -176.313 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.2 p -95.41 19.14 11.3 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.686 -0.688 . . . . 0.51 111.308 -175.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.489 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 32.7 m -92.09 156.6 3.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.798 -0.637 . . . . 0.24 109.855 173.048 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.539 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.1 mt -88.99 121.68 31.59 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 116.061 -0.518 . . . . 0.22 109.835 176.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.411 HD13 HD23 ' A' ' 29' ' ' LEU . 12.1 pt -102.74 133.57 46.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-O 121.247 0.546 . . . . 0.15 110.053 176.685 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.818 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -105.82 95.31 1.05 Allowed Glycine 0 N--CA 1.439 -1.166 0 CA-C-N 115.546 -0.752 . . . . 0.31 112.832 -174.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -76.83 141.91 40.48 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.235 -0.654 . . . . 0.57 109.235 176.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.421 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 70.57 38.8 68.44 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 119.71 -1.233 . . . . 0.21 111.825 -177.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.515 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -107.36 116.28 31.66 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.17 0.51 . . . . 0.25 111.351 -172.98 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.418 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 19.9 m-20 -102.02 134.52 20.04 Favored Pre-proline 0 C--N 1.317 -0.838 0 CA-C-N 115.632 -0.713 . . . . 2.21 109.362 175.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.424 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 16.5 Cg_exo -62.79 126.97 19.31 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.613 2.209 . . . . 0.44 111.351 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 47.1 mt . . . . . 0 C--N 1.326 -0.418 0 CA-C-O 120.958 0.409 . . . . 0.46 110.551 -175.753 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.8 t . . . . . 0 N--CA 1.451 -0.402 0 N-CA-C 110.278 -0.268 . . . . 0.74 110.278 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.3 p -100.79 -26.19 13.86 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.087 -0.506 . . . . 2.14 111.906 -177.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -105.74 -80.56 0.55 Allowed 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 121.067 -0.253 . . . . 0.54 111.585 -177.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 15.1 m -147.19 129.17 15.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.582 0.229 . . . . 0.29 110.797 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.21 131.87 34.14 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.902 0.382 . . . . 0.25 110.372 -178.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.735 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -144.4 171.82 6.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.238 0.542 . . . . 0.21 111.431 -176.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 42.0 t -139.28 106.26 5.44 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.301 -0.863 . . . . 0.39 109.744 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.731 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -88.41 134.57 33.8 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.472 0.653 . . . . 0.65 112.214 -177.474 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.8 m -85.42 -18.53 33.37 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.856 -1.066 . . . . 1.15 111.1 -179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -100.75 160.18 14.57 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.456 -0.572 . . . . 1.6 109.456 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -112.2 -7.89 14.01 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.962 0.411 . . . . 2.49 110.859 -176.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 34.5 t30 -75.71 108.24 8.41 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.077 -0.51 . . . . 2.27 110.862 -178.143 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.1 m -118.87 143.74 29.09 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.726 0 CA-C-N 116.078 -0.51 . . . . 1.1 110.257 177.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.619 ' OG ' HG12 ' A' ' 75' ' ' ILE . 90.7 p -84.5 -2.0 56.61 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.093 0.473 . . . . 1.41 110.494 -179.707 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.61 -32.18 3.58 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.669 -0.696 . . . . 0.48 112.288 -177.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 15.7 m -136.63 -16.07 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.533 -0.467 . . . . 0.49 112.043 178.013 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.619 HG12 ' OG ' ' A' ' 72' ' ' SER . 20.3 pt -87.75 -176.17 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.541 0.686 . . . . 0.3 111.884 -177.187 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.731 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.35 142.2 23.8 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-N 114.231 -1.35 . . . . 0.18 108.765 175.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 63.0 mt -117.75 130.22 72.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 120.594 -0.442 . . . . 0.26 111.646 -176.39 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.505 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.06 51.75 6.06 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.068 -0.587 . . . . 0.17 111.871 177.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.539 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.2 m -99.1 129.61 45.37 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.378 0.609 . . . . 0.65 112.072 -176.143 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 96.5 mt -98.97 132.19 24.08 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.517 -0.765 . . . . 0.29 109.664 173.087 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.438 ' HA ' HG12 ' A' ' 64' ' ' VAL . 13.8 Cg_exo -68.16 123.24 10.38 Favored 'Trans proline' 0 N--CA 1.463 -0.303 0 C-N-CA 122.78 2.32 . . . . 0.25 112.037 -179.071 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.2 m . . . . . 0 N--CA 1.441 -0.879 0 CA-C-N 116.09 -0.505 . . . . 0.42 110.399 179.844 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.2 m . . . . . 0 N--CA 1.442 -0.848 0 CA-C-O 120.732 0.301 . . . . 0.96 110.376 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 40.4 mt -90.93 137.66 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.804 0.811 . . . . 0.96 110.869 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.46 ' HA ' HG13 ' A' ' 50' ' ' ILE . 0.1 OUTLIER -145.74 158.05 43.89 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 114.605 -1.179 . . . . 0.91 109.958 -175.903 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 37.8 t -110.51 103.3 11.89 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-O 121.134 0.492 . . . . 0.34 110.009 -177.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.638 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 63.8 m -86.63 136.05 33.19 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.311 -0.858 . . . . 0.19 111.057 -175.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.465 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -73.33 -32.9 64.83 Favored 'General case' 0 N--CA 1.445 -0.69 0 CA-C-N 115.167 -0.924 . . . . 0.38 108.643 173.762 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . 0.501 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 3.7 t-20 -128.36 135.42 49.54 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.59 -0.732 . . . . 1.03 109.468 178.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 87.2 t -126.43 106.11 15.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 109.706 -0.479 . . . . 0.18 109.706 174.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.3 m -135.24 142.41 41.56 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 115.656 -0.702 . . . . 0.18 111.127 -173.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.551 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.8 Cg_exo -57.75 139.76 91.35 Favored 'Trans proline' 0 N--CA 1.462 -0.345 0 C-N-CA 122.257 1.971 . . . . 0.19 111.329 171.251 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.7 -23.12 70.51 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.839 -0.696 . . . . 0.18 112.31 -179.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -95.65 -1.47 50.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.95 0.405 . . . . 2.27 109.932 177.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.551 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 22.9 t -68.28 150.67 47.96 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.002 -0.544 . . . . 0.24 109.579 176.592 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -58.48 -32.56 68.88 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.2 0.524 . . . . 1.06 110.106 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.658 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.6 mm? -69.01 -64.56 0.85 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.433 -0.803 . . . . 1.11 110.701 172.009 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.44 -40.84 78.76 Favored Glycine 0 C--N 1.33 0.225 0 CA-C-N 115.959 -0.564 . . . . 0.16 113.364 -174.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 30.1 m -67.32 -41.15 85.77 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.168 -0.308 . . . . 0.24 110.168 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -64.91 -40.14 94.6 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.408 -0.59 . . . . 1.01 109.408 177.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.658 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.7 mt -67.92 -44.62 76.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.044 -0.526 . . . . 0.37 110.849 -175.168 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.547 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.8 pp -77.69 -25.1 49.21 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.372 -0.531 . . . . 0.41 110.899 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.528 ' N ' HD12 ' A' ' 29' ' ' LEU . 24.6 t70 -64.88 -36.7 85.21 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.766 0.793 . . . . 0.66 109.178 172.144 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -74.86 -12.13 60.3 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 114.149 -1.387 . . . . 2.07 110.388 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.5 mt -108.66 -9.95 15.24 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.146 -0.934 . . . . 0.71 111.259 -178.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 71.22 35.09 64.02 Favored Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.887 -0.597 . . . . 0.75 112.518 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.547 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 43.4 mt -91.55 131.05 39.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.709 0.255 . . . . 0.68 110.704 -178.159 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 p -91.87 112.75 26.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.42 0.629 . . . . 1.87 109.959 173.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.543 HD22 ' HB3' ' A' ' 39' ' ' PRO . 0.9 OUTLIER -81.62 134.29 35.47 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.92 -0.582 . . . . 2.76 110.908 -179.573 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -87.32 -35.42 18.42 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.828 -0.804 . . . . 2.65 108.828 173.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -143.71 102.5 4.97 Favored Pre-proline 0 N--CA 1.444 -0.745 0 N-CA-C 107.947 -1.131 . . . . 2.29 107.947 176.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.543 ' HB3' HD22 ' A' ' 36' ' ' LEU . 51.8 Cg_endo -69.53 -3.48 11.95 Favored 'Trans proline' 0 C--O 1.226 -0.119 0 C-N-CA 122.365 2.043 . . . . 0.64 111.673 -175.036 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.0 p -85.73 7.95 21.68 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.633 -0.712 . . . . 0.51 111.88 -174.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.5 m -92.18 158.42 2.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.958 0.408 . . . . 0.24 110.327 177.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.546 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 94.9 mt -89.07 121.76 31.73 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.076 -0.511 . . . . 0.22 110.084 178.494 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.501 HD13 HD23 ' A' ' 29' ' ' LEU . 22.4 pt -108.86 145.73 15.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.238 0.542 . . . . 0.15 110.44 177.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.638 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.02 142.09 17.18 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.667 -0.778 . . . . 0.31 112.338 -177.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.501 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 9.5 t70 -105.17 151.79 23.62 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.305 -0.998 . . . . 0.57 108.305 172.314 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.404 ' HA3' ' HB3' ' A' ' 15' ' ' GLN . . . 61.02 44.5 98.11 Favored Glycine 0 C--N 1.32 -0.339 0 C-N-CA 120.28 -0.962 . . . . 0.21 112.302 175.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.527 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.34 115.55 30.44 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.056 0.455 . . . . 0.25 110.984 -172.443 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.407 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 18.6 m-20 -101.29 129.32 27.25 Favored Pre-proline 0 C--N 1.316 -0.884 0 CA-C-N 115.666 -0.697 . . . . 2.21 109.304 175.744 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.433 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 17.8 Cg_exo -61.64 122.2 10.69 Favored 'Trans proline' 0 N--CA 1.46 -0.446 0 C-N-CA 122.739 2.293 . . . . 0.44 111.263 178.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.46 HG13 ' HA ' ' A' ' 12' ' ' GLN . 10.1 mt . . . . . 0 C--N 1.324 -0.52 0 CA-C-O 121.593 0.711 . . . . 0.46 109.835 -176.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.9 t . . . . . 0 N--CA 1.446 -0.627 0 N-CA-C 110.129 -0.323 . . . . 0.74 110.129 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 17.4 t -109.66 -22.25 12.03 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.518 -0.31 . . . . 2.14 111.143 -177.588 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.465 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -102.85 -82.06 0.49 Allowed 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.725 -0.39 . . . . 0.54 111.316 -179.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 23.2 m -148.78 127.67 12.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.8 0.333 . . . . 0.29 110.775 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -88.21 133.21 34.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.0 0.429 . . . . 0.25 110.909 -177.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.495 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.3 m -144.11 170.5 8.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.03 -0.532 . . . . 0.21 111.07 -178.571 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 46.3 t -130.87 115.77 17.01 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.022 -0.536 . . . . 0.39 110.045 178.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.815 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 4.4 m -101.71 154.88 18.5 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.814 0.816 . . . . 0.65 111.941 -176.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 49.0 m -103.45 -19.58 14.36 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 114.405 -1.27 . . . . 1.15 110.787 -177.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -106.24 142.82 35.28 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.706 -0.679 . . . . 1.6 109.561 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -116.77 2.94 12.95 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.076 0.465 . . . . 2.49 110.663 -176.749 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -92.62 58.69 3.16 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.62 0.724 . . . . 2.27 109.861 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 33.5 m -80.68 163.96 3.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.062 -0.972 . . . . 1.1 110.83 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.526 ' OG ' HG12 ' A' ' 75' ' ' ILE . 91.7 p -74.25 -8.04 54.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.281 -0.418 . . . . 1.41 111.339 -175.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.9 -32.06 3.56 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.923 -0.656 . . . . 0.48 112.68 -178.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 10.6 m -134.96 -6.12 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.318 -0.553 . . . . 0.49 111.989 178.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.526 HG12 ' OG ' ' A' ' 72' ' ' SER . 29.0 pt -93.92 -176.28 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 C-N-CA 120.063 -0.655 . . . . 0.3 111.419 179.583 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.815 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -144.58 143.23 30.69 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.782 -1.099 . . . . 0.18 109.73 175.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 64.0 mt -126.44 128.55 71.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.931 0.396 . . . . 0.26 111.606 -176.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.472 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 74.82 53.68 6.26 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.744 -0.662 . . . . 0.17 111.621 179.144 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.546 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 0.9 OUTLIER -104.2 141.9 35.45 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 112.652 0.612 . . . . 0.65 112.652 -175.539 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 84.2 mt -111.36 134.8 21.06 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.512 -0.767 . . . . 0.29 109.787 172.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.479 ' HA ' HG12 ' A' ' 64' ' ' VAL . 19.4 Cg_exo -65.14 124.04 12.42 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 123.067 2.512 . . . . 0.25 112.595 -179.012 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.3 m . . . . . 0 N--CA 1.444 -0.74 0 CA-C-N 116.089 -0.505 . . . . 0.42 110.223 177.619 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 40.1 t . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 110.139 -0.319 . . . . 0.96 110.139 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.3 mt -88.21 139.37 17.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.185 0.517 . . . . 0.96 110.448 172.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.64 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -140.02 164.37 30.2 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.578 -0.737 . . . . 0.91 110.676 176.616 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.53 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 28.3 t -107.79 101.91 11.17 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.311 -0.859 . . . . 0.34 109.468 179.718 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.824 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 55.6 m -87.72 126.29 34.9 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.984 -0.553 . . . . 0.19 111.298 -176.057 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.442 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -67.28 -33.4 75.22 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.074 -0.967 . . . . 0.38 109.471 174.878 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -139.43 113.01 8.41 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.953 -0.567 . . . . 1.03 110.501 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 51.2 t -101.17 104.55 16.43 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 109.67 -0.493 . . . . 0.18 109.67 177.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 m -129.97 140.58 39.07 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 116.072 -0.513 . . . . 0.18 111.43 -174.221 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.466 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.1 Cg_exo -59.61 138.44 83.51 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.37 2.047 . . . . 0.19 111.222 171.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -62.79 -26.05 68.27 Favored Glycine 0 C--O 1.227 -0.34 0 C-N-CA 121.272 -0.49 . . . . 0.18 113.146 -176.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -101.13 7.55 43.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.493 0.664 . . . . 2.27 110.245 177.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.466 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 26.6 t -71.31 159.02 35.33 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.52 -0.548 . . . . 0.24 109.52 175.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -53.4 -44.31 68.61 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.168 0.509 . . . . 1.06 109.767 176.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.701 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 6.2 mt -69.09 -60.27 2.47 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.314 -0.857 . . . . 1.11 110.456 178.25 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.429 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -53.51 -38.13 57.49 Favored Glycine 0 C--N 1.33 0.228 0 CA-C-N 116.101 -0.499 . . . . 0.16 113.218 -176.205 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 88.3 m -67.6 -47.61 69.2 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 110.361 -0.237 . . . . 0.24 110.361 -178.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.419 ' O ' HD13 ' A' ' 27' ' ' LEU . 3.1 tm? -62.71 -37.76 87.76 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.66 -0.496 . . . . 1.01 109.66 178.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.701 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.9 mt -69.01 -43.84 74.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.975 -0.557 . . . . 0.37 110.849 -175.543 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.489 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -82.41 -21.31 35.82 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.536 -0.466 . . . . 0.41 111.217 -178.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.44 ' N ' HD12 ' A' ' 29' ' ' LEU . 19.4 t70 -66.56 -34.92 78.98 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.634 0.731 . . . . 0.66 109.364 174.313 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -74.15 -32.96 63.35 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.793 -1.094 . . . . 2.07 109.18 179.141 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.4 mt -89.2 -10.56 46.61 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.903 -1.044 . . . . 0.71 111.982 -176.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.96 44.01 92.52 Favored Glycine 0 N--CA 1.452 -0.294 0 CA-C-N 115.849 -0.614 . . . . 0.75 112.766 178.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.489 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 51.3 mt -91.19 128.82 42.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.936 0.398 . . . . 0.68 111.41 -176.28 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.3 p -84.99 122.31 38.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.061 -0.518 . . . . 1.87 109.905 173.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.544 HD22 ' HB3' ' A' ' 39' ' ' PRO . 1.3 pp -94.88 131.26 40.97 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.265 0.555 . . . . 2.76 111.589 -176.227 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -90.36 -29.06 18.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.876 -0.787 . . . . 2.65 108.876 173.101 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -146.89 103.06 3.87 Favored Pre-proline 0 N--CA 1.444 -0.738 0 N-CA-C 107.435 -1.32 . . . . 2.29 107.435 175.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.544 ' HB3' HD22 ' A' ' 36' ' ' LEU . 66.7 Cg_endo -74.89 -1.09 10.73 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.135 1.89 . . . . 0.64 112.603 -174.029 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.3 p -99.6 4.48 45.79 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.176 -0.609 . . . . 0.51 111.092 -173.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.0 m -78.29 163.72 3.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.841 -0.618 . . . . 0.24 110.465 175.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.484 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 88.8 mt -91.5 120.09 32.02 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.933 -0.576 . . . . 0.22 110.011 176.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.413 HD13 HD23 ' A' ' 29' ' ' LEU . 17.3 pt -103.0 134.59 43.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 121.229 0.538 . . . . 0.15 110.095 176.091 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.824 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.94 104.75 2.21 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.699 -0.762 . . . . 0.31 112.878 -175.158 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -83.43 139.69 32.81 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 109.323 -0.621 . . . . 0.57 109.323 176.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.435 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 73.31 38.13 53.73 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.057 -1.068 . . . . 0.21 111.751 -179.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.53 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -103.25 116.17 31.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.065 0.46 . . . . 0.25 111.056 -172.708 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.504 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -101.56 134.02 20.48 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-N 115.857 -0.61 . . . . 2.21 109.858 177.371 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -54.57 119.11 5.87 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.747 2.298 . . . . 0.44 111.947 176.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.4 mt . . . . . 0 N--CA 1.447 -0.622 0 N-CA-C 108.662 -0.866 . . . . 0.46 108.662 177.451 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.4 t . . . . . 0 N--CA 1.447 -0.578 0 CA-C-O 120.727 0.299 . . . . 0.74 110.513 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 20.0 m -101.21 7.37 43.07 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.33 -0.396 . . . . 2.14 111.526 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.442 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -147.0 -83.96 0.12 Allowed 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.914 -0.315 . . . . 0.54 111.81 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 33.8 m -142.27 130.08 21.68 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-O 120.713 0.292 . . . . 0.29 110.99 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.97 129.25 34.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.465 -0.334 . . . . 0.25 110.267 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.659 HG21 ' SG ' ' A' ' 14' ' ' CYS . 4.0 m -140.6 169.9 15.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-O 121.248 0.546 . . . . 0.21 111.959 -176.574 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 29.1 t -132.98 103.66 6.16 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.191 -0.913 . . . . 0.39 110.061 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.748 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -91.11 138.79 31.33 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.647 0.737 . . . . 0.65 111.882 -178.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 47.9 t -92.8 -19.16 22.02 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 114.635 -1.166 . . . . 1.15 110.736 179.051 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -96.83 159.78 14.73 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.107 -0.497 . . . . 1.6 110.519 -175.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.2 t30 -117.68 -6.41 11.1 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.117 -0.492 . . . . 2.49 111.067 -173.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -81.04 83.25 6.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.249 0.547 . . . . 2.27 110.655 -177.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 30.0 m -101.81 139.57 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-N 116.0 -0.545 . . . . 1.1 110.885 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.567 ' OG ' HG12 ' A' ' 75' ' ' ILE . 99.9 p -80.38 -5.08 55.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.188 -0.46 . . . . 1.41 110.739 -178.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.3 -32.22 3.62 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.841 -0.618 . . . . 0.48 112.179 -177.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 m -135.44 -7.78 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 C-N-CA 120.559 -0.456 . . . . 0.49 111.945 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.567 HG12 ' OG ' ' A' ' 72' ' ' SER . 37.0 pt -97.39 179.78 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.522 0.677 . . . . 0.3 111.779 -178.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.748 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -149.85 140.4 22.49 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.255 -1.338 . . . . 0.18 109.094 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.0 mt -118.63 133.55 65.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.875 0.369 . . . . 0.26 111.333 -177.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 74.9 50.86 8.32 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.962 -0.637 . . . . 0.17 111.828 178.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.484 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.35 133.03 44.23 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.153 0.501 . . . . 0.65 111.89 -176.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.436 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 86.4 mt -108.23 132.1 21.31 Favored Pre-proline 0 C--N 1.318 -0.763 0 CA-C-N 115.728 -0.669 . . . . 0.29 109.811 172.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 21.7 Cg_exo -64.02 123.48 11.97 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.713 2.275 . . . . 0.25 111.889 -178.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 m . . . . . 0 N--CA 1.445 -0.693 0 CA-C-O 121.265 0.555 . . . . 0.42 111.274 -178.086 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.1 t . . . . . 0 N--CA 1.453 -0.309 0 N-CA-C 109.778 -0.453 . . . . 0.96 109.778 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 16.6 mt -103.07 130.94 52.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.641 0.734 . . . . 0.96 111.374 174.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.462 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -130.39 168.09 17.52 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 114.656 -1.156 . . . . 0.91 110.138 177.653 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 36.8 t -110.38 101.93 10.61 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.772 -0.649 . . . . 0.34 109.918 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.849 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 96.5 m -87.45 125.01 34.03 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.788 -0.642 . . . . 0.19 111.459 -175.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.479 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -69.13 -31.96 71.0 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.06 -0.973 . . . . 0.38 109.818 175.583 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -136.74 108.38 7.0 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.046 -0.525 . . . . 1.03 110.423 177.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 93.2 t -98.94 105.92 18.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 N-CA-C 109.746 -0.465 . . . . 0.18 109.746 177.121 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 m -131.12 142.88 47.14 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 116.012 -0.54 . . . . 0.18 110.763 -176.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.521 ' O ' ' HB3' ' A' ' 22' ' ' SER . 30.9 Cg_exo -61.19 136.91 67.67 Favored 'Trans proline' 0 N--CA 1.461 -0.396 0 C-N-CA 122.161 1.908 . . . . 0.19 111.434 173.2 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.62 -15.03 68.1 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.665 -0.779 . . . . 0.18 111.972 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -103.09 3.66 36.22 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.592 0.71 . . . . 2.27 109.657 176.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.521 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 21.3 t -74.99 155.78 36.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.186 -0.915 . . . . 0.24 110.031 177.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -53.68 -44.32 69.63 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.829 0.823 . . . . 1.06 109.142 176.54 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.594 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.2 mm? -67.36 -63.19 1.11 Allowed 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 114.25 -1.341 . . . . 1.11 111.002 177.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.38 -39.21 71.95 Favored Glycine 0 C--N 1.33 0.23 0 CA-C-N 116.217 -0.447 . . . . 0.16 113.392 -175.074 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 98.7 m -67.72 -38.74 84.0 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.87 0.366 . . . . 0.24 110.475 -178.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -75.44 -27.72 59.06 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 120.934 0.397 . . . . 1.01 110.132 178.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.594 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 13.1 mt -69.74 -48.67 58.53 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.185 -0.461 . . . . 0.37 110.182 178.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.576 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -76.95 -23.78 52.38 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.571 -0.452 . . . . 0.41 111.549 -175.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.499 ' N ' HD12 ' A' ' 29' ' ' LEU . 18.8 t70 -67.95 -32.81 73.5 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.525 0.678 . . . . 0.66 109.37 175.456 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -75.28 -19.78 59.51 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 114.91 -1.041 . . . . 2.07 109.762 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 80.7 mt -103.37 -6.94 21.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.907 -1.042 . . . . 0.71 111.696 -174.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.97 35.48 84.37 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.958 -0.564 . . . . 0.75 112.566 178.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.576 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 32.2 mt -88.96 138.53 19.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.523 0.201 . . . . 0.68 110.705 -177.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.1 p -99.14 110.59 26.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.444 0.64 . . . . 1.87 110.221 175.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.531 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.4 pp -80.74 130.89 35.33 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.915 -0.584 . . . . 2.76 110.725 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -90.34 -29.1 18.3 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.739 -0.837 . . . . 2.65 108.739 173.52 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -142.23 98.41 6.1 Favored Pre-proline 0 N--CA 1.444 -0.772 0 N-CA-C 107.802 -1.184 . . . . 2.29 107.802 176.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.01 -9.54 21.98 Favored 'Trans proline' 0 N--CA 1.466 -0.143 0 C-N-CA 121.965 1.777 . . . . 0.64 111.588 -175.392 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 p -80.36 -8.9 59.7 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.623 -0.717 . . . . 0.51 111.497 -175.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.483 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.8 m -76.28 159.72 5.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.266 0.555 . . . . 0.24 111.065 -178.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.6 mt -92.53 128.03 38.24 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.498 -0.774 . . . . 0.22 109.556 176.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.428 HD13 HD23 ' A' ' 29' ' ' LEU . 15.1 pt -106.32 139.12 28.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 116.011 -0.54 . . . . 0.15 109.995 177.184 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.849 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -107.79 99.37 1.36 Allowed Glycine 0 N--CA 1.437 -1.281 0 C-N-CA 120.633 -0.794 . . . . 0.31 112.967 -175.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -78.2 137.12 37.98 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 108.691 -0.855 . . . . 0.57 108.691 173.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.479 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 70.79 39.08 66.01 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 119.914 -1.136 . . . . 0.21 112.252 -177.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.568 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -103.61 111.88 24.55 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.335 0.588 . . . . 0.25 110.831 -174.887 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -94.53 136.47 23.18 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 115.269 -0.878 . . . . 2.21 109.242 178.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -66.1 119.47 6.5 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 122.303 2.002 . . . . 0.44 110.745 176.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.4 HG13 ' HA ' ' A' ' 12' ' ' GLN . 16.8 mt . . . . . 0 C--N 1.326 -0.438 0 CA-C-O 121.62 0.724 . . . . 0.46 110.213 -176.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.6 t . . . . . 0 N--CA 1.449 -0.512 0 N-CA-C 109.994 -0.373 . . . . 0.74 109.994 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.7 m -126.14 18.34 7.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.44 -0.345 . . . . 2.14 111.071 -177.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.4 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -163.01 -77.69 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 112.015 0.376 . . . . 0.54 112.015 -178.394 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 74.8 m -147.61 131.33 16.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.806 0.336 . . . . 0.29 111.417 -176.425 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -88.13 125.72 34.74 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.039 -0.528 . . . . 0.25 109.93 177.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.588 HG21 ' SG ' ' A' ' 14' ' ' CYS . 6.8 m -138.89 159.96 30.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-N 115.964 -0.562 . . . . 0.21 110.949 -178.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 53.6 t -117.91 103.41 9.91 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.602 -0.726 . . . . 0.39 109.727 179.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.734 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 20.1 m -91.75 132.55 36.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.36 0.6 . . . . 0.65 111.402 -176.35 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 10.9 m -94.78 -15.78 23.53 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.314 -0.857 . . . . 1.15 111.29 -177.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.423 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 9.7 t70 -109.98 131.94 54.61 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.623 -0.51 . . . . 1.6 109.623 -178.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -108.12 20.95 18.05 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.489 0.551 . . . . 2.49 112.489 -172.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 50.8 m-80 -83.38 61.91 6.44 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.5 0.667 . . . . 2.27 110.123 177.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 m -73.66 149.01 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 CA-C-N 115.541 -0.754 . . . . 1.1 111.181 -178.481 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.6 ' OG ' HG12 ' A' ' 75' ' ' ILE . 82.0 p -95.4 -5.93 42.09 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.887 -0.597 . . . . 1.41 110.34 179.035 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.12 -31.84 3.57 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.675 -0.693 . . . . 0.48 112.409 -176.022 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.0 m -136.59 -8.22 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 117.185 0.493 . . . . 0.49 111.961 177.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.6 HG12 ' OG ' ' A' ' 72' ' ' SER . 21.7 pt -94.63 179.7 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.642 0.734 . . . . 0.3 111.979 -178.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.734 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.22 145.33 26.17 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.007 -1.452 . . . . 0.18 108.502 176.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.423 ' HB ' ' HB3' ' A' ' 68' ' ' ASP . 58.9 mt -125.75 142.19 43.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 120.717 -0.393 . . . . 0.26 111.402 -175.321 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.483 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 69.34 50.55 31.96 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.115 -0.564 . . . . 0.17 111.898 178.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.566 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 9.0 m -103.86 131.55 50.96 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.158 0.504 . . . . 0.65 111.8 -173.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.437 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.8 mt -105.9 134.68 19.62 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.735 -0.666 . . . . 0.29 109.859 173.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 17.1 Cg_exo -66.09 122.58 10.14 Favored 'Trans proline' 0 N--CA 1.465 -0.204 0 C-N-CA 122.75 2.3 . . . . 0.25 111.789 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.324 -0.536 0 CA-C-O 121.445 0.641 . . . . 0.42 111.35 -177.446 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.4 t . . . . . 0 N--CA 1.451 -0.38 0 N-CA-C 109.14 -0.689 . . . . 0.96 109.14 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.472 HG22 HD12 ' A' ' 50' ' ' ILE . 40.6 mt -100.72 135.02 38.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.711 0.767 . . . . 0.96 111.122 176.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.593 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -132.28 165.61 23.78 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.702 -1.136 . . . . 0.91 109.82 177.058 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.5 t -112.29 101.39 9.61 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.891 -0.595 . . . . 0.34 109.409 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.812 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 68.5 m -84.32 130.22 34.82 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 115.326 -0.852 . . . . 0.19 110.988 -176.374 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.48 -30.63 68.56 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.26 -0.882 . . . . 0.38 109.053 172.849 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -141.16 121.02 13.54 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.972 -0.558 . . . . 1.03 110.538 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.6 t -109.06 107.78 23.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 109.969 -0.382 . . . . 0.18 109.969 176.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 20.8 m -133.39 145.97 58.77 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.153 -0.476 . . . . 0.18 110.777 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.471 ' HB2' ' HB2' ' A' ' 22' ' ' SER . 22.5 Cg_exo -63.42 137.37 59.84 Favored 'Trans proline' 0 N--CA 1.463 -0.309 0 C-N-CA 121.936 1.757 . . . . 0.19 110.934 171.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.45 -26.94 71.1 Favored Glycine 0 C--O 1.228 -0.232 0 C-N-CA 121.018 -0.611 . . . . 0.18 112.501 -177.295 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -98.18 9.15 43.62 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.099 0.476 . . . . 2.27 110.249 177.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.471 ' HB2' ' HB2' ' A' ' 19' ' ' PRO . 30.7 t -78.53 155.82 29.56 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 115.786 -0.643 . . . . 0.24 109.816 176.088 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -54.31 -41.68 69.25 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.001 0.429 . . . . 1.06 109.922 178.155 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.701 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.1 mm? -69.37 -60.27 2.45 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.648 -0.706 . . . . 1.11 110.94 177.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.93 -39.58 69.14 Favored Glycine 0 C--N 1.328 0.126 0 CA-C-N 116.203 -0.453 . . . . 0.16 113.216 -176.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.6 m -70.36 -41.48 73.09 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.974 0.416 . . . . 0.24 110.388 -177.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.418 HD22 ' HA ' ' A' ' 27' ' ' LEU . 1.1 tm? -63.75 -40.42 96.67 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.308 -0.627 . . . . 1.01 109.308 177.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.701 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.5 mt -68.05 -43.75 77.96 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.533 -0.758 . . . . 0.37 110.857 -175.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.545 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -76.54 -24.34 53.64 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.944 -0.302 . . . . 0.41 111.051 -178.005 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.487 ' N ' HD12 ' A' ' 29' ' ' LEU . 24.6 t70 -67.38 -31.28 71.4 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.406 0.622 . . . . 0.66 109.647 175.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -74.51 -38.7 62.75 Favored 'General case' 0 N--CA 1.443 -0.796 0 CA-C-N 115.037 -0.983 . . . . 2.07 109.513 177.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.7 mt -79.08 -20.17 49.44 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.522 -1.217 . . . . 0.71 111.921 -177.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.08 48.18 6.17 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.177 -0.535 . . . . 0.75 112.164 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.545 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 16.3 mt -110.92 142.83 22.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 110.449 -0.204 . . . . 0.68 110.449 -178.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.403 HG13 ' O ' ' A' ' 35' ' ' VAL . 6.5 p -126.54 103.47 11.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.596 0.712 . . . . 1.87 110.16 174.161 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.2 mt -87.6 137.25 32.5 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.825 -0.625 . . . . 2.76 110.824 -178.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -68.67 -36.78 78.98 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.661 -0.7 . . . . 2.65 109.442 175.072 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -132.88 88.86 36.21 Favored Pre-proline 0 N--CA 1.444 -0.764 0 N-CA-C 108.849 -0.797 . . . . 2.29 108.849 175.527 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -72.23 3.38 4.1 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.361 2.041 . . . . 0.64 111.56 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.2 p -75.77 -8.31 56.55 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.62 -0.718 . . . . 0.51 111.063 -178.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.1 m -82.41 162.76 3.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 116.055 -0.52 . . . . 0.24 110.561 176.479 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.407 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 94.8 mt -83.69 126.17 32.61 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.048 -0.524 . . . . 0.22 110.328 177.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 24.1 pt -107.6 140.77 24.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.244 0.545 . . . . 0.15 110.226 175.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.812 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -111.99 105.21 1.75 Allowed Glycine 0 N--CA 1.44 -1.094 0 C-N-CA 120.57 -0.824 . . . . 0.31 112.87 -177.11 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -83.06 132.39 35.12 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.057 -0.72 . . . . 0.57 109.057 176.009 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.93 38.01 24.24 Favored Glycine 0 N--CA 1.443 -0.86 0 C-N-CA 119.89 -1.148 . . . . 0.21 111.709 -178.01 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.93 111.76 24.54 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.043 0.449 . . . . 0.25 111.22 -174.017 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -100.61 134.67 20.45 Favored Pre-proline 0 C--N 1.315 -0.925 0 CA-C-N 115.647 -0.706 . . . . 2.21 109.269 174.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -59.96 130.8 36.23 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.908 2.405 . . . . 0.44 111.609 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.472 HD12 HG22 ' A' ' 11' ' ' ILE . 21.1 mt . . . . . 0 C--N 1.326 -0.435 0 CA-C-O 121.68 0.753 . . . . 0.46 109.475 -179.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.7 t . . . . . 0 N--CA 1.454 -0.272 0 CA-C-O 120.71 0.291 . . . . 0.74 110.858 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 27.3 p -117.06 5.38 12.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.179 -0.464 . . . . 2.14 111.509 -179.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -146.8 -80.99 0.14 Allowed 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 120.966 -0.293 . . . . 0.54 111.776 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 28.4 m -142.05 126.88 18.16 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.815 0.341 . . . . 0.29 111.234 -178.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.67 128.98 35.04 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.926 0.393 . . . . 0.25 110.254 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.667 HG21 ' SG ' ' A' ' 14' ' ' CYS . 4.6 m -142.4 165.96 16.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.138 -0.483 . . . . 0.21 111.208 -177.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . 0.566 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 40.6 t -127.72 109.27 11.49 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.819 -0.628 . . . . 0.39 110.259 -178.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.743 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.6 m -97.46 140.49 31.83 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.397 0.618 . . . . 0.65 111.808 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 65.2 m -99.85 -12.73 19.62 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.14 -0.936 . . . . 1.15 111.501 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -110.33 149.99 29.4 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.02 -0.363 . . . . 1.6 110.02 -178.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 42.8 m-80 -120.35 12.42 11.69 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.639 0.607 . . . . 2.49 112.639 -173.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -81.62 71.84 8.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.773 0.796 . . . . 2.27 109.37 177.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 34.3 m -94.35 152.18 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 CA-C-N 115.457 -0.792 . . . . 1.1 111.172 -175.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.54 ' H ' HG12 ' A' ' 75' ' ' ILE . 90.4 p -86.97 -8.68 56.98 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.657 -0.701 . . . . 1.41 110.309 178.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.92 -32.02 3.74 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 115.285 -0.87 . . . . 0.48 111.954 -176.471 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.9 m -132.84 -2.58 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 C-N-CA 120.517 -0.473 . . . . 0.49 112.007 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.54 HG12 ' H ' ' A' ' 72' ' ' SER . 23.5 pt -100.73 178.77 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.495 0.664 . . . . 0.3 111.924 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.743 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -148.26 139.71 23.54 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.575 -1.193 . . . . 0.18 109.393 177.061 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 68.9 mt -121.73 130.19 74.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.938 0.399 . . . . 0.26 111.301 -176.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 82.0 46.43 6.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.995 -0.621 . . . . 0.17 111.777 178.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.566 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -99.38 144.25 28.71 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.288 0.566 . . . . 0.65 112.387 -175.153 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 87.7 mt -119.81 134.11 23.91 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.246 -0.888 . . . . 0.29 109.743 172.092 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 21.6 Cg_exo -64.67 121.47 9.03 Favored 'Trans proline' 0 C--O 1.234 0.298 0 C-N-CA 123.034 2.489 . . . . 0.25 112.348 -179.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.8 m . . . . . 0 N--CA 1.444 -0.762 0 CA-C-N 116.039 -0.528 . . . . 0.42 110.629 -179.724 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 109.014 -0.736 . . . . 0.96 109.014 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 51.5 mt -99.9 134.75 38.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.606 0.717 . . . . 0.96 111.344 178.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.628 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -142.95 162.22 36.05 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.063 -0.971 . . . . 0.91 111.043 178.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 19.4 t -106.68 102.26 11.65 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.46 -0.791 . . . . 0.34 109.483 178.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.893 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 57.6 m -86.75 133.54 33.65 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.934 -0.575 . . . . 0.19 111.017 -175.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.12 -30.42 49.41 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.185 -0.916 . . . . 0.38 109.435 177.016 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . 0.636 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 17.1 m-20 -134.28 103.21 5.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.438 -0.346 . . . . 1.03 111.306 175.172 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.1 t -92.52 101.68 12.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.214 0.53 . . . . 0.18 109.727 174.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 m -131.71 140.38 38.11 Favored Pre-proline 0 C--N 1.319 -0.717 0 CA-C-N 115.748 -0.66 . . . . 0.18 110.75 -174.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.528 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.7 Cg_exo -57.94 138.75 87.56 Favored 'Trans proline' 0 N--CA 1.463 -0.302 0 C-N-CA 122.195 1.93 . . . . 0.19 111.304 172.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.29 -21.99 68.84 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.939 -0.648 . . . . 0.18 112.596 -178.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -101.2 4.94 42.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.239 0.542 . . . . 2.27 109.837 176.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.528 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 16.6 t -69.32 153.95 42.81 Favored 'General case' 0 CA--C 1.514 -0.438 0 CA-C-N 115.778 -0.646 . . . . 0.24 109.68 175.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -56.63 -38.42 72.09 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-O 121.122 0.487 . . . . 1.06 110.035 178.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.686 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 5.3 mt -70.19 -63.45 1.08 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.58 -0.737 . . . . 1.11 110.853 174.06 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.54 -40.87 55.52 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 116.035 -0.53 . . . . 0.16 113.443 -174.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 93.4 m -68.16 -44.53 75.77 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.761 0.315 . . . . 0.24 110.484 -178.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.4 tt -63.43 -35.52 80.71 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.075 -0.511 . . . . 1.01 110.814 178.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.686 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.3 mt -72.49 -46.09 56.41 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.096 -0.502 . . . . 0.37 110.365 -177.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.612 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -75.03 -21.76 58.85 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.71 -0.396 . . . . 0.41 110.934 -178.133 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -66.24 -32.22 73.51 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.708 0.766 . . . . 0.66 109.712 173.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -77.37 -47.7 19.19 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 114.906 -1.043 . . . . 2.07 109.261 177.103 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 72.4 mt -78.22 -13.11 59.99 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.705 -1.134 . . . . 0.71 112.893 -174.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.49 37.57 90.04 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-N 116.131 -0.486 . . . . 0.75 112.473 178.492 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.612 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 55.8 mt -75.46 137.35 23.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.104 0.478 . . . . 0.68 111.718 -173.265 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.4 p -88.11 113.55 25.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.687 -0.688 . . . . 1.87 110.762 175.471 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.457 ' H ' ' HG ' ' A' ' 36' ' ' LEU . 1.2 pp -103.0 134.6 46.17 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.03 -0.532 . . . . 2.76 110.796 177.589 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -90.06 -32.28 16.79 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.021 -1.104 . . . . 2.65 108.021 171.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -139.93 106.76 6.86 Favored Pre-proline 0 N--CA 1.446 -0.631 0 CA-C-N 114.588 -1.187 . . . . 2.29 108.227 174.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -71.9 -2.24 11.19 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.072 1.848 . . . . 0.64 111.327 -178.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.6 p -94.94 20.2 9.23 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.479 -0.782 . . . . 0.51 111.157 -175.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.2 m -105.77 160.83 5.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.81 -0.632 . . . . 0.24 110.226 178.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.405 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.6 mt -81.29 119.81 24.12 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.034 -0.53 . . . . 0.22 110.244 175.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 19.4 pt -104.06 137.11 34.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.871 -0.604 . . . . 0.15 109.684 175.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.893 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.91 106.75 1.78 Allowed Glycine 0 N--CA 1.438 -1.176 0 C-N-CA 120.538 -0.839 . . . . 0.31 113.05 -174.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.636 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 26.0 t70 -77.48 145.18 37.2 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 108.887 -0.783 . . . . 0.57 108.887 174.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 69.71 37.3 76.45 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 119.884 -1.15 . . . . 0.21 112.221 177.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.534 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -101.35 114.4 28.36 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.387 0.613 . . . . 0.25 111.215 -172.712 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.531 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 0.7 OUTLIER -101.54 130.98 23.56 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 115.4 -0.818 . . . . 2.21 109.702 177.438 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -56.48 120.39 8.24 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 C-N-CA 122.436 2.091 . . . . 0.44 111.102 177.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.406 HG13 ' HA ' ' A' ' 12' ' ' GLN . 43.7 mt . . . . . 0 C--N 1.326 -0.418 0 CA-C-O 121.158 0.504 . . . . 0.46 110.587 -174.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 40.1 t . . . . . 0 C--O 1.235 0.309 0 CA-C-O 120.94 0.4 . . . . 0.74 111.261 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 8.9 t -119.11 -13.63 9.37 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.974 -0.557 . . . . 2.14 110.782 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.12 -83.59 0.57 Allowed 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 121.121 -0.232 . . . . 0.54 110.86 -179.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 54.4 m -150.39 127.45 11.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.699 0.285 . . . . 0.29 110.551 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.44 140.58 29.85 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.03 0.443 . . . . 0.25 110.483 -178.049 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.656 HG21 ' SG ' ' A' ' 14' ' ' CYS . 2.7 m -147.78 170.38 3.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.229 0.538 . . . . 0.21 111.404 -176.651 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 50.3 t -129.6 107.97 9.86 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.319 -0.855 . . . . 0.39 109.788 178.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.724 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -99.58 138.89 36.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.286 0.565 . . . . 0.65 111.82 -177.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 50.4 m -99.69 -19.1 16.95 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.492 -0.776 . . . . 1.15 111.731 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.409 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 16.4 t70 -101.54 148.95 24.6 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.925 -0.398 . . . . 1.6 109.925 -177.051 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -120.18 18.51 12.31 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.581 0.586 . . . . 2.49 112.581 -173.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.415 ' HB2' HD12 ' A' ' 77' ' ' ILE . 42.9 m-80 -79.24 63.9 4.0 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.544 0.688 . . . . 2.27 109.967 176.489 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.886 HG12 ' H ' ' A' ' 73' ' ' GLY . 87.2 t -90.37 136.19 24.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.414 -0.812 . . . . 1.1 111.23 -173.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.671 ' H ' HG12 ' A' ' 75' ' ' ILE . 87.3 p -79.2 -3.01 43.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.345 -0.843 . . . . 1.41 110.939 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.886 ' H ' HG12 ' A' ' 71' ' ' VAL . . . 127.85 -31.56 3.69 Favored Glycine 0 N--CA 1.443 -0.868 0 CA-C-N 115.367 -0.833 . . . . 0.48 112.195 -176.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 17.2 m -138.68 -7.62 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 112.641 0.608 . . . . 0.49 112.641 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.671 HG12 ' H ' ' A' ' 72' ' ' SER . 7.2 pt -84.97 -178.54 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.581 0.705 . . . . 0.3 112.142 -178.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.724 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -149.43 139.2 21.83 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.639 -1.164 . . . . 0.18 109.51 175.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.415 HD12 ' HB2' ' A' ' 70' ' ' ASN . 65.3 mt -124.49 134.99 65.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.931 0.396 . . . . 0.26 111.364 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.512 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 79.21 47.98 7.17 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 121.002 -0.618 . . . . 0.17 111.785 179.377 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.557 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -100.14 136.73 39.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.24 0.543 . . . . 0.65 112.456 -175.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 93.7 mt -108.1 134.08 20.28 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 115.474 -0.784 . . . . 0.29 109.345 168.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.456 ' HA ' HG12 ' A' ' 64' ' ' VAL . 20.5 Cg_exo -64.3 128.35 21.29 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.937 2.424 . . . . 0.25 112.474 -178.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.0 m . . . . . 0 N--CA 1.441 -0.911 0 CA-C-N 115.878 -0.601 . . . . 0.42 109.658 177.012 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 28.6 t . . . . . 0 N--CA 1.45 -0.425 0 N-CA-C 109.87 -0.418 . . . . 0.96 109.87 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.6 mt -91.65 133.35 33.49 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.559 0 CA-C-O 121.737 0.78 . . . . 0.96 110.547 177.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.488 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -142.92 162.29 35.85 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 114.585 -1.189 . . . . 0.91 110.569 -175.006 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 26.6 t -111.44 101.69 10.12 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.846 -0.615 . . . . 0.34 109.847 -176.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.787 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 86.7 m -87.31 134.45 33.56 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.232 -0.895 . . . . 0.19 110.89 -175.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.43 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -76.1 -27.68 57.23 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 115.37 -0.832 . . . . 0.38 109.665 178.404 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -143.78 103.94 4.12 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.769 -0.651 . . . . 1.03 110.473 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 67.4 t -93.57 108.14 20.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 CA-C-N 116.062 -0.517 . . . . 0.18 109.688 178.253 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.05 146.12 60.3 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 116.032 -0.531 . . . . 0.18 110.757 -175.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.513 ' O ' ' HB3' ' A' ' 22' ' ' SER . 22.6 Cg_exo -62.79 136.94 60.35 Favored 'Trans proline' 0 N--CA 1.461 -0.401 0 C-N-CA 122.12 1.88 . . . . 0.19 111.181 173.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.93 -23.03 72.58 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.946 -0.645 . . . . 0.18 112.64 -176.472 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -101.07 9.92 41.58 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.724 0.774 . . . . 2.27 109.813 177.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.513 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.6 t -78.77 156.36 28.87 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.52 -0.764 . . . . 0.24 109.921 175.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -53.9 -40.94 67.07 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.201 0.524 . . . . 1.06 109.773 176.029 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.674 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER -67.88 -63.1 1.13 Allowed 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 115.462 -0.79 . . . . 1.11 111.046 176.796 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.411 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -57.01 -38.74 87.27 Favored Glycine 0 C--N 1.33 0.24 0 CA-C-N 115.999 -0.546 . . . . 0.16 113.304 -175.031 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.0 m -69.22 -40.64 77.85 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.646 0.26 . . . . 0.24 110.462 -178.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -62.99 -38.62 91.9 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.41 -0.589 . . . . 1.01 109.41 176.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.674 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.3 mt -67.82 -53.5 26.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.809 -0.632 . . . . 0.37 110.84 -177.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.554 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -70.87 -20.82 62.48 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.992 -0.283 . . . . 0.41 111.363 -176.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.425 ' N ' HD12 ' A' ' 29' ' ' LEU . 24.1 t70 -62.87 -38.95 92.9 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.602 0.715 . . . . 0.66 110.039 173.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -73.36 -16.97 61.33 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 114.816 -1.084 . . . . 2.07 109.615 -179.217 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.8 mt -105.86 -13.9 15.38 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.808 -1.087 . . . . 0.71 111.917 -174.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 71.82 42.71 52.65 Favored Glycine 0 C--N 1.331 0.302 0 CA-C-N 115.722 -0.672 . . . . 0.75 112.868 178.335 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.554 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 32.7 mt -101.2 124.92 55.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.689 0.28 . . . . 0.68 111.066 -176.756 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.6 p -110.43 102.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.814 0.816 . . . . 1.87 110.36 176.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.1 mt -85.95 141.9 29.2 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.556 -0.747 . . . . 2.76 111.094 -178.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -74.65 -23.58 58.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.552 0.692 . . . . 2.65 109.701 175.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -136.37 91.52 16.39 Favored Pre-proline 0 N--CA 1.447 -0.616 0 N-CA-C 108.22 -1.03 . . . . 2.29 108.22 172.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -66.18 -2.87 7.62 Favored 'Trans proline' 0 C--O 1.224 -0.22 0 C-N-CA 122.367 2.045 . . . . 0.64 111.808 -177.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 25.2 p -78.59 -12.67 60.03 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.577 -0.738 . . . . 0.51 111.322 -177.294 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 33.3 m -70.55 156.63 7.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.152 0.501 . . . . 0.24 111.295 -178.465 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 95.4 mt -86.38 129.09 34.97 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.778 -0.646 . . . . 0.22 110.333 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.406 HD13 HD23 ' A' ' 29' ' ' LEU . 23.7 pt -112.23 144.33 20.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.991 -0.55 . . . . 0.15 110.115 176.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.787 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.61 106.67 1.42 Allowed Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.48 -0.866 . . . . 0.31 113.102 -176.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -78.33 140.55 38.78 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.252 -0.647 . . . . 0.57 109.252 175.333 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 73.59 39.42 49.43 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.141 -1.028 . . . . 0.21 111.999 179.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.539 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.75 115.89 31.09 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.275 0.559 . . . . 0.25 111.346 -172.774 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.474 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.8 t70 -102.33 136.67 19.36 Favored Pre-proline 0 C--N 1.318 -0.78 0 CA-C-N 115.427 -0.806 . . . . 2.21 110.383 173.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.474 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 16.5 Cg_exo -60.79 119.61 6.87 Favored 'Trans proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.176 2.584 . . . . 0.44 111.03 178.393 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.45 HG13 ' HA ' ' A' ' 12' ' ' GLN . 43.0 mt . . . . . 0 C--N 1.329 -0.325 0 CA-C-O 121.297 0.57 . . . . 0.46 110.224 -175.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.7 t . . . . . 0 N--CA 1.453 -0.29 0 N-CA-C 109.942 -0.392 . . . . 0.74 109.942 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.5 t -117.31 15.06 14.84 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.737 -0.211 . . . . 2.14 111.532 -176.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.43 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -157.05 -78.0 0.08 Allowed 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.87 -0.332 . . . . 0.54 111.581 178.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 21.6 m -148.59 129.43 14.27 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.774 0.321 . . . . 0.29 110.77 -179.075 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.436 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -90.41 135.88 33.4 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.864 -0.421 . . . . 0.25 109.864 -179.424 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.569 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 6.7 m -143.87 158.55 16.17 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-O 121.277 0.561 . . . . 0.21 111.156 -177.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 15.0 t -109.35 104.51 13.64 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.338 -0.846 . . . . 0.39 109.476 175.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.776 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 61.3 m -91.16 120.96 32.53 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.169 0.509 . . . . 0.65 111.108 -178.035 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 17.6 t -78.22 -21.53 49.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.28 -0.873 . . . . 1.15 110.295 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.7 t0 -105.81 149.09 26.8 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.224 -0.658 . . . . 1.6 109.224 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.515 ' C ' HD22 ' A' ' 69' ' ' ASN . 0.3 OUTLIER -118.84 5.64 11.47 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 112.559 0.577 . . . . 2.49 112.559 -175.092 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.455 ' ND2' HD12 ' A' ' 77' ' ' ILE . 1.3 p30 -82.39 112.18 19.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.921 0.867 . . . . 2.27 109.563 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.945 HG12 ' H ' ' A' ' 73' ' ' GLY . 70.8 t -122.12 137.28 56.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.364 -0.835 . . . . 1.1 110.858 -172.485 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.529 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 95.0 p -76.88 -1.41 28.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.654 -0.703 . . . . 1.41 110.94 -178.185 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.945 ' H ' HG12 ' A' ' 71' ' ' VAL . . . 127.88 -31.82 3.62 Favored Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 115.43 -0.804 . . . . 0.48 112.372 -176.521 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.2 m -138.77 -5.92 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.203 0 N-CA-C 112.849 0.685 . . . . 0.49 112.849 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.529 ' CG1' ' H ' ' A' ' 72' ' ' SER . 5.1 pt -92.82 -177.1 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 113.359 0.874 . . . . 0.3 113.359 -174.236 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.776 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.68 142.59 23.87 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 114.117 -1.401 . . . . 0.18 108.602 174.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.455 HD12 ' ND2' ' A' ' 70' ' ' ASN . 66.5 mt -126.67 139.94 50.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.275 0.472 . . . . 0.26 112.275 -175.617 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 68.58 51.82 28.96 Favored Glycine 0 C--N 1.335 0.48 0 CA-C-N 115.736 -0.666 . . . . 0.17 111.682 177.411 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 8.3 m -109.0 138.94 44.55 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.049 0.452 . . . . 0.65 111.84 -172.369 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.434 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.8 mt -109.15 132.45 21.22 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.801 -0.636 . . . . 0.29 110.057 173.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.51 ' HA ' HG12 ' A' ' 64' ' ' VAL . 24.5 Cg_exo -63.23 123.06 11.51 Favored 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.194 2.596 . . . . 0.25 113.308 -177.18 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.436 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 9.2 m . . . . . 0 N--CA 1.445 -0.723 0 CA-C-N 116.018 -0.537 . . . . 0.42 110.063 177.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 32.3 t . . . . . 0 N--CA 1.454 -0.264 0 N-CA-C 109.704 -0.48 . . . . 0.96 109.704 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 21.0 mt -105.31 133.72 48.79 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.453 0 CA-C-O 121.651 0.739 . . . . 0.96 111.231 177.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.613 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -141.47 161.68 37.33 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 114.854 -1.066 . . . . 0.91 110.684 178.885 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.431 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 24.8 t -110.98 103.31 11.77 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.415 -0.812 . . . . 0.34 109.107 178.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.792 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 81.8 m -85.75 138.81 31.83 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.461 -0.79 . . . . 0.19 110.678 -175.531 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.423 HE21 ' HB2' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -73.98 -35.15 64.45 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.711 -0.848 . . . . 0.38 108.711 175.374 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . 0.783 ' ND2' ' HB3' ' A' ' 45' ' ' ASP . 0.1 OUTLIER -130.02 150.35 51.33 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 109.532 -0.544 . . . . 1.03 109.532 170.909 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.6 t -130.6 101.79 6.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 109.139 -0.689 . . . . 0.18 109.139 173.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.469 HG22 ' OD1' ' A' ' 16' ' ' ASN . 8.8 m -130.8 143.51 49.66 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.981 -0.554 . . . . 0.18 111.513 -173.073 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.435 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.4 Cg_exo -59.2 140.13 93.4 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.499 2.133 . . . . 0.19 111.853 172.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.85 -20.96 67.06 Favored Glycine 0 N--CA 1.453 -0.199 0 C-N-CA 120.979 -0.629 . . . . 0.18 112.603 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -103.91 14.98 29.68 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.736 0.779 . . . . 2.27 109.711 176.789 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.435 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.2 t -84.24 154.56 22.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.599 -0.728 . . . . 0.24 109.902 176.555 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -52.25 -41.01 62.44 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.185 0.517 . . . . 1.06 110.496 178.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.68 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 7.6 mt -71.96 -63.17 1.19 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.737 -0.665 . . . . 1.11 110.674 176.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.33 -40.39 53.21 Favored Glycine 0 C--N 1.33 0.212 0 CA-C-N 116.067 -0.515 . . . . 0.16 113.266 -175.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 96.5 m -68.62 -45.12 72.74 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.878 0.37 . . . . 0.24 110.826 -177.454 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.432 ' O ' HD13 ' A' ' 27' ' ' LEU . 1.8 tm? -65.38 -37.56 87.35 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.435 -0.58 . . . . 1.01 109.435 178.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.68 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.0 mt -69.42 -43.51 73.23 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.012 -0.54 . . . . 0.37 110.588 -176.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.586 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.3 pp -72.23 -26.54 62.07 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.662 -0.415 . . . . 0.41 110.765 -178.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.421 ' N ' HD12 ' A' ' 29' ' ' LEU . 19.5 t70 -66.19 -33.56 76.05 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.711 0.767 . . . . 0.66 109.066 173.399 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 29.3 mm-40 -80.22 -11.62 59.71 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.509 -1.223 . . . . 2.07 111.143 179.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.1 mt -115.41 -14.51 11.59 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.899 -0.591 . . . . 0.71 112.187 -174.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 78.88 39.68 19.71 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.139 -0.553 . . . . 0.75 112.751 177.054 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.586 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 15.9 mt -96.62 138.39 21.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.624 0.249 . . . . 0.68 110.761 -176.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.3 p -119.39 102.73 13.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.468 0.651 . . . . 1.87 110.264 174.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 20.0 mt -86.99 140.09 29.91 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.973 -0.558 . . . . 2.76 110.802 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -75.33 -27.74 59.37 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.936 -0.574 . . . . 2.65 109.752 174.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 61.1 t0 -139.02 104.31 7.36 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 108.663 -0.866 . . . . 2.29 108.663 175.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -72.12 4.03 3.57 Favored 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.518 2.145 . . . . 0.64 112.901 -176.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 64.9 p -93.04 2.55 56.72 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 120.445 -0.502 . . . . 0.51 110.936 -177.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.2 m -83.63 159.76 3.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.102 -0.499 . . . . 0.24 110.425 178.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.1 mt -88.7 122.24 31.91 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.832 -0.622 . . . . 0.22 110.475 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.5 pt -106.17 134.4 47.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 115.987 -0.551 . . . . 0.15 110.073 176.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.792 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -111.16 107.83 2.26 Favored Glycine 0 N--CA 1.443 -0.882 0 C-N-CA 120.593 -0.813 . . . . 0.31 112.908 -176.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.783 ' HB3' ' ND2' ' A' ' 16' ' ' ASN . 20.9 t70 -81.44 138.64 35.53 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.441 -0.577 . . . . 0.57 109.441 176.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.405 ' HA3' ' HB3' ' A' ' 15' ' ' GLN . . . 78.7 36.66 28.63 Favored Glycine 0 N--CA 1.443 -0.88 0 C-N-CA 120.248 -0.977 . . . . 0.21 111.787 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.4 OUTLIER -105.15 112.75 25.99 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.344 0.592 . . . . 0.25 111.559 -172.4 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -102.82 134.33 19.91 Favored Pre-proline 0 C--N 1.317 -0.828 0 CA-C-N 115.364 -0.834 . . . . 2.21 109.535 173.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -59.28 127.2 23.15 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.759 2.306 . . . . 0.44 111.616 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 19.1 mt . . . . . 0 C--N 1.326 -0.444 0 CA-C-O 121.479 0.657 . . . . 0.46 109.253 -179.842 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.1 t . . . . . 0 N--CA 1.455 -0.198 0 N-CA-C 110.071 -0.344 . . . . 0.74 110.071 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 8.3 p -102.4 -26.56 13.23 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.313 0.486 . . . . 2.14 112.313 -175.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 14' ' ' CYS . . . -123.14 -75.99 0.59 Allowed 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.56 -0.456 . . . . 0.54 111.91 -176.578 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 31.8 m -146.77 128.73 15.46 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.908 0.385 . . . . 0.29 111.39 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.67 137.89 32.1 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.261 -0.427 . . . . 0.25 110.512 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.606 HG21 ' SG ' ' A' ' 14' ' ' CYS . 2.7 m -146.3 170.45 4.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.037 -0.529 . . . . 0.21 111.302 -177.294 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . 0.411 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 41.3 t -132.64 109.68 9.9 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.351 -0.841 . . . . 0.39 109.589 177.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.756 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -95.91 137.67 34.64 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.454 0.645 . . . . 0.65 112.041 -178.074 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 33.0 t -82.88 -18.91 38.58 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 114.865 -1.061 . . . . 1.15 110.586 178.245 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -110.84 147.29 34.85 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.101 0.477 . . . . 1.6 111.151 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -115.62 4.48 14.14 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.637 -0.71 . . . . 2.49 110.522 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -75.67 73.81 2.66 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.34 0.591 . . . . 2.27 110.446 178.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 33.6 m -89.57 146.8 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 CA-C-N 115.801 -0.636 . . . . 1.1 110.947 -177.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.421 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 44.8 m -89.52 10.43 22.89 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.084 -0.507 . . . . 1.41 110.703 178.212 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.26 -33.93 3.2 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.561 -0.745 . . . . 0.48 113.552 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.6 m -140.57 -2.85 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 117.743 0.772 . . . . 0.49 112.218 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.421 ' CG1' ' H ' ' A' ' 72' ' ' SER . 16.4 pt -93.71 -176.45 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.769 0.795 . . . . 0.3 112.567 -176.432 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.756 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -147.53 137.82 23.13 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 114.206 -1.361 . . . . 0.18 108.745 174.049 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 70.4 mt -117.52 126.39 74.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.002 0.43 . . . . 0.26 111.628 -176.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.51 52.62 5.45 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.845 -0.616 . . . . 0.17 111.798 177.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.42 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 1.3 m -99.03 137.52 37.44 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 112.424 0.527 . . . . 0.65 112.424 -176.257 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 86.3 mt -105.36 131.49 21.71 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.505 -0.771 . . . . 0.29 109.719 170.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.438 ' HA ' HG12 ' A' ' 64' ' ' VAL . 19.1 Cg_exo -65.81 121.95 9.44 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.973 2.449 . . . . 0.25 112.303 -179.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.3 m . . . . . 0 N--CA 1.443 -0.78 0 CA-C-N 116.275 -0.421 . . . . 0.42 110.147 178.801 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.0 t . . . . . 0 N--CA 1.452 -0.374 0 N-CA-C 109.137 -0.69 . . . . 0.96 109.137 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 45.9 mt -102.08 136.76 32.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.629 0.728 . . . . 0.96 111.544 -179.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.526 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -144.13 169.27 18.18 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.97 -1.014 . . . . 0.91 110.556 -179.717 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 14.7 t -118.15 103.51 9.94 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.708 -0.678 . . . . 0.34 109.731 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.828 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 98.9 m -85.68 134.67 33.96 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.397 -0.819 . . . . 0.19 111.196 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.407 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -72.77 -30.05 63.8 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.162 -0.926 . . . . 0.38 109.082 174.652 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -139.66 115.74 10.36 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.611 -0.722 . . . . 1.03 110.369 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 88.9 t -105.53 105.45 18.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-O 120.927 0.394 . . . . 0.18 110.048 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.6 m -132.37 139.92 36.34 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 115.936 -0.574 . . . . 0.18 111.147 -175.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.455 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.4 Cg_exo -58.55 141.99 97.83 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.442 2.095 . . . . 0.19 111.717 171.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.51 -19.52 70.94 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.878 -0.677 . . . . 0.18 111.965 179.432 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -102.15 9.83 39.88 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.218 0.532 . . . . 2.27 110.009 176.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.455 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.5 t -80.8 154.62 27.07 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 115.628 -0.714 . . . . 0.24 109.728 175.575 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -54.56 -40.13 68.43 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.96 0.41 . . . . 1.06 110.357 179.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.67 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 5.1 mt -70.75 -62.19 1.48 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.686 -0.688 . . . . 1.11 110.529 176.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.56 -38.71 63.97 Favored Glycine 0 C--N 1.33 0.242 0 CA-C-N 116.052 -0.522 . . . . 0.16 113.421 -175.031 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 85.7 m -66.35 -42.71 87.69 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.798 0.333 . . . . 0.24 110.745 -178.215 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.456 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.6 tm? -69.97 -34.82 73.88 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.327 -0.62 . . . . 1.01 109.327 177.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.67 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.6 mt -65.04 -46.2 82.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.053 -0.521 . . . . 0.37 110.483 -178.131 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.492 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.64 -21.03 52.85 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.473 -0.491 . . . . 0.41 111.004 -178.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.456 ' N ' HD12 ' A' ' 29' ' ' LEU . 32.4 t70 -66.15 -37.81 86.59 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.391 0.615 . . . . 0.66 109.572 173.181 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -75.98 -12.85 60.21 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.029 -0.987 . . . . 2.07 109.928 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 75.3 mt -106.09 -12.03 15.91 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.195 -0.911 . . . . 0.71 111.318 -179.269 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.09 39.36 96.25 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.575 -0.738 . . . . 0.75 112.343 -178.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.492 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 53.9 mt -82.19 133.23 29.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 O-C-N 122.645 -0.326 . . . . 0.68 111.057 -176.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 11.4 p -87.45 116.43 29.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 109.336 -0.616 . . . . 1.87 109.336 172.393 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.492 HD22 ' HB3' ' A' ' 39' ' ' PRO . 0.9 OUTLIER -91.79 131.33 37.23 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.918 -0.583 . . . . 2.76 111.003 -179.454 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 45.2 tt0 -88.23 -34.27 17.82 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.261 -1.014 . . . . 2.65 108.261 173.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -145.06 102.75 4.43 Favored Pre-proline 0 N--CA 1.445 -0.711 0 CA-C-N 114.835 -1.075 . . . . 2.29 108.324 174.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.492 ' HB3' HD22 ' A' ' 36' ' ' LEU . 41.4 Cg_endo -67.71 -4.39 12.11 Favored 'Trans proline' 0 C--O 1.225 -0.152 0 C-N-CA 122.586 2.191 . . . . 0.64 112.075 -174.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 15.3 p -82.53 -10.05 59.16 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.823 -0.626 . . . . 0.51 111.407 -174.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.418 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.8 m -74.18 160.54 5.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.159 0.504 . . . . 0.24 111.01 -178.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.41 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 92.3 mt -91.52 129.81 37.44 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.795 -0.639 . . . . 0.22 110.397 179.195 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.2 pt -112.52 137.64 44.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.159 0.504 . . . . 0.15 110.433 176.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.828 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.8 103.31 1.32 Allowed Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 120.478 -0.867 . . . . 0.31 113.133 -175.338 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -79.11 139.91 37.96 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 109.445 -0.576 . . . . 0.57 109.445 177.078 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.74 39.82 38.92 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.077 -1.058 . . . . 0.21 111.804 -179.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.539 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -108.28 112.98 25.72 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.098 0.475 . . . . 0.25 111.717 -171.69 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.406 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 12.2 m-20 -101.83 137.13 19.45 Favored Pre-proline 0 C--N 1.318 -0.763 0 CA-C-N 115.395 -0.82 . . . . 2.21 109.581 175.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 25.2 Cg_exo -59.88 133.98 54.12 Favored 'Trans proline' 0 C--O 1.233 0.244 0 C-N-CA 122.86 2.373 . . . . 0.44 112.076 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 40.6 mt . . . . . 0 C--N 1.327 -0.387 0 CA-C-O 121.209 0.528 . . . . 0.46 109.881 -179.787 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.3 t . . . . . 0 N--CA 1.451 -0.405 0 N-CA-C 109.923 -0.399 . . . . 0.74 109.923 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 10.0 t -107.08 -28.68 9.85 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.557 -0.292 . . . . 2.14 111.085 -178.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.407 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -112.05 -80.2 0.59 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.837 -0.345 . . . . 0.54 111.783 -176.437 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 16.4 m -145.1 128.13 16.54 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.84 0.352 . . . . 0.29 111.154 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.48 136.91 32.92 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.903 0.382 . . . . 0.25 110.276 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.652 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.2 m -145.85 167.92 7.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.089 0.471 . . . . 0.21 111.59 -175.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . 0.449 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 17.8 t -130.54 105.94 8.18 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.45 -0.796 . . . . 0.39 110.121 178.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.723 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.8 m -92.45 133.58 35.77 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.698 0.761 . . . . 0.65 111.985 -179.28 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 8.7 t -86.16 -13.44 47.07 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.521 -1.218 . . . . 1.15 110.423 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -107.82 156.67 18.88 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.866 -0.606 . . . . 1.6 110.2 -179.145 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 30.4 p-10 -120.9 -15.1 8.38 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 113.084 0.772 . . . . 2.49 113.084 -172.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -88.16 73.21 9.01 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 121.985 0.898 . . . . 2.27 111.072 -173.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.7 m -85.68 164.77 2.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.049 -0.978 . . . . 1.1 110.999 -178.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.543 ' OG ' HG12 ' A' ' 75' ' ' ILE . 88.7 p -84.59 -2.72 57.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.051 -0.522 . . . . 1.41 111.66 -175.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.64 -31.89 3.83 Favored Glycine 0 CA--C 1.505 -0.592 0 C-N-CA 120.721 -0.752 . . . . 0.48 112.304 -178.071 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.4 m -135.49 -12.15 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.488 -0.485 . . . . 0.49 111.935 178.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.543 HG12 ' OG ' ' A' ' 72' ' ' SER . 35.4 pt -90.02 -175.14 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 119.986 -0.686 . . . . 0.3 111.581 -179.156 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.723 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -147.78 143.46 27.54 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.398 -1.273 . . . . 0.18 108.665 175.085 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 64.0 mt -122.55 131.23 73.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.966 0.412 . . . . 0.26 111.585 -175.41 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.448 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 76.38 50.71 7.18 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.097 -0.573 . . . . 0.17 112.188 177.751 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.486 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.92 141.84 31.19 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 112.826 0.676 . . . . 0.65 112.826 -175.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 95.0 mt -108.57 132.06 21.37 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.223 -0.899 . . . . 0.29 109.269 168.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.432 ' HA ' HG12 ' A' ' 64' ' ' VAL . 15.8 Cg_exo -67.29 128.4 18.33 Favored 'Trans proline' 0 C--O 1.234 0.297 0 C-N-CA 122.757 2.304 . . . . 0.25 112.292 -179.257 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.0 m . . . . . 0 N--CA 1.444 -0.729 0 CA-C-N 116.02 -0.536 . . . . 0.42 110.12 178.239 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.1 t . . . . . 0 N--CA 1.45 -0.457 0 N-CA-C 110.128 -0.323 . . . . 0.96 110.128 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 23.7 mt -112.1 135.92 49.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-O 121.482 0.658 . . . . 0.96 110.825 173.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.681 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -153.91 170.29 21.39 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 114.968 -1.015 . . . . 0.91 110.873 -177.187 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.587 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 42.1 t -118.69 108.59 15.1 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.434 -0.803 . . . . 0.34 109.593 177.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.871 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 60.9 m -90.11 129.62 36.38 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.311 0.577 . . . . 0.19 111.599 -172.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.442 ' HB3' ' HA3' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -75.54 -26.71 58.25 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 114.946 -1.025 . . . . 0.38 110.252 177.851 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . 0.608 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 1.6 t-20 -135.86 99.15 4.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.445 -0.343 . . . . 1.03 110.818 175.266 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 61.8 t -92.66 102.0 13.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.002 0.429 . . . . 0.18 110.039 177.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.6 m -133.42 142.92 45.89 Favored Pre-proline 0 C--N 1.32 -0.701 0 CA-C-N 115.896 -0.593 . . . . 0.18 110.905 -174.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.491 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.5 Cg_exo -61.1 139.38 83.79 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.086 1.858 . . . . 0.19 111.164 171.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.08 -24.42 70.3 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.84 -0.695 . . . . 0.18 112.627 -178.262 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -97.61 4.45 50.2 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.147 0.498 . . . . 2.27 110.048 177.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.491 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.2 t -73.2 152.99 40.86 Favored 'General case' 0 CA--C 1.513 -0.48 0 CA-C-N 115.758 -0.655 . . . . 0.24 109.994 177.597 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -54.31 -39.36 66.94 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.098 0.475 . . . . 1.06 110.227 178.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.704 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.7 mm? -70.89 -62.33 1.43 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.646 -0.706 . . . . 1.11 110.818 175.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.3 -40.34 60.44 Favored Glycine 0 C--N 1.33 0.232 0 CA-C-N 116.171 -0.468 . . . . 0.16 113.296 -175.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.1 m -69.0 -44.36 72.96 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.857 0.36 . . . . 0.24 110.692 -177.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.02 -38.95 93.23 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.316 -0.624 . . . . 1.01 109.316 178.443 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.704 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.2 mt -69.11 -44.4 72.48 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.668 -0.696 . . . . 0.37 110.764 -177.129 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.581 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.4 pp -76.02 -26.16 56.37 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.798 -0.361 . . . . 0.41 111.068 -178.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.447 ' N ' HD12 ' A' ' 29' ' ' LEU . 31.9 t70 -64.24 -34.44 78.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.859 0.837 . . . . 0.66 109.035 172.267 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -80.66 -12.27 59.51 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 114.152 -1.386 . . . . 2.07 111.162 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 88.5 mt -111.86 -13.55 13.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.969 -0.56 . . . . 0.71 112.065 -176.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.9 41.35 18.97 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.238 -0.506 . . . . 0.75 112.898 178.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.581 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 15.4 mt -104.16 140.58 21.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.824 0.345 . . . . 0.68 110.811 -177.551 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.0 p -123.96 102.6 11.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.513 0.673 . . . . 1.87 110.002 173.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 24.1 mt -78.06 141.41 38.85 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.851 -0.613 . . . . 2.76 110.986 -177.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -69.76 -33.22 72.13 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.348 -0.842 . . . . 2.65 109.124 175.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 -131.58 104.74 14.46 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 115.189 -0.914 . . . . 2.29 108.653 172.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.87 -1.72 6.52 Favored 'Trans proline' 0 CA--C 1.528 0.187 0 C-N-CA 122.119 1.879 . . . . 0.64 111.812 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.8 p -87.09 -7.65 57.83 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.709 -0.678 . . . . 0.51 111.261 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.447 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 17.7 m -77.31 159.37 5.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 CA-C-O 121.204 0.526 . . . . 0.24 110.82 -179.589 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.471 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 85.6 mt -90.3 123.5 34.12 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.74 -0.664 . . . . 0.22 110.153 177.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.2 pt -105.25 139.27 26.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 115.94 -0.573 . . . . 0.15 109.957 176.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.871 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.32 106.69 1.44 Allowed Glycine 0 N--CA 1.44 -1.037 0 C-N-CA 120.51 -0.852 . . . . 0.31 113.174 -175.037 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.608 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 12.6 t70 -73.41 148.65 43.11 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.015 -0.735 . . . . 0.57 109.015 175.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.447 ' H ' HG23 ' A' ' 74' ' ' VAL . . . 60.6 45.16 96.87 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.44 -0.886 . . . . 0.21 112.58 175.561 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.587 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -100.96 117.35 34.83 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.322 0.582 . . . . 0.25 110.701 -174.662 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.504 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 3.5 p-10 -100.84 131.55 23.31 Favored Pre-proline 0 C--N 1.318 -0.772 0 CA-C-N 115.528 -0.76 . . . . 2.21 110.333 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -60.84 118.22 5.06 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 121.909 1.74 . . . . 0.44 110.076 173.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 13.6 mt . . . . . 0 C--N 1.326 -0.456 0 CA-C-O 121.364 0.602 . . . . 0.46 110.935 -172.581 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 15.3 p . . . . . 0 N--CA 1.451 -0.385 0 N-CA-C 109.576 -0.527 . . . . 0.74 109.576 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 23.9 p -114.17 12.11 17.71 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.01 0.374 . . . . 2.14 112.01 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -134.78 -149.72 0.36 Allowed 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 121.227 -0.189 . . . . 0.54 110.95 -179.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 19.5 m -87.85 134.77 33.63 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.779 0.323 . . . . 0.29 111.055 -177.449 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.71 126.87 34.3 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.878 -0.416 . . . . 0.25 109.878 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.714 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -139.42 173.77 10.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.63 0 CA-C-O 121.51 0.671 . . . . 0.21 111.642 -176.083 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 48.8 t -141.82 103.76 4.4 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.974 -1.012 . . . . 0.39 109.165 -178.065 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.732 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.3 m -92.71 155.52 17.65 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.471 0.653 . . . . 0.65 111.913 -176.095 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 6.4 m -106.18 -13.98 15.27 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.264 -0.88 . . . . 1.15 110.879 -178.077 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.432 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 5.5 t70 -103.38 162.32 13.11 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.142 -0.481 . . . . 1.6 109.748 -178.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -120.85 -7.3 9.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.049 0.452 . . . . 2.49 111.14 -176.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -83.35 83.79 7.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.225 0.536 . . . . 2.27 111.403 -175.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 34.2 m -91.36 156.11 3.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.819 -0.628 . . . . 1.1 110.903 179.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.549 ' OG ' HG12 ' A' ' 75' ' ' ILE . 89.2 p -95.36 3.53 54.3 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.075 0.464 . . . . 1.41 110.53 179.435 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.31 -33.32 3.19 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.463 -0.79 . . . . 0.48 112.123 -176.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.447 HG23 ' H ' ' A' ' 46' ' ' GLY . 19.5 m -140.31 -21.69 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.325 0 N-CA-C 112.478 0.548 . . . . 0.49 112.478 174.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.549 HG12 ' OG ' ' A' ' 72' ' ' SER . 20.4 pt -71.75 172.99 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.373 0 CA-C-O 121.58 0.705 . . . . 0.3 112.187 -174.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.732 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -144.05 140.95 29.81 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.168 -1.378 . . . . 0.18 109.068 176.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.432 ' HB ' ' HB3' ' A' ' 68' ' ' ASP . 71.2 mt -119.5 129.33 75.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.032 0.444 . . . . 0.26 111.455 -176.296 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.458 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.08 51.93 5.96 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.972 -0.632 . . . . 0.17 112.035 178.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.503 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.92 139.04 35.17 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.135 0.493 . . . . 0.65 112.237 -176.503 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 97.9 mt -109.49 132.13 21.48 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 115.564 -0.744 . . . . 0.29 109.142 169.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 14.9 Cg_exo -68.01 119.37 6.38 Favored 'Trans proline' 0 N--CA 1.464 -0.246 0 C-N-CA 122.76 2.306 . . . . 0.25 112.058 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 N--CA 1.443 -0.787 0 CA-C-N 115.969 -0.56 . . . . 0.42 110.747 -177.983 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 31.4 t . . . . . 0 N--CA 1.454 -0.233 0 N-CA-C 109.967 -0.383 . . . . 0.96 109.967 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 48.3 mt -103.58 140.17 22.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.155 0.503 . . . . 0.96 110.678 175.602 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.681 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -150.16 163.71 37.53 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.571 0.701 . . . . 0.91 111.732 -179.557 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.8 t -116.03 105.07 12.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.162 -0.926 . . . . 0.34 108.901 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.863 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 90.1 m -85.16 139.65 31.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.409 -0.814 . . . . 0.19 111.308 -173.174 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.84 -30.32 58.92 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 115.065 -0.971 . . . . 0.38 109.086 175.252 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . 0.555 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 3.2 t-20 -136.13 111.52 9.16 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.797 -0.638 . . . . 1.03 110.618 178.532 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 85.5 t -102.15 106.16 19.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.022 0 N-CA-C 109.71 -0.478 . . . . 0.18 109.71 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.4 m -134.76 142.03 40.87 Favored Pre-proline 0 C--N 1.32 -0.676 0 CA-C-N 115.82 -0.627 . . . . 0.18 110.54 -178.078 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.509 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.5 Cg_exo -59.22 137.33 78.28 Favored 'Trans proline' 0 N--CA 1.46 -0.442 0 C-N-CA 122.31 2.007 . . . . 0.19 111.157 172.427 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.12 -25.55 69.66 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 121.111 -0.566 . . . . 0.18 112.666 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -100.52 6.55 44.3 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.612 0.72 . . . . 2.27 110.198 176.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.509 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 21.0 t -68.88 154.83 41.32 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.352 -0.61 . . . . 0.24 109.352 173.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -53.42 -43.2 67.78 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.098 0.475 . . . . 1.06 109.744 177.369 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.626 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.6 mm? -72.05 -57.72 4.04 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.318 -0.856 . . . . 1.11 111.097 177.776 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -53.71 -40.96 64.87 Favored Glycine 0 C--N 1.33 0.21 0 C-N-CA 121.225 -0.512 . . . . 0.16 112.962 -176.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 84.3 m -67.73 -39.3 84.27 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.731 0.301 . . . . 0.24 110.383 -179.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.429 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.5 tm? -68.25 -36.44 79.45 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.434 -0.58 . . . . 1.01 109.434 178.428 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.626 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 13.3 mt -67.57 -47.55 69.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.742 -0.663 . . . . 0.37 110.372 -177.614 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.566 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -77.56 -22.68 50.63 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.746 -0.382 . . . . 0.41 111.364 -178.562 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.505 ' N ' HD12 ' A' ' 29' ' ' LEU . 26.6 t70 -69.06 -31.53 70.37 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.422 0.63 . . . . 0.66 109.418 175.404 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -70.42 -24.29 62.89 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 114.79 -1.096 . . . . 2.07 109.305 176.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.1 mt -98.53 -15.58 19.49 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.585 -1.189 . . . . 0.71 111.71 -175.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.57 31.18 51.31 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 121.226 -0.512 . . . . 0.75 112.68 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.566 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 31.1 mt -95.38 140.66 16.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.721 0.296 . . . . 0.68 110.753 -178.072 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.9 t -124.75 101.41 8.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 109.708 -0.478 . . . . 1.87 109.708 176.081 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 30.7 mt -74.77 134.76 41.77 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.106 -0.497 . . . . 2.76 111.451 -177.48 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -70.34 -27.22 64.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.489 -0.778 . . . . 2.65 109.285 174.275 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -128.11 90.83 46.26 Favored Pre-proline 0 N--CA 1.446 -0.634 0 N-CA-C 108.38 -0.97 . . . . 2.29 108.38 176.001 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.5 8.36 0.96 Allowed 'Trans proline' 0 C--O 1.223 -0.248 0 C-N-CA 122.416 2.077 . . . . 0.64 112.408 -177.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.5 p -99.94 7.91 44.47 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.094 0.473 . . . . 0.51 110.996 -178.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.539 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 27.8 m -91.98 155.75 3.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.078 -0.51 . . . . 0.24 110.99 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.5 mt -86.56 127.12 34.87 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.663 -0.699 . . . . 0.22 109.875 176.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.493 HD13 HD23 ' A' ' 29' ' ' LEU . 13.4 pt -106.78 141.75 21.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.122 -0.49 . . . . 0.15 110.095 176.236 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.863 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.48 108.59 1.71 Allowed Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 120.523 -0.846 . . . . 0.31 113.419 -174.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.523 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 8.8 t70 -74.49 146.16 42.96 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.757 -0.831 . . . . 0.57 108.757 174.229 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 60.63 47.2 92.37 Favored Glycine 0 C--N 1.318 -0.453 0 C-N-CA 120.281 -0.961 . . . . 0.21 112.712 175.59 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.515 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -108.61 111.59 23.49 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.116 0.484 . . . . 0.25 111.568 -171.771 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.457 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 4.6 t70 -101.67 135.5 19.76 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.633 -0.712 . . . . 2.21 110.916 176.309 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 35.1 Cg_exo -54.76 123.52 13.93 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 124.032 3.155 . . . . 0.44 112.211 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 42.0 mt . . . . . 0 C--N 1.328 -0.368 0 CA-C-O 121.595 0.712 . . . . 0.46 109.402 -179.969 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.1 t . . . . . 0 N--CA 1.451 -0.405 0 CA-C-O 120.674 0.273 . . . . 0.74 110.556 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.1 p -106.89 -22.11 12.8 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.185 -0.461 . . . . 2.14 111.774 -178.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -117.09 -82.65 0.63 Allowed 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 121.016 -0.274 . . . . 0.54 111.129 -179.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 11.9 m -139.77 129.91 25.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.689 0.28 . . . . 0.29 111.363 -179.038 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.4 128.19 34.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.979 0.419 . . . . 0.25 110.777 -177.428 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.624 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -143.09 173.93 5.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.489 0.661 . . . . 0.21 111.579 -177.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 39.0 t -140.96 107.57 5.33 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.387 -0.824 . . . . 0.39 109.146 -177.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.75 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -93.56 138.08 32.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.62 0.724 . . . . 0.65 112.58 -174.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.6 t -85.8 -22.49 27.63 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 114.731 -1.122 . . . . 1.15 110.691 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.422 ' HB2' ' O ' ' A' ' 77' ' ' ILE . 1.2 m-20 -102.53 136.76 41.77 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.164 -0.471 . . . . 1.6 110.813 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -100.44 -4.45 28.89 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.757 -0.656 . . . . 2.49 110.036 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -75.56 90.29 2.76 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.556 -0.747 . . . . 2.27 110.495 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 26.7 m -105.95 156.53 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.579 0 CA-C-N 116.102 -0.499 . . . . 1.1 111.29 -177.125 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.623 ' OG ' HG12 ' A' ' 75' ' ' ILE . 82.5 p -85.83 -4.56 59.2 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.886 -0.597 . . . . 1.41 110.529 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.47 -32.34 3.56 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.594 -0.73 . . . . 0.48 112.436 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 m -136.48 -11.57 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 C-N-CA 120.251 -0.58 . . . . 0.49 112.094 179.105 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.623 HG12 ' OG ' ' A' ' 72' ' ' SER . 25.8 pt -92.54 -178.2 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.602 0.715 . . . . 0.3 111.928 -178.337 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.75 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -143.04 141.09 31.23 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.031 -1.441 . . . . 0.18 109.279 175.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.422 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 68.0 mt -121.17 129.12 75.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.867 0.365 . . . . 0.26 111.447 -177.088 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.539 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 79.59 50.24 5.76 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.803 -0.713 . . . . 0.17 111.816 178.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.483 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.2 m -99.67 133.55 43.85 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 112.453 0.538 . . . . 0.65 112.453 -175.529 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.404 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 92.4 mt -105.53 133.87 19.97 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 115.538 -0.755 . . . . 0.29 109.636 171.065 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 22.9 Cg_exo -63.59 125.75 16.16 Favored 'Trans proline' 0 C--O 1.234 0.3 0 C-N-CA 122.807 2.338 . . . . 0.25 112.022 -179.409 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 10.3 m . . . . . 0 N--CA 1.444 -0.747 0 CA-C-N 116.153 -0.476 . . . . 0.42 110.697 -178.445 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.451 -0.403 0 N-CA-C 109.296 -0.631 . . . . 0.96 109.296 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 18.3 mt -96.19 130.48 44.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.702 0.763 . . . . 0.96 111.281 176.264 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.678 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -137.7 166.55 23.68 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.528 -1.215 . . . . 0.91 110.329 176.6 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.671 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 16.2 t -106.85 100.9 10.37 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.294 -0.866 . . . . 0.34 109.853 179.086 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.813 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 58.1 m -87.01 131.8 33.98 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.148 0.499 . . . . 0.19 110.747 -177.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.403 ' HB2' HE21 ' A' ' 15' ' ' GLN . 0.0 OUTLIER -80.97 -29.72 35.27 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.285 -0.87 . . . . 0.38 109.593 178.23 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . 0.669 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 2.7 m-20 -134.78 104.01 5.85 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.395 -0.366 . . . . 1.03 110.843 176.464 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 59.1 t -95.99 103.07 14.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.152 0.501 . . . . 0.18 110.01 176.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.98 142.68 46.03 Favored Pre-proline 0 C--N 1.32 -0.71 0 CA-C-N 115.731 -0.668 . . . . 0.18 110.704 -175.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.47 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.6 Cg_exo -58.9 137.74 81.62 Favored 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.103 1.868 . . . . 0.19 111.19 172.302 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.88 -23.76 69.53 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.831 -0.7 . . . . 0.18 112.041 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -96.64 7.58 46.21 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.016 0.436 . . . . 2.27 110.286 176.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.47 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.6 t -80.5 152.4 28.73 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.015 -0.539 . . . . 0.24 110.001 177.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -53.12 -37.35 61.7 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.074 0.464 . . . . 1.06 110.709 178.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.692 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.9 mm? -70.53 -65.95 0.67 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.763 -0.653 . . . . 1.11 110.545 175.011 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.67 -40.04 55.3 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.951 -0.568 . . . . 0.16 113.428 -174.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 63.8 m -68.28 -45.13 73.93 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.909 0.385 . . . . 0.24 110.666 -177.196 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -65.97 -36.63 83.84 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.399 -0.593 . . . . 1.01 109.399 178.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.692 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 17.5 mt -66.56 -49.28 66.92 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.836 -0.62 . . . . 0.37 110.326 -178.304 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.612 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.1 pp -74.4 -25.71 59.64 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.42 -0.355 . . . . 0.41 111.622 -175.047 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.516 ' N ' HD12 ' A' ' 29' ' ' LEU . 31.7 t70 -65.66 -34.49 78.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.673 0.749 . . . . 0.66 109.536 176.055 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -78.82 -34.5 45.24 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 114.713 -1.13 . . . . 2.07 109.412 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 82.3 mt -82.63 -10.73 58.82 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.033 -0.985 . . . . 0.71 112.037 -177.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.63 47.71 20.12 Favored Glycine 0 N--CA 1.452 -0.282 0 CA-C-N 115.855 -0.611 . . . . 0.75 112.631 178.117 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.612 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 10.6 mt -109.75 139.01 34.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.723 0.297 . . . . 0.68 110.471 -179.077 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.0 p -123.59 105.37 15.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.396 0.617 . . . . 1.87 110.125 174.387 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 21.6 mt -81.6 144.08 31.5 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.879 -0.601 . . . . 2.76 111.191 -178.063 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 25.5 mm-40 -79.41 -21.16 45.98 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.608 -0.724 . . . . 2.65 109.356 174.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -138.2 99.35 8.97 Favored Pre-proline 0 N--CA 1.445 -0.696 0 N-CA-C 107.707 -1.22 . . . . 2.29 107.707 173.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.72 -1.45 9.29 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.272 1.982 . . . . 0.64 112.453 -175.407 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.2 p -101.37 20.26 16.24 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.21 0.528 . . . . 0.51 111.277 -176.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.459 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 33.4 m -93.01 161.63 2.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.978 -0.556 . . . . 0.24 110.094 174.723 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.426 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 96.4 mt -87.57 120.63 29.07 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.284 -0.416 . . . . 0.22 110.043 176.04 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 14.8 pt -103.66 138.35 28.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 116.078 -0.51 . . . . 0.15 110.092 176.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.813 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -115.55 107.4 1.72 Allowed Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.572 -0.823 . . . . 0.31 113.252 -175.401 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.669 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 12.7 t70 -74.82 146.52 41.96 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.488 -0.93 . . . . 0.57 108.488 174.59 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 67.18 36.87 90.78 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 119.882 -1.152 . . . . 0.21 112.165 176.336 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.671 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -100.34 111.31 23.57 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.376 0.608 . . . . 0.25 110.607 -174.497 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.598 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 1.6 p-10 -101.46 130.32 25.0 Favored Pre-proline 0 C--N 1.314 -0.956 0 CA-C-N 115.547 -0.751 . . . . 2.21 109.876 178.094 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -58.55 118.11 4.94 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.18 1.92 . . . . 0.44 110.911 177.079 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 8.6 mt . . . . . 0 N--CA 1.448 -0.555 0 N-CA-C 108.581 -0.896 . . . . 0.46 108.581 -179.299 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 35.4 t . . . . . 0 N--CA 1.449 -0.515 0 CA-C-O 120.51 0.195 . . . . 0.74 110.737 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 73.9 m -119.78 -3.45 10.26 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.34 -0.391 . . . . 2.14 111.226 176.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.46 -84.4 0.1 Allowed 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.076 -0.712 . . . . 0.54 109.076 172.292 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 29.9 m -151.96 129.27 11.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.913 0.387 . . . . 0.29 111.067 171.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.7 132.58 33.83 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.383 -0.599 . . . . 0.25 109.383 176.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.713 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -141.95 169.8 13.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.488 0.661 . . . . 0.21 112.334 -174.094 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 14.2 t -130.95 100.53 5.28 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.66 -1.155 . . . . 0.39 109.459 179.306 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.775 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -88.88 125.52 34.97 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.79 0.805 . . . . 0.65 111.872 -178.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 10.0 t -85.26 -18.38 34.13 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 114.281 -1.327 . . . . 1.15 110.252 -179.057 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -110.82 140.81 44.94 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.64 -0.709 . . . . 1.6 109.577 178.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -119.74 24.64 10.47 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 120.975 -0.29 . . . . 2.49 111.695 -173.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 49.1 m-80 -86.5 56.82 4.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.333 0.587 . . . . 2.27 110.187 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 35.8 m -73.95 139.79 18.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.505 -0.771 . . . . 1.1 111.574 -175.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.422 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 19.6 m -90.86 10.83 24.67 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.013 -0.54 . . . . 1.41 111.431 -178.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.62 -34.76 2.94 Favored Glycine 0 C--O 1.228 -0.265 0 C-N-CA 120.944 -0.646 . . . . 0.48 113.995 173.167 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.5 m -139.98 -7.11 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 117.936 0.868 . . . . 0.49 111.264 176.534 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.422 ' CG1' ' H ' ' A' ' 72' ' ' SER . 11.2 pt -89.87 178.5 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.336 0.589 . . . . 0.3 111.347 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.775 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -144.31 144.17 31.34 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 114.563 -1.199 . . . . 0.18 109.177 175.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 67.4 mt -123.01 132.52 71.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.915 0.388 . . . . 0.26 111.549 -176.163 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.459 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 74.22 50.22 10.75 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.743 -0.741 . . . . 0.17 112.017 177.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.517 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.2 m -98.46 136.07 39.13 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-O 121.177 0.513 . . . . 0.65 111.785 -176.336 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.441 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.2 mt -107.63 130.18 23.18 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.472 -0.785 . . . . 0.29 109.258 170.048 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 15.7 Cg_exo -67.12 121.41 8.57 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.808 2.339 . . . . 0.25 112.651 -177.569 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.0 m . . . . . 0 N--CA 1.442 -0.852 0 CA-C-N 115.686 -0.688 . . . . 0.42 109.346 176.838 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.8 t . . . . . 0 N--CA 1.451 -0.396 0 N-CA-C 109.186 -0.672 . . . . 0.96 109.186 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 23.8 mt -113.05 130.79 66.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.822 0.82 . . . . 0.96 111.196 177.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.566 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -146.72 170.64 16.57 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 114.363 -1.29 . . . . 0.91 110.479 -178.792 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.434 ' HB2' HD11 ' A' ' 50' ' ' ILE . 39.5 t -120.03 107.11 12.68 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.834 -0.621 . . . . 0.34 109.657 177.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.886 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 97.4 m -84.92 127.41 34.15 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.297 -0.865 . . . . 0.19 110.863 -176.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.475 ' HA ' ' HB1' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -67.79 -36.06 79.76 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-N 115.181 -0.918 . . . . 0.38 109.403 173.77 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -133.9 111.55 10.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 1.03 110.631 177.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 92.8 t -97.97 106.85 19.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.786 -0.45 . . . . 0.18 109.786 176.28 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.1 m -131.79 140.49 38.42 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 116.31 -0.404 . . . . 0.18 111.013 -176.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.436 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.5 Cg_exo -60.36 140.31 91.1 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.389 2.059 . . . . 0.19 111.75 172.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.8 -19.81 69.8 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 121.02 -0.609 . . . . 0.18 112.488 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -100.76 5.45 43.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.112 0.482 . . . . 2.27 109.899 176.579 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.436 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 30.1 t -77.17 152.8 34.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.834 -0.621 . . . . 0.24 110.015 177.294 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -51.29 -41.02 60.17 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.959 0.409 . . . . 1.06 110.365 178.741 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.717 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 3.1 mm? -72.77 -62.91 1.28 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.757 -0.656 . . . . 1.11 110.618 178.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.47 -39.03 52.13 Favored Glycine 0 C--N 1.331 0.271 0 CA-C-N 116.153 -0.476 . . . . 0.16 113.15 -175.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.8 m -66.96 -47.8 70.5 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.728 0.299 . . . . 0.24 110.514 -178.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.449 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.4 tm? -65.75 -33.84 76.8 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.751 -0.463 . . . . 1.01 109.751 178.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.717 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 17.2 mt -67.92 -44.26 77.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.37 110.738 -178.012 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.587 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -79.62 -23.08 42.88 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.75 -0.38 . . . . 0.41 110.595 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.423 ' N ' HD12 ' A' ' 29' ' ' LEU . 15.0 t70 -64.09 -35.17 79.86 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.872 0.844 . . . . 0.66 109.568 172.664 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -74.85 -38.62 61.92 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 114.53 -1.214 . . . . 2.07 109.875 179.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 69.5 mt -81.88 -20.11 39.51 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 114.745 -1.116 . . . . 0.71 112.298 -176.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.86 34.39 30.91 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 121.183 -0.532 . . . . 0.75 112.347 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.587 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 40.4 mt -85.79 131.12 35.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.802 0.334 . . . . 0.68 110.929 -176.721 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 48.2 t -89.61 100.68 11.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 116.294 -0.412 . . . . 1.87 109.958 175.204 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.576 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.2 pp -72.06 126.36 29.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.426 0.632 . . . . 2.76 110.705 179.292 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -78.4 -35.62 46.91 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 108.695 -0.854 . . . . 2.65 108.695 172.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -144.46 108.35 4.83 Favored Pre-proline 0 N--CA 1.442 -0.837 0 CA-C-N 114.606 -1.179 . . . . 2.29 107.892 176.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.468 ' HB3' HD22 ' A' ' 36' ' ' LEU . 56.1 Cg_endo -70.88 -4.71 15.33 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.22 1.946 . . . . 0.64 111.522 -176.706 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 24.2 p -88.35 14.0 10.49 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.456 -0.793 . . . . 0.51 111.412 -174.211 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.412 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 19.3 m -102.84 158.36 4.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.045 -0.525 . . . . 0.24 110.448 179.143 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.423 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 92.6 mt -86.0 119.6 26.48 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.79 -0.641 . . . . 0.22 109.955 177.257 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.454 HD13 HD23 ' A' ' 29' ' ' LEU . 13.5 pt -102.81 134.13 44.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.213 0.53 . . . . 0.15 110.056 176.31 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.886 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -105.39 101.47 1.87 Allowed Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 120.531 -0.842 . . . . 0.31 112.944 -175.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -81.62 129.44 34.69 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.792 -0.818 . . . . 0.57 108.792 175.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.12 35.94 16.55 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 119.793 -1.194 . . . . 0.21 111.48 -175.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.79 110.02 22.2 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.194 0.521 . . . . 0.25 110.995 -174.373 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.455 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.4 t70 -101.96 135.77 19.63 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-N 115.424 -0.807 . . . . 2.21 110.495 175.089 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 12.4 Cg_exo -61.95 122.13 10.5 Favored 'Trans proline' 0 N--CA 1.462 -0.377 0 C-N-CA 123.453 2.769 . . . . 0.44 111.734 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.434 HD11 ' HB2' ' A' ' 13' ' ' CYS . 22.1 mt . . . . . 0 C--N 1.327 -0.372 0 CA-C-O 121.4 0.619 . . . . 0.46 109.433 -178.389 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 45.5 t . . . . . 0 N--CA 1.452 -0.329 0 N-CA-C 109.225 -0.657 . . . . 0.74 109.225 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.4 t -107.62 -3.75 18.96 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.177 0.436 . . . . 2.14 112.177 -171.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.475 ' HB1' ' HA ' ' A' ' 15' ' ' GLN . . . -77.78 -89.09 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 C-N-CA 120.605 -0.438 . . . . 0.54 111.201 -179.357 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 28.4 m -151.08 125.75 9.62 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.684 0.278 . . . . 0.29 110.528 178.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.91 132.17 34.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.02 0.438 . . . . 0.25 110.066 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.753 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.4 m -143.14 172.04 8.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.261 0.553 . . . . 0.21 111.247 -177.7 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 51.9 t -138.11 104.72 5.3 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.238 -0.892 . . . . 0.39 109.3 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.74 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.3 m -89.24 132.38 34.91 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.555 0.693 . . . . 0.65 111.629 -178.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 33.5 t -76.22 -24.87 54.65 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.96 -1.018 . . . . 1.15 109.906 177.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -110.61 133.91 52.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.648 -0.705 . . . . 1.6 110.482 176.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -100.35 18.14 19.68 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.385 0.612 . . . . 2.49 109.968 179.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 -77.89 94.84 4.62 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.487 -0.779 . . . . 2.27 109.872 178.077 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 28.3 m -106.6 140.87 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 CA-C-N 116.166 -0.47 . . . . 1.1 111.739 -176.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.481 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 19.5 m -91.96 10.32 29.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.046 -0.525 . . . . 1.41 110.853 176.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.37 -34.63 3.01 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.159 -0.543 . . . . 0.48 113.668 174.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.0 m -140.7 -2.63 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 117.965 0.882 . . . . 0.49 111.692 176.426 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.481 ' CG1' ' H ' ' A' ' 72' ' ' SER . 3.8 pt -95.99 -177.64 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-O 121.431 0.634 . . . . 0.3 112.322 -175.034 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.74 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.51 140.44 21.92 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.368 -1.287 . . . . 0.18 108.783 174.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.0 mt -117.14 126.08 74.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.982 0.42 . . . . 0.26 111.675 -175.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 79.15 52.02 5.07 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.957 -0.64 . . . . 0.17 111.825 177.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.28 132.29 43.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.396 0.617 . . . . 0.65 112.164 -176.46 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 87.9 mt -102.19 129.86 25.41 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.427 -0.806 . . . . 0.29 109.538 171.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.45 ' HA ' HG12 ' A' ' 64' ' ' VAL . 15.9 Cg_exo -67.33 120.16 7.2 Favored 'Trans proline' 0 C--O 1.235 0.361 0 C-N-CA 122.859 2.373 . . . . 0.25 112.111 -178.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 11.2 m . . . . . 0 N--CA 1.441 -0.902 0 CA-C-N 115.813 -0.63 . . . . 0.42 110.015 179.848 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 65' ' ' CYS . 30.4 t . . . . . 0 N--CA 1.453 -0.31 0 N-CA-C 109.915 -0.402 . . . . 0.96 109.915 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 28.0 mt -108.65 132.93 55.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.782 0.801 . . . . 0.96 111.325 177.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.58 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -140.34 165.53 27.16 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.559 -1.201 . . . . 0.91 110.501 179.843 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.472 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 40.1 t -110.81 104.22 12.82 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.666 -0.697 . . . . 0.34 109.443 178.327 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.777 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 69.3 m -90.73 130.6 36.7 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.012 -0.54 . . . . 0.19 111.585 -174.474 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.412 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -73.42 -28.94 62.26 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.069 -0.969 . . . . 0.38 110.007 176.374 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . 0.441 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 5.2 t-20 -138.44 104.05 5.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.35 -0.386 . . . . 1.03 110.75 179.327 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 80.9 t -99.96 104.67 16.42 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 N-CA-C 109.917 -0.401 . . . . 0.18 109.917 178.122 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.0 m -132.37 143.86 50.64 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 116.064 -0.516 . . . . 0.18 110.976 -175.495 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.484 ' O ' ' HB3' ' A' ' 22' ' ' SER . 35.4 Cg_exo -60.85 136.61 67.23 Favored 'Trans proline' 0 N--CA 1.463 -0.307 0 C-N-CA 122.152 1.901 . . . . 0.19 111.36 172.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.38 -22.13 69.13 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 121.046 -0.597 . . . . 0.18 112.462 -178.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -98.15 3.14 49.08 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.144 0.497 . . . . 2.27 110.1 176.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.484 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.8 t -75.38 154.85 36.96 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.838 -0.619 . . . . 0.24 109.795 176.107 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -54.53 -41.03 69.23 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.367 0.603 . . . . 1.06 109.619 177.039 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.639 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.2 mm? -65.14 -65.05 0.72 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.875 -1.057 . . . . 1.11 110.698 175.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -56.6 -40.2 87.11 Favored Glycine 0 C--N 1.33 0.241 0 CA-C-N 115.972 -0.558 . . . . 0.16 113.614 -174.337 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 61.6 m -66.12 -42.06 89.7 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.918 0.39 . . . . 0.24 110.236 -178.586 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.401 HD22 ' HA ' ' A' ' 27' ' ' LEU . 2.6 tm? -65.92 -38.17 87.98 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.378 -0.601 . . . . 1.01 109.378 177.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.639 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.2 mt -65.4 -47.21 77.1 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 116.032 -0.531 . . . . 0.37 110.716 -176.7 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.551 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.87 -22.57 49.63 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.603 -0.439 . . . . 0.41 111.539 -176.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.492 ' N ' HD12 ' A' ' 29' ' ' LEU . 33.9 t70 -69.39 -34.58 74.72 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.518 0.675 . . . . 0.66 109.471 175.529 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -80.92 -10.71 59.69 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.058 -0.973 . . . . 2.07 110.118 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -108.93 -1.77 18.81 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.504 -0.771 . . . . 0.71 111.276 -178.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.51 43.48 98.96 Favored Glycine 0 C--N 1.331 0.272 0 CA-C-N 115.662 -0.699 . . . . 0.75 113.024 178.216 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.551 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 30.4 mt -95.36 137.96 22.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.962 0.41 . . . . 0.68 111.026 -177.211 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -97.99 103.19 14.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.867 -0.606 . . . . 1.87 110.055 175.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.468 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.2 pp -74.31 133.28 42.57 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.356 0.598 . . . . 2.76 111.136 -179.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -88.78 -32.02 18.09 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 108.378 -0.971 . . . . 2.65 108.378 174.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -145.84 109.66 4.41 Favored Pre-proline 0 N--CA 1.439 -0.982 0 N-CA-C 107.269 -1.382 . . . . 2.29 107.269 175.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.428 ' HB3' HD22 ' A' ' 36' ' ' LEU . 61.5 Cg_endo -74.24 -3.97 14.66 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 121.937 1.758 . . . . 0.64 112.429 -174.085 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 65.2 p -97.43 21.71 9.78 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.49 0.662 . . . . 0.51 111.188 -174.26 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.437 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 23.8 m -99.8 156.19 4.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.467 -0.788 . . . . 0.24 110.096 174.829 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.436 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.5 mt -85.07 124.18 31.46 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.24 -0.437 . . . . 0.22 110.123 177.215 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.407 HD13 HD23 ' A' ' 29' ' ' LEU . 14.4 pt -106.35 133.69 50.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.184 0.516 . . . . 0.15 110.134 175.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.777 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.38 100.48 1.08 Allowed Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.613 -0.803 . . . . 0.31 112.803 -176.087 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -80.6 146.44 31.22 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 109.564 -0.532 . . . . 0.57 109.564 177.217 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.412 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 74.18 36.46 50.88 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.07 -1.062 . . . . 0.21 111.571 -178.673 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -102.9 118.53 37.03 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.262 0.553 . . . . 0.25 111.456 -173.061 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.53 139.21 20.21 Favored Pre-proline 0 C--N 1.32 -0.697 0 CA-C-N 115.468 -0.787 . . . . 2.21 109.157 175.018 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -71.12 123.24 9.47 Favored 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 122.095 1.863 . . . . 0.44 111.287 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.406 HG13 ' HA ' ' A' ' 12' ' ' GLN . 13.1 mt . . . . . 0 C--N 1.325 -0.497 0 CA-C-O 121.645 0.736 . . . . 0.46 109.853 -176.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.1 t . . . . . 0 N--CA 1.448 -0.536 0 N-CA-C 110.014 -0.365 . . . . 0.74 110.014 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.2 p -90.61 -22.97 20.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.983 -0.553 . . . . 2.14 111.707 -178.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -129.49 -87.95 0.52 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 120.7 -0.4 . . . . 0.54 112.012 -177.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 60.3 m -131.28 130.67 43.12 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.808 0.337 . . . . 0.29 111.616 -175.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.73 131.64 34.08 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.34 -0.391 . . . . 0.25 109.962 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.631 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -143.06 166.67 14.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.062 0.458 . . . . 0.21 111.494 -175.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . 0.487 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 31.5 t -128.27 104.64 7.85 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.435 -0.802 . . . . 0.39 110.15 178.485 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.746 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.6 m -93.2 136.92 33.01 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.61 0.719 . . . . 0.65 111.79 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.7 t -89.01 -20.52 24.3 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 114.784 -1.098 . . . . 1.15 110.458 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.482 ' HB3' ' OD1' ' A' ' 70' ' ' ASN . 44.6 m-20 -103.53 148.09 26.38 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.902 -0.59 . . . . 1.6 110.401 -177.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.4 HD22 ' HA ' ' A' ' 69' ' ' ASN . 11.6 m120 -119.75 3.75 11.09 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.511 -0.313 . . . . 2.49 111.155 -179.683 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.482 ' OD1' ' HB3' ' A' ' 68' ' ' ASP . 18.2 p-10 -79.56 63.29 4.11 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.736 0.779 . . . . 2.27 110.21 178.446 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.9 m -97.41 162.48 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.709 0 CA-C-N 115.372 -0.831 . . . . 1.1 111.29 -176.108 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.566 ' H ' HG12 ' A' ' 75' ' ' ILE . 87.9 p -85.14 -2.51 58.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.692 -0.685 . . . . 1.41 111.105 -177.554 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.42 -32.67 4.24 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.799 -0.715 . . . . 0.48 112.13 -179.108 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.6 m -130.86 -11.88 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.399 -0.52 . . . . 0.49 111.859 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.566 HG12 ' H ' ' A' ' 72' ' ' SER . 29.1 pt -87.69 178.88 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 C-N-CA 119.879 -0.729 . . . . 0.3 110.976 177.146 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.746 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -148.0 137.94 22.61 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 114.685 -1.143 . . . . 0.18 108.826 176.568 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 61.7 mt -120.05 130.74 73.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.874 0.368 . . . . 0.26 111.322 -175.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.498 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.58 50.52 6.52 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 121.139 -0.553 . . . . 0.17 112.042 178.528 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -99.41 136.07 39.89 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 112.446 0.535 . . . . 0.65 112.446 -175.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 97.4 mt -106.62 129.47 24.39 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.562 -0.745 . . . . 0.29 109.478 169.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 15.3 Cg_exo -67.63 124.89 12.51 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 123.092 2.528 . . . . 0.25 112.567 -177.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.8 m . . . . . 0 N--CA 1.444 -0.746 0 CA-C-N 116.128 -0.487 . . . . 0.42 110.273 179.696 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.9 t . . . . . 0 N--CA 1.451 -0.378 0 N-CA-C 109.492 -0.558 . . . . 0.96 109.492 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 22.6 mt -105.63 131.47 54.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.682 0.753 . . . . 0.96 111.0 175.621 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.539 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -141.53 163.14 33.74 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.736 -1.12 . . . . 0.91 110.941 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.535 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 47.3 t -107.61 101.66 10.97 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.305 -0.861 . . . . 0.34 109.523 178.477 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.821 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 60.2 m -85.68 129.78 34.73 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.177 0.513 . . . . 0.19 111.281 -175.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.413 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -75.28 -30.17 60.33 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 115.17 -0.923 . . . . 0.38 109.644 177.311 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . 0.416 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 4.8 t-20 -135.43 110.11 8.63 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.832 -0.622 . . . . 1.03 110.091 178.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.7 t -105.85 104.55 17.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.998 0.428 . . . . 0.18 109.887 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.0 m -135.86 146.31 56.45 Favored Pre-proline 0 C--N 1.322 -0.623 0 CA-C-N 115.984 -0.553 . . . . 0.18 111.191 -173.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.478 ' O ' ' HB3' ' A' ' 22' ' ' SER . 26.6 Cg_exo -62.18 137.98 69.48 Favored 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.16 1.907 . . . . 0.19 110.996 170.601 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.26 -30.16 76.68 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.002 -0.618 . . . . 0.18 112.547 -178.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -96.66 10.45 38.57 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.089 0.471 . . . . 2.27 110.272 177.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.478 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.9 t -77.59 154.85 31.93 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.502 -0.555 . . . . 0.24 109.502 174.436 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -49.69 -46.08 49.59 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.534 -0.543 . . . . 1.06 109.534 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.694 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.0 OUTLIER -64.07 -64.47 0.88 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 114.934 -1.03 . . . . 1.11 110.921 178.821 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.91 -37.65 62.92 Favored Glycine 0 C--N 1.331 0.298 0 CA-C-N 115.972 -0.558 . . . . 0.16 113.317 -175.135 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.1 m -69.54 -39.9 77.19 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.888 0.375 . . . . 0.24 110.666 -177.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.42 HD22 ' HA ' ' A' ' 27' ' ' LEU . 1.2 tm? -66.05 -39.76 90.39 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.024 -0.732 . . . . 1.01 109.024 177.04 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.694 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 18.9 mt -64.6 -53.41 48.12 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 114.848 -1.069 . . . . 0.37 110.914 -177.188 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.555 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -71.65 -22.88 61.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.445 -0.343 . . . . 0.41 111.307 -175.455 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.474 ' N ' HD12 ' A' ' 29' ' ' LEU . 20.6 t70 -63.59 -38.19 90.17 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.507 0.67 . . . . 0.66 109.915 174.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -76.34 -29.76 57.36 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.128 -0.942 . . . . 2.07 109.64 -178.659 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.5 mt -85.62 -12.01 52.5 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 114.779 -1.1 . . . . 0.71 111.451 -177.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.25 32.38 52.21 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.929 -0.578 . . . . 0.75 112.747 177.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.555 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 11.9 mt -94.11 141.59 14.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.664 0.269 . . . . 0.68 110.498 -177.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.9 p -128.11 102.85 9.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.497 0.665 . . . . 1.87 110.078 174.232 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.0 mt -94.58 145.6 24.7 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.898 -0.592 . . . . 2.76 110.557 -178.454 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -76.38 -27.88 56.53 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.924 -0.58 . . . . 2.65 109.892 178.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -139.31 92.52 10.52 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 115.621 -0.718 . . . . 2.29 109.251 174.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.44 6.61 1.82 Allowed 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.492 2.128 . . . . 0.64 111.749 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.5 p -75.01 -7.26 53.16 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.668 -0.696 . . . . 0.51 111.188 -179.084 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.4 m -83.02 163.04 3.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.858 -0.61 . . . . 0.24 110.711 178.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.449 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.3 mt -87.56 123.05 32.03 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.994 -0.548 . . . . 0.22 110.469 178.287 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.7 pt -105.33 138.26 31.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.073 -0.512 . . . . 0.15 110.092 175.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.821 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -116.64 102.71 1.06 Allowed Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.654 -0.784 . . . . 0.31 112.918 -175.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -81.06 143.59 32.36 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.397 -0.594 . . . . 0.57 109.397 177.019 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.405 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 72.28 38.8 58.51 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 119.958 -1.115 . . . . 0.21 111.752 -179.34 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.535 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -103.94 116.57 32.49 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.969 0.414 . . . . 0.25 110.999 -173.273 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.462 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 2.5 p-10 -101.35 131.41 23.12 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 115.969 -0.56 . . . . 2.21 110.16 177.336 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -58.87 119.44 6.7 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.31 2.007 . . . . 0.44 110.642 175.075 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 14.4 mt . . . . . 0 C--N 1.327 -0.401 0 CA-C-O 121.597 0.713 . . . . 0.46 110.131 -175.114 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.5 t . . . . . 0 N--CA 1.446 -0.665 0 N-CA-C 109.861 -0.422 . . . . 0.74 109.861 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 19.9 m -92.6 -24.05 18.83 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.479 -0.328 . . . . 2.14 111.377 -179.224 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.413 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -97.72 -86.42 0.34 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.841 -0.344 . . . . 0.54 111.675 -177.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 33.4 m -148.46 126.65 12.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.762 0.315 . . . . 0.29 110.83 -178.256 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.73 132.39 33.87 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.877 0.37 . . . . 0.25 110.14 -178.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.664 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.7 m -142.77 172.17 8.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-O 121.352 0.596 . . . . 0.21 111.521 -176.092 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 38.1 t -133.26 104.69 6.59 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.023 -0.99 . . . . 0.39 109.645 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.766 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -92.56 130.4 38.22 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.667 0.746 . . . . 0.65 111.828 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 55.0 m -76.93 -32.4 57.33 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.613 -1.176 . . . . 1.15 110.948 178.699 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -109.64 138.57 45.81 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.659 -0.701 . . . . 1.6 109.855 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -120.85 23.76 10.55 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.813 0.339 . . . . 2.49 111.453 -174.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 25.3 p-10 -81.31 56.89 3.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.858 0.837 . . . . 2.27 109.813 176.122 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 18.1 m -83.01 158.55 3.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 114.967 -1.015 . . . . 1.1 112.197 -171.14 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.521 ' H ' HG12 ' A' ' 75' ' ' ILE . 95.1 p -82.75 -3.04 56.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.27 -0.877 . . . . 1.41 111.05 -178.2 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.84 -32.2 3.71 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 121.04 -0.6 . . . . 0.48 112.465 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.3 m -136.15 -7.56 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 C-N-CA 120.5 -0.48 . . . . 0.49 111.899 179.169 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.521 HG12 ' H ' ' A' ' 72' ' ' SER . 32.2 pt -92.0 -177.45 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 C-N-CA 120.006 -0.678 . . . . 0.3 111.369 178.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.766 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.38 140.37 21.98 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 114.791 -1.095 . . . . 0.18 109.161 177.295 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 68.4 mt -122.02 123.94 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.071 0.462 . . . . 0.26 111.657 -175.508 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 81.95 51.85 4.32 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.904 -0.665 . . . . 0.17 111.596 179.361 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.449 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.23 136.43 39.2 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.244 0.545 . . . . 0.65 112.187 -175.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.446 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 92.1 mt -110.66 131.28 22.17 Favored Pre-proline 0 C--N 1.321 -0.65 0 CA-C-N 115.54 -0.754 . . . . 0.29 109.703 171.653 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 22.6 Cg_exo -64.93 131.87 30.38 Favored 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 123.137 2.558 . . . . 0.25 112.868 -177.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.4 m . . . . . 0 N--CA 1.446 -0.666 0 CA-C-N 115.75 -0.659 . . . . 0.42 109.58 177.275 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.7 t . . . . . 0 N--CA 1.455 -0.182 0 N-CA-C 109.656 -0.498 . . . . 0.96 109.656 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 22.8 mt -104.43 133.61 48.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.664 0.745 . . . . 0.96 111.619 178.699 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.452 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -144.28 163.03 34.89 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 114.524 -1.216 . . . . 0.91 110.121 178.165 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.489 ' HB2' HD11 ' A' ' 50' ' ' ILE . 34.6 t -114.92 109.36 18.02 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.076 -0.713 . . . . 0.34 109.076 176.547 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.796 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 96.8 m -88.96 134.93 33.8 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.392 -0.822 . . . . 0.19 111.35 -173.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.443 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -75.39 -28.25 59.39 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.158 -0.928 . . . . 0.38 109.775 178.461 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -141.77 103.52 4.37 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.147 -0.479 . . . . 1.03 110.73 177.555 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 98.6 t -93.85 105.93 17.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 116.178 -0.465 . . . . 0.18 109.787 177.235 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.41 142.42 45.33 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.149 -0.478 . . . . 0.18 111.067 -176.144 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.563 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.4 Cg_exo -58.92 139.21 89.84 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.382 2.054 . . . . 0.19 111.392 172.167 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.37 -20.01 71.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.824 -0.703 . . . . 0.18 112.317 -179.187 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 17.2 p-10 -101.87 7.4 41.61 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.311 0.577 . . . . 2.27 109.962 176.316 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.563 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 13.5 t -74.12 154.27 39.21 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.554 -0.748 . . . . 0.24 109.78 174.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -56.28 -39.88 73.37 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.955 0.407 . . . . 1.06 110.08 177.17 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.656 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER -70.45 -60.19 2.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.545 -0.752 . . . . 1.11 110.431 175.825 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.491 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.43 -41.5 80.71 Favored Glycine 0 C--N 1.331 0.252 0 CA-C-N 115.922 -0.581 . . . . 0.16 113.33 -175.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.4 m -66.05 -41.73 90.43 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.748 0.308 . . . . 0.24 110.37 -178.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.407 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.8 tm? -64.76 -37.58 88.08 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.561 -0.533 . . . . 1.01 109.561 177.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.656 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.4 mt -66.16 -49.65 66.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.924 -0.58 . . . . 0.37 110.637 -177.596 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.563 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -76.32 -21.76 55.79 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.481 -0.327 . . . . 0.41 111.172 -177.377 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.499 ' N ' HD12 ' A' ' 29' ' ' LEU . 29.8 t70 -66.51 -33.36 75.52 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.723 0.773 . . . . 0.66 109.64 175.007 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -76.21 -25.07 54.73 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.586 -1.188 . . . . 2.07 109.361 179.092 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 94.6 mt -94.46 -17.19 22.7 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.814 -1.084 . . . . 0.71 111.811 -175.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 80.44 35.69 25.47 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.155 -0.545 . . . . 0.75 112.582 178.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.563 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 22.7 mt -98.52 130.83 46.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.684 0.278 . . . . 0.68 110.713 -177.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.6 p -118.72 100.05 9.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.917 0.865 . . . . 1.87 110.569 176.29 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 23.0 mt -82.57 143.44 31.03 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.469 -0.787 . . . . 2.76 111.558 -176.593 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -71.02 -38.47 72.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.225 -0.898 . . . . 2.65 109.254 174.157 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -125.15 91.63 48.83 Favored Pre-proline 0 N--CA 1.447 -0.583 0 CA-C-N 115.069 -0.969 . . . . 2.29 108.438 174.017 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.02 4.12 1.66 Allowed 'Trans proline' 0 C--O 1.225 -0.147 0 C-N-CA 122.54 2.16 . . . . 0.64 111.971 -178.076 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 18.3 p -82.79 -10.9 58.66 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.931 -0.577 . . . . 0.51 111.1 -177.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.9 m -71.24 160.56 5.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.24 111.331 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 97.4 mt -91.17 127.42 36.59 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.855 -0.611 . . . . 0.22 110.505 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.472 HD13 HD23 ' A' ' 29' ' ' LEU . 13.8 pt -107.41 136.85 41.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.098 0.475 . . . . 0.15 110.335 176.372 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.796 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -110.2 98.82 1.12 Allowed Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 120.815 -0.707 . . . . 0.31 113.199 -175.156 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -79.63 141.68 36.28 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.439 -0.578 . . . . 0.57 109.439 177.421 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.443 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 71.99 41.41 54.88 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.151 -1.023 . . . . 0.21 112.161 -179.347 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.551 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.74 117.94 35.34 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.196 0.522 . . . . 0.25 111.614 -172.533 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.488 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 1.6 t70 -101.91 136.03 19.59 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 115.401 -0.818 . . . . 2.21 110.35 174.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.488 ' HD2' ' OD1' ' A' ' 48' ' ' ASP . 1.3 Cg_endo -67.6 120.94 7.98 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.046 2.497 . . . . 0.44 111.868 -177.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.489 HD11 ' HB2' ' A' ' 13' ' ' CYS . 17.7 mt . . . . . 0 C--N 1.327 -0.387 0 CA-C-O 121.277 0.56 . . . . 0.46 109.962 -177.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 42.6 t . . . . . 0 N--CA 1.456 -0.135 0 CA-C-O 120.788 0.328 . . . . 0.74 110.887 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 20.2 m -90.48 -15.53 30.63 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 112.133 0.42 . . . . 2.14 112.133 -176.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 14' ' ' CYS . . . -133.14 -83.25 0.47 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.349 -0.54 . . . . 0.54 112.254 -177.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 23.0 m -138.5 129.57 26.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.787 0.327 . . . . 0.29 111.608 -175.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.24 129.28 34.9 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-O 120.981 0.42 . . . . 0.25 110.319 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.556 HG21 ' SG ' ' A' ' 14' ' ' CYS . 6.4 m -141.64 157.87 21.28 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 121.446 0.641 . . . . 0.21 111.236 -177.249 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 35.3 t -116.18 111.2 19.87 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.206 -0.906 . . . . 0.39 108.722 173.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.654 ' HA ' ' HA ' ' A' ' 79' ' ' CYS . 0.5 OUTLIER -103.71 135.91 44.4 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.744 0.783 . . . . 0.65 111.91 -173.043 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 32.2 t -81.53 -35.22 30.58 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 114.55 -1.205 . . . . 1.15 111.309 -174.501 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -91.95 131.62 37.12 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.01 0.433 . . . . 1.6 110.419 -179.701 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.429 HD22 ' N ' ' A' ' 69' ' ' ASN . 0.9 OUTLIER -106.11 11.11 31.77 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.94 -0.573 . . . . 2.49 111.034 -177.749 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -95.28 72.57 3.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.468 0.651 . . . . 2.27 109.786 -178.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 35.2 m -74.97 153.06 6.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.35 -0.841 . . . . 1.1 111.606 -176.429 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -90.72 8.25 35.46 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.807 -0.633 . . . . 1.41 110.148 179.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.98 -34.08 3.2 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.63 -0.714 . . . . 0.48 112.83 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 m -140.99 -17.05 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 117.218 0.509 . . . . 0.49 111.958 176.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 18.3 pt -81.95 -175.41 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.478 0.656 . . . . 0.3 112.298 -176.28 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -151.05 141.73 22.71 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.236 -1.347 . . . . 0.18 107.874 173.548 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.2 mt -119.05 123.54 71.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 118.32 0.509 . . . . 0.26 112.226 -174.272 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.85 53.29 4.62 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.926 -0.654 . . . . 0.17 111.547 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.654 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 3.8 m -99.94 143.34 30.27 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.153 0.501 . . . . 0.65 111.305 -176.804 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 80.3 mt -109.25 131.76 21.65 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 115.484 -0.78 . . . . 0.29 110.372 175.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.434 ' HA ' HG12 ' A' ' 64' ' ' VAL . 15.9 Cg_exo -67.41 121.99 9.17 Favored 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.891 2.394 . . . . 0.25 111.902 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.8 m . . . . . 0 N--CA 1.445 -0.699 0 CA-C-O 121.674 0.75 . . . . 0.42 111.167 -178.773 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.6 t . . . . . 0 N--CA 1.45 -0.47 0 N-CA-C 108.852 -0.796 . . . . 0.96 108.852 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.531 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.1 mp -98.47 141.96 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 121.652 0.739 . . . . 0.96 111.509 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.596 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -145.75 166.39 26.01 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 114.793 -1.094 . . . . 0.91 110.723 178.75 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.407 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 37.1 t -114.83 104.93 12.43 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.613 -0.721 . . . . 0.34 109.552 179.286 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.782 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 63.4 m -87.69 133.06 33.9 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.519 -0.764 . . . . 0.19 111.199 -175.505 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.406 ' HB2' HE21 ' A' ' 15' ' ' GLN . 0.0 OUTLIER -71.27 -27.31 63.35 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 115.251 -0.886 . . . . 0.38 108.939 173.529 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -145.63 128.39 16.27 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.64 -0.709 . . . . 1.03 110.135 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.6 t -115.73 106.09 19.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.906 0.384 . . . . 0.18 110.27 177.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.9 m -131.91 143.35 48.67 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.026 -0.534 . . . . 0.18 110.922 -175.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.489 ' O ' ' HB3' ' A' ' 22' ' ' SER . 26.6 Cg_exo -62.8 139.85 76.89 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.225 1.95 . . . . 0.19 111.339 172.258 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.9 -22.57 70.43 Favored Glycine 0 C--N 1.329 0.159 0 C-N-CA 120.967 -0.635 . . . . 0.18 112.62 -177.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -100.39 5.83 44.39 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.636 0.732 . . . . 2.27 109.793 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.6 t -75.13 155.11 37.39 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.656 -0.702 . . . . 0.24 110.272 177.114 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -54.51 -41.31 69.49 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.185 0.517 . . . . 1.06 110.116 177.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.682 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.7 mm? -73.34 -57.75 3.79 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.692 -0.685 . . . . 1.11 110.66 177.427 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -54.52 -40.06 68.33 Favored Glycine 0 C--N 1.33 0.205 0 C-N-CA 121.249 -0.5 . . . . 0.16 113.095 -176.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 90.7 m -69.81 -40.75 75.74 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.7 0.286 . . . . 0.24 110.311 -178.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.448 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.6 tm? -66.85 -36.85 83.27 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.539 -0.541 . . . . 1.01 109.539 177.059 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.682 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 12.5 mt -68.21 -47.32 68.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.89 -0.595 . . . . 0.37 110.801 -177.13 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.568 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.5 pp -74.11 -23.67 59.34 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.808 -0.357 . . . . 0.41 110.676 -179.063 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.404 ' N ' HD12 ' A' ' 29' ' ' LEU . 25.7 t70 -61.68 -36.61 81.35 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.474 0.654 . . . . 0.66 109.762 173.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -73.95 -29.63 62.11 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-N 114.983 -1.008 . . . . 2.07 110.03 179.418 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 90.9 mt -93.13 -16.53 24.81 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.832 -1.076 . . . . 0.71 112.157 -172.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.76 35.8 34.74 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 121.263 -0.494 . . . . 0.75 112.624 178.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.568 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 18.4 mt -94.25 139.8 17.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.702 0.287 . . . . 0.68 110.63 -177.145 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.9 t -122.16 98.17 5.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 109.83 -0.433 . . . . 1.87 109.83 176.287 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 22.7 mt -83.13 135.56 34.77 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.17 -0.468 . . . . 2.76 111.251 -177.141 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 -73.36 -24.18 60.3 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.717 -0.674 . . . . 2.65 109.907 174.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -136.77 89.57 17.52 Favored Pre-proline 0 N--CA 1.446 -0.659 0 N-CA-C 108.026 -1.102 . . . . 2.29 108.026 178.285 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.29 -1.04 9.03 Favored 'Trans proline' 0 CA--C 1.519 -0.27 0 C-N-CA 122.193 1.929 . . . . 0.64 112.096 -177.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.7 p -93.36 20.57 6.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.407 0.622 . . . . 0.51 111.246 -177.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.427 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 32.0 m -101.75 162.72 3.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.551 -0.75 . . . . 0.24 110.064 174.176 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.442 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.7 mt -86.62 121.47 29.19 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.142 -0.481 . . . . 0.22 109.969 176.413 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 17.5 pt -104.15 137.69 31.93 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 CA-C-O 121.208 0.528 . . . . 0.15 110.132 176.301 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.782 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -107.42 110.05 3.13 Favored Glycine 0 N--CA 1.44 -1.059 0 C-N-CA 120.605 -0.807 . . . . 0.31 112.82 -176.608 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -86.05 132.73 33.99 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.032 -0.729 . . . . 0.57 109.032 175.278 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.43 37.69 26.93 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.001 -1.095 . . . . 0.21 111.734 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.557 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.23 116.42 32.14 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.139 0.495 . . . . 0.25 111.368 -173.373 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.432 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 6.6 m-20 -100.35 131.9 23.31 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.405 -0.816 . . . . 2.21 109.158 175.099 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.467 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 12.4 Cg_exo -63.87 123.28 11.71 Favored 'Trans proline' 0 N--CA 1.461 -0.408 0 C-N-CA 122.742 2.294 . . . . 0.44 110.965 178.39 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.455 HG13 ' HA ' ' A' ' 12' ' ' GLN . 24.8 mt . . . . . 0 C--N 1.326 -0.422 0 CA-C-O 121.498 0.666 . . . . 0.46 110.417 -175.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.0 t . . . . . 0 N--CA 1.454 -0.252 0 CA-C-O 120.939 0.4 . . . . 0.74 110.837 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.6 p -102.71 -40.78 6.45 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.98 -0.554 . . . . 2.14 111.604 -179.333 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.401 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -101.14 -85.99 0.41 Allowed 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 121.051 -0.26 . . . . 0.54 111.567 -176.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 26.9 m -132.47 129.18 38.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.666 0.269 . . . . 0.29 111.302 -177.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -86.63 130.57 34.43 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.911 0.386 . . . . 0.25 110.142 179.249 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.675 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.7 m -143.06 169.82 11.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.259 0.552 . . . . 0.21 111.415 -176.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . 0.43 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 38.0 t -137.29 107.67 6.47 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.478 -0.783 . . . . 0.39 109.862 -178.669 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.765 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.8 m -93.48 137.63 32.57 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.442 0.639 . . . . 0.65 111.735 -177.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.2 t -87.24 -20.09 27.41 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.128 -0.942 . . . . 1.15 110.955 179.45 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.4 t70 -98.92 160.41 14.28 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.161 -0.472 . . . . 1.6 109.993 -177.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -118.67 5.72 11.59 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 111.928 0.344 . . . . 2.49 111.928 -173.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -84.7 89.63 7.54 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.014 0.435 . . . . 2.27 110.764 -179.019 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.9 m -100.06 130.93 48.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.03 0.443 . . . . 1.1 111.327 179.275 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.501 ' H ' HG12 ' A' ' 75' ' ' ILE . 9.2 t -80.5 -1.47 41.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.046 -0.524 . . . . 1.41 110.484 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.2 -33.89 3.21 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.833 -0.621 . . . . 0.48 112.585 178.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.7 m -140.72 4.58 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 117.202 0.501 . . . . 0.49 111.788 175.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.501 HG12 ' H ' ' A' ' 72' ' ' SER . 19.2 pt -100.2 176.63 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.466 0.651 . . . . 0.3 112.039 179.726 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.765 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -145.93 140.57 27.04 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 114.291 -1.322 . . . . 0.18 109.411 174.722 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 71.0 mt -120.84 127.22 75.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.894 0.378 . . . . 0.26 111.461 -177.377 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.541 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 81.77 48.92 5.61 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 121.026 -0.607 . . . . 0.17 112.064 177.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.442 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.3 140.42 33.5 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 112.665 0.617 . . . . 0.65 112.665 -175.36 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.9 mt -111.34 132.75 21.63 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.43 -0.805 . . . . 0.29 109.603 170.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 16.9 Cg_exo -66.6 121.75 9.04 Favored 'Trans proline' 0 C--O 1.232 0.217 0 C-N-CA 122.974 2.449 . . . . 0.25 112.638 -178.835 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.412 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 6.2 m . . . . . 0 N--CA 1.446 -0.671 0 CA-C-N 115.917 -0.583 . . . . 0.42 110.042 -179.607 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 41.1 t . . . . . 0 N--CA 1.455 -0.222 0 N-CA-C 110.299 -0.26 . . . . 0.96 110.299 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 41.3 mt -102.83 137.49 30.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.517 0.675 . . . . 0.96 110.709 173.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.528 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -144.08 159.34 42.78 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.01 -0.995 . . . . 0.91 110.531 179.007 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 41.7 t -105.5 102.58 12.04 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.794 -0.639 . . . . 0.34 109.686 178.598 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.814 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 81.9 m -85.77 135.43 33.74 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.489 -0.778 . . . . 0.19 110.817 -176.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.431 HE21 ' HB2' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -75.74 -31.04 59.41 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 115.408 -0.815 . . . . 0.38 109.298 174.708 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -138.12 118.29 13.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.81 -0.632 . . . . 1.03 110.245 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.3 t -110.69 103.04 14.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 121.042 0.448 . . . . 0.18 110.094 178.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.0 m -133.31 142.67 45.11 Favored Pre-proline 0 C--N 1.32 -0.688 0 CA-C-N 115.83 -0.623 . . . . 0.18 110.993 -174.392 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.481 ' O ' ' HB3' ' A' ' 22' ' ' SER . 38.3 Cg_exo -60.17 139.9 89.55 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.161 1.907 . . . . 0.19 111.407 172.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.23 -21.78 70.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.814 -0.708 . . . . 0.18 112.342 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -94.22 -4.97 48.0 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.211 0.529 . . . . 2.27 110.524 175.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.481 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 30.0 t -68.79 154.5 41.88 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.813 -0.63 . . . . 0.24 110.54 179.041 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -52.42 -44.27 65.33 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.332 0.587 . . . . 1.06 110.1 178.067 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.663 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.2 mm? -70.6 -58.05 4.09 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.503 -0.771 . . . . 1.11 110.847 178.197 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.461 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.56 -39.41 74.66 Favored Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.227 -0.511 . . . . 0.16 113.307 -176.452 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 87.1 m -67.84 -42.1 81.95 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 120.827 0.346 . . . . 0.24 110.325 -179.015 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -61.89 -43.1 99.53 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.216 -0.661 . . . . 1.01 109.216 175.222 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.663 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.7 mt -61.46 -51.55 68.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.135 -0.939 . . . . 0.37 111.125 -175.633 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.543 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -76.37 -23.89 54.14 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.723 -0.391 . . . . 0.41 111.677 -175.322 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.508 ' N ' HD12 ' A' ' 29' ' ' LEU . 11.8 t70 -68.11 -33.49 74.61 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.512 0.672 . . . . 0.66 109.363 176.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -78.33 -23.83 46.85 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.287 -0.869 . . . . 2.07 109.962 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.7 mt -97.34 -5.24 36.95 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.193 -0.912 . . . . 0.71 111.878 -174.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 68.31 44.48 74.59 Favored Glycine 0 N--CA 1.453 -0.229 0 CA-C-N 115.74 -0.663 . . . . 0.75 112.896 177.348 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.543 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 23.3 mt -97.57 145.53 9.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.673 0.273 . . . . 0.68 110.637 -178.43 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.8 t -107.88 116.27 50.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.127 -0.488 . . . . 1.87 109.695 176.06 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.555 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.5 pp -90.81 129.95 36.83 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.25 0.547 . . . . 2.76 111.25 -179.241 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -90.96 -26.79 19.08 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.917 -0.771 . . . . 2.65 108.917 170.289 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -139.42 94.92 9.3 Favored Pre-proline 0 N--CA 1.447 -0.613 0 CA-C-N 114.92 -1.037 . . . . 2.29 108.495 177.369 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -68.43 -3.93 11.94 Favored 'Trans proline' 0 N--CA 1.466 -0.137 0 C-N-CA 122.256 1.971 . . . . 0.64 111.564 -177.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.8 p -87.89 6.2 36.73 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.337 -0.847 . . . . 0.51 111.45 -175.497 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.428 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.9 m -92.73 158.26 2.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.209 0.528 . . . . 0.24 110.875 179.407 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.9 mt -88.21 128.62 35.46 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.476 -0.784 . . . . 0.22 109.806 175.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.431 HD13 HD23 ' A' ' 29' ' ' LEU . 10.2 pt -106.83 133.07 52.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.203 0.525 . . . . 0.15 110.091 176.118 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.814 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.78 98.16 1.3 Allowed Glycine 0 N--CA 1.438 -1.19 0 CA-C-N 115.385 -0.825 . . . . 0.31 113.02 -175.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -77.4 137.84 38.94 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.583 -0.525 . . . . 0.57 109.583 177.286 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.482 ' H ' HG23 ' A' ' 74' ' ' VAL . . . 71.48 41.08 58.82 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.431 -0.89 . . . . 0.21 112.072 -178.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.528 ' SG ' ' HB2' ' A' ' 12' ' ' GLN . 0.1 OUTLIER -105.14 111.28 23.99 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.294 0.569 . . . . 0.25 111.225 -175.312 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.454 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.5 t70 -101.43 138.53 19.93 Favored Pre-proline 0 C--N 1.316 -0.849 0 CA-C-N 115.483 -0.781 . . . . 2.21 110.927 175.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 25.7 Cg_exo -58.9 119.3 6.46 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 123.626 2.884 . . . . 0.44 111.628 177.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 29.7 mt . . . . . 0 C--N 1.327 -0.388 0 CA-C-O 121.054 0.454 . . . . 0.46 110.501 -177.205 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.8 t . . . . . 0 N--CA 1.451 -0.389 0 N-CA-C 109.786 -0.45 . . . . 0.74 109.786 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 28.5 t -94.4 -37.76 11.29 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.381 -0.372 . . . . 2.14 111.101 -178.205 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -86.59 -86.46 0.15 Allowed 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 121.181 -0.208 . . . . 0.54 111.499 -176.655 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 19.2 m -149.89 130.98 14.41 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.773 0.321 . . . . 0.29 111.145 -178.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -94.95 139.47 31.29 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.852 0.358 . . . . 0.25 110.4 -178.284 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.552 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 7.2 m -145.55 162.97 11.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.315 0.578 . . . . 0.21 111.285 -177.6 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . 0.455 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 30.2 t -115.44 107.8 15.67 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.122 -0.944 . . . . 0.39 109.703 175.678 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.634 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 28.3 m -100.12 140.04 34.93 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.212 0.53 . . . . 0.65 111.441 -176.682 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 40.0 m -97.35 -20.54 17.76 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.633 -0.712 . . . . 1.15 111.241 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -110.43 139.59 45.49 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.997 -0.547 . . . . 1.6 110.372 -176.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -117.14 25.8 10.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.4 -0.364 . . . . 2.49 111.939 -175.033 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 54.8 t30 -80.55 71.61 7.41 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.597 0.713 . . . . 2.27 109.635 176.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.409 HG12 ' O ' ' A' ' 75' ' ' ILE . 32.7 m -84.66 146.57 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 CA-C-N 115.541 -0.754 . . . . 1.1 112.125 -173.549 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.553 ' OG ' HG12 ' A' ' 75' ' ' ILE . 80.2 p -95.4 5.26 52.1 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.387 -0.824 . . . . 1.41 110.222 177.457 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.71 -32.7 3.43 Favored Glycine 0 N--CA 1.445 -0.711 0 CA-C-N 115.361 -0.836 . . . . 0.48 111.88 -176.253 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.482 HG23 ' H ' ' A' ' 46' ' ' GLY . 21.3 m -140.24 -21.42 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 112.558 0.577 . . . . 0.49 112.558 176.162 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.553 HG12 ' OG ' ' A' ' 72' ' ' SER . 7.4 pt -73.21 175.45 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.707 0.765 . . . . 0.3 112.343 -173.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.634 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.21 141.39 23.12 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.233 -1.348 . . . . 0.18 108.565 178.312 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.5 mt -120.78 140.27 45.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 C-N-CA 120.514 -0.474 . . . . 0.26 111.484 -175.056 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.428 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 72.06 52.75 10.49 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-N 115.95 -0.568 . . . . 0.17 111.908 178.163 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.552 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 12.2 m -106.58 145.03 32.4 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.04 0.448 . . . . 0.65 111.969 -174.079 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 91.3 mt -115.92 132.2 23.33 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 115.514 -0.766 . . . . 0.29 109.811 173.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.51 ' HA ' HG12 ' A' ' 64' ' ' VAL . 18.3 Cg_exo -64.77 129.06 22.41 Favored 'Trans proline' 0 C--O 1.234 0.297 0 C-N-CA 123.19 2.593 . . . . 0.25 112.982 -176.686 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.403 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 5.4 m . . . . . 0 N--CA 1.447 -0.596 0 CA-C-N 115.812 -0.631 . . . . 0.42 110.333 178.532 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.1 p . . . . . 0 N--CA 1.447 -0.611 0 N-CA-C 110.62 -0.141 . . . . 0.96 110.62 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.453 HG22 HD12 ' A' ' 50' ' ' ILE . 27.7 mt -102.72 133.99 44.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.843 0.83 . . . . 0.96 111.338 175.739 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.519 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -138.75 159.97 40.81 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.599 -1.182 . . . . 0.91 109.797 177.042 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.453 ' HB2' HD11 ' A' ' 50' ' ' ILE . 41.1 t -109.46 108.45 18.96 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.428 -0.582 . . . . 0.34 109.428 178.084 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.81 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 94.1 m -90.62 129.96 36.69 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.523 -0.762 . . . . 0.19 111.404 -174.597 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.401 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -70.76 -34.65 72.04 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.028 -0.987 . . . . 0.38 109.622 174.433 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -130.91 116.29 17.69 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.87 -0.604 . . . . 1.03 110.085 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 99.3 t -110.2 102.6 14.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.058 0.456 . . . . 0.18 109.981 178.606 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.7 m -130.11 143.59 49.75 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 115.896 -0.593 . . . . 0.18 111.231 -174.053 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.521 ' O ' ' HB3' ' A' ' 22' ' ' SER . 35.5 Cg_exo -61.83 141.11 88.94 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.42 2.08 . . . . 0.19 111.36 171.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.96 -25.52 72.02 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.987 -0.625 . . . . 0.18 112.584 -178.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -97.87 7.1 46.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.238 0.542 . . . . 2.27 110.118 177.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.521 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 28.9 t -75.13 154.23 37.86 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.523 -0.762 . . . . 0.24 109.753 176.168 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -58.69 -31.94 68.69 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.18 0.514 . . . . 1.06 110.389 178.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.697 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.1 mm? -73.39 -64.52 0.97 Allowed 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 115.722 -0.672 . . . . 1.11 110.408 173.076 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.78 -38.35 64.17 Favored Glycine 0 C--N 1.33 0.223 0 CA-C-N 115.788 -0.642 . . . . 0.16 113.707 -174.013 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 87.7 m -68.43 -44.72 74.35 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.818 0.342 . . . . 0.24 110.692 -177.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.433 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.7 tm? -64.72 -36.89 85.74 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.261 -0.644 . . . . 1.01 109.261 177.613 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.697 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 18.9 mt -65.56 -49.54 68.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.881 -0.599 . . . . 0.37 110.436 -178.272 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.491 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -75.31 -22.08 57.97 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.469 -0.332 . . . . 0.41 111.584 -176.257 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.45 ' N ' HD12 ' A' ' 29' ' ' LEU . 19.8 t70 -66.56 -34.81 78.72 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.325 0.584 . . . . 0.66 109.656 175.697 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -72.92 -20.21 61.11 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.126 -0.943 . . . . 2.07 109.594 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.5 mt -98.14 -19.58 17.83 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.346 -1.297 . . . . 0.71 111.308 -176.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.42 24.55 60.71 Favored Glycine 0 N--CA 1.452 -0.271 0 CA-C-N 115.891 -0.595 . . . . 0.75 112.609 179.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.491 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 28.7 mt -78.9 133.28 30.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.967 0.413 . . . . 0.68 110.913 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.5 t -113.1 97.96 6.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.018 -0.537 . . . . 1.87 110.038 176.616 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.4 mt -93.73 138.26 32.11 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.169 -0.468 . . . . 2.76 110.739 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -78.96 -23.81 44.28 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.279 0.561 . . . . 2.65 109.589 175.505 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 24.7 m-20 -133.05 92.21 26.22 Favored Pre-proline 0 N--CA 1.446 -0.628 0 CA-C-N 115.446 -0.797 . . . . 2.29 109.117 176.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -72.8 6.96 2.16 Favored 'Trans proline' 0 N--CA 1.463 -0.287 0 C-N-CA 122.262 1.975 . . . . 0.64 111.445 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.7 p -83.71 -8.25 59.31 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.534 -0.757 . . . . 0.51 110.878 -178.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.471 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 33.4 m -78.54 151.08 5.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.909 -0.587 . . . . 0.24 110.792 179.283 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.0 mt -81.61 120.78 25.51 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.609 -0.723 . . . . 0.22 110.094 177.191 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 12.6 pt -102.52 131.85 49.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.29 0.567 . . . . 0.15 110.119 176.107 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.81 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.11 99.9 1.58 Allowed Glycine 0 N--CA 1.438 -1.207 0 CA-C-N 115.529 -0.76 . . . . 0.31 113.175 -174.54 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -80.67 139.15 36.33 Favored 'General case' 0 C--N 1.314 -0.953 0 N-CA-C 109.028 -0.731 . . . . 0.57 109.028 175.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.33 34.64 35.9 Favored Glycine 0 N--CA 1.444 -0.82 0 C-N-CA 119.629 -1.272 . . . . 0.21 111.523 -178.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.535 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -102.4 118.72 37.47 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.144 0.497 . . . . 0.25 111.121 -174.315 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -100.55 134.5 20.59 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 115.669 -0.696 . . . . 2.21 109.412 175.148 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -63.98 123.13 11.43 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.589 2.193 . . . . 0.44 110.967 177.423 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.453 HD11 ' HB2' ' A' ' 13' ' ' CYS . 12.4 mt . . . . . 0 N--CA 1.45 -0.467 0 CA-C-O 121.482 0.658 . . . . 0.46 109.75 -178.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.3 t . . . . . 0 N--CA 1.449 -0.508 0 CA-C-O 120.854 0.359 . . . . 0.74 110.063 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 51.1 m -108.25 17.17 22.52 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.225 -0.443 . . . . 2.14 111.735 -177.163 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.401 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -144.52 -82.18 0.16 Allowed 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.752 -0.379 . . . . 0.54 111.536 178.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 87.1 m -150.11 123.96 9.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.864 0.364 . . . . 0.29 110.825 -179.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -86.44 129.59 34.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.057 0.456 . . . . 0.25 110.209 -177.433 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.567 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 6.4 m -140.88 161.58 23.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 115.937 -0.574 . . . . 0.21 111.023 -177.702 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 52.8 t -120.18 110.33 16.48 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.633 -0.712 . . . . 0.39 109.389 177.092 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.782 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 15.8 m -97.57 132.23 43.43 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.133 0.492 . . . . 0.65 111.286 -176.292 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.4 m -84.11 -25.78 29.45 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.583 -0.735 . . . . 1.15 111.04 -178.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -102.01 134.66 44.88 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.791 -0.64 . . . . 1.6 110.145 -177.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -100.99 10.1 41.49 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.322 -0.399 . . . . 2.49 111.311 -174.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -79.57 103.21 9.32 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.086 0.47 . . . . 2.27 110.131 179.427 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.871 HG12 ' H ' ' A' ' 73' ' ' GLY . 73.0 t -122.84 133.04 70.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.019 -0.537 . . . . 1.1 111.244 -173.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.586 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 88.8 p -80.12 2.58 23.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.531 -0.758 . . . . 1.41 111.257 -177.296 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.871 ' H ' HG12 ' A' ' 71' ' ' VAL . . . 126.57 -32.31 3.73 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.664 -0.698 . . . . 0.48 112.04 -178.387 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.0 m -138.69 -9.77 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 112.315 0.487 . . . . 0.49 112.315 -179.381 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.586 ' CG1' ' H ' ' A' ' 72' ' ' SER . 4.1 pt -88.79 -179.43 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.707 0.765 . . . . 0.3 112.705 -175.546 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.782 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -151.51 142.17 22.73 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 114.287 -1.324 . . . . 0.18 108.798 174.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.9 mt -120.4 137.1 55.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.915 0.388 . . . . 0.26 111.945 -175.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.471 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 69.89 52.14 20.89 Favored Glycine 0 C--N 1.333 0.371 0 CA-C-N 115.922 -0.581 . . . . 0.17 111.778 177.723 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.567 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 12.8 m -103.02 134.35 46.62 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.274 0.559 . . . . 0.65 111.909 -173.634 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 90.4 mt -107.79 131.82 21.46 Favored Pre-proline 0 C--N 1.322 -0.614 0 CA-C-N 115.563 -0.744 . . . . 0.29 110.032 175.202 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.427 ' HA ' HG12 ' A' ' 64' ' ' VAL . 25.4 Cg_exo -63.24 120.67 8.22 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.917 2.412 . . . . 0.25 112.678 -179.315 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.427 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 4.3 m . . . . . 0 N--CA 1.447 -0.601 0 CA-C-N 115.968 -0.56 . . . . 0.42 110.201 178.23 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 34.1 t . . . . . 0 N--CA 1.45 -0.445 0 N-CA-C 109.502 -0.555 . . . . 0.96 109.502 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.418 HG22 HD12 ' A' ' 50' ' ' ILE . 43.1 mt -95.7 137.16 24.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 121.664 0.745 . . . . 0.96 110.989 178.058 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . 0.532 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -132.24 163.06 29.43 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.775 -1.102 . . . . 0.91 109.949 176.781 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 42.0 t -106.28 99.49 9.07 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.809 -0.632 . . . . 0.34 109.556 179.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.865 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 54.0 m -86.01 130.66 34.47 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-N 115.707 -0.678 . . . . 0.19 111.352 -175.554 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.445 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -77.82 -30.87 51.37 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.196 -0.911 . . . . 0.38 109.77 177.506 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . 0.641 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 19.3 m-20 -133.3 98.59 4.29 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.117 -0.492 . . . . 1.03 111.256 175.609 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 71.8 t -89.48 100.85 11.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.162 0.506 . . . . 0.18 109.732 174.234 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 29.6 m -128.45 141.1 40.35 Favored Pre-proline 0 C--N 1.318 -0.768 0 CA-C-N 115.843 -0.617 . . . . 0.18 110.697 -174.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.466 ' HB2' ' HB2' ' A' ' 22' ' ' SER . 31.9 Cg_exo -59.24 135.58 66.65 Favored 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 122.073 1.849 . . . . 0.19 111.521 172.741 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.8 -15.22 64.23 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.888 -0.673 . . . . 0.18 112.136 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -103.44 4.56 36.25 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.053 0.454 . . . . 2.27 110.248 175.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.466 ' HB2' ' HB2' ' A' ' 19' ' ' PRO . 29.0 t -78.53 158.35 28.59 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.051 -0.522 . . . . 0.24 109.898 177.717 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -53.19 -42.79 66.61 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.974 0.416 . . . . 1.06 109.991 176.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.701 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.9 mm? -67.7 -65.08 0.74 Allowed 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 115.669 -0.696 . . . . 1.11 110.493 178.259 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.69 -36.44 59.29 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.983 -0.553 . . . . 0.16 113.329 -174.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 84.9 m -68.55 -45.67 71.53 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.79 0.329 . . . . 0.24 110.298 -178.175 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.432 ' O ' HD13 ' A' ' 27' ' ' LEU . 1.3 tm? -65.96 -36.38 83.17 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.15 -0.685 . . . . 1.01 109.15 178.212 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.701 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.7 mt -67.34 -46.55 73.12 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.603 -0.726 . . . . 0.37 111.033 -177.363 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.514 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.26 -22.87 51.49 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 120.321 -0.551 . . . . 0.41 111.137 -178.695 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.478 ' N ' HD12 ' A' ' 29' ' ' LEU . 13.0 t70 -67.98 -35.8 78.97 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.044 -0.724 . . . . 0.66 109.044 173.135 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -69.1 -33.22 73.16 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 114.717 -1.129 . . . . 2.07 109.429 178.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 67.6 mt -91.87 -10.86 38.13 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.56 -1.2 . . . . 0.71 111.867 -176.412 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.29 35.71 88.33 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.767 -0.651 . . . . 0.75 112.6 179.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.514 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 56.5 mt -76.08 129.0 37.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 120.814 0.34 . . . . 0.68 111.163 -176.528 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.2 p -86.56 101.0 10.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.746 0.784 . . . . 1.87 109.415 172.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.516 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.8 pp -76.29 132.7 39.98 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.722 -0.672 . . . . 2.76 111.18 -177.358 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -86.83 -29.73 22.01 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.745 -0.835 . . . . 2.65 108.745 172.248 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -144.96 112.33 4.84 Favored Pre-proline 0 N--CA 1.443 -0.803 0 N-CA-C 107.493 -1.299 . . . . 2.29 107.493 174.01 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.407 ' HB3' HD22 ' A' ' 36' ' ' LEU . 70.9 Cg_endo -75.52 -1.5 11.4 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.197 1.931 . . . . 0.64 112.808 -173.228 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 35.2 p -106.55 20.51 18.89 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.261 0.553 . . . . 0.51 111.121 -175.727 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.46 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 34.8 m -87.72 156.59 3.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.589 -0.732 . . . . 0.24 110.081 175.143 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.454 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.9 mt -85.6 121.26 28.04 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.808 -0.442 . . . . 0.22 109.808 176.638 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 22.2 pt -106.41 140.75 23.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.101 0.477 . . . . 0.15 110.256 177.493 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.865 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.2 107.35 1.55 Allowed Glycine 0 N--CA 1.439 -1.111 0 C-N-CA 120.586 -0.816 . . . . 0.31 112.949 -175.102 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.641 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 9.4 t70 -80.62 147.91 30.5 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.693 -0.854 . . . . 0.57 108.693 175.257 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 67.46 37.81 90.34 Favored Glycine 0 C--N 1.317 -0.515 0 C-N-CA 120.162 -1.018 . . . . 0.21 111.958 178.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -102.63 115.44 30.59 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.01 0.433 . . . . 0.25 111.088 -172.895 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.45 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 2.1 p-10 -100.84 132.07 22.63 Favored Pre-proline 0 C--N 1.318 -0.796 0 CA-C-N 115.698 -0.683 . . . . 2.21 110.161 177.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.94 119.55 6.87 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.399 2.066 . . . . 0.44 110.696 175.058 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.418 HD12 HG22 ' A' ' 11' ' ' ILE . 12.9 mt . . . . . 0 N--CA 1.449 -0.488 0 CA-C-O 121.879 0.847 . . . . 0.46 109.913 -177.098 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.5 t . . . . . 0 N--CA 1.451 -0.387 0 CA-C-O 120.848 0.356 . . . . 0.74 110.28 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 12.8 p -93.6 -15.37 25.46 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.089 -0.505 . . . . 2.14 111.742 -177.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.445 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -128.44 -83.44 0.58 Allowed 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.623 0.601 . . . . 0.54 112.623 -175.172 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.8 m -142.11 131.59 23.8 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.783 0.325 . . . . 0.29 111.301 -176.147 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.94 125.98 34.4 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.031 0.443 . . . . 0.25 110.125 178.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.663 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -141.33 164.99 19.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.119 -0.492 . . . . 0.21 110.806 -177.546 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' CYS . . . . . 0.401 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 29.3 t -131.28 113.0 13.27 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 116.172 -0.467 . . . . 0.39 109.935 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.783 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -95.53 136.73 35.54 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.647 0.737 . . . . 0.65 112.233 -175.406 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.7 m -89.44 -18.45 26.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.641 -1.163 . . . . 1.15 110.806 -179.281 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.467 ' HB2' ' O ' ' A' ' 77' ' ' ILE . 19.8 m-20 -98.31 151.71 20.21 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.887 -0.597 . . . . 1.6 110.332 178.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -103.68 -12.28 17.12 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.019 -0.537 . . . . 2.49 110.581 -178.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -67.84 110.2 3.72 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.892 -0.594 . . . . 2.27 110.915 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.5 m -125.19 150.29 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 CA-C-N 116.158 -0.473 . . . . 1.1 110.932 177.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.506 ' H ' HG12 ' A' ' 75' ' ' ILE . 8.1 t -95.31 10.58 35.66 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.651 0.738 . . . . 1.41 109.636 177.008 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.15 -33.42 5.31 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 115.476 -0.784 . . . . 0.48 112.748 177.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.5 m -138.01 -0.52 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.644 -0.422 . . . . 0.49 111.64 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.506 HG12 ' H ' ' A' ' 72' ' ' SER . 24.3 pt -100.21 173.84 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 C-N-CA 120.187 -0.605 . . . . 0.3 111.63 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.783 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -141.41 141.08 33.76 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 114.485 -1.234 . . . . 0.18 109.35 176.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.467 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 67.0 mt -122.02 131.93 72.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.742 0.306 . . . . 0.26 111.342 -177.43 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.46 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 75.53 51.68 7.11 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.978 -0.629 . . . . 0.17 111.911 178.638 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.2 m -99.89 138.74 36.55 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.231 0.538 . . . . 0.65 112.232 -176.345 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 92.1 mt -106.98 133.01 20.46 Favored Pre-proline 0 C--N 1.32 -0.689 0 CA-C-N 115.475 -0.784 . . . . 0.29 109.445 170.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.406 ' HA ' HG12 ' A' ' 64' ' ' VAL . 17.3 Cg_exo -65.77 124.62 12.99 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.82 2.347 . . . . 0.25 111.961 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.6 m . . . . . 0 N--CA 1.442 -0.828 0 CA-C-O 121.033 0.444 . . . . 0.42 110.659 -179.828 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.754 0 N-CA-C 111.918 -0.473 . . . . 5.63 111.918 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.0 m -142.86 116.24 9.05 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.815 0.341 . . . . 4.28 110.983 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.423 ' HA ' ' O ' ' A' ' 50' ' ' ILE . 20.4 m95 -81.78 -55.9 4.33 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.949 -0.569 . . . . 4.74 110.216 175.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.09 163.2 13.67 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 111.119 -0.793 . . . . 2.03 111.119 -178.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 53.3 tp60 -89.44 107.11 18.89 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.871 0.336 . . . . 4.17 110.263 -178.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 44.0 t 176.7 115.69 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.562 -0.744 . . . . 1.88 110.381 177.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 35.1 m -99.5 14.92 28.18 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.106 0.479 . . . . 2.4 110.265 178.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.2 m -84.03 -8.44 59.13 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.366 0.603 . . . . 3.75 110.508 178.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 162.89 -125.98 1.48 Allowed Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.769 -0.729 . . . . 1.12 112.051 178.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 35.3 t -112.86 149.6 32.89 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.155 -0.683 . . . . 0.96 109.155 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.507 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.3 mp -99.27 138.08 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 CA-C-O 121.722 0.772 . . . . 0.96 111.675 176.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.525 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -148.98 167.76 24.92 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.598 -1.183 . . . . 0.91 111.003 178.301 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 37.3 t -116.45 106.71 13.9 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.38 -0.827 . . . . 0.34 109.293 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.818 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 90.4 m -91.8 132.1 36.67 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.753 -0.658 . . . . 0.19 111.597 -173.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.421 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -73.2 -35.97 66.44 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 114.91 -1.041 . . . . 0.38 109.501 173.869 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 19.7 m-20 -128.84 100.57 5.74 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.051 -0.522 . . . . 1.03 111.334 177.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.8 t -92.52 99.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.497 -0.557 . . . . 0.18 109.497 173.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 19.6 m -129.06 140.4 38.5 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 115.761 -0.654 . . . . 0.18 110.863 -174.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.557 ' O ' ' HB3' ' A' ' 22' ' ' SER . 33.4 Cg_exo -58.36 140.9 96.27 Favored 'Trans proline' 0 N--CA 1.464 -0.252 0 C-N-CA 122.371 2.047 . . . . 0.19 111.709 173.313 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.86 -19.47 69.61 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.907 -0.663 . . . . 0.18 112.589 -179.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -103.22 7.43 38.53 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.388 0.613 . . . . 2.27 109.97 176.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.557 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 13.8 t -73.28 155.78 39.13 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.328 -0.851 . . . . 0.24 110.014 176.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -55.93 -41.01 73.95 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.212 0.529 . . . . 1.06 109.685 176.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.735 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.1 mm? -70.11 -60.52 2.24 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 115.325 -0.852 . . . . 1.11 110.694 176.347 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.44 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -56.03 -41.51 85.21 Favored Glycine 0 CA--C 1.517 0.171 0 CA-C-N 116.053 -0.521 . . . . 0.16 113.348 -174.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 91.5 m -67.84 -39.39 83.85 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.916 0.389 . . . . 0.24 110.499 -178.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -64.71 -39.24 93.32 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.244 -0.65 . . . . 1.01 109.244 176.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.735 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.6 mt -68.13 -50.04 57.22 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.701 -0.681 . . . . 0.37 110.987 -176.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.548 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.8 pp -73.18 -23.72 60.45 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.546 -0.462 . . . . 0.41 111.509 -176.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.532 ' N ' HD12 ' A' ' 29' ' ' LEU . 28.2 t70 -68.97 -31.71 70.76 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.58 0.705 . . . . 0.66 109.192 175.64 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -75.04 -15.29 60.64 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-N 114.988 -1.005 . . . . 2.07 109.918 177.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.8 mt -111.7 0.04 16.17 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.932 -1.031 . . . . 0.71 111.464 -174.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.21 34.66 85.32 Favored Glycine 0 C--N 1.333 0.363 0 CA-C-N 115.855 -0.611 . . . . 0.75 113.015 178.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.548 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 53.9 mt -84.07 125.9 40.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.817 0.341 . . . . 0.68 110.828 -176.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 50.4 t -88.17 121.28 38.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.278 -0.638 . . . . 1.87 109.278 175.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.489 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.6 pp -95.23 130.62 41.91 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.425 0.631 . . . . 2.76 111.703 -176.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -90.87 -29.2 17.66 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 108.56 -0.904 . . . . 2.65 108.56 170.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -142.34 96.1 6.47 Favored Pre-proline 0 N--CA 1.442 -0.838 0 N-CA-C 107.724 -1.213 . . . . 2.29 107.724 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.428 ' HB3' HD22 ' A' ' 36' ' ' LEU . 50.7 Cg_endo -69.84 -5.89 17.34 Favored 'Trans proline' 0 CA--C 1.521 -0.149 0 C-N-CA 122.561 2.174 . . . . 0.64 111.819 -176.313 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.2 p -95.41 19.14 11.3 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.686 -0.688 . . . . 0.51 111.308 -175.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.489 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 32.7 m -92.09 156.6 3.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.798 -0.637 . . . . 0.24 109.855 173.048 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.539 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.1 mt -88.99 121.68 31.59 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 116.061 -0.518 . . . . 0.22 109.835 176.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.411 HD13 HD23 ' A' ' 29' ' ' LEU . 12.1 pt -102.74 133.57 46.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-O 121.247 0.546 . . . . 0.15 110.053 176.685 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.818 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -105.82 95.31 1.05 Allowed Glycine 0 N--CA 1.439 -1.166 0 CA-C-N 115.546 -0.752 . . . . 0.31 112.832 -174.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -76.83 141.91 40.48 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.235 -0.654 . . . . 0.57 109.235 176.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.421 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 70.57 38.8 68.44 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 119.71 -1.233 . . . . 0.21 111.825 -177.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.515 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -107.36 116.28 31.66 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.17 0.51 . . . . 0.25 111.351 -172.98 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.418 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 19.9 m-20 -102.02 134.52 20.04 Favored Pre-proline 0 C--N 1.317 -0.838 0 CA-C-N 115.632 -0.713 . . . . 2.21 109.362 175.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.424 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 16.5 Cg_exo -62.79 126.97 19.31 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.613 2.209 . . . . 0.44 111.351 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.464 ' CG2' ' HB1' ' A' ' 58' ' ' ALA . 47.1 mt -80.81 103.42 7.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 120.958 0.409 . . . . 0.46 110.551 -175.753 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 7.5 t -138.74 20.24 2.68 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.755 0.788 . . . . 0.88 109.871 179.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 9.9 p -128.34 161.58 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 CA-C-N 115.234 -0.894 . . . . 1.44 109.832 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . 73.18 -63.98 0.41 Allowed 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 123.344 0.658 . . . . 2.94 112.09 175.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 64.85 40.45 97.3 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.304 -0.95 . . . . 3.5 111.459 -175.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 29.1 m -149.34 -167.47 2.84 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.242 -0.651 . . . . 4.9 109.242 -178.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 13.8 p -61.96 -33.9 75.14 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.923 0.392 . . . . 4.06 110.934 178.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -82.16 25.27 0.6 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 3.13 111.752 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.464 ' HB1' ' CG2' ' A' ' 50' ' ' ILE . . . -80.53 -11.3 59.68 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.282 0.563 . . . . 0.99 110.65 178.707 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.8 t -146.58 135.16 22.08 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.633 -0.712 . . . . 0.74 110.278 178.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.3 p -100.79 -26.19 13.86 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.087 -0.506 . . . . 2.14 111.906 -177.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -105.74 -80.56 0.55 Allowed 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 121.067 -0.253 . . . . 0.54 111.585 -177.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 15.1 m -147.19 129.17 15.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.582 0.229 . . . . 0.29 110.797 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.21 131.87 34.14 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.902 0.382 . . . . 0.25 110.372 -178.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.735 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -144.4 171.82 6.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.238 0.542 . . . . 0.21 111.431 -176.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 42.0 t -139.28 106.26 5.44 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.301 -0.863 . . . . 0.39 109.744 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.731 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -88.41 134.57 33.8 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.472 0.653 . . . . 0.65 112.214 -177.474 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.8 m -85.42 -18.53 33.37 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.856 -1.066 . . . . 1.15 111.1 -179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -100.75 160.18 14.57 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.456 -0.572 . . . . 1.6 109.456 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -112.2 -7.89 14.01 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.962 0.411 . . . . 2.49 110.859 -176.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 34.5 t30 -75.71 108.24 8.41 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.077 -0.51 . . . . 2.27 110.862 -178.143 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.1 m -118.87 143.74 29.09 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.726 0 CA-C-N 116.078 -0.51 . . . . 1.1 110.257 177.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.619 ' OG ' HG12 ' A' ' 75' ' ' ILE . 90.7 p -84.5 -2.0 56.61 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.093 0.473 . . . . 1.41 110.494 -179.707 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.61 -32.18 3.58 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.669 -0.696 . . . . 0.48 112.288 -177.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 15.7 m -136.63 -16.07 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 120.533 -0.467 . . . . 0.49 112.043 178.013 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.619 HG12 ' OG ' ' A' ' 72' ' ' SER . 20.3 pt -87.75 -176.17 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.541 0.686 . . . . 0.3 111.884 -177.187 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.731 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.35 142.2 23.8 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-N 114.231 -1.35 . . . . 0.18 108.765 175.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 63.0 mt -117.75 130.22 72.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 120.594 -0.442 . . . . 0.26 111.646 -176.39 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.505 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.06 51.75 6.06 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.068 -0.587 . . . . 0.17 111.871 177.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.539 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.2 m -99.1 129.61 45.37 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.378 0.609 . . . . 0.65 112.072 -176.143 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 96.5 mt -98.97 132.19 24.08 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.517 -0.765 . . . . 0.29 109.664 173.087 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.438 ' HA ' HG12 ' A' ' 64' ' ' VAL . 13.8 Cg_exo -68.16 123.24 10.38 Favored 'Trans proline' 0 N--CA 1.463 -0.303 0 C-N-CA 122.78 2.32 . . . . 0.25 112.037 -179.071 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.2 m -124.9 157.19 33.47 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 CA-C-N 116.09 -0.505 . . . . 0.42 110.399 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.43 HG22 ' HG ' ' A' ' 84' ' ' LEU . 25.5 m -156.07 139.75 16.04 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.9 -0.591 . . . . 2.07 109.426 176.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.43 ' HG ' HG22 ' A' ' 83' ' ' THR . 98.3 mt . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.851 -0.595 . . . . 3.91 110.916 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.511 0 N-CA-C 111.603 -0.599 . . . . 5.63 111.603 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.4 p -82.59 -14.94 53.94 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.862 0.363 . . . . 4.28 111.139 -177.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 48.3 m95 -102.91 38.0 1.83 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.049 0.452 . . . . 4.74 110.137 -178.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.57 149.76 24.32 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.994 -0.622 . . . . 2.03 112.274 -179.39 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.3 mm100 -87.08 109.26 19.3 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.24 -0.281 . . . . 4.17 110.24 178.608 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.455 ' HB3' ' O ' ' A' ' 9' ' ' GLY . 42.3 t -156.6 136.61 12.7 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.963 0.411 . . . . 1.88 110.645 -178.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 11.0 p -83.6 -17.79 40.44 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.976 -0.556 . . . . 2.4 111.075 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.431 ' HB ' ' SG ' ' A' ' 65' ' ' CYS . 91.6 m -82.46 -24.32 34.31 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.123 -0.49 . . . . 3.75 110.937 178.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.455 ' O ' ' HB3' ' A' ' 6' ' ' CYS . . . 153.63 -139.41 6.84 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.658 -0.782 . . . . 1.12 112.465 178.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.2 m -92.51 139.1 30.93 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-O 120.732 0.301 . . . . 0.96 110.376 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 40.4 mt -90.93 137.66 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.804 0.811 . . . . 0.96 110.869 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.46 ' HA ' HG13 ' A' ' 50' ' ' ILE . 0.1 OUTLIER -145.74 158.05 43.89 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 114.605 -1.179 . . . . 0.91 109.958 -175.903 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 37.8 t -110.51 103.3 11.89 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-O 121.134 0.492 . . . . 0.34 110.009 -177.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.638 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 63.8 m -86.63 136.05 33.19 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.311 -0.858 . . . . 0.19 111.057 -175.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.465 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -73.33 -32.9 64.83 Favored 'General case' 0 N--CA 1.445 -0.69 0 CA-C-N 115.167 -0.924 . . . . 0.38 108.643 173.762 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.501 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 3.7 t-20 -128.36 135.42 49.54 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.59 -0.732 . . . . 1.03 109.468 178.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 87.2 t -126.43 106.11 15.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 109.706 -0.479 . . . . 0.18 109.706 174.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.3 m -135.24 142.41 41.56 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 115.656 -0.702 . . . . 0.18 111.127 -173.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.551 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.8 Cg_exo -57.75 139.76 91.35 Favored 'Trans proline' 0 N--CA 1.462 -0.345 0 C-N-CA 122.257 1.971 . . . . 0.19 111.329 171.251 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.7 -23.12 70.51 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.839 -0.696 . . . . 0.18 112.31 -179.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -95.65 -1.47 50.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.95 0.405 . . . . 2.27 109.932 177.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.551 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 22.9 t -68.28 150.67 47.96 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.002 -0.544 . . . . 0.24 109.579 176.592 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -58.48 -32.56 68.88 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.2 0.524 . . . . 1.06 110.106 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.658 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.6 mm? -69.01 -64.56 0.85 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.433 -0.803 . . . . 1.11 110.701 172.009 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.44 -40.84 78.76 Favored Glycine 0 C--N 1.33 0.225 0 CA-C-N 115.959 -0.564 . . . . 0.16 113.364 -174.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 30.1 m -67.32 -41.15 85.77 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.168 -0.308 . . . . 0.24 110.168 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -64.91 -40.14 94.6 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.408 -0.59 . . . . 1.01 109.408 177.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.658 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.7 mt -67.92 -44.62 76.47 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.044 -0.526 . . . . 0.37 110.849 -175.168 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.547 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.8 pp -77.69 -25.1 49.21 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.372 -0.531 . . . . 0.41 110.899 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.528 ' N ' HD12 ' A' ' 29' ' ' LEU . 24.6 t70 -64.88 -36.7 85.21 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.766 0.793 . . . . 0.66 109.178 172.144 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -74.86 -12.13 60.3 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 114.149 -1.387 . . . . 2.07 110.388 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.5 mt -108.66 -9.95 15.24 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.146 -0.934 . . . . 0.71 111.259 -178.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 71.22 35.09 64.02 Favored Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.887 -0.597 . . . . 0.75 112.518 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.547 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 43.4 mt -91.55 131.05 39.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.709 0.255 . . . . 0.68 110.704 -178.159 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.5 p -91.87 112.75 26.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.42 0.629 . . . . 1.87 109.959 173.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.543 HD22 ' HB3' ' A' ' 39' ' ' PRO . 0.9 OUTLIER -81.62 134.29 35.47 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.92 -0.582 . . . . 2.76 110.908 -179.573 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -87.32 -35.42 18.42 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.828 -0.804 . . . . 2.65 108.828 173.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -143.71 102.5 4.97 Favored Pre-proline 0 N--CA 1.444 -0.745 0 N-CA-C 107.947 -1.131 . . . . 2.29 107.947 176.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.543 ' HB3' HD22 ' A' ' 36' ' ' LEU . 51.8 Cg_endo -69.53 -3.48 11.95 Favored 'Trans proline' 0 C--O 1.226 -0.119 0 C-N-CA 122.365 2.043 . . . . 0.64 111.673 -175.036 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.0 p -85.73 7.95 21.68 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.633 -0.712 . . . . 0.51 111.88 -174.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.5 m -92.18 158.42 2.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 120.958 0.408 . . . . 0.24 110.327 177.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.546 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 94.9 mt -89.07 121.76 31.73 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.076 -0.511 . . . . 0.22 110.084 178.494 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.501 HD13 HD23 ' A' ' 29' ' ' LEU . 22.4 pt -108.86 145.73 15.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.238 0.542 . . . . 0.15 110.44 177.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.638 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.02 142.09 17.18 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.667 -0.778 . . . . 0.31 112.338 -177.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.501 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 9.5 t70 -105.17 151.79 23.62 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.305 -0.998 . . . . 0.57 108.305 172.314 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.404 ' HA3' ' HB3' ' A' ' 15' ' ' GLN . . . 61.02 44.5 98.11 Favored Glycine 0 C--N 1.32 -0.339 0 C-N-CA 120.28 -0.962 . . . . 0.21 112.302 175.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.527 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.34 115.55 30.44 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.056 0.455 . . . . 0.25 110.984 -172.443 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.407 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 18.6 m-20 -101.29 129.32 27.25 Favored Pre-proline 0 C--N 1.316 -0.884 0 CA-C-N 115.666 -0.697 . . . . 2.21 109.304 175.744 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.433 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 17.8 Cg_exo -61.64 122.2 10.69 Favored 'Trans proline' 0 N--CA 1.46 -0.446 0 C-N-CA 122.739 2.293 . . . . 0.44 111.263 178.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.46 HG13 ' HA ' ' A' ' 12' ' ' GLN . 10.1 mt -82.32 88.55 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.593 0.711 . . . . 0.46 109.835 -176.363 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 12.4 t -125.08 9.76 8.09 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.968 -1.015 . . . . 0.88 110.293 -177.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.5 p -89.58 131.07 37.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 115.577 -0.738 . . . . 1.44 110.652 -177.295 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -98.75 133.52 42.95 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.088 -0.505 . . . . 2.94 110.582 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 99.39 35.28 4.76 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.877 -0.677 . . . . 3.5 111.809 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 8.5 t -138.12 106.59 5.83 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.864 0.364 . . . . 4.9 110.168 -177.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.4 m -75.56 -37.84 59.68 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.142 0.496 . . . . 4.06 109.711 177.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -97.78 58.43 1.4 Allowed 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 109.133 -0.692 . . . . 3.13 109.133 173.014 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -70.25 -14.95 62.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.333 -0.849 . . . . 0.99 111.216 -176.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.9 t -132.1 131.36 42.29 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.506 -0.77 . . . . 0.74 110.129 176.586 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 17.4 t -109.66 -22.25 12.03 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.518 -0.31 . . . . 2.14 111.143 -177.588 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.465 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -102.85 -82.06 0.49 Allowed 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.725 -0.39 . . . . 0.54 111.316 -179.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 23.2 m -148.78 127.67 12.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.8 0.333 . . . . 0.29 110.775 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -88.21 133.21 34.09 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.0 0.429 . . . . 0.25 110.909 -177.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.495 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.3 m -144.11 170.5 8.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.03 -0.532 . . . . 0.21 111.07 -178.571 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 46.3 t -130.87 115.77 17.01 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.022 -0.536 . . . . 0.39 110.045 178.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.815 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 4.4 m -101.71 154.88 18.5 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.814 0.816 . . . . 0.65 111.941 -176.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 49.0 m -103.45 -19.58 14.36 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 114.405 -1.27 . . . . 1.15 110.787 -177.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -106.24 142.82 35.28 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.706 -0.679 . . . . 1.6 109.561 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -116.77 2.94 12.95 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.076 0.465 . . . . 2.49 110.663 -176.749 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -92.62 58.69 3.16 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.62 0.724 . . . . 2.27 109.861 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 33.5 m -80.68 163.96 3.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.062 -0.972 . . . . 1.1 110.83 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.526 ' OG ' HG12 ' A' ' 75' ' ' ILE . 91.7 p -74.25 -8.04 54.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.281 -0.418 . . . . 1.41 111.339 -175.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.9 -32.06 3.56 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.923 -0.656 . . . . 0.48 112.68 -178.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 10.6 m -134.96 -6.12 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.318 -0.553 . . . . 0.49 111.989 178.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.526 HG12 ' OG ' ' A' ' 72' ' ' SER . 29.0 pt -93.92 -176.28 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 C-N-CA 120.063 -0.655 . . . . 0.3 111.419 179.583 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.815 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -144.58 143.23 30.69 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.782 -1.099 . . . . 0.18 109.73 175.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 64.0 mt -126.44 128.55 71.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.931 0.396 . . . . 0.26 111.606 -176.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.472 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 74.82 53.68 6.26 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.744 -0.662 . . . . 0.17 111.621 179.144 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.546 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 0.9 OUTLIER -104.2 141.9 35.45 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 112.652 0.612 . . . . 0.65 112.652 -175.539 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 84.2 mt -111.36 134.8 21.06 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.512 -0.767 . . . . 0.29 109.787 172.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.479 ' HA ' HG12 ' A' ' 64' ' ' VAL . 19.4 Cg_exo -65.14 124.04 12.42 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 123.067 2.512 . . . . 0.25 112.595 -179.012 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.3 m -125.59 157.67 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.74 0 CA-C-N 116.089 -0.505 . . . . 0.42 110.223 177.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.585 HG22 HD13 ' A' ' 84' ' ' LEU . 39.0 m -110.15 132.05 54.51 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 116.171 -0.468 . . . . 2.07 110.452 -179.729 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.585 HD13 HG22 ' A' ' 83' ' ' THR . 10.9 mp . . . . . 0 C--O 1.25 1.126 0 O-C-N 123.939 0.775 . . . . 3.91 111.761 -178.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.81 0 N-CA-C 111.756 -0.538 . . . . 5.63 111.756 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 50.4 m 54.38 52.56 12.25 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 121.393 0.616 . . . . 4.28 110.301 -176.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 32.2 t-105 -138.89 -76.24 0.37 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.488 -0.778 . . . . 4.74 109.906 -177.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 134.86 69.45 0.07 OUTLIER Glycine 0 N--CA 1.448 -0.533 0 N-CA-C 111.279 -0.728 . . . . 2.03 111.279 -174.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -92.18 114.84 27.49 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-O 121.309 0.576 . . . . 4.17 110.458 -178.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 5.8 p -93.1 -45.16 8.02 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.462 -0.79 . . . . 1.88 110.465 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 79.9 p -144.96 -155.44 0.61 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.259 -0.882 . . . . 2.4 108.688 -178.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.3 m -62.26 -23.38 66.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.184 0.516 . . . . 3.75 110.214 175.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -83.45 -135.26 2.59 Favored Glycine 0 N--CA 1.447 -0.58 0 CA-C-N 115.725 -0.67 . . . . 1.12 112.479 178.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 40.1 t -150.07 153.09 35.84 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 110.139 -0.319 . . . . 0.96 110.139 -176.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 38.3 mt -88.21 139.37 17.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.185 0.517 . . . . 0.96 110.448 172.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.64 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -140.02 164.37 30.2 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.578 -0.737 . . . . 0.91 110.676 176.616 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.53 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 28.3 t -107.79 101.91 11.17 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.311 -0.859 . . . . 0.34 109.468 179.718 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.824 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 55.6 m -87.72 126.29 34.9 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.984 -0.553 . . . . 0.19 111.298 -176.057 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.442 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -67.28 -33.4 75.22 Favored 'General case' 0 N--CA 1.445 -0.707 0 CA-C-N 115.074 -0.967 . . . . 0.38 109.471 174.878 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -139.43 113.01 8.41 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.953 -0.567 . . . . 1.03 110.501 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 51.2 t -101.17 104.55 16.43 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 109.67 -0.493 . . . . 0.18 109.67 177.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 m -129.97 140.58 39.07 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 116.072 -0.513 . . . . 0.18 111.43 -174.221 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.466 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.1 Cg_exo -59.61 138.44 83.51 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.37 2.047 . . . . 0.19 111.222 171.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -62.79 -26.05 68.27 Favored Glycine 0 C--O 1.227 -0.34 0 C-N-CA 121.272 -0.49 . . . . 0.18 113.146 -176.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -101.13 7.55 43.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.493 0.664 . . . . 2.27 110.245 177.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.466 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 26.6 t -71.31 159.02 35.33 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.52 -0.548 . . . . 0.24 109.52 175.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -53.4 -44.31 68.61 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.168 0.509 . . . . 1.06 109.767 176.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.701 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 6.2 mt -69.09 -60.27 2.47 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.314 -0.857 . . . . 1.11 110.456 178.25 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.429 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -53.51 -38.13 57.49 Favored Glycine 0 C--N 1.33 0.228 0 CA-C-N 116.101 -0.499 . . . . 0.16 113.218 -176.205 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 88.3 m -67.6 -47.61 69.2 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 110.361 -0.237 . . . . 0.24 110.361 -178.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.419 ' O ' HD13 ' A' ' 27' ' ' LEU . 3.1 tm? -62.71 -37.76 87.76 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.66 -0.496 . . . . 1.01 109.66 178.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.701 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.9 mt -69.01 -43.84 74.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.975 -0.557 . . . . 0.37 110.849 -175.543 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.489 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -82.41 -21.31 35.82 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.536 -0.466 . . . . 0.41 111.217 -178.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.44 ' N ' HD12 ' A' ' 29' ' ' LEU . 19.4 t70 -66.56 -34.92 78.98 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.634 0.731 . . . . 0.66 109.364 174.313 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -74.15 -32.96 63.35 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.793 -1.094 . . . . 2.07 109.18 179.141 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.4 mt -89.2 -10.56 46.61 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.903 -1.044 . . . . 0.71 111.982 -176.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.96 44.01 92.52 Favored Glycine 0 N--CA 1.452 -0.294 0 CA-C-N 115.849 -0.614 . . . . 0.75 112.766 178.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.489 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 51.3 mt -91.19 128.82 42.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.936 0.398 . . . . 0.68 111.41 -176.28 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.3 p -84.99 122.31 38.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.061 -0.518 . . . . 1.87 109.905 173.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.544 HD22 ' HB3' ' A' ' 39' ' ' PRO . 1.3 pp -94.88 131.26 40.97 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.265 0.555 . . . . 2.76 111.589 -176.227 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -90.36 -29.06 18.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.876 -0.787 . . . . 2.65 108.876 173.101 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -146.89 103.06 3.87 Favored Pre-proline 0 N--CA 1.444 -0.738 0 N-CA-C 107.435 -1.32 . . . . 2.29 107.435 175.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.544 ' HB3' HD22 ' A' ' 36' ' ' LEU . 66.7 Cg_endo -74.89 -1.09 10.73 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.135 1.89 . . . . 0.64 112.603 -174.029 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.3 p -99.6 4.48 45.79 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.176 -0.609 . . . . 0.51 111.092 -173.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.0 m -78.29 163.72 3.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.841 -0.618 . . . . 0.24 110.465 175.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.484 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 88.8 mt -91.5 120.09 32.02 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.933 -0.576 . . . . 0.22 110.011 176.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.413 HD13 HD23 ' A' ' 29' ' ' LEU . 17.3 pt -103.0 134.59 43.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 121.229 0.538 . . . . 0.15 110.095 176.091 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.824 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.94 104.75 2.21 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.699 -0.762 . . . . 0.31 112.878 -175.158 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -83.43 139.69 32.81 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 109.323 -0.621 . . . . 0.57 109.323 176.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.435 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 73.31 38.13 53.73 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.057 -1.068 . . . . 0.21 111.751 -179.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.53 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -103.25 116.17 31.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.065 0.46 . . . . 0.25 111.056 -172.708 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.504 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -101.56 134.02 20.48 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-N 115.857 -0.61 . . . . 2.21 109.858 177.371 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -54.57 119.11 5.87 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.747 2.298 . . . . 0.44 111.947 176.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.4 mt -82.59 105.4 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 N-CA-C 108.662 -0.866 . . . . 0.46 108.662 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.9 t -119.7 19.4 12.53 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 121.778 0.799 . . . . 0.88 110.224 -177.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.4 p -107.25 133.09 52.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.358 -0.837 . . . . 1.44 110.081 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -86.88 78.82 8.96 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.376 0.608 . . . . 2.94 110.189 177.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -167.14 69.51 0.18 Allowed Glycine 0 N--CA 1.447 -0.633 0 N-CA-C 110.799 -0.92 . . . . 3.5 110.799 179.184 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 11.4 t -61.05 -18.72 59.35 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 122.643 0.377 . . . . 4.9 111.981 -172.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 2.2 p -52.8 -41.88 64.56 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.843 0.354 . . . . 4.06 110.838 176.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -152.51 70.44 0.9 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.503 0.668 . . . . 3.13 109.459 174.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -106.68 -1.69 22.48 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.495 -0.775 . . . . 0.99 110.539 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.4 t -140.36 140.3 35.54 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.672 -0.694 . . . . 0.74 110.513 -178.403 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 20.0 m -101.21 7.37 43.07 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.33 -0.396 . . . . 2.14 111.526 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.442 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -147.0 -83.96 0.12 Allowed 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.914 -0.315 . . . . 0.54 111.81 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 33.8 m -142.27 130.08 21.68 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-O 120.713 0.292 . . . . 0.29 110.99 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.97 129.25 34.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.465 -0.334 . . . . 0.25 110.267 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.659 HG21 ' SG ' ' A' ' 14' ' ' CYS . 4.0 m -140.6 169.9 15.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-O 121.248 0.546 . . . . 0.21 111.959 -176.574 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 29.1 t -132.98 103.66 6.16 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.191 -0.913 . . . . 0.39 110.061 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.748 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -91.11 138.79 31.33 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.647 0.737 . . . . 0.65 111.882 -178.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 47.9 t -92.8 -19.16 22.02 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 114.635 -1.166 . . . . 1.15 110.736 179.051 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -96.83 159.78 14.73 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.107 -0.497 . . . . 1.6 110.519 -175.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.2 t30 -117.68 -6.41 11.1 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.117 -0.492 . . . . 2.49 111.067 -173.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -81.04 83.25 6.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.249 0.547 . . . . 2.27 110.655 -177.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 30.0 m -101.81 139.57 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-N 116.0 -0.545 . . . . 1.1 110.885 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.567 ' OG ' HG12 ' A' ' 75' ' ' ILE . 99.9 p -80.38 -5.08 55.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.188 -0.46 . . . . 1.41 110.739 -178.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.3 -32.22 3.62 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.841 -0.618 . . . . 0.48 112.179 -177.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.2 m -135.44 -7.78 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 C-N-CA 120.559 -0.456 . . . . 0.49 111.945 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.567 HG12 ' OG ' ' A' ' 72' ' ' SER . 37.0 pt -97.39 179.78 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.522 0.677 . . . . 0.3 111.779 -178.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.748 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -149.85 140.4 22.49 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.255 -1.338 . . . . 0.18 109.094 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.0 mt -118.63 133.55 65.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.875 0.369 . . . . 0.26 111.333 -177.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 74.9 50.86 8.32 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.962 -0.637 . . . . 0.17 111.828 178.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.484 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.35 133.03 44.23 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.153 0.501 . . . . 0.65 111.89 -176.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.436 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 86.4 mt -108.23 132.1 21.31 Favored Pre-proline 0 C--N 1.318 -0.763 0 CA-C-N 115.728 -0.669 . . . . 0.29 109.811 172.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 21.7 Cg_exo -64.02 123.48 11.97 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.713 2.275 . . . . 0.25 111.889 -178.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 m -114.53 160.12 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 CA-C-O 121.265 0.555 . . . . 0.42 111.274 -178.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.415 HG22 ' HG ' ' A' ' 84' ' ' LEU . 26.8 m -142.29 137.0 30.31 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.252 -0.885 . . . . 2.07 109.494 176.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.415 ' HG ' HG22 ' A' ' 83' ' ' THR . 96.5 mt . . . . . 0 C--O 1.245 0.862 0 O-C-N 123.725 0.641 . . . . 3.91 111.264 -179.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.535 0 N-CA-C 111.773 -0.531 . . . . 5.63 111.773 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.488 ' HB3' HG22 ' A' ' 50' ' ' ILE . 25.8 t -71.93 -36.65 70.01 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 110.313 -0.254 . . . . 4.28 110.313 178.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.413 ' HB2' ' O ' ' A' ' 2' ' ' SER . 69.4 m95 70.27 -70.84 0.14 Allowed 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.63 -0.714 . . . . 4.74 111.985 178.414 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 80.16 87.19 0.57 Allowed Glycine 0 N--CA 1.444 -0.781 0 C-N-CA 120.373 -0.918 . . . . 2.03 111.339 -173.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 17.1 mm100 -72.58 133.29 44.65 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.927 0.394 . . . . 4.17 110.439 -179.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.429 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 31.4 t -126.58 -87.88 0.58 Allowed 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.905 -0.589 . . . . 1.88 110.431 -178.013 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 48.8 m -159.22 -76.02 0.07 Allowed 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.677 -0.49 . . . . 2.4 109.677 176.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 28.4 p -120.73 -27.28 5.1 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.077 0.465 . . . . 3.75 110.649 177.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -92.21 179.58 40.83 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.67 -0.695 . . . . 1.12 112.486 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.1 t -98.14 151.63 20.2 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.778 -0.453 . . . . 0.96 109.778 -178.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.429 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 16.6 mt -103.07 130.94 52.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.641 0.734 . . . . 0.96 111.374 174.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.462 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -130.39 168.09 17.52 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 114.656 -1.156 . . . . 0.91 110.138 177.653 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 36.8 t -110.38 101.93 10.61 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.772 -0.649 . . . . 0.34 109.918 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.849 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 96.5 m -87.45 125.01 34.03 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.788 -0.642 . . . . 0.19 111.459 -175.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.479 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -69.13 -31.96 71.0 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.06 -0.973 . . . . 0.38 109.818 175.583 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -136.74 108.38 7.0 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.046 -0.525 . . . . 1.03 110.423 177.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 93.2 t -98.94 105.92 18.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 N-CA-C 109.746 -0.465 . . . . 0.18 109.746 177.121 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 m -131.12 142.88 47.14 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 116.012 -0.54 . . . . 0.18 110.763 -176.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.521 ' O ' ' HB3' ' A' ' 22' ' ' SER . 30.9 Cg_exo -61.19 136.91 67.67 Favored 'Trans proline' 0 N--CA 1.461 -0.396 0 C-N-CA 122.161 1.908 . . . . 0.19 111.434 173.2 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.62 -15.03 68.1 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.665 -0.779 . . . . 0.18 111.972 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -103.09 3.66 36.22 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.592 0.71 . . . . 2.27 109.657 176.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.521 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 21.3 t -74.99 155.78 36.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.186 -0.915 . . . . 0.24 110.031 177.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -53.68 -44.32 69.63 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.829 0.823 . . . . 1.06 109.142 176.54 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.594 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.2 mm? -67.36 -63.19 1.11 Allowed 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 114.25 -1.341 . . . . 1.11 111.002 177.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.38 -39.21 71.95 Favored Glycine 0 C--N 1.33 0.23 0 CA-C-N 116.217 -0.447 . . . . 0.16 113.392 -175.074 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 98.7 m -67.72 -38.74 84.0 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.87 0.366 . . . . 0.24 110.475 -178.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -75.44 -27.72 59.06 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 120.934 0.397 . . . . 1.01 110.132 178.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.594 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 13.1 mt -69.74 -48.67 58.53 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.185 -0.461 . . . . 0.37 110.182 178.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.576 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -76.95 -23.78 52.38 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.571 -0.452 . . . . 0.41 111.549 -175.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.499 ' N ' HD12 ' A' ' 29' ' ' LEU . 18.8 t70 -67.95 -32.81 73.5 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.525 0.678 . . . . 0.66 109.37 175.456 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -75.28 -19.78 59.51 Favored 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 114.91 -1.041 . . . . 2.07 109.762 178.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 80.7 mt -103.37 -6.94 21.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.907 -1.042 . . . . 0.71 111.696 -174.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.97 35.48 84.37 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.958 -0.564 . . . . 0.75 112.566 178.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.576 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 32.2 mt -88.96 138.53 19.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.523 0.201 . . . . 0.68 110.705 -177.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.1 p -99.14 110.59 26.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.444 0.64 . . . . 1.87 110.221 175.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.531 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.4 pp -80.74 130.89 35.33 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.915 -0.584 . . . . 2.76 110.725 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -90.34 -29.1 18.3 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.739 -0.837 . . . . 2.65 108.739 173.52 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -142.23 98.41 6.1 Favored Pre-proline 0 N--CA 1.444 -0.772 0 N-CA-C 107.802 -1.184 . . . . 2.29 107.802 176.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.01 -9.54 21.98 Favored 'Trans proline' 0 N--CA 1.466 -0.143 0 C-N-CA 121.965 1.777 . . . . 0.64 111.588 -175.392 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 p -80.36 -8.9 59.7 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.623 -0.717 . . . . 0.51 111.497 -175.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.483 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.8 m -76.28 159.72 5.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.266 0.555 . . . . 0.24 111.065 -178.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.6 mt -92.53 128.03 38.24 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.498 -0.774 . . . . 0.22 109.556 176.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.428 HD13 HD23 ' A' ' 29' ' ' LEU . 15.1 pt -106.32 139.12 28.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 116.011 -0.54 . . . . 0.15 109.995 177.184 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.849 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -107.79 99.37 1.36 Allowed Glycine 0 N--CA 1.437 -1.281 0 C-N-CA 120.633 -0.794 . . . . 0.31 112.967 -175.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -78.2 137.12 37.98 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 108.691 -0.855 . . . . 0.57 108.691 173.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.479 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 70.79 39.08 66.01 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 119.914 -1.136 . . . . 0.21 112.252 -177.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.568 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -103.61 111.88 24.55 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.335 0.588 . . . . 0.25 110.831 -174.887 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -94.53 136.47 23.18 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 115.269 -0.878 . . . . 2.21 109.242 178.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -66.1 119.47 6.5 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 122.303 2.002 . . . . 0.44 110.745 176.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.488 HG22 ' HB3' ' A' ' 2' ' ' SER . 16.8 mt -77.23 88.25 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 121.62 0.724 . . . . 0.46 110.213 -176.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 13.4 t -134.27 8.09 3.68 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.244 -0.889 . . . . 0.88 110.156 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.5 p -98.77 160.13 3.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.304 -0.862 . . . . 1.44 109.201 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . 63.51 -172.15 0.17 Allowed 'General case' 0 C--O 1.233 0.211 0 O-C-N 123.665 0.603 . . . . 2.94 111.099 177.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.91 -1.55 6.85 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 121.032 -0.604 . . . . 3.5 111.663 176.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 42.1 m -97.25 149.16 22.36 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.783 0.325 . . . . 4.9 110.228 179.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 15.1 m -67.12 -26.83 66.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.041 -0.527 . . . . 4.06 110.7 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -83.27 57.68 4.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 122.043 0.925 . . . . 3.13 109.855 178.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -104.04 18.32 22.28 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.786 -1.097 . . . . 0.99 109.485 176.121 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.6 t -111.24 153.95 25.14 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.02 -0.991 . . . . 0.74 109.994 -177.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.7 m -126.14 18.34 7.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.44 -0.345 . . . . 2.14 111.071 -177.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.4 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -163.01 -77.69 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 112.015 0.376 . . . . 0.54 112.015 -178.394 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 74.8 m -147.61 131.33 16.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.806 0.336 . . . . 0.29 111.417 -176.425 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -88.13 125.72 34.74 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.039 -0.528 . . . . 0.25 109.93 177.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.588 HG21 ' SG ' ' A' ' 14' ' ' CYS . 6.8 m -138.89 159.96 30.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-N 115.964 -0.562 . . . . 0.21 110.949 -178.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 53.6 t -117.91 103.41 9.91 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.602 -0.726 . . . . 0.39 109.727 179.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.734 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 20.1 m -91.75 132.55 36.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.36 0.6 . . . . 0.65 111.402 -176.35 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 10.9 m -94.78 -15.78 23.53 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.314 -0.857 . . . . 1.15 111.29 -177.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.423 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 9.7 t70 -109.98 131.94 54.61 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.623 -0.51 . . . . 1.6 109.623 -178.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -108.12 20.95 18.05 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.489 0.551 . . . . 2.49 112.489 -172.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 50.8 m-80 -83.38 61.91 6.44 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.5 0.667 . . . . 2.27 110.123 177.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 m -73.66 149.01 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 CA-C-N 115.541 -0.754 . . . . 1.1 111.181 -178.481 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.6 ' OG ' HG12 ' A' ' 75' ' ' ILE . 82.0 p -95.4 -5.93 42.09 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.887 -0.597 . . . . 1.41 110.34 179.035 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.12 -31.84 3.57 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.675 -0.693 . . . . 0.48 112.409 -176.022 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.0 m -136.59 -8.22 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 117.185 0.493 . . . . 0.49 111.961 177.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.6 HG12 ' OG ' ' A' ' 72' ' ' SER . 21.7 pt -94.63 179.7 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.642 0.734 . . . . 0.3 111.979 -178.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.734 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.22 145.33 26.17 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.007 -1.452 . . . . 0.18 108.502 176.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.423 ' HB ' ' HB3' ' A' ' 68' ' ' ASP . 58.9 mt -125.75 142.19 43.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 120.717 -0.393 . . . . 0.26 111.402 -175.321 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.483 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 69.34 50.55 31.96 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.115 -0.564 . . . . 0.17 111.898 178.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.566 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 9.0 m -103.86 131.55 50.96 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.158 0.504 . . . . 0.65 111.8 -173.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.437 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.8 mt -105.9 134.68 19.62 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.735 -0.666 . . . . 0.29 109.859 173.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 17.1 Cg_exo -66.09 122.58 10.14 Favored 'Trans proline' 0 N--CA 1.465 -0.204 0 C-N-CA 122.75 2.3 . . . . 0.25 111.789 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.1 m -111.55 153.06 13.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.445 0.641 . . . . 0.42 111.35 -177.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.499 HG22 HD13 ' A' ' 84' ' ' LEU . 49.3 m -157.52 128.36 6.57 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.927 -1.033 . . . . 2.07 109.914 179.185 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.499 HD13 HG22 ' A' ' 83' ' ' THR . 11.0 mp . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.396 -0.811 . . . . 3.91 112.281 178.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.877 0 N-CA-C 112.276 -0.33 . . . . 5.63 112.276 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.9 m -79.82 -68.54 0.66 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.744 0.272 . . . . 4.28 110.757 -178.368 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 84.7 m95 -135.48 16.04 3.41 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-O 121.069 0.461 . . . . 4.74 110.396 -179.634 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.52 ' HA3' ' HB ' ' A' ' 11' ' ' ILE . . . 89.31 110.19 1.23 Allowed Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 115.631 -0.713 . . . . 2.03 112.44 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 13.4 mm-40 -76.13 109.52 9.87 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.642 -0.503 . . . . 4.17 109.642 177.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 14.1 t -131.78 -70.95 0.56 Allowed 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.42 -0.355 . . . . 1.88 111.077 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.7 p -168.05 -81.73 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.892 0.377 . . . . 2.4 110.568 -177.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 11.8 m -120.5 -31.05 4.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.935 0.398 . . . . 3.75 110.91 178.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -88.78 -132.05 4.17 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.955 -0.64 . . . . 1.12 113.232 -176.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.4 t -145.36 152.63 40.18 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.14 -0.689 . . . . 0.96 109.14 -175.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.52 ' HB ' ' HA3' ' A' ' 4' ' ' GLY . 40.6 mt -100.72 135.02 38.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.711 0.767 . . . . 0.96 111.122 176.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.593 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -132.28 165.61 23.78 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.702 -1.136 . . . . 0.91 109.82 177.058 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.5 t -112.29 101.39 9.61 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 115.891 -0.595 . . . . 0.34 109.409 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.812 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 68.5 m -84.32 130.22 34.82 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 115.326 -0.852 . . . . 0.19 110.988 -176.374 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.48 -30.63 68.56 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.26 -0.882 . . . . 0.38 109.053 172.849 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -141.16 121.02 13.54 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.972 -0.558 . . . . 1.03 110.538 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.6 t -109.06 107.78 23.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 109.969 -0.382 . . . . 0.18 109.969 176.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 20.8 m -133.39 145.97 58.77 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.153 -0.476 . . . . 0.18 110.777 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.471 ' HB2' ' HB2' ' A' ' 22' ' ' SER . 22.5 Cg_exo -63.42 137.37 59.84 Favored 'Trans proline' 0 N--CA 1.463 -0.309 0 C-N-CA 121.936 1.757 . . . . 0.19 110.934 171.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.45 -26.94 71.1 Favored Glycine 0 C--O 1.228 -0.232 0 C-N-CA 121.018 -0.611 . . . . 0.18 112.501 -177.295 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -98.18 9.15 43.62 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.099 0.476 . . . . 2.27 110.249 177.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.471 ' HB2' ' HB2' ' A' ' 19' ' ' PRO . 30.7 t -78.53 155.82 29.56 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 115.786 -0.643 . . . . 0.24 109.816 176.088 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -54.31 -41.68 69.25 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.001 0.429 . . . . 1.06 109.922 178.155 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.701 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.1 mm? -69.37 -60.27 2.45 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.648 -0.706 . . . . 1.11 110.94 177.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.93 -39.58 69.14 Favored Glycine 0 C--N 1.328 0.126 0 CA-C-N 116.203 -0.453 . . . . 0.16 113.216 -176.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.6 m -70.36 -41.48 73.09 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.974 0.416 . . . . 0.24 110.388 -177.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.418 HD22 ' HA ' ' A' ' 27' ' ' LEU . 1.1 tm? -63.75 -40.42 96.67 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.308 -0.627 . . . . 1.01 109.308 177.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.701 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.5 mt -68.05 -43.75 77.96 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.533 -0.758 . . . . 0.37 110.857 -175.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.545 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -76.54 -24.34 53.64 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.944 -0.302 . . . . 0.41 111.051 -178.005 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.487 ' N ' HD12 ' A' ' 29' ' ' LEU . 24.6 t70 -67.38 -31.28 71.4 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.406 0.622 . . . . 0.66 109.647 175.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -74.51 -38.7 62.75 Favored 'General case' 0 N--CA 1.443 -0.796 0 CA-C-N 115.037 -0.983 . . . . 2.07 109.513 177.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.7 mt -79.08 -20.17 49.44 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.522 -1.217 . . . . 0.71 111.921 -177.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.08 48.18 6.17 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.177 -0.535 . . . . 0.75 112.164 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.545 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 16.3 mt -110.92 142.83 22.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 110.449 -0.204 . . . . 0.68 110.449 -178.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.403 HG13 ' O ' ' A' ' 35' ' ' VAL . 6.5 p -126.54 103.47 11.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.596 0.712 . . . . 1.87 110.16 174.161 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.2 mt -87.6 137.25 32.5 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.825 -0.625 . . . . 2.76 110.824 -178.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -68.67 -36.78 78.98 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.661 -0.7 . . . . 2.65 109.442 175.072 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -132.88 88.86 36.21 Favored Pre-proline 0 N--CA 1.444 -0.764 0 N-CA-C 108.849 -0.797 . . . . 2.29 108.849 175.527 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -72.23 3.38 4.1 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.361 2.041 . . . . 0.64 111.56 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.2 p -75.77 -8.31 56.55 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.62 -0.718 . . . . 0.51 111.063 -178.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.1 m -82.41 162.76 3.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 116.055 -0.52 . . . . 0.24 110.561 176.479 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.407 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 94.8 mt -83.69 126.17 32.61 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.048 -0.524 . . . . 0.22 110.328 177.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 24.1 pt -107.6 140.77 24.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.244 0.545 . . . . 0.15 110.226 175.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.812 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -111.99 105.21 1.75 Allowed Glycine 0 N--CA 1.44 -1.094 0 C-N-CA 120.57 -0.824 . . . . 0.31 112.87 -177.11 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -83.06 132.39 35.12 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.057 -0.72 . . . . 0.57 109.057 176.009 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.93 38.01 24.24 Favored Glycine 0 N--CA 1.443 -0.86 0 C-N-CA 119.89 -1.148 . . . . 0.21 111.709 -178.01 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.93 111.76 24.54 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.043 0.449 . . . . 0.25 111.22 -174.017 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -100.61 134.67 20.45 Favored Pre-proline 0 C--N 1.315 -0.925 0 CA-C-N 115.647 -0.706 . . . . 2.21 109.269 174.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -59.96 130.8 36.23 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.908 2.405 . . . . 0.44 111.609 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.472 HD12 HG22 ' A' ' 11' ' ' ILE . 21.1 mt -83.78 88.94 2.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.68 0.753 . . . . 0.46 109.475 -179.468 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 8.8 t -114.46 28.42 8.75 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.789 -1.096 . . . . 0.88 109.3 -178.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.445 HG22 ' H ' ' A' ' 54' ' ' GLY . 14.6 p -107.22 143.8 17.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.511 -1.222 . . . . 1.44 109.827 -179.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -87.24 -25.01 24.2 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.445 -0.343 . . . . 2.94 111.6 -177.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.445 ' H ' HG22 ' A' ' 52' ' ' VAL . . . -74.4 109.91 2.93 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.975 -0.631 . . . . 3.5 112.015 178.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 19.4 m -70.49 -17.9 62.97 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.862 0.363 . . . . 4.9 111.517 -176.4 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 22.9 t -70.79 -28.11 64.41 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.338 -0.392 . . . . 4.06 110.872 -178.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -124.8 27.88 6.67 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.933 0.397 . . . . 3.13 110.715 -178.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -67.63 -30.04 69.51 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.252 0.549 . . . . 0.99 111.495 -177.102 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.7 t -154.16 146.17 23.61 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.887 -0.597 . . . . 0.74 110.858 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 27.3 p -117.06 5.38 12.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.179 -0.464 . . . . 2.14 111.509 -179.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -146.8 -80.99 0.14 Allowed 'General case' 0 C--N 1.331 -0.214 0 C-N-CA 120.966 -0.293 . . . . 0.54 111.776 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 28.4 m -142.05 126.88 18.16 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.815 0.341 . . . . 0.29 111.234 -178.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.67 128.98 35.04 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.926 0.393 . . . . 0.25 110.254 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.667 HG21 ' SG ' ' A' ' 14' ' ' CYS . 4.6 m -142.4 165.96 16.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.138 -0.483 . . . . 0.21 111.208 -177.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . 0.566 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 40.6 t -127.72 109.27 11.49 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.819 -0.628 . . . . 0.39 110.259 -178.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.743 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.6 m -97.46 140.49 31.83 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.397 0.618 . . . . 0.65 111.808 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 65.2 m -99.85 -12.73 19.62 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.14 -0.936 . . . . 1.15 111.501 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -110.33 149.99 29.4 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 110.02 -0.363 . . . . 1.6 110.02 -178.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 42.8 m-80 -120.35 12.42 11.69 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.639 0.607 . . . . 2.49 112.639 -173.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -81.62 71.84 8.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.773 0.796 . . . . 2.27 109.37 177.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 34.3 m -94.35 152.18 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 CA-C-N 115.457 -0.792 . . . . 1.1 111.172 -175.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.54 ' H ' HG12 ' A' ' 75' ' ' ILE . 90.4 p -86.97 -8.68 56.98 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.657 -0.701 . . . . 1.41 110.309 178.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.92 -32.02 3.74 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 115.285 -0.87 . . . . 0.48 111.954 -176.471 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.9 m -132.84 -2.58 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 C-N-CA 120.517 -0.473 . . . . 0.49 112.007 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.54 HG12 ' H ' ' A' ' 72' ' ' SER . 23.5 pt -100.73 178.77 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.495 0.664 . . . . 0.3 111.924 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.743 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -148.26 139.71 23.54 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.575 -1.193 . . . . 0.18 109.393 177.061 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 68.9 mt -121.73 130.19 74.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.938 0.399 . . . . 0.26 111.301 -176.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 82.0 46.43 6.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.995 -0.621 . . . . 0.17 111.777 178.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.566 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -99.38 144.25 28.71 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.288 0.566 . . . . 0.65 112.387 -175.153 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 87.7 mt -119.81 134.11 23.91 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.246 -0.888 . . . . 0.29 109.743 172.092 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 21.6 Cg_exo -64.67 121.47 9.03 Favored 'Trans proline' 0 C--O 1.234 0.298 0 C-N-CA 123.034 2.489 . . . . 0.25 112.348 -179.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.8 m -123.03 150.59 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.762 0 CA-C-N 116.039 -0.528 . . . . 0.42 110.629 -179.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 3.0 t -161.11 159.58 29.27 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.864 -0.607 . . . . 2.07 109.785 177.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 11.1 mp . . . . . 0 C--O 1.247 0.96 0 CA-C-O 118.1 -0.953 . . . . 3.91 111.579 -179.281 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.819 0 N-CA-C 112.149 -0.38 . . . . 5.63 112.149 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 34.3 t -133.91 105.74 6.91 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.692 -0.485 . . . . 4.28 109.692 -179.374 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.643 ' HB2' ' HA ' ' A' ' 51' ' ' THR . 69.2 t-105 -79.64 83.0 5.67 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.378 -0.601 . . . . 4.74 109.378 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 129.72 128.5 3.03 Favored Glycine 0 N--CA 1.442 -0.911 0 N-CA-C 110.924 -0.87 . . . . 2.03 110.924 -175.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -78.81 119.24 21.73 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.964 0.412 . . . . 4.17 110.607 -177.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.444 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 34.5 t -79.3 -67.63 0.74 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.801 -0.636 . . . . 1.88 110.129 178.067 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 5.7 p -176.02 -76.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.924 -0.58 . . . . 2.4 110.229 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.4 m -118.57 -28.32 5.7 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.934 0.397 . . . . 3.75 111.165 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -103.08 -145.78 15.99 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.581 -0.819 . . . . 1.12 113.376 -176.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.1 t -128.05 153.43 46.79 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 109.014 -0.736 . . . . 0.96 109.014 -177.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.444 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 51.5 mt -99.9 134.75 38.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.606 0.717 . . . . 0.96 111.344 178.079 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.628 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -142.95 162.22 36.05 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.063 -0.971 . . . . 0.91 111.043 178.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 19.4 t -106.68 102.26 11.65 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.46 -0.791 . . . . 0.34 109.483 178.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.893 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 57.6 m -86.75 133.54 33.65 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.934 -0.575 . . . . 0.19 111.017 -175.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.12 -30.42 49.41 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.185 -0.916 . . . . 0.38 109.435 177.016 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.636 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 17.1 m-20 -134.28 103.21 5.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.438 -0.346 . . . . 1.03 111.306 175.172 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.1 t -92.52 101.68 12.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.214 0.53 . . . . 0.18 109.727 174.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 m -131.71 140.38 38.11 Favored Pre-proline 0 C--N 1.319 -0.717 0 CA-C-N 115.748 -0.66 . . . . 0.18 110.75 -174.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.528 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.7 Cg_exo -57.94 138.75 87.56 Favored 'Trans proline' 0 N--CA 1.463 -0.302 0 C-N-CA 122.195 1.93 . . . . 0.19 111.304 172.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.29 -21.99 68.84 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.939 -0.648 . . . . 0.18 112.596 -178.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -101.2 4.94 42.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.239 0.542 . . . . 2.27 109.837 176.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.528 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 16.6 t -69.32 153.95 42.81 Favored 'General case' 0 CA--C 1.514 -0.438 0 CA-C-N 115.778 -0.646 . . . . 0.24 109.68 175.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -56.63 -38.42 72.09 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-O 121.122 0.487 . . . . 1.06 110.035 178.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.686 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 5.3 mt -70.19 -63.45 1.08 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.58 -0.737 . . . . 1.11 110.853 174.06 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.54 -40.87 55.52 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 116.035 -0.53 . . . . 0.16 113.443 -174.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 93.4 m -68.16 -44.53 75.77 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.761 0.315 . . . . 0.24 110.484 -178.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.4 tt -63.43 -35.52 80.71 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.075 -0.511 . . . . 1.01 110.814 178.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.686 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.3 mt -72.49 -46.09 56.41 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.096 -0.502 . . . . 0.37 110.365 -177.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.612 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -75.03 -21.76 58.85 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.71 -0.396 . . . . 0.41 110.934 -178.133 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -66.24 -32.22 73.51 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.708 0.766 . . . . 0.66 109.712 173.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -77.37 -47.7 19.19 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 114.906 -1.043 . . . . 2.07 109.261 177.103 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 72.4 mt -78.22 -13.11 59.99 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.705 -1.134 . . . . 0.71 112.893 -174.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.49 37.57 90.04 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-N 116.131 -0.486 . . . . 0.75 112.473 178.492 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.612 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 55.8 mt -75.46 137.35 23.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.104 0.478 . . . . 0.68 111.718 -173.265 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.4 p -88.11 113.55 25.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.687 -0.688 . . . . 1.87 110.762 175.471 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.457 ' H ' ' HG ' ' A' ' 36' ' ' LEU . 1.2 pp -103.0 134.6 46.17 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.03 -0.532 . . . . 2.76 110.796 177.589 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -90.06 -32.28 16.79 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.021 -1.104 . . . . 2.65 108.021 171.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -139.93 106.76 6.86 Favored Pre-proline 0 N--CA 1.446 -0.631 0 CA-C-N 114.588 -1.187 . . . . 2.29 108.227 174.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -71.9 -2.24 11.19 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.072 1.848 . . . . 0.64 111.327 -178.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.6 p -94.94 20.2 9.23 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.479 -0.782 . . . . 0.51 111.157 -175.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 23.2 m -105.77 160.83 5.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.81 -0.632 . . . . 0.24 110.226 178.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.405 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.6 mt -81.29 119.81 24.12 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.034 -0.53 . . . . 0.22 110.244 175.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 19.4 pt -104.06 137.11 34.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.871 -0.604 . . . . 0.15 109.684 175.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.893 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.91 106.75 1.78 Allowed Glycine 0 N--CA 1.438 -1.176 0 C-N-CA 120.538 -0.839 . . . . 0.31 113.05 -174.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.636 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 26.0 t70 -77.48 145.18 37.2 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 108.887 -0.783 . . . . 0.57 108.887 174.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 69.71 37.3 76.45 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 119.884 -1.15 . . . . 0.21 112.221 177.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.534 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -101.35 114.4 28.36 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.387 0.613 . . . . 0.25 111.215 -172.712 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.531 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 0.7 OUTLIER -101.54 130.98 23.56 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 115.4 -0.818 . . . . 2.21 109.702 177.438 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -56.48 120.39 8.24 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 C-N-CA 122.436 2.091 . . . . 0.44 111.102 177.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.406 HG13 ' HA ' ' A' ' 12' ' ' GLN . 43.7 mt -80.18 101.66 5.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.158 0.504 . . . . 0.46 110.587 -174.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.643 ' HA ' ' HB2' ' A' ' 3' ' ' TRP . 4.4 t -139.3 18.37 2.58 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 122.159 0.981 . . . . 0.88 109.989 177.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 12.2 p -91.55 142.97 12.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.042 -0.981 . . . . 1.44 109.655 175.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -107.42 120.06 41.13 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.882 0.372 . . . . 2.94 110.776 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -163.45 -154.09 7.56 Favored Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 111.662 -0.575 . . . . 3.5 111.662 179.159 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -94.34 -58.82 2.1 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.567 -0.531 . . . . 4.9 109.567 178.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.2 t -130.24 22.3 5.23 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.814 -0.81 . . . . 4.06 108.814 174.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -73.41 -15.95 61.34 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 114.81 -1.086 . . . . 3.13 111.037 -177.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -61.07 -31.22 70.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.804 -0.635 . . . . 0.99 112.467 -173.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 40.1 t -165.12 146.83 7.73 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-O 120.94 0.4 . . . . 0.74 111.261 -177.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 8.9 t -119.11 -13.63 9.37 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.974 -0.557 . . . . 2.14 110.782 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.12 -83.59 0.57 Allowed 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 121.121 -0.232 . . . . 0.54 110.86 -179.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 54.4 m -150.39 127.45 11.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.699 0.285 . . . . 0.29 110.551 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.44 140.58 29.85 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.03 0.443 . . . . 0.25 110.483 -178.049 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.656 HG21 ' SG ' ' A' ' 14' ' ' CYS . 2.7 m -147.78 170.38 3.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.229 0.538 . . . . 0.21 111.404 -176.651 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 50.3 t -129.6 107.97 9.86 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.319 -0.855 . . . . 0.39 109.788 178.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.724 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -99.58 138.89 36.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.286 0.565 . . . . 0.65 111.82 -177.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 50.4 m -99.69 -19.1 16.95 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.492 -0.776 . . . . 1.15 111.731 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.409 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 16.4 t70 -101.54 148.95 24.6 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.925 -0.398 . . . . 1.6 109.925 -177.051 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -120.18 18.51 12.31 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.581 0.586 . . . . 2.49 112.581 -173.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.415 ' HB2' HD12 ' A' ' 77' ' ' ILE . 42.9 m-80 -79.24 63.9 4.0 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.544 0.688 . . . . 2.27 109.967 176.489 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.886 HG12 ' H ' ' A' ' 73' ' ' GLY . 87.2 t -90.37 136.19 24.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.414 -0.812 . . . . 1.1 111.23 -173.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.671 ' H ' HG12 ' A' ' 75' ' ' ILE . 87.3 p -79.2 -3.01 43.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.345 -0.843 . . . . 1.41 110.939 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.886 ' H ' HG12 ' A' ' 71' ' ' VAL . . . 127.85 -31.56 3.69 Favored Glycine 0 N--CA 1.443 -0.868 0 CA-C-N 115.367 -0.833 . . . . 0.48 112.195 -176.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 17.2 m -138.68 -7.62 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 112.641 0.608 . . . . 0.49 112.641 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.671 HG12 ' H ' ' A' ' 72' ' ' SER . 7.2 pt -84.97 -178.54 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.581 0.705 . . . . 0.3 112.142 -178.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.724 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -149.43 139.2 21.83 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.639 -1.164 . . . . 0.18 109.51 175.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.415 HD12 ' HB2' ' A' ' 70' ' ' ASN . 65.3 mt -124.49 134.99 65.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.931 0.396 . . . . 0.26 111.364 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.512 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 79.21 47.98 7.17 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 121.002 -0.618 . . . . 0.17 111.785 179.377 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.557 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -100.14 136.73 39.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.24 0.543 . . . . 0.65 112.456 -175.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 93.7 mt -108.1 134.08 20.28 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 115.474 -0.784 . . . . 0.29 109.345 168.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.456 ' HA ' HG12 ' A' ' 64' ' ' VAL . 20.5 Cg_exo -64.3 128.35 21.29 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.937 2.424 . . . . 0.25 112.474 -178.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.0 m -133.05 160.51 42.56 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.911 0 CA-C-N 115.878 -0.601 . . . . 0.42 109.658 177.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.44 HG22 ' HG ' ' A' ' 84' ' ' LEU . 50.6 m -144.58 149.37 35.69 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 110.25 -0.278 . . . . 2.07 110.25 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.44 ' HG ' HG22 ' A' ' 83' ' ' THR . 86.3 mt . . . . . 0 C--O 1.246 0.899 0 CA-C-O 117.953 -1.022 . . . . 3.91 110.897 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.846 0 N-CA-C 111.76 -0.536 . . . . 5.63 111.76 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 39.4 m 59.2 79.44 0.22 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.338 0.59 . . . . 4.28 110.057 -176.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.424 ' HA ' ' HA ' ' A' ' 51' ' ' THR . 34.4 p90 -111.6 179.83 3.91 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.5 -0.773 . . . . 4.74 111.062 -175.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -63.52 106.09 1.26 Allowed Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 121.07 -0.586 . . . . 2.03 112.404 179.132 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -82.38 110.44 17.53 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.997 0.427 . . . . 4.17 110.206 178.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.483 ' HB2' HG13 ' A' ' 11' ' ' ILE . 52.2 t -94.89 -64.65 1.04 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.886 -0.597 . . . . 1.88 110.896 -176.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 7.5 t -172.04 -69.98 0.02 OUTLIER 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 116.215 -0.448 . . . . 2.4 110.145 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 12.1 m -121.42 -30.93 4.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.241 0.543 . . . . 3.75 111.013 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -90.45 -136.85 6.69 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.818 -0.705 . . . . 1.12 112.138 -178.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 28.6 t -145.92 144.27 30.07 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.87 -0.418 . . . . 0.96 109.87 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.483 HG13 ' HB2' ' A' ' 6' ' ' CYS . 38.6 mt -91.65 133.35 33.49 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.559 0 CA-C-O 121.737 0.78 . . . . 0.96 110.547 177.77 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.488 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -142.92 162.29 35.85 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 114.585 -1.189 . . . . 0.91 110.569 -175.006 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 26.6 t -111.44 101.69 10.12 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.846 -0.615 . . . . 0.34 109.847 -176.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.787 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 86.7 m -87.31 134.45 33.56 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.232 -0.895 . . . . 0.19 110.89 -175.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.43 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -76.1 -27.68 57.23 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 115.37 -0.832 . . . . 0.38 109.665 178.404 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -143.78 103.94 4.12 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.769 -0.651 . . . . 1.03 110.473 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 67.4 t -93.57 108.14 20.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 CA-C-N 116.062 -0.517 . . . . 0.18 109.688 178.253 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.05 146.12 60.3 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 116.032 -0.531 . . . . 0.18 110.757 -175.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.513 ' O ' ' HB3' ' A' ' 22' ' ' SER . 22.6 Cg_exo -62.79 136.94 60.35 Favored 'Trans proline' 0 N--CA 1.461 -0.401 0 C-N-CA 122.12 1.88 . . . . 0.19 111.181 173.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.93 -23.03 72.58 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.946 -0.645 . . . . 0.18 112.64 -176.472 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -101.07 9.92 41.58 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.724 0.774 . . . . 2.27 109.813 177.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.513 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.6 t -78.77 156.36 28.87 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.52 -0.764 . . . . 0.24 109.921 175.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -53.9 -40.94 67.07 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.201 0.524 . . . . 1.06 109.773 176.029 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.674 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER -67.88 -63.1 1.13 Allowed 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 115.462 -0.79 . . . . 1.11 111.046 176.796 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.411 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -57.01 -38.74 87.27 Favored Glycine 0 C--N 1.33 0.24 0 CA-C-N 115.999 -0.546 . . . . 0.16 113.304 -175.031 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.0 m -69.22 -40.64 77.85 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.646 0.26 . . . . 0.24 110.462 -178.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -62.99 -38.62 91.9 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.41 -0.589 . . . . 1.01 109.41 176.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.674 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.3 mt -67.82 -53.5 26.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.809 -0.632 . . . . 0.37 110.84 -177.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.554 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -70.87 -20.82 62.48 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.992 -0.283 . . . . 0.41 111.363 -176.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.425 ' N ' HD12 ' A' ' 29' ' ' LEU . 24.1 t70 -62.87 -38.95 92.9 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.602 0.715 . . . . 0.66 110.039 173.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -73.36 -16.97 61.33 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 114.816 -1.084 . . . . 2.07 109.615 -179.217 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.8 mt -105.86 -13.9 15.38 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.808 -1.087 . . . . 0.71 111.917 -174.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 71.82 42.71 52.65 Favored Glycine 0 C--N 1.331 0.302 0 CA-C-N 115.722 -0.672 . . . . 0.75 112.868 178.335 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.554 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 32.7 mt -101.2 124.92 55.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.689 0.28 . . . . 0.68 111.066 -176.756 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.6 p -110.43 102.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.814 0.816 . . . . 1.87 110.36 176.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 19.1 mt -85.95 141.9 29.2 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.556 -0.747 . . . . 2.76 111.094 -178.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -74.65 -23.58 58.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.552 0.692 . . . . 2.65 109.701 175.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -136.37 91.52 16.39 Favored Pre-proline 0 N--CA 1.447 -0.616 0 N-CA-C 108.22 -1.03 . . . . 2.29 108.22 172.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -66.18 -2.87 7.62 Favored 'Trans proline' 0 C--O 1.224 -0.22 0 C-N-CA 122.367 2.045 . . . . 0.64 111.808 -177.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 25.2 p -78.59 -12.67 60.03 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.577 -0.738 . . . . 0.51 111.322 -177.294 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 33.3 m -70.55 156.63 7.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.152 0.501 . . . . 0.24 111.295 -178.465 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 95.4 mt -86.38 129.09 34.97 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.778 -0.646 . . . . 0.22 110.333 178.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.406 HD13 HD23 ' A' ' 29' ' ' LEU . 23.7 pt -112.23 144.33 20.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.991 -0.55 . . . . 0.15 110.115 176.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.787 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.61 106.67 1.42 Allowed Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.48 -0.866 . . . . 0.31 113.102 -176.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -78.33 140.55 38.78 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.252 -0.647 . . . . 0.57 109.252 175.333 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 73.59 39.42 49.43 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.141 -1.028 . . . . 0.21 111.999 179.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.539 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.75 115.89 31.09 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.275 0.559 . . . . 0.25 111.346 -172.774 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.474 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.8 t70 -102.33 136.67 19.36 Favored Pre-proline 0 C--N 1.318 -0.78 0 CA-C-N 115.427 -0.806 . . . . 2.21 110.383 173.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.474 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 16.5 Cg_exo -60.79 119.61 6.87 Favored 'Trans proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.176 2.584 . . . . 0.44 111.03 178.393 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.45 HG13 ' HA ' ' A' ' 12' ' ' GLN . 43.0 mt -74.66 89.59 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.297 0.57 . . . . 0.46 110.224 -175.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.424 ' HA ' ' HA ' ' A' ' 3' ' ' TRP . 14.2 t -125.63 8.91 7.66 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 115.234 -0.894 . . . . 0.88 109.862 179.699 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 12.1 p -84.18 149.0 4.56 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.137 -0.938 . . . . 1.44 109.975 178.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -87.18 69.91 10.11 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.014 0.435 . . . . 2.94 110.697 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -101.28 -6.85 50.54 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.823 -0.703 . . . . 3.5 112.287 -178.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 26.7 t 66.08 -84.51 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.051 0.54 . . . . 4.9 110.804 179.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 15.9 m -112.62 -7.91 13.84 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.126 0.489 . . . . 4.06 110.196 178.447 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -119.88 68.52 0.83 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.652 -0.704 . . . . 3.13 109.372 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -117.84 8.83 12.74 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.723 -0.671 . . . . 0.99 111.444 -176.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.7 t -139.08 146.61 40.95 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.197 -0.456 . . . . 0.74 109.942 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.5 t -117.31 15.06 14.84 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.737 -0.211 . . . . 2.14 111.532 -176.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.43 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -157.05 -78.0 0.08 Allowed 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.87 -0.332 . . . . 0.54 111.581 178.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 21.6 m -148.59 129.43 14.27 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.774 0.321 . . . . 0.29 110.77 -179.075 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.436 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -90.41 135.88 33.4 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.864 -0.421 . . . . 0.25 109.864 -179.424 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.569 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 6.7 m -143.87 158.55 16.17 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-O 121.277 0.561 . . . . 0.21 111.156 -177.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 15.0 t -109.35 104.51 13.64 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.338 -0.846 . . . . 0.39 109.476 175.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.776 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 61.3 m -91.16 120.96 32.53 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.169 0.509 . . . . 0.65 111.108 -178.035 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 17.6 t -78.22 -21.53 49.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.28 -0.873 . . . . 1.15 110.295 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.7 t0 -105.81 149.09 26.8 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.224 -0.658 . . . . 1.6 109.224 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.515 ' C ' HD22 ' A' ' 69' ' ' ASN . 0.3 OUTLIER -118.84 5.64 11.47 Favored 'General case' 0 C--N 1.325 -0.476 0 N-CA-C 112.559 0.577 . . . . 2.49 112.559 -175.092 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.455 ' ND2' HD12 ' A' ' 77' ' ' ILE . 1.3 p30 -82.39 112.18 19.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.921 0.867 . . . . 2.27 109.563 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.945 HG12 ' H ' ' A' ' 73' ' ' GLY . 70.8 t -122.12 137.28 56.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.364 -0.835 . . . . 1.1 110.858 -172.485 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.529 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 95.0 p -76.88 -1.41 28.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.654 -0.703 . . . . 1.41 110.94 -178.185 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.945 ' H ' HG12 ' A' ' 71' ' ' VAL . . . 127.88 -31.82 3.62 Favored Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 115.43 -0.804 . . . . 0.48 112.372 -176.521 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.2 m -138.77 -5.92 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.225 -0.203 0 N-CA-C 112.849 0.685 . . . . 0.49 112.849 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.529 ' CG1' ' H ' ' A' ' 72' ' ' SER . 5.1 pt -92.82 -177.1 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 113.359 0.874 . . . . 0.3 113.359 -174.236 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.776 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.68 142.59 23.87 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 114.117 -1.401 . . . . 0.18 108.602 174.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.455 HD12 ' ND2' ' A' ' 70' ' ' ASN . 66.5 mt -126.67 139.94 50.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.275 0.472 . . . . 0.26 112.275 -175.617 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 68.58 51.82 28.96 Favored Glycine 0 C--N 1.335 0.48 0 CA-C-N 115.736 -0.666 . . . . 0.17 111.682 177.411 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 8.3 m -109.0 138.94 44.55 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.049 0.452 . . . . 0.65 111.84 -172.369 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.434 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.8 mt -109.15 132.45 21.22 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.801 -0.636 . . . . 0.29 110.057 173.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.51 ' HA ' HG12 ' A' ' 64' ' ' VAL . 24.5 Cg_exo -63.23 123.06 11.51 Favored 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.194 2.596 . . . . 0.25 113.308 -177.18 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.436 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 9.2 m -128.35 159.48 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 CA-C-N 116.018 -0.537 . . . . 0.42 110.063 177.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.543 HG23 ' HG ' ' A' ' 84' ' ' LEU . 5.5 t -154.65 174.86 14.41 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 110.226 -0.287 . . . . 2.07 110.226 177.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.543 ' HG ' HG23 ' A' ' 83' ' ' THR . 82.0 mt . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.307 -0.854 . . . . 3.91 111.005 178.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.699 0 N-CA-C 112.175 -0.37 . . . . 5.63 112.175 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 30.7 t -131.27 160.25 35.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.002 -0.369 . . . . 4.28 110.002 -178.323 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 88.6 m95 -109.57 25.32 11.93 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.973 -0.558 . . . . 4.74 109.709 177.154 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 99.92 16.0 29.54 Favored Glycine 0 N--CA 1.449 -0.434 0 CA-C-N 115.709 -0.678 . . . . 2.03 111.711 -176.173 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 76.3 mt-30 -76.43 124.64 27.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.556 -0.322 . . . . 4.17 111.088 -176.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.487 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 34.8 t -164.32 142.69 7.11 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.031 -0.531 . . . . 1.88 109.909 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 34.2 m -72.68 -14.57 61.61 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.248 -0.433 . . . . 2.4 111.681 -176.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.829 ' HB ' ' SG ' ' A' ' 65' ' ' CYS . 19.1 m -91.07 -28.21 18.1 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.226 0.536 . . . . 3.75 110.041 176.287 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 159.81 -117.04 0.75 Allowed Glycine 0 N--CA 1.446 -0.657 0 CA-C-N 115.806 -0.634 . . . . 1.12 112.131 -179.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 32.3 t -105.0 152.08 23.15 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.704 -0.48 . . . . 0.96 109.704 -178.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.487 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 21.0 mt -105.31 133.72 48.79 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.453 0 CA-C-O 121.651 0.739 . . . . 0.96 111.231 177.296 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.613 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -141.47 161.68 37.33 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 114.854 -1.066 . . . . 0.91 110.684 178.885 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.431 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 24.8 t -110.98 103.31 11.77 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.415 -0.812 . . . . 0.34 109.107 178.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.792 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 81.8 m -85.75 138.81 31.83 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.461 -0.79 . . . . 0.19 110.678 -175.531 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.423 HE21 ' HB2' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -73.98 -35.15 64.45 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.711 -0.848 . . . . 0.38 108.711 175.374 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.783 ' ND2' ' HB3' ' A' ' 45' ' ' ASP . 0.1 OUTLIER -130.02 150.35 51.33 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 109.532 -0.544 . . . . 1.03 109.532 170.909 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 72.6 t -130.6 101.79 6.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 109.139 -0.689 . . . . 0.18 109.139 173.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.469 HG22 ' OD1' ' A' ' 16' ' ' ASN . 8.8 m -130.8 143.51 49.66 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.981 -0.554 . . . . 0.18 111.513 -173.073 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.435 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.4 Cg_exo -59.2 140.13 93.4 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.499 2.133 . . . . 0.19 111.853 172.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.85 -20.96 67.06 Favored Glycine 0 N--CA 1.453 -0.199 0 C-N-CA 120.979 -0.629 . . . . 0.18 112.603 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -103.91 14.98 29.68 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.736 0.779 . . . . 2.27 109.711 176.789 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.435 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.2 t -84.24 154.56 22.94 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.599 -0.728 . . . . 0.24 109.902 176.555 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -52.25 -41.01 62.44 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.185 0.517 . . . . 1.06 110.496 178.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.68 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 7.6 mt -71.96 -63.17 1.19 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.737 -0.665 . . . . 1.11 110.674 176.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.33 -40.39 53.21 Favored Glycine 0 C--N 1.33 0.212 0 CA-C-N 116.067 -0.515 . . . . 0.16 113.266 -175.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 96.5 m -68.62 -45.12 72.74 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.878 0.37 . . . . 0.24 110.826 -177.454 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.432 ' O ' HD13 ' A' ' 27' ' ' LEU . 1.8 tm? -65.38 -37.56 87.35 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.435 -0.58 . . . . 1.01 109.435 178.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.68 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.0 mt -69.42 -43.51 73.23 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.012 -0.54 . . . . 0.37 110.588 -176.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.586 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.3 pp -72.23 -26.54 62.07 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.662 -0.415 . . . . 0.41 110.765 -178.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.421 ' N ' HD12 ' A' ' 29' ' ' LEU . 19.5 t70 -66.19 -33.56 76.05 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.711 0.767 . . . . 0.66 109.066 173.399 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 29.3 mm-40 -80.22 -11.62 59.71 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.509 -1.223 . . . . 2.07 111.143 179.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.1 mt -115.41 -14.51 11.59 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.899 -0.591 . . . . 0.71 112.187 -174.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 78.88 39.68 19.71 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.139 -0.553 . . . . 0.75 112.751 177.054 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.586 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 15.9 mt -96.62 138.39 21.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 120.624 0.249 . . . . 0.68 110.761 -176.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.3 p -119.39 102.73 13.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.468 0.651 . . . . 1.87 110.264 174.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 20.0 mt -86.99 140.09 29.91 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.973 -0.558 . . . . 2.76 110.802 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -75.33 -27.74 59.37 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.936 -0.574 . . . . 2.65 109.752 174.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 61.1 t0 -139.02 104.31 7.36 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 108.663 -0.866 . . . . 2.29 108.663 175.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -72.12 4.03 3.57 Favored 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.518 2.145 . . . . 0.64 112.901 -176.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 64.9 p -93.04 2.55 56.72 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 120.445 -0.502 . . . . 0.51 110.936 -177.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.2 m -83.63 159.76 3.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.102 -0.499 . . . . 0.24 110.425 178.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.1 mt -88.7 122.24 31.91 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.832 -0.622 . . . . 0.22 110.475 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.5 pt -106.17 134.4 47.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 115.987 -0.551 . . . . 0.15 110.073 176.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.792 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -111.16 107.83 2.26 Favored Glycine 0 N--CA 1.443 -0.882 0 C-N-CA 120.593 -0.813 . . . . 0.31 112.908 -176.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.783 ' HB3' ' ND2' ' A' ' 16' ' ' ASN . 20.9 t70 -81.44 138.64 35.53 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.441 -0.577 . . . . 0.57 109.441 176.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.405 ' HA3' ' HB3' ' A' ' 15' ' ' GLN . . . 78.7 36.66 28.63 Favored Glycine 0 N--CA 1.443 -0.88 0 C-N-CA 120.248 -0.977 . . . . 0.21 111.787 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.4 OUTLIER -105.15 112.75 25.99 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.344 0.592 . . . . 0.25 111.559 -172.4 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -102.82 134.33 19.91 Favored Pre-proline 0 C--N 1.317 -0.828 0 CA-C-N 115.364 -0.834 . . . . 2.21 109.535 173.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -59.28 127.2 23.15 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.759 2.306 . . . . 0.44 111.616 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 19.1 mt -82.97 89.1 2.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.479 0.657 . . . . 0.46 109.253 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.9 t -129.1 9.47 5.73 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.075 -0.966 . . . . 0.88 110.212 -177.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 14.2 p -99.78 144.97 11.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.15 -0.932 . . . . 1.44 109.775 178.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -86.79 44.65 1.18 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.043 0.449 . . . . 2.94 110.686 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -83.64 77.52 2.11 Favored Glycine 0 N--CA 1.447 -0.583 0 CA-C-N 115.846 -0.616 . . . . 3.5 112.313 -177.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 84.4 p 52.24 -163.22 0.08 Allowed 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 123.682 0.793 . . . . 4.9 112.198 178.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.3 m -83.59 -16.62 44.63 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.465 0.65 . . . . 4.06 109.555 174.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -94.18 62.43 3.0 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.298 -0.864 . . . . 3.13 109.065 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -94.28 18.15 11.52 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.346 -0.843 . . . . 0.99 111.796 -177.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.1 t -144.44 143.03 30.7 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 110.071 -0.344 . . . . 0.74 110.071 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 8.3 p -102.4 -26.56 13.23 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.313 0.486 . . . . 2.14 112.313 -175.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 14' ' ' CYS . . . -123.14 -75.99 0.59 Allowed 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.56 -0.456 . . . . 0.54 111.91 -176.578 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 31.8 m -146.77 128.73 15.46 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.908 0.385 . . . . 0.29 111.39 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.67 137.89 32.1 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.261 -0.427 . . . . 0.25 110.512 -178.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.606 HG21 ' SG ' ' A' ' 14' ' ' CYS . 2.7 m -146.3 170.45 4.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.037 -0.529 . . . . 0.21 111.302 -177.294 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . 0.829 ' SG ' ' HB ' ' A' ' 8' ' ' THR . 41.3 t -132.64 109.68 9.9 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.351 -0.841 . . . . 0.39 109.589 177.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.756 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -95.91 137.67 34.64 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.454 0.645 . . . . 0.65 112.041 -178.074 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 33.0 t -82.88 -18.91 38.58 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 114.865 -1.061 . . . . 1.15 110.586 178.245 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -110.84 147.29 34.85 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.101 0.477 . . . . 1.6 111.151 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -115.62 4.48 14.14 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.637 -0.71 . . . . 2.49 110.522 -179.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -75.67 73.81 2.66 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.34 0.591 . . . . 2.27 110.446 178.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 33.6 m -89.57 146.8 5.74 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 CA-C-N 115.801 -0.636 . . . . 1.1 110.947 -177.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.421 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 44.8 m -89.52 10.43 22.89 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.084 -0.507 . . . . 1.41 110.703 178.212 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.26 -33.93 3.2 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.561 -0.745 . . . . 0.48 113.552 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.6 m -140.57 -2.85 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 117.743 0.772 . . . . 0.49 112.218 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.421 ' CG1' ' H ' ' A' ' 72' ' ' SER . 16.4 pt -93.71 -176.45 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.769 0.795 . . . . 0.3 112.567 -176.432 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.756 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -147.53 137.82 23.13 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 114.206 -1.361 . . . . 0.18 108.745 174.049 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 70.4 mt -117.52 126.39 74.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.002 0.43 . . . . 0.26 111.628 -176.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.51 52.62 5.45 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.845 -0.616 . . . . 0.17 111.798 177.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.42 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 1.3 m -99.03 137.52 37.44 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 112.424 0.527 . . . . 0.65 112.424 -176.257 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 86.3 mt -105.36 131.49 21.71 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.505 -0.771 . . . . 0.29 109.719 170.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.438 ' HA ' HG12 ' A' ' 64' ' ' VAL . 19.1 Cg_exo -65.81 121.95 9.44 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.973 2.449 . . . . 0.25 112.303 -179.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.414 ' O ' ' HB ' ' A' ' 83' ' ' THR . 5.3 m -122.72 152.57 27.25 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 CA-C-N 116.275 -0.421 . . . . 0.42 110.147 178.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.416 HG22 ' HG ' ' A' ' 84' ' ' LEU . 67.4 m 67.25 137.86 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.448 0 O-C-N 123.761 0.663 . . . . 2.07 111.654 -177.399 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.416 ' HG ' HG22 ' A' ' 83' ' ' THR . 89.5 mt . . . . . 0 C--O 1.251 1.149 0 CA-C-O 117.977 -1.011 . . . . 3.91 110.994 -178.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.798 0 N-CA-C 111.833 -0.507 . . . . 5.63 111.833 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.466 ' O ' ' HA ' ' A' ' 51' ' ' THR . 23.3 t -130.63 100.42 5.3 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.924 -0.399 . . . . 4.28 109.924 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 19.2 m-90 -84.51 127.51 34.08 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.1 -0.5 . . . . 4.74 110.482 -177.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -73.65 115.83 5.17 Favored Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.883 -0.599 . . . . 2.03 111.806 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -70.84 131.79 44.32 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 120.98 0.419 . . . . 4.17 110.319 178.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.412 ' O ' ' HB3' ' A' ' 7' ' ' SER . 30.3 t -119.88 -15.65 8.8 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.759 -0.655 . . . . 1.88 110.971 -177.229 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.412 ' HB3' ' O ' ' A' ' 6' ' ' CYS . 47.4 t 73.02 -50.35 0.7 Allowed 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.383 0.673 . . . . 2.4 110.923 -177.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 5.5 m -65.33 -28.19 69.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.311 0.576 . . . . 3.75 110.264 177.2 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 172.65 -146.39 9.11 Favored Glycine 0 N--CA 1.444 -0.823 0 CA-C-N 115.426 -0.806 . . . . 1.12 111.87 179.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.0 t -101.68 151.74 21.66 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.137 -0.69 . . . . 0.96 109.137 -179.106 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 45.9 mt -102.08 136.76 32.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.629 0.728 . . . . 0.96 111.544 -179.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.526 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -144.13 169.27 18.18 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.97 -1.014 . . . . 0.91 110.556 -179.717 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 14.7 t -118.15 103.51 9.94 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.708 -0.678 . . . . 0.34 109.731 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.828 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 98.9 m -85.68 134.67 33.96 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.397 -0.819 . . . . 0.19 111.196 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.407 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -72.77 -30.05 63.8 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.162 -0.926 . . . . 0.38 109.082 174.652 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -139.66 115.74 10.36 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.611 -0.722 . . . . 1.03 110.369 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 88.9 t -105.53 105.45 18.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-O 120.927 0.394 . . . . 0.18 110.048 177.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.6 m -132.37 139.92 36.34 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 115.936 -0.574 . . . . 0.18 111.147 -175.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.455 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.4 Cg_exo -58.55 141.99 97.83 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.442 2.095 . . . . 0.19 111.717 171.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.51 -19.52 70.94 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.878 -0.677 . . . . 0.18 111.965 179.432 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -102.15 9.83 39.88 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.218 0.532 . . . . 2.27 110.009 176.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.455 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.5 t -80.8 154.62 27.07 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 115.628 -0.714 . . . . 0.24 109.728 175.575 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -54.56 -40.13 68.43 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.96 0.41 . . . . 1.06 110.357 179.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.67 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 5.1 mt -70.75 -62.19 1.48 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.686 -0.688 . . . . 1.11 110.529 176.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.56 -38.71 63.97 Favored Glycine 0 C--N 1.33 0.242 0 CA-C-N 116.052 -0.522 . . . . 0.16 113.421 -175.031 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 85.7 m -66.35 -42.71 87.69 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.798 0.333 . . . . 0.24 110.745 -178.215 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.456 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.6 tm? -69.97 -34.82 73.88 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.327 -0.62 . . . . 1.01 109.327 177.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.67 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.6 mt -65.04 -46.2 82.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.053 -0.521 . . . . 0.37 110.483 -178.131 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.492 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.64 -21.03 52.85 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.473 -0.491 . . . . 0.41 111.004 -178.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.456 ' N ' HD12 ' A' ' 29' ' ' LEU . 32.4 t70 -66.15 -37.81 86.59 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.391 0.615 . . . . 0.66 109.572 173.181 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -75.98 -12.85 60.21 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.029 -0.987 . . . . 2.07 109.928 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 75.3 mt -106.09 -12.03 15.91 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.195 -0.911 . . . . 0.71 111.318 -179.269 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.09 39.36 96.25 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.575 -0.738 . . . . 0.75 112.343 -178.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.492 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 53.9 mt -82.19 133.23 29.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 O-C-N 122.645 -0.326 . . . . 0.68 111.057 -176.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 11.4 p -87.45 116.43 29.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 109.336 -0.616 . . . . 1.87 109.336 172.393 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.492 HD22 ' HB3' ' A' ' 39' ' ' PRO . 0.9 OUTLIER -91.79 131.33 37.23 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.918 -0.583 . . . . 2.76 111.003 -179.454 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 45.2 tt0 -88.23 -34.27 17.82 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.261 -1.014 . . . . 2.65 108.261 173.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -145.06 102.75 4.43 Favored Pre-proline 0 N--CA 1.445 -0.711 0 CA-C-N 114.835 -1.075 . . . . 2.29 108.324 174.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.492 ' HB3' HD22 ' A' ' 36' ' ' LEU . 41.4 Cg_endo -67.71 -4.39 12.11 Favored 'Trans proline' 0 C--O 1.225 -0.152 0 C-N-CA 122.586 2.191 . . . . 0.64 112.075 -174.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 15.3 p -82.53 -10.05 59.16 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.823 -0.626 . . . . 0.51 111.407 -174.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.418 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.8 m -74.18 160.54 5.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.159 0.504 . . . . 0.24 111.01 -178.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.41 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 92.3 mt -91.52 129.81 37.44 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.795 -0.639 . . . . 0.22 110.397 179.195 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.2 pt -112.52 137.64 44.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.159 0.504 . . . . 0.15 110.433 176.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.828 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.8 103.31 1.32 Allowed Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 120.478 -0.867 . . . . 0.31 113.133 -175.338 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -79.11 139.91 37.96 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 109.445 -0.576 . . . . 0.57 109.445 177.078 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.74 39.82 38.92 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.077 -1.058 . . . . 0.21 111.804 -179.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.539 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -108.28 112.98 25.72 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.098 0.475 . . . . 0.25 111.717 -171.69 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.406 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 12.2 m-20 -101.83 137.13 19.45 Favored Pre-proline 0 C--N 1.318 -0.763 0 CA-C-N 115.395 -0.82 . . . . 2.21 109.581 175.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 25.2 Cg_exo -59.88 133.98 54.12 Favored 'Trans proline' 0 C--O 1.233 0.244 0 C-N-CA 122.86 2.373 . . . . 0.44 112.076 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.461 HG23 ' HB1' ' A' ' 58' ' ' ALA . 40.6 mt -87.89 106.13 16.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.209 0.528 . . . . 0.46 109.881 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.466 ' HA ' ' O ' ' A' ' 2' ' ' SER . 11.8 t -142.1 19.82 2.1 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.529 -0.76 . . . . 0.88 110.594 -174.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.1 p -152.25 158.44 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 CA-C-N 115.626 -0.715 . . . . 1.44 110.164 -177.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . 58.97 45.77 14.53 Favored 'General case' 0 N--CA 1.464 0.266 0 O-C-N 123.661 0.601 . . . . 2.94 112.372 172.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -59.29 118.58 14.76 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.086 -0.578 . . . . 3.5 112.451 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 36.8 m 65.87 21.61 11.41 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.189 0.519 . . . . 4.9 111.015 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 48.0 m -127.46 26.28 5.99 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.643 -0.708 . . . . 4.06 110.035 -178.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 23.0 t70 76.04 72.36 0.08 Allowed 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 115.215 -0.902 . . . . 3.13 109.381 -175.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.461 ' HB1' HG23 ' A' ' 50' ' ' ILE . . . -92.36 3.29 55.73 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.965 -1.016 . . . . 0.99 111.261 -176.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.3 t -143.11 143.46 31.84 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.921 -0.581 . . . . 0.74 109.923 179.43 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 10.0 t -107.08 -28.68 9.85 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.557 -0.292 . . . . 2.14 111.085 -178.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.407 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -112.05 -80.2 0.59 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.837 -0.345 . . . . 0.54 111.783 -176.437 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 16.4 m -145.1 128.13 16.54 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.84 0.352 . . . . 0.29 111.154 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.48 136.91 32.92 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.903 0.382 . . . . 0.25 110.276 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.652 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.2 m -145.85 167.92 7.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.089 0.471 . . . . 0.21 111.59 -175.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . 0.449 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 17.8 t -130.54 105.94 8.18 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.45 -0.796 . . . . 0.39 110.121 178.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.723 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.8 m -92.45 133.58 35.77 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.698 0.761 . . . . 0.65 111.985 -179.28 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 8.7 t -86.16 -13.44 47.07 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.521 -1.218 . . . . 1.15 110.423 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -107.82 156.67 18.88 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.866 -0.606 . . . . 1.6 110.2 -179.145 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 30.4 p-10 -120.9 -15.1 8.38 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 113.084 0.772 . . . . 2.49 113.084 -172.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -88.16 73.21 9.01 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 121.985 0.898 . . . . 2.27 111.072 -173.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.7 m -85.68 164.77 2.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.049 -0.978 . . . . 1.1 110.999 -178.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.543 ' OG ' HG12 ' A' ' 75' ' ' ILE . 88.7 p -84.59 -2.72 57.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.051 -0.522 . . . . 1.41 111.66 -175.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.64 -31.89 3.83 Favored Glycine 0 CA--C 1.505 -0.592 0 C-N-CA 120.721 -0.752 . . . . 0.48 112.304 -178.071 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 6.4 m -135.49 -12.15 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 C-N-CA 120.488 -0.485 . . . . 0.49 111.935 178.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.543 HG12 ' OG ' ' A' ' 72' ' ' SER . 35.4 pt -90.02 -175.14 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 C-N-CA 119.986 -0.686 . . . . 0.3 111.581 -179.156 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.723 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -147.78 143.46 27.54 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.398 -1.273 . . . . 0.18 108.665 175.085 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 64.0 mt -122.55 131.23 73.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.966 0.412 . . . . 0.26 111.585 -175.41 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.448 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 76.38 50.71 7.18 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.097 -0.573 . . . . 0.17 112.188 177.751 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.486 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.92 141.84 31.19 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 112.826 0.676 . . . . 0.65 112.826 -175.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 95.0 mt -108.57 132.06 21.37 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.223 -0.899 . . . . 0.29 109.269 168.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.432 ' HA ' HG12 ' A' ' 64' ' ' VAL . 15.8 Cg_exo -67.29 128.4 18.33 Favored 'Trans proline' 0 C--O 1.234 0.297 0 C-N-CA 122.757 2.304 . . . . 0.25 112.292 -179.257 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.0 m -130.42 160.17 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.729 0 CA-C-N 116.02 -0.536 . . . . 0.42 110.12 178.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 23.9 m -132.61 136.55 46.59 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 116.475 -0.33 . . . . 2.07 110.448 177.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 93.3 mt . . . . . 0 C--O 1.249 1.026 0 O-C-N 123.915 0.76 . . . . 3.91 111.338 -179.537 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.661 0 N-CA-C 112.198 -0.361 . . . . 5.63 112.198 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.8 t -134.11 -168.08 2.07 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.808 -0.442 . . . . 4.28 109.808 -177.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 98.5 m95 58.53 -154.21 0.37 Allowed 'General case' 0 C--O 1.234 0.277 0 O-C-N 123.424 0.453 . . . . 4.74 110.531 -178.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.42 159.34 23.28 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.883 -0.675 . . . . 2.03 111.543 177.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -107.92 109.16 20.59 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.528 -0.545 . . . . 4.17 109.528 178.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 35.3 t -130.49 -73.19 0.55 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.285 -0.416 . . . . 1.88 111.12 -176.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 66.6 m -157.32 -174.56 4.95 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.638 -0.504 . . . . 2.4 109.638 -177.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 25.0 p -81.37 13.15 3.1 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 112.465 0.543 . . . . 3.75 112.465 -174.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -95.33 -110.58 2.44 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.904 -0.665 . . . . 1.12 111.928 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.1 t -151.04 150.31 30.58 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 110.128 -0.323 . . . . 0.96 110.128 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 23.7 mt -112.1 135.92 49.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-O 121.482 0.658 . . . . 0.96 110.825 173.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.681 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -153.91 170.29 21.39 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 114.968 -1.015 . . . . 0.91 110.873 -177.187 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.587 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 42.1 t -118.69 108.59 15.1 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.434 -0.803 . . . . 0.34 109.593 177.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.871 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 60.9 m -90.11 129.62 36.38 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.311 0.577 . . . . 0.19 111.599 -172.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.442 ' HB3' ' HA3' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -75.54 -26.71 58.25 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 114.946 -1.025 . . . . 0.38 110.252 177.851 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.608 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 1.6 t-20 -135.86 99.15 4.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.445 -0.343 . . . . 1.03 110.818 175.266 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 61.8 t -92.66 102.0 13.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.002 0.429 . . . . 0.18 110.039 177.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.6 m -133.42 142.92 45.89 Favored Pre-proline 0 C--N 1.32 -0.701 0 CA-C-N 115.896 -0.593 . . . . 0.18 110.905 -174.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.491 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.5 Cg_exo -61.1 139.38 83.79 Favored 'Trans proline' 0 N--CA 1.463 -0.311 0 C-N-CA 122.086 1.858 . . . . 0.19 111.164 171.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.08 -24.42 70.3 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.84 -0.695 . . . . 0.18 112.627 -178.262 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -97.61 4.45 50.2 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.147 0.498 . . . . 2.27 110.048 177.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.491 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.2 t -73.2 152.99 40.86 Favored 'General case' 0 CA--C 1.513 -0.48 0 CA-C-N 115.758 -0.655 . . . . 0.24 109.994 177.597 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -54.31 -39.36 66.94 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.098 0.475 . . . . 1.06 110.227 178.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.704 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.7 mm? -70.89 -62.33 1.43 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.646 -0.706 . . . . 1.11 110.818 175.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.3 -40.34 60.44 Favored Glycine 0 C--N 1.33 0.232 0 CA-C-N 116.171 -0.468 . . . . 0.16 113.296 -175.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.1 m -69.0 -44.36 72.96 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.857 0.36 . . . . 0.24 110.692 -177.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.02 -38.95 93.23 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.316 -0.624 . . . . 1.01 109.316 178.443 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.704 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.2 mt -69.11 -44.4 72.48 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.668 -0.696 . . . . 0.37 110.764 -177.129 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.581 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.4 pp -76.02 -26.16 56.37 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.798 -0.361 . . . . 0.41 111.068 -178.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.447 ' N ' HD12 ' A' ' 29' ' ' LEU . 31.9 t70 -64.24 -34.44 78.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.859 0.837 . . . . 0.66 109.035 172.267 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -80.66 -12.27 59.51 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 114.152 -1.386 . . . . 2.07 111.162 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 88.5 mt -111.86 -13.55 13.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.969 -0.56 . . . . 0.71 112.065 -176.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.9 41.35 18.97 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.238 -0.506 . . . . 0.75 112.898 178.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.581 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 15.4 mt -104.16 140.58 21.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.824 0.345 . . . . 0.68 110.811 -177.551 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.0 p -123.96 102.6 11.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.513 0.673 . . . . 1.87 110.002 173.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 24.1 mt -78.06 141.41 38.85 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.851 -0.613 . . . . 2.76 110.986 -177.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -69.76 -33.22 72.13 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.348 -0.842 . . . . 2.65 109.124 175.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 -131.58 104.74 14.46 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 115.189 -0.914 . . . . 2.29 108.653 172.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.87 -1.72 6.52 Favored 'Trans proline' 0 CA--C 1.528 0.187 0 C-N-CA 122.119 1.879 . . . . 0.64 111.812 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.8 p -87.09 -7.65 57.83 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.709 -0.678 . . . . 0.51 111.261 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.447 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 17.7 m -77.31 159.37 5.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 CA-C-O 121.204 0.526 . . . . 0.24 110.82 -179.589 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.471 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 85.6 mt -90.3 123.5 34.12 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.74 -0.664 . . . . 0.22 110.153 177.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.2 pt -105.25 139.27 26.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 115.94 -0.573 . . . . 0.15 109.957 176.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.871 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.32 106.69 1.44 Allowed Glycine 0 N--CA 1.44 -1.037 0 C-N-CA 120.51 -0.852 . . . . 0.31 113.174 -175.037 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.608 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 12.6 t70 -73.41 148.65 43.11 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.015 -0.735 . . . . 0.57 109.015 175.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.447 ' H ' HG23 ' A' ' 74' ' ' VAL . . . 60.6 45.16 96.87 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.44 -0.886 . . . . 0.21 112.58 175.561 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.587 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -100.96 117.35 34.83 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.322 0.582 . . . . 0.25 110.701 -174.662 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.504 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 3.5 p-10 -100.84 131.55 23.31 Favored Pre-proline 0 C--N 1.318 -0.772 0 CA-C-N 115.528 -0.76 . . . . 2.21 110.333 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -60.84 118.22 5.06 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 121.909 1.74 . . . . 0.44 110.076 173.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 13.6 mt -75.08 93.29 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.364 0.602 . . . . 0.46 110.935 -172.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 8.9 t -142.2 26.53 1.82 Allowed 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 122.326 1.06 . . . . 0.88 109.415 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 6.1 p -139.04 132.74 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.577 0 CA-C-N 114.491 -1.231 . . . . 1.44 109.813 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -95.91 -13.07 24.21 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.633 0.254 . . . . 2.94 111.325 -177.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -75.79 78.07 1.23 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 121.097 -0.573 . . . . 3.5 112.473 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.1 t -163.35 -165.97 1.16 Allowed 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.914 -0.773 . . . . 4.9 108.914 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 13.2 m -57.7 -68.22 0.26 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.916 0.388 . . . . 4.06 110.125 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -118.3 -72.0 0.71 Allowed 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.405 -0.591 . . . . 3.13 109.405 173.004 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -120.22 -19.99 7.5 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.466 -0.788 . . . . 0.99 109.969 173.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 15.3 p -168.67 -178.65 3.51 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.995 -1.002 . . . . 0.74 109.576 -179.166 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 23.9 p -114.17 12.11 17.71 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.01 0.374 . . . . 2.14 112.01 -175.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -134.78 -149.72 0.36 Allowed 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 121.227 -0.189 . . . . 0.54 110.95 -179.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 19.5 m -87.85 134.77 33.63 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.779 0.323 . . . . 0.29 111.055 -177.449 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.71 126.87 34.3 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.878 -0.416 . . . . 0.25 109.878 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.714 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -139.42 173.77 10.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.63 0 CA-C-O 121.51 0.671 . . . . 0.21 111.642 -176.083 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 48.8 t -141.82 103.76 4.4 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.974 -1.012 . . . . 0.39 109.165 -178.065 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.732 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.3 m -92.71 155.52 17.65 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.471 0.653 . . . . 0.65 111.913 -176.095 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 6.4 m -106.18 -13.98 15.27 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.264 -0.88 . . . . 1.15 110.879 -178.077 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.432 ' HB3' ' HB ' ' A' ' 77' ' ' ILE . 5.5 t70 -103.38 162.32 13.11 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.142 -0.481 . . . . 1.6 109.748 -178.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -120.85 -7.3 9.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.049 0.452 . . . . 2.49 111.14 -176.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -83.35 83.79 7.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.225 0.536 . . . . 2.27 111.403 -175.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 34.2 m -91.36 156.11 3.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.819 -0.628 . . . . 1.1 110.903 179.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.549 ' OG ' HG12 ' A' ' 75' ' ' ILE . 89.2 p -95.36 3.53 54.3 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.075 0.464 . . . . 1.41 110.53 179.435 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.31 -33.32 3.19 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.463 -0.79 . . . . 0.48 112.123 -176.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.447 HG23 ' H ' ' A' ' 46' ' ' GLY . 19.5 m -140.31 -21.69 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.325 0 N-CA-C 112.478 0.548 . . . . 0.49 112.478 174.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.549 HG12 ' OG ' ' A' ' 72' ' ' SER . 20.4 pt -71.75 172.99 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.373 0 CA-C-O 121.58 0.705 . . . . 0.3 112.187 -174.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.732 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -144.05 140.95 29.81 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.168 -1.378 . . . . 0.18 109.068 176.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.432 ' HB ' ' HB3' ' A' ' 68' ' ' ASP . 71.2 mt -119.5 129.33 75.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.032 0.444 . . . . 0.26 111.455 -176.296 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.458 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.08 51.93 5.96 Favored Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.972 -0.632 . . . . 0.17 112.035 178.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.503 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.92 139.04 35.17 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.135 0.493 . . . . 0.65 112.237 -176.503 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 97.9 mt -109.49 132.13 21.48 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 115.564 -0.744 . . . . 0.29 109.142 169.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 14.9 Cg_exo -68.01 119.37 6.38 Favored 'Trans proline' 0 N--CA 1.464 -0.246 0 C-N-CA 122.76 2.306 . . . . 0.25 112.058 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.7 m -112.41 147.25 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 CA-C-N 115.969 -0.56 . . . . 0.42 110.747 -177.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.44 HG22 ' HG ' ' A' ' 84' ' ' LEU . 32.8 m -156.04 134.39 11.53 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.561 -0.745 . . . . 2.07 109.878 178.135 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.44 ' HG ' HG22 ' A' ' 83' ' ' THR . 94.4 mt . . . . . 0 C--O 1.249 1.049 0 O-C-N 123.903 0.752 . . . . 3.91 111.463 -179.306 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.585 0 N-CA-C 112.007 -0.437 . . . . 5.63 112.007 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.61 ' O ' ' HA ' ' A' ' 51' ' ' THR . 17.5 p -80.28 71.95 7.1 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.028 0.442 . . . . 4.28 111.159 -178.58 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 67.3 t-105 -175.0 -66.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.516 -0.765 . . . . 4.74 110.523 174.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.29 -24.6 2.17 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.228 -0.987 . . . . 2.03 113.835 -172.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 77.4 mm-40 -60.3 108.03 0.74 Allowed 'General case' 0 C--O 1.233 0.211 0 CA-C-N 117.479 0.64 . . . . 4.17 111.101 -176.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.52 ' HB2' HD11 ' A' ' 11' ' ' ILE . 5.5 t 165.44 -40.18 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 114.19 -1.368 . . . . 1.88 107.678 -171.619 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.4 t -167.41 -160.57 0.37 Allowed 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.346 -1.297 . . . . 2.4 108.662 178.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.1 m -82.45 -8.46 59.62 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.138 0.494 . . . . 3.75 110.624 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -97.67 -125.93 5.29 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.836 -0.697 . . . . 1.12 113.314 -175.406 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 31.4 t -143.24 153.96 43.33 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 122.673 0.389 . . . . 0.96 109.967 -173.063 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.52 HD11 ' HB2' ' A' ' 6' ' ' CYS . 48.3 mt -103.58 140.17 22.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.155 0.503 . . . . 0.96 110.678 175.602 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.681 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -150.16 163.71 37.53 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.571 0.701 . . . . 0.91 111.732 -179.557 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.8 t -116.03 105.07 12.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.162 -0.926 . . . . 0.34 108.901 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.863 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 90.1 m -85.16 139.65 31.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.409 -0.814 . . . . 0.19 111.308 -173.174 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.84 -30.32 58.92 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 115.065 -0.971 . . . . 0.38 109.086 175.252 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.555 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 3.2 t-20 -136.13 111.52 9.16 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.797 -0.638 . . . . 1.03 110.618 178.532 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 85.5 t -102.15 106.16 19.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.022 0 N-CA-C 109.71 -0.478 . . . . 0.18 109.71 175.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.4 m -134.76 142.03 40.87 Favored Pre-proline 0 C--N 1.32 -0.676 0 CA-C-N 115.82 -0.627 . . . . 0.18 110.54 -178.078 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.509 ' O ' ' HB3' ' A' ' 22' ' ' SER . 32.5 Cg_exo -59.22 137.33 78.28 Favored 'Trans proline' 0 N--CA 1.46 -0.442 0 C-N-CA 122.31 2.007 . . . . 0.19 111.157 172.427 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.12 -25.55 69.66 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 121.111 -0.566 . . . . 0.18 112.666 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -100.52 6.55 44.3 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.612 0.72 . . . . 2.27 110.198 176.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.509 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 21.0 t -68.88 154.83 41.32 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.352 -0.61 . . . . 0.24 109.352 173.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -53.42 -43.2 67.78 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.098 0.475 . . . . 1.06 109.744 177.369 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.626 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.6 mm? -72.05 -57.72 4.04 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.318 -0.856 . . . . 1.11 111.097 177.776 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -53.71 -40.96 64.87 Favored Glycine 0 C--N 1.33 0.21 0 C-N-CA 121.225 -0.512 . . . . 0.16 112.962 -176.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 84.3 m -67.73 -39.3 84.27 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.731 0.301 . . . . 0.24 110.383 -179.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.429 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.5 tm? -68.25 -36.44 79.45 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.434 -0.58 . . . . 1.01 109.434 178.428 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.626 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 13.3 mt -67.57 -47.55 69.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.742 -0.663 . . . . 0.37 110.372 -177.614 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.566 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -77.56 -22.68 50.63 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.746 -0.382 . . . . 0.41 111.364 -178.562 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.505 ' N ' HD12 ' A' ' 29' ' ' LEU . 26.6 t70 -69.06 -31.53 70.37 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.422 0.63 . . . . 0.66 109.418 175.404 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -70.42 -24.29 62.89 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 114.79 -1.096 . . . . 2.07 109.305 176.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 76.1 mt -98.53 -15.58 19.49 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.585 -1.189 . . . . 0.71 111.71 -175.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.57 31.18 51.31 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 121.226 -0.512 . . . . 0.75 112.68 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.566 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 31.1 mt -95.38 140.66 16.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.721 0.296 . . . . 0.68 110.753 -178.072 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.9 t -124.75 101.41 8.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 109.708 -0.478 . . . . 1.87 109.708 176.081 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 30.7 mt -74.77 134.76 41.77 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.106 -0.497 . . . . 2.76 111.451 -177.48 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -70.34 -27.22 64.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.489 -0.778 . . . . 2.65 109.285 174.275 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -128.11 90.83 46.26 Favored Pre-proline 0 N--CA 1.446 -0.634 0 N-CA-C 108.38 -0.97 . . . . 2.29 108.38 176.001 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.5 8.36 0.96 Allowed 'Trans proline' 0 C--O 1.223 -0.248 0 C-N-CA 122.416 2.077 . . . . 0.64 112.408 -177.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.5 p -99.94 7.91 44.47 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.094 0.473 . . . . 0.51 110.996 -178.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.539 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 27.8 m -91.98 155.75 3.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 116.078 -0.51 . . . . 0.24 110.99 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 95.5 mt -86.56 127.12 34.87 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.663 -0.699 . . . . 0.22 109.875 176.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.493 HD13 HD23 ' A' ' 29' ' ' LEU . 13.4 pt -106.78 141.75 21.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.122 -0.49 . . . . 0.15 110.095 176.236 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.863 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.48 108.59 1.71 Allowed Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 120.523 -0.846 . . . . 0.31 113.419 -174.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.523 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 8.8 t70 -74.49 146.16 42.96 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.757 -0.831 . . . . 0.57 108.757 174.229 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 60.63 47.2 92.37 Favored Glycine 0 C--N 1.318 -0.453 0 C-N-CA 120.281 -0.961 . . . . 0.21 112.712 175.59 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.515 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -108.61 111.59 23.49 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.116 0.484 . . . . 0.25 111.568 -171.771 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.457 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 4.6 t70 -101.67 135.5 19.76 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.633 -0.712 . . . . 2.21 110.916 176.309 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 35.1 Cg_exo -54.76 123.52 13.93 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 124.032 3.155 . . . . 0.44 112.211 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 42.0 mt -79.84 88.34 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.595 0.712 . . . . 0.46 109.402 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.61 ' HA ' ' O ' ' A' ' 2' ' ' SER . 9.5 t -109.25 15.93 22.8 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.038 -0.983 . . . . 0.88 109.535 -179.507 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.3 p -131.51 144.41 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 CA-C-N 114.719 -1.128 . . . . 1.44 109.37 178.349 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -107.4 -56.47 2.21 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 110.106 -0.331 . . . . 2.94 110.106 178.593 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 53.58 -124.93 30.72 Favored Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.865 -0.607 . . . . 3.5 112.334 178.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.1 t -122.87 -70.57 0.77 Allowed 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.644 -0.502 . . . . 4.9 109.644 177.412 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 32.2 m -130.44 23.51 5.13 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.569 0.699 . . . . 4.06 109.403 176.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -109.53 22.78 15.32 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.323 -0.853 . . . . 3.13 111.261 -176.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -86.04 -19.77 29.79 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.409 0.623 . . . . 0.99 110.638 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.1 t -157.21 137.34 12.67 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.422 -0.808 . . . . 0.74 110.556 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.1 p -106.89 -22.11 12.8 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.185 -0.461 . . . . 2.14 111.774 -178.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -117.09 -82.65 0.63 Allowed 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 121.016 -0.274 . . . . 0.54 111.129 -179.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 11.9 m -139.77 129.91 25.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.689 0.28 . . . . 0.29 111.363 -179.038 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.4 128.19 34.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.979 0.419 . . . . 0.25 110.777 -177.428 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.624 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -143.09 173.93 5.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.489 0.661 . . . . 0.21 111.579 -177.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 39.0 t -140.96 107.57 5.33 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.387 -0.824 . . . . 0.39 109.146 -177.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.75 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -93.56 138.08 32.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.62 0.724 . . . . 0.65 112.58 -174.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.6 t -85.8 -22.49 27.63 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 114.731 -1.122 . . . . 1.15 110.691 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.422 ' HB2' ' O ' ' A' ' 77' ' ' ILE . 1.2 m-20 -102.53 136.76 41.77 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.164 -0.471 . . . . 1.6 110.813 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -100.44 -4.45 28.89 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.757 -0.656 . . . . 2.49 110.036 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -75.56 90.29 2.76 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.556 -0.747 . . . . 2.27 110.495 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 26.7 m -105.95 156.53 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.579 0 CA-C-N 116.102 -0.499 . . . . 1.1 111.29 -177.125 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.623 ' OG ' HG12 ' A' ' 75' ' ' ILE . 82.5 p -85.83 -4.56 59.2 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.886 -0.597 . . . . 1.41 110.529 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.47 -32.34 3.56 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.594 -0.73 . . . . 0.48 112.436 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 m -136.48 -11.57 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 C-N-CA 120.251 -0.58 . . . . 0.49 112.094 179.105 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.623 HG12 ' OG ' ' A' ' 72' ' ' SER . 25.8 pt -92.54 -178.2 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.602 0.715 . . . . 0.3 111.928 -178.337 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.75 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -143.04 141.09 31.23 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.031 -1.441 . . . . 0.18 109.279 175.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.422 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 68.0 mt -121.17 129.12 75.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.867 0.365 . . . . 0.26 111.447 -177.088 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.539 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 79.59 50.24 5.76 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.803 -0.713 . . . . 0.17 111.816 178.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.483 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.2 m -99.67 133.55 43.85 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 112.453 0.538 . . . . 0.65 112.453 -175.529 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.404 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 92.4 mt -105.53 133.87 19.97 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 115.538 -0.755 . . . . 0.29 109.636 171.065 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 22.9 Cg_exo -63.59 125.75 16.16 Favored 'Trans proline' 0 C--O 1.234 0.3 0 C-N-CA 122.807 2.338 . . . . 0.25 112.022 -179.409 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 10.3 m -122.85 161.49 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 CA-C-N 116.153 -0.476 . . . . 0.42 110.697 -178.445 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.453 HG22 ' HG ' ' A' ' 84' ' ' LEU . 25.4 m -145.75 131.03 18.52 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.946 -0.57 . . . . 2.07 110.279 176.148 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.453 ' HG ' HG22 ' A' ' 83' ' ' THR . 96.6 mt . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.266 -0.874 . . . . 3.91 111.593 179.359 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.459 ' HA3' ' O ' ' A' ' 51' ' ' THR . . . . . . . . 0 N--CA 1.482 1.727 0 N-CA-C 111.637 -0.585 . . . . 5.63 111.637 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.3 m -88.78 -1.5 58.12 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.988 0.394 . . . . 4.28 110.917 -178.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 79.4 m95 65.22 178.45 0.19 Allowed 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.66 -0.7 . . . . 4.74 111.269 179.034 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -124.03 76.44 0.37 Allowed Glycine 0 N--CA 1.444 -0.801 0 N-CA-C 110.901 -0.88 . . . . 2.03 110.901 176.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . 0.422 HE21 ' N ' ' A' ' 5' ' ' GLN . 0.0 OUTLIER -87.03 121.8 29.98 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.403 0.621 . . . . 4.17 110.867 -173.621 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.516 ' HB3' ' O ' ' A' ' 9' ' ' GLY . 14.3 t -111.3 -81.35 0.58 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.406 -0.815 . . . . 1.88 109.676 178.197 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 12.8 p 177.77 -82.23 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.095 0.474 . . . . 2.4 110.487 179.232 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 7.8 p -92.96 17.19 11.08 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.608 -0.724 . . . . 3.75 110.293 178.531 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.516 ' O ' ' HB3' ' A' ' 6' ' ' CYS . . . -169.21 176.19 43.34 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 115.166 -0.925 . . . . 1.12 111.633 -179.527 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.1 t -97.98 153.63 18.24 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.296 -0.631 . . . . 0.96 109.296 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.51 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 18.3 mt -96.19 130.48 44.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.702 0.763 . . . . 0.96 111.281 176.264 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.678 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -137.7 166.55 23.68 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.528 -1.215 . . . . 0.91 110.329 176.6 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.671 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 16.2 t -106.85 100.9 10.37 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.294 -0.866 . . . . 0.34 109.853 179.086 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.813 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 58.1 m -87.01 131.8 33.98 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.148 0.499 . . . . 0.19 110.747 -177.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.403 ' HB2' HE21 ' A' ' 15' ' ' GLN . 0.0 OUTLIER -80.97 -29.72 35.27 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.285 -0.87 . . . . 0.38 109.593 178.23 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.669 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 2.7 m-20 -134.78 104.01 5.85 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.395 -0.366 . . . . 1.03 110.843 176.464 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 59.1 t -95.99 103.07 14.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.152 0.501 . . . . 0.18 110.01 176.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.98 142.68 46.03 Favored Pre-proline 0 C--N 1.32 -0.71 0 CA-C-N 115.731 -0.668 . . . . 0.18 110.704 -175.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.47 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.6 Cg_exo -58.9 137.74 81.62 Favored 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.103 1.868 . . . . 0.19 111.19 172.302 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.88 -23.76 69.53 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.831 -0.7 . . . . 0.18 112.041 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -96.64 7.58 46.21 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.016 0.436 . . . . 2.27 110.286 176.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.47 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.6 t -80.5 152.4 28.73 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.015 -0.539 . . . . 0.24 110.001 177.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -53.12 -37.35 61.7 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.074 0.464 . . . . 1.06 110.709 178.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.692 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.9 mm? -70.53 -65.95 0.67 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.763 -0.653 . . . . 1.11 110.545 175.011 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.67 -40.04 55.3 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.951 -0.568 . . . . 0.16 113.428 -174.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 63.8 m -68.28 -45.13 73.93 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.909 0.385 . . . . 0.24 110.666 -177.196 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -65.97 -36.63 83.84 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.399 -0.593 . . . . 1.01 109.399 178.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.692 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 17.5 mt -66.56 -49.28 66.92 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.836 -0.62 . . . . 0.37 110.326 -178.304 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.612 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.1 pp -74.4 -25.71 59.64 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.42 -0.355 . . . . 0.41 111.622 -175.047 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.516 ' N ' HD12 ' A' ' 29' ' ' LEU . 31.7 t70 -65.66 -34.49 78.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.673 0.749 . . . . 0.66 109.536 176.055 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -78.82 -34.5 45.24 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 114.713 -1.13 . . . . 2.07 109.412 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 82.3 mt -82.63 -10.73 58.82 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.033 -0.985 . . . . 0.71 112.037 -177.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 73.63 47.71 20.12 Favored Glycine 0 N--CA 1.452 -0.282 0 CA-C-N 115.855 -0.611 . . . . 0.75 112.631 178.117 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.612 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 10.6 mt -109.75 139.01 34.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 120.723 0.297 . . . . 0.68 110.471 -179.077 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.0 p -123.59 105.37 15.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.396 0.617 . . . . 1.87 110.125 174.387 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 21.6 mt -81.6 144.08 31.5 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.879 -0.601 . . . . 2.76 111.191 -178.063 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 25.5 mm-40 -79.41 -21.16 45.98 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.608 -0.724 . . . . 2.65 109.356 174.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -138.2 99.35 8.97 Favored Pre-proline 0 N--CA 1.445 -0.696 0 N-CA-C 107.707 -1.22 . . . . 2.29 107.707 173.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.72 -1.45 9.29 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.272 1.982 . . . . 0.64 112.453 -175.407 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.2 p -101.37 20.26 16.24 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.21 0.528 . . . . 0.51 111.277 -176.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.459 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 33.4 m -93.01 161.63 2.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.978 -0.556 . . . . 0.24 110.094 174.723 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.426 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 96.4 mt -87.57 120.63 29.07 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.284 -0.416 . . . . 0.22 110.043 176.04 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 14.8 pt -103.66 138.35 28.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 116.078 -0.51 . . . . 0.15 110.092 176.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.813 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -115.55 107.4 1.72 Allowed Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.572 -0.823 . . . . 0.31 113.252 -175.401 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.669 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 12.7 t70 -74.82 146.52 41.96 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.488 -0.93 . . . . 0.57 108.488 174.59 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 67.18 36.87 90.78 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 119.882 -1.152 . . . . 0.21 112.165 176.336 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.671 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -100.34 111.31 23.57 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.376 0.608 . . . . 0.25 110.607 -174.497 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.598 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 1.6 p-10 -101.46 130.32 25.0 Favored Pre-proline 0 C--N 1.314 -0.956 0 CA-C-N 115.547 -0.751 . . . . 2.21 109.876 178.094 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -58.55 118.11 4.94 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.18 1.92 . . . . 0.44 110.911 177.079 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 8.6 mt -79.71 110.78 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 108.581 -0.896 . . . . 0.46 108.581 -179.299 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.459 ' O ' ' HA3' ' A' ' 1' ' ' GLY . 8.8 t -141.72 16.19 2.15 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.442 0.639 . . . . 0.88 110.672 -174.078 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.3 p -77.93 154.85 5.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.485 -0.78 . . . . 1.44 110.459 -177.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -68.57 113.35 6.01 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.178 -0.464 . . . . 2.94 110.278 175.485 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.3 73.03 1.26 Allowed Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 120.951 -0.642 . . . . 3.5 111.613 -176.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 48.9 m -93.19 46.31 1.21 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.02 0.438 . . . . 4.9 111.136 -177.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.6 p -70.25 -40.61 74.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 4.06 110.867 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -154.96 76.91 1.01 Allowed 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.412 0.625 . . . . 3.13 109.588 175.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -105.45 17.98 23.01 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.49 -0.777 . . . . 0.99 109.988 179.242 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 35.4 t -151.71 128.9 11.17 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.351 -0.84 . . . . 0.74 110.737 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 73.9 m -119.78 -3.45 10.26 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.34 -0.391 . . . . 2.14 111.226 176.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.46 -84.4 0.1 Allowed 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.076 -0.712 . . . . 0.54 109.076 172.292 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 29.9 m -151.96 129.27 11.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.913 0.387 . . . . 0.29 111.067 171.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.7 132.58 33.83 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 109.383 -0.599 . . . . 0.25 109.383 176.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.713 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -141.95 169.8 13.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.488 0.661 . . . . 0.21 112.334 -174.094 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 14.2 t -130.95 100.53 5.28 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.66 -1.155 . . . . 0.39 109.459 179.306 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.775 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -88.88 125.52 34.97 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.79 0.805 . . . . 0.65 111.872 -178.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 10.0 t -85.26 -18.38 34.13 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 114.281 -1.327 . . . . 1.15 110.252 -179.057 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -110.82 140.81 44.94 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.64 -0.709 . . . . 1.6 109.577 178.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -119.74 24.64 10.47 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 120.975 -0.29 . . . . 2.49 111.695 -173.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 49.1 m-80 -86.5 56.82 4.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.333 0.587 . . . . 2.27 110.187 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 35.8 m -73.95 139.79 18.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.505 -0.771 . . . . 1.1 111.574 -175.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.422 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 19.6 m -90.86 10.83 24.67 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.013 -0.54 . . . . 1.41 111.431 -178.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.62 -34.76 2.94 Favored Glycine 0 C--O 1.228 -0.265 0 C-N-CA 120.944 -0.646 . . . . 0.48 113.995 173.167 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.5 m -139.98 -7.11 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 117.936 0.868 . . . . 0.49 111.264 176.534 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.422 ' CG1' ' H ' ' A' ' 72' ' ' SER . 11.2 pt -89.87 178.5 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.336 0.589 . . . . 0.3 111.347 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.775 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -144.31 144.17 31.34 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 114.563 -1.199 . . . . 0.18 109.177 175.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 67.4 mt -123.01 132.52 71.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 120.915 0.388 . . . . 0.26 111.549 -176.163 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.459 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 74.22 50.22 10.75 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.743 -0.741 . . . . 0.17 112.017 177.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.517 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.2 m -98.46 136.07 39.13 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-O 121.177 0.513 . . . . 0.65 111.785 -176.336 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.441 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.2 mt -107.63 130.18 23.18 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.472 -0.785 . . . . 0.29 109.258 170.048 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 15.7 Cg_exo -67.12 121.41 8.57 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.808 2.339 . . . . 0.25 112.651 -177.569 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.0 m -111.39 149.15 14.21 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.852 0 CA-C-N 115.686 -0.688 . . . . 0.42 109.346 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.433 HG22 ' HG ' ' A' ' 84' ' ' LEU . 8.9 m -132.46 149.35 52.35 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 116.445 -0.343 . . . . 2.07 110.84 -174.45 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.433 ' HG ' HG22 ' A' ' 83' ' ' THR . 78.5 mt . . . . . 0 C--O 1.252 1.207 0 O-C-N 123.773 0.67 . . . . 3.91 111.298 176.473 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.751 0 N-CA-C 111.774 -0.531 . . . . 5.63 111.774 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.9 t -94.2 136.84 34.06 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.037 -0.357 . . . . 4.28 110.037 -179.546 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 70.4 m95 69.96 -64.54 0.35 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.4 0.68 . . . . 4.74 111.474 -178.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 126.98 169.66 12.75 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 121.228 -0.51 . . . . 2.03 111.875 179.37 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -100.93 112.86 25.39 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.08 -0.341 . . . . 4.17 110.08 178.498 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.542 ' HB2' HD11 ' A' ' 11' ' ' ILE . 33.3 t -150.85 74.05 1.14 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.882 0.372 . . . . 1.88 110.59 177.791 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 12.1 t 55.46 -143.64 0.72 Allowed 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 115.751 -0.659 . . . . 2.4 110.868 176.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.4 p -94.32 20.47 8.16 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.014 0.435 . . . . 3.75 110.839 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -101.29 -165.12 27.55 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.842 -0.694 . . . . 1.12 112.839 -176.374 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.8 t -123.09 151.44 42.03 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.186 -0.672 . . . . 0.96 109.186 -179.353 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.542 HD11 ' HB2' ' A' ' 6' ' ' CYS . 23.8 mt -113.05 130.79 66.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.822 0.82 . . . . 0.96 111.196 177.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.566 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -146.72 170.64 16.57 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 114.363 -1.29 . . . . 0.91 110.479 -178.792 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.434 ' HB2' HD11 ' A' ' 50' ' ' ILE . 39.5 t -120.03 107.11 12.68 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.834 -0.621 . . . . 0.34 109.657 177.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.886 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 97.4 m -84.92 127.41 34.15 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.297 -0.865 . . . . 0.19 110.863 -176.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.475 ' HA ' ' HB1' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -67.79 -36.06 79.76 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-N 115.181 -0.918 . . . . 0.38 109.403 173.77 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -133.9 111.55 10.55 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 1.03 110.631 177.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 92.8 t -97.97 106.85 19.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.786 -0.45 . . . . 0.18 109.786 176.28 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.1 m -131.79 140.49 38.42 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 116.31 -0.404 . . . . 0.18 111.013 -176.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.436 ' O ' ' HB3' ' A' ' 22' ' ' SER . 36.5 Cg_exo -60.36 140.31 91.1 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.389 2.059 . . . . 0.19 111.75 172.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.8 -19.81 69.8 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 121.02 -0.609 . . . . 0.18 112.488 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -100.76 5.45 43.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.112 0.482 . . . . 2.27 109.899 176.579 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.436 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 30.1 t -77.17 152.8 34.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.834 -0.621 . . . . 0.24 110.015 177.294 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -51.29 -41.02 60.17 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.959 0.409 . . . . 1.06 110.365 178.741 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.717 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 3.1 mm? -72.77 -62.91 1.28 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.757 -0.656 . . . . 1.11 110.618 178.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.47 -39.03 52.13 Favored Glycine 0 C--N 1.331 0.271 0 CA-C-N 116.153 -0.476 . . . . 0.16 113.15 -175.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.8 m -66.96 -47.8 70.5 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 120.728 0.299 . . . . 0.24 110.514 -178.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.449 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.4 tm? -65.75 -33.84 76.8 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.751 -0.463 . . . . 1.01 109.751 178.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.717 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 17.2 mt -67.92 -44.26 77.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.37 110.738 -178.012 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.587 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -79.62 -23.08 42.88 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.75 -0.38 . . . . 0.41 110.595 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.423 ' N ' HD12 ' A' ' 29' ' ' LEU . 15.0 t70 -64.09 -35.17 79.86 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.872 0.844 . . . . 0.66 109.568 172.664 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -74.85 -38.62 61.92 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 114.53 -1.214 . . . . 2.07 109.875 179.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 69.5 mt -81.88 -20.11 39.51 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 114.745 -1.116 . . . . 0.71 112.298 -176.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.86 34.39 30.91 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 121.183 -0.532 . . . . 0.75 112.347 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.587 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 40.4 mt -85.79 131.12 35.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.802 0.334 . . . . 0.68 110.929 -176.721 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 48.2 t -89.61 100.68 11.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 116.294 -0.412 . . . . 1.87 109.958 175.204 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.576 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.2 pp -72.06 126.36 29.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.426 0.632 . . . . 2.76 110.705 179.292 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -78.4 -35.62 46.91 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 108.695 -0.854 . . . . 2.65 108.695 172.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -144.46 108.35 4.83 Favored Pre-proline 0 N--CA 1.442 -0.837 0 CA-C-N 114.606 -1.179 . . . . 2.29 107.892 176.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.468 ' HB3' HD22 ' A' ' 36' ' ' LEU . 56.1 Cg_endo -70.88 -4.71 15.33 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.22 1.946 . . . . 0.64 111.522 -176.706 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 24.2 p -88.35 14.0 10.49 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.456 -0.793 . . . . 0.51 111.412 -174.211 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.412 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 19.3 m -102.84 158.36 4.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 116.045 -0.525 . . . . 0.24 110.448 179.143 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.423 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 92.6 mt -86.0 119.6 26.48 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.79 -0.641 . . . . 0.22 109.955 177.257 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.454 HD13 HD23 ' A' ' 29' ' ' LEU . 13.5 pt -102.81 134.13 44.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.213 0.53 . . . . 0.15 110.056 176.31 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.886 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -105.39 101.47 1.87 Allowed Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 120.531 -0.842 . . . . 0.31 112.944 -175.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -81.62 129.44 34.69 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.792 -0.818 . . . . 0.57 108.792 175.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 83.12 35.94 16.55 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 119.793 -1.194 . . . . 0.21 111.48 -175.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.79 110.02 22.2 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.194 0.521 . . . . 0.25 110.995 -174.373 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.455 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.4 t70 -101.96 135.77 19.63 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-N 115.424 -0.807 . . . . 2.21 110.495 175.089 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 12.4 Cg_exo -61.95 122.13 10.5 Favored 'Trans proline' 0 N--CA 1.462 -0.377 0 C-N-CA 123.453 2.769 . . . . 0.44 111.734 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.434 HD11 ' HB2' ' A' ' 13' ' ' CYS . 22.1 mt -79.22 88.39 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.4 0.619 . . . . 0.46 109.433 -178.389 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 12.5 t -118.03 11.98 13.52 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.427 -0.806 . . . . 0.88 110.248 -178.162 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 5.9 p -98.78 120.45 48.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.593 -0.73 . . . . 1.44 109.672 175.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -105.04 158.03 16.83 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.812 -0.631 . . . . 2.94 110.748 -176.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 134.74 -34.36 2.35 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.841 -0.695 . . . . 3.5 112.07 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.3 p -137.43 151.06 48.11 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.82 0.343 . . . . 4.9 110.736 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 32.3 t -74.65 -35.6 62.86 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.943 -0.572 . . . . 4.06 109.987 178.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -89.44 57.13 3.85 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.853 0.835 . . . . 3.13 109.53 176.649 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -70.34 -6.46 35.38 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.006 -0.997 . . . . 0.99 111.427 -179.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 45.5 t -162.01 143.33 10.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.564 -0.744 . . . . 0.74 109.225 175.728 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.4 t -107.62 -3.75 18.96 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.177 0.436 . . . . 2.14 112.177 -171.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.475 ' HB1' ' HA ' ' A' ' 15' ' ' GLN . . . -77.78 -89.09 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 C-N-CA 120.605 -0.438 . . . . 0.54 111.201 -179.357 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 28.4 m -151.08 125.75 9.62 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.684 0.278 . . . . 0.29 110.528 178.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.91 132.17 34.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.02 0.438 . . . . 0.25 110.066 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.753 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.4 m -143.14 172.04 8.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.261 0.553 . . . . 0.21 111.247 -177.7 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 51.9 t -138.11 104.72 5.3 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.238 -0.892 . . . . 0.39 109.3 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.74 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.3 m -89.24 132.38 34.91 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.555 0.693 . . . . 0.65 111.629 -178.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 33.5 t -76.22 -24.87 54.65 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.96 -1.018 . . . . 1.15 109.906 177.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -110.61 133.91 52.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.648 -0.705 . . . . 1.6 110.482 176.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -100.35 18.14 19.68 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.385 0.612 . . . . 2.49 109.968 179.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 -77.89 94.84 4.62 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.487 -0.779 . . . . 2.27 109.872 178.077 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 28.3 m -106.6 140.87 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 CA-C-N 116.166 -0.47 . . . . 1.1 111.739 -176.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.481 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 19.5 m -91.96 10.32 29.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.046 -0.525 . . . . 1.41 110.853 176.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.37 -34.63 3.01 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.159 -0.543 . . . . 0.48 113.668 174.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.0 m -140.7 -2.63 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 117.965 0.882 . . . . 0.49 111.692 176.426 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.481 ' CG1' ' H ' ' A' ' 72' ' ' SER . 3.8 pt -95.99 -177.64 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-O 121.431 0.634 . . . . 0.3 112.322 -175.034 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.74 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.51 140.44 21.92 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.368 -1.287 . . . . 0.18 108.783 174.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.0 mt -117.14 126.08 74.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.982 0.42 . . . . 0.26 111.675 -175.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 79.15 52.02 5.07 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.957 -0.64 . . . . 0.17 111.825 177.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.3 m -98.28 132.29 43.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.396 0.617 . . . . 0.65 112.164 -176.46 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 87.9 mt -102.19 129.86 25.41 Favored Pre-proline 0 C--N 1.32 -0.677 0 CA-C-N 115.427 -0.806 . . . . 0.29 109.538 171.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.45 ' HA ' HG12 ' A' ' 64' ' ' VAL . 15.9 Cg_exo -67.33 120.16 7.2 Favored 'Trans proline' 0 C--O 1.235 0.361 0 C-N-CA 122.859 2.373 . . . . 0.25 112.111 -178.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 11.2 m -118.96 150.63 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.902 0 CA-C-N 115.813 -0.63 . . . . 0.42 110.015 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.461 HG22 ' HG ' ' A' ' 84' ' ' LEU . 26.0 m -138.61 133.97 33.15 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.277 -0.42 . . . . 2.07 110.155 179.111 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.461 ' HG ' HG22 ' A' ' 83' ' ' THR . 96.5 mt . . . . . 0 C--O 1.246 0.912 0 O-C-N 123.881 0.738 . . . . 3.91 111.128 -179.443 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.634 0 N-CA-C 112.171 -0.372 . . . . 5.63 112.171 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 32.4 t -96.24 4.92 52.02 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.075 0.464 . . . . 4.28 110.397 -179.124 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 71.9 t-105 -152.98 135.89 15.46 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.369 -0.604 . . . . 4.74 109.369 178.213 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.462 ' HA3' ' HB ' ' A' ' 11' ' ' ILE . . . -70.79 95.59 0.55 Allowed Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.93 -0.653 . . . . 2.03 112.589 179.623 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 16.0 mm-40 -75.76 134.08 40.55 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 110.239 -0.282 . . . . 4.17 110.239 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.48 ' HB2' HG13 ' A' ' 11' ' ' ILE . 40.6 t -141.28 53.93 1.54 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.956 0.408 . . . . 1.88 110.179 -179.451 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 37.3 m 63.14 -79.37 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 115.438 -0.801 . . . . 2.4 111.707 179.311 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.8 m -116.35 -28.43 6.5 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.965 0.412 . . . . 3.75 110.235 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -94.89 -175.23 38.11 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.828 -0.624 . . . . 1.12 112.968 -175.371 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 65' ' ' CYS . 30.4 t -114.07 152.06 31.6 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.915 -0.402 . . . . 0.96 109.915 -177.309 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.48 HG13 ' HB2' ' A' ' 6' ' ' CYS . 28.0 mt -108.65 132.93 55.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.782 0.801 . . . . 0.96 111.325 177.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.58 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -140.34 165.53 27.16 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.559 -1.201 . . . . 0.91 110.501 179.843 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.472 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 40.1 t -110.81 104.22 12.82 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.666 -0.697 . . . . 0.34 109.443 178.327 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.777 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 69.3 m -90.73 130.6 36.7 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.012 -0.54 . . . . 0.19 111.585 -174.474 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.412 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -73.42 -28.94 62.26 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.069 -0.969 . . . . 0.38 110.007 176.374 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.441 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 5.2 t-20 -138.44 104.05 5.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.35 -0.386 . . . . 1.03 110.75 179.327 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 80.9 t -99.96 104.67 16.42 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 N-CA-C 109.917 -0.401 . . . . 0.18 109.917 178.122 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 21.0 m -132.37 143.86 50.64 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 116.064 -0.516 . . . . 0.18 110.976 -175.495 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.484 ' O ' ' HB3' ' A' ' 22' ' ' SER . 35.4 Cg_exo -60.85 136.61 67.23 Favored 'Trans proline' 0 N--CA 1.463 -0.307 0 C-N-CA 122.152 1.901 . . . . 0.19 111.36 172.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.38 -22.13 69.13 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 121.046 -0.597 . . . . 0.18 112.462 -178.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -98.15 3.14 49.08 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.144 0.497 . . . . 2.27 110.1 176.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.484 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 29.8 t -75.38 154.85 36.96 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.838 -0.619 . . . . 0.24 109.795 176.107 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -54.53 -41.03 69.23 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.367 0.603 . . . . 1.06 109.619 177.039 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.639 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.2 mm? -65.14 -65.05 0.72 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.875 -1.057 . . . . 1.11 110.698 175.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -56.6 -40.2 87.11 Favored Glycine 0 C--N 1.33 0.241 0 CA-C-N 115.972 -0.558 . . . . 0.16 113.614 -174.337 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 61.6 m -66.12 -42.06 89.7 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.918 0.39 . . . . 0.24 110.236 -178.586 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.401 HD22 ' HA ' ' A' ' 27' ' ' LEU . 2.6 tm? -65.92 -38.17 87.98 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.378 -0.601 . . . . 1.01 109.378 177.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.639 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.2 mt -65.4 -47.21 77.1 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 116.032 -0.531 . . . . 0.37 110.716 -176.7 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.551 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.87 -22.57 49.63 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.603 -0.439 . . . . 0.41 111.539 -176.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.492 ' N ' HD12 ' A' ' 29' ' ' LEU . 33.9 t70 -69.39 -34.58 74.72 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.518 0.675 . . . . 0.66 109.471 175.529 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -80.92 -10.71 59.69 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.058 -0.973 . . . . 2.07 110.118 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -108.93 -1.77 18.81 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.504 -0.771 . . . . 0.71 111.276 -178.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.51 43.48 98.96 Favored Glycine 0 C--N 1.331 0.272 0 CA-C-N 115.662 -0.699 . . . . 0.75 113.024 178.216 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.551 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 30.4 mt -95.36 137.96 22.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.962 0.41 . . . . 0.68 111.026 -177.211 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -97.99 103.19 14.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.867 -0.606 . . . . 1.87 110.055 175.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.468 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.2 pp -74.31 133.28 42.57 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.356 0.598 . . . . 2.76 111.136 -179.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -88.78 -32.02 18.09 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 108.378 -0.971 . . . . 2.65 108.378 174.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -145.84 109.66 4.41 Favored Pre-proline 0 N--CA 1.439 -0.982 0 N-CA-C 107.269 -1.382 . . . . 2.29 107.269 175.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.428 ' HB3' HD22 ' A' ' 36' ' ' LEU . 61.5 Cg_endo -74.24 -3.97 14.66 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 121.937 1.758 . . . . 0.64 112.429 -174.085 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 65.2 p -97.43 21.71 9.78 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.49 0.662 . . . . 0.51 111.188 -174.26 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.437 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 23.8 m -99.8 156.19 4.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.467 -0.788 . . . . 0.24 110.096 174.829 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.436 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.5 mt -85.07 124.18 31.46 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.24 -0.437 . . . . 0.22 110.123 177.215 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.407 HD13 HD23 ' A' ' 29' ' ' LEU . 14.4 pt -106.35 133.69 50.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.184 0.516 . . . . 0.15 110.134 175.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.777 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -113.38 100.48 1.08 Allowed Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.613 -0.803 . . . . 0.31 112.803 -176.087 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -80.6 146.44 31.22 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 109.564 -0.532 . . . . 0.57 109.564 177.217 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.412 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 74.18 36.46 50.88 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.07 -1.062 . . . . 0.21 111.571 -178.673 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -102.9 118.53 37.03 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.262 0.553 . . . . 0.25 111.456 -173.061 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.53 139.21 20.21 Favored Pre-proline 0 C--N 1.32 -0.697 0 CA-C-N 115.468 -0.787 . . . . 2.21 109.157 175.018 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -71.12 123.24 9.47 Favored 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 122.095 1.863 . . . . 0.44 111.287 -179.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.406 HG13 ' HA ' ' A' ' 12' ' ' GLN . 13.1 mt -77.29 89.47 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.645 0.736 . . . . 0.46 109.853 -176.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 7.9 t -123.54 12.9 9.37 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 114.762 -1.108 . . . . 0.88 110.257 -176.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.5 p -95.31 141.12 15.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.231 -0.895 . . . . 1.44 110.045 177.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -121.43 165.04 16.17 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.275 -0.421 . . . . 2.94 110.765 -178.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 94.99 0.71 63.56 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.93 -0.652 . . . . 3.5 112.512 178.195 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 33.7 t -156.86 124.55 5.43 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.941 -0.392 . . . . 4.9 109.941 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.0 p -73.79 -21.72 60.07 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.094 -0.503 . . . . 4.06 110.47 177.425 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -81.46 52.43 1.86 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 122.017 0.913 . . . . 3.13 109.154 175.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -92.59 17.15 10.61 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.133 -0.94 . . . . 0.99 110.98 -176.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.1 t -138.67 131.44 29.31 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.816 -0.629 . . . . 0.74 110.014 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.2 p -90.61 -22.97 20.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.983 -0.553 . . . . 2.14 111.707 -178.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -129.49 -87.95 0.52 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 120.7 -0.4 . . . . 0.54 112.012 -177.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 60.3 m -131.28 130.67 43.12 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.808 0.337 . . . . 0.29 111.616 -175.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.73 131.64 34.08 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.34 -0.391 . . . . 0.25 109.962 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.631 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.6 m -143.06 166.67 14.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.062 0.458 . . . . 0.21 111.494 -175.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . 0.487 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 31.5 t -128.27 104.64 7.85 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.435 -0.802 . . . . 0.39 110.15 178.485 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.746 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.6 m -93.2 136.92 33.01 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.61 0.719 . . . . 0.65 111.79 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.7 t -89.01 -20.52 24.3 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 114.784 -1.098 . . . . 1.15 110.458 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.482 ' HB3' ' OD1' ' A' ' 70' ' ' ASN . 44.6 m-20 -103.53 148.09 26.38 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.902 -0.59 . . . . 1.6 110.401 -177.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.4 HD22 ' HA ' ' A' ' 69' ' ' ASN . 11.6 m120 -119.75 3.75 11.09 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.511 -0.313 . . . . 2.49 111.155 -179.683 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.482 ' OD1' ' HB3' ' A' ' 68' ' ' ASP . 18.2 p-10 -79.56 63.29 4.11 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.736 0.779 . . . . 2.27 110.21 178.446 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.9 m -97.41 162.48 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.709 0 CA-C-N 115.372 -0.831 . . . . 1.1 111.29 -176.108 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.566 ' H ' HG12 ' A' ' 75' ' ' ILE . 87.9 p -85.14 -2.51 58.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.692 -0.685 . . . . 1.41 111.105 -177.554 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 123.42 -32.67 4.24 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.799 -0.715 . . . . 0.48 112.13 -179.108 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 7.6 m -130.86 -11.88 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.399 -0.52 . . . . 0.49 111.859 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.566 HG12 ' H ' ' A' ' 72' ' ' SER . 29.1 pt -87.69 178.88 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 C-N-CA 119.879 -0.729 . . . . 0.3 110.976 177.146 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.746 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -148.0 137.94 22.61 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 114.685 -1.143 . . . . 0.18 108.826 176.568 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 61.7 mt -120.05 130.74 73.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 120.874 0.368 . . . . 0.26 111.322 -175.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.498 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 77.58 50.52 6.52 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 121.139 -0.553 . . . . 0.17 112.042 178.528 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 65' ' ' CYS . 1.3 m -99.41 136.07 39.89 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 112.446 0.535 . . . . 0.65 112.446 -175.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 97.4 mt -106.62 129.47 24.39 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 115.562 -0.745 . . . . 0.29 109.478 169.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 15.3 Cg_exo -67.63 124.89 12.51 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 123.092 2.528 . . . . 0.25 112.567 -177.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.8 m -126.68 159.91 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 116.128 -0.487 . . . . 0.42 110.273 179.696 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.419 HG22 ' HG ' ' A' ' 84' ' ' LEU . 22.6 m -124.3 134.47 53.19 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.365 -0.38 . . . . 2.07 110.333 177.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.419 ' HG ' HG22 ' A' ' 83' ' ' THR . 95.6 mt . . . . . 0 C--O 1.248 0.982 0 CA-C-O 118.068 -0.968 . . . . 3.91 111.552 -179.547 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.655 0 N-CA-C 111.735 -0.546 . . . . 5.63 111.735 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.402 ' O ' ' HA ' ' A' ' 51' ' ' THR . 15.6 m -127.51 123.98 37.2 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.989 -0.375 . . . . 4.28 109.989 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -128.87 8.11 5.68 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.043 0.449 . . . . 4.74 110.902 177.276 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.15 58.5 2.08 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 120.946 -0.645 . . . . 2.03 113.107 177.395 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -78.98 110.97 14.71 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.829 -0.434 . . . . 4.17 109.829 175.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.466 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 44.4 t -128.22 -64.48 0.95 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.131 -0.486 . . . . 1.88 110.137 -179.224 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.7 p -172.74 -85.49 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.734 -0.666 . . . . 2.4 110.464 178.705 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.2 p -121.31 20.54 11.28 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.348 -0.387 . . . . 3.75 111.254 -179.77 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -139.08 -131.91 2.89 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.345 -0.931 . . . . 1.12 112.858 -176.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 33.9 t -145.86 152.21 39.11 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.492 -0.558 . . . . 0.96 109.492 -178.055 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.466 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 22.6 mt -105.63 131.47 54.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.682 0.753 . . . . 0.96 111.0 175.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.539 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -141.53 163.14 33.74 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.736 -1.12 . . . . 0.91 110.941 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.535 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 47.3 t -107.61 101.66 10.97 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.305 -0.861 . . . . 0.34 109.523 178.477 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.821 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 60.2 m -85.68 129.78 34.73 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.177 0.513 . . . . 0.19 111.281 -175.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.413 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -75.28 -30.17 60.33 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 115.17 -0.923 . . . . 0.38 109.644 177.311 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.416 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 4.8 t-20 -135.43 110.11 8.63 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.832 -0.622 . . . . 1.03 110.091 178.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.7 t -105.85 104.55 17.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.998 0.428 . . . . 0.18 109.887 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.0 m -135.86 146.31 56.45 Favored Pre-proline 0 C--N 1.322 -0.623 0 CA-C-N 115.984 -0.553 . . . . 0.18 111.191 -173.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.478 ' O ' ' HB3' ' A' ' 22' ' ' SER . 26.6 Cg_exo -62.18 137.98 69.48 Favored 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.16 1.907 . . . . 0.19 110.996 170.601 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.26 -30.16 76.68 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.002 -0.618 . . . . 0.18 112.547 -178.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -96.66 10.45 38.57 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.089 0.471 . . . . 2.27 110.272 177.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.478 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.9 t -77.59 154.85 31.93 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.502 -0.555 . . . . 0.24 109.502 174.436 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -49.69 -46.08 49.59 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.534 -0.543 . . . . 1.06 109.534 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.694 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.0 OUTLIER -64.07 -64.47 0.88 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 114.934 -1.03 . . . . 1.11 110.921 178.821 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.91 -37.65 62.92 Favored Glycine 0 C--N 1.331 0.298 0 CA-C-N 115.972 -0.558 . . . . 0.16 113.317 -175.135 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.1 m -69.54 -39.9 77.19 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.888 0.375 . . . . 0.24 110.666 -177.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.42 HD22 ' HA ' ' A' ' 27' ' ' LEU . 1.2 tm? -66.05 -39.76 90.39 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.024 -0.732 . . . . 1.01 109.024 177.04 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.694 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 18.9 mt -64.6 -53.41 48.12 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 114.848 -1.069 . . . . 0.37 110.914 -177.188 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.555 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -71.65 -22.88 61.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.445 -0.343 . . . . 0.41 111.307 -175.455 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.474 ' N ' HD12 ' A' ' 29' ' ' LEU . 20.6 t70 -63.59 -38.19 90.17 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.507 0.67 . . . . 0.66 109.915 174.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -76.34 -29.76 57.36 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.128 -0.942 . . . . 2.07 109.64 -178.659 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.5 mt -85.62 -12.01 52.5 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 114.779 -1.1 . . . . 0.71 111.451 -177.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.25 32.38 52.21 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.929 -0.578 . . . . 0.75 112.747 177.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.555 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 11.9 mt -94.11 141.59 14.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.664 0.269 . . . . 0.68 110.498 -177.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.9 p -128.11 102.85 9.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 121.497 0.665 . . . . 1.87 110.078 174.232 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 14.0 mt -94.58 145.6 24.7 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.898 -0.592 . . . . 2.76 110.557 -178.454 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -76.38 -27.88 56.53 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.924 -0.58 . . . . 2.65 109.892 178.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -139.31 92.52 10.52 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 115.621 -0.718 . . . . 2.29 109.251 174.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.44 6.61 1.82 Allowed 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.492 2.128 . . . . 0.64 111.749 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.5 p -75.01 -7.26 53.16 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.668 -0.696 . . . . 0.51 111.188 -179.084 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.4 m -83.02 163.04 3.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.858 -0.61 . . . . 0.24 110.711 178.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.449 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.3 mt -87.56 123.05 32.03 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.994 -0.548 . . . . 0.22 110.469 178.287 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.7 pt -105.33 138.26 31.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 116.073 -0.512 . . . . 0.15 110.092 175.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.821 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -116.64 102.71 1.06 Allowed Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.654 -0.784 . . . . 0.31 112.918 -175.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -81.06 143.59 32.36 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.397 -0.594 . . . . 0.57 109.397 177.019 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.405 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 72.28 38.8 58.51 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 119.958 -1.115 . . . . 0.21 111.752 -179.34 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.535 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -103.94 116.57 32.49 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.969 0.414 . . . . 0.25 110.999 -173.273 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.462 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 2.5 p-10 -101.35 131.41 23.12 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 115.969 -0.56 . . . . 2.21 110.16 177.336 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -58.87 119.44 6.7 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.31 2.007 . . . . 0.44 110.642 175.075 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 14.4 mt -78.4 89.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.597 0.713 . . . . 0.46 110.131 -175.114 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.402 ' HA ' ' O ' ' A' ' 2' ' ' SER . 10.6 t -119.1 16.88 13.28 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.958 -1.019 . . . . 0.88 110.475 -177.061 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.3 p -85.83 137.82 20.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.483 -0.781 . . . . 1.44 110.584 179.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -111.52 142.82 43.3 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.434 -0.348 . . . . 2.94 110.647 179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 69.51 54.75 11.62 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 121.14 -0.553 . . . . 3.5 112.331 178.796 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 10.5 t -158.09 118.47 3.36 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 110.225 -0.287 . . . . 4.9 110.225 -178.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 6.2 p -73.68 -32.84 64.16 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.29 0.567 . . . . 4.06 109.614 176.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -83.26 54.39 2.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.91 0.862 . . . . 3.13 109.049 172.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -75.91 -10.84 59.76 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.335 -0.848 . . . . 0.99 109.937 177.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.5 t -157.55 118.47 3.55 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.895 -1.048 . . . . 0.74 109.861 177.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 19.9 m -92.6 -24.05 18.83 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.479 -0.328 . . . . 2.14 111.377 -179.224 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.413 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -97.72 -86.42 0.34 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.841 -0.344 . . . . 0.54 111.675 -177.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 33.4 m -148.46 126.65 12.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.762 0.315 . . . . 0.29 110.83 -178.256 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.73 132.39 33.87 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.877 0.37 . . . . 0.25 110.14 -178.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.664 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.7 m -142.77 172.17 8.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-O 121.352 0.596 . . . . 0.21 111.521 -176.092 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 38.1 t -133.26 104.69 6.59 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.023 -0.99 . . . . 0.39 109.645 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.766 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.4 m -92.56 130.4 38.22 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.667 0.746 . . . . 0.65 111.828 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 55.0 m -76.93 -32.4 57.33 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.613 -1.176 . . . . 1.15 110.948 178.699 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -109.64 138.57 45.81 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.659 -0.701 . . . . 1.6 109.855 -179.034 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -120.85 23.76 10.55 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.813 0.339 . . . . 2.49 111.453 -174.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 25.3 p-10 -81.31 56.89 3.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.858 0.837 . . . . 2.27 109.813 176.122 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 18.1 m -83.01 158.55 3.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 114.967 -1.015 . . . . 1.1 112.197 -171.14 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.521 ' H ' HG12 ' A' ' 75' ' ' ILE . 95.1 p -82.75 -3.04 56.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.27 -0.877 . . . . 1.41 111.05 -178.2 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.84 -32.2 3.71 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 121.04 -0.6 . . . . 0.48 112.465 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.3 m -136.15 -7.56 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 C-N-CA 120.5 -0.48 . . . . 0.49 111.899 179.169 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.521 HG12 ' H ' ' A' ' 72' ' ' SER . 32.2 pt -92.0 -177.45 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 C-N-CA 120.006 -0.678 . . . . 0.3 111.369 178.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.766 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.38 140.37 21.98 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 114.791 -1.095 . . . . 0.18 109.161 177.295 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 68.4 mt -122.02 123.94 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 121.071 0.462 . . . . 0.26 111.657 -175.508 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 81.95 51.85 4.32 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.904 -0.665 . . . . 0.17 111.596 179.361 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.449 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.23 136.43 39.2 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.244 0.545 . . . . 0.65 112.187 -175.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.446 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 92.1 mt -110.66 131.28 22.17 Favored Pre-proline 0 C--N 1.321 -0.65 0 CA-C-N 115.54 -0.754 . . . . 0.29 109.703 171.653 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 22.6 Cg_exo -64.93 131.87 30.38 Favored 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 123.137 2.558 . . . . 0.25 112.868 -177.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.4 m -133.71 159.51 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 CA-C-N 115.75 -0.659 . . . . 0.42 109.58 177.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 6.9 m -95.6 112.55 24.25 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 121.13 -0.228 . . . . 2.07 111.171 -179.023 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 10.0 mp . . . . . 0 C--O 1.251 1.168 0 O-C-N 124.549 1.156 . . . . 3.91 112.773 174.246 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.804 0 N-CA-C 112.5 -0.24 . . . . 5.63 112.5 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.6 m -80.16 77.54 6.88 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.04 0.448 . . . . 4.28 111.274 -177.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 97.6 m95 -132.12 27.27 4.52 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.915 -0.584 . . . . 4.74 110.065 177.336 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 75.17 17.64 80.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.803 -0.713 . . . . 2.03 112.387 -178.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 76.4 mm-40 -84.31 109.57 17.91 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.105 0.479 . . . . 4.17 111.198 -178.196 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.497 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 44.2 t -143.91 142.93 31.04 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.59 -0.732 . . . . 1.88 109.866 179.632 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 12.1 p -72.14 -17.89 61.93 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.0 -0.545 . . . . 2.4 111.785 -175.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.6 p -108.47 9.61 27.5 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.709 0.29 . . . . 3.75 111.713 179.154 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 142.86 -127.58 3.18 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.286 -0.959 . . . . 1.12 113.211 177.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.7 t -113.85 153.62 28.86 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.656 -0.498 . . . . 0.96 109.656 -175.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.497 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 22.8 mt -104.43 133.61 48.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.664 0.745 . . . . 0.96 111.619 178.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.452 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -144.28 163.03 34.89 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 114.524 -1.216 . . . . 0.91 110.121 178.165 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.489 ' HB2' HD11 ' A' ' 50' ' ' ILE . 34.6 t -114.92 109.36 18.02 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.076 -0.713 . . . . 0.34 109.076 176.547 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.796 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 96.8 m -88.96 134.93 33.8 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.392 -0.822 . . . . 0.19 111.35 -173.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.443 ' HB3' ' O ' ' A' ' 46' ' ' GLY . 0.0 OUTLIER -75.39 -28.25 59.39 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.158 -0.928 . . . . 0.38 109.775 178.461 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -141.77 103.52 4.37 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.147 -0.479 . . . . 1.03 110.73 177.555 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 98.6 t -93.85 105.93 17.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 116.178 -0.465 . . . . 0.18 109.787 177.235 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -131.41 142.42 45.33 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.149 -0.478 . . . . 0.18 111.067 -176.144 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.563 ' O ' ' HB3' ' A' ' 22' ' ' SER . 31.4 Cg_exo -58.92 139.21 89.84 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.382 2.054 . . . . 0.19 111.392 172.167 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.37 -20.01 71.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.824 -0.703 . . . . 0.18 112.317 -179.187 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 17.2 p-10 -101.87 7.4 41.61 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.311 0.577 . . . . 2.27 109.962 176.316 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.563 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 13.5 t -74.12 154.27 39.21 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.554 -0.748 . . . . 0.24 109.78 174.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -56.28 -39.88 73.37 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.955 0.407 . . . . 1.06 110.08 177.17 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.656 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER -70.45 -60.19 2.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.545 -0.752 . . . . 1.11 110.431 175.825 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.491 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.43 -41.5 80.71 Favored Glycine 0 C--N 1.331 0.252 0 CA-C-N 115.922 -0.581 . . . . 0.16 113.33 -175.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.4 m -66.05 -41.73 90.43 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.748 0.308 . . . . 0.24 110.37 -178.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.407 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.8 tm? -64.76 -37.58 88.08 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 109.561 -0.533 . . . . 1.01 109.561 177.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.656 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 15.4 mt -66.16 -49.65 66.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.924 -0.58 . . . . 0.37 110.637 -177.596 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.563 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.0 pp -76.32 -21.76 55.79 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.481 -0.327 . . . . 0.41 111.172 -177.377 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.499 ' N ' HD12 ' A' ' 29' ' ' LEU . 29.8 t70 -66.51 -33.36 75.52 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.723 0.773 . . . . 0.66 109.64 175.007 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -76.21 -25.07 54.73 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.586 -1.188 . . . . 2.07 109.361 179.092 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 94.6 mt -94.46 -17.19 22.7 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.814 -1.084 . . . . 0.71 111.811 -175.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 80.44 35.69 25.47 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.155 -0.545 . . . . 0.75 112.582 178.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.563 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 22.7 mt -98.52 130.83 46.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.684 0.278 . . . . 0.68 110.713 -177.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.6 p -118.72 100.05 9.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.917 0.865 . . . . 1.87 110.569 176.29 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 23.0 mt -82.57 143.44 31.03 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.469 -0.787 . . . . 2.76 111.558 -176.593 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -71.02 -38.47 72.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.225 -0.898 . . . . 2.65 109.254 174.157 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -125.15 91.63 48.83 Favored Pre-proline 0 N--CA 1.447 -0.583 0 CA-C-N 115.069 -0.969 . . . . 2.29 108.438 174.017 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.02 4.12 1.66 Allowed 'Trans proline' 0 C--O 1.225 -0.147 0 C-N-CA 122.54 2.16 . . . . 0.64 111.971 -178.076 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 18.3 p -82.79 -10.9 58.66 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.931 -0.577 . . . . 0.51 111.1 -177.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.9 m -71.24 160.56 5.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.926 -0.579 . . . . 0.24 111.331 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 97.4 mt -91.17 127.42 36.59 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.855 -0.611 . . . . 0.22 110.505 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.472 HD13 HD23 ' A' ' 29' ' ' LEU . 13.8 pt -107.41 136.85 41.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.098 0.475 . . . . 0.15 110.335 176.372 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.796 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -110.2 98.82 1.12 Allowed Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 120.815 -0.707 . . . . 0.31 113.199 -175.156 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -79.63 141.68 36.28 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.439 -0.578 . . . . 0.57 109.439 177.421 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.443 ' O ' ' HB3' ' A' ' 15' ' ' GLN . . . 71.99 41.41 54.88 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.151 -1.023 . . . . 0.21 112.161 -179.347 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.551 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.74 117.94 35.34 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.196 0.522 . . . . 0.25 111.614 -172.533 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.488 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 1.6 t70 -101.91 136.03 19.59 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 115.401 -0.818 . . . . 2.21 110.35 174.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.488 ' HD2' ' OD1' ' A' ' 48' ' ' ASP . 1.3 Cg_endo -67.6 120.94 7.98 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.046 2.497 . . . . 0.44 111.868 -177.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.489 HD11 ' HB2' ' A' ' 13' ' ' CYS . 17.7 mt -80.02 92.64 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.277 0.56 . . . . 0.46 109.962 -177.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.6 t -133.66 21.06 3.9 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.556 -0.747 . . . . 0.88 111.026 -176.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.8 p -97.99 128.48 49.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.249 0.547 . . . . 1.44 110.427 176.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -95.83 157.29 15.96 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.854 -0.612 . . . . 2.94 110.341 179.107 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 81.05 -56.84 4.85 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.849 -0.691 . . . . 3.5 112.033 -178.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.9 m -67.9 103.45 1.47 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.956 0.408 . . . . 4.9 110.525 178.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 7.6 m -75.53 -23.61 56.69 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.009 -0.542 . . . . 4.06 110.535 -178.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -82.42 50.96 1.73 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.893 -0.594 . . . . 3.13 109.998 179.131 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.416 ' HB1' HG23 ' A' ' 50' ' ' ILE . . . -93.8 17.7 11.58 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.785 -0.643 . . . . 0.99 112.61 -172.186 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 42.6 t -149.38 116.68 6.09 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.825 -0.35 . . . . 0.74 110.887 178.497 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 20.2 m -90.48 -15.53 30.63 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 112.133 0.42 . . . . 2.14 112.133 -176.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 14' ' ' CYS . . . -133.14 -83.25 0.47 Allowed 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.349 -0.54 . . . . 0.54 112.254 -177.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 23.0 m -138.5 129.57 26.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.787 0.327 . . . . 0.29 111.608 -175.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.24 129.28 34.9 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-O 120.981 0.42 . . . . 0.25 110.319 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.556 HG21 ' SG ' ' A' ' 14' ' ' CYS . 6.4 m -141.64 157.87 21.28 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 121.446 0.641 . . . . 0.21 111.236 -177.249 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . . . . . . . . . 35.3 t -116.18 111.2 19.87 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.206 -0.906 . . . . 0.39 108.722 173.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.654 ' HA ' ' HA ' ' A' ' 79' ' ' CYS . 0.5 OUTLIER -103.71 135.91 44.4 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.744 0.783 . . . . 0.65 111.91 -173.043 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 32.2 t -81.53 -35.22 30.58 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 114.55 -1.205 . . . . 1.15 111.309 -174.501 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -91.95 131.62 37.12 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.01 0.433 . . . . 1.6 110.419 -179.701 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.429 HD22 ' N ' ' A' ' 69' ' ' ASN . 0.9 OUTLIER -106.11 11.11 31.77 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.94 -0.573 . . . . 2.49 111.034 -177.749 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -95.28 72.57 3.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.468 0.651 . . . . 2.27 109.786 -178.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 35.2 m -74.97 153.06 6.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.35 -0.841 . . . . 1.1 111.606 -176.429 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -90.72 8.25 35.46 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.807 -0.633 . . . . 1.41 110.148 179.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 126.98 -34.08 3.2 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.63 -0.714 . . . . 0.48 112.83 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 m -140.99 -17.05 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 117.218 0.509 . . . . 0.49 111.958 176.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 18.3 pt -81.95 -175.41 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.478 0.656 . . . . 0.3 112.298 -176.28 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -151.05 141.73 22.71 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.236 -1.347 . . . . 0.18 107.874 173.548 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.2 mt -119.05 123.54 71.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 118.32 0.509 . . . . 0.26 112.226 -174.272 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.85 53.29 4.62 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.926 -0.654 . . . . 0.17 111.547 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.654 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 3.8 m -99.94 143.34 30.27 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.153 0.501 . . . . 0.65 111.305 -176.804 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 80.3 mt -109.25 131.76 21.65 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 115.484 -0.78 . . . . 0.29 110.372 175.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.434 ' HA ' HG12 ' A' ' 64' ' ' VAL . 15.9 Cg_exo -67.41 121.99 9.17 Favored 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.891 2.394 . . . . 0.25 111.902 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.8 m -115.21 141.68 31.14 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-O 121.674 0.75 . . . . 0.42 111.167 -178.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 15.3 t -148.46 30.22 0.84 Allowed 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 123.563 1.649 . . . . 2.07 108.892 -178.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 69.6 mt . . . . . 0 C--N 1.296 -1.757 0 CA-C-N 111.88 -2.418 . . . . 3.91 110.007 -175.028 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.811 0 N-CA-C 111.757 -0.537 . . . . 5.63 111.757 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.1 t -126.97 126.65 43.55 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.964 -0.384 . . . . 4.28 109.964 -179.277 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 11.7 m-90 -103.26 -3.51 25.58 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.408 0.623 . . . . 4.74 109.992 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 146.53 176.78 20.63 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.624 -0.99 . . . . 2.03 110.624 -176.165 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 12.3 mm100 -81.98 107.58 14.8 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 117.163 0.482 . . . . 4.17 110.486 -178.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 42.5 t 174.21 158.2 0.15 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.42 -0.809 . . . . 1.88 109.434 -178.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 9.5 p -132.59 16.69 4.37 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.95 0.405 . . . . 2.4 111.258 178.323 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.42 HG22 ' HB2' ' A' ' 67' ' ' SER . 30.8 m -87.43 -23.28 24.55 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.269 -0.423 . . . . 3.75 111.49 -175.554 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 169.07 -103.87 0.2 Allowed Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.438 -0.887 . . . . 1.12 112.306 -178.674 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.6 t -124.59 144.86 49.92 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 108.852 -0.796 . . . . 0.96 108.852 178.374 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.531 HD12 ' N ' ' A' ' 11' ' ' ILE . 4.1 mp -98.47 141.96 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 121.652 0.739 . . . . 0.96 111.509 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.596 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -145.75 166.39 26.01 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 114.793 -1.094 . . . . 0.91 110.723 178.75 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.407 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 37.1 t -114.83 104.93 12.43 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.613 -0.721 . . . . 0.34 109.552 179.286 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.782 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 63.4 m -87.69 133.06 33.9 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.519 -0.764 . . . . 0.19 111.199 -175.505 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.406 ' HB2' HE21 ' A' ' 15' ' ' GLN . 0.0 OUTLIER -71.27 -27.31 63.35 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 115.251 -0.886 . . . . 0.38 108.939 173.529 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.8 t-20 -145.63 128.39 16.27 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.64 -0.709 . . . . 1.03 110.135 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.6 t -115.73 106.09 19.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.906 0.384 . . . . 0.18 110.27 177.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.9 m -131.91 143.35 48.67 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.026 -0.534 . . . . 0.18 110.922 -175.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.489 ' O ' ' HB3' ' A' ' 22' ' ' SER . 26.6 Cg_exo -62.8 139.85 76.89 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.225 1.95 . . . . 0.19 111.339 172.258 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.9 -22.57 70.43 Favored Glycine 0 C--N 1.329 0.159 0 C-N-CA 120.967 -0.635 . . . . 0.18 112.62 -177.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -100.39 5.83 44.39 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.636 0.732 . . . . 2.27 109.793 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 27.6 t -75.13 155.11 37.39 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.656 -0.702 . . . . 0.24 110.272 177.114 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -54.51 -41.31 69.49 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.185 0.517 . . . . 1.06 110.116 177.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.682 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.7 mm? -73.34 -57.75 3.79 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.692 -0.685 . . . . 1.11 110.66 177.427 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -54.52 -40.06 68.33 Favored Glycine 0 C--N 1.33 0.205 0 C-N-CA 121.249 -0.5 . . . . 0.16 113.095 -176.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 90.7 m -69.81 -40.75 75.74 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.7 0.286 . . . . 0.24 110.311 -178.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.448 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.6 tm? -66.85 -36.85 83.27 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.539 -0.541 . . . . 1.01 109.539 177.059 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.682 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 12.5 mt -68.21 -47.32 68.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.89 -0.595 . . . . 0.37 110.801 -177.13 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.568 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.5 pp -74.11 -23.67 59.34 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.808 -0.357 . . . . 0.41 110.676 -179.063 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.404 ' N ' HD12 ' A' ' 29' ' ' LEU . 25.7 t70 -61.68 -36.61 81.35 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.474 0.654 . . . . 0.66 109.762 173.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -73.95 -29.63 62.11 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-N 114.983 -1.008 . . . . 2.07 110.03 179.418 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 90.9 mt -93.13 -16.53 24.81 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.832 -1.076 . . . . 0.71 112.157 -172.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.76 35.8 34.74 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 121.263 -0.494 . . . . 0.75 112.624 178.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.568 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 18.4 mt -94.25 139.8 17.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.702 0.287 . . . . 0.68 110.63 -177.145 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.9 t -122.16 98.17 5.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 109.83 -0.433 . . . . 1.87 109.83 176.287 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 22.7 mt -83.13 135.56 34.77 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.17 -0.468 . . . . 2.76 111.251 -177.141 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 -73.36 -24.18 60.3 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.717 -0.674 . . . . 2.65 109.907 174.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -136.77 89.57 17.52 Favored Pre-proline 0 N--CA 1.446 -0.659 0 N-CA-C 108.026 -1.102 . . . . 2.29 108.026 178.285 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.29 -1.04 9.03 Favored 'Trans proline' 0 CA--C 1.519 -0.27 0 C-N-CA 122.193 1.929 . . . . 0.64 112.096 -177.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.7 p -93.36 20.57 6.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.407 0.622 . . . . 0.51 111.246 -177.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.427 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 32.0 m -101.75 162.72 3.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.551 -0.75 . . . . 0.24 110.064 174.176 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.442 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.7 mt -86.62 121.47 29.19 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.142 -0.481 . . . . 0.22 109.969 176.413 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 17.5 pt -104.15 137.69 31.93 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 CA-C-O 121.208 0.528 . . . . 0.15 110.132 176.301 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.782 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -107.42 110.05 3.13 Favored Glycine 0 N--CA 1.44 -1.059 0 C-N-CA 120.605 -0.807 . . . . 0.31 112.82 -176.608 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -86.05 132.73 33.99 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.032 -0.729 . . . . 0.57 109.032 175.278 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.43 37.69 26.93 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.001 -1.095 . . . . 0.21 111.734 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.557 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -104.23 116.42 32.14 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.139 0.495 . . . . 0.25 111.368 -173.373 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.432 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 6.6 m-20 -100.35 131.9 23.31 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.405 -0.816 . . . . 2.21 109.158 175.099 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.467 ' HA ' ' HB3' ' A' ' 12' ' ' GLN . 12.4 Cg_exo -63.87 123.28 11.71 Favored 'Trans proline' 0 N--CA 1.461 -0.408 0 C-N-CA 122.742 2.294 . . . . 0.44 110.965 178.39 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.455 HG13 ' HA ' ' A' ' 12' ' ' GLN . 24.8 mt -80.67 89.29 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.498 0.666 . . . . 0.46 110.417 -175.622 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.8 t -126.45 14.02 7.64 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.666 0.746 . . . . 0.88 109.768 177.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 13.0 p -82.01 147.15 6.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.095 -0.957 . . . . 1.44 109.786 178.051 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -80.68 59.94 3.81 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.327 0.584 . . . . 2.94 110.746 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -123.65 112.6 1.9 Allowed Glycine 0 N--CA 1.445 -0.744 0 CA-C-N 115.648 -0.705 . . . . 3.5 111.662 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 32.4 m -90.08 -29.54 18.29 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 120.902 0.382 . . . . 4.9 110.758 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 28.0 m -90.24 -24.69 20.89 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.912 0.387 . . . . 4.06 110.588 177.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -134.41 80.22 1.84 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.832 -0.622 . . . . 3.13 109.861 -177.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -101.24 -30.18 11.67 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.735 -0.666 . . . . 0.99 111.032 178.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.0 t -147.67 142.47 26.78 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.413 -0.812 . . . . 0.74 110.837 -178.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.6 p -102.71 -40.78 6.45 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.98 -0.554 . . . . 2.14 111.604 -179.333 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.401 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -101.14 -85.99 0.41 Allowed 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 121.051 -0.26 . . . . 0.54 111.567 -176.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 26.9 m -132.47 129.18 38.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.666 0.269 . . . . 0.29 111.302 -177.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -86.63 130.57 34.43 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.911 0.386 . . . . 0.25 110.142 179.249 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.675 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.7 m -143.06 169.82 11.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.259 0.552 . . . . 0.21 111.415 -176.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . 0.43 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 38.0 t -137.29 107.67 6.47 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.478 -0.783 . . . . 0.39 109.862 -178.669 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.765 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.8 m -93.48 137.63 32.57 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.442 0.639 . . . . 0.65 111.735 -177.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.42 ' HB2' HG22 ' A' ' 8' ' ' THR . 38.2 t -87.24 -20.09 27.41 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.128 -0.942 . . . . 1.15 110.955 179.45 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.4 t70 -98.92 160.41 14.28 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.161 -0.472 . . . . 1.6 109.993 -177.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -118.67 5.72 11.59 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 111.928 0.344 . . . . 2.49 111.928 -173.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -84.7 89.63 7.54 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.014 0.435 . . . . 2.27 110.764 -179.019 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.9 m -100.06 130.93 48.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.03 0.443 . . . . 1.1 111.327 179.275 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.501 ' H ' HG12 ' A' ' 75' ' ' ILE . 9.2 t -80.5 -1.47 41.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.046 -0.524 . . . . 1.41 110.484 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.2 -33.89 3.21 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.833 -0.621 . . . . 0.48 112.585 178.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 12.7 m -140.72 4.58 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 117.202 0.501 . . . . 0.49 111.788 175.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.501 HG12 ' H ' ' A' ' 72' ' ' SER . 19.2 pt -100.2 176.63 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.466 0.651 . . . . 0.3 112.039 179.726 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.765 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -145.93 140.57 27.04 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 114.291 -1.322 . . . . 0.18 109.411 174.722 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 71.0 mt -120.84 127.22 75.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.894 0.378 . . . . 0.26 111.461 -177.377 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.541 ' O ' ' HA ' ' A' ' 66' ' ' CYS . . . 81.77 48.92 5.61 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 121.026 -0.607 . . . . 0.17 112.064 177.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.442 ' O ' ' HB2' ' A' ' 42' ' ' LEU . 1.3 m -99.3 140.42 33.5 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 112.665 0.617 . . . . 0.65 112.665 -175.36 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 93.9 mt -111.34 132.75 21.63 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.43 -0.805 . . . . 0.29 109.603 170.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 80' ' ' LEU . 16.9 Cg_exo -66.6 121.75 9.04 Favored 'Trans proline' 0 C--O 1.232 0.217 0 C-N-CA 122.974 2.449 . . . . 0.25 112.638 -178.835 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.412 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 6.2 m -124.22 161.23 27.48 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.671 0 CA-C-N 115.917 -0.583 . . . . 0.42 110.042 -179.607 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.418 HG22 ' HG ' ' A' ' 84' ' ' LEU . 28.8 m -144.98 133.7 22.23 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 116.656 -0.247 . . . . 2.07 110.761 176.828 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.418 ' HG ' HG22 ' A' ' 83' ' ' THR . 89.0 mt . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.365 -0.826 . . . . 3.91 111.963 178.632 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.753 0 N-CA-C 112.061 -0.416 . . . . 5.63 112.061 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.4 m -88.56 46.95 1.44 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.805 0.336 . . . . 4.28 111.574 -177.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 28.5 m-90 -117.55 125.31 50.6 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.797 0.332 . . . . 4.74 110.281 176.002 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -89.58 65.01 3.1 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 121.022 -0.608 . . . . 2.03 111.804 178.502 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -87.83 133.99 33.78 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.013 0.435 . . . . 4.17 110.437 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.474 ' HB2' ' CG1' ' A' ' 11' ' ' ILE . 21.9 t -134.47 143.99 47.83 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.692 -0.686 . . . . 1.88 109.954 -177.209 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 11.9 p -74.04 -10.46 59.65 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.255 -0.43 . . . . 2.4 111.551 -177.009 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.6 ' HB ' ' SG ' ' A' ' 65' ' ' CYS . 5.5 m -103.19 -8.83 20.11 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.185 0.517 . . . . 3.75 110.367 177.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 152.93 -126.19 1.94 Allowed Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.559 -0.829 . . . . 1.12 112.651 -179.416 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 41.1 t -107.63 151.25 25.89 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 110.299 -0.26 . . . . 0.96 110.299 -177.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.474 ' CG1' ' HB2' ' A' ' 6' ' ' CYS . 41.3 mt -102.83 137.49 30.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 121.517 0.675 . . . . 0.96 110.709 173.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.528 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -144.08 159.34 42.78 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 115.01 -0.995 . . . . 0.91 110.531 179.007 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 41.7 t -105.5 102.58 12.04 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.794 -0.639 . . . . 0.34 109.686 178.598 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.814 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 81.9 m -85.77 135.43 33.74 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.489 -0.778 . . . . 0.19 110.817 -176.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.431 HE21 ' HB2' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -75.74 -31.04 59.41 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 115.408 -0.815 . . . . 0.38 109.298 174.708 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -138.12 118.29 13.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.81 -0.632 . . . . 1.03 110.245 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 65.3 t -110.69 103.04 14.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 121.042 0.448 . . . . 0.18 110.094 178.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.0 m -133.31 142.67 45.11 Favored Pre-proline 0 C--N 1.32 -0.688 0 CA-C-N 115.83 -0.623 . . . . 0.18 110.993 -174.392 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.481 ' O ' ' HB3' ' A' ' 22' ' ' SER . 38.3 Cg_exo -60.17 139.9 89.55 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.161 1.907 . . . . 0.19 111.407 172.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.23 -21.78 70.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.814 -0.708 . . . . 0.18 112.342 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -94.22 -4.97 48.0 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.211 0.529 . . . . 2.27 110.524 175.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.481 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 30.0 t -68.79 154.5 41.88 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.813 -0.63 . . . . 0.24 110.54 179.041 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -52.42 -44.27 65.33 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.332 0.587 . . . . 1.06 110.1 178.067 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.663 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 1.2 mm? -70.6 -58.05 4.09 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.503 -0.771 . . . . 1.11 110.847 178.197 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.461 ' HA3' ' O ' ' A' ' 19' ' ' PRO . . . -55.56 -39.41 74.66 Favored Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.227 -0.511 . . . . 0.16 113.307 -176.452 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 87.1 m -67.84 -42.1 81.95 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 120.827 0.346 . . . . 0.24 110.325 -179.015 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -61.89 -43.1 99.53 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.216 -0.661 . . . . 1.01 109.216 175.222 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.663 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 14.7 mt -61.46 -51.55 68.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.135 -0.939 . . . . 0.37 111.125 -175.633 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.543 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -76.37 -23.89 54.14 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.723 -0.391 . . . . 0.41 111.677 -175.322 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.508 ' N ' HD12 ' A' ' 29' ' ' LEU . 11.8 t70 -68.11 -33.49 74.61 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.512 0.672 . . . . 0.66 109.363 176.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -78.33 -23.83 46.85 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.287 -0.869 . . . . 2.07 109.962 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.7 mt -97.34 -5.24 36.95 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.193 -0.912 . . . . 0.71 111.878 -174.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 68.31 44.48 74.59 Favored Glycine 0 N--CA 1.453 -0.229 0 CA-C-N 115.74 -0.663 . . . . 0.75 112.896 177.348 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.543 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 23.3 mt -97.57 145.53 9.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.673 0.273 . . . . 0.68 110.637 -178.43 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.8 t -107.88 116.27 50.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 116.127 -0.488 . . . . 1.87 109.695 176.06 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.555 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.5 pp -90.81 129.95 36.83 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.25 0.547 . . . . 2.76 111.25 -179.241 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -90.96 -26.79 19.08 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.917 -0.771 . . . . 2.65 108.917 170.289 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -139.42 94.92 9.3 Favored Pre-proline 0 N--CA 1.447 -0.613 0 CA-C-N 114.92 -1.037 . . . . 2.29 108.495 177.369 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -68.43 -3.93 11.94 Favored 'Trans proline' 0 N--CA 1.466 -0.137 0 C-N-CA 122.256 1.971 . . . . 0.64 111.564 -177.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.8 p -87.89 6.2 36.73 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.337 -0.847 . . . . 0.51 111.45 -175.497 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.428 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 18.9 m -92.73 158.26 2.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.209 0.528 . . . . 0.24 110.875 179.407 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.9 mt -88.21 128.62 35.46 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.476 -0.784 . . . . 0.22 109.806 175.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.431 HD13 HD23 ' A' ' 29' ' ' LEU . 10.2 pt -106.83 133.07 52.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.203 0.525 . . . . 0.15 110.091 176.118 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.814 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.78 98.16 1.3 Allowed Glycine 0 N--CA 1.438 -1.19 0 CA-C-N 115.385 -0.825 . . . . 0.31 113.02 -175.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -77.4 137.84 38.94 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.583 -0.525 . . . . 0.57 109.583 177.286 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.482 ' H ' HG23 ' A' ' 74' ' ' VAL . . . 71.48 41.08 58.82 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.431 -0.89 . . . . 0.21 112.072 -178.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.528 ' SG ' ' HB2' ' A' ' 12' ' ' GLN . 0.1 OUTLIER -105.14 111.28 23.99 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.294 0.569 . . . . 0.25 111.225 -175.312 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.454 ' HA ' ' HD3' ' A' ' 49' ' ' PRO . 2.5 t70 -101.43 138.53 19.93 Favored Pre-proline 0 C--N 1.316 -0.849 0 CA-C-N 115.483 -0.781 . . . . 2.21 110.927 175.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 48' ' ' ASP . 25.7 Cg_exo -58.9 119.3 6.46 Favored 'Trans proline' 0 C--O 1.233 0.273 0 C-N-CA 123.626 2.884 . . . . 0.44 111.628 177.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 29.7 mt -80.48 102.3 6.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.054 0.454 . . . . 0.46 110.501 -177.205 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.9 t -133.68 16.36 3.96 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.521 0.677 . . . . 0.88 110.601 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 5.4 p -128.68 154.24 39.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.637 -0.71 . . . . 1.44 109.853 178.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . 70.39 -63.27 0.41 Allowed 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 123.387 0.675 . . . . 2.94 112.396 175.567 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 174.68 -114.43 0.5 Allowed Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 121.133 -0.556 . . . . 3.5 111.837 -178.505 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 67.8 m -150.83 -37.05 0.14 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.618 0.247 . . . . 4.9 111.186 177.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 31.1 m -81.52 -62.22 1.71 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.884 0.373 . . . . 4.06 110.522 178.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -89.88 41.7 1.06 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 122.102 0.953 . . . . 3.13 109.656 -179.712 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -129.88 17.81 5.66 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.152 -0.931 . . . . 0.99 110.386 -179.396 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 51.8 t -151.34 127.99 10.83 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.77 -0.65 . . . . 0.74 109.786 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 28.5 t -94.4 -37.76 11.29 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.381 -0.372 . . . . 2.14 111.101 -178.205 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -86.59 -86.46 0.15 Allowed 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 121.181 -0.208 . . . . 0.54 111.499 -176.655 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 19.2 m -149.89 130.98 14.41 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.773 0.321 . . . . 0.29 111.145 -178.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.445 ' HB3' ' HB ' ' A' ' 83' ' ' THR . . . -94.95 139.47 31.29 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.852 0.358 . . . . 0.25 110.4 -178.284 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.552 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 7.2 m -145.55 162.97 11.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.315 0.578 . . . . 0.21 111.285 -177.6 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . 0.6 ' SG ' ' HB ' ' A' ' 8' ' ' THR . 30.2 t -115.44 107.8 15.67 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.122 -0.944 . . . . 0.39 109.703 175.678 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.634 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 28.3 m -100.12 140.04 34.93 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.212 0.53 . . . . 0.65 111.441 -176.682 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 40.0 m -97.35 -20.54 17.76 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.633 -0.712 . . . . 1.15 111.241 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -110.43 139.59 45.49 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.997 -0.547 . . . . 1.6 110.372 -176.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -117.14 25.8 10.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.4 -0.364 . . . . 2.49 111.939 -175.033 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 54.8 t30 -80.55 71.61 7.41 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.597 0.713 . . . . 2.27 109.635 176.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.409 HG12 ' O ' ' A' ' 75' ' ' ILE . 32.7 m -84.66 146.57 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 CA-C-N 115.541 -0.754 . . . . 1.1 112.125 -173.549 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.553 ' OG ' HG12 ' A' ' 75' ' ' ILE . 80.2 p -95.4 5.26 52.1 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.387 -0.824 . . . . 1.41 110.222 177.457 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.71 -32.7 3.43 Favored Glycine 0 N--CA 1.445 -0.711 0 CA-C-N 115.361 -0.836 . . . . 0.48 111.88 -176.253 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.482 HG23 ' H ' ' A' ' 46' ' ' GLY . 21.3 m -140.24 -21.42 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 112.558 0.577 . . . . 0.49 112.558 176.162 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.553 HG12 ' OG ' ' A' ' 72' ' ' SER . 7.4 pt -73.21 175.45 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.707 0.765 . . . . 0.3 112.343 -173.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.634 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -150.21 141.39 23.12 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.233 -1.348 . . . . 0.18 108.565 178.312 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.5 mt -120.78 140.27 45.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 C-N-CA 120.514 -0.474 . . . . 0.26 111.484 -175.056 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.428 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 72.06 52.75 10.49 Favored Glycine 0 C--N 1.332 0.352 0 CA-C-N 115.95 -0.568 . . . . 0.17 111.908 178.163 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.552 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 12.2 m -106.58 145.03 32.4 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.04 0.448 . . . . 0.65 111.969 -174.079 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 91.3 mt -115.92 132.2 23.33 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 115.514 -0.766 . . . . 0.29 109.811 173.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.51 ' HA ' HG12 ' A' ' 64' ' ' VAL . 18.3 Cg_exo -64.77 129.06 22.41 Favored 'Trans proline' 0 C--O 1.234 0.297 0 C-N-CA 123.19 2.593 . . . . 0.25 112.982 -176.686 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.403 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 5.4 m -136.7 157.67 36.62 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.596 0 CA-C-N 115.812 -0.631 . . . . 0.42 110.333 178.532 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.471 HG22 ' HG ' ' A' ' 84' ' ' LEU . 85.0 m 65.72 162.79 0.15 Allowed 'General case' 0 CA--C 1.545 0.784 0 O-C-N 123.395 0.434 . . . . 2.07 111.755 176.079 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.471 ' HG ' HG22 ' A' ' 83' ' ' THR . 75.6 mt . . . . . 0 C--O 1.248 1.011 0 CA-C-O 119.017 -0.516 . . . . 3.91 111.16 177.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.7 0 N-CA-C 111.75 -0.54 . . . . 5.63 111.75 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 31.8 t -125.19 140.07 53.19 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.88 0.372 . . . . 4.28 110.427 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 44.0 p90 -138.35 31.63 2.35 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.639 0.733 . . . . 4.74 109.439 178.156 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.434 ' HA3' ' HB ' ' A' ' 11' ' ' ILE . . . 91.52 138.67 8.09 Favored Glycine 0 N--CA 1.444 -0.788 0 CA-C-N 115.045 -0.979 . . . . 2.03 111.553 -176.487 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -85.03 108.78 17.79 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-O 120.868 0.366 . . . . 4.17 110.208 -178.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 46.9 t -151.29 139.84 20.6 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.752 -0.462 . . . . 1.88 109.752 178.537 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 18.1 m -91.32 -17.01 26.6 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.583 -0.28 . . . . 2.4 111.293 -176.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.2 p -100.52 4.87 43.9 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 112.286 0.476 . . . . 3.75 112.286 -177.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 149.19 -157.17 27.14 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.442 -0.885 . . . . 1.12 112.927 177.05 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.1 p -85.25 152.31 23.41 Favored 'General case' 0 N--CA 1.447 -0.611 0 C-N-CA 122.745 0.418 . . . . 0.96 110.62 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.453 HG22 HD12 ' A' ' 50' ' ' ILE . 27.7 mt -102.72 133.99 44.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.843 0.83 . . . . 0.96 111.338 175.739 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.519 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -138.75 159.97 40.81 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.599 -1.182 . . . . 0.91 109.797 177.042 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.453 ' HB2' HD11 ' A' ' 50' ' ' ILE . 41.1 t -109.46 108.45 18.96 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.428 -0.582 . . . . 0.34 109.428 178.084 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.81 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 94.1 m -90.62 129.96 36.69 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.523 -0.762 . . . . 0.19 111.404 -174.597 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.401 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -70.76 -34.65 72.04 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.028 -0.987 . . . . 0.38 109.622 174.433 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -130.91 116.29 17.69 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.87 -0.604 . . . . 1.03 110.085 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 99.3 t -110.2 102.6 14.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.058 0.456 . . . . 0.18 109.981 178.606 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.7 m -130.11 143.59 49.75 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 115.896 -0.593 . . . . 0.18 111.231 -174.053 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.521 ' O ' ' HB3' ' A' ' 22' ' ' SER . 35.5 Cg_exo -61.83 141.11 88.94 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.42 2.08 . . . . 0.19 111.36 171.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.96 -25.52 72.02 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.987 -0.625 . . . . 0.18 112.584 -178.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -97.87 7.1 46.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.238 0.542 . . . . 2.27 110.118 177.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.521 ' HB3' ' O ' ' A' ' 19' ' ' PRO . 28.9 t -75.13 154.23 37.86 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.523 -0.762 . . . . 0.24 109.753 176.168 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -58.69 -31.94 68.69 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.18 0.514 . . . . 1.06 110.389 178.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.697 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.1 mm? -73.39 -64.52 0.97 Allowed 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 115.722 -0.672 . . . . 1.11 110.408 173.076 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.78 -38.35 64.17 Favored Glycine 0 C--N 1.33 0.223 0 CA-C-N 115.788 -0.642 . . . . 0.16 113.707 -174.013 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 87.7 m -68.43 -44.72 74.35 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.818 0.342 . . . . 0.24 110.692 -177.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.433 ' O ' HD13 ' A' ' 27' ' ' LEU . 2.7 tm? -64.72 -36.89 85.74 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.261 -0.644 . . . . 1.01 109.261 177.613 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.697 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 18.9 mt -65.56 -49.54 68.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.881 -0.599 . . . . 0.37 110.436 -178.272 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.491 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 4.2 pp -75.31 -22.08 57.97 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.469 -0.332 . . . . 0.41 111.584 -176.257 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.45 ' N ' HD12 ' A' ' 29' ' ' LEU . 19.8 t70 -66.56 -34.81 78.72 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.325 0.584 . . . . 0.66 109.656 175.697 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 21.5 tt0 -72.92 -20.21 61.11 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.126 -0.943 . . . . 2.07 109.594 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.5 mt -98.14 -19.58 17.83 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.346 -1.297 . . . . 0.71 111.308 -176.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.42 24.55 60.71 Favored Glycine 0 N--CA 1.452 -0.271 0 CA-C-N 115.891 -0.595 . . . . 0.75 112.609 179.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.491 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 28.7 mt -78.9 133.28 30.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.967 0.413 . . . . 0.68 110.913 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.5 t -113.1 97.96 6.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.018 -0.537 . . . . 1.87 110.038 176.616 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 17.4 mt -93.73 138.26 32.11 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.169 -0.468 . . . . 2.76 110.739 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -78.96 -23.81 44.28 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.279 0.561 . . . . 2.65 109.589 175.505 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 24.7 m-20 -133.05 92.21 26.22 Favored Pre-proline 0 N--CA 1.446 -0.628 0 CA-C-N 115.446 -0.797 . . . . 2.29 109.117 176.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -72.8 6.96 2.16 Favored 'Trans proline' 0 N--CA 1.463 -0.287 0 C-N-CA 122.262 1.975 . . . . 0.64 111.445 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.7 p -83.71 -8.25 59.31 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.534 -0.757 . . . . 0.51 110.878 -178.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.471 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 33.4 m -78.54 151.08 5.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.909 -0.587 . . . . 0.24 110.792 179.283 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.0 mt -81.61 120.78 25.51 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.609 -0.723 . . . . 0.22 110.094 177.191 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 12.6 pt -102.52 131.85 49.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.29 0.567 . . . . 0.15 110.119 176.107 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.81 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -106.11 99.9 1.58 Allowed Glycine 0 N--CA 1.438 -1.207 0 CA-C-N 115.529 -0.76 . . . . 0.31 113.175 -174.54 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -80.67 139.15 36.33 Favored 'General case' 0 C--N 1.314 -0.953 0 N-CA-C 109.028 -0.731 . . . . 0.57 109.028 175.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.33 34.64 35.9 Favored Glycine 0 N--CA 1.444 -0.82 0 C-N-CA 119.629 -1.272 . . . . 0.21 111.523 -178.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.535 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -102.4 118.72 37.47 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.144 0.497 . . . . 0.25 111.121 -174.315 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -100.55 134.5 20.59 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 115.669 -0.696 . . . . 2.21 109.412 175.148 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -63.98 123.13 11.43 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.589 2.193 . . . . 0.44 110.967 177.423 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.453 HD11 ' HB2' ' A' ' 13' ' ' CYS . 12.4 mt -83.55 89.58 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-O 121.482 0.658 . . . . 0.46 109.75 -178.062 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 10.6 t -119.09 16.68 13.28 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.255 -0.884 . . . . 0.88 109.878 -178.304 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 13.1 p -92.38 139.91 17.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.34 -0.845 . . . . 1.44 110.312 179.553 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -79.81 145.01 33.03 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.259 -0.428 . . . . 2.94 110.097 177.122 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 83.96 69.64 1.37 Allowed Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.49 -0.862 . . . . 3.5 111.304 -175.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.0 m -78.85 53.47 1.39 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.995 0.426 . . . . 4.9 111.7 -175.575 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.5 m -85.54 -57.5 3.04 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.301 -0.629 . . . . 4.06 109.301 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -122.34 50.25 1.5 Allowed 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 109.011 -0.737 . . . . 3.13 109.011 174.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -88.67 -2.84 58.8 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.524 -0.762 . . . . 0.99 110.731 -177.463 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.3 t -140.24 118.58 12.11 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.575 -0.739 . . . . 0.74 110.063 176.472 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 51.1 m -108.25 17.17 22.52 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.225 -0.443 . . . . 2.14 111.735 -177.163 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.401 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -144.52 -82.18 0.16 Allowed 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.752 -0.379 . . . . 0.54 111.536 178.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 87.1 m -150.11 123.96 9.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.864 0.364 . . . . 0.29 110.825 -179.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 82' ' ' VAL . . . -86.44 129.59 34.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.057 0.456 . . . . 0.25 110.209 -177.433 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.567 ' HB ' ' HB3' ' A' ' 79' ' ' CYS . 6.4 m -140.88 161.58 23.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 115.937 -0.574 . . . . 0.21 111.023 -177.702 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 52.8 t -120.18 110.33 16.48 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.633 -0.712 . . . . 0.39 109.389 177.092 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.782 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 15.8 m -97.57 132.23 43.43 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.133 0.492 . . . . 0.65 111.286 -176.292 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.4 m -84.11 -25.78 29.45 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.583 -0.735 . . . . 1.15 111.04 -178.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -102.01 134.66 44.88 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.791 -0.64 . . . . 1.6 110.145 -177.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -100.99 10.1 41.49 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.322 -0.399 . . . . 2.49 111.311 -174.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 -79.57 103.21 9.32 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.086 0.47 . . . . 2.27 110.131 179.427 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.871 HG12 ' H ' ' A' ' 73' ' ' GLY . 73.0 t -122.84 133.04 70.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.019 -0.537 . . . . 1.1 111.244 -173.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.586 ' H ' ' CG1' ' A' ' 75' ' ' ILE . 88.8 p -80.12 2.58 23.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.531 -0.758 . . . . 1.41 111.257 -177.296 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.871 ' H ' HG12 ' A' ' 71' ' ' VAL . . . 126.57 -32.31 3.73 Favored Glycine 0 N--CA 1.446 -0.691 0 CA-C-N 115.664 -0.698 . . . . 0.48 112.04 -178.387 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.0 m -138.69 -9.77 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 112.315 0.487 . . . . 0.49 112.315 -179.381 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.586 ' CG1' ' H ' ' A' ' 72' ' ' SER . 4.1 pt -88.79 -179.43 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.707 0.765 . . . . 0.3 112.705 -175.546 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.782 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -151.51 142.17 22.73 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 114.287 -1.324 . . . . 0.18 108.798 174.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.9 mt -120.4 137.1 55.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.915 0.388 . . . . 0.26 111.945 -175.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.471 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 69.89 52.14 20.89 Favored Glycine 0 C--N 1.333 0.371 0 CA-C-N 115.922 -0.581 . . . . 0.17 111.778 177.723 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.567 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 12.8 m -103.02 134.35 46.62 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.274 0.559 . . . . 0.65 111.909 -173.634 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 90.4 mt -107.79 131.82 21.46 Favored Pre-proline 0 C--N 1.322 -0.614 0 CA-C-N 115.563 -0.744 . . . . 0.29 110.032 175.202 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.427 ' HA ' HG12 ' A' ' 64' ' ' VAL . 25.4 Cg_exo -63.24 120.67 8.22 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.917 2.412 . . . . 0.25 112.678 -179.315 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.427 ' O ' ' HB3' ' A' ' 63' ' ' ALA . 4.3 m -120.31 140.2 45.16 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 CA-C-N 115.968 -0.56 . . . . 0.42 110.201 178.23 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.453 HG22 ' HG ' ' A' ' 84' ' ' LEU . 95.0 m 63.81 142.59 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 115.799 -0.637 . . . . 2.07 111.681 -176.031 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.453 ' HG ' HG22 ' A' ' 83' ' ' THR . 79.4 mt . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.145 -0.931 . . . . 3.91 111.509 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.645 0 N-CA-C 111.662 -0.575 . . . . 5.63 111.662 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.5 p -88.28 -73.93 0.47 Allowed 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.679 0.239 . . . . 4.28 110.378 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 89.6 m95 58.24 93.55 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.258 0 O-C-N 123.864 0.728 . . . . 4.74 111.384 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -70.06 107.98 2.32 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.884 -0.674 . . . . 2.03 112.432 -179.538 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -110.84 137.55 48.34 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.482 -0.562 . . . . 4.17 109.482 172.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.477 ' SG ' ' N ' ' A' ' 7' ' ' SER . 29.1 p -83.66 -58.51 2.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.805 0.336 . . . . 1.88 110.302 -178.514 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.477 ' N ' ' SG ' ' A' ' 6' ' ' CYS . 65.5 m -163.05 -65.48 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.075 -0.511 . . . . 2.4 109.715 -179.728 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.8 p -100.26 -24.53 14.52 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.247 -0.433 . . . . 3.75 112.015 -177.352 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -128.93 -177.03 14.67 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.675 -0.774 . . . . 1.12 112.518 -178.247 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 34.1 t -90.98 151.24 21.15 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 109.502 -0.555 . . . . 0.96 109.502 177.414 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.418 HG22 HD12 ' A' ' 50' ' ' ILE . 43.1 mt -95.7 137.16 24.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 121.664 0.745 . . . . 0.96 110.989 178.058 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . 0.532 ' OE1' ' HB2' ' A' ' 66' ' ' CYS . 0.0 OUTLIER -132.24 163.06 29.43 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.775 -1.102 . . . . 0.91 109.949 176.781 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 47' ' ' CYS . 42.0 t -106.28 99.49 9.07 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.809 -0.632 . . . . 0.34 109.556 179.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.865 ' SG ' ' HA3' ' A' ' 44' ' ' GLY . 54.0 m -86.01 130.66 34.47 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-N 115.707 -0.678 . . . . 0.19 111.352 -175.554 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.445 ' HA ' ' CB ' ' A' ' 61' ' ' ALA . 0.0 OUTLIER -77.82 -30.87 51.37 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.196 -0.911 . . . . 0.38 109.77 177.506 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.641 ' HB2' ' HB3' ' A' ' 45' ' ' ASP . 19.3 m-20 -133.3 98.59 4.29 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.117 -0.492 . . . . 1.03 111.256 175.609 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 71.8 t -89.48 100.85 11.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.162 0.506 . . . . 0.18 109.732 174.234 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 29.6 m -128.45 141.1 40.35 Favored Pre-proline 0 C--N 1.318 -0.768 0 CA-C-N 115.843 -0.617 . . . . 0.18 110.697 -174.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.466 ' HB2' ' HB2' ' A' ' 22' ' ' SER . 31.9 Cg_exo -59.24 135.58 66.65 Favored 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 122.073 1.849 . . . . 0.19 111.521 172.741 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -66.8 -15.22 64.23 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.888 -0.673 . . . . 0.18 112.136 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -103.44 4.56 36.25 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.053 0.454 . . . . 2.27 110.248 175.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.466 ' HB2' ' HB2' ' A' ' 19' ' ' PRO . 29.0 t -78.53 158.35 28.59 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.051 -0.522 . . . . 0.24 109.898 177.717 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -53.19 -42.79 66.61 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.974 0.416 . . . . 1.06 109.991 176.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.701 ' O ' ' HG ' ' A' ' 28' ' ' LEU . 2.9 mm? -67.7 -65.08 0.74 Allowed 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 115.669 -0.696 . . . . 1.11 110.493 178.259 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.69 -36.44 59.29 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.983 -0.553 . . . . 0.16 113.329 -174.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 84.9 m -68.55 -45.67 71.53 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.79 0.329 . . . . 0.24 110.298 -178.175 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.432 ' O ' HD13 ' A' ' 27' ' ' LEU . 1.3 tm? -65.96 -36.38 83.17 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.15 -0.685 . . . . 1.01 109.15 178.212 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.701 ' HG ' ' O ' ' A' ' 24' ' ' LEU . 16.7 mt -67.34 -46.55 73.12 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.603 -0.726 . . . . 0.37 111.033 -177.363 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.514 ' HB2' ' HB ' ' A' ' 34' ' ' ILE . 3.9 pp -77.26 -22.87 51.49 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 120.321 -0.551 . . . . 0.41 111.137 -178.695 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.478 ' N ' HD12 ' A' ' 29' ' ' LEU . 13.0 t70 -67.98 -35.8 78.97 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.044 -0.724 . . . . 0.66 109.044 173.135 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 23.9 tt0 -69.1 -33.22 73.16 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 114.717 -1.129 . . . . 2.07 109.429 178.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 67.6 mt -91.87 -10.86 38.13 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.56 -1.2 . . . . 0.71 111.867 -176.412 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.29 35.71 88.33 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.767 -0.651 . . . . 0.75 112.6 179.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.514 ' HB ' ' HB2' ' A' ' 29' ' ' LEU . 56.5 mt -76.08 129.0 37.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 120.814 0.34 . . . . 0.68 111.163 -176.528 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 3.2 p -86.56 101.0 10.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.746 0.784 . . . . 1.87 109.415 172.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.516 ' O ' HD12 ' A' ' 36' ' ' LEU . 1.8 pp -76.29 132.7 39.98 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.722 -0.672 . . . . 2.76 111.18 -177.358 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -86.83 -29.73 22.01 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 108.745 -0.835 . . . . 2.65 108.745 172.248 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -144.96 112.33 4.84 Favored Pre-proline 0 N--CA 1.443 -0.803 0 N-CA-C 107.493 -1.299 . . . . 2.29 107.493 174.01 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.407 ' HB3' HD22 ' A' ' 36' ' ' LEU . 70.9 Cg_endo -75.52 -1.5 11.4 Favored 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.197 1.931 . . . . 0.64 112.808 -173.228 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 35.2 p -106.55 20.51 18.89 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.261 0.553 . . . . 0.51 111.121 -175.727 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.46 ' HB ' ' HA2' ' A' ' 78' ' ' GLY . 34.8 m -87.72 156.59 3.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.589 -0.732 . . . . 0.24 110.081 175.143 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.454 ' HB2' ' O ' ' A' ' 79' ' ' CYS . 93.9 mt -85.6 121.26 28.04 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.808 -0.442 . . . . 0.22 109.808 176.638 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 22.2 pt -106.41 140.75 23.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-O 121.101 0.477 . . . . 0.15 110.256 177.493 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.865 ' HA3' ' SG ' ' A' ' 14' ' ' CYS . . . -117.2 107.35 1.55 Allowed Glycine 0 N--CA 1.439 -1.111 0 C-N-CA 120.586 -0.816 . . . . 0.31 112.949 -175.102 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.641 ' HB3' ' HB2' ' A' ' 16' ' ' ASN . 9.4 t70 -80.62 147.91 30.5 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.693 -0.854 . . . . 0.57 108.693 175.257 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 67.46 37.81 90.34 Favored Glycine 0 C--N 1.317 -0.515 0 C-N-CA 120.162 -1.018 . . . . 0.21 111.958 178.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -102.63 115.44 30.59 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.01 0.433 . . . . 0.25 111.088 -172.895 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.45 ' OD2' ' HB3' ' A' ' 13' ' ' CYS . 2.1 p-10 -100.84 132.07 22.63 Favored Pre-proline 0 C--N 1.318 -0.796 0 CA-C-N 115.698 -0.683 . . . . 2.21 110.161 177.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -57.94 119.55 6.87 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.399 2.066 . . . . 0.44 110.696 175.058 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.418 HD12 HG22 ' A' ' 11' ' ' ILE . 12.9 mt -79.53 88.92 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 CA-C-O 121.879 0.847 . . . . 0.46 109.913 -177.098 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.7 t -111.45 17.87 19.69 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.512 -1.222 . . . . 0.88 109.415 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 10.6 p -102.39 145.1 12.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 114.737 -1.119 . . . . 1.44 109.252 175.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -88.06 81.4 7.44 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.852 0.358 . . . . 2.94 110.848 -179.048 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -133.87 128.6 5.01 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.823 -0.703 . . . . 3.5 111.819 179.508 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 19.2 m -72.45 -34.93 68.12 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.888 0.375 . . . . 4.9 111.498 -177.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 23.1 t -130.61 -51.67 1.07 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.837 0.351 . . . . 4.06 110.773 -179.533 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -79.89 43.79 0.61 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.16 0.505 . . . . 3.13 111.55 -176.03 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -112.03 -2.45 15.06 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.944 -0.571 . . . . 0.99 110.547 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 52.5 t -146.81 130.92 17.33 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.818 -0.628 . . . . 0.74 110.28 -179.265 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 12.8 p -93.6 -15.37 25.46 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.089 -0.505 . . . . 2.14 111.742 -177.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.445 ' CB ' ' HA ' ' A' ' 15' ' ' GLN . . . -128.44 -83.44 0.58 Allowed 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.623 0.601 . . . . 0.54 112.623 -175.172 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.8 m -142.11 131.59 23.8 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.783 0.325 . . . . 0.29 111.301 -176.147 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -86.94 125.98 34.4 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.031 0.443 . . . . 0.25 110.125 178.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.663 HG21 ' SG ' ' A' ' 14' ' ' CYS . 3.9 m -141.33 164.99 19.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.119 -0.492 . . . . 0.21 110.806 -177.546 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' CYS . . . . . 0.401 ' O ' ' HA ' ' A' ' 79' ' ' CYS . 29.3 t -131.28 113.0 13.27 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 116.172 -0.467 . . . . 0.39 109.935 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.783 ' SG ' ' HB1' ' A' ' 76' ' ' ALA . 1.5 m -95.53 136.73 35.54 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.647 0.737 . . . . 0.65 112.233 -175.406 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.7 m -89.44 -18.45 26.75 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.641 -1.163 . . . . 1.15 110.806 -179.281 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.467 ' HB2' ' O ' ' A' ' 77' ' ' ILE . 19.8 m-20 -98.31 151.71 20.21 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.887 -0.597 . . . . 1.6 110.332 178.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -103.68 -12.28 17.12 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.019 -0.537 . . . . 2.49 110.581 -178.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -67.84 110.2 3.72 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.892 -0.594 . . . . 2.27 110.915 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.5 m -125.19 150.29 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 CA-C-N 116.158 -0.473 . . . . 1.1 110.932 177.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.506 ' H ' HG12 ' A' ' 75' ' ' ILE . 8.1 t -95.31 10.58 35.66 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.651 0.738 . . . . 1.41 109.636 177.008 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.15 -33.42 5.31 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 115.476 -0.784 . . . . 0.48 112.748 177.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 13.5 m -138.01 -0.52 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 C-N-CA 120.644 -0.422 . . . . 0.49 111.64 179.311 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.506 HG12 ' H ' ' A' ' 72' ' ' SER . 24.3 pt -100.21 173.84 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 C-N-CA 120.187 -0.605 . . . . 0.3 111.63 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.783 ' HB1' ' SG ' ' A' ' 66' ' ' CYS . . . -141.41 141.08 33.76 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 114.485 -1.234 . . . . 0.18 109.35 176.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.467 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 67.0 mt -122.02 131.93 72.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.742 0.306 . . . . 0.26 111.342 -177.43 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.46 ' HA2' ' HB ' ' A' ' 41' ' ' VAL . . . 75.53 51.68 7.11 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.978 -0.629 . . . . 0.17 111.911 178.638 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 66' ' ' CYS . 1.2 m -99.89 138.74 36.55 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.231 0.538 . . . . 0.65 112.232 -176.345 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 92.1 mt -106.98 133.01 20.46 Favored Pre-proline 0 C--N 1.32 -0.689 0 CA-C-N 115.475 -0.784 . . . . 0.29 109.445 170.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.406 ' HA ' HG12 ' A' ' 64' ' ' VAL . 17.3 Cg_exo -65.77 124.62 12.99 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.82 2.347 . . . . 0.25 111.961 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.6 m -123.6 159.51 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-O 121.033 0.444 . . . . 0.42 110.659 -179.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.4 HG22 ' HG ' ' A' ' 84' ' ' LEU . 15.2 m -132.76 142.57 49.08 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.585 -0.734 . . . . 2.07 109.52 178.439 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.4 ' HG ' HG22 ' A' ' 83' ' ' THR . 85.6 mt . . . . . 0 C--O 1.248 0.977 0 O-C-N 123.607 0.567 . . . . 3.91 110.714 179.222 . . . . . . . . 1 1 . 1 stop_ save_